Printed in the United States of America. Available from
National Technical Information Service
U.S. Department of Commerce
5285 Port Royal Road, Springfield, Virginia 22161
NTIS price codes—Printed Copy: A20 Microfiche: A01

This report was prepared under contract to an agency of the United States Government. Neither the United States Government nor any of their employees, contractors, subcontractors, or their employees, makes any warranty, express or implied, nor assumes any legal liability or responsibility for any third party's use or the results of such use of any information, apparatus, product, or process disclosed in this report, nor represents that its use by such third party would not infringe privately owned rights.

Publication of the data in this document does not signify that the contents necessarily reflect the joint or separate views and policies of each sponsoring agency. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

EPA 560/5-82-002
ORNL/EIS-163/V4

CHEMICALS IDENTIFIED IN HUMAN BIOLOGICAL MEDIA, A DATA BASE

Interim Report, May 1982
Volume IV

NOTICE MN ONLY
PORTIONS OF THIS REPORT ARE ILLEGIBLE.
It has been reproduced from the best available copy to permit the broadest possible availability.

Compiled by

M. Virginia Cone, Margaret F. Baldauf,
Dennis M. Opresko, and Mary S. Uziel

Chemical Effects Information Center
Information Center Complex
Information Division
OAK RIDGE NATIONAL LABORATORY
Oak Ridge, Tennessee 37830
operated by
UNION CARBIDE CORPORATION
for the
DEPARTMENT OF ENERGY
Contract No. W-7405-eng-26

EPA--560/5-82-002
DE82 010319

This effort was accomplished under the aegis of the Interagency Collaborative Group on Environmental Carcinogenesis, National Cancer Institute, National Institutes of Health, Chairperson, Dr. Herman F. Kraybill.

Date Published - May 1982

Cindy Stroup, Project Officer
Design and Development Branch
Exposure Evaluation Division
Office of Toxic Substances
U.S. Environmental Protection Agency
Washington, D.C. 20460

DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED

CONTENTS

Acknowledgments v

Introduction 1

Users' Guide 3

Abbreviations for Analytical Methods 7

Data Base
- Nondrugs 9
- Drugs 145

References for Data Base (Vol. IV) 217

References for Physical and Chemical Data 241

Appendix A. Journals Searched 245

Appendix B. Chemicals (Vols. I-IV) by CAS Preferred Names 249

Appendix C. Chemicals (Vol. IV) by CAS Registry Numbers and Preferred Names 273

Appendix D. Cross-Referenced Chemical Lists (Vol. IV) 283
1. CAS Preferred Names — Common Names 285
2. Common Names — CAS Preferred Names 301

Appendix E. Tissues and Body Fluids (Vols. I-IV) 399

Indices (Vol. IV) 403
- Author 405
- Corporate Author 413
- Tissue 423
- Keyword 425

Directory of Chemicals (Vol. IV) 431
- CAS Preferred Names 433
- Formulas 439

ACKNOWLEDGMENTS

We gratefully acknowledge the assistance of Janis Pruett and the staff of the Toxicology Information Response Center in the preparation of this document. Janet Scott, of the Computer Services Group, was responsible for the computer production of the document. Both of these groups are part of the Information Center Complex, Information Division, Oak Ridge National Laboratory.

For his continuing support and valuable advice, the U.S. Environmental Protection Agency project officer expresses special thanks to Dr. Herman F. Kraybill, the National Cancer Institute coproject officer and the chairperson of the Interagency Collaborative Group on Environmental Carcinogenesis (ICGEC). In addition, thanks are due the members of the ICGEC Task Group on Chemicals in Human Tissues.

INTRODUCTION

A comprehensive data base of chemicals identified in human biological media (tissues and body fluids) has been established under the direction of the Exposure Evaluation Division in the U.S. Environmental Protection Agency's Office of Toxic Substances. This centralized resource of body-burden information has grown out of the concern of government scientists over continuing reports of toxic chemicals in human tissues and body fluids. This interim report is the fourth publication of the data base.

Body burden is a reflection of exposures to food, air, and water contaminants, as well as administration of pharmaceuticals. The systematic acquisition of body-burden data will facilitate a more relevant assessment of human exposure to xenobiotics (including toxic chemicals) than was previously possible using environmental contamination levels.

Data were obtained primarily from the open literature through manual searches (retrospective to 1974) of the journals listed in Appendix A. The data base now contains information on over 950 different substances, all of which are listed by Chemical Abstracts Service (CAS) preferred names in Appendix B. Appendix C lists, by CAS registry numbers and preferred names, the chemicals in Volume IV. For the user's convenience, cross-referenced chemical lists of CAS preferred names and common names are provided in Appendix D. The human tissues and body fluids found to be contaminated by these chemicals are listed in Appendix E.

The data base is published annually in tabular format with indices and chemical listings that allow specific searching. Because a large volume of data has been input since the third annual report, this interim report is being published. The next annual report (for 1982) will be published in October, 1982. The file is now available online in the U.S. Department of Energy's RECON and is being prepared for Lockheed's DIALOG.

The purpose of the data base is to provide a centralized resource of body-burden data, and in no way is it intended to obviate the need for the user to ultimately refer to the original literature or data

source. It is not the intent of this program to conduct any screening or evaluation of the data.

This data base was established under the aegis of the Interagency Collaborative Group on Environmental Carcinogenesis (ICGEC), National Cancer Institute. Funding is through the National Cancer Institute-Environmental Protection Agency Collaborative Program. The work is being done by the Oak Ridge National Laboratory's Chemical Effects Information Center (formerly Health and Environmental Studies Program), Information Center Complex, through interagency agreements involving the National Cancer Institute, the Environmental Protection Agency, and the Department of Energy. Members of the ICGEC Task Group on Chemicals in Human Tissues provide support to the program's activities. Agencies represented by members of the task group include the Armed Forces Institute of Pathology, the Centers for Disease Control, the Department of Agriculture, the Department of Energy, the Environmental Protection Agency, the Food and Drug Administration, the National Bureau of Standards, the National Cancer Institute, the National Center for Toxicological Research, the National Institute for Environmental Health Sciences, the National Institute for Occupational Safety and Health, and the National Library of Medicine.

Comments by the users of this document are invited. Questions, comments, and requests for additional information about the data base and/or searches thereof should be directed to:

Cindy Stroup, Project Officer
Design and Development Branch
Exposure Evaluation Division (TS-798)
Office of Toxic Substances
U.S. Environmental Protection Agency
401 M Street SW
Washington, D.C. 20460
Telephone (202) 382-3891

USERS' GUIDE

Volume IV is published in a single document containing introductory materials, references, full literature citations, appendices, indices, and directories as well as the body-burden data extracted since the latest publication of the data base.

Data from almost 2000 of the 4000 body-burden documents collected to date have been entered in the data base as of May, 1982. The emphasis on including recent literature and significant research documents has resulted in a chronological mix of articles from 1974 to the present.

When body-burden articles are identified, data are extracted and entered in the data base by chemical and tissue/body fluid. Each data entry comprises a single record (or line entry) and is assigned a record number. If a particular document deals with more than one chemical and/or tissue, there will be multiple records for that document. For example, a study of 5 chemicals in each of 3 tissues has 15 different records (or 15 line entries) in the data base with 15 record numbers. Record numbers are assigned consecutively throughout the entire data base and appear in the upper left corner of the first column for each record.

The tabular portion of this document contains the body-burden data. It is divided into two sections, the first with records on nondrug substances, and the second with records on drugs. Chemicals in each section are arranged alphabetically by CAS preferred name. Chemicals not normally used in drug therapy may appear in the drug section of the table if they were part of drug abuse activity (e.g., Toluene). Record numbers for both sections appear in the directories. The sample record on the next page illustrates the format. The chemical, in this case Arsenic, is given along with its CAS registry number, formula, atomic weight, melting point, boiling point, and vapor pressure. Tissues are listed alphabetically in the first column with the record number. In the sample record, the tissue is hair and the record number is 41.

Information in the next five columns — exposure route, analytical method, number of cases, range, and mean — is self-explanatory and is provided when available in the source document. A list of abbreviations

Arsenic
7440-38-2
As
AtW 74.9216, MP 817 C at 28 atm, BP 613 C (sublimes), VP 1 mm Hg at 380 C, 10 mm Hg at 440 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
41 Hair	Inhalation Ingestion	Colorimetry	46, 44 controls	a) 0.630-8.080 µg/g b) 0-0.900 µg/g c) 0-1.130 µg/g	a) 3.261 µg/g b) 0.295 µg/g c) 0.152 µg/g	a) Heavily polluted area b) 36 km from source c) Controls 10 yr old boys near coal-burning plant in Czechoslovakia ARSENIC; HAIR; URINE; BLOOD; CHILDREN; CZECHOSLOVAKIA; COAL; FOSSIL FUELED POWER PLANTS; POPULATION EXPOSURE; AIR POLLUTION; BIOINDICATORS	Bencko, V. Symon, K. 1977a Envir. Res. 13:378-385

used for analytical methods is provided on page 7. Exponential values are written as in the following example: 5×10^{-15} is 5 × 10(E-15). All means are arithmetic unless designated geometric. When included, standard error is indicated by S.E. However, values for standard deviations, when given, have no such designations. When only graphically displayed data were available, values have been estimated by the extractor and so indicated in the table under GENERAL INFORMATION.

In the GENERAL INFORMATION column, a variety of information may be included that is pertinent to the range and mean as well as experimental design, demography, health effects, pathology, morphology, and toxicity. In general, supporting information deemed important for understanding the data presented appears in this column. Abbreviations are generally standard, accepted usage. For example, AUC refers to area under the curve.

The REFERENCE column includes author(s), publication date, and source. Complete literature citations are listed alphabetically, by author, starting on page 219.

Because not all details of the research can be included in this publication, keywords, in uppercase letters, are provided for further insight into important aspects of the source documents. The use of a different chemical as a keyword indicates studies on that chemical were also reported in the same document. For example, CADMIUM may appear as a keyword in a record on mercury when the work includes data on both chemicals. In the same way, a different tissue occurring as a keyword indicates the document also deals with that tissue.

Review articles are included in the data base; however, no data have been extracted from such documents because the original research articles are included. Review articles are designated in the GENERAL INFORMATION column by the word *Review*.

CAS preferred names are from the *Ninth Collective Index*, and, when different, names from both eighth and ninth indices (8 CI, 9 CI) are given. Appendix D provides cross-referenced alphabetical lists of commonly used synonyms paired with the CAS preferred names.

For accessing information in the data base when only the CAS registry number is known, the user should refer to Appendix C, which lists CAS registry numbers coupled with the preferred names. For help in locating chemicals in the tabular portion of the document, an alphabetically arranged directory of chemicals by CAS names and record numbers is provided at the end of the document. The second part of the directory lists formulas alphabetically along with the corresponding CAS preferred names and record numbers. This directory includes only chemicals in Volume IV of the data base (i.e., records 5272-6011). A list, by CAS preferred names, of chemicals in the entire data base (Vols. I-IV) is found in Appendix B. Indices by author, corporate authority, tissue or body fluid, and keywords refer the user to the appropriate record number(s) in Volume IV.

PLEASE NOTE: Because of computer programming, chemical names preceded by numbers (such as 1-Hexadecanol) are listed at the end of the alphabetical listings. Check the CAS preferred names section of the Directory of Chemicals for the exact locations of such compounds in the table.

ABBREVIATIONS FOR ANALYTICAL METHODS

AAS	Atomic absorption spectrometry
APDC-MIBK	Ammonium pyrrolidine diethiocarbamate-methylisoburyl ketone extraction
ASV	Anodic stripping voltammetry
CC	Column chromatography
Chem	Chemical methods
Electrochem	Electrochemical methods
EM	Electron microscopy
ES	Emission spectrometry
GC	Gas chromatography
GC-EC	Gas chromatography; electron-capture detection
GC/MF	Gas chromatography coupled with mass fragmentography
GC/MS	Gas chromatography coupled with mass spectrometry
Histochem	Histochemistry
HPLC	High-pressure liquid chromatography
IR	Infrared analysis
ISE	Ion-specific electrode
LSV	Linear sweep voltammetry
MAS	Molecular absorption spectrophotometry
MED	Microwave emission detector (ion)
MS	Mass spectrometry
NA	Neutron activation
NMR	Nuclear magnetic resonance
PIXE	Proton-induced X-ray emission
RIA	Radioimmunoassay
TLC	Thin-layer chromatography
UV	Ultraviolet analysis
X-ray fluores	X-ray fluorescence
X-ray spectrom	X-ray spectrometry

DATA BASE

NONDRUGS

Aluminum
7429-90-5
Al
Atw 26.98154, MP 660 C, BP 2327 C, VP 1 mm Hg at 1540 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5272 Blood, plasma	Ingestion	AAS	13	a) Not given b) Not given c) Not given d) Not given	a) 17 +or- 13 ug/l b) 18 +or- 7 ug/l c) 17 +or- 7 ug/l d) 9 +or- 2 ug/l	a) 13 subjects, after 2.2 g as hydroxide b) 7 subjects, after 2.2 g as carbonate c) 6 subjects, after 2.2 g as dihydroxyaluminum aminoacetate d) 6 subjects, after 2.2 g as phosphate Control samples before treatment were 6-7 ug/l Healthy adults BLOOD PLASMA; DRINK; DRUGS; ALUMINUM	Maehny, W.D. Hegg, A.E. Alfrey, A.C. 1977 New England Journal of Medicine 296(24):1389-1390
5273 Blood, serum		AAS	23	12-46 ug/l	28 +or- 9 ug/l	Persons not taking Al-antiacids Size, sex, and age not significant BLOOD SERUM; DRINK; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS; ALUMINUM; METALS	Gorsky, J.E. Dietz, A.A. 1976 Clinical Chemistry 24(9):1485-1490
5274 Bone		AAS		Not given	3.88 +or- 1.73 mg/kg dry wt	Biopsies, autopsies. No other data or sample numbers. AUTOPSIES; BONES; BRAIN; MUSCLES; ALUMINUM; METALS	LeGendre, G.R. Alfrey, A.C. 1976 Clinical Chemistry 22(1):53-56
5275 Brain		AAS		Not given	1.30 +or- 0.68 mg/kg dry wt	Biopsies, autopsies. No other data or sample numbers. AUTOPSIES; BONES; BRAIN; MUSCLES; ALUMINUM; METALS	LeGendre, G.R. Alfrey, A.C. 1976 Clinical Chemistry 22(1):53-56
5276 Hair		AAS	1	0-20.3 ppm	Not given	Data for various body regions. Maximum level in axillary hair. Estimated from graph 23 yr old, United Kingdom ADULTS; HAIR; COMPARATIVE EVALUATIONS; ALUMINUM; CHROMIUM; COBALT; COPPER; IRON; MANGANESE; METALS; NICKEL; SILICON; SILVER; UNITED KINGDOM	Alder, J.F. Samuel, A.J. West, T.S. 1977 Analytica Chimica Acta 92:217-227
5277 Muscle		AAS		Not given	1.22 +or- 0.72 mg/kg dry wt	Biopsies, autopsies. No other data or sample numbers. AUTOPSIES; BONES; BRAIN; MUSCLES; ALUMINUM; METALS	LeGendre, G.R. Alfrey, A.C. 1976 Clinical Chemistry 22(1):53-56
5278 Teeth		MS	208	a) Not given b) Not given	a) 19.13 +or- 3.48 ppm b) 8.38 +or- 1.31 ppm S.E.	a) High caries donors (>7 decayed, missing, filled teeth (DMFT)), 34 teeth b) Low caries donors (<8 DMFT), 26 teeth Values for enamel a) and b) differed, P<0.01 Premolars extracted, patients <20 yr old, New England ZIRCONIUM; NEW HAMPSHIRE; SOUTH CAROLINA; VERMONT; DENTAL CARIES; TEETH; ALUMINUM; BARIUM; COPPER; FLUORINE; LITHIUM; METALS; SILVER; STRONTIUM; TIN	Curzon, M.E.J. Losee, F.L. 1977 Journal of the American Dental Association 94(6):1146-1150

(NEXT PAGE)

Aluminum
7429-90-5
Al
Atw 26.98154, BP 660 C, MP 2327 C, VP 1 mm Hg at 1540 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5279 Urine		AAS	12	6-92 ug/24 hr	45 +or- 32 ug/24 hr	Persons not taking Al-antiacids Normal subjects BLOOD SERUM; URINE; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS; ALUMINUM; METALS	Gorsky, J.E. Dietz, A.A. 1978 Clinical Chemistry 24(9):1485-1490
5280 Urine	Ingestion	AAS	13	a) Not given b) Not given c) Not given d) Not given	a) 730 +or- 487 ug b) 567 +or- 437 ug c) 1,430 +or- 1,157 ug d) 323 +or- 77 ug	a) After 2.2 g as hydroxide, 16 +or- 8 ug/day before treatment, 13 subjects b) After 2.2 g as carbonate, 8 +or- 5 ug/day before treatment, 7 subjects c) After 2.2 g as dihydroxyaluminum aminoacetate, 18 +or- 6 ug/day before treatment, 6 subjects d) After 2.2 g as phosphate, 15 +or- 6 ug/day before treatment, 6 subjects Cumulative increase in excretion 3 days after treatment Healthy adults BLOOD PLASMA; URINE; DRUGS; ALUMINUM	Kaehny, W.D. Hegg, A.P. Alfrey, A.C. 1977 New England Journal of Medicine 296(24):1389-1390

Arsenic
7440-38-2
As
Atw 74.9216, BP 817 C at 28 atm, BP 613 C (sublimes), VP 1 mm Hg at 380 C, 10 mm Hg at 440 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5281 Blood						Review. An illustration of the exposure commitment method is presented. Environmental sources are summarized and relationships are formulated between environmental sources and body burden. BLOOD; BODY; BONES; HAIR; LIVER; LUNGS; MUSCLES; NAILS; SKIN; ARSENIC; AIR POLLUTION; DIETS; DRINKING WATER; INHALATION; RURAL AREAS; SOILS; URBAN AREAS	Bennett, B.G. 1981 Science of the Total Environment 20:99-107
5282 Bone						Review. An illustration of the exposure commitment method is presented. Environmental sources are summarized and relationships are formulated between environmental sources and body burden. BLOOD; BODY; BONES; HAIR; LIVER; LUNGS; MUSCLES; NAILS; SKIN; ARSENIC; AIR POLLUTION; DIETS; DRINKING WATER; INHALATION; RURAL AREAS; SOILS; URBAN AREAS	Bennett, B.G. 1981 Science of the Total Environment 20:99-107

(NEXT PAGE)

Arsenic
7440-38-2
As
At# 74.9216, MP 817 C at 28 atm, BP 613 C (sublimes), VP 1 mm Hg at 380 C, 10 mm Hg at 440 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5283 Hair		AAS	a) 139 b) 20 c) 184 d) 57	a) Not given b) Not given c) Not given d) Not given	a) 1.28 +or- 0.12 ppm b) 1.20 +or- 0.13 ppm c) 1.05 +or- 0.06 ppm d) 1.04 +or- 0.07 ppm	a) Controls, girls b) Learning disability, girls c) Controls, boys d) Learning disability, boys No significant differences. Mean air levels 6.7 +or- 4.9 ng/cu m and 9.2 +or- 2.5 ng/cu m at two schools. 9-12 yr olds, Akron, OH CHILDREN; HAIR; ARSENIC; CADMIUM; LEAD; MERCURY; METALS; SELENIUM; POPULATION EXPOSURE	Ely, D.L. Montardi, M.A. Woebkenberg, M. Worstell, D. 1981 Environmental Research 25:325-339
*294 Hair						Review. An illustration of the exposure commitment method is presented. Environmental sources are summarized and relationships are formulated between environmental sources and body burden. BLOOD; BODY; BONES; HAIR; LIVER; LUNGS; MUSCLES; NAILS; SKIN; ARSENIC; AIR POLLUTION; DIETS; DRINKING WATER; INHALATION; RURAL AREAS; SOILS; URBAN AREAS	Bennett, B.G. 1981 Science of the Total Environment 20:99-107
*285 Kidney		AA	a) 10 b) 8 c) 3 d) 8	a) 2-20 ppb b) 4-15 ppb c) 4-52 ppb d) 2-14 ppb	a) 5 ppb b) 10 ppb c) Not given d) 5 ppb Medians	a) Workers with malignancies, employed 30.9 +or- 7.1 yr, 9 smokers b) Workers with cardiovascular disease, employed 32.5 +or- 8.2 yr, 7 smokers c) Workers with other diagnoses, employed 28.8 +or- 10 yr, 2 smokers d) Controls, 1 smoker Autopsies Workers, mean age 66.6 yr, smelter and refinery in northern Sweden Controls, mean age 67.4 yr, rural area 50 km from factory Highest levels in lung cancer cases. Higher As/Se ratio in workers with malignancies ARSENIC; SELENIUM; INDUSTRIAL AREAS; INDUSTRIAL ATMOSPHERES; INDUSTRIAL PLANTS; SMELTERS; SWEDEN; CARCINOMAS; CARDIOVASCULAR DISEASES; OCCUPATIONAL DISEASES; SARCOMAS; KIDNEYS; LIVER; LUNGS	Wester, P.O. Brune, D. Nordberg, G. 1981 British Journal of Industrial Medicine 38:179-184

(NEXT PAGE)

Arsenic
7440-38-2
As
Atw 74.9216, MP 817 C at 28 atm, BP 613 C (sublimes), VP 1 mm Hg at 380 C, 10 mm Hg at 440 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5286 Liver		NA	a) 10 b) 8 c) 3 d) 8	a) 2-30 ppb b) 6-43 ppb c) 2-3 ppb d) 1-13 ppb	a) 7 ppb b) 9 ppb c) Not given d) 4 ppb Medians	a) Workers with malignancies, employed 30.9 +or- 7.1 yr, 9 smokers b) Workers with cardiovascular disease, employed 32.5 +or- 8.2 yr, 7 smokers c) Workers with other diagnoses, employed 28.8 +or- 10 yr, 2 smokers d) Controls, 1 smoker Autopsies Workers, mean age 66.6 yr, smelter and refinery in northern Sweden Controls, mean age 67.4 yr, rural area 50 km from factory Highest levels in lung cancer cases. Higher As/Se ratio in workers with malignancies ARSENIC; SELENIUM; INDUSTRIAL AREAS; INDUSTRIAL ATMOSPHERES; INDUSTRIAL PLANTS; SMELTERS; SWEDEN; CARCINOMAS; CARDIOVASCULAR DISEASES; OCCUPATIONAL DISEASES; SARCOMAS; KIDNEYS; LIVER; LUNGS	Wester, P.O. Brune, D. Nordberg, G. 1981 British Journal of Industrial Medicine 38:179-184
5287 Liver						Review. An illustration of the exposure commitment method is presented. Environmental sources are summarized and relationships are formulated between environmental sources and body burden. BLOOD; BODY; BONES; HAIR; LIVER; LUNGS; MUSCLES; NAILS; SKIN; ARSENIC; AIR POLLUTION; DIETS; DRINKING WATER; INHALATION; RURAL AREAS; SOILS; URBAN AREAS	Bennett, B.G. 1981 Science of the Total Environment 20:99-107
5288 Lung		NA	a) 15 b) 17 c) 8 d) 11	a) 29-205 ppb b) 19-880 ppb c) 14-85 ppb d) 1-10 ppb	a) 54 ppb b) 44 ppb c) 49 ppb d) 7 ppb Median values	a) Workers with malignancies, employed 30.9 +or- 7.1 yr, 9 smokers b) Workers with cardiovascular disease, employed 32.5 +or- 8.2 yr, 7 smokers c) Workers with other diagnoses, employed 28.8 +or- 10 yr, 2 smokers d) Controls, 1 smoker Autopsies Workers, mean age 66.6 yr, smelter and refinery in northern Sweden Controls, mean age 67.4 yr, rural area 50 km from factory Highest levels in lung cancer cases. Higher As/Se ratio in workers with malignancies ARSENIC; SELENIUM; INDUSTRIAL AREAS; INDUSTRIAL ATMOSPHERES; INDUSTRIAL PLANTS; SMELTERS; SWEDEN; CARCINOMAS; CARDIOVASCULAR DISEASES; OCCUPATIONAL DISEASES; SARCOMAS; KIDNEYS; LIVER; LUNGS	Wester, P.O. Brune, D. Nordberg, G. 1981 British Journal of Industrial Medicine 38:179-184

(NEXT PAGE)

Arsenic
7440-38-2
As
AtW 74.9216, BP 817 C at 28 atm, BP 613 C (sublimes), VP 1 mm Hg at 380 C, 10 mm Hg at 440 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5289 Lung						Review. An illustration of the exposure commitment method is presented. Environmental sources are summarized and relationships are formulated between environmental sources and body burden. BLOOD; BODY; BONES; HAIR; LIVER; LUNGS; MUSCLES; NAILS; SKIN; ARSENIC; AIR POLLUTION; DIETS; DRINKING WATER; INHALATION; RURAL AREAS; SOILS; URBAN AREAS	Bennett, B.G. 1981 Science of the Total Environment 20:99-107
5290 Muscle						Review. An illustration of the exposure commitment method is presented. Environmental sources are summarized and relationships are formulated between environmental sources and body burden. BLOOD; BODY; BONES; HAIR; LIVER; LUNGS; MUSCLES; NAILS; SKIN; ARSENIC; AIR POLLUTION; DIETS; DRINKING WATER; INHALATION; RURAL AREAS; SOILS; URBAN AREAS	Bennett, B.G. 1981 Science of the Total Environment 20:99-107
5291 Nail						Review. An illustration of the exposure commitment method is presented. Environmental sources are summarized and relationships are formulated between environmental sources and body burden. BLOOD; BODY; BONES; HAIR; LIVER; LUNGS; MUSCLES; NAILS; SKIN; ARSENIC; AIR POLLUTION; DIETS; DRINKING WATER; INHALATION; RURAL AREAS; SOILS; URBAN AREAS	Bennett, B.G. 1981 Science of the Total Environment 20:99-107
5292 Skin						Review. An illustration of the exposure commitment method is presented. Environmental sources are summarized and relationships are formulated between environmental sources and body burden. BLOOD; BODY; BONES; HAIR; LIVER; LUNGS; MUSCLES; NAILS; SKIN; ARSENIC; AIR POLLUTION; DIETS; DRINKING WATER; INHALATION; RURAL AREAS; SOILS; URBAN AREAS	Bennett, B.G. 1981 Science of the Total Environment 20:99-107
5293 Urine	Ingestion		a) 1 b) 1 c) 1 d) 1	a) Not given b) Not given c) Not given d) Not given	a) 335 ug b) 909 ug c) 1836 ug d) 3207 ug	a) 58% of 125 ug/day for 5 days b) 73% of 250 ug/day for 5 days c) 74% of 500 ug/day for 5 days d) 64% of 1000 ug/day for 5 days Administered as Na metaarsenite Total urinary output over 14 days (7-26% as inorganic As, 20-38% as monomethyl arsonic acid, and 42-73% as dimethylarsinic acid). ADULTS; URINE; ARSENIC; ARSENIC ORGANIC COMPOUNDS	Buchet, J.P. Lauwerys, R. Roels, H. 1981 International Archives of Occupational and Environmental Health 48:111-118

Asbestos
1332-21-4
EXACT COMPOSITION UNKNOWN OR UNDETERMINED

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5294 Lung	Inhalation	EM	27	1-420X10(E+5) fibers/cu cm	57X10(E+5) +or-104X10(E+5) fibers/cu cm	Lung parenchyma Diverse exposures Autopsies, 39-78 yr old workers with 1-37 yr exposures (latent period 17-59 yr). Lung fibrosis, bronchogenic carcinoma, pleural fibrosis, pleural effusion or pleural mesothelioma AUTOPSIES; CARCINOMAS; LUNGS; ASBESTOS; FIBERS; OCCUPATIONAL HAZARDS; NEOPLASMS; ETIOLOGIES	Sebastien, P. Janson, X. Piba, G. Masse, P. Bonnaud, G. Bignon, J. 1977 Occupational Exposures to Fibrous and Particulate Dust and Their Extension into the Environment, Proceedings of the Conference of the Society for Occupational and Environmental Health, Washington, DC, December 6-7, 1977
5295 Lung		Microscopy	252	a) 0-99 asbestos bodies b) 100-499 asbestos bodies c) > 500 asbestos bodies Per gram tissue	a) Not given b) Not given c) Not given	a) 95 white-collar workers, 70 blue-collar workers, 28 steel and construction workers b) 4 white-collar workers, 19 blue-collar workers, 24 steel and construction workers c) 2 blue-collar workers, 10 steel and construction workers 234 autopsies, 18 surgeries Urban patients > 40 yr old. AUTOPSIES; CARCINOMAS; LUNGS; SURGERY; CARCINOGEN; FIBERS; HEALTH HAZARDS; OCCUPATIONAL HAZARDS; URBAN AREAS; ASBESTOS	Churg, A. Warnock, M.L. 1977 Archives of Pathological and Laboratory Medicine 101:629-634
5296 Lung		Microscopy	a) 9 b) 15	a) 124-433 asbestos bodies b) 115-622 asbestos bodies Per gram tissue	a) 235 asbestos bodies b) 222.8 asbestos bodies Per gram tissue	a) White-collar workers, men and women, blue-collar workers, men b) Blue-collar workers, men Selected individuals with counts > 100 asbestos bodies/g tissue Urban patients > 40 yr old AUTOPSIES; CARCINOMAS; LUNGS; SURGERY; CARCINOGEN; FIBERS; HEALTH HAZARDS; OCCUPATIONAL HAZARDS; URBAN AREAS; ASBESTOS	Churg, A. Warnock, M.L. 1977 Archives of Pathological and Laboratory Medicine 101:629-634

Attapulgite (VAN)
1337-76-8
EXACT COMPOSITION UNKNOWN OR UNDETERMINED

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5297 Lung	Inhalation	EM	1	Not applicable	42,000 fibers/ml	Lung washing fluid from broncho-alveolar lavage 41 yr old, 3 yr exposure during mining and processing (1973-75). France Lung fibrosis DUST; FIBERS; INHALATION; MINING; FRANCE; OCCUPATIONAL DISEASES; LUNGS; URINE; DRUG THERAPY; LAVAGE	Bignon, J. Sebastien, P. Gaudichet, A. Jaurand, M.C. 1980 Biological Effects of Mineral Fibres, Vol. 1, J.C. Wagner. Lyon, France: IARC Scientific Publications No. 30, pp.163-181

Barium
7440-39-3
Ba
Atw 137.34, MP 710 C (approx), BP 1600 C (approx), VP 10 mm Hg at 1049 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5298 Hair		NA	71	a) 1-25 ug/g b) 5-26 ug/g c) Not given d) Not given e) Not given f) Not given	a) Not given b) Not given c) 9.85 ug/g d) 9.1 ug/g e) 4.3 ug/g f) 6.1 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; WAXIS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5299 Teeth		NS	208	a) Not given b) Not given	a) 6.8 +or- 2.26 ppm b) 2.1 +or- 0.57 ppm S.E.	a) High caries area, New England, 108 teeth b) Low caries area, South Caroina, 100 teeth Values for enamel a) and b) differed, P<0.05 Premolars extracted, patients <20 yr old ZIRCONIUM; NEW HAMPSHIRE; SOUTH CAROLINA; VERMONT; DENTAL CARIES; TEETH; ALUMINUM; BARIUM; COPPER; FLUORINE; LITHIUM; METALS; SILVER; STRONTIUM; TIN	Curzon, M.E.J. Lomee, F.L. 1977 Journal of the American Dental Association 94(6):1146-1150

Benzene, hexachloro-
118-74-1
C6-C16
MW 284.80, MP 231 C, BP 323-326 C, VP 1 mm Hg at 114.4 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5300 Adipose		GC	11	Not given	0.15 ppm	Autopsies, 1975 Northern Ireland SEWAGE; IRELAND; UNITED KINGDOM; ADIPOSE TISSUE; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEXACHLOROBENZENE; URBAN AREAS; WATER POLLUTION; ADULTS; AUTOPSIES; PESTICIDE RESIDUES	Harper, D.B. Saith, R.V. Gotto, D.M. 1977 Environmental Pollution 12(3):223-233

(NEXT PAGE)

Benzene, hexachloro-
118-74-1
C6-C16
MW 284.80, MP 231 C, BP 323-326 C, VP 1 mm Hg at 114.4 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5301 Adipose			a) 1 b) 12 c) 13 d) 15 e) 1 f) 3 g) 13 h) 39 i) 39 j) 12	a) 0.05 ppm b) 0-0.50 ppm c) 0.03-0.50 ppm d) 0.02-0.23 ppm e) 0.06 ppm f) 0-0.08 ppm g) 0.04-0.20 ppm h) 0.05-0.25 ppm i) 0.02-0.43 ppm j) 0.06-0.30 ppm	a) 0.05 ppm b) 0.13 ppm c) 0.14 ppm d) 0.12 ppm e) 0.06 ppm f) 0.04 ppm g) 0.10 ppm h) 0.10 ppm i) 0.14 ppm j) 0.12 ppm	a) 1971-72, 0-20 yr olds b) 1971-72, 21-40 yr olds c) 1971-72, 41-60 yr olds d) 1971-72, 61-80 yr olds e) 1971-72, 81-100 yr olds f) 1973-74, 0-20 yr olds g) 1973-74, 21-40 yr olds h) 1973-74, 41-60 yr olds i) 1973-74, 61-80 yr olds j) 1973-74, 81-100 yr olds In extractable fat Autopsies by year and age group Level of exposure unknown Ontario, Canada INDUSTRIAL CHEMICALS; CANADA; AGE; AUTOPSIES; ADIPOSE TISSUE; MILK; CHLORINE ORGANIC COMPOUNDS; CHLOROBENZENES; DDT; DIELDRIN; HEXACHLOROBENZENE; PESTICIDES; POLYCHLORINATED BIPHENYLS; PESTICIDE RESIDUES; POPULATION EXPOSURE	Holdrinet, M.V.H. Braun, H.E. Frank, R. Stoppe, G.J. Smout, M.S. McWade, J.W. 1977 Canadian Journal of Public Health 68:74-80
5302 Milk			14	0-0.25 ppm	0.10 ppm	Collected in 1973, 1974 Ontario residents, mean age 24 yr. INDUSTRIAL CHEMICALS; CANADA; AGE; AUTOPSIES; ADIPOSE TISSUE; MILK; CHLORINE ORGANIC COMPOUNDS; CHLOROBENZENES; DDT; DIELDRIN; HEXACHLOROBENZENE; PESTICIDES; POLYCHLORINATED BIPHENYLS; PESTICIDE RESIDUES; POPULATION EXPOSURE	Holdrinet, M.V.H. Braun, H.E. Frank, R. Stoppe, G.J. Smout, M.S. McWade, J.W. 1977 Canadian Journal of Public Health 68:74-80
5303 Milk		GC	50	18-63 ppb	40 ppb	Extracted lipids, Jan 1979 to Feb 1980, 3-46 days postpartum. No significant correlation with residence, age, weight, number of children previously nursed, household use of non-persistent pesticides, or occupation of spouse. Higher, but nonsignificant levels in women with higher frequency of meat consumption, and in those in homes with pest control treatment. Healthy 18-37 yr old Hawaiins ADULTS; AGE; HAWAII; MILK; CHLORINATED HYDROCARBONS; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; HEXACHLOROBENZENE; LINDANE; MCNACHLOR; OXYCHLORDANE; PESTICIDES; POLYCHLORINATED BIPHENYLS; DIETS; LACTATION; PESTICIDE RESIDUES; POPULATION EXPOSURE	Takahashi, W. Saidin, B. Takei, G. Wong, L. 1981 Bulletin of Environmental Contamination and Toxicology 27:506-511

BHC, Total (No postings in CHEMLINE).
58-89-9
C6-H6-Cl6
MW 290.85

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5304 Adipose		GC	11	Not given	0.45 ppm	Autopsies, 1975 Northern Ireland SEWAGE; IRELAND; UNITED KINGDOM; ADIPOSE TISSUE; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEXACHLOROBENZENE; URBAN AREAS; WATER POLLUTION; ADULTS; AUTOPSIES; PESTICIDE RESIDUES	Harper, D.B. Smith, M.V. Gotto, D.H. 1977 Environmental Pollution 12(3):223-233
5305 Blood		GC TLC	a) 25 b) 25	a) 0.0131-0.0490 ppm b) 0.0092-0.2160 ppm	a) 0.022 +or- 0.0018 ppm b) 0.0305 +or- 0.0107 ppm S.E.	a) Mothers, 24 hr after parturition b) Fetal (cord) blood, parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDT; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NEWBORN	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, D. 1981 Environmental Research 24:24-32
5306 Blood, fetal		GC-EC	100	a) 6.9-278.3 ppb b) 4.20-104.92 ppb c) 6.9-278.43 ppb d) 4.18-104.92 ppb e) 2.0-507.84 ppb f) 3.0-76.97 ppb	a) 32.97 +or- 16.89 ppb b) 45.79 +or- 5.90 ppb c) 38.3 +or- 7.29 ppb d) 35.64 +or- 3.13 ppb e) 87.38 +or- 13.87 ppb f) 27.06 +or- 2.31 ppb	a) Newborn of 18-25 yr olds (58) b) Newborn of 26-34 yr olds (42) c) Mothers had vegetarian diets (36) d) Mothers had nonvegetarian diets (64) e) Urban area (48) f) Rural area (52) e) and f) significantly different India INDIA; AGE; NEWBORN; BLOOD; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; DDD; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; PESTICIDES; DIETS; PESTICIDE RESIDUES; POPULATION EXPOSURE; RURAL AREAS; URBAN AREAS	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Krishna Murti, C.R. Kutty, D. 1981 Pesticides Monitoring Journal 15(2):77-79
5307 Blood, serum		GC-EC	a) 20 b) 15	a) 11-150 ppb b) 21-270 ppb	a) 55 +or- 41 ppb b) 131 +or- 105 ppb	a) DDT sprayers, 1-32 (mean 14) yr exposure b) Controls 25-42 yr olds, India INDIA; ADULTS; BLOOD SERUM; DDD; DDE; DDT; HEPTACHLOROCYCLOHEXANE; LINDANE; HEALTH HAZARDS; OCCUPATIONAL HAZARDS; PESTICIDE RESIDUES	Siddiqui, M.K.J. Saxena, M.C. Mishra, U.K. Krishna Murti, C.R. Naq, D. 1981 International Archives of Occupational and Environmental Health 48:301-308

(NEXT PAGE)

PBC, Total (No postings in CHEMLINE).
92-89-9
C6-96-C16
MW 290.85

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5308 Milk		GC	50	0-480 ppb	86 ppb	Extracted lipids, Jan 1979 to Feb 1980, 3-46 days postpartum. No significant correlation residence, age, weight, number of children previously nursed, household use of non persistent pesticides, or occupation of spouse. Higher, but nonsignificant levels in women with higher frequency of meat consumption, and in those living in homes treated by pest control operators Healthy 18-37 yr old Hawaiians ADULTS; AGE; HAWAII; MILK; CHLORINATED HYDROCARBONS; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; HEXACHLOROBENZENE; LINDANE; MONACHLOR; OXYCHLORDANE; PESTICIDES; POLYCHLORINATED BIPHENYLS; DIPTS; LACTATION; PESTICIDE RESIDUES; POPULATION EXPOSURE	Takahashi, W. Saidin, D. Takei, G. Wong, L. 1981 Bulletin of Environmental Contamination and Toxicology 27:506-511
5309 Milk, whole		GC TLC	25	0.0326-0.2384 ppm	0.1077 +or- 0.0124 ppm S.E.	24 hr after parturition 19-35 yr old mothers, no history of exposure to pesticides. India BHC; BDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NEWBORN	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, D. 1981 Environmental Research 24:24-32

Biphenyl, chloro (8 CI)
1,1'-Biphenyl, chloro derivs (9 CI)
1336-36-3
EXACT COMPOSITION UNKNOWN OR UNDETERMINED

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5310 Adipose			a) 2 b) 1 c) 7 d) 16 e) 3 f) 8 g) 40 h) 96 i) 119 j) 19 k) 3 l) 13 m) 39 n) 39 o) 12	a) 1.0 ppm b) 2.0 ppm c) 1.0-2.0 ppm d) 1.0-2.0 ppm e) 2.0 ppm f) 0.5-3.5 ppm g) 0.5-6.0 ppm h) 0-8.0 ppm i) 0.5-10.0 ppm j) 1.0-18.0 ppm k) 0.8-4.0 ppm l) 0.6-6.0 ppm m) 0.7-7.0 ppm n) 0.6-11.0 ppm o) 0.8-3.6 ppm	a) 1.0 ppm b) 2.0 ppm c) 1.3 ppm d) 1.3 ppm e) 2.0 ppm f) 1.9 ppm g) 2.2 ppm h) 2.6 ppm i) 2.6 ppm j) 3.3 ppm k) 2.0 ppm l) 2.1 ppm m) 2.2 ppm n) 2.5 ppm o) 2.0 ppm	a) 1969-70, 0-20 yr olds b) 1969-70, 21-40 yr olds c) 1969-70, 41-60 yr olds d) 1969-70, 61-80 yr olds e) 1969-70, 81-100 yr olds f) 1971-72, 0-20 yr olds g) 1971-72, 21-40 yr olds h) 1971-72, 41-60 yr olds i) 1971-72, 61-80 yr olds j) 1971-72, 81-100 yr olds k) 1973-74, 0-20 yr olds l) 1973-74, 21-40 yr olds m) 1973-74, 41-60 yr olds n) 1973-74, 61-80 yr olds o) 1973-74, 81-100 yr olds In extractable fat Autopsies by year and age group. Level of exposure unknown Values before 1971 are estimations Ontario, Canada INDUSTRIAL CHEMICALS; CANADA; AGE; AUTOPSIES; ADIPOSE TISSUE; MILK; CHLORINE ORGANIC COMPOUNDS; CHLOROBENZENES; DDT; DIELDRIN; HEXACHLOROBENZENE; PESTICIDES; POLYCHLORINATED BIPHENYLS; PESTICIDE RESIDUES; POPULATION EXPOSURE	Moldrinet, N.V.M. Braun, M.E. Frank, R. Stoppa, G.J. Smout, M.S. McWade, J.W. 1977 Canadian Journal of Public Health 68:74-80

(NEXT PAGE)

Biphenyl, chloro (8 CI)
1,1'-Biphenyl, chloro deriv (9 CI)
1336-36-3
EXACT COMPOSITION UNKNOWN OR UNDETERMINED

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5311 Adipose		GC-EC	a) 168 b) 57 c) 111	a) 0.11-6.60 mg/kg b) Not given c) Not given Wet wt	a) 0.907 mg/kg b) 0.685 mg/kg c) 1.030 mg/kg Wet wt	a) All subjects b) Women c) Men Canadians from the Atlantic provinces (16), Quebec (49), Ontario (55), Saskatchewan and Manitoba (22), Alberta and B.C. (26) CANADA; ADULTS; AGE; AUTOPSIES; SEX; ADIPOSE TISSUE; MILK; POLYCHLORINATED BIPHENYLS; BIOACCUMULATION	Grant, D.L. Mes, J. Frank, R. 1976 Proceedings of the National Conference on Polychlorinated Biphenyls, Chicago, IL, November 19-21, 1975 (pp. 144-146)
5312 Adipose		GC	a) 11 b) 16 c) 22 d) 22 e) 71	a) Not given b) Not given c) Not given d) Not given e) Not given	a) 8.805 ppm b) 8.686 ppm c) 5.912 ppm d) 4.515 ppm e) 6.55 ppm Extracted lipids	a) 25->75 yr old men with cancer b) 0->75 yr old women with cancer c) 0->75 old men, other illnesses d) 0->75 yr old women, other illnesses e) All Significant age correlation in noncancer group Higher levels in terminal cancer patients Data also for other age groups and by cancer type. Autopsies, Denmark, 1978-79 DENMARK; AUTOPSIES; CARCINOMAS; ADIPOSE TISSUE; BIOACCUMULATION; PESTICIDE RESIDUES; DDE; POLYCHLORINATED BIPHENYLS	Unger, M. Olsen, J. 1980 Environmental Research 23:257-263
5313 Adipose		GC	a) 439 b) 198	a) 0-<1.0 ppm b) >1.0 ppm c) 1-2 ppm d) >2 ppm	a) Not given b) Not given c) Not given d) Not given	a) 50.3% male, 49.7% female, 86.8% white, 13.2% nonwhite b) 64.1% male, 35.9% female, 76.3% white 23.7% nonwhite c) 163 samples from group b) d) 33 samples from group b) Level of exposure unknown U.S. residents, autopsy and surgery data UNITED STATES; ADULTS; AUTOPSIES; RACIAL STUDIES; SEX; ADIPOSE TISSUE; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; BIOACCUMULATION; POPULATION EXPOSURE; INDUSTRIAL CHEMICALS	Kobs, A.B. 1972 Environmental Health Perspectives 1:79-81
5314 Adipose	Ingestion	GC/MS	a) 3 b) 3	a) 270.5-6091.3 ppb b) 248.0-1477.8 ppb	a) Not given b) Not given	a) Yusho victims b) Unexposed controls 25-70 yr olds, Japan JAPAN; ADULTS; AUTOPSIES; CHILDREN; INFANTS; DISEASES; ADIPOSE TISSUE; BLOOD; INTESTINES; LIVER; MILK; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; POLYCHLORINATED QUATERPHENYLS; FOOD CONTAMINATION; HEALTH HAZARDS	Kashimoto, T. Miyata, H. Kunita, N. 1981 Food and Cosmetics Toxicology 19:335-340

(NEXT PAGE)

Biphenyl, chloro (8 Cl)
1,1'-Biphenyl, chloro deriva (9 Cl)
1336-36-3
EXACT COMPOSITION UNKNOWN OR UNDETERMINED

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5315 Blood	Ingestion	GC/MS	a) 29 b) 15 c) 81 d) 6 e) 29	a) 1.8-22.6 ppb b) 0.6-10.7 ppb c) 1.3-4.6 ppb d) 19.9-88.9 ppb e) 0.8-8.4 ppb	a) 7.3 +or- 4.5 ppb b) 5.4 +or- 3.6 ppb c) 2.7 +or- 1.2 ppb d) 55.6 +or- 20.7 ppb e) 2.3 +or- 1.5 ppb	a) GC pattern indicative of Yusho exposure b) GC pattern similar to that of (a) c) GC pattern of unexposed individuals d) PCB workers e) Unexposed individuals Individuals in a)-c) reportedly consumed Yusho oil Japanese JAPAN; ADULTS; AUTOPSIES; CHILDREN; INFANTS; DISEASES; ADIPOSE TISSUE; BLOOD; INTESTINES; LIVER; MILK; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; POLYCHLORINATED QUATERPHENYLS; FOOD CONTAMINATION; HEALTH HAZARDS	Kashimoto, T. Miyata, H. Kunita, N. 1981 Food and Cosmetics Toxicology 19:335-340
5316 Blood, whole	Ingestion		137	6.9-11.5 ppb	Not given	Range of means after 621-888 ml contaminated oil/yr Significant positive correlations between concentrations and total amount of rice oil consumed but not amount consumed per kg/day Estimated from graph 29-50 yr old Japanese Yusho patients, 1973-1976. JAPAN; BLOOD; COMPARATIVE EVALUATIONS; BIPHENYL COMPOUNDS; POLYCHLORINATED BIPHENYLS; FOOD CONTAMINATION	Hayabuchi, H. Ikeda, M. Yoshimura, T. Yamada, T. 1981 Food and Cosmetics Toxicology 19:53-55
5317 Intestine	Ingestion	GC/MS	3	1273.4-3630.3 ppb	Not given	Yusho victims. (29.7 ppm in intestine of stillborn baby). 59-72 yr old Japanese JAPAN; ADULTS; AUTOPSIES; CHILDREN; INFANTS; DISEASES; ADIPOSE TISSUE; BLOOD; INTESTINES; LIVER; MILK; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; POLYCHLORINATED QUATERPHENYLS; FOOD CONTAMINATION; HEALTH HAZARDS	Kashimoto, T. Miyata, H. Kunita, N. 1981 Food and Cosmetics Toxicology 19:335-340
5318 Liver	Ingestion	GC/MS	a) 7 b) 3	a) 7.4-225.9 ppb b) 17.9-71.1 ppb	a) Not given b) Not given	a) Yusho victims b) Unexposed individuals Stillborn-72 yr olds, Japan JAPAN; ADULTS; AUTOPSIES; CHILDREN; INFANTS; DISEASES; ADIPOSE TISSUE; BLOOD; INTESTINES; LIVER; MILK; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; POLYCHLORINATED QUATERPHENYLS; FOOD CONTAMINATION; HEALTH HAZARDS	Kashimoto, T. Miyata, H. Kunita, N. 1981 Food and Cosmetics Toxicology 19:335-340

(NEXT PAGE)

Biphenyl, chloro (8 CI)
1,1'-Biphenyl, chloro deriv (9 CI)
1336-36-3
EXACT COMPOSITION UNKNOWN OR UNDETERMINED

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5319 Milk			a) 83 b) 34 c) 99	a) 0.7-1.2 ppm b) 0.2-3.0 ppm c) 0.1-2.5 ppm	a) 1.0 ppm b) 1.2 ppm c) 1.2 ppm	a) 1969-70 b) 1971-72 c) 1973-74 Sampling periods Level of exposure unknown Ontario residents, mean age 26-28 yr. INDUSTRIAL CHEMICALS; CANADA; AGE; AUTOPSIES; ADIPOSE TISSUE; MILK; CHLORINE ORGANIC COMPOUNDS; CHLOROBENZENES; DDT; DIELDRIN; HEXACHLOROBENZENE; PESTICIDES; POLYCHLORINATED BIPHENYLS; PESTICIDE RESIDUES; POPULATION EXPOSURE	Holdrinet, M.V.H. Braun, H.E. Frank, R. Stoppe, G.J. Smout, M.S. McRede, J.W. 1977 Canadian Journal of Public Health 68:76-80
5320 Milk			80	a) Not given b) Not given	a) 1.80 ppm b) 2.68 ppm	a) All subjects, from 11 states b) North Carolina residents, state with highest mean Studies by U.S. Environmental Protection Agency NORTH CAROLINA; UNITED STATES; MILK; POLYCHLORINATED BIPHENYLS	Anon 1977 c Pollution 7(1):6
5321 Milk	Ingestion	GC/MS	1	Not applicable	6241.9 ppb	PCB worker 37 yr old Japanese JAPAN; ADULTS; AUTOPSIES; CHILDREN; INFANTS; DISEASES; ADIPOSE TISSUE; BLOOD; INTESTINES; LIVER; MILK; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; POLYCHLORINATED QUATERPHENYLS; FOOD CONTAMINATION; HEALTH HAZARDS	Kashimoto, T. Miyata, H. Kunita, N. 1981 Food and Cosmetics Toxicology 19:335-340
5322 Milk		GC-EC	154	a) 0-4.34 ug/kg fat b) Not given c) Not given	a) 0.837 +or- 0.529 ug/kg fat b) 0.59 +or- 0.32 ug/kg fat c) 0.86 +or- 0.40 ug/kg fat	a) 153 samples, 0.029 +or- 0.019 ug/kg whole milk b) Rural residents, 19 samples c) Urban residents, 51 samples 3-6 days postpartum. b) and c) significantly different. Positive correlation with age. 93% exceeded the USA acceptable daily intake. 18-38 yr olds, Canada ALDRIN; CANADA; AGE; MILK; DDE; DDT; CHLORINE ORGANIC COMPOUNDS; HEXACHLOROCYCLOHEXANE; LINDANE; POLYCHLORINATED BIPHENYLS; POPULATION EXPOSURE; RURAL AREAS; SMOKING; URBAN AREAS	Dillon, J.C. Martin, G.T. O'Brien, M.T. 1981 Food and Cosmetics Toxicology 19:437-442
5323 Milk						Review Recommendations for breast milk testing and infant feeding made following discovery of PCBs in breast milk of Michigan residents. ADULTS; INFANTS; MILK; REVIEW; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; HEALTH HAZARDS; LACTATION; MICHIGAN	Wichizer, T.M. Brilliant, L.B. 1981 Pediatrics 68(3):411-415

(NEXT PAGE)

Biphenyl, chloro (8 CI)
1,1'-Biphenyl, chloro derivs (9 CI)
1336-36-3
EXACT COMPOSITION UNKNOWN OR UNSPECIFIED

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5320 Milk		GC	50	16-1800 ppb	780 ppb	Extracted lipids, Jan 1979 to Feb 1980, 3-46 days postpartum. No significant correlation with residence, age, weight, number of children previously nursed, household use of non persistent pesticides, or occupation of spouse. Higher, but nonsignificant levels in women with higher frequency of meat consumption, and in those in homes with pest control treatment. Healthy 18-37 yr old Hawaiians ADULTS; AGE; HAWAII; MILK; CHLORINATED HYDROCARBONS; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; HEXACHLOROBENZENE; LINDANE; NONACHLOR; OXYCHLORDANE; PESTICIDES; POLYCHLORINATED BIPHENYLS; DIETS; LACTATION; PESTICIDE RESIDUES; POPULATION EXPOSURE	Takahashi, M. Saldin, D. Takei, G. Wong, L. 1981 Bulletin of Environmental Contamination and Toxicology 27:506-511

Bromine
7726-95-6
Br
Atm 79.904, MP -7.25 C, BP 59.47 C, VP 1 mm Hg at -60 C, 10 mm Hg at -30 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5325 Hair		NA	71	a) 0.9-19 ug/g b) 5-30 ug/g c) Not given d) Not given e) Not given f) Not given	a) Not given b) Not given c) 5.3 ug/g d) 8 ug/g e) 12 ug/g f) 4.5 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Otham, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278

Cadmium
7440-43-9
Cd
AtW 112.40, MP 321 C, BP 765 C, VP 1 mm Hg at 394 C, 10 mm Hg at 486 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5326 Blood		AAS	a) 148 b) 88	a) 0.08-18.4 ug/100 ml b) 0.02-1.16 ug/100 ml	a) 1.88 ug/100 ml b) 0.23 ug/100 ml	a) Exposed group b) Controls 23.7-63.4 yr old workers in smelters and production plant, 70.9% smokers, mean exposure 15.4 yr. 19.8-64.8 yr old controls, 38% smokers. Increased urinary excretion of proteins and tubular enzymes CADMIUM; LEAD; MERCURY; METALS; OCCUPATIONAL HAZARDS; POPULATION EXPOSURE; BLOOD; URINE; SMELTERS; INDUSTRIAL PLANTS; SMOKING; COMPARATIVE EVALUATIONS; HEALTH HAZARDS	Bucket, J.P. Roels, H. Bernard, A. Lauwerys, R. 1980 Journal of Occupational Medicine 22(11):741-750
5327 Blood			a) 8 b) 8 c) 16	a) 0.2-0.5 ug/100 ml b) 4.9-10.4 ug/100 ml c) 0.7-4.3 ug/100 ml creatinine	a) 0.36 ug/100 ml b) 13.6 ug/100 ml c) 2.4 ug/100 ml	a) Smelter workers, did not handle Cd b) Factory workers, employed 0.4-5.2 yr (mean 2.5 yr) c) Smelter workers in a), employed 12.8-40.5 yr (mean 26 yr) Belgium, 18-35 yr olds BELGIUM; KIDNEY DISEASES; UNITED STATES; METAL POISONING; OCCUPATIONAL DISEASES; BLOOD; URINE; CADMIUM; METALLOPROTEINS; INDUSTRIAL PLANTS; SMELTERS; METALS; NEW YORK	Chang, C.C. Lauwerys, R. Bernard, A. Roels, H. Bucket, J.P. Garvey, J.S. 1980 Environmental Research 23:422-428
5328 Blood, plasma		AAS	35	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given	a) 1.7 +or- 0.2 ug/l b) 1.8 +or- 0.4 ug/l c) 1.7 +or- 0.2 ug/l d) 1.4 +or- 0.2 ug/l e) 1.3 +or- 0.3 ug/l f) 1.5 +or- 0.3 ug/l S.E.	a) Exposed, all (16) b) Exposed smokers (7) c) Exposed nonsmokers (9) d) Unexposed, all (19) e) Unexposed smokers (9) f) Unexposed nonsmokers (10) Mean exposure 6.1 yr 20-60 yr old zinc refinery workers CANADA; ADULTS; BLOOD; BLOOD PLASMA; SALIVA; INDUSTRIAL MEDICINE; CADMIUM; METALS; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Gervais, L. LaCasse, Y. Brodeur, J. P'An, A. 1981 Toxicology Letters 8:63-66
5329 Blood, serum			17	0.3-4.0 ug/l	1.5 ug/l	No correlation with age or exposure (3 mo-14 yr). 29-61 yr olds occupationally exposed to Cd dust in the production of plastics and pigments. ADULTS; METAL POISONING; BLOOD SERUM; HAIR; URINE; INDUSTRIAL MEDICINE; CADMIUM; METALS; DUST; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Murray, T. Walker, B.R. Spratt, D.M. Chappelka, R. 1981 Archives of Environmental Health 36(6):165-171

(NEXT PAGE)

Cadmium
7440-43-9
Cd
AtW 112.40, MP 321 C, BP 765 C, VP 1 at Hg at 394 C, 10 mm Hg at 486 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5330 Blood, whole		AAS	35	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given	a) 9.8 +or- 1.3 ug/l b) 12.2 +or- 1.7 ug/l c) 8.0 +or- 1.8 ug/l d) 6.6 +or- 0.8 ug/l e) 9.7 +or- 0.9 ug/l f) 7.8 +or- 0.4 ug/l S.E.	a) Exposed, all (16) b) Exposed smokers (7) c) Exposed nonsmokers (9) d) Unexposed, all (19) e) Unexposed smokers (9) f) Unexposed nonsmokers (10) Mean exposure 6.1 yr Significantly higher in exposed workers 20-60 yr old workers in zinc refinery CANADA; ADULTS; BLOOD; BLOOD PLASMA; SALIVA; INDUSTRIAL MEDICINE; CADMIUM; METALS; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Gervais, L. LeCanne, Y. Brodeur, J. P'An, A. 1981 Toxicology Letters 8:63-66
5331 Gall stone		AAS	25	a) Not given b) Not given c) Not given	a) 0.22 +or- 0.16 ug/g b) 0.30 +or- 0.16 ug/g c) 0.28 +or- 0.13 ug/g	a) 10 men b) 15 women c) Total Nchurika, Japan JAPAN; SEX; GALL STONES; KIDNEYS; COMPARATIVE EVALUATIONS; CADMIUM; COPPER; METALS; ZINC	Yamamoto, T. Itoh, M. Tsukada, S. Takenaka, S. Kiyozumi, M. Kojima, S. 1980 Proceedings of the 7th Symposium on Environmental Pollutants and Toxicology, Kobe, Japan, 5-60
5332 Hair		AAS	a) 139 b) 20 c) 184 d) 57	a) Not given b) Not given c) Not given d) Not given	a) 1.07 +or- 0.10 ppm b) 1.20 +or- 0.07 ppm c) 0.97 +or- 0.03 ppm d) 1.13 +or- 0.05 ppm	a) Controls, girls b) Learning disability, girls c) Controls, boys d) Learning disability, boys d) significantly higher than c) (P<0.01). Mean air levels 1.9 +or- 1.7 and 1.9 +or- 1.1 ng/cu m at two schools. 9-12 yr olds, Akron, OH CHILDREN; HAIR; ARSENIC; CADMIUM; LEAD; MERCURY; METALS; SELENIUM; POPULATION EXPOSURE	Ely, D.L. Montardi, M.A. Voohheuberg, H. Worstell, D. 1981 Environmental Research 25:325-339
5333 Hair			a) 19 b) 10	a) 0.3-68.2 ug/g b) 0-0.4 ug/g	a) 8.7 +or- 2.3 ug/g b) 0.33 +or- 0.08 ug/g	a) Occupationally exposed (3 mo-14 yr) b) Controls Significantly higher in a). 29-61 yr olds occupationally exposed to Cd dust in the production of plastics and pigments. ADULTS; METAL POISONING; BLOOD SERUM; HAIR; URINE; INDUSTRIAL MEDICINE; CADMIUM; METALS; DUST; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Murray, T. Walker, B.E. Spratt, D.M. Chappelka, E. 1981 Archives of Environmental Health 36(4):165-171
5334 Kidney						Review Data on current mean Cd kidney levels, normal dietary Cd intake and rates of bioaccumulation indicate that sludge amended soils containing not more than 0.5 kg Cd/ha would not increase daily Cd intake beyond the 70 ug/day safe limit recognized by FAO/WHO and EPA. KIDNEYS; CADMIUM; METALS; AGRICULTURE; FOODS; POPULATION EXPOSURE; SMOKING; SOILS; VEGETABLES	Baylor, L.H. Loehr, R.C. 1981 Environmental Science and Technology 15(8):881-886

(NEXT PAGE)

Cadmium
7440-43-9
Cd
Atw 112.40, BP 321 C, BP 765 C, VP 1 mm Hg at 394 C, 10 mm Hg at 486 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5335 Kidney	Ingestion Inhalation		28	a) 9-174 ug/g b) 21-395 ug/g c) 190-846 ug/g Wet wt	a) Not given b) Not given c) Not given	a) Proteinuria, pathological changes in cortex, 14 cases b) Proteinuria, no pathology in cortex, 8 cases c) No proteinuria, no pathology, 3 cases Cannot establish critical level in cortex. Autopsies and biopsies, 20 Cd workers and 8 residents of Cd-polluted areas. Dust, fumes exposures. BIOPSIES; AUTOPSIES; KIDNEY DISEASES; METAL POISONING; KIDNEYS; CADMIUM; AIR POLLUTION; DUST; FUMES; INDUSTRIAL ATMOSPHERES	Nonizawa, K. 1977 Journal of Toxicology and Environmental Health 3:607-609
5336 Kidney						Review. Cd may interfere with Zn/hormone relationship in the prostate, causing cancer in heavily exposed individuals JAPAN; SWEDEN; UNITED STATES; RACIAL STUDIES; SARCOMAS; KIDNEYS; LIVER; PROSTATE; TESTES; URINE; CADMIUM; ZINC; CARCINOGEN; DIETS; DRINKING WATER; OCCUPATIONAL HAZARDS; FATS	Fiscator, M. 1981 Environmental Health Perspectives 40:107-120
5337 Kidney		AAS	60	a) Not given b) Not given c) Not given Renal calculi	a) 2.60 +or- 0.49 ug/g b) 1.10 +or- 0.35 ug/g c) 1.99 +or- 0.34 ug/g	a) 29 men b) 20 women c) Total Nokuriku, Japan JAPAN; SEX; GALL STONES; KIDNEYS; COMPARATIVE EVALUATIONS; CADMIUM; COPPER; METALS; ZINC	Yamamoto, I. Itoh, M. Tsukada, S. Takenaka, S. Kiyozumi, M. Kojima, S. 1980 Proceedings of the 7th Symposium on Environmental Pollutants and Toxicology, Kobe, Japan, 5-68
5338 Kidney		AAS	1	a) Not applicable b) Not applicable	a) 28.0 ug/g b) 26.0 ug/g Wet wt	a) Analysis by low-temperature plasma ashing followed by AAS b) Analysis by standard wet-tissue degradation technique followed by AAS Autopsy KIDNEYS; LIVER; MEASUREMENT METHODS; CADMIUM; COPPER; LEAD; THALLIUM; METALS	Carpenter, R.C. 1981 Analytica Chimica Acta 125:209-213
5339 Liver		AAS	16	Not given	6 ug/ug	Normal upper limit estimated to be 10 ug/ug dry wt Autopsies, normal liver AUTOPSIES; LIVER; MEASUREMENT METHODS; CADMIUM; COPPER; ZINC; METALS	Svenson, H.A. Anderson, C.T., Jr. 1975 Clinical Chemistry 21(8):537-543

(NEXT PAGE)

Cadmium
7440-43-9
Cd
Atw 112.40, BP 321 C, BP 765 C, VP 1 mm Hg at 394 C, 10 mm Hg at 486 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
*5340 Liver						Review. Cd may interfere with Zn/hormone relationship in the prostate, causing cancer in heavily exposed individuals JAPAN; SWEDEN; UNITED STATES; RACIAL STUDIES; SARCOMAS; KIDNEYS; LIVER; PROSTATE; TESTES; URINE; CADMIUM; ZINC; CARCINOGEN; DIETS; DRINKING WATER; OCCUPATIONAL HAZARDS; RATS	Piscator, M. 1981 Environmental Health Perspectives 40:107-120
*5341 Liver		AAS	3	a) 0.9-3.1 ug/g b) 0.9-2.9 ug/g Wet wt	a) 3.2 ug/g b) 1.8 ug/g Wet wt	a) Analysis by low-temperature plasma ashing followed by AAS b) Analysis by standard subtilisn tissue degradation technique followed by AAS Autopsies KIDNEYS; LIVER; MEASUREMENT METHODS; CADMIUM; COPPER; LEAD; THALLIUM; METALS	Carpenter, R.C. 1981 Analytica Chimica Acta 125:209-213
5342 Prostate						Review. Epidemiological studies on cancer morbidity and mortality in Cd-exposed people are presented. The role of Cd metabolism, toxicity and of Cd/Zn relationships in the development of prostatic cancer is also given. JAPAN; SWEDEN; UNITED STATES; RACIAL STUDIES; SARCOMAS; KIDNEYS; LIVER; PROSTATE; TESTES; URINE; CADMIUM; ZINC; CARCINOGEN; DIETS; DRINKING WATER; OCCUPATIONAL HAZARDS; RATS	Piscator, M. 1981 Environmental Health Perspectives 40:107-120
5343 Saliva		AAS	35	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given	a) 58.7 +or- 19.2 ug/l b) 50.7 +or- 23.8 ug/l c) 66.7 +or- 29.7 ug/l d) 10.9 +or- 0.8 ug/l e) 11.9 +or- 1.1 ug/l f) 10.0 +or- 1.0 ug/l S.E.	a) Exposed, all (16) b) Exposed smokers (7) c) Exposed nonsmokers (9) d) Unexposed, all (19) e) Unexposed smokers (9) f) Unexposed nonsmokers (10) Mean exposure 6.1 yr Significantly higher in exposed workers 28-60 yr old zinc refinery workers CANADA; ADULTS; BLOOD; BLOOD PLASMA; SALIVA; INDUSTRIAL MEDICINE; CADMIUM; METALS; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Gervais, L. LaCasse, Y. Brodeur, J. P'an, R. 1981 Toxicology Letters 8:63-66
5344 Tooth			13	Not given	4.2 +or- 1.6 ppm	Median, 3.8 ppm Stillborn or neonatal deaths, 1972-73, Bristol, United Kingdom UNITED KINGDOM; AUTOPSIES; NEWBORN; TEETH; CADMIUM; IRON; LEAD; MANGANESE; METALS; NICKEL; ZINC	Stack, M.V. Burkitt, A.J. Nicklaus, G. 1976 Bulletin of Environmental Contamination and Toxicology 16(6):764-766

(NEXT PAGE)

Cadmium
7440-43-9
Cd
Atw 112.40, MP 321 C, BP 765 C, VP 1 mm Hg at 394 C, 10 mm Hg at 486 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5305 Testes						Review. Cd may interfere with Fe/hormone relationship in the prostate, causing cancer in heavily exposed individuals JAPAN; SWEDEN; UNITED STATES; RACIAL STUDIES; SARCOMAS; KIDNEYS; LIVER; PROSTATE; TESTES; URINE; CADMIUM; ZINC; CARCINOGEN; DIETS; DRINKING WATER; OCCUPATIONAL HAZARDS; RATS	Piscator, M. 1981 Environmental Health Perspectives 40:107-120
5306 Urine		AAS	a) 189 b) 88	a) 2.0-150.4 ug/g creatinine b) 0.07-1.93 ug/g creatinine	a) 15.76 ug/g creatinine b) 0.88 ug/g creatinine	a) Exposed group b) Controls 23.7-63.4 yr old workers in smelters and production plant, 70.9% smokers, mean exposure 15.4 yr. 19.8-64.8 yr old controls, 38% smokers. Increased urinary excretion of proteins and tubular enzymes CADMIUM; LEAD; MERCURY; METALS; OCCUPATIONAL HAZARDS; POPULATION EXPOSURE; BLOOD; URINE; SMELTERS; INDUSTRIAL PLANTS; SMOKING; COMPARATIVE EVALUATIONS; HEALTH HAZARDS	Buchet, J.P. Roels, H. Bernard, A. Lauwerys, R. 1980 Journal of Occupational Medicine 22(11):741-750
5307 Urine			a) 8 b) 8 c) 8 d) 16	a) 0.1-0.34 ug/g creatinine b) 1.4-5.0 ug/g creatinine c) 16.6-246.3 ug/g creatinine d) 9.7-59.3 ug/g creatinine	a) 0.2 ug/g creatinine b) 2.8 ug/g creatinine c) 96.2 ug/g creatinine d) 25.1 ug/g creatinine	a) Controls, never worked in Cd factory b) Controls, smelter workers, did not handle Cd c) Factory workers employed 0.1-5.2 yr (mean 2.5 yr) d) Smelter workers, employed 12.8-40.5 yr (mean 26 yr) 23.8-68.2 yr old Belgians and New Yorkers, mean age 25.1 yr BELGIUM; UNITED STATES; KIDNEY DISEASES; METAL POISONING; OCCUPATIONAL DISEASES; BLOOD; URINE; CADMIUM; METALLOPROTEINS; INDUSTRIAL PLANTS; SMELTERS; NEW YORK; METALS	Chang, C.C. Lauwerys, R. Bernard, A. Roels, H. Buchet, J.P. Garvey, J.S. 1980 Environmental Research 23:422-428
5308 Urine						Review. Cd may interfere with Fe/hormone relationship in the prostate, causing cancer in heavily exposed individuals JAPAN; SWEDEN; UNITED STATES; RACIAL STUDIES; SARCOMAS; KIDNEYS; LIVER; PROSTATE; TESTES; URINE; CADMIUM; ZINC; CARCINOGEN; DIETS; DRINKING WATER; OCCUPATIONAL HAZARDS; RATS	Piscator, M. 1981 Environmental Health Perspectives 40:107-120
5309 Urine			19	0.7-22.0 ug/l	5.4 ug/l	No correlation with age or exposure (3 mo-14 yr). Urine cytology did not distinguish between exposed and unexposed. Renal function tests were abnormal in a few workers 24 hr samples. 29-61 yr olds occupationally exposed to Cd dust in the production of plastics and pigments. ADULTS; METAL POISONING; BLOOD SERUM; MAN; URINE; INDUSTRIAL MEDICINE; CADMIUM; METALS; DUST; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Murray, T. Walker, B.R. Spratt, T.M. Chappelka, H. 1981 Archives of Environmental Health 36(4):165-171

Calcium
7440-70-2
Ca
AtW 40.08, MP 850 C, BP 1440 C, VP 10 mm Hg at 983 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5350 Blood, fetal						Review. Calcium-phosphorus metabolism and clinical implications of Ca deficiency in pregnancy. ADULTS; FETUS; INFANTS; NUTRITIONAL DEFICIENCIES; NUTRITIONAL DISORDERS; BLOOD SERUM; BONES; CALCIUM; PHOSPHORUS; VITAMIN D; DIETS; PREGNANCY; METABOLISM	Pitkin, R.M. 1975 American Journal of Obstetrics and Gynecology 121(5):724-737
5351 Blood, serum						Review. Calcium-phosphorus metabolism and clinical implications of Ca deficiency in pregnancy. ADULTS; FETUS; INFANTS; NUTRITIONAL DEFICIENCIES; NUTRITIONAL DISORDERS; BLOOD SERUM; BONES; CALCIUM; PHOSPHORUS; VITAMIN D; DIETS; PREGNANCY; METABOLISM	Pitkin, R.M. 1975 American Journal of Obstetrics and Gynecology 121(5):724-737
5352 Blood, serum			166	a) 2.70->4.00 mmol/l	Not given	Hypercalcemic hospital patients, some with malignant diseases or hyperparathyroidism UNITED KINGDOM; CARCINOMAS; DISEASES; PARATHYROID DYSFUNCTION; BLOOD SERUM; CALCIUM	Fisken, R.A. Heath, D.A. Somers, S. Bold, A.M. 1981 Lancet 1(8213):202-207
5353 Bone						Review. Calcium-phosphorus metabolism and clinical implications of Ca deficiency in pregnancy. ADULTS; FETUS; INFANTS; NUTRITIONAL DEFICIENCIES; NUTRITIONAL DISORDERS; BLOOD SERUM; BONES; CALCIUM; PHOSPHORUS; VITAMIN D; DIETS; PREGNANCY; METABOLISM	Pitkin, R.M. 1975 American Journal of Obstetrics and Gynecology 121(5):724-737
5354 Fetal						Review. Calcium-phosphorus metabolism and clinical implications of Ca deficiency in pregnancy. ADULTS; FETUS; INFANTS; NUTRITIONAL DEFICIENCIES; NUTRITIONAL DISORDERS; BLOOD SERUM; BONES; CALCIUM; PHOSPHORUS; VITAMIN D; DIETS; PREGNANCY; METABOLISM	Pitkin, R.M. 1975 American Journal of Obstetrics and Gynecology 121(5):724-737
5355 Hair		NA	71	a) 290-1290 ug/g b) 220-1150 ug/g c) Not given d) Not given e) Not given f) Not given	a) 620 +or- 260 ug/g b) 510 +or- 250 ug/g c) 600 ug/g d) 640 ug/g e) 560 ug/g f) 480 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278

(NEXT PAGE)

Calcium
7440-70-2
Ca
Atw 40.08, MP 850 C, BP 1440 C, VP 10 mm Hg at 983 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5356 Milk		ES		Not given	29 +or- 2.3 mg/100 ml	Milk from mothers of 12 preterm and 2 low birth wt infants, or from Human Milk Bureau, St. David's Hospital, Cardiff, Wales UNITED KINGDOM; INFANTS; NUTRITIONAL DEFICIENCIES; MILK; URINE; CALCIUM; DIETS	Shaw, J.C.L. 1976 Pediatrics 57(1):16-25
5357 Wall		EA	Not given	a) Not given	b) Not given	a) Women b) Men Toenail sample of about 6 mg Machakos district, Kenya, 1978 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5358 Urine	Ingestion	ES	a) 3 b) 3 c) 3 d) 2 e) 2	a) Not given b) Not given c) Not given d) Not given e) Not given	a) 3.5 +or- 1.5 mg/kg/day b) 3.5 +or- 1.5 mg/kg/day c) 3.5 +or- 1.9 mg/kg/day d) 5.7 mg/kg/day (estimate) e) 5.7 +or- 3.1 mg/kg/day	a) Full-cream cow's milk, Ca intake 214 +or- 1.5 mg/kg/day b) Half-skimmed cow's milk, Ca intake 209 +or- 27.0 mg/kg/day c) S.M.A. infant formula, Ca intake 132 +or- 12.0 mg/kg/day d) Breast milk, Ca intake 56 +or- 8.0 mg/kg/day e) Breast milk, Ca intake 75 +or- 7.0 mg/kg/day a)-d) preterm infants, e) full-term, low birthweight infants UNITED KINGDOM; INFANTS; NUTRITIONAL DEFICIENCIES; MILK; URINE; CALCIUM; DIETS	Shaw, J.C.L. 1976 Pediatrics 57(1):16-25
5359 Urine		Flame photometry AAS	a) 1013 b) 693 c) 171 d) 347 e) 96 Estimates	a) 9.4-7.8 mmol/24 hr b) 7.5-9.6 mmol/24 hr c) 6.4-7.8 mmol/24 hr d) 9.0-10.3 mmol/24 hr e) 4.6-6.2 mmol/24 hr	a) Not given b) Not given c) Not given d) Not given e) Not given	a) Treated and untreated patients b) Patients treated with thiazide diuretics (bendroflazide, 5-10 mg/day) c) Patients treated with cellulose phosphate (10-30 mg/day, taken with meals) d) Patients treated or untreated, mild calcium restriction e) Normals Range of mean monthly levels for a 1 yr period. No significant seasonal variation Estimated from graph CALCIUM; DIETS; URINE; DIURETICS; DRUG THERAPY; DRUGS; KIDNEY DISEASES	Hallson, P.C. Kasidas, G.P. Rose, G.A. 1977 British Journal of Urology 49(1):1-10

Carbanilide, trichloro- (8 CI)
Urea, N,N'-diphenyl-, trichloro deriv. (9 CI)
1322-40-3
C13-H9-Cl3-N2-O
MW 315.6

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5360 Skin	Dermal	Radiometry		a) 0.103-<0.001 ug/cu cm b) 0.086-<0.001 ug/cu cm c) 0.141-<0.001 ug/cu cm d) 0.188-<0.001 ug/cu cm e) 0.312-<0.001 ug/cu cm f) 0.148-<0.001 ug/cu cm	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given	a) Convential soap, freshly prepared b) Conventional soap, equilibrated c) 10% nonsoap detergent d) Same as a) e) Same as b) f) Same as c) Single wash (a-c) or 6 washings (d-f) Aqueous 8% solutions with 0.06%, 0.25 ml applied to 20 cu cm for 2 min. 10 min and 4 day measurements, sum of epidermis and dermis values Volunteers GERMICIDE; SKIN; CHLORINE ORGANIC COMPOUNDS	Black, J.G. Howes, T. Rutherford, T. 1975 Toxicology 3:253-264

Carbon disulfide
75-15-0
C-S2
MW 76.14, MP -110.8 C, BP 46.5 C, VP 400 mm Hg at 20 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5361 Urine						Review. Critique of data from workers exposed to toxic chemicals. Wide variations reflect lack of standardizations in sampling and analytical design. INDUSTRIAL CHEMICALS; BLOOD; URINE; INDUSTRIAL MEDICINE; REVIEW; CARBON INORGANIC COMPOUNDS; MERCURY; METALS; ORGANOPHOSPHATES; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Ramaswamy, S.S. 1975 Environmental Pollution and Human Health: Proceedings of the International Symposium on Industrial Toxicology, pp. 166-177

Carbon monoxide
630-08-0
C-O
MW 28.01, MP -205 C, BP -191.5 C, VP 10 mm Hg at -215 C, 100 mm Hg at -205.7 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5362 Blood						Review Distribution, sources, human body burden, mortality data and toxicological effects of Pb. Accumulation, distribution and effects on plants. CO data includes sources, ambient levels, mortality and morbidity statistics, air quality standards, toxicological data, occupational exposure, impact of cigarette smoking and laboratory studies. CARBON MONOXIDE; METAL POISONING; NERVOUS SYSTEM DISEASES; BLOOD; POWER; KIDNEYS; LUNGS; REVIEW; CARBON INORGANIC COMPOUNDS; LEAD; METALS; AIR POLLUTION; ATMOSPHERE; DRINKING WATER; DUST; ENZYMES; FOODS; FOSSIL FUELED POWER PLANTS; INDUSTRIAL POLLUTION; INHALATION; OCCUPATIONAL HAZARDS; PAINTS; SMOKING; VEGETABLES; VEGETATION	Amos, R.G. Amos, F.E., Jr. Thompson, J.C., Jr. 1974 NSF-RA-E-74-467, 43 pp.
5363 Blood						Review. Critique of data from workers exposed to toxic chemicals. Wide variations reflect lack of standardizations in sampling and analytical design. INDUSTRIAL CHEMICALS; BLOOD; URINE; INDUSTRIAL MEDICINE; REVIEW; CARBON INORGANIC COMPOUNDS; MERCURY; METALS; ORGANOPHOSPHATES; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Ramaswamy, S.S. 1975 Environmental Pollution and Human Health: Proceedings of the International Symposium on Industrial Toxicology, pp. 166-177
5364 Blood	Inhalation					Review. Experimental and technical studies on carbon monoxide toxicity in pregnancy. CARBON MONOXIDE; SWITZERLAND; FETUS; NEWBORN; MENTAL RETARDATION; AIR POLLUTION; FISHES; HEALTH HAZARDS; INHALATION; PREGNANCY; RATS; SMOKING; URBAN AREAS; CARBON INORGANIC COMPOUNDS; BLOOD; PLACENTA	Longo, L.D. 1977 American Journal of Obstetrics and Gynecology 129(69):69-103
5365 Blood	Inhalation	MS	165	a) 0-9% b) 10-39% c) > 40%	a) Not given b) Not given c) Not given	a) 61 cases b) 40 cases c) 64 cases Blood saturation in fire related traumatic deaths New York City, 1974 NEW YORK; AUTOPSIES; SUICIDE; BLOOD; LIVER; DRUG ABUSE; DRUGS; NARCOTICS; TRANQUILIZERS; ALCOHOLS; CARBON INORGANIC COMPOUNDS	Baston, M.L. Galante, L. 1976 Journal of Forensic Sciences 21(1):176-186

(NEXT PAGE)

Carbon monoxide
630-08-0
C-O
MW 28.01, MP -205 C, BP -191.5 C, VP 10 mm Hg at -215 C, 100 mm Hg at -205.7 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5366 Breath	Inhalation		17	a) 14-56 ppm b) 15-65 ppm c) 3-12 ppm d) 8-42 ppm	a) 20.8 ppm b) 37.3 ppm c) 6.5 ppm d) 19.3 ppm	a) Non-smoking smokers, before work (8 subjects) b) Non-smoking smokers, after work (8 subjects) c) Non-smokers, before work (9 subjects) d) Non-smokers, after work (9 subjects) Data also for different work periods California/Mexico border guards CALIFORNIA; ADULTS; BLOOD; BREATH; CARBON INORGANIC COMPOUNDS; AUTOMOTIVE; FUMES; INHALATION; OCCUPATIONAL HAZARDS; SMOKING	Hickey, R.J. Clelland, R.C. Boyce, D.E. Haraer, E.B. 1974 Lancet 1(7854):409-410

Carbon tetrachloride (8 CI)
Methane, tetrachloro- (9 CI)
56-23-5
C-Cl4
MW 153.84, MP -22.6 C, BP 76.8 C, VP 100 mm Hg at 23.0 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5367 Urine		GC-EC	20	0.50-0.60 ug/l	Not given	Tap water samples 0.5-2.5 ug/l Healthy 20-30 yr olds ADULTS; URINE; MEASUREMENT METHODS; BROMINATED HYDROCARBONS; CHLORINATED HYDROCARBONS; DRINKING WATER	Youssefi, M. Faust, S.D. Zenchelsky, S.T. 1978 Clinical Chemistry 24(7):1109-1111

Carboxyhemoglobin
9061-29-4
EXACT COMPOSITION UNKNOWN OR UNDETERMINED

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5368 Blood	Inhalation		17	a) Not given b) Not given c) Not given d) Not given	a) 4.04% b) 6.77% c) 1.54% d) 3.71%	a) Non-smoking smokers, before work (8 subjects) b) Non-smoking smokers, after work (8 subjects) c) Non-smokers, before work (9 subjects) d) Non-smokers, after work (9 subjects) Levels estimated from regression analysis of expired air CO California/Mexico border guards CALIFORNIA; ADULTS; BLOOD; BREATH; CARBON INORGANIC COMPOUNDS; AUTOMOTIVE; FUMES; INHALATION; OCCUPATIONAL HAZARDS; SMOKING	Hickey, R.J. Clelland, R.C. Boyce, D.E. Haraer, E.B. 1974 Lancet 1(7854):409-410

Chlorine
7782-50-5
Cl
AtW 35.753, MP -101 C, BP -34.05 C, VP 4830 mm Hg at 20 C, 1 mm Hg at -123 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5369 Hair		NA	71	a) 110-794 ug/g b) 7-574 ug/g c) Not given d) Not given e) Not given f) Not given	a) Not given b) Not given c) 203 ug/g d) 232 ug/g e) 243 ug/g f) 138 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5370 Nail		NA	Not given	a) Not given b) Not given	a) 1490 +or- 1800 ug/g b) 1130 +or- 1020 ug/g	a) Women b) Men Toenail sample of about 6 mg Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278

Chloroform (8 CI)
Methane, trichloro- (9 CI)
67-66-3
C-H-Cl3
MW 119.39, MP -63.5 C, VP 100 mm Hg at 10.4 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5371 Urine		GC-EC	20	36.5-48.7 ug/l	Not given	Tap water samples 40.5-60.0 ug/l Healthy 20-30 yr olds. ADULTS; URINE; MEASUREMENT METHODS; BROMINATED HYDROCARBONS; CHLORINATED HYDROCARBONS; DRINKING WATER	Youssefi, M. Faust, S.D. Zenchelsky, S.T. 1978 Clinical Chemistry 24(7):1109-1111

Cholesterol (8 CI)
Cholest-5-en-3-ol (3beta)- (9 CI)
57-88-5
C27-H46-O
MW 386.64, MP 148.5 C (anhydrous), BP 233 C at 0.5 mm Hg, 360 C at 760 mm Hg (some decomp)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5372 Blood			59	a) 101-187 mg/100 ml b) 67-150 mg/100 ml c) 118-190 mg/100 ml d) 181-267 mg/100 ml e) 50-185 mg/100 ml f) 115-300 mg/100 ml g) Not given h) Not given i) 99-158 mg j) Not given k) Not given l) 82-172 mg/100 ml	a) 138 +or- 37 mg/100 ml b) 95 +or- 35 mg/100 ml c) 161 +or- 27 mg/100 ml d) 136 +or- 47 mg/100 ml e) 90 +or- 42 mg/100 ml f) 233 +or- 59 mg/100 ml g) 66 +or- 14 mg/100 ml h) 32 +or- 8 mg/100 ml i) 135 +or- 19 mg/100 ml j) 61 +or- 11 mg/100 ml k) 31 +or- 7 mg/100 ml l) 131 +or- 33 mg/100 ml	a) Cord blood, (hypercholesterolemic neonates (same in b-f) b) Cord, low density lipoprotein (LDL) cholesterol c) Plasma, at 12 mo d) Cord e) Cord, LDL cholesterol f) Plasma, at 12 mo g) Cord blood, normal neonates (same in h-l) h) Cord, LDL cholesterol i) Plasma at 12 mo j) Cord k) Cord, LDL cholesterol l) Plasma at 12 mo Dietary intake <300 g/day, 5 children in a)-c), 10 children in g)-i), and >500 mg/day, 12 children in d)-f), 32 children in j)-l). AGE; INFANTS; NEWBORN; CARDIOVASCULAR DISEASES; BLOOD; COMPARATIVE EVALUATIONS; CHOLESTEROLS; DIETS; GENETIC EFFECTS	Tsang, R.C. Fellat, R.W. Glueck, C.J. 1974 Pediatrics 53(6):858-870

Chromium
7440-47-3
Cr
AtW 51.996, MP 1900 C, BP 2642 C, VP 1 mm Hg at 1616 C, 10 mm Hg at 1890 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5373 Blood, serum						Review. Discussion of trace elements as inhibitory or causative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; SKIN; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGEN; RATS	Schwartz, M.K. 1975 Cancer Research 35:3481-3487
5374 Blood, serum		NA	14	0.0382-0.351 ug/l	0.160 +or- 0.083 ug/l	Healthy individuals BLOOD SERUM; MEASUREMENT METHODS; CHROMIUM; COBALT; METALS	Versieck, J. Hoste, J. Barbier, F. Steyaert, H. DeRedder, J. Nichels, N. 1978 Clinical Chemistry 24(2):303-308

(NEXT PAGE)

Chrom
7440-
Cr
AtW 51.996, MP 1900 C, BP 2642 C, VP 1 mm Hg at 1616 C, 10 mm Hg at 1840 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5375 Hair		AAS	a) 17 b) 73 c) 16 d) 16 e) 16	a) Not given b) Not given c) 65-340 ng/g d) 58-287 ng/g e) 53-227 ng/g	a) 221 +or- 24 ng/g b) 164 +or- 9 ng/g c) 191 +or- 22 ng/g d) 164 + or - 16 ng/g e) 141 +or- 13 ng/g S.E.	a) Nulliparous b) Multiparous c) 1st trimester pregnancy d) 2nd trimester pregnancy e) 3rd trimester pregnancy Significant decrease each consecutive trimester in women with initial levels of > 200 ng/g. Women with initial levels of < 200 ng/g had significant decreases only in final trimester. 16-40 yr olds, parity 1-6 TURKEY; HAIR; CHROMIUM; PREGNANCY; METALS	Saner, G. 1981 American Journal of Clinical Nutrition 34:853-855
5376 Hair		AAS	1	0-8.3 ppm	Not given	Data for various body regions. Maximum level in beard. Estimated from graph 23 yr old, United Kingdom ADULTS; HAIR; COMPARATIVE EVALUATIONS; ALUMINUM; CHROMIUM; COBALT; COPPER; IRON; MANGANESE; METALS; NICKEL; SILICON; SILVER; UNITED KINGDOM	Alder, J.F. Samuel, A.J. West, T.S. 1977 Analytica Chimica Acta 92:217-221
5377 Milk	Ingestion	AAS	a) 5 b) 5	a) 0.19-0.69 ug/ml b) 0.24-0.54 ug/ml	a) 0.39 ug/ml b) 0.34 ug/ml	a) 6 to 8 wk postpartum b) 17 to 22 wk postpartum Mean maternal dietary intake, 31 ug/day. No correlation with breast milk. Lactating Finnish mothers CHROMIUM; METALS; BIOACCUMULATION; DIETS; FOOD CONTAMINATION; LACTATION; MILK; FINLAND	Kumpulainen, J. Vuori, E. Makinen, S. Kara, R. 1980 British Journal of Nutrition 44:257-263

Chrysotile (8 CI) (VAN)
Chrysotile ($Mg_3(Si_2O_5)(OH)_4$) (9 CI)
12001-29-5
#10-09-S12.38g
#9 282

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5378 Lung	Inhalation	EM	16	1-51X10(E+5) fibers/cu cm	13X10(E+5) +or- 12X10(E+5) fibers/cu cm Geometric	Parietal pleura Diverse exposures Autopsies, 39-78 yr old workers with 1-37 yr exposures (latent period 17-59 yr). AUTOPSIES; CARCINOMAS; LUNGS; ASBESTOS; FIBERS; OCCUPATIONAL HAZARDS; NEOPLASMS; DISEASES	Sebastien, P. Janson, X. Biba, G. Masse, R. Bonnaud, G. Bignon, J. 1977 Occupational Exposures to Fibrous and Particulate Dust and Their Extension into the Environment, Proceedings of the Conference of the Society for Occupational and Environmental Health, Washington, DC, December 4-7, 1977

Cobalt
7440-48-4
Co
Atw 58.9332, MP 1493 C, BP 3100 C, VP 1 mm Hg at 1910 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5379 Blood, serum		NA	14	0.0398-0.271 ug/l	0.108 +or- 0.060 ug/l	Healthy individuals BLOOD SERUM; MEASUREMENT METHODS; CHROMIUM; COBALT; METALS	Versieck, J. Hoste, J. Barbier, F. Steyaert, W. DeRudder, J. Nichels, H. 1978 Clinical Chemistry 24(2):303-308
5380 Hair		AAS	1	0-9.7 ppm	Not given	Data for various body regions. Maximum level in axillary hair. Estimated from graph 23 yr old, United Kingdom ADULTS; HAIR; COMPARATIVE EVALUATIONS; ALUMINUM; CHROMIUM; COBALT; COPPER; IRON; MANGANESE; METALS; NICKEL; SILICON; SILVER; UNITED KINGDOM	Alder, J.F. Samuel, A.J. West, T.S. 1977 Analytica Chimica Acta 92:217-221

Copper
7440-50-8
Cu
Atw 63.546, MP 1083 C, BP 2595 C, VP 1 mm Hg at 1628 C, 10 mm Hg at 1870 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5381 Blood, cells		AAS	6	99-117 ug/100 ml	110 ug/100 ml	Erythrocytes Healthy individuals ERYTHROCYTES; MEASUREMENT METHODS; METALS; COPPER	Fobbins, W.B. DeKoven, B.M. Caraso, J.A. 1975 Biochemical Medicine 14:184-190
5382 Blood, cells		NA	a) 25 b) 21 c) 10 d) 10 e) 8 f) 8 g) 5	a) 0.54-0.88 ug/g b) 0.53-0.96 ug/g c) Not given d) Not given e) Not given f) Not given g) Not given	a) 0.66 +or- 0.06 ug/g b) 0.66 +or- 0.10 ug/g c) 0.66 +or- 0.08 ug/g d) 0.66 +or- 0.05 ug/g e) 0.65 +or- 0.07 ug/g f) 0.66 +or- 0.07 ug/g g) 0.62 +or- 0.07 ug/g Not wt	a) Controls, male b) Controls, female c) Acute viral hepatitis, active phase d) Acute viral hepatitis, subsiding phase e) Chronic persistent hepatitis f) Chronic aggressive hepatitis g) Postnecrotic cirrhosis Patients with hepatic disease LIVER DISEASES; BLOOD SERUM; ERYTHROCYTES; COPPER; MANGANESE; METALS; ZINC; BELGIUM	Versieck, J. Barbier, F. Speecke, A. Hoste, J. 1978 Clinical Chemistry 24(9):1141-1145
5383 Blood, serum						Review. Discussion of trace elements as inhibitory or causative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SI COMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGEN; RATS	Schwartz, M.K. 1975 Cancer Research 35:3481-3487

(NEXT PAGE)

Copper
7440-50-8
Cu
Atm 63.546, MP 1083 C, BP 2595 C, VP 1 mm Hg at 1628 C, 10 mm Hg at 1870 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5304 Blood, serum		AAS	a) 40 b) 15 c) 36 d) 60 e) 18 f) 10 g) 65 h) 28	a) 70-140 ug/100 ml b) 100-240 ug/100 ml c) 120-240 ug/100 ml d) 120-280 ug/100 ml e) 120-220 ug/100 ml f) 140-240 ug/100 ml g) 150-280 ug/100 ml h) 150-300 ug/100 ml	a) 114.25 +or- 22.75 ug/100 ml b) 139.63 +or- 37.32 ug/100 ml c) 162.78 +or- 25.56 ug/100 ml d) 181.75 +or- 29.16 ug/100 ml e) 158.82 +or- 27.13 ug/100 ml f) 167.22 +or- 4.12 ug/100 ml g) 195.11 +or- 28.25 ug/100 ml h) 209.82 +or- 42.69 ug/100 ml	a) Controls b) Suspected silicosis c) p,q,r, (2,3) silicosis (round, regular opacities) d) A,B, and C silicosis (large opacities) e) Second silicosis (p,q,r,) f) Third silicosis (p,q,r) g) Silicotuberculosis h) Active lung tuberculosis p,q,r and A,B,C, international pneumoconioses nomenclature Silicotic patients, coal miners 5 or more yr prior to study, Russia Serum Cu increased with increasing severity of silicosis. Serum Zn and Fe lowered. BIBLIA: INDUSTRIAL DISEASES; OCCUPATIONAL DISEASES; BLOOD SERUM; COPPER; IRON; METALS; PROTEINS; ZINC; COAL; DUST; MINING	Niculescu, T. Dumitru, E. Burnea, D. 1981 Environmental Research 25:260-268
5305 Blood, serum				a) Not given b) Not given c) Not given d) Not given e) Not given	a) 1.38 +or- 0.24 ug/ml b) 0.96 +or- 0.19 ug/ml c) 0.99 +or- 0.25 ug/ml d) 1.42 +or- 0.22 ug/ml e) 1.55 +or- 0.11 ug/ml	a) 33 oral contraceptive agent (OCA) users b) 24 controls c) 12 subjects, before using OCA d) Same 12, 3 mo OCA use e) Same 12, 6 mo OCA use Significant differences between a) and b), d) and c). Healthy 18-23 yr olds ADULTS; BLOOD SERUM; HAIR; COPPER; METALS; ZINC	Vir, S.C. Love, A.H.G. 1981 American Journal of Clinical Nutrition 34:1479-1483
5306 Blood, serum		RA	a) 25 b) 21 c) 10 d) 10 e) 4 f) 4 g) 5	a) 0.73-1.51 ug/ml b) 0.77-1.99 ug/ml c) Not given d) Not given e) Not given f) Not given g) Not given	a) 1.03 +or- 0.18 ug/ml b) 1.13 +or- 0.29 ug/ml c) 1.43 +or- 0.36 ug/ml d) 1.27 +or- 0.41 ug/ml e) 1.04 +or- 0.17 ug/ml f) 1.25 +or- 0.31 ug/ml g) 1.09 +or- 0.30 ug/ml	a) Controls, male b) Controls, female c) Acute viral hepatitis, active phase d) Acute viral hepatitis, subsiding phase e) Chronic persistent hepatitis f) Chronic aggressive hepatitis g) Postnecrotic cirrhosis Patients with hepatic disease LIVER DISEASES; BLOOD SERUM; ERYTHROCYTES; COPPER; MANGANESE; METALS; ZINC; RELIGION	Versieck, J. Barbier, F. Speecke, A. Roste, J. 1978 Clinical Chemistry 24(9):1141-1145

(NEXT PAGE)

Copper
7440-50-8
Cu
AtW 63.546, MP 1083 C, BP 2595 C, VP 1 mm Hg at 1628 C, 10 mm Hg at 1870 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5387 Blood, serum	Ingestion	AAS	97	a) 134.8-145.8 ug/dl b) Not given c) Not given d) 22.1-33.5 ug/dl e) Not given f) Not given g) 33.8-46.0 ug/dl h) Not given i) Not given j) 32.8-54.6 ug/dl k) Not given l) 69.8-80.9 ug/dl m) Not given	a) 139.5 +or- 25.4 ug/dl b) 140 +or- 30 ug/dl c) 150 +or- 25 ug/dl d) 26.0 +or- 10.8 ug/dl e) 50 +or- 21 ug/dl f) 32 +or- 21 ug/dl g) 36.4 +or- 12.9 ug/dl h) 55 +or- 14 ug/dl i) 45 +or- 25 ug/dl j) 43.1 +or- 19.9 ug/dl k) 70 +or- 15 ug/dl l) 63.3 +or- 24.3 ug/dl m) 84 +or- 18 ug/dl	a) Maternal blood, premature infants b) Maternal blood, small, term infants c) Maternal blood, avg. size, term infants d) Cord blood, premature infants e) Cord blood, small, term infants f) Cord blood, avg. size, term infants g) Premature infants, 1 wk old h) Small, term infants, 1 wk old i) Avg size, term infants, 1 wk old j) Premature infants, 3 wk old k) Small, term infants, 3 wk old l) Premature infants, 6 wk old m) Small, term infants, 6 wk old Data also by gestational, postnatal and postconceptional age Premature infants had Cu intake of 70-90 ug/kg at 120-150 calories/kg Range of means Premature infants, mean wt 1117.9 +or- 278 g, and small term infants, mean wt 1766 +or- 340 g UNITED STATES; AGE; INFANTS; NEWBORN; BLOOD SERUM; COMPARATIVE EVALUATIONS; COPPER; METALS	Hillman, L.S. 1981 Journal of Pediatrics 98(2):305-308
5388 Blood, serum				a) Not given b) Not given c) Not given d) Not given e) Not given	a) 0.98 +or- 0.19 ug/ml b) 1.79 +or- 0.25 ug/ml c) 1.71 +or- 0.35 ug/ml d) 1.77 +or- 0.36 ug/ml e) 0.33 +or- 0.66 ug/ml	a) 28 controls b) 60 in 2nd trimester pregnancy c) 51 in 3rd trimester pregnancy d) 29, postpartum e) 7, umbilical cord blood Values significantly higher in pregnant women. In b) and c), primigravida had significantly higher levels. Prior oral contraceptive usage and alcohol had no effect. Healthy 18-42 yr olds, Northern Ireland IRELAND; ADULTS; BLOOD SERUM; HAIR; COPPER; METALS; PREGNANCY; SMOKING	Yir, S.C. Love, A.H.G. Thompson, W. 1981 American Journal of Clinical Nutrition 34:2382-2388
5389 Body						Review. Discussion of trace elements as inhibitory or cumulative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGENS; RATS	Schwartz, H.K. 1975 Cancer Research 35:3481-3487
5390 Breast						Review. Discussion of trace elements as inhibitory or cumulative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGENS; RATS	Schwartz, H.K. 1975 Cancer Research 35:3481-3487

(NEXT PAGE)

Copper
7440-50-8
Cu
Atw 63.546, MP 1083 C, BP 2595 C, VP 1 mm Hg at 1520 C, 10 mm Hg at 1870 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5391 Gall stone		AAS	20	a) Not given b) Not given c) Not given	a) 28.05 +or- 9.23 ug/g b) 22.72 +or- 1.84 ug/g c) 25.12 +or- 5.35 ug/g	a) 9 men b) 11 women c) Total Hokuriku, Japan JAPAN; SEX; GALL STONES; KIDNEYS; COMPARATIVE EVALUATIONS; CADMIUM; COPPER; METALS; ZINC	Yasamoto, Y. Itoh, H. Tsukada, S. Takemaka, S. Kiyomasi, H. Kojima, S. 1980 Proceedings of the 7th Symposium on Environmental Pollutants and Toxicology, Kobe, Japan, 5-68
5392 Hair		NA	71	a) 12-27 ug/g b) 6-80 ug/g c) Not given d) Not given e) Not given f) Not given	a) 18 +or- 5 ug/g b) 18 +or- 7 ug/g c) 16 ug/g d) 19.5 ug/g e) 19 ug/g f) 16.5 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AC2; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5393 Hair				a) Not given b) Not given c) Not given d) Not given e) Not given	a) 16.39 +or- 8.68 ug/g b) 13.98 +or- 5.97 ug/g c) 15.67 +or- 7.69 ug/g d) 13.08 +or- 2.48 ug/g e) 14.24 +or- 7.99 ug/g	a) 33 oral contraceptive agent (OCA) users b) 24 controls c) 12 subjects, before using OCA d) Same 12, 3 no OCA use e) Same 12 6 no OCA use No significant differences. Healthy 18-23 yr olds ADULTS; BLOOD SERUM; HAIR; COPPER; METALS; ZINC	Vir, S.C. Love, A.H.G. 1981 American Journal of Clinical Nutrition 34:1479-1483
5394 Hair		AAS	1	0-150 ppm	Not given	Data for various body regions. Maximum level in leg hair. Estimated from graph 23 yr old, United Kingdom ADULTS; HAIR; COMPARATIVE EVALUATIONS; ALUMINUM; CHROMIUM; COBALT; COPPER; IRON; MANGANESE; METALS; NICKEL; SILICON; SILVER; UNITED KINGDOM	Alder, J.F. Samuel, A.J. West, T.S. 1977 Analytica Chimica Acta 92:217-221
5395 Hair				a) Not given b) Not given c) Not given d) Not given	a) 14.33 +or- 6.16 ug/g b) 14.70 +or- 5.34 ug/g c) 12.29 +or- 4.02 ug/g d) 14.14 +or- 5.46 ug/g	a) 28 controls b) 60 in 2nd trimester pregnancy c) 51 in 3rd trimester pregnancy d) 29, postpartus Significant decrease in c) which also showed a significantly lower level in primigravida than in those with higher parity. Healthy 18-42 yr olds, Northern Ireland IRELAND; ADULTS; BLOOD SERUM; HAIR; COPPER; METALS; PREGNANCY; SMOKING	Vir, S.C. Love, A.H.G. Thompson, W. 1981 American Journal of Clinical Nutrition 34:2382-2388

(NEXT PAGE)

Copper
7440-50-8
Cu
At# 63.546, MP 1083 C, BP 2595 C, VP 1 mm Hg at 1628 C, 10 mm Hg at 1870 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5396 Kidney		AAS	49	a) Not given b) Not given c) Not given	a) 2.57 +or- 0.47 ug/g b) 2.21 +or- 0.38 ug/g c) 2.43 +or- 0.38 ug/g	a) 29 men b) 20 women c) Total Renal calculi Nchuriku, Japan JAPAN; SEX; GALL STONES; KIDNEYS; COMPARATIVE EVALUATIONS; CADMIUM; COPPER; METALS; ZINC	Yamamoto, T. Itoh, H. Tsukada, S. Takemata, S. Kiyozumi, M. Kojima, S. 1980 Proceedings of the 7th Symposium on Environmental Pollutants and Toxicology, Kobe, Japan, 5-68
5397 Kidney		AAS	1	a) Not applicable b) Not applicable	a) 2.6 ug/g b) 2.5 ug/g Wet wt	a) Analysis by low-temperature plasma ashing followed by AAS b) Analysis by standard subtilisn tissue degradation technique followed by AAS Autopsy KIDNEYS; LIVER; MEASUREMENT METHODS; CADMIUM; COPPER; LEAD; THALLIUM	Carpenter, R.C. 1981 Analytica Chimica Acta 125:209-213
5398 Liver		AAS	16	Not given	26 ug/ug	Normal upper limit estimated to be 40 ug/ug dry wt Autopsies, normal liver AUTOPSIES; LIVER; MEASUREMENT METHODS; CADMIUM; COPPER; METALS; ZINC	Svenson, H.A. Anderson, C.T., Jr. 1975 Clinical Chemistry 21(8):537-543
5399 Liver		AAS	3	a) 4.8-10.4 ug/g b) 4.5-17.7 ug/g Wet wt	a) 9.4 ug/g b) 8.9 ug/g Wet wt	a) Analysis by low-temperature plasma ashing followed by AAS b) Analysis by standard subtilisn tissue degradation technique followed by AAS Autopsies KIDNEYS; LIVER; MEASUREMENT METHODS; CADMIUM; COPPER; LEAD; THALLIUM; METALS	Carpenter, R.C. 1981 Analytica Chimica Acta 125:209-213
5400 Nail		NA	Not given	a) Not given b) Not given	a) 32 +or- 9.2 ug/g b) 29 +or- 12 ug/g	a) Women b) Men Toenail samples of about 6 mg Machakos district, Kenya, 1978 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5401 Pleural fluid						Review. Discussion of trace elements as inhibitory or causative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGEN; RATS	Schwartz, M.K. 1975 Cancer Research 35:3481-3487

(NEXT PAGE)

Copper
7440-50-8
Cu
Atw 63.546, MP 1083 C, BP 2595 C, VP 1 mm Hg at 1628 C, 10 mm Hg at 1870 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5402 Sweat	Ingestion	AAS	13	Not given	0.34 +or- 0.24 mg/day	Surface losses after mean dietary intake of 1.3 mg/day (range 1.1-1.5 mg/day) Healthy 19-58 yr olds in controlled environment 4-9 mo ADULTS; SWEAT; COPPER; IRON	Jacob, R.A. Sandstead, H.H. Munoz, J.M. Klevay, L.M. Milne, D.B. 1981 The American Journal of Clinical Nutrition 34:1379-1383
5403 Teeth		MS	208	a) Not given b) Not given	a) 1.68 +or- 0.48 ppm b) 0.51 +or- 0.06 ppm S.E.	a) High caries donors (>7 decayed, missing, filled teeth (DMFT)), 35 teeth b) Low caries donors (<4 DMFT), 26 teeth Values for enamel a) and b) differed, P<0.02 Premolars extracted, patients <20 yr old, New England ZIRCONIUM; NEW HAMPSHIRE; SOUTH CAROLINA; VERMONT; DENTAL CARIES; TEETH; ALUMINUM; BARIUM; COPPER; FLUORINE; LITHIUM; METALS; SILVER; STRONTIUM; TIN	Curzon, M.E.J. Losee, F.L. 1977 Journal of the American Dental Association 94(6):1146-1150
5404 Urine						Review. Discussion of trace elements as inhibitory or causative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGEN; RATS	Schwartz, M.K. 1975 Cancer Research 35:3481-3487

Cyanide
57-12-5
C-N
MW 26.02

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5405 Blood		GC-EC	a) 1 b) 1	a) Not applicable b) Not applicable	a) 60 ug/ml b) 4.3 ug/ml	a) Suspected cyanide fatality b) Suspected cyanide fatality Dose unknown. Values also for colorimetric method. AUTOPSIES; SUICIDE; BLOOD; MEASUREMENT METHODS; CYANIDE	Valentour, J.C. Aggarwal, V. Sunshine, I. 1974 Analytical Chemistry 46(7):926-925

Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI)
Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)
58-89-9
C6-H6-C16
MW 290.85, BP gamma-isomer crystals 112.5 C, BP 323.4 C, 176.2 C at 10 mm Hg, VP 0.14 mm Hg at 40 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5806 Adipose		GC-EC	a) 12 b) 28	a) 0.009-0.036 ppm b) 0-0.030 ppm	a) 0.018 ppm b) 0.015 ppm	a) Rural b) Urban Autopsies, Spain SPAIN; AUTOPSIES; ADIPOSE TISSUE; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; DDD; LINDANE; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; ORGANOPHOSPHATES; PESTICIDES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Herrera Marteache, A. Polo Villar, L.M. Jodral Villarejo, M. Polo Villar, G. Mallol, J. Pozo Lora, R. 1978 Revista de Sanidad e Higiene Publica 52, 20 pp.
5807 Blood		GC TLC	a) 25 b) 25	a) 0.0022-0.0350 ppm b) 0.0018-0.0280 ppm	a) 0.0075 +or- 0.0013 ppm b) 0.0056 +or- 0.001 ppm S.E.	a) Mothers, 24 hr after parturition b) Fetal (cord) blood, collected at parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDT; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NEWBORN	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, R. 1981 Environmental Research 24:24-32
5808 Blood, fetal		GC-EC	186	a) 1.60-78.69 ppb b) 3.10-27.98 ppb c) 2.1-78.68 ppb d) 1.8-29.81 ppb e) 1.28-175.73 ppb f) 1.8-33.43 ppb	a) 10.27 +or- 2.18 ppb b) 14.99 +or- 1.23 ppb c) 12.47 +or- 0.34 ppb d) 11.41 +or- 1.10 ppb e) 16.94 +or- 0.72 ppb f) 8.88 +or- 1.63 ppb	a) Newborn of 18-25 yr olds (58) b) Newborn of 26-34 yr olds (42) c) Mothers had vegetarian diets (64) d) Mothers had nonvegetarian diets (36) e) Urban area (48) f) Rural area (52) a) and b), and e) and f) significantly different India INDIA; AGE; NEWBORN; BLOOD; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; DDD; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; PESTICIDES; DIETS; PESTICIDE RESIDUES; POPULATION EXPOSURE; RURAL AREAS; URBAN AREAS	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Krishna Murti, C.R. Kutty, R. 1981 Pesticides Monitoring Journal 15(2):77-79
5809 Blood, serum		GC-EC	a) 20 b) 15	a) 6-28 ppb b) 8-47 ppb	a) 11 +or- 6 ppb b) 25 +or- ppb	a) DDT sprayers, 1-32 (mean 14) yr exposure b) Controls 25-52 yr olds, India INDIA; ADULTS; BLOOD SERUM; DDD; DDE; DDT; HEPTACHLOROCYCLOHEXANE; LINDANE; HEALTH HAZARDS; OCCUPATIONAL HAZARDS; PESTICIDE RESIDUES	Siddiqui, M.K.J. Saxena, M.C. Mishra, U.K. Krishna Murti, C.R. Wag, D. 1981 International Archives of Occupational and Environmental Health 48:301-308

(NEXT PAGE)

Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI)
Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)
58-89-9
C6-H6-Cl6
MW 290.85, MP gamma-isomer crystals 112.5 C, BP 323.4 C, 176.2 C at 10 mm Hg, VP 0.14 mm Hg at 40 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5810 Milk		GC-EC	154	a) 0-1.56 mg/kg fat b) Not given c) Not given	a) 0.047 +or- 0.131 mg/kg fat b) 0.04 +or- 0.07 mg/kg fat c) 0.03 +or- 0.03 mg/kg fat	a) 0.002 +or- 0.0001 mg/kg whole milk, all samples, 3% exceeded limits set by Codex Alimentarius Commission b) Rural residents, 19 samples c) Urban residents, 51 samples 3-6 days postpartum. Previous breast feeding inversely correlated with lindane levels. No correlation with age or place of residence 18-38 yr olds, Canada ALDRIN; CANADA; HCH; MILK; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; POLYCHLORINATED BIPHENYLS; POPULATION EXPOSURE; RURAL AREAS; SMOKING; URBAN AREAS	Dillon, J.C. Martin, G.B. O'Brien, H.T. 1981 Food and Cosmetics Toxicology 19:437-442
5811 Milk, whole		GC TLC	25	0.0106-0.810 ppm	0.0402 +or- 0.0051 ppm S.E.	24 hr after parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDE; DDT; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NURSING	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, R. 1981 Environmental Research 24:24-32

Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6aalpha,9aalpha-tetrahydro-4-methoxy- (8 CI)
Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-4-methoxy-, (6aR-cis)- (9 CI)
1162-65-8
C17-H12-O6
MW 312.3, MP 268-269 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5812 Blood		HPLC	a) 68 b) 6	a) 2-8 ng/ml b) 3.4-12 ng/ml	a) Not given b) Not given	a) Controls (2 of 68) b) Reye's syndrome patients (4 of 6) ARIZONA; MISSISSIPPI; OHIO; CARCINOMAS; BLOOD; LIVER; URINE; MEASUREMENT METHODS; FUNGAL TOXIN; REYE'S SYNDROME	Siraj, M.Y. Hayes, A.W. Unger, P.T. Hogan, G.R. Ryan, N.J. Wray, B.B. 1981 Toxicology and Applied Pharmacology 58:422-430
5813 Liver		HPLC	a) 6 b) 21 c) 15 d) 22	a) 2-60 ng/g b) <2 ng/g c) <1-62 ng/g d) <1-12 ng/g	a) Not given b) Not given c) Not given d) Not given	a) Hepatocellular carcinoma patients (4 of 6) b) Controls (3 of 21) c) Reye's syndrome patients (11 of 15) d) Controls (5 of 22) Reye's syndrome patients from Mississippi, Ohio, and Arizona ARIZONA; MISSISSIPPI; OHIO; CARCINOMAS; BLOOD; LIVER; URINE; MEASUREMENT METHODS; FUNGAL TOXIN; REYE'S SYNDROME	Siraj, M.Y. Hayes, A.W. Unger, P.D. Hogan, G.R. Ryan, N.J. Wray, B.P. 1981 Toxicology and Applied Pharmacology 58:422-430

(NEXT PAGE)

Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6aalpha,9aalpha-tetrahydro-4-methoxy- (8 CI)
Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-4-methoxy-, (6aR-cis)- (9 CI)
1162-65-8
C17-H12-O6
MW 312.3, MP 268-269 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5414 Urine		HPLC	a) 5 b) 5	a) 2.7-8.9 ng/ml b) 0	a) Not given b) Not applicable	a) Reye's syndrome patients (4 of 5) b) Controls (0 of 5) ARIZONA; MISSISSIPPI; OHIO; CARCINOMAS; BLOOD; LIVER; URINE; MEASUREMENT METHODS; FUNGAL TOXIN; REYE'S SYNDROME	Siraj, M.Y. Hayes, A.W. Unger, P.D. Hogan, G.R. Ryan, N.J. Gray, D.H. 1981 Toxicology and Applied Pharmacology 58:422-430

DDT, Total (No postings in CHEMLINE).
50-29-3
C14-H9-Cl5
MW 354.50

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5415 Adipose			a) 3 b) 2 c) 10 d) 19 e) 3 f) 8 g) 40 h) 96 i) 118 j) 19 k) 3 l) 13 m) 47 n) 54 o) 12	a) 2.10-5.55 ppm b) 12.0-12.3 ppm c) 0.40-11.9 ppm d) 0.68-18.3 ppm e) 4.69-29.6 ppm f) 1.85-4.72 ppm g) 0.89-18.5 ppm h) 0.50-19.8 ppm i) 0.81-28.5 ppm j) 1.11-13.6 ppm k) 1.66-2.03 ppm l) 1.47-6.42 ppm m) 0.92-8.99 ppm n) 0.46-10.4 ppm o) 0.47-13.4 ppm	a) 3.38 ppm b) 12.41 ppm c) 7.57 ppm d) 6.37 ppm e) 16.54 ppm f) 3.27 ppm g) 4.48 ppm h) 6.28 ppm i) 5.86 ppm j) 4.48 ppm k) 1.86 ppm l) 3.09 ppm m) 3.73 ppm n) 3.91 ppm o) 4.19 ppm	a) 1969-70, 0-20 yr olds b) 1969-70, 21-40 yr olds c) 1969-70, 41-60 yr olds d) 1969-70, 61-80 yr olds e) 1969-70, 81-100 yr olds f) 1971-72, 0-20 yr olds g) 1971-72, 21-40 yr olds h) 1971-72, 41-60 yr olds i) 1971-72, 61-80 yr olds j) 1971-72, 81-100 yr olds k) 1973-74, 0-20 yr olds l) 1973-74, 21-40 yr olds m) 1973-74, 41-60 yr olds n) 1973-74, 61-80 yr olds o) 1973-74, 81-100 yr olds Extractable fat. Autopsies by year and age group. Percentages of metabolite p,p'-DDE increased from 69.9 to 81.6 to 85.3 during sampling periods 1969-70 to 1971-72 to 1973-74 respectively. Percentages of p,p'-DDD and p,p'-DDT declined during the same time periods. Ontario, Canada INDUSTRIAL CHEMICALS; CANADA; AGE; AUTOPSIES; ADIPOSE TISSUE; MILK; CHLORINE ORGANIC COMPOUNDS; CHLOROBENZENES; DDT; DIELDRIN; HEXACHLOROBENZENE; PESTICIDES; POLYCHLORINATED BIPHENYLS; PESTICIDE RESIDUES; POPULATION EXPOSURE	Moldrinet, M.V.H. Braun, H.E. Frank, R. Stoppa, G.J. Smout, M.S. McNabb, J.W. 1977 Canadian Journal of Public Health 68:74-80
5416 Adipose		GC-EC	a) 12 b) 28	a) 1.367-7.516 ppm b) 0.832-8.781 ppm	a) 4.212 ppm b) 4.694 ppm	a) Rural b) Urban Autopsies, Spain SPAIN; AUTOPSIES; ADIPOSE TISSUE; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; DDE; LINDANE; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; ORGANOPHOSPHATES; PESTICIDES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Herrera Marteache, A. Polo Villar, L.M. Jodral Villarejo, M. Polo Villar, G. Mallol, J. Pozo Lora, R. 1978 Revista de Sanidad e Higiene Publica 52, 20 pp.

(NEXT PAGE)

DDT, Total (No postings in CHEMLINE).
50-29-3
C14-H9-Cl5
MW 354.53

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5817 Blood		GC TLC	a) 25 b) 25	a) 0.0090-0.0594 ppm b) 0.0119-0.0280 ppm	a) 0.0202 +or- 0.0023 ppm b) 0.0153 +or- 0.0012 ppm S.E.	a) Mothers, 24 hr after parturition b) Fetal (cord) blood, parturition Total DDT equivalent (DDT, DDD, and DDE) 19-35 yr old mothers, no history of exposure to pesticides. India DDE; DDD; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NEWBORN	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, D. 1981 Environmental Research 24:24-32
5818 Blood, fetal		GC-EC	100	a) 7.79-1029.85 ppb b) 4.59-149.62 ppb c) 4.03-1029.85 ppb d) 2.73-240.41 ppb e) 2.73-338.43 ppb f) 7.14-222.11 ppb	a) 49.55 +or- 23.23 ppb b) 51.18 +or- 8.51 ppb c) 62.22 +or- 8.50 ppb d) 50.07 +or- 7.78 ppb e) 41.60 +or- 10.88 ppb f) 40.65 +or- 8.98 ppb	a) Newborn of 18-25 yr olds (58) b) Newborn of 26-34 yr olds (42) c) Mothers had vegetarian diets (64) d) Mothers had nonvegetarian diets (36) e) Urban area (48) f) Rural area (52) India INDIA; AGE; NEWBORN; BLOOD; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; DDD; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; PESTICIDES; DIETS; PESTICIDE RESIDUES; POPULATION EXPOSURE; RURAL AREAS; URBAN AREAS	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Krishna Murti, C.R. Kutty, D. 1981 Pesticides Monitoring Journal 15(2):77-79
5819 Blood, serum		GC-EC	a) 20 b) 15	43-791 ppb b) 30-120 ppb	a) 409 +or- 196 ppb b) 38 +or- 29 ppb	a) DDT sprayers, 1-32 (mean 14) yr exposure b) Controls 25-52 yr olds, India Abnormal nerve conduction in a few cases INDIA; ADULTS; BLOOD SERUM; DDD; DDE; DDT; HEPTACHLOROCYCLOHEXANE; LINDANE; HEALTH HAZARDS; OCCUPATIONAL HAZARDS; PESTICIDE RESIDUES	Siddiqui, M.K.J. Saxena, M.C. Mishra, U.K. Krishna Murti, C.R. Haq, D. 1981 International Archives of Occupational and Environmental Health 48:301-308
5820 Milk			a) 48 b) 34 c) 19	a) 0.11-11.4 ppm b) 0.33-18.8 ppm c) 0.22-2.58 ppm	a) 3.48 ppm b) 3.48 ppm c) 1.39 ppm	a) 1969-70 b) 1971-72 c) 1973-74 Percentages of metabolite p,p'-DDE increased from 75.6 t 81.6 to 88.5 during sampling periods 1969-70, 1971-72 and 1973-74 respectively. p,p'-DDD and p,p'-DDT declined during the same time periods. Ontario residents, mean age 24-28 yr. INDUSTRIAL CHEMICALS; CANADA; AGE; AUTOPSIES; ADIPOSE TISSUE; MILK; CHLORINE ORGANIC COMPOUNDS; CHLOROBENZENES; DDT; DIELDRIN; HEXACHLOROBENZENE; PESTICIDES; POLYCHLORINATED BIPHENYLS; PESTICIDE RESIDUES; POPULATION EXPOSURE	Holdrinet, M.V.H. Braun, H.E. Frank, R. Stopps, G.J. Smout, M.S. McWade, J.W. 1977 Canadian Journal of Public Health 68:74-80

(NEXT PAGE)

DDT, Total (No postings in CHEMLINE).
50-29-3
C14-H9-Cl5
MW 354.50

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5421 Milk		GC-EC	154	a) 0.01-6.81 mg/kg fat b) Not given c) Not given	a) 1.087 +or- 0.880 mg/kg fat b) 0.72 +or- 0.43 mg/kg fat c) 1.17 +or- 1.02 mg/kg fat	a) 154 samples, 0.039 +or- 0.031 mg/kg whole milk b) Rural residents, 19 samples c) Urban residents, 51 samples 3-6 days postpartum. 30% exceeded Codex Alimentarius Commission limits. levels increased with urban residence and smoking 18-38 yr olds, Canada ALDRIN; CANADA; AGE; MILK; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; POLYCHLORINATED BIPHENYLS; POPULATION EXPOSURE; RURAL AREAS; SMOKING; URBAN AREAS	Dillon, J.C. Martin, G.B. O'Brien, H.T. 1981 Food and Cosmetics Toxicology 19:437-442
5422 Milk, whole		GC TLC	25	0.0211-0.3039 ppm	0.1272 +or- 0.0198 ppm S.E.	24 hr after parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDT; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NEWBORN	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, D. 1981 Environmental Research 24:24-32

Diethylamine, N-nitroso- (8 CI)
Ethanamine, N-ethyl-N-nitroso- (9 CI)
55-18-5
C4-H10-N2-O
MW 102.14, BP 175-177 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5423 Blood	Ingestion	GC HPLC	1	a) Not given b) Not given c) Not given d) Not given	a) 0.51 ug/total body blood b) 0.57 ug/total body blood c) 2.6 ug/total body blood d) 0 ug/total body blood Assuming total body blood at 5640 ml	a) 50 min before meal b) 35 min after meal c) 65 min later d) Next day (1300 min after meal) Test meal of spinach, cooked bacon, tomatoes, bread, and beer Discusses extensively exposure from foods, tobacco smoke, herbicides, drinking water, industrial pollution. BLOOD; NITROSAMINES; AIR POLLUTION; CARCINOGEN; DRINKING WATER; FOOD PRESERVATIVES; FOODS; INDUSTRIAL ACCIDENTS; INDUSTRIAL EMISSIONS; MEATS; PESTICIDE RESIDUES; POPULATION EXPOSURE; SMOKING; TOBACCOS; WATER POLLUTION	Fine, D.H. Rounbehler, D.P. Fan, T. Ross, R. 1977 Cold Springs Harbor Conference on Cell Proliferation, 1977. Origins of Human Cancer, Book A, pp. 293-307

Dimethylamine, N-nitroso- (8 CI)
Methanamine, N-methyl-N-nitroso- (9 CI)
62-75-9
C2-H6-N2-O
MW 74.1, MP 152 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5026 Blood	Ingestion	GC HPLC	1	a) Not given b) Not given c) Not given d) Not given	a) 2.0 ug/total body blood b) 4.4 ug/total body blood c) 0.86 ug/total body blood d) 0.76 ug/total body blood Assuming total body blood of 5640 ml	a) 50 min before meal b) 35 min after meal c) 65 min later d) Next day (1300 min after the meal) After 1.6 ug, preformed, in meal of spinach, cooked bacon, tomatoes, bread and beer Data also for levels in 6 herbicides Discusses extensively exposure from foods, tobacco smoke, drinking water, industrial pollution. FICOD; NITROSAMINES; AIR POLLUTION; CARCINOGEN; DRINKING WATER; FOOD PRESERVATIVES; FOODS; INDUSTRIAL ACCIDENTS; INDUSTRIAL EMISSIONS; MEATS; PESTICIDE RESIDUES; POPULATION EXPOSURE; SMOKING; TOBACCOS; WATER POLLUTION	Fine, D.H. Rounbehler, D.P. Fan, T. Ross, R. 1977 Cold Spriags Harbor Conference on Cell Proliferation, 1977. Origins of Human Cancer, Book A, pp. 293-307

Dipyrido(1,2-a:2',1'-c)pyrazinediium, 6,7-dihydro-
2764-72-9
C12-H12-N2
MW 184.26

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5025 Blood, serum	Ingestion	Colorimetry	1	1.038-0.196 ppm	Not applicable	8 and 27 hr after admission to hospital. Hemodialysis at 4-10 and 22-27 hr. Initial measurement 0.75 ppm. Dose unknown. 43 yr old, wt 56 kg Shock, soporous, anuric, and with hemorrhagic mucosal necroses in mouth, throat, esophagus. Protracted cardiac collapse and death. SUICIDE; BLOOD SERUM; HERBICIDES	Okonek, S. Hofmann, A. 1975 Archives of Toxicology 33:251-257

Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI)
Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)
72-54-8
C14-H10-Cl4
MW 350.46, MP 221-222 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5026 Adipose		GC-EC	a) 12 b) 28	a) 0-0.269 ppm b) 0-0.325 ppm	a) 0.085 ppm b) 0.096 ppm	a) Rural b) Urban Autopsies, Spain SPAIN; AUTOPSIES; ADIPOSE TISSUE; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; DDD; LINDANE; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; ORGANOPHOSPHATES; PESTICIDES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Herrera Marteache, A. Polo Villar, L.M. Jodral Villarejo, M. Polo Villar, G. Mallol, J. Pozo Lora, E. 1978 Revista de Sanidad e Higiene Publica 52, 20 pp.

(NEXT PAGE)

Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI)
Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)
72-54-8
C14-H10-Cl4
MW 350.46, MP 221-222 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5027 Blood		GC TLC	a) 25 b) 25	a) 0.0010-0.0091 ppm b) 0.0009-0.0055 ppm	a) 0.0031 +or- 0.0004 ppm b) 0.0024 +or- nil ppm S.E.	a) Mothers, 24 hr after parturition b) Fetal (cord) blood, parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDE; DDT; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NEWBORN	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, D. 1981 Environmental Research 24:24-32
5028 Blood, fetal		GC-EC	100	a) Not detected-48.21 ppb b) Not detected-48.21 ppb c) Not detected-48.21 ppb d) 0.89-32.09 ppb e) Not detected-48.21 ppb f) Not detected-32.09 ppb	a) 5.84 +or- 1.25 ppb b) 8.01 +or- 2.85 ppb c) 6.55 +or- 1.85 ppb d) 8.49 +or- 1.80 ppb e) 7.33 +or- 3.68 ppb f) 6.25 +or- 1.43 ppb SE	a) Newborn of 18-25 yr olds (58) b) Newborn of 26-38 yr olds (42) c) Mothers had vegetarian diets (64) d) Mothers had nonvegetarian diets (36) e) Urban area (48) f) Rural area (52) India INDIA; AGE; NEWBORN; BLOOD; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; DDD; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; PESTICIDES; DIETS; PESTICIDE RESIDUES; POPULATION EXPOSURE; RURAL AREAS; URBAN AREAS	Siddiqui, M.K.J. Saxena, M.C. Bhargava A.K. Krishna Murti, C.R. Kutty, D. 1981 Pesticides Monitoring Journal 15(2):77-79
5029 Blood, serum		GC-EC	a) 20 b) 15	a) Not detected-99 ppb b) Not detected-99 ppb	a) 32 +or- 28 ppb b) 21 +or- 15 ppb	a) DDT sprayers, 1-32 (mean 14) yr exposure b) Controls 25-52 yr olds, India INDIA; ADULTS; BLOOD SERUM; DDE; DDE; DDT; HEPTACHLOROCYCLOHEXANE; LINDANE; HEALTH HAZARDS; OCCUPATIONAL HAZARDS; PESTICIDE RESIDUES	Siddiqui, M.K.J. Saxena, M.C. Mishra, U.K. Krishna Murti, C.R. Nag, D. 1981 International Archives of Occupational and Environmental Health 48:301-308
5030 Milk, whole		GC TLC	25	0.0027-0.0370 ppm	0.0129 +or- 0.0018 ppm S.E.	24 hr after parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDE; DDT; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NEWBORN	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, D. 1981 Environmental Research 24:24-32

Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI)
Benzene, 1,1'-(2,2,2-trichloroethylidene) bis(4-chloro- (9 CI)
50-29-3
C14-H9-Cl5
MW 354.50, MP 108.5-109 C, BP 260 C, VP 1.5E10(E-7) mm Hg at 20 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5831 Adipose		GC	11	Not given	0.34 ppm	Autopsies, 1975 Northern Ireland SEWAGE; IRELAND; UNITED KINGDOM; ADIPOSE TISSUE; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEXACHLOROBENZENE; URBAN AREAS; WATER POLLUTION; ADULTS; AUTOPSIES; PESTICIDE RESIDUES	Harper, D.B. Smith, R.V. Gotto, D.B. 1977 Environmental Pollution 12(3):223-233
5832 Adipose		GC-EC	a) 12 b) 20	a) 0.256-4.041 ppm b) 0-4.933 ppm	a) 1.662 ppm b) 1.832 ppm	a) Rural b) Urban Autopsies, Spain SPAIN; AUTOPSIES; ADIPOSE TISSUE; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; DDD; LINDANE; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; ORGANOPHOSPHATES; PESTICIDES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Herrera Marteache, A. Polo Villar, L.M. Jodral Villarejo, M. Polo Villar, G. Mallol, J. Poro Lora, M. 1978 Revista de Sanidad e Higiene Publica 52, 20 pp.
5833 Blood		GC TLC	a) 25 b) 25	a) 0.0020-0.0162 ppm b) 0.0052-0.0100 ppm	a) 0.0059 +or- 0.0007 ppm b) 0.0073 +or-nil ppm S.E.	a) Mothers, 24 hr after parturition b) Fetal (cord) blood, parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDT; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NEWBORN	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, D. 1981 Environmental Research 24:24-32
5834 Blood, fetal		GC-EC	100	a) 1.43-49.21 ppb b) Not detected-57.52 ppb c) Not detected-55.56 ppb d) 1.78-140.00 ppb e) 0.5-50.23 ppb f) Not detected-140.00 ppb	a) 7.30 +or- 2.32 ppb b) 22.13 +or- 2.37 ppb c) 14.89 +or- 3.05 ppb d) 17.08 +or- 3.55 ppb e) 13.71 +or- 2.19 ppb f) 17.08 +or- 4.83 ppb	a) Newborn of 18-25 yr olds (58) b) Newborn of 26-38 yr olds (42) c) Mothers had vegetarian diets (64) d) Mothers had nonvegetarian diets (36) e) Urban area (48) f) Rural area (52) e) and b) significantly different India INDIA; AGE; NEWBORN; BLOOD; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; DDD; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; PESTICIDES; DIETS; PESTICIDE RESIDUES; POPULATION EXPOSURE; RURAL AREAS; URBAN AREAS	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Krishna Murti, C.R. Kutty, D. 1981 Pesticides Monitoring Journal 15(2):77-79
5835 Blood, serum		GC-EC	a) 20 b) 15	a) 9-548 ppb b) Not detected-81 ppb	a) 203 +or- 94 ppb b) 32 +or- 24 ppb	a) DDT sprayers, 1-32 (mean 14) yr exposure b) Controls 25-52 yr olds, India INDIA; ADULTS; BLOOD SERUM; DDD; DDE; DDT; HEPTACHLOROCYCLOHEXANE; LINDANE; HEALTH HAZARDS; OCCUPATIONAL HAZARDS; PESTICIDE RESIDUES	Siddiqui, M.K.J. Saxena, M.C. Mishra, U.K. Krishna Murti, C.R. Haq, D. 1981 International Archives of Occupational and Environmental Health 48:301-308

(NEXT PAGE)

Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI)
Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)
50-29-3
C14-H9-Cl5
MW 354.50, MP 108.5-109 C, BP 260 C, VP 1.5E10(E-7) mm Hg at 20 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5436 Milk		GC-EC	154	a) 0-2.51 ng/kg fat b) Not given c) Not given	a) 0.204 +or- 0.262 ng/kg fat b) 0.14 +or- 0.11 ng/kg fat c) 0.18 +or- 0.12 ng/kg fat	a) 154 samples, 0.007 +or- 0.009 ng/kg whole milk b) Rural, residents 19 samples c) Urban, residents 51 samples 3-6 days postpartum 18-38 yr olds, Canada ALDRIN; CANADA; AGE; MILK; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; POLYCHLORINATED BIPHENYLS; POPULATION EXPOSURE; RURAL AREAS; SMOKING; URBAN AREAS	Dillon, J.C. Martin, G.R. O'Brien, M.Y. 1981 Food and Cosmetics Toxicology 19:437-442
5437 Milk		GC	50	32-520 ppb	160 ppb	Extracted lipids, Jan 1979 to Feb 1980, 3-46 days postpartum. No significant correlation with residence, age, weight, number of children previously nursed, household use of non-persistent pesticides, or occupation of spouse. Higher, but nonsignificant levels in women with higher frequency of meat consumption, and in those in homes with pest control treatment. Healthy 18-37 yr old Hawaiians ADULTS; AGE; HAWAII; MILK; CHLORINATED HYDROCARBONS; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; HEXACHLOROBENZENE; LINDANE; MIREX; OXYCHLORDANE; PESTICIDES; POLYCHLORINATED BIPHENYLS; DIETS; LACTATION; PESTICIDE RESIDUES; POPULATION EXPOSURE	Takahashi, M. Saidin, D. Takei, G. Wong, L. 1981 Bulletin of Environmental Contamination and Toxicology 27:506-511
5438 Milk, whole		GC TLC	25	0.0072-0.1134 ppm	0.0441 +or- 0.0091 ppm S.E.	24 hr after parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDE; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NURSES	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, D. 1981 Environmental Research 24:28-32

Ethane, 1,2-dichloro-
107-06-2
C2-H4-Cl2
MW 98.96, MP -35.36 C, BP 83.5 C, VP 100 mm Hg at 29.4 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5439 Urine			20	Not applicable	<0.1 ug/l	Tap water samples <0.1 ug/l Healthy 20-30 yr olds ADULTS; URINE; MEASUREMENT METHODS; BROMINATED HYDROCARBONS; CHLORINATED HYDROCARBONS; DRINKING WATER	Tosamafi, N. Faust, S.D. Zenchelsky, S.T. 1978 Clinical Chemistry 24(7):1109-1111

Ethylene glycol, dinitrate (8 CI)
1,2-Ethanediol, dinitrate (9 CI)
628-96-6
C2-H4-N2-O6
MW 152.07, MP -20 C, BP 114 C (explodes)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5440 Blood, whole	Dermal	GC-EC	2	a) 1.5-2040.5 ng/ml b) <1-26 ng/ml c) 3.65-46.5 ng/ml d) 151-526 ng/ml e) 62-281 ng/ml f) 13-157 ng/ml	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given	a) 15 and 120 min of hand-exposure through rubber gloves smeared with 1.5 g dynamite, 1 subject b) 30 and 90 min of bare-hand exposure to 3.1 and 2.3 mg/cu m (vapor from 0.1 g dynamite). Same subject as a) c) 30 and 90 min of hand-exposure through cotton-lined rubber gloves to 4.1 and 3.7 mg/cu m (vapor from 0.1 g dynamite. Same subject as a) d) Bare hands e) Cotton gloved f) Rubber plus cotton gloved d)-f) 30 and 90 min grasping a glass tube smeared with 0.1 g dynamite. Blood from arm of exposed hand, 1 subject Volunteers Severe headache, nausea, dizziness and drop in blood pressure at blood levels of 331-2184 ng/ml. INDUSTRIAL HYGIENE; OCCUPATIONAL HAZARDS; BLOOD; BLOOD PRESSURE; SWEDEN	Hogstedt, C. Stahl, B. 1980 American Industrial Hygiene Association Journal 41(5):367-372

Ethylene, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8 CI)
Pentane, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)- (9 CI)
3428-82-6
C14-H8-Cl4
MW 318.03

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5461 Adipose		GC-EC	a) 12 b) 20	a) 0-0.026 ppm b) 0-0.020 ppm	a) 0.007 ppm b) 0.007 ppm	a) Rural b) Urban Autopsies, Spain SPAIN; AUTOPSIES; ADIPOSE TISSUE; CHLORINE ORGANIC COMPOUNDS; DDT; DDE; DDT; HEXACHLOROCICLOHEXANE; HEPTACHLOR EPOXIDE; LINDANE; ORGANOPHOSPHATES; PESTICIDES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Herrera Marteache, A. Polo Villar, L.M. Jodral Villarejo, M. Polo Villar, G. Mallol, J. Poza Lora, M. 1978 Revista de Sanidad e Higiene Publica 52, 20 pp.

Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI)
Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro- (9 CI)
72-55-9
C14-H8-Cl4
MW 318.02, MP 88.6 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5462 Adipose		GC	11	Not given	1.60 ppm	Autopsies, 1975 Northern Ireland SPRAGE; IRELAND; UNITED KINGDOM; ADIPOSE TISSUE; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEXACHLOROBENZENE; URBAN AREAS; WATER POLLUTION; ADULTS; AUTOPSIES; PESTICIDE RESIDUES	Harper, N.R. Smith, R.V. Cotte, G.E. 1977 Environmental Pollution 12(3):223-233
5463 Adipose		GC-EC	a) 12 b) 28	a) 1.058-4.658 ppm b) 0.807-6.534 ppm	a) 2.458 ppm b) 2.758 ppm	a) Rural b) Urban Autopsies, Spain SPAIN; AUTOPSIES; ADIPOSE TISSUE; CHLORINE ORGANIC COMPOUNDS; DEP; DDT; DDD; LINDANE; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; ORGANOPHOSPHATES; PESTICIDES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Herrera Hartencho, A. Polo Villar, L.E. Jodral Villarejo, M. Polo Villar, G. Vallol, J. Poro Lora, M. 1978 Revista de Sanidad e Higiene Publica 52, 20 pp.
5464 Adipose		GC	a) 11 b) 16 c) 22 d) 22 e) 71	a) Not given b) Not given c) Not given d) Not given e) Not given	a) 5.668 ppm b) 5.026 ppm c) 2.860 ppm d) 2.138 ppm e) 3.55 ppm Extracted lipids	a) 25->75 yr old men with cancer b) 0->75 yr old women with cancer c) 0->75 yr old men, other illnesses d) 0->75 yr old women, other illnesses e) Mean of a)-d) Significant age correlation in noncancer group Higher levels in terminal cancer patients Data also for other age groups and by cancer type. Autopsies, Denmark, 1970-74 DENMARK; AUTOPSIES; CARCINOMAS; ADIPOSE TISSUE; BIOACCUMULATION; PESTICIDE RESIDUES; DDE; POLYCHLORINATED BIPHENYLS	Unger, M. Olsen, J. 1980 Environmental Research 23:257-263
5465 Blood		GC TLC	a) 25 b) 25	a) 0.0029-0.0316 ppm b) 0.0018-0.0144 ppm	a) 0.0092 +or- 0.0012 ppm b) 0.0048 +or- 0.0004 ppm S.E.	a) Mothers, 24 hr after parturition b) Fetal (cord) blood, parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDT; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NEWBORN	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, D. 1981 Environmental Research 24:24-32
5466 Blood, fetal		GC-EC	100	a) 2.16-184.37 ppb b) 2.05-78.14 ppb c) 1.8-850.00 ppb d) 1.9-150.00 ppb e) 1.02-257.50 ppb f) 2.2-144.37 ppb	a) 12.33 +or- 1.98 ppb b) 23.10 +or- 4.75 ppb c) 35.33 +or- 23.26 ppb d) 20.53 +or- 6.39 ppb e) 22.81 +or- 7.05 ppb f) 15.48 +or- 6.38 ppb	a) Newborn of 18-25 yr olds (50) b) Newborn of 26-30 yr olds (42) c) Mothers had vegetarian diets (64) d) Mothers had nonvegetarian diet (36) e) Urban area (48) f) Rural area (52) India INDIA; AGE; NEWBORN; BLOOD; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; DDD; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; PESTICIDES; DIETS; PESTICIDE RESIDUES; POPULATION EXPOSURE; RURAL AREAS; URBAN AREAS	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Krishna Murti, C.R. Kutty, D. 1981 Pesticides Monitoring Journal 15(2):77-79

(NEXT PAGE)

Ethyle..., 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI)
Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro- (9 CI)
72-55-9
C14-H8-Cl4
HH 318.02, HP 88.4 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	MEANS	MEAN	GENERAL INFORMATION	REFERENCE
5447 Blood, serum			a) 283 b) 40 c) 153 d) 28 e) 20 f) 55 g) 46	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given g) Not given	a) 12.9 +or- 13.3 ppb b) 16.1 +or- 11.9 ppb c) 13.0 +or- 9.8 ppb d) 9.9 +or- 7.1 ppb e) 8.5 +or- 8.9 ppb f) 21.4 +or- 18.1 ppb g) 11.4 +or- 7.4 ppb	a) Residents, quarantined farms b) Consumers, products from quarantined farms c) Residents, nonquarantined farms d) Consumers, products from nonquarantined farms e) Farm resident < 1 yr, or infants < 1 yr old f) Employees, manufacturing PBBs g) Controls, unexposed farm residents Farm feed accidentally contaminated with 2,000 lb PBBs Levels related to age rather than exposure. Residents of MI (exposed) and of WI (controls) MICHIGAN; WISCONSIN; ADULTS; INFANTS; NEUROLOGIC MANIFESTATIONS; SKIN DISEASES; BLOOD STUDY; DDE; POLYBROMINATED BIPHENYLS; FARMS; FOOD CONTAMINATION; HEALTH HAZARDS; INDUSTRIAL PLANTS; METABOLITES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Selikoff, I.J. 1976 Interim Summary Report to the National Institute of Environmental Health Sciences. ES 00920. PBA 804568, 46 pp.
5448 Blood, serum		GC-EC	a) 20 b) 15	a) 20-320 ppb b) 0-60 ppb	a) 152 +or- 86 ppb b) 19 +or- 12 ppb	a) DDT sprayers, 1-32 (mean 18) yr exposure b) Controls 25-52 yr olds, India INDIA; ADULTS; BLOOD SERUM; DDD; DDE; DDT; HEPTACHLOROCYCLOHEXANE; LINDANE; HEALTH HAZARDS; OCCUPATIONAL HAZARDS; PESTICIDE RESIDUES	Siddiqui, S.K.J. Saxena, H.C. Mishra, S.K. Krishna Murti, C.R. Haq, B. 1981 International Archives of Occupational and Environmental Health 48:301-308
5449 Milk		GC-EC	154	a) 0.01-6.79 mg/kg fat b) Not given c) Not given	a) 0.883 +or- 0.773 mg/kg fat b) 0.58 +or- 0.35 mg/kg fat c) 0.99 +or- 0.99 mg/kg fat	a) 154 samples, 0.032 +or- 0.028 mg/kg whole milk b) Rural residents, 19 samples c) Urban residents, 51 samples 3-6 days postpartum. Higher levels with smoking and urban residence 18-38 yr olds, Canada ALBERTA; CANADA; AGE; MILK; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; POLYCHLORINATED BIPHENYLS; POPULATION EXPOSURE; RURAL AREAS; SMOKING; URBAN AREAS	Dillon, J.C. Martin, G.R. O'Brien, R.T. 1981 Food and Cosmetics Toxicology 19:437-442

(NEXT PAGE)

Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl) - (8 CI)
Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro- (9 CI)
72-55-9
C14-H8-Cl4
MW 318.02, MP 88.6 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5450 Milk		GC	50	260-5700 ppb	2000 ppb	Extracted lipids, Jan 1979 to Feb 1980, 3-46 days postpartum. No significant correlation with residence, age, weight, number of children previously nursed, household use of non-persistent pesticides, or occupation of spouse. Higher, but nonsignificant levels in women with higher frequency of meat consumption, and in those in homes with pest control treatment. Healthy 18-37 yr old Hawaiians ADULTS; AGE; HAWAII; *TLV*; CHLORINATED HYDROCARBONS; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; HEXACHLOROBENZENE; LINDANE; MCHACHLOR; OXYCHLORDANE; PESTICIDES; POLYCHLORINATED BIPHENYLS; DIETS; LACTATION; PESTICIDE RESIDUES; POPULATION EXPOSURE	Takahashi, M. Saldin, D. Takei, G. Wong, L. 1981 Bulletin of Environmental Contamination and Toxicology 27:506-511
5451 Milk, whole		GC TLC	25	0.0095-0.1500 ppm	0.0717 +or- 0.0114 ppm S.E.	24 hr after parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDE; DDT; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; HUMANS	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Katty, D. 1981 Environmental Research 24:24-32

Fluoride
16984-48-8
F
Atm 18.9984

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5452 Tooth		UR	40	a) 1450-800 ppm b) 1000-400 ppm c) 800-675 ppm d) 400-450 ppm e) 700-350 ppm f) 500-250 ppm g) 600-250 ppm h) 400-150 ppm	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given g) Not given h) Not given	a) Dentin, 5% NaF2, fine cut analgam b) Enamel, 5% NaF2, fine cut analgam c) Dentin, 1% NaF2, fine cut analgam d) Enamel, 1% NaF2, fine cut analgam e) Dentin, 5% NaF2, regular analgam f) Enamel, 5% NaF2, regular analgam g) Dentin, 1% NaF2, regular analgam h) Enamel, 1% NaF2, regular analgam Maximum levels (after 15-30 days) adjacent to fillings Levels decreased with distance from filling Control values < 150 ppm Estimated from graph. 11-21 yr olds TEETH; DENTISTRY; FLUORIDE	Bougenidis, D.J. Athanassouli, T.N.E. Papastathopoulos, D.E. 1981 Journal of Dental Research 60(2):105-108

(NEXT PAGE)

Fluoride
16984-48-8
F
AtW 18.9984

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5453 Teeth			a) 101 b) 150	a) Not given b) Not given	a) 2360 ppm b) 2120 ppm	a) Children with high enamel Pb (2770 +or- 1,120 ppm) b) Children with low enamel Pb (1070 +or- 550 ppm) Biopsy of surface enamel Group a) had highest caries score. 9-12 yr olds, Cambridge, MA MASSACHUSETTS; ADULTS; CHILDREN; DENTAL CARIES; LEAD POISONING; BLOOD; SALIVA; TEETH; FLUORIDE; LEAD; BIOACCUMULATION; METALS	Brudevold, F. Aasenden, R. Srinivasian, B.N. Bakhos, Y. 1977 Journal of Dental Research 56(10):1165-1171
5454 Urine	Ingestion		a) 10 b) 10 c) 3 d) 5	a) Not given b) Not given c) Not given d) Not given	a) 2.5 mg/day b) 7.5 mg/day c) 14.0 mg/day d) 21.0 mg/day	a) 4.0 mg/day b) 14.0 mg/day c) 25.0 mg/day d) 44.0 mg/day Doses as Na salt. Mean of 4.36 mg/day from diet and drinking water. Fluoride balance increased from +1.2 in a) to +18.5 in d) 44-77 yr old patients with osteoporosis BONE DISEASES; URINE; DRUG THERAPY; FLUORIDE; DRUGS	Spencer, H. Osis, D. Wistrowski, E. 1975 Clinical Chemistry 21(4):613-618

Fluorine
7782-41-4
F
AtW 18.9984, MP -219.61 C, BP -188.13 C, VP 100 mm Hg at -203 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5455 Teeth		MS	208	a) Not given b) Not given c) Not given d) Not given	a) 73.9 +or- 5.95 ppm b) 126.7 +or- 8.63 ppm c) 82.1 +or- 7.99 ppm d) 125.7 +or- 11.23 ppm S.E.	a) High caries area, New England, 107 teeth b) Low caries area, South Carolina, 99 teeth c) High caries donors (>7 decayed, missing, filled teeth (DMFT)), from a) and b), 53 teeth d) Low caries donors (<4 DMFT) from a) and b), 75 teeth Values for enamel a) and b) differed, P<0.0001 c) and d) differed, P<0.005 Premolars extracted, patients <20 yr old ZIRCONIUM; NEW HAMPSHIRE; SOUTH CAROLINA; VERMONT; DENTAL CARIES; TEETH; ALUMINUM; BARIUM; COPPER; FLUORINE; LITHIUM; METALS; SILVER; STRONTIUM; TIN	Curzon, M.E.J. Losee, F.L. 1977 Journal of the American Dental Association 94(6):1146-1150

Gold
7440-57-5
Au
Atw 196.9665, MP 1064.76 C, BP 2700 C, VP 1 mm Hg at 1869 C, 10 mm Hg at 2160 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5856 Hair		NA	71	a) 4X10(E-3)-6X10(E-3) ug/g b) 2.5X10(E-3)-8X10(E-3) ug/g c) Not given d) Not given e) Not given f) Not given	a) Not given b) Not given c) 4.7X10(E-3) ug/g d) 5.9X10 (E-3) ug/g e) 3.9X10(E-3) ug/g f) 5.2X10(E-3) ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278

Iodine
7553-56-2
I
Atw 126.9045, MP 113.60 C, BP 185.24 C, VP (solid) 0.03 mm Hg at 0 C, 0.305 mm Hg at 25 C, 2.154 mm Hg at 50 C, 26.78 mm Hg at 90 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5857 Hair		NA	71	a) 0.28-3 ug/g b) 0.2-4.5 ug/g c) Not given d) Not given e) Not given f) Not given	a) Not given b) Not given c) 0.44 ug/g d) 1.1 ug/g e) 0.8 ug/g f) 0.6 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5858 Thyroid gland	Ingestion	Radiometry	a) 31 b) 49 c) 10 d) 10 e) 5 f) 44 g) 9	a) 16-88% b) 11-84% c) 12-71% d) 5-42% e) Not given f) Not given g) Not given	a) 51.1 +or- 18% b) 43.8 +or- 13% c) 37.3 +or- 18% d) 21.1 +or- 10% e) 32.8% f) 12.1 +or- 6.1% g) 9.7 +or- 4%	a) Patients with Graves disease, diagnosed 1970-72 b) Patients with Graves disease, diagnosed 1975-76 c) Patients with toxic nodular goiter, diagnosed 1970-72 d) Patients with toxic nodular goiter, diagnosed 1975-76 e) Patients with toxic uninodular goiter, diagnosed 1975-76 f) Euthyroid patients, 1969 g) Euthyroid patients, 1974 24 hr after 10-50 uCi of labelled Na iodide Uptake of radioactive iodine is demonstrated as being a poor test for hyperthyroidism Range and SD estimated from graph 16-78 yr old patients IODINE; DIETS; FOOD ADDITIVES; RADIOISOTOPES; THYROID GLANDS; URINE; WISCONSIN; ADULTS; DISEASES	Hooper, P.L. Caplan, R.M. 1977 Journal of the American Medical Association 238(5):411-413

(NEXT PAGE)

Iodine
7553-56-2
I
AtW 126.9045, MP 113.60 C, BP 185.24 C, VP (solid) 0.03 mm Hg at 0 C, 0.305 mm Hg at 25 C, 2.154 mm Hg at 50 C, 26.78 mm Hg at 90 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5059 Urine	Ingestion	Radiometry	a) 48 b) 15	a) Not given b) 205-1124 ug/24 hr	a) 351 +or- 290 ug/24 hr b) 571 +or- 283 ug/24 hr	b) 1969 b) 1974 Euthyroid subjects, after 10-50 uCi labelled Na iodide ICCINE; DIETS; FOOD ADDITIVES; RADIOISOTOPES; THYROID GLANDS; URINE; WISCONSIN; ADULTS; DISEASES	Hooper, F.L. Caplan, E.H. 1977 Journal of the American Medical Association 238(5):411-413

Iron
7439-89-6
Fe
AtW 55.847, MP 1535 C (pure), 1000-1300 C (cast), 1500 C (wrought), 1300 C (steel), BP 3000 C, VP 1 mm Hg at 1787 C, 10 mm Hg at 2080 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5460 Blood						Review. Research leading to present understanding of human requirements. BIOACCUMULATION; DIETS; FOOD ADDITIVES; FOODS; LACTATION; MENSTRUATION; PREGNANCY; RADIOISOTOPES; RATS; PIGS; IRON; METALS; BLOOD; BODY; HAIR; LIVER; MILK; RATS; SKIN; SPLEEN; URINE; REVIEW; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; ANEMIA	Bowering, J. Sanchez, A.M. Irwin, M.I. 1976 Journal of Nutrition 106(7):985-1078
5461 Blood	Ingestion	Radiometry	70	a) 3.8-14.8% of dose b) 3.9-12.2% of dose c) 1.6-3.9% of dose d) 0.7-2.0% of dose e) 0.7-2.4% of dose f) 3.4-5.4% of dose	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given	a) Standard meal, beef, total Fe 8.1 mg b) Standard meal, pork, lamb, liver, chicken or fish substituted for beef c) Standard meal, milk, cheese, eggs or egg albumin substituted for beef d) Semisynthetic meal, ovalbumin, total Fe 8.1 mg e) Semisynthetic meal, milk, cheese or eggs substituted for ovalbumin f) Semisynthetic meal, pork, lamb, liver, chicken, fish or beef substituted for ovalbumin Fe content 0.3-7.7 mg Range of means % of dose calculated from radioactive Fe label 18-37 yr olds ADULTS; BLOOD; IRON; METALS; DIETS; FOODS; MEATS	Cook, J.D. Monsen, E.R. 1976a American Journal of Clinical Nutrition 29:859-867
5462 Blood	Ingestion	Radiometry	116	a) 4.9-11.9% of dose b) 2.3-4.3% of dose c) 5.9-6.7% of dose d) 35.0-42.8% of dose	a) Not given b) Not given c) Not given d) Not given	a) Hamburger meal b) Rice-vegetable-fruit meal c) Composite meal d) Reference dose (3 mg Fe) Healthy 19-60 yr olds IRON; METALS; TRACE ELEMENTS; DIETS	Bjorn-Rasmussen, E. Hallberg, L. Magnusson, B. Rossander, L. Svanberg, B. Arvidsson, B. 1976 American Journal of Clinical Nutrition 29:772-778

(NEXT PAGE)

Iron
7439-89-6
Fe
AtW 55.847, BP 1535 C (pure), 1000-1300 C (cast), 1500 C (wrought), 1300 C (steel), BP 3000 C, VP 1 mm Hg at 1787 C, 10 mm Hg at 2040 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5863 Blood	Ingestion	Radiometry	82	a) 1.17-2.54% of dose b) 1.49-2.35% of dose c) 5.23-17.41% of dose d) 1.38-4.55% of dose e) 8.79-24.69% of dose f) 8.92-36.80% of dose g) 6.89-50.46% of dose Geometric	a) Not given b) Not given c) Not given d) Not given e) Not given f) 7.98% of dose g) 23.01% of dose Geometric	a) Central Venezuela diet b) Andes region diet c) Coastal region diet d) Maize alone 100 g Maize plus 150 g papaya f) Maize plus 70 mg ascorbic acid g) Maize plus papaya plus 100 g fish Non-heme Fe absorption Range of means (a-e) Rural residents of Venezuela VENEZUELA; ADULTS; BLOOD; IRON; METALS; DIETS; FOODS; TRACE ELEMENTS	Layrisse, M. Martinez Torres, C. Gonzalez, M. 1976 American Journal of Clinical Nutrition 27(Feb 74):152-162
5864 Blood		Radiometry	39	a) 0.3-7.8% of dose b) 0.1-10.6% of dose c) 1.3-26.7% of dose d) 0.4-19.8% of dose e) 0.6-10.7% of dose f) 0.2-2.2% of dose g) 0.3-3.7% of dose h) 0.5-11.0% of dose	a) 1.7% of dose b) 0.8% of dose c) 8.8% of dose d) 4.0% of dose e) 2.2% of dose f) 0.6% of dose g) 1.5% of dose h) 1.5% of dose Geometric	a) Synthetic meal, 24 mg Ca, 40 mg P, (21 women) b) Synthetic meal plus 178 mg Ca and 378 mg P, (21 women) c) Semi-synthetic meal, 70 mg Ca, 216 mg P, (11 women) d) Semi-synthetic meal plus 182 mg Ca, 198 mg P, (11 women) e) Synthetic meal as in a), (13 men) f) Synthetic meal plus 178 mg Ca and 378 mg P, (13 men) g) Synthetic meal plus 178 mg Ca, (13 men) h) Synthetic meal plus 378 mg P, (13 men) Fe content, 4.1 mg semi-synthetic meal, 100 g beef substituted for protein and fat in synthetic meal Non-heme absorption significantly reduced ($p < 0.001$) by combined Ca and P Healthy 17-35 yr olds BLOOD; IRON; METALS; DIETS; FOOD ADDITIVES; TRACE ELEMENTS	Monsen, E.R. Cook, J.D. 1976 American Journal of Clinical Nutrition 29:1142-1148
5865 Blood	Ingestion	Radiometry	85	a) 2.1-7.2% of dose b) 3.8-26.0% of dose c) 1.1-5.8% of dose d) 0.3-4.8% of dose e) 2.3-42.5% of dose f) 0.3-1.2% of dose g) 2.3-28.0% of dose h) 3.8-24.4% of dose i) 0.7-13.9% of dose j) 0.9-7.8% of dose k) 0.9-11.0% of dose l) 1.1-10.1% of dose m) 0.6-3.7% of dose n) 0.4-1.7% of dose	a) 4.4% of dose b) 11.6% of dose c) 2.1% of dose d) 1.3% of dose e) 17.6% of dose f) 0.7% of dose g) 5.6% of dose h) 6.1% of dose i) 4.0% of dose j) 1.7% of dose k) 3.2% of dose l) 3.2% of dose m) 1.5% of dose n) 0.7% of dose Geometric	a) Standard meal, no EDTA, 4.1 mg Fe (9 subjects) b) Reference dose, 3 mg Fe as ferrous sulfate (9 subjects) c) Standard meal, plus 50 mg EDTA, 4.2 mg Fe (9 subjects) d) Semisynthetic meal, no EDTA, 4.1 mg Fe (10 subjects) e) Reference dose, 3 mg Fe as ferrous sulfate (10 subjects) f) Semisynthetic meal, plus 50 mg EDTA, 4.2 mg Fe (10 subjects) g) 0 mg EDTA (14 subjects) h) 6 mg EDTA (14 subjects) i) 25 mg EDTA (14 subjects) j) 100 mg EDTA (14 subjects) k) 0 mg EDTA (12 subjects) l) 10 mg EDTA (12 subjects) m) 50 mg EDTA (12 subjects) n) 500 mg EDTA (12 subjects) g)-n) Standard meal, 4.1 mg Fe. Non-heme Fe absorption reduced significantly by EDTA dose of 50 mg or more Healthy 18-33 yr olds CHELATING AGENTS; ADULTS; BLOOD; IRON; METALS; FOOD ADDITIVES; FOOD PRESERVATIVES; FOODS; TRACE ELEMENTS	Cook, J.D. Monsen, E.R. 1976b American Journal of Clinical Nutrition 29:614-620

(NEXT PAGE)

Iron
7439-89-6
Fe
At# 55.847, MP 1535 C (pure), 1000-1300 C (cast), 1500 C (wrought), 1300 C (steel), BP 3000 C, VP 1 mm Hg at 1787 C, 10 mm Hg at 2040 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5466 Blood	Ingestion	Radiometry	160	a) 2.7-5.5% of dose b) 18.8-23.4% of dose c) 3.1-18.6% of dose d) 23.3-55.9% of dose e) 27.8-40.7% of dose	a) Not given b) Not given c) Not given d) Not given e) Not given	a) Standard diet plus sugar (10 g) enriched with ferrous sulfate (5 mg Fe) b) Reference dose, 3 mg Fe, as ascorbate c) Beverages containing sugar enriched with 3 or 5 mg Fe d) Reference dose, 3 mg Fe, as ascorbate e) Beverages with sugar enriched with 3 mg Fe, plus 50 mg ascorbic acid Residents of Venezuela VENEZUELA; BLOOD; IRON; METALS-DIETS; FOODS	Layrisse, M. Martinez-Torres, C. Renzi, M. Velez, F. Gonzalez, M. 1976 American Journal of Clinical Nutrition 29:8-18
5467 Blood	Ingestion	Radiometry	77	a) 1.8-5.3% of dose b) 2.1-27.9% of dose c) 26.2-53.6% of dose d) 0.9-2.5% of dose e) 23.4-36.5% of dose f) 5.4% of dose g) 15.5-17.7% of dose h) 10.8-18.4% of dose Geometric	a) Not given b) 6.2% of dose c) Not given d) Not given e) Not given f) Not given g) Not given h) Not given Geometric	a) Standard meal (0.3 mg Fe), plus 10 g sugar and 5 mg Fe as ferric ammonium citrate, in liquid (20 subjects) b) 5 mg Fe as ferric ammonium citrate (11 subjects) c) 3 mg Fe as iron ascorbate (48 subjects) d) Standard meal (0.3 mg Fe), plus 5 g sugar and 3 mg Fe as ferric chloride or ferrous sulfate in liquid (11 subjects) e) Sugar fortified with 3 mg Fe, as ferric chloride or ferrous sulfate, in Coca Cola (13 subjects) f) Standard meal (0.3 mg Fe), plus sugar (5 g) and 3 mg Fe as Fe(III)-EDTA or ferrous sulfate in liquid (9 subjects) g) Sugar enriched with 3 mg Fe as Fe(III)-EDTA or ferrous sulfate in Coca Cola (9 subjects) h) Sugar enriched with 3 mg Fe, as ferrous sulfate, in soft drinks (24 subjects) Range of means (a and c-h) FOOD; IRON; METALS; FOOD ADDITIVES; FOODS; TRACE ELEMENTS	Layrisse, M. Martinez-Torres, C. Renzi, M. 1976 American Journal of Clinical Nutrition 29:274-279
5468 Blood, serum			a) 40 b) 15 c) 36 d) 60 e) 18 f) 18 g) 45 h) 28	a) 87-165 ug/100 ml b) 60-161 ug/100 ml c) 60-160 ug/100 ml d) 51-154 ug/100 ml e) 70-160 ug/100 ml f) 60-160 ug/100 ml g) 51-154 ug/100 ml h) 50-81 ug/100 ml	a) 134.17 +or- 22.07 ug/100 ml b) 117.24 +or- 32.53 ug/100 ml c) 116.84 +or- 30.88 ug/100 ml d) 95.25 +or- 24.04 ug/100 ml e) 118.00 +or- 30.48 ug/100 ml f) 118.59 +or- 34.55 ug/100 ml g) 92.91 +or- 23.76 ug/100 ml h) 68.64 +or- 8.81 ug/100 ml	a) Controls b) Suspected silicosis c) p,q,r, (2,3) silicosis (round, regular opacities) d) A,B, and C silicosis (large opacities) e) Second silicosis (p,q,r,) f) Third silicosis (p,q,r) g) Silicotuberculosis h) Active lung tuberculosis p,q,r and A,B,C, international pneumoconioses nomenclature Serum Cu increased with increasing severity of silicosis. Serum Zn and Fe lowered. ROMANIA; INDUSTRIAL DISEASES; OCCUPATIONAL DISEASES; BLOOD SERUM; COPPER; IRON; METALS; PROTEINS; ZINC; COAL; DUST; MINING	Niculescu, T. Dumitru, R. Burnea, D. 1981 Environmental Research 25:260-268

(NEXT PAGE)

Iron
7439-89-6
Fe
Atw 55.847, MP 1535 C (pure), 1000-1300 C (cast), 1500 C (wrought), 1300 C (steel), BP 3000 C, VP 1 mm Hg at 1787 C, 10 mm Hg at 2040 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5469 Blood, serum	Injection Ingestion		38	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given g) Not given h) Not given	a) 4.15 +or- 1.34 umol/l b) 3.93 +or- 0.53 umol/l c) 3.40 +or- 0.34 umol/l d) 3.77 +or- 0.50 umol/l e) 20.40 +or- 1.25 umol/l f) 19.33 + or - 2.68 umol/l g) 22.55 +or- 5.72 umol/l h) 20.76 +or- 1.96 umol/l	a) Total dose infusion Fe dextran, 12 patients b) Ferrous sulfate, 200 mg thrice daily, 7 patients c) Ferro-Gradumet, one 525 mg tablet daily, 8 patients d) Ferrograd-C, 1 tablet (525 mg + 500 mg ascorbic acid) daily, 11 patients e) Same as a) f) Same as b) g) Same as c) h) Same as d) Pretreatment (a-d) and after hemoglobin levels had returned to normal (e-h). Data also for serum ferritin. Patients with Fe-deficiency anemia (hypochromic, microcytic) ADULTS; ANEMIA; BLOOD SERUM; DRUG THERAPY; COMPARATIVE EVALUATIONS; IRON; METALS	Bentley, D.P. Jacobs, A. 1975 British Medical Journal 2(5962):64-66
5470 Blood, serum	Ingestion		a) 37 b) 9 c) 18 d) 6	a) Not given b) Not given c) Not given d) Not given	a) 94.1 +or- 5.3 ug/dl b) 92.4 +or- 4.1 ug/dl c) 104.9 +or- 6.9 ug/dl d) 105.5 +or- 8.4 ug/dl S.E.	a) Nursing home residents, unsupplemented diet, intake 8.3 +or- 0.6 mg/day b) Nursing home residents, supplemented diet, intake 55.2 +or- 16.2 mg/day c) Private home residents, unsupplemented diet, intake 9.8 +or- 0.7 mg/day d) Private home residents, supplemented diet, intake 31.1 +or- 10.1 mg/day 62-99 yr olds (mean 80 yr), wt 34.0-101.2 kg (mean 56.2 kg) Total Fe-binding capacity elevated in 80% of subjects ADULTS; AGE; ANEMIA; BLOOD SERUM; IRON; DIETS; TRACE ELEMENTS	Janssen, C. Harrill, I. 1977 American Journal of Clinical Nutrition 30:1419-1422
5471 Body						Review. Research leading to present understanding of human requirements. BIOACCUMULATION; DIETS; FOOD ADDITIVES; FOODS; LACTATION; MENSTRUATION; PREGNANCY; RADIOISOTOPES; RATS; PIGS; IRON; METALS; BLOOD; BODY; HAIR; LIVER; MILK; NAILS; SKIN; SPLEEN; URINE; REVIEW; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; ANEMIA	Bowering, J. Sanchez, A.M. Irwin, M.I. 1976 Journal of Nutrition 106(7):985-1017
5472 Hair		AAS	1	0-132 ppm	Not given	Data for various body regions. Maximum level in leg hair. Estimated from graph 23 yr old, United Kingdom ADULTS; HAIR; COMPARATIVE EVALUATIONS; ALUMINUM; CHROMIUM; COBALT; COPPER; IRON; MANGANESE; METALS; NICKEL; SILICON; SILVER; UNITED KINGDOM	Alder, J.F. Samuel, A.J. West, T.S. 1977 Analytica Chimica Acta 92:217-221

(NEXT PAGE)

Iron
7439-89-6
Fe
Atw 55.847, MP 1535 C (pure), 1000-1300 C (cast), 1500 C (wrought), 1300 C (steel), BP 3000 C, VP 1 mm Hg at 1787 C, 10 mm Hg at 2040 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5873 Liver						Review. Research leading to present understanding of human requirements. BIOACCUMULATION; DIETS; FOOD ADDITIVES; FOODS; LACTATION; MENSTRUATION; PREGNANCY; RADIOISOTOPES; RATS; PIGS; IRON; METALS; BLOOD; BODY; HAIR; LIVER; MILK; NAILS; SKIN; SPLEEN; URINE; REVIEW; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; ANEMIA	Bowering, J. Sanchez, A.M. Irwin, M.I. 1976 Journal of Nutrition 106(7):985-1074
5874 Menstrual fluid						Review. Research leading to present understanding of human requirements. BIOACCUMULATION; DIETS; FOOD ADDITIVES; FOODS; LACTATION; MENSTRUATION; PREGNANCY; RADIOISOTOPES; RATS; PIGS; IRON; METALS; BLOOD; BODY; HAIR; LIVER; MILK; NAILS; SKIN; SPLEEN; URINE; REVIEW; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; ANEMIA	Bowering, J. Sanchez, A.M. Irwin, M.I. 1976 Journal of Nutrition 106(7):985-1074
5875 Milk						Review. Research leading to present understanding of human requirements. BIOACCUMULATION; DIETS; FOOD ADDITIVES; FOODS; LACTATION; MENSTRUATION; PREGNANCY; RADIOISOTOPES; RATS; PIGS; IRON; METALS; BLOOD; BODY; HAIR; LIVER; MILK; NAILS; SKIN; SPLEEN; URINE; REVIEW; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; ANEMIA	Bowering, J. Sanchez, A.M. Irwin, M.I. 1976 Journal of Nutrition 106(7):985-1074
5876 Nail						Review. Research leading to present understanding of human requirements. BIOACCUMULATION; DIETS; FOOD ADDITIVES; FOODS; LACTATION; MENSTRUATION; PREGNANCY; RADIOISOTOPES; RATS; PIGS; IRON; METALS; BLOOD; BODY; HAIR; LIVER; MILK; NAILS; SKIN; SPLEEN; URINE; REVIEW; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; ANEMIA	Bowering, J. Sanchez, A.M. Irwin, M.I. 1976 Journal of Nutrition 106(7):985-1074
5877 Skin						Review. Research leading to present understanding of human requirements. BIOACCUMULATION; DIETS; FOOD ADDITIVES; FOODS; LACTATION; MENSTRUATION; PREGNANCY; RADIOISOTOPES; RATS; PIGS; IRON; METALS; BLOOD; BODY; HAIR; LIVER; MILK; NAILS; SKIN; SPLEEN; URINE; REVIEW; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; ANEMIA	Bowering, J. Sanchez, A.M. Irwin, M.I. 1976 Journal of Nutrition 106(7):985-1074
5878 Spleen						Review. Research leading to present understanding of human requirements. BIOACCUMULATION; DIETS; FOOD ADDITIVES; FOODS; LACTATION; MENSTRUATION; PREGNANCY; RADIOISOTOPES; RATS; PIGS; IRON; METALS; BLOOD; BODY; HAIR; LIVER; MILK; NAILS; SKIN; SPLEEN; URINE; REVIEW; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; ANEMIA	Bowering, J. Sanchez, A.M. Irwin, M.I. 1976 Journal of Nutrition 106(7):985-1074

(NEXT PAGE)

Iron
7439-89-6
Fe
AtW 55.847, MP 1535 C (pure), 1000-1300 C (cast), 1500 C (wrought), 1300 C (steel), BP 3000 C, VP 1 mm Hg at 1787 C, 10 mm Hg at 2040 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5479 Sweat	Ingestion	AAS	13	Not given	0.33 +or- 0.15 mg/day	Surface losses after mean dietary intake of 15.7 mg/day (range 12.1-22.3 mg/day) Healthy 10-14 yr olds in controlled environment 8-9 wo ADULTS; SWEAT; COPPER; IRON	Jacob, R.A. Sandstead, H.H. Munoz, J.M. Klevay, L.M. Milne, D.B. 1981 The American Journal of Clinical Nutrition 34:1379-1383
5480 Sweat						Review. Research leading to present understanding of human requirements. BIOACCUMULATION; DIETS; FOOD ADDITIVES; FOODS; LACTATION; MENSTRUATION; PREGNANCY; RADIOISOTOPES; RATS; PIGS; IRON; METALS; BLOOD; BODY; HAIR; LIVER; MILK; NAILS; SKIN; SPLEEN; URINE; REVIEW; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; ANEMIA	Bowering, J. Sanchez, A.M. Irwin, M.I. 1976 Journal of Nutrition 106(7):985-1074
5481 Teeth		AAS	10	Not given	22.5 +or- 7.2 ppm	Median, 21.5 ppm Stillborn or neonatal deaths, 1972-73, Bristol, United Kingdom UNITED KINGDOM; AUTOPSIES; NEWBORN; TEETH; CADMIUM; IRON; LEAD; MANGANESE; METALS; NICKEL; ZINC	Stack, M.V. Purkitt, A.J. Nickless, G. 1976 Bulletin of Environmental Contamination and Toxicology 16(6):764-766
5482 Urine						Review. Research leading to present understanding of human requirements. BIOACCUMULATION; DIETS; FOOD ADDITIVES; FOODS; LACTATION; MENSTRUATION; PREGNANCY; RADIOISOTOPES; RATS; PIGS; IRON; METALS; BLOOD; BODY; HAIR; LIVER; MILK; NAILS; SKIN; SPLEEN; URINE; REVIEW; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; ANEMIA	Bowering, J. Sanchez, A.M. Irwin, M.I. 1976 Journal of Nutrition 106(7):985-1074

l-Ascorbic acid
50-81-7
C6-H8-O6
MW 176.12, MP 190-192 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5483 Blood						Review. Research leading to present understanding of human requirements. Data on saturation levels in plasma, serum and white blood cells. Levels in body, milk and urine also reported. GUINEA PIGS; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; SEX; ORAL DISEASES; SKIN DISEASES; BLOOD; BODY; FISH; URINE; DRUGS; ORAL CONTRACEPTIVES; REVIEW; VITAMIN C; DIETS; FOODS; LACTATION; MENSTRUATION; METABOLITES; PREGNANCY; RADIOISOTOPES; SMOKING; VITAMINS	Irwin, M.I. Hutchins, B.K. 1976 Journal of Nutrition 106(6):823-879

(NEXT PAGE)

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5484 Body						Review. Research leading to present understanding of human requirements. Data on saturation levels in plasma, serum and white blood cells. Levels in body, milk and urine also reported. GUINEA PIGS; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; SEX; ORAL DISEASES; SKIN DISEASES; BLOOD; BODY; MILK; URINE; DRUGS; ORAL CONTRACEPTIVES; REVIEW; VITAMIN C; DIETS; FOODS; LACTATION; MENSTRUATION; METABOLITES; PREGNANCY; RADIOISOTOPES; SMOKING	Irwin, M.I. Hutchins, B.K. 1976 Journal of Nutrition 106(6):823-879
5485 Milk						Review. Research leading to present understanding of human requirements. Data on saturation levels in plasma, serum and white blood cells. Levels in body, milk and urine also reported. GUINEA PIGS; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; SEX; ORAL DISEASES; SKIN DISEASES; BLOOD; BODY; MILK; URINE; DRUGS; ORAL CONTRACEPTIVES; REVIEW; VITAMIN C; DIETS; FOODS; LACTATION; MENSTRUATION; METABOLITES; PREGNANCY; RADIOISOTOPES; SMOKING	Irwin, M.I. Hutchins, B.K. 1976 Journal of Nutrition 106(6):823-879
5486 Urine						Review. Research leading to present understanding of human requirements. Data on saturation levels in plasma, serum and white blood cells. Levels in body, milk and urine also reported. GUINEA PIGS; ADOLESCENTS; ADULTS; AGE; CHILDREN; INFANTS; SEX; ORAL DISEASES; SKIN DISEASES; BLOOD; BODY; MILK; URINE; DRUGS; ORAL CONTRACEPTIVES; REVIEW; VITAMIN C; DIETS; FOODS; LACTATION; MENSTRUATION; METABOLITES; PREGNANCY; RADIOISOTOPES; SMOKING; VITAMINS	Irwin, M.I. Hutchins, B.K. 1976 Journal of Nutrition 106(6):823-879

Lead
7439-92-1
Pb
Atw 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5487 Adipose		Dithizone AAS	a) 9 b) 6 c) 10 d) 15 e) 8 f) 23 g) 20	a) 0.02-0.34 ppm b) 0.05-0.55 ppm c) 0.01-0.30 ppm d) 0.02-0.74 ppm e) 0.03-0.58 ppm f) 0.01-0.40 ppm g) 0.02-0.16 ppm Wet wt	a) 0.18 +or- 0.12 ppm b) 0.23 +or- 0.20 ppm c) 0.14 +or- 0.09 ppm d) 0.24 +or- 0.19 ppm e) 0.21 +or- 0.26 ppm f) 0.08 +or- 0.08 ppm g) 0.06 +or- 0.04 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5488 Adrenal gland		Dithizone AAS	a) 11 b) 14 c) 14 d) 16 e) 5 f) 58 g) 27	a) 0.02-0.46 ppm b) 0.03-0.82 ppm c) 0.01-1.60 ppm d) 0.09-1.20 ppm e) 0.04-0.27 ppm f) 0.01-0.62 ppm g) 0.05-0.48 ppm Wet wt	a) 0.15 +or- 0.15 ppm b) 0.23 +or- 0.23 ppm c) 0.30 +or- 0.41 ppm d) 0.30 +or- 0.30 ppm e) 0.13 +or- 0.09 ppm f) 0.15 +or- 0.11 ppm g) 0.17 +or- 0.11 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71

(NEXT PAGE)

Lead
7439-92-1
Pb
AtW 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5089 Aorta		Dithizone AAS	a) 11 b) 9 c) 16 d) 17 e) 6 f) 32 g) 42 h) 16 i) 22	a) 0.03-0.87 ppm b) 0.02-1.10 ppm c) 0.05-9.48 ppm d) 0.04-1.10 ppm e) 0.04-9.90 ppm f) 0.21-17.20 ppm g) 0.09-12.70 ppm h) 0.09-4.20 ppm i) 0.07-12.20 ppm Wet wt	a) 0.17 +or- 0.24 ppm b) 0.27 +or- 0.34 ppm c) 0.19 +or- 0.15 ppm d) 0.25 +or- 0.28 ppm e) 1.89 +or- 3.53 ppm f) 2.56 +or- 3.49 ppm g) 1.82 +or- 2.87 ppm h) 1.17 +or- 1.23 ppm i) 1.70 +or- 2.64 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men, atheroma g) Men, non-atheroma h) Women, atheroma i) Women, non-atheroma Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5090 Blood		AAS	95	Not given	161 ug/l Geometric	Environmental Pb values: air 0.28-0.52 ug/cu m, soil 21-1126 mg/kg, deposited dust 457-8097 mg/kg, tapwater <0.5-90.0 ug/l. 1-3 yr olds living within 1000 m of secondary Pb smelter, Arnhem, The Netherlands NETHERLANDS; CHILDREN; BLOOD; LEAD; METALS; ATMOSPHERE; DRINKING WATER; DUST; POPULATION EXPOSURE; SMELTERS; SOILS	Brunekreef, B. Veenstra, S.J. Biersteker, K. Boleij, J.S.M. 1981 Environmental Research 25:441-448
5091 Blood		ASV	a) 85 b) 79 c) 25 d) 63	a) 5-37 ug/100 ml b) 6-36 ug/100 ml c) 3-15 ug/100 ml d) 2-16 ug/100 ml	a) 17.3 +or- 6.9 ug/100 ml b) 16.9 +or- 5.5 ug/100 ml c) 8.7 +or- 2.8 ug/100 ml d) 7.6 +or- 2.9 ug/100 ml	a) Nursery school near Pb smelter b) Primary school near Pb smelter c) Nursery school 4 km from smelter d) Primary school 4 km from smelter Near smelter, significantly higher levels and free erythrocyte porphyrin, lower delta-aminolevulinic acid dehydratase. Zinc protoporphyrin not significantly different. 3-11 yr olds, Italy ITALY; CHILDREN; BLOOD; LEAD; METALS; PORPHYRINS; PROTOPORPHYRINS; HEALTH HAZARDS; INDUSTRIAL AREAS; RURAL AREAS; SMELTERS	Cavalleri, A. Baruffini, A. Minoia, C. Bianco, L. 1981 Environmental Research 25:415-423

(NEXT PAGE)

Lead
7439-92-1
Pb
AtW 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5492 Blood			a) 48 b) 45	a) 20-125 ug/100 ml b) 22-80 ug/100 ml	a) Not given b) Not given	a) Current occupational exposure (1 yr or more) b) Past occupational exposure (ending 1 yr prior to study) Pb levels in b) generally lower than those in a) for given urinary Pb output. 30-35 yr old Italians Erythrocyte protoporphyrin and delta-aminolevulinic acid dehydratase useful in establishing persistence, extent of Pb in subjects with past exposure. ITALY; ADULTS; BLOOD; URINE; LEAD; LEVULINIC ACIDS; METALS; PROTOPORPHYRINS; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Alessio, L. Cantoldi, M.R. Odone, V. Franchini, I. 1981 British Journal of Industrial Medicine 38: 262-267
5493 Blood			a) 196 b) 204 c) 202 d) 189	a) Not given b) Not given c) Not given d) Not given	a) 12.2 +or- 3.8 ug/100 ml b) 14.9 +or- 7.4 ug/100 ml c) 18.5 +or- 12.3 ug/100 ml d) 16.4 +or- 7.5 ug/100 ml	a) Port Keatla, 1973, 1978-1979. Geometric mean 12.8 ug/100 ml b) Cockiecreek, 1973. Approximate value c) New South Wales hospital survey. Geometric mean 16.0 ug/100 ml d) Same as c) excluding 13 cases of known Pb contamination in the home. Geometric mean 14.8 ug/100 ml 3-14 yr olds, Australia AUSTRALIA; CHILDREN; BLOOD; LEAD; METALS; INDUSTRIAL AREAS; POPULATION EXPOSURE; SMELTERS	Bell, A. 1981 Medical Journal of Australia 1:23-26
5494 Blood	Ingestion		475	Not given	0.39 umol/l Geometric	About 2 yr after pH of drinking water was raised to 8 or higher. In prior years pH was as low as 6.3 and mean Pb blood level in a comparable group was 0.8-0.9 umol/l Residents of Glasgow, Scotland SCOTLAND; ADULTS; BLOOD; LEAD; METALS; DRINKING WATER; HEALTH HAZARDS; URBAN AREAS	Moore, M.R. Goldberg, A. Fyfe, W.M. Richards, W.N. 1981 Lancet 2(8239):203-204
5495 Blood		AAS	a) 45 b) 40	a) 6-15 ug/100 ml b) 17-65 ug/100 ml	a) 10 +or- 2 ug/100 ml b) 38 +or- 12 ug/100 ml	a) Controls b) Occupational exposure Negative correlation with erythrocyte delta-aminolevulinic acid dehydratase (ALA-D) activity. ALA-D markedly activated by heating hemolysate. Positive correlation with ratio of heated to nonheated ALA-D activity. BLOOD; LEAD; METALS; ENZYMES	Tomokuni, K. Kawanishi, T. 1975 Archives of Toxicology 34:253-258

(NEXT PAGE)

Lead
7439-92-1
Pb
At# 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5496 Blood			a) 16 b) 10 c) 25 d) 26 e) 13 f) 61 g) 5 h) 6 i) 8	a) Not given b) Not given c) 9-40 ug/100 ml d) Not given e) Not given f) 11-44 ug/100 ml g) Not given h) Not given i) 13-19 ug/100 ml	a) 19.1 ug/100 ml b) 22.5 ug/100 ml c) 18.1 ug/100 ml d) 23.6 ug/100 ml e) 24.3 ug/100 ml f) 18.7 ug/100 ml g) 26.7 ug/100 ml h) 29.0 ug/100 ml i) 14.8 ug/100 ml Geometric	a) < 1000 ppm (mean 420 ppm), children, no pica b) < 1000 ppm (mean 420 ppm), children, pica c) < 1000 ppm (mean 420 ppm), mothers of a) and b) d) 1,000-10,000 ppm (mean 3390 ppm), children, no pica e) 1,000-10,000 ppm (mean 3390 ppm), children, pica f) 1,000-10,000 ppm (mean 3390 ppm), mothers of d) and e) g) > 10,000 ppm (mean 13,969 ppm), children, no pica h) > 10,000 ppm (mean 13,969 ppm), children, pica i) > 10,000 ppm (mean 13,969 ppm), mothers of g) and h) Soil Pb levels Mean levels in house dust, 531 ppm for a)-c), 1548 ppm for d)-f), and 2782 ppm for g)-i) Residents of Derbyshire, United Kingdom UNITED KINGDOM; ADULTS; CHILDREN; BLOOD; HAIR; LEAD; METALS; DUST; PICA; POPULATION EXPOSURE; RURAL AREAS; SOILS	Barltrop, D. Thornton, I. Strehlow, C.D. Webb, J.S. 1975 Postgraduate Medical Journal 51:801-808
5497 Blood						Review An evaluation of major studies of effects of airborne Pb on blood Pb levels of male and female adults and children. BLOOD; COMPARATIVE EVALUATIONS; REVIEW; LEAD; METALS; AIR POLLUTION; ATMOSPHERE; POPULATION EXPOSURE	Snee, P.D. 1981 International Archives of Occupational and Environmental Health 48:219-242
5498 Blood						Review. Given epidemiological evidence for increased Pb absorption in preschool children. Because of long-lasting effects such as minimal brain dysfunction, preventive programs are emphasized. MARYLAND; SOUTH CAROLINA; TEXAS; UNITED STATES; CHILDREN; LEAD POISONING; BLOOD; LEAD; METALS; REVIEW	Chisolm, J.J., Jr. 1977 Clinical Chemistry 23(2):252-255
5499 Blood		AAS	a) 10 b) 10	a) Not given b) Not given	a) 100.3 + or - 11.7 ug/dl b) 55.5 + or - 10.1 ug/dl	a) Mentally retarded. Max level 215.68 ug/dl b) Normal Source of exposure unknown Delta-Aminolevulinic acid dehydratase significantly lower in 5-15 yr olds, low socioeconomic level, India In mentally retarded group: coproporphyrinuria, basophilic stippling, plumbism. HEALTH HAZARDS; LEAD; METALS; BLOOD; INDIA; CHILDREN; MENTAL RETARDATION	Tandon, D.S. Seth, T.D. Satija, N.N. 1976 Journal of Pediatrics 88(5):898-899

(NEXT PAGE)

Lead
7439-92-1
Pb
AW 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
9500 Blood		AAS	a) 165 b) 165 c) 165 d) 27 e) 19 f) 20 g) 23	a) 0.8-1.1 umol/l b) 0.3-1.0 umol/l c) Not given d) Not given e) Not given f) Not given g) Not given	a) 0.64 umol/l b) 0.51 umol/l c) 0.59 +or- 0.15 umol/l d) 0.64 +or- 0.14 umol/l e) 0.76 +or- 0.13 umol/l f) 0.82 +or- 0.15 umol/l g) 0.53 +or- 0.2 umol/l	a) 8th wk pregnancy, rural area b) At term, rural area c) Pregnant, rural area d) Controls, rural area e) Pregnant, urban area f) Controls, urban area g) Neonates, 4 da old, rural areas Range estimated from graph Women and infants in mining town of Ashington, Northumberland (rural area), and Newcastle upon Tyne (urban area), U.K. LEAD; METALS; BIOACCUMULATION; PREGNANCY; RURAL AREAS; URBAN AREAS; UNITED KINGDOM; NEWBORN; BLOOD	Alexander, F.W. Delves, H.T. 1981 International Archives of Occupational and Environmental Health 48:35-39
9501 Blood						Review Distribution, sources, human body burden, mortality data and toxicological effects of Pb. Accumulation, distribution and effects on plants. CO data include sources, ambient levels, mortality and morbidity statistics, air quality standards, toxicological data, occupational exposure, impact of cigarette smoking and laboratory studies. CARBON MONOXIDE; METAL POISONING; NERVOUS SYSTEM DISEASES; BLOOD; BONES; KIDNEYS; LUNGS; REVIEW; CARBON INORGANIC COMPOUNDS; LEAD; METALS; AIR POLLUTION; ATMOSPHERE; DRINKING WATER; DUST; ENZYMES; FOODS; FOSSIL FUELED POWER PLANTS; INDUSTRIAL POLLUTION; INHALATION; OCCUPATIONAL HAZARDS; PAINTS; SMOKING; VEGETABLES; VEGETATION	Amon, R.G. Amon, F.P., Jr. Thompson, J.C., Jr. 1974 NSF-RA-E-74-467, 43 pp.
9502 Blood			70	a) 5.1-26.1 ug/dl b) 5.3-26.3 ug/dl c) 3.8-24.9 ug/dl d) 2.9-22.1 ug/dl	a) 10.6 ug/dl b) 13.8 ug/dl c) 8.8 ug/dl d) 12.1 ug/dl	a) Maternal, subjects drinking water with 0.2-49.8 ug/l (mean 11.8 ug/l), 41 cases b) Maternal, subjects drinking water with 61.9-1228.5 ug/l (mean 247.4 ug/l), 29 cases c) Cord, subjects from group a) d) Cord, subjects from group b) Drinking water did not seem to contribute greatly to Pb exposure but highly significant curvilinear correlation between water- and blood-Pb ($P < 0.01$). Strong positive correlation between maternal and cord blood-Pb ($r = 0.86$). Residents of Libramont, rural area in south Belgium. BELGIUM; FETUS; NEWBORN; BLOOD; PLACENTA; LEAD; DRINKING WATER; PREGNANCY; RURAL AREAS	Lauwerys, R. Hubermont, G. Buchet, J.P. Roels, H. 1977 Lancet 2(8049):1188
9503 Blood			6	a) 180-190 ppb b) 550-760 ppb	a) Not given b) Not given	a) 2 normal adults c) 4 Pb-poisoned infants Massachusetts MASSACHUSETTS; ADULTS; CHILDREN; DENTAL CARIES; LEAD POISONING; BLOOD; SALIVA; TEETH; FLUORIDE; LEAD; BIOACCUMULATION; METALS	Brudevold, F. Aasenden, R. Srinivasan, B.N. Bakhos, Y. 1977 Journal of Dental Research 56(10):1165-1171

(NEXT PAGE)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5504 Blood						Review. History, symptoms of poisoning, experimental data, ingestion and inhalation measurements. ILLINOIS; ADULTS; CHILDREN; INFANTS; LEAD POISONING; BLOOD; LEAD; AIR POLLUTION; BIOACCUMULATION; DRINKING WATER; HEALTH HAZARDS; INHALATION; OCCUPATIONAL HAZARDS; PAINTS; POPULATION EXPOSURE; RURAL AREAS; URBAN AREAS; REVIEW; METALS	Wessel, M.A. Dominski, A. 1977 American Scientist 65(3):294-298
5505 Blood						Review. Intake by children, body burden of total population, sources of exposure, and toxicological significance. MASSACHUSETTS; ADULTS; CHILDREN; INFANTS; LEAD POISONING; MENTAL RETARDATION; NEUROLOGIC MANIFESTATIONS; BLOOD; TEETH; URINE; LEAD; DIETS; INDUSTRIAL EMISSIONS; PAINTS; RURAL AREAS; URBAN AREAS; REVIEW; METALS	Anon 1975 Food and Cosmetics Toxicology 13:277-282
5506 Blood						Review. Pb implicated as a serious public health problem. Effects on mental function and development in children discussed. FINLAND; GERMANY; ITALY; SWEDEN; UNITED KINGDOM; CHILDREN; NEUROSE; ANEMIA; LEAD POISONING; MENTAL RETARDATION; BLOOD; TEETH; LEAD; AUTOMOTIVE; AIR POLLUTION; ATMOSPHERE; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; FOODS; FUMES; INDUSTRIAL EMISSIONS; INHALATION; PAINTS; PREGNANCY; RURAL AREAS; URBAN AREAS; VEGETABLES; REVIEW; METALS	Bryce-Smith, D. Mathews, J. Stephens, R. 1978 Ambio 7(5-6):193-203
5507 Blood			7	1.8-2.8 mcol/l	Not given	After firing or in close proximity to firing of about 1100 rounds of ammunition/wk, plus clean-up of target area 2-3 times per year. Indoor and outdoor ranges. Air levels 0.03-0.16 mg/cu m. Police small-arms instructors, United Kingdom No symptoms of toxicity UNITED KINGDOM; ADULTS; BLOOD; LEAD; AIR POLLUTION; DUST; INHALATION; OCCUPATIONAL HAZARDS	Smith, D.L. 1976 Society of Occupational Medicine 26:139-140
5508 Blood						Review Current knowledge, recommendations for screening, diagnosis, treatment, follow-up of children with increased Pb absorption and poisoning. CHILDREN; METAL POISONING; BLOOD; REVIEW; LEAD; METALS; PROTOPORPHYRINS; HEALTH HAZARDS; POPULATION EXPOSURE	Chisolm, J.J., Jr. Curran, A.S. Finberg, L. Hopkins, D.R. Lin-Fu, J.S. Piomelli, S. Reigart, J.R. 1975 Journal of Pediatrics 87(5):824-830

(NEXT PAGE)

Lead
7439-92-1
Pb
Atw 207.2, MP 327.6 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5509 Blood		AAS	a) 25 b) 88	a) 33.8-61.3 ug/100 ml b) 5.5-36.2 ug/100 ml	a) 44.3 ug/100 ml b) 16.6 ug/100 ml	a) Exposed group b) Controls 22.7-62.9 yr old workers at smelter, 68% smokers, mean exposure 13.2 yr. 19.8-68.8 yr old controls, 38% smokers. Free erythrocyte porphyrins and urinary delta-aminolevulinic acid increased CADMIUM; LEAD; MERCURY; METALS; OCCUPATIONAL HAZARDS; POPULATION EXPOSURE; BLOOD; URINE; SMELTERS; INDUSTRIAL PLANTS; SMOKING; COMPARATIVE EVALUATIONS; HEALTH HAZARDS	Buchet, J.P. Roels, H. Bernard, A. Lauwerys, R. 1980 Journal of Occupational Medicine 22(11):741-750
5510 Blood			1	<40-212 ug/dl	Not applicable	Background and maximum level attained after accidental exposure. Dose unknown. Free erythrocyte protoporphyrin levels 310 ug/dl on admission. 49 yr old laboratory worker who handled Pb oxide Lethargy and abdominal pain. Treated with D-penicillamine ADULTS; CASE HISTORIES; METAL POISONING; INDUSTRIAL MEDICINE; LEAD; OCCUPATIONAL HAZARDS; INDUSTRIAL CHEMICALS; METALS	Stewart, M. Hughes, E.G. Barltrop, D. 1981 Lancet 1(8231):1210-1211
5511 Blood		ASV	a) 22 b) 7	a) 27-256 ug/100 ml b) 24-72 ug/100 ml	a) Not given b) Not given	a) Family members, automobile battery casings used as fuel. Dust in home contained 6.8-41 ppt pb b) Family members, home battery recycling operation. Nearby soil samples contained up to 49.2 % Pb Residents of North Carolina Encephalopathy in 3 yr old girl in family a)	Delcourt, J.L. Finch, C. Coleman, G.D. Fliess, A.J. Hilar, C.B. 1981 Pediatrics 68(2):225-230
						NORTH CAROLINA; ADULTS; CHILDREN; METAL POISONING; BLOOD; LEAD; METALS; HEALTH HAZARDS	
5512 Blood		AAS	a) 54 b) 8 c) 9 d) 8 e) 37	a) Not given b) Not given c) Not given d) Not given e) Not given	a) 26.23 +or- 8.61 ug/100 ml b) 41.06 +or- 12.18 ug/100 ml c) 22.89 +or- 6.60 ug/100 ml d) 29.94 +or- 7.35 ug/100 ml e) 22.16 +or- 9.59 ug/100 ml	a) Hyperactive b) History of Pb poisoning c) Hyperactivity not Pb related d) Hyperactivity probably not Pb related e) Normal controls Significant differences between controls and a), b) and d) 3.5-12 yr olds NEW YORK; CHILDREN; METAL POISONING; BEHAVIOR DISORDERS; BLOOD; URINE; LEAD; METALS	David, O. 1977 International Symposium, Proceedings of Recent Advances in the Assessment of the Health Effects of Environmental Pollution, Volume 3, Paris, 1976:1549-1555

(NEXT PAGE)

Lead
7439-92-1
Pb
At# 207.2, BP 327.4 C, MP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5513 Blood		AAS		10-90 ug/ml	Not given	Micro-scale method utilizing a graphite furnace, and blood samples as small as 20 ul, showed a high correlation (r=0.98) with the standard macro-AAS technique. Patients at Yale-New Haven Medical Center, CT BLOOD; MEASUREMENT METHODS; LEAD; METALS; CONNECTICUT	Fernander, P.J. 1975 Clinical Chemistry 21:558-561
5514 Blood		Dithizone AAS	a) 13 b) 15 c) 15 d) 16 e) 5 f) 53 g) 30	a) 4.2-25.0 ug/100 ml b) 6.0-25.0 ug/100 ml c) 1.1-28.0 ug/100 ml d) 5.0-40.0 ug/100 ml e) 7.0-28.0 ug/100 ml f) 3.0-79.0 ug/100 ml g) 4.0-41.0 ug/100 ml	a) 10.6 +or- 5.2 ug/100 ml b) 12.3 +or- 6.4 ug/100 ml c) 11.5 +or- 7.9 ug/100 ml d) 15.6 +or- 8.0 ug/100 ml e) 16.0 +or- 8.2 ug/100 ml f) 20.0 +or- 12.0 ug/100 ml g) 16.0 +or- 10.0 ug/100 ml	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. TRYNDS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5515 Blood	Ingestion Inhalation		10	Not given	19.7 +or- 5.8 ug/100 cc	20% due to atmospheric pollution and 80% due to naturally high Pb soil levels (4.5 ug/g) Nonsmoking residents of southwest France FRANCE; ADULTS; BLOOD; LEAD; METALS; ATMOSPHERE; BIOACCUMULATION; FOODS; INHALATION; POPULATION EXPOSURE; RURAL AREAS; SOILS; VEGETABLES	Servant, J. Delapart, M. 1981 Health Physics 41(3):483-487
5516 Blood			83	0.3-3.6 umol/l	Not given	Negative correlation with plasma 25-hydroxyvitamin D (3.0-78.3 nmol/l). 2-5 yr old Asians, Birmingham, England. UNITED KINGDOM; CHILDREN; BLOOD; BLOOD PLASMA; LEAD; METALS; VITAMIN D; DIETS; URBAN AREAS	Fox, V. Cherry, N. Waldron, H.A. Dattani, J. Griffiths, K.D. Hill, F.G.H. 1981 Lancet 2(8242):373
5517 Blood		AAS	1	Not applicable	4.1 ug/dl	Child with convulsive disorder 12 yr old boy CANADA; ADULTS; CHILDREN; BEHAVIOR DISORDERS; NEUROLOGIC MANIFESTATIONS; NUTRITIONAL DEFICIENCIES; BLOOD; MANGANESE	Sampson, P. 1977 Journal of American the Medical Association 238(17):1805

(NEXT PAGE)

Lead
7439-92-1
Pb
AtW 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5518 Blood, whole		AAS	a) 1 b) 1 c) 1 d) 1 e) 1 f) 1 g) 1 h) 1 i) 1	a) 0.18-0.30 mg/l b) 0.13-0.25 mg/l c) 0.18-0.35 mg/l d) 0.09-0.20 mg/l e) 0.10-0.19 mg/l f) 0.12-0.25 mg/l g) 0.12-0.25 mg/l h) 0.12-0.25 mg/l i) 0.10-0.25 mg/l	a) Not applicable b) Not applicable c) Not applicable d) Not applicable e) Not applicable f) Not applicable g) Not applicable h) Not applicable i) Not applicable	a) Pb-poisoned 2 yr old girl b) Sister (4 yr old) c) Father (29 yr old) d) Mother (28 yr old) e) Playmate (8 yr old) f) Playmate (6 yr old) g) Playmate (5 yr old) h) Playmate (3 yr old) i) Playmate (8 yr old) Range reflects differing methods Inner city residents ADULTS; CHILDREN; METAL POISONING; BLOOD; MEASUREMENT METHODS; LEAD; METALS; URBAN AREAS	Garaya, V.P. Matousek, J.P. 1975 Clinical Chemistry 21:891-893
5519 Blood, whole		AAS	a) 20 b) 23 c) 40 d) 26 e) 92 f) 37 g) 14	a) 8.8-22.5 ug/100 ml b) 9.4-18.4 ug/100 ml c) 16.6-43.8 ug/100 ml d) 18.7-48.4 ug/100 ml e) 8.7-15.6 ug/100 ml f) 14.9-27.6 ug/100 ml g) 19.7-41.1 ug/100 ml	a) 17.6 ug/100 ml b) 12.6 ug/100 ml c) 29 ug/100 ml d) 29 ug/100 ml e) 9.8 ug/100 ml f) 21.1 ug/100 ml g) 30.1 ug/100 ml	a) Controls, men b) Controls, women c) Moderately exposed men, Pb smelter d) Moderately exposed women, Pb smelter e) Controls, children 10-13 yr old. Ambient air and drinking water 0.3 ug/cu m and 5 ug/l f) Children, schools and homes more than 1.5 km from Pb smelter. Air Pb 2.6 ug/cu m near homes. Drinking water Pb < 5 ug/l g) Children, schools and homes within 1 km of Pb smelter. Ambient air Pb at one school, 5.4 ug/cu m. Belgium METALS; LEAD; BLOOD; ADULTS; CHILDREN; SEX; POPULATION EXPOSURE; URBAN AREAS; RURAL AREAS; SMELTERS; INDUSTRIAL EMISSIONS; AIR POLLUTION; DRINKING WATER; LEVULINIC ACIDS; PROTOPORPHYRINS	Roels, H.A. Buchet, J.P. Lauwerys, R. Hubermont, G. Bruaux, P. 1975 An International Conference on Heavy Metals in the Environment, Toronto, Ontario, Canada, Oct. 27-31, pp. 105-124
5520 Blood, whole		AAS	a) 250 b) 35	a) 12-93 ug/100 ml b) 21-95 ug/100 ml	a) Not given b) Not given	a) Children from Newark, NJ b) Smelting plant workers Linear correlation between blood Pb and log of porphyrin fluorescence at 594 nm ADULTS; NEW JERSEY; CHILDREN; BLOOD; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS; LEAD; METALS; PROTOPORPHYRINS; POPULATION EXPOSURE; URBAN AREAS	Lamola, A.A. Joselow, M. Yamane, T. 1975 Clinical Chemistry 21(1):93-97
5521 Blood, whole		AAS		a) Not given b) Not given c) Not given	a) 276.6 +or- 105.8 ug/l b) 273.2 +or- 99.0 ug/l c) 243 +or- 101.3 ug/l	a) 207 venipunctures, Delves microscale technique b) 207 venipunctures, macroscale technique c) 299 finger-sticks, microscale technique. Coefficient of variation, micro-scale technique, 5.75 +or- 1.9%. 480 ug/l or less significantly lower than toxic level of 600 ug/l. Residents of New York City, NY. Finger-sticks from 1-6 yr olds. NEW YORK; CHILDREN; BLOOD; LEAD; METALS; MEASUREMENT METHODS	Marcus, M. Hollander, M. Lucas, H.F. Pfeiffer, H.C. 1975 Clinical Chemistry 21(4):533-536

(NEXT PAGE)

Lead
7439-92-1
Pb
AW 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5522 Blood, whole		AAS	a) 20 b) 29 c) 7 d) 18 e) 41 f) 11 g) 21 h) 18 i) 11 j) 25 k) 16 l) 28	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given g) Not given h) Not given i) Not given j) Not given k) Not given l) Not given	a) 23.5 +or- 2.5 ug/100 ml b) 16.6 +or- 1.1 ug/100 ml c) 18.5 +or- 2.0 ug/100 ml d) 16.7 +or- 1.8 ug/100 ml e) 12.9 +or- 0.6 ug/100 ml f) 14.7 +or- 1.5 ug/100 ml g) 11.1 +or- 0.8 ug/100 ml h) 11.8 +or- 0.9 ug/100 ml i) 13.0 +or- 2.0 ug/100 ml j) 10.2 +or- 0.7 ug/100 ml k) 9.1 +or- 1.2 ug/100 ml l) 9.3 +or- 0.5 ug/100 ml	a) Males, 1-16 yr old, Los Angeles (also b-f) c) Males, 17-34 yr old c) Males, >35 yr old d) Females, 1-16 yr old e) Females, 17-34 yr old f) Females, >35 yr old g) Males, 1-16 yr old, Lancaster, CA (also h-l) h) Males, 17-34 yr old i) Males, >35 yr old j) Females, 1-16 yr old k) Females, 17-34 yr old l) Females, >35 yr old Air and soil Pb, 6.3 ug/cu m and 673-3633 ug/g for a-f, 0.64 ug/cu m and 42.5-98.8 (mean 66.8) ug/g for h-l Residents of CA CALIFORNIA; ADULTS; CHILDREN; BLOOD; HAIR; URINE; COMPARATIVE EVALUATIONS; LEAD; METALS; PALLADIUM; PLATINUM; ATMOSPHERE; POPULATION EXPOSURE; RURAL AREAS; SOILS; URBAN AREAS	Jchason, D.E. Tillery, J.B. Prevost, R.J. 1975 Environmental Health Perspectives 12:27-33
5523 Blood, whole		AAS	54	200-800 ug/l	Not given	Workers at smelter, 0.5-20 yr exposure. NETHERLANDS; BLOOD; INDUSTRIAL HYGIENE; AMINO ACIDS; LEAD; LEVULINIC ACIDS; PORPHYRINS; BIOINDICATORS; OCCUPATIONAL HAZARDS; METALS	Herber, R.F.M. 1980 International Archives of Occupational and Environmental Health 45:169-179
5524 Blood, whole		AAS	7	0.011-0.055 ug/g	Not applicable	Analysis by method of standard additions and by comparison with aqueous and spiked blood standards. Compared with isotopic dilution mass spectrometry technique. BLOOD; MEASUREMENT METHODS; LEAD; METALS	Ealy, J.A. Bolton, N.F. McElheny, R.J. Morrow, R.W. 1974 American Industrial Hygiene Association Journal 35(9):566-570
5525 Blood, whole			10	48-68 ug/dl	57.6 ug/dl	Prior to chelation therapy No significant relationship between, blood-Pb and urinary delta-aminolevulinic acid. Latter linearly related to erythrocyte protoporphyrin. Children MARYLAND; CHILDREN; METAL POISONING; BLOOD; URINE; LEAD; METALS	Chisolm, J.J. Barrett, M.B. Mellits, E.D. 1975 Journal of Pediatrics 87(6):1152-1160

(NEXT PAGE)

Lead
7439-92-1
Pb
At# 207.2, MP 327.5 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1169 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5526 Bone						Review Distribution, sources, human body burden, mortality data and toxicological effects of Pb. Accumulation, distribution and effects on plants. CO data includes sources, ambient levels, mortality and morbidity statistics, air quality standards, toxicological data, occupational exposure, impact of cigarette smoking and laboratory studies. CARBON MONOXIDE; METAL POISONING; NERVOUS SYSTEM DISEASES; BLOOD; BONES; KIDNEYS; LUNGS; REVIEW; CARBON INORGANIC COMPOUNDS; LEAD; METALS; AIR POLLUTION; ATMOSPHERE; DRINKING WATER; DUST; ENZYMES; FOODS; FOSSIL FUELED POWER PLANTS; INDUSTRIAL POLLUTION; INHALATION; OCCUPATIONAL HAZARDS; PAINTS; SMOKING; VEGETABLES; VEGETATION	Amos, P.C. Amos, P.S., Jr. Thompson, J.C., Jr. 1974 NSF-RA-E-74-067, 83 pp.
5527 Bone			28	a) 195-62,000 ppm, dry wt b) 195-8,200 ppm, dry wt c) 250-85,000 ppm, ash d) 250-12,200 ppm, ash	a) 2,657 ppm, dry wt b) 1,453 ppm, dry wt c) 3,576 ppm, ash d) 1,882 ppm, ash	a) All samples including tibia, fibula, rib, calvarium, scapula, petrous temporal b) 4 samples, levels >10,000 ppm excluded c) Same as a) d) Same as b) Highest levels in ribs No correlation with age or sex Measurements greatly in excess of contemporary populations Soil levels similar to those in bones 103 samples 13th, 15th century cadavers, Cheshire, England. 22 men, 2 women, 4 children LEAD; SOILS; UNITED KINGDOM; ADULTS; CHILDREN; BONES; CADAVERS	Barry, P.S.I. Connolly, R. 1981 International Archives of Occupational and Environmental Health 48:173-177
5528 Bone		Dithizone AAS	a) 14 b) 15 c) 20 d) 18 e) 6 f) 60 g) 36	a) 0.09-1.51 ppm b) 0.07-5.40 ppm c) 0.01-2.90 ppm d) 0.01-5.50 ppm e) 1.00-3.30 ppm f) 0.90-28.50 ppm g) 0.05-22.60 ppm Wet wt	a) 0.62 +or- 0.58 ppm b) 1.25 +or- 1.30 ppm c) 0.90 +or- 0.98 ppm d) 2.34 +or- 1.50 ppm e) 2.05 +or- 0.97 ppm f) 6.85 +or- 5.81 ppm g) 6.77 +or- 5.08 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Rib Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. TRUNKS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71

(NEXT PAGE)

Lead
7439-92-1
Pb
At# 207.2, BP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5529 Bone		Dithizone AAS	a) 14 b) 15 c) 16 d) 17 e) 5 f) 60 g) 36	a) 0.02-1.53 ppm b) 0.06-1.90 ppm c) 0.04-4.00 ppm d) 0.16-6.20 ppm e) 1.50-4.40 ppm f) 3.00-73.00 ppm g) 1.50-48.00 ppm Wet wt	a) 0.49 +or- 0.40 ppm b) 0.63 +or- 0.46 ppm c) 0.82 +or- 0.93 ppm d) 2.76 +or- 1.98 ppm e) 2.68 +or- 1.06 ppm f) 23.40 +or- 15.96 ppm g) 15.99 +or- 12.49 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Tibia Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5530 Bone		Dithizone AAS	a) 11 b) 14 c) 14 d) 16 e) 5 f) 31 g) 17	a) 0.14-0.96 ppm b) 0.10-2.10 ppm c) 0.06-0.84 ppm d) 0.49-6.70 ppm e) 0.43-9.00 ppm f) 3.90-79.00 ppm g) 5.00-54.20 ppm Wet wt	a) 0.46 +or- 0.29 ppm b) 0.87 +or- 0.62 ppm c) 0.61 +or- 0.42 ppm d) 3.41 +or- 2.29 ppm e) 4.01 +or- 3.28 ppm f) 20.17 +or- 16.00 ppm g) 16.46 +or- 13.08 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Calvaria Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71

(NEXT PAGE)

Lead
7439-92-1
Pb
AtW 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5531 Brain		Dithizone AAS	a) 12 b) 15 c) 19 d) 18 e) 6 f) 58 g) 34	a) 0.01-0.09 ppm b) 0.01-0.20 ppm c) 0.01-0.34 ppm d) 0.02-0.21 ppm e) 0.02-0.13 ppm f) 0.02-0.78 ppm g) 0.01-0.67 ppm Wet wt	a) 0.03 +or- 0.03 ppm b) 0.07 +or- 0.07 ppm c) 0.07 +or- 0.08 ppm d) 0.07 +or- 0.05 ppm e) 0.06 +or- 0.04 ppm f) 0.10 +or- 0.14 ppm g) 0.12 +or- 0.15 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5532 Cartilage		Dithizone AAS	a) 13 b) 12 c) 14 d) 16 e) 6 f) 18 g) 12	a) 0.01-0.38 ppm b) 0.02-0.46 ppm c) 0.02-2.10 ppm d) 0.05-0.44 ppm e) 0.04-0.22 ppm f) 0.05-4.80 ppm g) 0.08-1.75 ppm Wet wt	a) 0.09 +or- 0.10 ppm b) 0.23 +or- 0.16 ppm c) 0.27 +or- 0.54 ppm d) 0.20 +or- 0.15 ppm e) 0.15 +or- 0.08 ppm f) 1.29 +or- 1.58 ppm g) 0.56 +or- 0.53 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71

(NEXT PAGE)

Lead
7439-92-1
Pb
At# 207.2, BP 327.4 C, SP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5533 Connectiv e tissue		Dithizone AAS	a) 10 b) 13 c) 13 d) 11 e) 4 f) 16 g) 11	a) 0.02-0.13 ppm b) 0.01-0.48 ppm c) 0.03-0.35 ppm d) 0.02-0.57 ppm e) 0.09-1.00 ppm f) 0.03-0.90 ppm g) 0.10-0.86 ppm Wet wt	a) 0.06 +or- 0.04 ppm b) 0.21 +or- 0.15 ppm c) 0.12 +or- 0.08 ppm d) 0.18 +or- 0.18 ppm e) 0.32 +or- 0.43 ppm f) 0.33 +or- 0.29 ppm g) 0.37 +or- 0.23 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. TRIMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5534 Hair		AAS	a) 139 b) 20 c) 184 d) 57	a) Not given b) Not given c) Not given d) Not given	a) 15.39 +or- 1.3 ppm b) 11.9 +or- 1.9 ppm c) 14.27 +or- 0.88 ppm d) 16.2 +or- 1.4 ppm	a) Controls, girls b) Learning disability, girls c) Controls, boys d) Learning disability, boys No significant differences. Mean air levels 246 +or- 134 and 307 +or- 98 ng/cu m at two schools. 9-12 yr olds, Akron, OH Blood pressure significantly lowered in disabled. CHILDREN; HAIR; ARSENIC; CADMIUM; LEAD; MERCURY; METALS; SPECTRUM; POPULATION EXPOSURE	Ely, D.L. Mostardi, R.A. Woebkenberg, M. Horstell, D. 1981 Environmental Research 25:325-339
5535 Hair			a) 16 b) 16 c) 29 d) 26 e) 13 f) 43 g) 5 h) 6 i) 10	a) Not given b) Not given c) 2-36 ppm d) Not given e) Not given f) 2-62 ppm g) Not given h) Not given i) 10-39 ppm	a) 6.0 ppm b) 8.9 ppm c) 7.7 ppm d) 9.1 ppm e) 17.4 ppm f) 10.5 ppm g) 22.8 ppm h) 20.9 ppm i) 20.2 ppm	a) Children, no pica b) Children, pica c) Mothers of a) and b), house dust lead 531 ppm (mean) d) Children, no pica e) Children, pica f) Mothers of e) and b), house dust lead 1564 ppm (mean) g) Children, no pica h) Children, pica i) Mothers of g) and h), house dust Pb, 2582 ppm (mean) Soil < 1,000 ppm for a)-c), 1,000-10,000 ppm for d)-f), and > 10,000 ppm for g)-h) Residents of Derbyshire, United Kingdom UNITED KINGDOM; ADULTS; CHILDREN; BLOOD; HAIR; LEAD; METALS; DUST; PICA; POPULATION EXPOSURE; RURAL AREAS; SOILS	Barltrop, D. Thorton, I. Strehlow, C.D. Webb, J.S. 1975 Postgraduate Medical Journal 51:801-804

(NEXT PAGE)

Lead
7439-92-1
Pb
AtW 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5536 Hair		AAS	a) 18 b) 24 c) 3 d) 25 e) 35 f) 10 g) 20 h) 16 i) 8 j) 22 k) 17 l) 26	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given g) Not given h) Not given i) Not given j) Not given k) Not given l) Not given	a) 59.4 +or- 9.0 ug/g b) 35.3 +or- 12.7 ug/g c) 20.5 +or- 10.0 ug/g d) 76.7 +or- 9.9 ug/g e) 26.7 +or- 3.6 ug/g f) 33.2 +or- 10.3 ug/g g) 20.7 +or- 3.0 ug/g h) 20.2 +or- 3.5 ug/g i) 24.6 +or- 12.3 ug/g j) 17.3 +or- 2.5 ug/g k) 10.9 +or- 1.9 ug/g l) 23.4 +or- 12.1 ug/g	a) Males, 1-16 yr old, Los Angeles (also b-f) b) Males, 17-34 yr old c) Males >35 yr old d) Females 1-16 yr old e) Females 17-34 yr old f) Females >35 yr old g) Males, 1-16 yr old, Lancaster, CA (also h-l) h) Males, 17-34 yr old i) Males, >35 yr old j) Females, 1-16 yr old k) Females, 17-34 yr old l) Females, >35 yr old Air and soil Pb, 6.3 ug/cu m and 573-3633 ug/g for a-f, 0.64 ug/cu m and 42.5-98.4 (mean 66.8) ug/g for h-l Values for long hair Data also for short hair Residents of CA CALIFORNIA; ADULTS; CHILDREN; BLOOD; HAIR; URINE; COMPARATIVE EVALUATIONS; LEAD; METALS; PALLADIUM; PLATINUM; ATMOSPHERE; POPULATION EXPOSURE; RURAL AREAS; SOILS; URBAN AREAS	Johnson, D.E. Tillery, J.B. Prevost, P.J. 1975 Environmental Health Perspectives 12:27-33
5537 Heart		Dithizone AAS	a) 14 b) 15 c) 19 d) 17 e) 6 f) 59 g) 36	a) 0.01-0.09 ppm b) 0.01-1.30 ppm c) 0.01-0.19 ppm d) 0.02-0.17 ppm e) 0.03-0.18 ppm f) 0.01-0.30 ppm g) 0.02-0.31 ppm Wet wt	a) 0.04 +or- 0.02 ppm b) 0.16 +or- 0.33 ppm c) 0.05 +or- 0.04 ppm d) 0.08 +or- 0.05 ppm e) 0.09 +or- 0.07 ppm f) 0.07 +or- 0.05 ppm g) 0.08 +or- 0.06 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71

(NEXT PAGE)

Lead
7439-92-1
Pb
At# 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5538 Intestine		Dithizone AAS	a) 12 b) 11 c) 16 d) 16 e) 8 f) 32 g) 27	a) 0.01-0.40 ppm b) 0.07-1.10 ppm c) 0.01-0.37 ppm d) 0.04-0.25 ppm e) 0.06-0.47 ppm f) 0.03-0.27 ppm g) 0.02-0.68 ppm Wet wt	a) 0.15 +or- 0.13 ppm b) 0.37 +or- 0.32 ppm c) 0.09 +or- 0.08 ppm d) 0.11 +or- 0.07 ppm e) 0.22 +or- 0.18 ppm f) 0.09 +or- 0.06 ppm g) 0.14 +or- 0.14 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Cecum Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Disease factors in deaths of infants did not appear to be related to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5539 Intestine		Dithizone AAS	a) 14 b) 15 c) 17 d) 16 e) 3 f) 31 g) 27	a) 0.02-0.24 ppm b) 0.05-0.37 ppm c) 0.02-0.22 ppm d) 0.04-0.52 ppm e) 0.06-0.18 ppm f) 0.05-0.32 ppm g) 0.03-0.48 ppm Wet wt	a) 0.10 +or- 0.06 ppm b) 0.19 +or- 0.11 ppm c) 0.09 +or- 0.05 ppm d) 0.17 +or- 0.14 ppm e) 0.14 +or- 0.07 ppm f) 0.12 +or- 0.06 ppm g) 0.12 +or- 0.10 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Midgut Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Disease factors in deaths of infants did not appear to be related to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71

(NEXT PAGE)

Lead
7439-92-1
Pb
AtW 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5580 Kidney						Review Distribution, sources, human body burden, mortality data and toxicological effects of Pb. Accumulation, distribution and effects on plants. CO data includes sources, ambient levels, mortality and morbidity statistics, air quality standards, toxicological data, occupational exposure, impact of cigarette smoking and laboratory studies. CARBON MONOXIDE; METAL POISONING; NERVOUS SYSTEM DISEASES; BLOOD; BONES; KIDNEYS; LUNGS; NERVES; CARBON INORGANIC COMPOUNDS; LEAD; METALS; AIR POLLUTION; ATMOSPHERE; DRINKING WATER; DUST; ENZYMES; FOODS; FOSSIL FUELED POWER PLANTS; INDUSTRIAL POLLUTION; INHALATION; OCCUPATIONAL HAZARDS; PAINTS; SMOKING; VEGETABLES; VEGETATION	Agon, N.C. Agon, P.B., Jr. Thompson, J.C., Jr. 1974 NSF-RA-N-74-067, 83 pp.
5581 Kidney		Dithizone AAS	a) 14 b) 15 c) 20 d) 17 e) 5 f) 59 g) 36	a) 0.02-0.26 ppm b) 0.02-0.27 ppm c) 0.01-1.42 ppm d) 0.11-0.93 ppm e) 0.33-0.83 ppm f) 0.14-1.40 ppm g) 0.11-1.31 ppm Wet wt	a) 0.08 +or- 0.06 ppm b) 0.13 +or- 0.07 ppm c) 0.21 +or- 0.30 ppm d) 0.48 +or- 0.26 ppm e) 0.46 +or- 0.19 ppm f) 0.66 +or- 0.32 ppm g) 0.46 +or- 0.29 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5582 Kidney		AAS	1	a) Not applicable b) Not applicable	a) 8.3 ug/g b) 8.9 ug/g Wet wt	a) Analysis by low-temperature plasma ashing followed by AAS b) Analysis by standard subtilisn tissue degradation technique followed by AAS Autopsy KIDNEYS; LIVER; MEASUREMENT METHODS; CADMIUM; COPPER; LEAD; THALLIUM	Carpenter, R.C. 1981 Analytica Chimica Acta 125:209-213

(NEXT PAGE)

Lead
7439-92-1
Pb
AtW 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5543 Liver		Dithizone AAS	a) 18 b) 15 c) 20 d) 18 e) 6 f) 58 g) 36	a) 0.03-0.17 ppm b) 0.05-0.37 ppm c) 0.06-2.10 ppm d) 0.05-1.40 ppm e) 0.26-0.92 ppm f) 0.18-3.13 ppm g) 0.19-1.72 ppm Wet wt	a) 0.10 +or- 0.04 ppm b) 0.16 +or- 0.08 ppm c) 0.41 +or- 0.50 ppm d) 0.69 +or- 0.38 ppm e) 0.57 +or- 0.26 ppm f) 1.03 +or- 0.62 ppm g) 0.66 +or- 0.38 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5544 Liver		AAS	3	a) 0.0-13.4 ug/g b) <2-12.4 ug/g Wet wt	a) 5.2 ug/g b) Not given Wet wt	a) Analysis by low-temperature plasma ashing followed by AAS b) Analysis by standard nitric tissue degradation technique followed by AAS Autopsies KIDNEYS; LIVER; BIOASSAY METHODS; CADMIUM; COPPER; LEAD; THALLIUM	Carpenter, R.C. 1981 Analytica Chimica Acta 125:209-213
5545 Lung						Review Distribution, sources, human body burden, mortality data and toxicological effects of Pb. Accumulation, distribution and effects on plants. CO data includes sources, ambient levels, mortality and morbidity statistics, air quality standards, toxicological data, occupational exposure, impact of cigarette smoking and laboratory studies. CARBON MONOXIDE; METAL POISONING; NERVOUS SYSTEM DISEASES; BLOOD; BONES; KIDNEYS; LUNGS; REVIEW; CARBON INORGANIC COMPOUNDS; LEAD; METALS; AIR POLLUTION; ATMOSPHERE; DRINKING WATER; DUST; ENZYMES; FOODS; FOSSIL FUELED POWER PLANTS; INDUSTRIAL POLLUTION; INHALATION; OCCUPATIONAL HAZARDS; PAINTS; SMOKING; VEGETABLES; VEGETATION	Anon, R.G. Anon, P.B., Jr. Thompson, J.C., Jr. 1974 NSF-RA-E-74-A67, 43 pp.

(NEXT PAGE)

Lead
7439-92-1
Pb
At# 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5586 Lung		Dithizone AAS	a) 18 b) 15 c) 20 d) 18 e) 6 f) 59 g) 36	a) 0.01-0.16 ppm b) 0.02-0.14 ppm c) 0.02-0.10 ppm d) 0.05-0.59 ppm e) 0.07-0.25 ppm f) 0.05-0.59 ppm g) 0.04-0.55 ppm Wet wt	a) 0.05 +or- 0.04 ppm b) 0.06 +or- 0.04 ppm c) 0.07 +or- 0.04 ppm d) 0.19 +or- 0.15 ppm e) 0.14 +or- 0.07 ppm f) 0.22 +or- 0.11 ppm g) 0.22 +or- 0.12 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. TRYNOS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5587 Muscle		Dithizone AAS	a) 18 b) 15 c) 17 d) 16 e) 4 f) 35 g) 29	a) 0.01-0.28 ppm b) 0.02-0.48 ppm c) 0.02-0.36 ppm d) 0.02-0.30 ppm e) 0.02-0.11 ppm f) 0.02-0.23 ppm g) 0.01-0.15 ppm Wet wt	a) 0.07 +or- 0.08 ppm b) 0.14 +or- 0.13 ppm c) 0.08 +or- 0.09 ppm d) 0.08 +or- 0.07 ppm e) 0.07 +or- 0.05 ppm f) 0.05 +or- 0.04 ppm g) 0.05 +or- 0.03 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. TRYNOS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71

(NEXT PAGE)

Lead
7439-92-1
Pb
At# 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5548 Pancreas		Dithizone AAS	a) 9 b) 8 c) 15 d) 18 e) 6 f) 50 g) 36	a) 0.02-0.53 ppm b) 0.09-0.35 ppm c) 0.01-2.50 ppm d) 0.00-0.68 ppm e) 0.19-0.61 ppm f) 0.09-1.42 ppm g) 0.11-0.95 ppm Wet wt	a) 0.16 +or- 0.17 ppm b) 0.22 +or- 0.10 ppm c) 0.39 +or- 0.61 ppm d) 0.32 +or- 0.15 ppm e) 0.34 +or- 0.15 ppm f) 0.37 +or- 0.26 ppm g) 0.27 +or- 0.17 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. TRIMMS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5549 Placenta			a) 41 b) 29	a) 48-269 ng/g b) 71-289 ng/g	a) 97 ng/g b) 133 ng/g	a) Subjects drinking water with C.2-43.8 ug/l (mean 11.8 ug/l) b) Subjects drinking water with 61.5-1228.5 ug/l (mean 247.4 ug/l) Residents of Libramont, rural area in south Belgium. BELGIUM; FETUS; NEWBORN; BLOOD; PLACENTA; LEAD; DRINKING WATER; PREGNANCY; RURAL AREAS	Lauwerys, R. Hubermont, G. Buchet, J.P. Roels, H. 1977 Lancet 2(8049):1188
5550 Saliva				a) 6-320 ppb b) 8-45 ppb c) 20-35 ppb d) 10-30 ppb e) Not given f) Not Applicable	a) 44 +or- 41 ppb b) Not given c) Not given d) Not given e) 3 ppb f) 18 ppb	a) Whole saliva, 270 cases, 9-12 yr olds b) Whole saliva, 4 mo later, children in a) with high saliva Pb c) Whole saliva, 2 normal adults d) Whole saliva, 4 Pb-poisoned infants e) Whole saliva, 1 normal infant f) Parotid saliva from adults measured in c) High values in a) possibly caused by intraoral contamination. Massachusetts MASSACHUSETTS; ADULTS; CHILDREN; DENTAL CARIES; LEAD POISONING; BLOOD; SALIVA; TEETH; FLUORIDE; LEAD; BIOACCUMULATION; METALS	Prudevold, F. Aasenden, R. Srinivasian, B.P. Bakhos, Y. 1977 Journal of Dental Research 56(10):1165-1171

(NEXT PAGE)

Lead
7439-92-1
Pb
At# 207.2, BP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5551 Skin		Dithizone AAS	a) 13 b) 14 c) 14 d) 15 e) 4 f) 26 g) 20	a) 0.02-1.90 ppm b) 0.02-1.70 ppm c) 0.01-0.63 ppm d) 0.04-1.80 ppm e) 0.15-0.70 ppm f) 0.01-0.60 ppm g) 0.03-0.42 ppm Wet wt	a) 0.20 +or- 0.51 ppm b) 0.46 +or- 0.40 ppm c) 0.18 +or- 0.18 ppm d) 0.43 +or- 0.48 ppm e) 0.34 +or- 0.25 ppm f) 0.19 +or- 0.14 ppm g) 0.15 +or- 0.11 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5552 Spleen		Dithizone AAS	a) 13 b) 15 c) 20 d) 17 e) 5 f) 59 g) 34	a) 0.02-0.53 ppm b) 0.04-0.54 ppm c) 0.02-0.71 ppm d) 0.03-0.23 ppm e) 0.05-0.21 ppm f) 0.03-1.43 ppm g) 0.04-1.40 ppm Wet wt	a) 0.12 +or- 0.14 ppm b) 0.17 +or- 0.14 ppm c) 0.15 +or- 0.13 ppm d) 0.12 +or- 0.05 ppm e) 0.14 +or- 0.06 ppm f) 0.23 +or- 0.25 ppm g) 0.21 +or- 0.26 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71

(NEXT PAGE)

Lead
7439-[redacted]
PE
AtW 207.2, BP 327.4 C, BP 1740 C, VP [illegible] mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5553 Stomach		Dithizone AAS	a) 14 b) 15 c) 13 d) 16 e) 4 f) 32 g) 26	a) 0.03-0.32 ppm b) 0.03-0.47 ppm c) 0.01-0.14 ppm d) 0.03-0.20 ppm e) 0.04-0.14 ppm f) 0.03-0.25 ppm g) 0.02-0.42 ppm Wet wt	a) 0.10 +or- 0.10 ppm b) 0.16 +or- 0.12 ppm c) 0.06 +or- 0.04 ppm d) 0.10 +or- 0.05 ppm e) 0.09 +or- 0.04 ppm f) 0.09 +or- 0.05 ppm g) 0.11 +or- 0.10 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Disease factors in deaths of infants did not appear to be related to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5554 Teeth		AAS	13	Not given	39 +or- 4.4 ppm	Median, 39 ppm Comparison with data from stored specimens indicates an increase of about 20% in half a generation. Stillborn or neonatal deaths, 1972-73, Bristol, United Kingdom AUTOPSIES; NEWBORN; UNITED KINGDOM; TEETH; CADMIUM; IRON; LEAD; MANGANESE; METALS; NICKEL; ZINC	Stack, M.V. Burkitt, A.J. Wicklens, G. 1976 Bulletin of Environmental Contamination and Toxicology 16(6):764-766
5555 Teeth			270	a) 170-5920 ppm b) Not given c) Not given d) Not given e) Not given f) Not given	a) Not given b) 4430 +or- 1660 ppm c) 2060 +or- 1110 ppm d) 1250 +or- 810 ppm e) 1800 +or- 1160 ppm f) 1670 +or- 1160 ppm	a) 0.6-3.6 um, 251 cases b) 0.6-< 0.9 um (means 0.75 um), 3 cases c) 1.5-<1.8 um (mean 1.7 um), 35 cases d) 2.4-3.6 um (mean 2.8 um), 55 cases e) Mean 2.1 +or- 0.6 um, mean age 121 +or- 6 mo, 135 cases f) Mean 2.1 +or- 0.5 um, mean age 103 +or- 7 mo, 135 cases Depth of enamel biopsy, maxillary central incisor Levels greater in shallow biopsies and younger children High enamel Pb associated with high prevalence of caries. 9-12 yr olds, Cambridge, MA MASSACHUSETTS; ADULTS; CHILDREN; DENTAL CARIES; LEAD POISONING; BLOOD; SALIVA; TEETH; FLUORIDE; LEAD; BIOACCUMULATION; METALS	Brudevold, F. Aasenden, R. Srinivasan, S.R. Bakhos, Y. 1977 Journal of Dental Research 56(10):1165-1171
5556 Teeth						Review. Intake by children, body burden of total population, sources of exposure, and toxicological significance. MASSACHUSETTS; ADULTS; CHILDREN; INFANTS; LEAD POISONING; MENTAL RETARDATION; NEUROLOGIC MANIFESTATIONS; BLOOD; TEETH; URINE; LEAD; DIETS; INDUSTRIAL EMISSIONS; PAINTS; RURAL AREAS; URBAN AREAS; REVIEW; METALS	Anon 1975 Food and Cosmetics Toxicology 13:277-282

(NEXT PAGE)

Lead
7439-92-1
Pb
Atw 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5557 Teeth						Review. Pb implicated as a serious public health problem. Effects on mental function and development in children discussed. FINLAND; GERMANY; ITALY; SWEDEN; UNITED KINGDOM; CHILDREN; NEWBORN; ANEMIA; LEAD POISONING; MENTAL RETARDATION; BLOOD; TEETH; LEAD; AUTOMOTIVE; AIR POLLUTION; ATMOSPHERE; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; FOODS; FUMES; INDUSTRIAL EMISSIONS; INHALATION; PAINTS; PREGNANCY; RURAL AREAS; URBAN AREAS; VEGETABLES; REVIEW; METALS	Bryce-Smith, D. Mathews, J. Stephens, R. 1978 Ambio 7(5-6):193-203
5558 Teeth		AAS	a) 51 b) 42 c) 38	a) 5.4-110.7 ppm b) 2.3-68.0 ppm c) 1.2-69.3 ppm	a) 35.35 ppm b) 17.72 ppm c) 21.45 ppm	a) Hoboken (industrial), mean tooth age 33.35 yr b) Brussels (urban), mean tooth age 38.91 yr c) Arlon (rural), mean tooth age 35.91 yr Regression analysis indicates highest levels for a) and lowest for c) Residents of Belgium BELGIUM; ADULTS; AGE; CHILDREN; TEETH; LEAD; METALS; INDUSTRIAL AREAS; POPULATION EXPOSURE; RURAL AREAS; URBAN AREAS	Steenhout, A. Pourtois, M. 1981 British Journal of Industrial Medicine 38:297-303
5559 Thymus		Dithizone AAS	a) 11 b) 8 c) 11 d) 8	a) 0.02-0.78 ppm b) 0.03-0.12 ppm c) 0.01-0.36 ppm d) 0.05-0.10 ppm Wet wt	a) 0.17 +or- 0.22 ppm b) 0.07 +or- 0.03 ppm c) 0.11 +or- 0.11 ppm d) 0.08 +or- 0.02 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71

(NEXT PAGE)

Lead
7439-92-1
Pb
AtW 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5560 Thyroid gland		Dithizone AAS	a) 8 b) 8 c) 13 d) 17 e) 5 f) 5a g) 30	a) 0.02-0.26 ppm b) 0.05-1.30 ppm c) 0.01-1.10 ppm d) 0.04-0.80 ppm e) 0.07-0.26 ppm f) 0.05-1.45 ppm g) 0.04-1.73 ppm Wet wt	a) 0.11 +or- 0.09 ppm b) 0.41 +or- 0.55 ppm c) 0.21 +or- 0.28 ppm d) 0.21 +or- 0.18 ppm e) 0.16 +or- 0.07 ppm f) 0.19 +or- 0.23 ppm g) 0.21 +or- 0.30 ppm Wet wt	a) Stillbirths b) Live births c) Children, 1-11 mo d) Children, 1-9 yr e) Boys, 11-16 yr f) Men g) Women Cortex Autopsies from children, 1966-1979 and from contemporary adults. Industrial area, northwest England Infant deaths apparently unrelated to Pb. THYMUS; CONNECTIVE TISSUE; UNITED KINGDOM; ADOLESCENTS; ADULTS; AGE; AUTOPSIES; CHILDREN; INFANTS; NEWBORN; ADIPOSE TISSUE; ADRENAL GLANDS; AORTA; BLOOD; BONES; BRAIN; CARTILAGE; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; RIBS; SKIN; SPLEEN; STOMACH; THYROID GLANDS; LEAD; INDUSTRIAL AREAS; POPULATION EXPOSURE	Barry, P.S.I. 1981 British Journal of Industrial Medicine 38:61-71
5561 Urine			a) 48 b) 45	a) 250-4700 ug b) 100-3500 ug	a) Not given b) Not given	a) Current occupational exposure (1 yr or more) b) Past occupational exposure (ending 1 yr prior to study) 24 hr excretion after 1 g EDTA, IV Erythrocyte protoporphyrin and delta-aminolevulinic acid dehydratase useful in establishing persistence, extent of Pb in subjects with past exposure. ITALY; ADULTS; BLOOD; URINE; LEAD; LEVULINIC ACIDS; METALS; PROTOPORPHYRINS; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Alessio, L. Castoldi, M.P. Odone, P. Franchini, I. 1981 British Journal of Industrial Medicine 38: 262-267
5562 Urine						Review. Intake by children, body burden of total population, sources of exposure, and toxicological significance. MASSACHUSETTS; ADULTS; CHILDREN; INFANTS; LEAD POISONING; MENTAL RETARDATION; NEUROLOGIC MANIFESTATIONS; BLOOD; TEETH; URINE; LEAD; DIETS; INDUSTRIAL EMISSIONS; PAINTS; RURAL AREAS; URBAN AREAS; REVIEW; METALS	Anon 1975 Food and Cosmetics Toxicology 13:277-282

(NEXT PAGE)

Lead
7439-92-1
Pb
Atw 207.2, MP 327.4 C, BP 1740 C, VP 1.77 mm Hg at 1000 C, 1 mm Hg at 970 C, 10 mm Hg at 1160 C
(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5563 Urine		AAS	a) 25 b) 68	a) 15.2-297.9 ug/g creatinine b) 2.53-42.9 ug/g creatinine	a) 89.1 ug/g creatinine b) 13.3 ug/g creatinine	a) Exposed group b) Controls 22.7-62.9 yr old workers at smelter, 68% smokers, mean exposure 13.2 yr. 19.8-64.8 yr old controls, 38% smokers. Free erythrocyte porphyrins and urinary delta-aminolevulinic acid increased CADMIUM; LEAD; MERCURY; METALS; OCCUPATIONAL HAZARDS; POPULATION EXPOSURE; BLOOD; URINE; SMELTERS; INDUSTRIAL PLANTS; SMOKING; COMPARATIVE EVALUATIONS; HEALTH HAZARDS	Buchet, J.P. Roels, H. Bernard, A. Lauwerys, R. 1980 Journal of Occupational Medicine 22(11) 741-750
5564 Urine		AAS	a) 23 b) 29 c) 7 d) 25 e) 41 f) 11 g) 21 h) 19 i) 11 j) 26 k) 16 l) 28	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given g) Not given h) Not given i) Not given j) Not given k) Not given l) Not given	17.7 +or- 1.6 ug/l b) 14.9 +or- 1.7 ug/l c) 15.8 +or- 2.5 ug/l d) 16.4 +or- 2.2 ug/l e) 10.8 +or- 0.9 ug/l f) 12.4 +or- 1.8 ug/l g) 11.0 +or - 1.1 ug/l h) 9.0 +or- 0.9 ug/l i) 12.5 +or- 2.9 ug/l j) 14.7 +or- 1.3 ug/l k) 8.9 +or- 1.2 ug/l l) 7.6 +or- 0.8 ug/l	a) Males, 1-16 yr old, Los Angeles, CA (also b-f) b) Males, 17-34 yr old c) Males, >35 yr old d) Females 1-16 yr old e) Females 17-34 yr old f) Females >35 yr old g) Males, 1-16 yr old, Lancaster, CA (also h-l) h) Males, 17-34 yr old i) Males, >35 yr old j) Females, 1-16 yr old k) Females, 17-34 yr old l) Females, >35 yr old Air and soil Pb, 6.3 ug/cu m and 673-3633 ug/g for a-f, 0.64 ug/cu m and 82.5-98.4 (mean 66.8) ug/g for h-l Residents of CA CALIFORNIA; ADULTS; CHILDREN; BLOOD; HAIR; URINE; COMPARATIVE EVALUATIONS; LEAD; METALS; PALLADIUM; PLATINUM; ATMOSPHERE; POPULATION EXPOSURE; RURAL AREAS; SOILS; URBAN AREAS	Johnson, D.E. Tillery, J.B. Prevost, R.J. 1975 Environmental Health Perspectives 12:27-33
5565 Urine			10	1.0-5.0 uM/mM EDTA	Not given	Excretion after Ca EDTA, 50 mg/kg/day, IM Estimated from graph Dose-effect, dose response and critical organ, critical effect concepts reviewed. Chelatable Pb linearly related to both urinary delta-amino levulinic acid and erythrocyte protoporphyrin. Children MARYLAND; CHILDREN; METAL POISONING; BLOOD; URINE; LEAD; METALS	Chisolm, J.J. Barrett, M.B. Kellits, E.D. 1975 Journal of Pediatrics 87(6):1152-1160
5566 Urine		AAS	a) 50 b) 4 c) 5 d) 9 e) 28	a) Not given b) Not given c) Not given d) Not given e) Not given	a) 146 +or- 144 ug/l b) 325 +or- 167 ug/l c) 46 +or- 32 ug/l d) 189 +or- 155 ug/l e) 77 +or- 92 ug/l	a) Hyperactive b) History of Pb poisoning c) Hyperactivity not Pb related d) Hyperactivity probably Pb related e) Controls Significant differences between controls and a), b) and d) 3.5-12 yr olds NEW YORK; CHILDREN; METAL POISONING; BEHAVIOR DISORDERS; BLOOD; URINE; LEAD; METALS	David, O. 1977 International Symposium, Proceedings of Recent Advances in the Assessment of the Health Effects of Environmental Pollution, Volume 3, Paris, 1976:1549-1555

Lithium
7439-93-2
Li
At# 6.941, MP 180.54 C, BP 1336 C, VP 1 mm Hg at 723 C, 10 mm Hg at 890 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5567 Blood, plasma	Injection	Flame photometry		a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given g) Not given h) Not given i) Not given	a) 0.00322 +or- 0.00046 mEq/l b) 0.00475 +or- 0.00100 mEq/l c) 0.01236 +or- 0.00227 mEq/l d) 0.00330 mEq/l e) 0.00315 mEq/l f) 0.00470 mEq/l g) 0.00480 mEq/l h) 0.01249 mEq/l i) 0.01224 mEq/l	a) Andean cordillera region (Parinacota), 10 subjects b) Sierra region (Putre), 10 subjects c) Coastal region (Poconchile), 10 subjects d) Men, region a) e) Women, region b) f) Men, region b) g) Women, region b) h) Men, region c) i) Women, region c) Because of cell preservative used for collection of specimens, increase arithmetic means by about 20% to obtain absolute measures. Exposed 10-62 yr olds, northern Chile, 1968-70. Increased death rates from arteriosclerotic heart disease in Poconchile possibly related to high Li exposure. CHILE; ADULTS; CHILDREN; SEX; HEART DISEASES; BLOOD PLASMA; COMPARATIVE EVALUATIONS; LITHIUM; METALS; BIOACCUMULATION; DRINKING WATER; HEALTH HAZARDS	Zaldivar, F. 1980 Archives of Toxicology 46:319-320
5568 Teeth		MS	208	a) Not given b) Not given	a) 0.35 +or- 0.02 ppm b) 0.07 +or- 0.02 ppm S.E.	a) High caries donors (>7 decayed, missing, filled teeth (DMFT)), 13 teeth b) Low caries donors (<4 DMFT), 7 teeth Values for enamel a) and b) differed, P<0.05 Premolars extracted, patients <20 yr old New England ZIRCONIUM; NEW HAMPSHIRE; SOUTH CAROLINA; VERMONT; DENTAL CARIES; TEETH; ALUMINUM; BARIUM; COPPER; FLUORINE; LITHIUM; METALS; SILVER; STRONTIUM; TIN	Curzon, M.E.J. Losee, F.L. 1977 Journal of the American Dental Association 94(6):1146-1150

o-Xylene (8 CI)
Benzene, 1,3-dimethyl- (9 CI)
108-38-3
C8-H10
MW 106.16, MP -47.4 C, VP 10 mm Hg at 28.3 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5569 Blood	Inhalation	GC	22	a) 6-12 umol/l b) 12-18 umol/l c) 24-48 umol/l d) 60 umol/l e) 117 umol/l	a) Not given b) Not given c) Not given d) Not given e) Not given	a) Sedentary subjects, constant atmospheric exposure of 8.1 umol/l b) Exercising subjects, constant exposure of 8.1 umol/l c) Exercising subjects, fluctuating exposure of 3.7-8.2 umol/l d) Resting subjects, constant exposure of 8.2 umol/l e) Exercising subjects, constant exposure of 8.2 umol/l Healthy men, mean age 28.0 yr, mean wt 71.4 kg. Vestibular equilibrium affected. Subjects adapted except when exposure conditions fluctuated. INDUSTRIAL CHEMICALS; ADULTS; BLOOD; HEALTH HAZARDS; INHALATION; BENZENES	Savolainen, K. Riihimaki, V. 1981 Acta Pharmacologica et Toxicologica 48:279-283

Magnesium
7439-95-4
Mg
Atw 24.30?, MP 651 C, BP 1100 C, VP 1 mm Hg at 621 C, 10 mm Hg at 740 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5570 Blood, plasma	Ingestion	AAS	a) 46 b) 81	a) Not given b) Not given	a) 1.58 +or- 0.037 mEq/l b) 1.45 +or- 0.025 mEq/l	a) Retained < 40% of load b) Retained > than 40% of load Levels before 20-24 mEq of Mg (0.4-0.5 mEq/kg of estimated lean body wt) IV over 45 min Plasma Mg unreliable guide to Mg status of individual. Only values <1.2 mEq/l could be matched with high Mg retention Postpartum women, 17-30 yr old MISSOURI; NUTRITIONAL DEFICIENCIES; BLOOD PLASMA; BODY; MAGNESIUM; DIETS; PREGNANCY	Caddell, J.L. Saier, W.L. Thomason, C.R. 1975 American Journal of Clinical Nutrition 28(10):1099-1103
5571 Hair		NA	71	a) 140-775 ug/g b) 80-1010 ug/g c) Not given d) Not given e) Not given f) Not given	a) 380 +or- 200 ug/g b) 320 +or- 220 ug/g c) 320 ug/g d) 460 ug/g e) 360 ug/g f) 280 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278

(NEXT PAGE)

Magnesium
7439-95-4
Mg
AtW 24.305, MP 651 C, BP 1190 C, VP 1 mm Hg at 621 C, 10 mm Hg at 740 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5572 Nail		NR	Not given	a) Not given b) Not given	a) 740 +or- 650 ug/g b) 650 +or- 300 ug/g	a) Women b) Men Toenail sample of about 6 mg Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5573 Urine	Injection	AAS	185	a) 0-100% b) Not given c) Not given d) Not given e) Not given f) Not given	a) 51.0 +or- 2.2% b) 90.5 +or- 7.6% c) 96.6 +or- 1.6% d) 56.9 +or- 3.3% e) 77.91 +or- 7.82% f) 45.0 +or- 3.52% S.E.	a) All mothers b) 3 multiparous mothers under 17 yr old c) 8 17-30 yr old mothers of twins d) 76 17-30 yr old mothers of singletons e) 6 primiparous mothers with labor exceeding 18 hr f) 70 primiparous mothers with labor less than 18 hr % retention after 20-24 meq Mg (0.4-0.5 mEq/kg of estimated lean body wt) IV over 45 min Calculated from net urinary excretion 24 hr after load e) different from f) (P<0.005) Postpartum women MISSOURI; NUTRITIONAL DEFICIENCIES; BLOOD PLASMA; BODY; MAGNESIUM; DIETS; PREGNANCY	Caddell, J.L. Saier, E.L. Thomasson, C.A. 1975 American Journal of Clinical Nutrition 28(10):1099-1103

Magnetite (8 CI)
Magnetite (Fe_3O_4) (9 CI)
1309-38-2
Fe3-O4
MW 231.55, MP 1538 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5574 Lung		Magnetometry				Review Lung contamination was determined in welders, foundry workers, and iron and steel factory workers in Finland, by measuring the remanent magnetic moment of lung retained particles FINLAND; LUNGS; IN VIVO ANALYSIS; MEASUREMENT METHODS; REVIEW; IRON; METALS; DUST; FUMES; INDUSTRIAL PLANTS; OCCUPATIONAL HAZARDS; PARTICULATES	Kalliomaki, K. Aittoniemi, K. Kalliomaki, P-L. Moilanen, M. 1981 American Industrial Hygiene Association Journal 42(3):234-238

Manganese
7439-96-5
Mn
AtW 54.9380. MP 1244 C, BP 2095 C, VP 1 mm Hg at 1292 C, 10 mm Hg at 1510 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5575 Blood, cells		NA	a) 25 b) 21 c) 10 d) 10 e) 8 f) 4 g) 5	a) 8.1-20.5 ng/g b) 9.3-36.9 ng/g c) Not given d) Not given e) Not given f) Not given g) Not given	a) 13.6 +or- 3.2 ng/g b) 16.9 +or- 6.0 ng/g c) 18.8 +or- 9.2 ng/g d) 18.9 +or- 10.3 ng/g e) 13.7 +or- 2.8 ng/g f) 14.8 +or- 4.0 ng/g g) 18.2 +or- 10.2 ng/g Wet wt	a) Controls, male b) Controls, female c) Acute viral hepatitis, active phase d) Acute viral hepatitis, subsiding phase e) Chronic persistent hepatitis f) Chronic aggressive hepatitis g) Postnecrotic cirrhosis Patients with hepatic disease, Belgium LIVER DISEASES; BLOOD SERUM; ERYTHROCYTES; COPPER; MANGANESE; METALS; ZINC; BELGIUM	Versieck, J. Barbier, F. Speecke, A. Hoste, J. 1974 Clinical Chemistry 20(9):1141-1145
5576 Blood, serum						Review. Discussion of trace elements as inhibitory or causative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGEN; RATS	Schwartz, M.K. 1975 Cancer Research 35:3481-3487
5577 Blood, serum		NA	a) 25 b) 21 c) 10 d) 10 e) 8 f) 4 g) 5	a) 0.45-1.01 ng/ml b) 0.38-1.04 ng/ml c) Not given d) Not given e) Not given f) Not given g) Not given	a) 0.59 +or- 0.12 ng/ml b) 0.55 +or- 0.14 ng/ml c) 2.32 +or- 0.96 ng/ml d) 0.60 +or- 0.12 ng/ml e) 0.58 +or- 0.13 ng/ml f) 0.84 +or- 0.24 ng/ml g) 0.84 +or- 0.20 ng/ml	a) Controls, male b) Controls, female c) Acute viral hepatitis, active phase d) Acute viral hepatitis, subsiding phase e) Chronic persistent hepatitis f) Chronic aggressive hepatitis g) Postnecrotic cirrhosis Patients with hepatic disease, Belgium LIVER DISEASES; BLOOD SERUM; ERYTHROCYTES; COPPER; MANGANESE; METALS; ZINC	Versieck, J. Barbier, F. Speecke, A. Hoste, J. 1974 Clinical Chemistry 20(9):1141-1145
5578 Bone						Review. Discussion of trace elements as inhibitory or causative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGEN; RATS	Schwartz, M.K. 1975 Cancer Research 35:3481-3487
5579 Breast						Review. Discussion of trace elements as inhibitory or causative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGEN; RATS	Schwartz, M.K. 1975 Cancer Research 35:3481-3487

(NEXT PAGE)

Manganese
7439-96-5
Mn
At# 54.9380, MP 1244 C, BP 2095 C, VP 1 mm Hg at 1292 C, 10 mm Hg at 1510 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5580 Hair		NA	71	a) 2-83 ug/g b) 2-87 ug/g c) Not given d) Not given e) Not given f) Not given	a) Not given b) Not given c) 16 ug/g d) 30 ug/g e) 10 ug/g f) 14 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5581 Hair		AAS	1	0-1.3 ppm	Not given	Data for various body regions. Maximum levels in leg and beard. Estimated from graph 23 yr old, United Kingdom ADULTS; HAIR; COMPARATIVE EVALUATIONS; ALUMINUM; CHROMIUM; COBALT; COPPER; IRON; MANGANESE; METALS; NICKEL; SILICON; SILVER; UNITED KINGDOM	Alder, J.F. Samuel, A.J. West, T.S. 1977 Analytica Chimica Acta 92:217-221
5582 Liver						Review. Discussion of trace elements as inhibitory or causative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGEN; RATS	Schwartz, M.K. 1975 Cancer Research 35:3481-3487
5583 Nail		NA	Not given	a) Not given b) Not given	a) 6.8 +or- 9.8 ug/g b) 3.8 +or- 1.9 ug/g	a) Women b) Men Toenail samples of about 6 mg Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5584 Teeth		AAS	13	Not given	6 +or- 2 ppm	Median, 6.5 ppm Stillborn or neonatal deaths, 1972-73, Bristol, United Kingdom UNITED KINGDOM; AUTOPSIES; NEWBORN; TEETH; CADMIUM; IRON; LEAD; MANGANESE; METALS; NICKEL; ZINC	Stack, M.V. Burbitt, A.J. Nickless, G. 1976 Bulletin of Environmental Contamination and Toxicology 16(6):764-766

(NEXT PAGE)

Manganese
7439-96-5
Mn
Atw 54.9380, MP 1244 C, BP 2095 C, VP 1 mm Hg at 1292 C, 10 mm Hg at 1519 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5585 Urine			8	45.00-1350.00 ug/l	288 ug/l	Welders exposed to fumes from a low hydrogen electrode welding torch. INDUSTRIAL CHEMICALS; URINE; INDUSTRIAL MEDICINE; MANGANESE; FUMES; INDUSTRIAL AREAS; INHALATION; OCCUPATIONAL HAZARDS	Singh, N. Gupta, V.P. 1975 Environmental Pollution and Human Health: Proceedings of the International Symposium on Industrial Toxicology, November 4-7, 1975

Mercury
7439-97-6
Hg
Atw 200.59, MP -38.87 C, BP 356.72 C, VP 2X10(E-3) mm Hg at 25 C, 100 mm Hg at 260 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5586 Adrenal gland	Ingestion	AAS	24	0.03-0.33 ug/g wet wt	0.14 +or- 0.073 ug/g wet wt	30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-299)
5587 Amniotic fluid						Review. Mercury poisoning in pregnancy, data based on sources of contamination, maternal uptake, and distribution. Mental confusion, convulsions, & coma in adults. Children born with brain damage, chorea, ataxia, tremors, seizures, and mental retardation. ICWA; IRAQ; JAPAN; NEW MEXICO; SWEDEN; TENNESSEE; FETUS; INFANTS; MENTAL RETARDATION; METAL POISONING; AMNIOTIC FLUID; BLOOD; BODY; BRAIN; HAIR; MILK; PLACENTA; URINE; MERCURY; METALS; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; INHALATION; LACTATION; PREGNANCY; REVIEW	Koos, B.J. Longo, L.D. 1976 American Journal of Obstetrics and Gynecology 126(3):390-409
5588 Blood	Ingestion	AAS	19	0.016-0.11 ug/g wet wt	0.059 +or- 0.026 ug/g wet wt	30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)

(NEXT PAGE)

Mercury
7439-97-6
Hg
Atw 200.59, MP -38.87 C, BP 356.72 C, VP 2X10(E-3) mm Hg at 25 C, 100 mm Hg at 260 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5589 Blood						Review. Mercury poisoning in pregnancy, data based on sources of contamination, maternal uptake, and distribution. Mental confusion, convulsions, & coma in adults. Children born with brain damage, chorea, ataxia, tremors, seizures, and mental retardation. IOWA; IRAQ; JAPAN; NEW MEXICO; SWEDEN; TENNESSEE; FETUS; INFANTS; MENTAL RETARDATION; METAL POISONING; AMNIOTIC FLUID; BLOOD; BODY; BRAIN; HAIR; MILK; PLACENTA; URINE; MERCURY; METALS; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; INHALATION; LACTATION; PREGNANCY; REVIEW	Koos, B.J. Longo, L.D. 1976 American Journal of Obstetrics and Gynecology 126(3):390-409
5590 Blood	Ingestion		a) 1 b) 1 c) 1	a) 78-81 ng/ml b) 44-68 ng/ml c) 33-75 ng/ml	a) Not applicable b) Not applicable c) Not applicable	a) 25 yr old woman b) 10 yr old boy c) 10 yr old girl About 1-2 mo and 7 mo after eating bread made from methyl-Hg treated wheat Iraq Patients a) and b) had neuromuscular disorders responsive to neostigmine therapy. All had CNS disorders typical of Hg poisoning. IRAQ; ADULTS; CASE HISTORIES; CHILDREN; METAL POISONING; BLOOD; MERCURY; MERCURY INORGANIC COMPOUNDS; MERCURY ORGANIC COMPOUNDS; FOOD CONTAMINATION; POPULATION EXPOSURE; WHEAT; METALS	Rustam, H. Von Burg, R. Asim-Zaki, L. Hassani, S.E. 1975 Archives of Environmental Health 30(2):190-195
5591 Blood			a) 63 b) 88	a) 1.16-8.14 ug/100 ml b) 0.84-3.15 ug/100 ml	a) 2.85 ug/100 ml b) 1.71 ug/100 ml	a) Exposed group b) Controls 21.5-54.8 yr old workers in chloralkali plants, 63.5% smokers, mean exposure 6.8 yr. 19.8-64.8 yr old controls, 38% smokers. Glomerular dysfunction. Increased beta-galactosidase activity CADMIUM; LEAD; MERCURY; METALS; OCCUPATIONAL HAZARDS; POPULATION EXPOSURE; BLOOD; URINE; SMELTERS; INDUSTRIAL PLANTS; SMOKING; COMPARATIVE EVALUATIONS; HEALTH HAZARDS	Buchet, J.P. Roels, H. Bernard, A. Lauwerys, R. 1980 Journal of Occupational Medicine 22(11):741-750

(NEXT PAGE)

Mercury
7439-97-6
Hg
AtW 200.59, MP -38.87 C, BP 356.72 C, VP 2X10(E-3) mm Hg at 25 C, 100 mm Hg at 260 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5592 Body						Review. Mercury poisoning in pregnancy, data based on sources of contamination, maternal uptake, and distribution. Mental confusion, convulsions, & coma in adults. Children born with brain damage, chorea, ataxia, tremors, seizures, and mental retardation. IOWA; IRAQ; JAPAN; NEW MEXICO; SWEDEN; TENNESSEE; FETUS; INFANTS; MENTAL RETARDATION; METAL POISONING; AMNIOTIC FLUID; BLOOD; BODY; BRAIN; HAIR; MILK; PLACENTA; URINE; MERCURY; METALS; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; INHALATION; LACTATION; PREGNANCY; REVIEW	Koos, B.J. Longo, L.D. 1976 American Journal of Obstetrics and Gynecology 126(3):390-409
5593 Brain	Ingestion	AAS		a) 0.039-0.17 ug/g wet wt b) 0.048-0.23 ug/g wet wt	a) 0.10 +or- 0.042 ug/g wet wt b) 0.1 +or- 0.045 ug/g wet wt	a) Cerebrum, 20 cases b) Cerebellum, 21 cases Values for males > females, 0.11 and 0.089 ug/g respectively 30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5594 Brain						Review. Mercury poisoning in pregnancy, data based on sources of contamination, maternal uptake, and distribution. Mental confusion, convulsions, & coma in adults. Children born with brain damage, chorea, ataxia, tremors, seizures, and mental retardation. IOWA; IRAQ; JAPAN; NEW MEXICO; SWEDEN; TENNESSEE; FETUS; INFANTS; MENTAL RETARDATION; METAL POISONING; AMNIOTIC FLUID; BLOOD; BODY; BRAIN; HAIR; MILK; PLACENTA; URINE; MERCURY; METALS; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; INHALATION; LACTATION; PREGNANCY; REVIEW	Koos, B.J. Longo, L.D. 1976 American Journal of Obstetrics and Gynecology 126(3):390-409
5595 Hair	Ingestion	AAS		a) 1.4-15 ug/g wet wt b) 1.0-14 ug/g wet wt	a) 4.1 +or- 2.6 ug/g wet wt b) 3.8 +or- 2.5 ug/g wet wt	a) Scalp, 29 cases b) Pubic, 24 cases Values for males > females, 5.1 and 2.7 ug/g respectively 30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)

(NEXT PAGE)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5596 Hair		AAS	a) 139 b) 20 c) 184 d) 57	a) Not given b) Not given c) Not given d) Not given	a) 18.11 +or- 1.1 ppm b) 15.9 +or- 0.96 ppm c) 17.0 +or- 0.71 ppm d) 14.3 +or- 0.62 ppm	a) Controls, girls b) Learning disability, girls c) Controls, boys d) Learning disability, boys d) significantly lower than c) (P<0.005). Mean air levels 1.1 +or- 0.6 and 1.9 +or- 1.2 ng/cu m at two schools. 9-12 yr olds, Akron, OH CHILDREN; HAIR; ARSENIC; CADMIUM; LEAD; MERCURY; METALS; SELENIUM; POPULATION EXPOSURE	Ely, D.L. Mostardi, R.A. Woebkenberg, M. Worstell, D. 1981 Environmental Research 25:325-339
5597 Hair		NA	71	a) 3-15 ug/g b) 1.1-27 ug/g c) Not given d) Not given e) Not given f) Not given	a) Not given b) Not given c) 8 ug/g d) 6.7 ug/g e) 9.1 ug/g f) 8 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1978 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5598 Hair						Review. Mercury poisoning in pregnancy, data based on sources of contamination, maternal uptake, and distribution. Mental confusion, convulsions, & coma in adults. Children born with brain damage, chorea, ataxia, tremors, seizures, and mental retardation. IOWA; IRAQ; JAPAN; NEW MEXICO; SWEDEN; TENNESSEE; FETUS; INFANTS; MENTAL RETARDATION; METAL POISONING; AMNIOTIC FLUID; BLOOD; BODY; BRAIN; HAIR; MILK; PLACENTA; URINE; MERCURY; METALS; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; INHALATION; LACTATION; PREGNANCY; REVIEW	Koos, B.J. Longo, L.D. 1976 American Journal of Obstetrics and Gynecology 126(3):390-409
5599 Heart	Ingestion	AAS	29	0.023-0.13 ug/g wet wt	0.069 +or- 0.28 ug/g wet wt	Values for females > males, 0.085 and 0.058 ug/g respectively 30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 250-298)

(NEXT PAGE)

Mercury
7439-97-6
Hg
At# 200.59, MP -38.87 C, BP 356.72 C, VP 2X10(E-3) mm Hg at 25 C, 100 mm Hg at 260 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5600 Intestine	Ingestion	AAS		a) 0.024-0.19 ug/g wet wt b) 0.032-0.16 ug/g wet wt	a) 0.069 +or- 0.037 ug/g wet wt b) 0.083 +or- 0.037 ug/g wet wt	a) Small intestine, 25 cases b) Colon, 27 cases Values for females > males, 0.08 and 0.057 ug/g respectively 30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Nayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5601 Kidney	Ingestion	AAS	30	0.18-2.6 ug/g wet wt	1.1 +or- 0.67 ug/g wet wt	Values for females > males, 1.2 and 0.97 ug/g respectively 30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Nayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5602 Liver	Ingestion	AAS	30	0.16-1.3 ug/g wet wt	0.47 +or- 0.26 ug/g wet wt	Values for females > males, 0.52 and 0.42 ug/g respectively 30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Nayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5603 Lung	Ingestion	AAS	28	0.015-0.30 ug/g wet wt	0.080 +or- 0.054 ug/g wet wt	30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Nayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)

(NEXT PAGE)

Mercuri,
7439-97-6
Hg
At# 200.59, MP -38.87 C, BP 356.72 C, VP 2X10(E-3) mm Hg at 25 C, 100 mm Hg at 260 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5604 Milk						Review. Mercury poisoning in pregnancy, data based on sources of contamination, maternal uptake, and distribution. Mental confusion, convulsions, & coma in adults. Children born with brain damage, chorea, ataxia, tremors, seizures, and mental retardation. IOWA; IRAQ; JAPAN; NEW MEXICO; SWEDEN; TENNESSEE; FETUS; INFANTS; MENTAL RETARDATION; METAL POISONING; AMNIOTIC FLUID; BLOOD; BODY; BRAIN; HAIR; MILK; PLACENTA; URINE; MERCURY; METALS; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; INHALATION; LACTATION; PREGNANCY; REVIEW	Koos, B.J. Longo, L.D. 1976 American Journal of Obstetrics and Gynecology 126(3):390-409
5605 Muscle	Ingestion	AAS	27	0.018-0.15 ug/g wet wt	0.060 +or- 0.027 ug/g wet wt	Values for females > males, 0.064 and 0.056 ug/g respectively 30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5606 Ovary	Ingestion	AAS	14	Not given	0.069 ug/g wet wt	30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5607 Pancreas	Ingestion	AAS	30	0.023-0.29 ug/g wet wt	0.083 +or- 0.048 ug/g wet wt	30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)

(NEXT PAGE)

Mercury
7439-97-6
Hg
AtW 200.59, MP -38.87 C, BP 356.72 C, VP 2X10(E-3) mm Hg at 25 C, 100 mm Hg at 260 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5608 Pituitary	Ingestion	AAS	17	0.022-0.81 ug/g wet wt	0.17 +or- 0.11 ug/g wet wt	30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5609 Placenta						Review. Mercury poisoning in pregnancy, data based on sources of contamination, maternal uptake, and distribution. Mental confusion, convulsions, & coma in adults. Children born with brain damage, chorea, ataxia, tremors, seizures, and mental retardation. IOWA; IRAQ; JAPAN; NEW MEXICO; SWEDEN; TENNESSEE; FETUS; INFANTS; MENTAL RETARDATION; METAL POISONING; AMNIOTIC FLUID; BLOOD; BODY; BRAIN; HAIR; MILK; PLACENTA; URINE; MERCURY; METALS; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; INHALATION; LACTATION; PREGNANCY; REVIEW	Koos, B.J. Longo, L.D. 1976 American Journal of Obstetrics and Gynecology 126(3):390-409
5610 Skin	Ingestion	AAS	27	0.017-0.15 ug/g wet wt	0.059 +or- 0.034 ug/g wet wt	Values for females > males, 0.066 and 0.051 ug/g respectively 30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5611 Spleen	Ingestion	AAS	28	0.021-0.14 ug/g wet wt	0.068 +or- 0.028 ug/g wet wt	Value for males > females, 0.073 and 0.064 ug/g respectively 30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)

(NEXT PAGE)

Merc[illegible]
7439[illegible]6
Hg
Atw 200.59, MP -38.87 C, BP 356.72 C, VP 2X10(E-3) mm Hg at 25 C, 100 mm Hg at 260 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5612 Testes	Ingestion	AAS	14	Not given	0.067 ug/g wet wt	30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5613 Trachea	Ingestion	AAS	16	0.015-0.11 ug/g wet wt	0.047 +or- 0.029 ug/g wet wt	Values for females > males, 0.079 and 0.036 ug/g respectively 30 autopsies, mean age 39 yr, Kobe University School of Medicine, 1971-1972. JAPAN; AUTOPSIES; ADRENAL GLANDS; BLOOD; BRAIN; HAIR; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; OVARIES; PANCREAS; PITUITARY GLAND; SKIN; SPLEEN; TESTES; TRACHEA; MERCURY; MERCURY ORGANIC COMPOUNDS; METALS; METHYL RADICALS	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5614 Urine			a) 101 b) 74 c) 33	a) 2-110 ug/l b) 2-300 ug/l c) 2-92 ug/l	a) 23.4 ug/l b) 37.6 ug/l c) 16.8 ug/l	a) Dentists b) Dental assistants preparing amalgams c) Nonexposed dental assistants 8 hr samples 18-56 yr old Californians MERCURY; METALS; OCCUPATIONAL HAZARDS; CALIFORNIA; DENTISTRY; URINE	Schneider, P.P. Bleier, P.P. 1976 Proceedings of a Conference on Women in the Workplace held in Washington, DC, June 17-19, 1976. Eula Bingham (Ed.) Published by Society for Occupational and Environmental Health, pp. 202-213
5615 Urine		AAS	80	a) 0.002-0.56 umol/l b) Undetectable-0.45 umol/l	a) 0.069 umol/l b) 0.038 umol/l	a) Single samples, 80 children, Dec. 1975 b) 24 hr levels, 45 children (Same as in a)), May 1976 No evidence of increased Hg levels in children with mild peripheral neuropathy Tap water Hg undetectable-0.018 umol/l (mean 0.002 umol/l), May 1976 7-13 yr olds, Broadlands hydrothermal area, central North Island, New Zealand NEW ZEALAND; CHILDREN; BLOOD; URINE; MERCURY; METALS; SPINNING; BIOACCUMULATION; DIETS; DRINKING WATER; FISHES; HEALTH HAZARDS; MEATS; SOILS; VEGETABLES; VEGETATION	Bierre, A.P. Gordon, A.S.D. Pybus, J. Lines, D.R. 1977 New Zealand Medical Journal 85(589):468-466
5616 Urine		AAS	a) 12 b) 2	a) 0.035-0.405 umol/24 hr b) 0.743-1.32 umol/24 hr	a) Not given b) Not given	a) Dental workers b) Workers at a Hg switch factory Exposure times and levels not given ADULTS; URINE; MEASUREMENT METHODS; MERCURY; METALS; OCCUPATIONAL HAZARDS	Richardson, R.A. 1976 Clinical Chemistry 22(10):1604-1607

(NEXT PAGE)

Mercury
7439-97-6
Hg
AtW 200.59, MP -38.87 C, BP 356.72 C, VP 2X10(P-3) mm Hg at 25 C, 100 mm Hg = 260 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5617 Urine						Review. Mercury poisoning in pregnancy, data based on sources of contamination, maternal uptake, and distribution. Mental confusion, convulsions, & coma in adults. Children born with brain damage, chorea, ataxia, tremors, seizures, and mental retardation. IOWA; IRAQ; JAPAN; NEW MEXICO; SWEDEN; TENNESSEE; FETUS; INFANTS; MENTAL RETARDATION; METAL POISONING; AMNIOTIC FLUID; BLOOD; BODY; BRAIN; HAIR; MILK; PLACENTA; URINE; MERCURY; METALS; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; INHALATION; LACTATION; PREGNANCY; REVIEW	Koos, B.J. Longo, L.D. 1976 American Journal of Obstetrics and Gynecology 126(3):390-409
5618 Urine			a) 63 b) 88	a) 5.2-236.2 ug/g creatinine b) 0.08-4.96 ug/g creatinine	a) 59.1 ug/g creatinine b) 1.48 ug/g creatinine	a) Exposed group b) Controls 21.6-58.8 yr old workers in chloralkali plants, 63.5% smokers, mean exposure 6.8 yr. 19.8-68.8 yr old controls, 38% smokers. Glomerular dysfunction. Increased beta-galactosidase activity CADMIUM; LEAD; MERCURY; METALS; OCCUPATIONAL HAZARDS; POPULATION EXPOSURE; BLOOD; URINE; SMELTERS; INDUSTRIAL PLANTS; SMOKING; COMPARATIVE EVALUATIONS; HEALTH HAZARDS	Buchet, J.P. Roels, H. Bernard, A. Lauwerys, R. 1980 Journal of Occupational Medicine 22(11):741-750
5619 Urine						Review. Critique of data from workers exposed to toxic chemicals. Wide variations reflect lack of standardizations in sampling and analytical design. INDUSTRIAL CHEMICALS; BLOOD; URINE; INDUSTRIAL MEDICINE; REVIEW; CARBON INORGANIC COMPOUNDS; MERCURY; METALS; ORGANOPHOSPHATES; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Ramaswamy, S.S. 1975 Environmental Pollution and Human Health: Proceedings of the International Symposium on Industrial Toxicology, pp. 166-177
5620 Urine	Inhalation		a) 1 b) 1 c) 1 d) 1 e) 1 f) 1	a) 82-229 ug/24 hr b) 332-784 ug/24 hr c) 16-91 ug/24 hr d) 13-67 ug/24 hr e) 5700-881 ug/24 hr f) 1900-287 ug/24 hr	a) Not applicable b) Not applicable c) Not applicable d) Not applicable e) Not applicable f) Not applicable	a) Before and 1 day after start of chelation, woman b) Same as a), man c) Same as a), 11 yr old d) Same as a), 7 yr old e) 1st and ninth day of chelation therapy, woman f) Same as e), man Two incidents (a-d and e-f) of accidental exposure to mercury fumes. Exact dose unknown. e) and f) estimated from graph Nausea, headache, chills, dry cough and vomiting within 30 min, followed by weakness, perioral numbness, slowed speech and sore gums. Hyperemic gingivae. Pulmonary complications. ADULTS; CASE HISTORIES; CHILDREN; METAL POISONING; URINE; MERCURY; METALS; INHALATION; FUMES	Snodgrass, W. Sullivan, J.B. Rumack, B.H. Hashimoto, C. 1981 Journal of the American Medical Association 246(17):1929-1931

Mercury(1+), methyl-, ion (8 CI)
Mercury(1+), methyl- (9 CI)
22967-92-6
C-83-Hg
MW 215.63

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5621 Blood	Ingestion	GC-EC	12	0.0036-0.026 ug/g wet wt	0.011 +or- 0.0073 ug/g wet wt	30 autopsies, average age 39 yr, Kobe University School of Medicine 1971-1972. MERCURY; METHYL MERCURY COMPOUNDS; MERCURY INGESTION; JAPAN; METALS; BRAIN; PITUITARY GLAND; TRACHEA; LUNGS; HEART; LIVER; PANCREAS; SPLEEN; KIDNEYS; ADRENAL GLANDS; INTESTINES; TESTES; OVARIES; MUSCLES; SKIN; BLOOD; HAIR	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5622 Blood	Ingestion		a) 1 b) 1 c) 1	a) 1092-297 ng/ml b) 2500-768 ng/ml c) 738-446 ng/ml	a) Not applicable b) Not applicable c) Not applicable	a) 25 yr old woman b) 10 yr old boy c) 10 yr old girl About 1-2 mo and 7 mo after eating bread made from methyl-Hg treated wheat. Dose unknown Residents of Iraq Patients a) and b) had neuromuscular disorders responsive to neostigmine therapy. All had CNS disorders typical of Hg poisoning. IRAQ; ADULTS; CASE HISTORIES; CHILDREN; METAL POISONING; BLOOD; MERCURY; MERCURY INORGANIC COMPOUNDS; MERCURY ORGANIC COMPOUNDS; FOOD CONTAMINATION; POPULATION EXPOSURE; WHEAT; METALS	Bustan, H. Von Burg, R. Amin-Zaki, L. Hassani, S.N. 1975 Archives of Environmental Health 30(2):190-195
5623 Blood						Review. Contaminated fish and game caused high levels and mild neurological symptoms in Canadian Indians and Eskimos. 1970-1976 means of 6.7-136 ppb with highest levels of 16-385 ppb for various regions. INDIANS; ESKIMOS; CANADA; CENTRAL NERVOUS SYSTEM DISEASES; METAL POISONING; BLOOD; MERCURY; BIOACCUMULATION; FISHES; FOODS; HEALTH HAZARDS; INDUSTRIAL POLLUTION; WATER POLLUTION	Charlebois, C.T. 1978 Ambio 7(5-6):208-210
5624 Brain	Ingestion	GC-EC		a) 0.0015-0.069 ug/g wet wt b) 0.0015-0.096 ug/g wet wt	a) 0.016 +or- 0.014 ug/g wet wt b) 0.19 +or- 0.020 ug/g wet wt	a) Cerebrum, 20 cases b) Cerebellum, 20 cases Values for males > females, 0.028 and 0.012 ug/g respectively (cerebellum) 30 autopsies, average age 39 yr, Kobe University School of Medicine 1971-1972. MERCURY; METHYL MERCURY COMPOUNDS; MERCURY INGESTION; JAPAN; METALS; BRAIN; PITUITARY GLAND; TRACHEA; LUNGS; HEART; LIVER; PANCREAS; SPLEEN; KIDNEYS; ADRENAL GLANDS; INTESTINES; TESTES; OVARIES; MUSCLES; SKIN; BLOOD; HAIR	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)

(NEXT PAGE)

Mercury(1+), methyl-, ion (8 CI)
Mercury(1+), methyl- (9 CI)
22967-92-6
C-H3-Hg
MW 215.63

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5625 Hair	Ingestion	GC-EC	29	0.63-18 ug/g wet wt	2.6 +or- 2.1 ug/g wet wt	Values for males > females, 3.8 and 1.8 ug/g respectively 30 autopsies, average age 39 yr, Kobe University School of Medicine 1971-1972. MERCURY; METHYL MERCURY COMPOUNDS; MERCURY INGESTION; JAPAN; METALS; BRAIN; PITUITARY GLAND; TRACHEA; LUNGS; HEART; LIVER; PANCREAS; SPLEEN; KIDNEYS; ADRENAL GLANDS; INTESTINES; TESTES; OVARIES; MUSCLES; SKIN; BLOOD; HAIR	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5626 Heart	Ingestion	GC-EC	13	0.0030-0.027 ug/g wet wt	0.0092 +or- 0.0056 ug/g wet wt	Values for males > females, 0.011 and 0.0067 ug/g respectively 30 autopsies, average age 39 yr, Kobe University School of Medicine 1971-1972. MERCURY; METHYL MERCURY COMPOUNDS; MERCURY INGESTION; JAPAN; METALS; BRAIN; PITUITARY GLAND; TRACHEA; LUNGS; HEART; LIVER; PANCREAS; SPLEEN; KIDNEYS; ADRENAL GLANDS; INTESTINES; TESTES; OVARIES; MUSCLES; SKIN; BLOOD; HAIR	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5627 Intestine	Ingestion	GC-EC		a) 0.0030-0.069 ug/g wet wt b) 0.0018-0.026 ug/g wet wt	a) 0.014 +or- 0.017 ug/g wet wt b) 0.0065 +or- 0.0061 ug/g wet wt	a) Small intestine, 24 cases b) Colon, 20 cases Values for males > females, 0.0086 and 0.0047 ug/g respectively (colon) 30 autopsies, average age 39 yr, Kobe University School of Medicine 1971-1972. MERCURY; METHYL MERCURY COMPOUNDS; MERCURY INGESTION; JAPAN; METALS; BRAIN; PITUITARY GLAND; TRACHEA; LUNGS; HEART; LIVER; PANCREAS; SPLEEN; KIDNEYS; ADRENAL GLANDS; INTESTINES; TESTES; OVARIES; MUSCLES; SKIN; BLOOD; HAIR	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
5628 Kidney	Ingestion	GC-EC	29	0.010-0.080 ug/g wet wt	0.023 +or- 0.015 ug/g wet wt	Values for males > females, 0.029 and 0.018 ug/g respectively 30 autopsies, average age 39 yr, Kobe University School of Medicine 1971-1972. MERCURY; METHYL MERCURY COMPOUNDS; MERCURY INGESTION; JAPAN; METALS; BRAIN; PITUITARY GLAND; TRACHEA; LUNGS; HEART; LIVER; PANCREAS; SPLEEN; KIDNEYS; ADRENAL GLANDS; INTESTINES; TESTES; OVARIES; MUSCLES; SKIN; BLOOD; HAIR	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)

(NEXT PAGE)

Mercury(1+), methyl-, ion (8 CI)
Mercury(1+), methyl- (9 CI)
22967-92-6
C-H3-Hg
MW 215.63

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
%629 Liver	Ingestion	GC-EC	30	0.012-0.080 ug/g wet wt	0.044 +or- 0.019 ug/g wet wt	30 autopsies, average age 39 yr, Kobe University School of Medicine 1971-1972. MERCURY; METHYL MERCURY COMPOUNDS; MERCURY INGESTION; JAPAN; METALS; BRAIN; PITUITARY GLAND; TRACHEA; LUNGS; HEART; LIVER; PANCREAS; SPLEEN; KIDNEYS; ADRENAL GLANDS; INTESTINES; TESTES; OVARIES; MUSCLES; SKIN; BLOOD; HAIR	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
%630 Lung	Ingestion	GC-EC	11	0.0023-0.015 ug/g wet wt	0.0065 +or- 0.0034 ug/g wet wt	Values for males > females, 0.0083 and 0.0050 ug/g respectively 30 autopsies, average age 39 yr, Kobe University School of Medicine 1971-1972. MERCURY; METHYL MERCURY COMPOUNDS; MERCURY INGESTION; JAPAN; METALS; BRAIN; PITUITARY GLAND; TRACHEA; LUNGS; HEART; LIVER; PANCREAS; SPLEEN; KIDNEYS; ADRENAL GLANDS; INTESTINES; TESTES; OVARIES; MUSCLES; SKIN; BLOOD; HAIR	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
%631 Muscle	Ingestion	GC-EC	12	0.0041-0.019 ug/g wet wt	0.0078 +or- 0.0043 ug/g wet wt	Values for males > females, 0.0090 and 0.0065 ug/g respectively 30 autopsies, average age 39 yr, Kobe University School of Medicine 1971-1972. MERCURY; METHYL MERCURY COMPOUNDS; MERCURY INGESTION; JAPAN; METALS; BRAIN; PITUITARY GLAND; TRACHEA; LUNGS; HEART; LIVER; PANCREAS; SPLEEN; KIDNEYS; ADRENAL GLANDS; INTESTINES; TESTES; OVARIES; MUSCLES; SKIN; BLOOD; HAIR	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)
%632 Pancreas	Ingestion	GC-EC	29	0.0013-0.033 ug/g wet wt	0.010 +or- 0.0078 ug/g wet wt	30 autopsies, average age 39 yr, Kobe University School of Medicine 1971-1972. MERCURY; METHYL MERCURY COMPOUNDS; MERCURY INGESTION; JAPAN; METALS; BRAIN; PITUITARY GLAND; TRACHEA; LUNGS; HEART; LIVER; PANCREAS; SPLEEN; KIDNEYS; ADRENAL GLANDS; INTESTINES; TESTES; OVARIES; MUSCLES; SKIN; BLOOD; HAIR	Kitamura, S. Sumino, K. Hayakawa, K. Shibata, T. 1976 Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)

Methane, dibromochloro-
124-48-1
C-H-Br2-Cl
MW 208.3, MP 118-122 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5633 Urine		GC-EC	20	5.4-7.50 ug/l	Not given	Tapwater samples 2.6-7.0 ug/l Healthy 20-30 yr olds ADULTS; URINE; MEASUREMENT METHODS; BROMINATED HYDROCARBONS; CHLORINATED HYDROCARBONS; DRINKING WATER	Youssefi, M. Faust, S.D. Zenchelsky, S.T. 1978 Clinical Chemistry 24(7):1109-1111

Methane, dibromodichloro-
594-18-3
C-Br2-Cl2
MW 242.74, MP 38 C, BP 150.2 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5634 Urine		GC-EC	20	12.8-20.5 ug/l	Not given	Tap water samples 16.0-41.0 ug/l Healthy 20-30 yr olds ADULTS; URINE; MEASUREMENT METHODS; BROMINATED HYDROCARBONS; CHLORINATED HYDROCARBONS; DRINKING WATER	Youssefi, M. Faust, S.D. Zenchelsky, S.T. 1978 Clinical Chemistry 24(7):1109-1111

Methane, dichloro-
75-09-2
C-H2-Cl2
MW 84.94, MP -95.1 C, BP 39.75 C, VP 380 mm Hg at 22 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5635 Blood	Inhalation	GC	4-6	a) 0.2-0.3 mg/l b) 0.6-0.8 mg/l c) 1.0-1.2 mg/l d) 0.7-1.8 mg/l	a) Not given b) Not given c) Not given d) Not given	a) 1 and 8 hr during 50 ppm air exposure. Decreased to 0.05 mg/l 2 hr post exposure b) 1 and 8 hr during 100 ppm air exposure. Decreased to 0.1 mg/l 2 hr post exposure c) 2 and 8 hr during 150 ppm air exposure. Decreased to 0.2 mg/l 2 hr post exposure d) 1 and 8 hr during 200 ppm air exposure. Decreased to 0.3 mg/l 2 hr post exposure Range of means, estimated from graph Healthy 21-42 yr old nonsmokers Peak blood carboxyhemoglobin saturations of 1.9-6.8% resulted from exposures to 50-200 ppm INDUSTRIAL CHEMICALS; ADULTS; BLOOD; INDUSTRIAL HYGIENE; CHLORINATED HYDROCARBONS; HEALTH HAZARDS; INHALATION; OCCUPATIONAL HAZARDS	DiVincenzo, G.D. Kaplan, C.J. 1981 Toxicology and Applied Pharmacology 59:130-140

Methane, dichlorofluoro-
75-43-4
C-M-C12-F
MW 103, MP -135 C, BP 8.9 C, VP 2 atm at 28.4 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5636 Blood		GC	4	0.1-1.2 ug/100 g wet wt	0.5 ug/100 g wet wt	Autopsies Cook County, IL INDUSTRIAL CHEMICALS; BLOOD; BRAIN; LIVER; LUNGS; FORENSIC MEDICINE; MEASUREMENT METHODS; CHLORINATED HYDROCARBONS; CHLORINE ORGANIC COMPOUNDS	Christopoulos, G.N. Kirch, F.P. 1974 Journal of Forensic Sciences 19(1):168-171
5637 Brain		GC	1	Not given	0.05 ug/100 g wet wt	Autopsies Cook County, IL INDUSTRIAL CHEMICALS; BLOOD; BRAIN; LIVER; LUNGS; FORENSIC MEDICINE; MEASUREMENT METHODS; CHLORINATED HYDROCARBONS; CHLORINE ORGANIC COMPOUNDS	Christopoulos, G.N. Kirch, F.P. 1974 Journal of Forensic Sciences 19(1):168-171
5638 Liver		GC	4	0.1-1.0 ug/100 g wet wt	0.42 ug/100 g wet wt	Autopsies Cook County, IL INDUSTRIAL CHEMICALS; BLOOD; BRAIN; LIVER; LUNGS; FORENSIC MEDICINE; MEASUREMENT METHODS; CHLORINATED HYDROCARBONS; CHLORINE ORGANIC COMPOUNDS	Christopoulos, G.N. Kirch, F.P. 1974 Journal of Forensic Sciences 19(1):168-171
5639 Lung	Inhalation	GC	4	0.6-4.0 ug/100 g wet wt	1.9 ug/100 g wet wt	Autopsies Cook County, IL INDUSTRIAL CHEMICALS; BLOOD; BRAIN; LIVER; LUNGS; FORENSIC MEDICINE; MEASUREMENT METHODS; CHLORINATED HYDROCARBONS; CHLORINE ORGANIC COMPOUNDS	Christopoulos, G.N. Kirch, F.P. 1974 Journal of Forensic Sciences 19(1):168-171

Methane, trichlorofluoro-
75-69-4
C-C13-F
MW 137.38, MP -111 C, BP 23.7 C at 760 mm Hg, 6.8 C at 400 mm Hg, -9.1 C at 200 mm Hg, -23.0 C at 100 mm Hg,-32.3 C at 60 mm Hg, -39.0 C at 40 mm Hg, -49.7 C at 20 mm Hg, -59.0 C at 10 mm Hg, -67.6 C at 5 mm Hg, 84.3 C at 1.0 mm Hg

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5640 Blood		GC	3	0.3-2.0 ug/100 g wet wt	1.0 ug/100 g wet wt	Autopsies Cook County, IL INDUSTRIAL CHEMICALS; BLOOD; BRAIN; LIVER; LUNGS; FORENSIC MEDICINE; MEASUREMENT METHODS; CHLORINATED HYDROCARBONS; CHLORINE ORGANIC COMPOUNDS	Christopoulos, G.N. Kirch, F.P. 1974 Journal of Forensic Sciences 19(1):168-171
5641 Brain		GC	1	Not given	0.08 ug/100 g wet wt	Autopsies Cook County, IL INDUSTRIAL CHEMICALS; BLOOD; BRAIN; LIVER; LUNGS; FORENSIC MEDICINE; MEASUREMENT METHODS; CHLORINATED HYDROCARBONS; CHLORINE ORGANIC COMPOUNDS	Christopoulos, G.N. Kirch, F.P. 1974 Journal of Forensic Sciences 19(1):168-171

(NEXT PAGE)

Methane, trichlorofluoro-
75-69-4
C-Cl3-F
MW 137.38, MP -111 C, BP 23.7 C at 760 mm Hg, 6.8 C at 400 mm Hg, -9.1 C at 200 mm Hg, -23.0 C at 100 mm Hg,-32.3 C at 60 mm Hg, -39.0 C at 40 mm Hg, -49.7 C at 20 mm Hg, -59.0 C at 10 mm Hg, -67.6 C at 5 mm Hg, 84.3 C at 1.0 mm Hg

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5642 Liver		GC	3	0.5-3.0 ug/100 g wet wt	1.4 ug/100 g wet wt	Autopsies Cook County, IL INDUSTRIAL CHEMICALS; BLOOD; BRAIN; LIVER; LUNGS; FORENSIC MEDICINE; MEASUREMENT METHODS; CHLORINATED HYDROCARBONS; CHLORINE ORGANIC COMPOUNDS	Christopoulos, G.N. Kirch, W.B. 1974 Journal of Forensic Sciences 19(1):168-171
5643 Lung		GC	3	1.0-5.0 ug/100 g wet wt	2.6 ug/100 g wet wt	Autopsies Cook County, IL INDUSTRIAL CHEMICALS; BLOOD; BRAIN; LIVER; LUNGS; FORENSIC MEDICINE; MEASUREMENT METHODS; CHLORINATED HYDROCARBONS; CHLORINE ORGANIC COMPOUNDS	Christopoulos, G.N. Kirch, W.B. 1974 Journal of Forensic Sciences 19(1):168-171

Methanol
67-56-1
C-H4-O
MW 32.04, MP -97.8 C, BP 64.7 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5644 Breath	Ingestion Dermal	Colorimetry		a) 215.0-22.2 ug/min b) 285.4-22.8 ug/min	a) Not given b) Not given	a) 30 and 300 min after 1.67-1.71 g dermal, 2 experiments b) 30 and 300 min after 1.67 g oral, 6 experiments (3 subjects) Volunteers SKIN; URINE; BREATH; ALCOHOLS; METHANOL	Dutkiewicz, B. Konczalik, J. Karwacki, W. 1980 International Archives of Occupational and Environmental Health 47:81-88
5645 Skin	Dermal		6	0.131-0.241 ug/sq cm/min	0.192 ug/sq cm/min	Absorption rate following exposure to 0.19-0.21 cc on an area of 11.2 sq cm 22 experiments Volunteers SKIN; URINE; BREATH; ALCOHOLS; METHANOL	Dutkiewicz, B. Konczalik, J. Karwacki, W. 1980 International Archives of Occupational and Environmental Health 47:81-88
5646 Urine	Ingestion Dermal	Colorimetry		a) 0.02-0.687 ug/hr b) 0.03-1.312 ug/hr	a) Not given b) Not given	a) 1 and 4 hr after 1.67-1.71 g dermal. Final measurements 0.088-0.107 ug/hr at 8 hr. Total 8 hr output 0.13% of dose, 2 experiments b) 1 and 2 hr after 1.67 g oral. Final measurements 0.298-0.393 ug/hr at 8 hr. Total 8 hr output 0.31% of dose, 6 experiments (3 subjects) Volunteers SKIN; URINE; BREATH; ALCOHOLS; METHANOL	Dutkiewicz, B. Konczalik, J. Karwacki, W. 1980 International Archives of Occupational and Environmental Health 47:81-88

(NEXT PAGE)

Methanol
67-56-1
C-Bb-O
MW 32.04, MP -97.8 C, BP 64.7 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5647 Urine	Inhalation	GC	a) 31 b) 4 c) 4 d) 4	a) 0.32-2.61 mg/l b) 0.8-3.3 mg/l c) 0.8-6.5 mg/l d) 0.8-9.5 mg/l	a) 0.73 mg/l b) Not given c) Not given d) Not given	a) Controls b) Initial level and after 8 hr exposure to 102 mg/cu m c) Initial level and after 8 hr exposure to 205 mg/cu m d) Initial level and after 8 hr exposure to 390 mg/cu m Range of means Levels returned to normal after 24 hr. Mean urine level/8 hr significantly correlated with dose as long as there were no large discontinuities in air levels Healthy 31-56 yr olds INDUSTRIAL CHEMICALS; ADULTS; URINE; ALCOHOLS; METHANOL	Sedivec, V. Mraz, M. Flek, J. 1981 International Archives of Occupational and Environmental Health 48:267-271

Nickel
7440-02-0
Ni
AtW 58.71, MP 1455 C, BP 2837 C, VP 10 mm Hg at 2090 C, 100 mm Hg at 2370 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5648 Hair		NA	a) 29 b) 21	a) 0.75-1.50 ppm b) 3.00-5.25 ppm	a) 1.01 +or- 0.09 ppm b) 4.21 +or- 0.23 ppm	a) Males b) Females No relationships between age, Ni exposure, or Ni sensitivity AGE; SEX; HAIR; MEASUREMENT METHODS; METALS; NICKEL; POPULATION EXPOSURE	Katz, S.A. Samitz, M.H. 1970 Transactions of the American Nuclear Society 13:66
5649 Hair		AAS	1	0-14 ppm	Not given	Data for various body regions. Maximum level in arm hair. Estimated from graph 23 yr old, United Kingdom ADULTS; HAIR; COMPARATIVE EVALUATIONS; ALUMINUM; CHROMIUM; COBALT; COPPER; IRON; MANGANESE; METALS; NICKEL; SILICON; SILVER; UNITED KINGDOM	Alder, J.F. Samuel, A.J. West, T.S. 1977 Analytica Chimica Acta 92:217-221
5650 Heart						Review. Accumulation, body burden, and distribution in organs and tissues NICKEL; MINING; HEART; KIDNEYS; LIVER; LUNGS; ALASKA; CANADA; EGYPT; INDIA; JAPAN; SWITZERLAND; THAILAND; TAIWAN; HONG KONG; PHILIPPINES; LEBANON; AFRICA; REVIEW	National Academy of Science, National Research Council 1975 Medical and Biological Effects of Environmental Pollutants, National Academy of Sciences, Washington, DC, 277 pp.
5651 Kidney						Review. Accumulation, body burden, and distribution in organs and tissues NICKEL; MINING; HEART; KIDNEYS; LIVER; LUNGS; ALASKA; CANADA; EGYPT; INDIA; JAPAN; SWITZERLAND; THAILAND; TAIWAN; HONG KONG; PHILIPPINES; LEBANON; AFRICA; REVIEW	National Academy of Science, National Research Council 1975 Medical and Biological Effects of Environmental Pollutants, National Academy of Sciences, Washington, DC, 277 pp.

(NEXT PAGE)

Nickel
7440-02-0
Ni
AtW 58.71, MP 1455 C, BP 2837 C, VP 10 mm Hg at 2090 C, 100 mm Hg at 2370 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5652 Liver						Review. Accumulation, body burden, and distribution in organs and tissues NICKEL; MINING; HEART; KIDNEYS; LIVER; LUNGS; ALASKA; CANADA; EGYPT; INDIA; JAPAN; SWITZERLAND; THAILAND; TAIWAN; HONG KONG; PHILIPPINES; LEBANON; AFRICA; REVIEW	National Academy of Science, National Research Council 1975 Medical and Biological Effects of Environmental Pollutants, National Academy of Sciences, Washington, DC, 277 pp.
5653 Lung						Review. Accumulation, body burden, and distribution in organs and tissues NICKEL; MINING; HEART; KIDNEYS; LIVER; LUNGS; ALASKA; CANADA; EGYPT; INDIA; JAPAN; SWITZERLAND; THAILAND; TAIWAN; HONG KONG; PHILIPPINES; LEBANON; AFRICA; REVIEW	National Academy of Science, National Research Council 1975 Medical and Biological Effects of Environmental Pollutants, National Academy of Sciences, Washington, DC, 277 pp.
5654 Teeth		AAS	13	Not given	23 +or- 7.2 ppm	Median, 21 ppm Stillborn or neonatal deaths, 1972-73, Bristol, United Kingdom UNITED KINGDOM; AUTOPSIES; NEWBORN; TEETH; CADMIUM; IRON; LEAD; MANGANESE; METALS; NICKEL; ZINC	Stack, M.V. Burkitt, A.J. Wickless, G. 1976 Bulletin of Environmental Contamination and Toxicology 16(6):764-766
5655 Urine		AAS		a) 0-18.3 ug/l b) 0.5-36 ug/l c) 28-108.0 ug/l	a) Not given b) Not given c) Not given	a) Unexposed, pooled samples b) Ni refinery, laboratory workers c) Ni refinery, production staff, pooled samples Data also for different analytical techniques and instrumentation URINE; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS; METALS; NICKEL; OCCUPATIONAL HAZARDS	Adams, P.E. Brown, S.S. Sunderman, F.W., Jr. Zachariasen, H. 1978 Clinical Chemistry 24(8):862-867

Nickel carbonyl [Ni(CO)4] (8 CI)
Nickel carbonyl [Ni(CO)4], (T-4)- (9 CI)
13463-39-3
C4-Ni-O4
MW 170.8, MP -25 C, BP 43 C, VP 400 mm Hg at 25.8 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5656 Liver						Review. Clinical observations and pathology in acute nickel carbonyl poisoning. Historical perspective of Legionnaires Disease. Congestion of central and portal vein branches with slight central hepatic degeneration PENNSYLVANIA; ADULTS; METAL POISONING; LIVER; LUNGS; NICKEL; AIR POLLUTION; CARCINOGEN; DOGS; HEALTH HAZARDS; INDUSTRIAL ACCIDENTS; INHALATION; OCCUPATIONAL HAZARDS; POPULATION EXPOSURE; RATS	Sunderman, F.W. 1977 Annals of Clinical and Laboratory Science 7(3):187-200

(NEXT PAGE)

Nickel carbonyl [Ni(CO)4] (8 CI)
Nickel carbonyl [Ni(CO)4], (T-4)- (9 CI)
13463-39-3
C4-Ni-O4
MW 170.8, MP -25 C, BP 43 C, VP 400 mm Hg at 25.8 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5457 Lung						Review. Clinical observations and pathology in acute nickel carbonyl poisoning. Historical perspective of Legionnaires Disease. Immediate symptoms of headache, epigastric pain, nausea and vomiting. Possible 1-5 days essentially asymptomatic. Delayed symptoms include constriction in chest, shortness of breath, unproductive cough, muscle pains, weakness, fatique, GI symptoms, convulsions, delirium. Hyaline membrane formation, degenerative changes in alveolar lining cells. PENNSYLVANIA; ADULTS; METAL POISONING; LIVER; LUNGS; NICKEL; AIR POLLUTION; CARCINOGEN; DOGS; HEALTH HAZARDS; INDUSTRIAL ACCIDENTS; INHALATION; OCCUPATIONAL HAZARDS; POPULATION EXPOSURE; RATS	Sunderman, P.W. 1977 Annals of Clinical and Laboratory Science 7(3):187-200

Oxalic acid (8 CI)
Ethanedioic acid (9 CI)
144-62-7
C2-H2-O4
MW 90.04, MP 101-102 C, BP 150 C (sublimes)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5650 Urine		Enzymatic	a) 9 b) Not given c) 59 d) 65 e) 110 f) 58	a) 0.19-0.37 mmol/24 hr b) 0.28-0.40 mmol/24 hr c) Not given d) Not given e) Not given f) Not given	a) Not given b) Not given c) 0.27 mmol/24 hrr c) 0.26 mmol/24 hr e) 0.35 mmol/24 hr f) 0.28 mmol/24 hr	a) Normals, range of monthly means for 1 yr period b) Patients with idiopathic hypercalciuria, range of bimonthly means for 1 yr period c) Normals, mean for 6 summer months d) Normals, mean for 6 winter months e) Men with untreated idiopathic hypercalciuria, mean for 6 summer months f) Men with untreated idiopathic hypercalciuria, mean for 6 winter months Urinary oxalate higher in summer in patients with idiopathic hypercalciuria, attributed to higher intake of oxalate-rich foods and low calcium diet CALCIUM; DIETS; URINE; DIURETICS; DRUG THERAPY; DRUGS; KIDNEY DISEASES	Hallson, P.C. Kasidas, G.P. Rose, G.A. 1977 British Journal of Urology 49(1):1-10

Palladium
7440-0?-3
Pd
At? 106.4, MP 1555 C, BP 3167 C, VP 1 mm Hg at 1870 C, 10 mm Hg at 2290 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5659 Blood, whole		AAS	a) 181 b) 142	a) Not given b) Not given	a) <0.01 ug/100 ml b) <0.01 ug/100 ml	a) Los Angeles, CA, near highway b) Lancaster, CA, rural area Composite blood samples below detectable limits CALIFORNIA; ADULTS; CHILDREN; BLOOD; HAIR; URINE; COMPARATIVE EVALUATIONS; LEAD; METALS; PALLADIUM; PLATINUM; ATMOSPHERE; POPULATION EXPOSURE; RURAL AREAS; SOILS; URBAN AREAS	Johnson, D.E. Tillery, J.B. Prevost, R.J. 1975 Environmental Health Perspectives 12:27-33
5660 Hair		AAS	283	Not given	<0.02 ug/g	Below detectable limits Los Angeles and Lancaster, CA CALIFORNIA; ADULTS; CHILDREN; BLOOD; HAIR; URINE; COMPARATIVE EVALUATIONS; LEAD; METALS; PALLADIUM; PLATINUM; ATMOSPHERE; POPULATION EXPOSURE; RURAL AREAS; SOILS; URBAN AREAS	Johnson, D.E. Tillery, J.B. Prevost, R.J. 1975 Environmental Health Perspectives 12:27-33
5661 Urine		AAS	283	Not given	<0.3 ug/l	Below detectable limits for all age groups Los Angeles and Lancaster, CA CALIFORNIA; ADULTS; CHILDREN; BLOOD; HAIR; URINE; COMPARATIVE EVALUATIONS; LEAD; METALS; PALLADIUM; PLATINUM; ATMOSPHERE; POPULATION EXPOSURE; RURAL AREAS; SOILS; URBAN AREAS	Johnson, D.E. Tillery, J.B. Prevost, R.J. 1975 Environmental Health Perspectives 12:27-33

Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI)
Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)
86-50-0
C10-H12-N3-O3-P-S2
MW 317.34, MP 73-74 C (crystals from methanol)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5662 Urine		GC	a) 3 b) 4 c) 4 d) 7	a) 270-353 ug b) 270-2148 ug c) 250-723 ug d) 244-883 ug	a) 310 ug b) 770 ug c) 440 ug d) 440 ug	a) Workers wearing rubberized coats and pants b) Same as group (a), but including one unexplainably high value c) Workers wearing rubberized coats d) Workers wearing non-rubberized clothing Total 48 hr output of metabolites (O,O-dimethyl-O-ethyl phosphorothioate and O,O-dimethyl-S-ethyl phosphorothioate) for spray day and postexposure day, normalized for total amount sprayed (2.3-2.5 kg) Orchard sprayers, British Columbia, Canada. CANADA; ADULTS; URINE; ORGANOPHOSPHATES; AGRICULTURE; CROP DUSTING; HEALTH HAZARDS; METABOLITES; OCCUPATIONAL HAZARDS; PESTICIDE RESIDUES; POPULATION EXPOSURE; INSECTICIDES	Franklin, C.A. Fenske, R.A. Greenhalgh, R. Mathieu, L. Denley, H.V. Leffingwell, J.T. Spear, R.C. 1981 Journal of Toxicology and Environmental Health 7:715-731

Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI)
Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)
56-38-2
C10-H14-N-05-P-S
MW 291.27, MP 6 C, BP 375 C at 760 mm Hg, 157-162 C at 0.6 mm Hg

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5663 Blood, plasma	Ingestion	GC	a) 1 b) 1 c) 1 d) 1	a) 409-1 ng/ml b) 110-1 ng/ml c) 184-1 ng/ml d) 21-1 ng/ml	a) Not applicable b) Not applicable c) Not applicable d) Not applicable	a) 2 and 20 days after 80 ml b) 1 and 20 days after 60 ml (30 g) c) 2 and 21 days after 30 ml d) 3 and 20 days after 60 ml Estimated from graph No correlation with clinical condition, acetylcholine levels, acetylcholinesterase activity 15-58 yr olds Muscarinic and nicotinic symptoms. Coma and respiratory inhibition CASE HISTORIES; SUICIDE; BLOOD PLASMA; INSECTICIDES; ORGANOPHOSPHATES	Okonek, S. Kilbinger, H. 1974 Archives of Toxicology 32:97-108
5664 Urine						Review. Critique of data from workers exposed to toxic chemicals. Wide variations reflect lack of standardizations in sampling and analytical design. INDUSTRIAL CHEMICALS; BLOOD; URINE; INDUSTRIAL MEDICINE; REVIEWS; CARBON INORGANIC COMPOUNDS; MERCURY; METALS; ORGANOPHOSPHATES; HEALTH HAZARDS; OCCUPATIONAL HAZARDS	Ramaswamy, S.S. 1975 Environmental Pollution and Human Health: Proceedings of the International Symposium on Industrial Toxicology, pp. 166-177

Phosphorus
7723-14-0
P
Atw 30.97376, MP 44.1 C, BP 280 C, VP 10 mm Hg at 127 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5665 Blood, serum						Review. Calcium-phosphorus metabolism and clinical implications of Ca deficiency in pregnancy. ADULTS; FETUS; INFANTS; NUTRITIONAL DEFICIENCIES; NUTRITIONAL DISORDERS; BLOOD SERUM; BONES; CALCIUM; PHOSPHORUS; VITAMIN D; DIETS; PREGNANCY; METABOLISM	Pitkin, R.M. 1975 American Journal of Obstetrics and Gynecology 121(5):724-737
5666 Metal						Review. Calcium-phosphorus metabolism and clinical implications of Ca deficiency in pregnancy. ADULTS; FETUS; INFANTS; NUTRITIONAL DEFICIENCIES; NUTRITIONAL DISORDERS; BLOOD SERUM; BONES; CALCIUM; PHOSPHORUS; VITAMIN D; DIETS; PREGNANCY; METABOLISM	Pitkin, R.M. 1975 American Journal of Obstetrics and Gynecology 121(5):724-737

Phthalic acid, bis(2-ethylhexyl) ester (8 CI)
1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)
117-81-7
C24-H38-04
MW 390.56

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5667 Blood, serum		GC/MS	a) 1 b) 5	a) Not applicable b) 3-10 ug/ml	a) 3 ug/ml b) 7 ug/ml	a) Control b) Patients Levels highest soon after blood transfusion and with renal dysfunction Surgical patients on parenteral therapy from 12 to 85 days. Control had no intravenou infusions. PHTHALIC ACIDS; BLOOD SERUM; KIDNEY DISEASES; SURGERY	Ching, W.P.H. Jham, G.N. Subbaravan, C. Bowen, D.V. Smit, A.I.C. Jr. Grossi, C.F. Hicks, R.G. Field, F.H. Nealon, T.F. Jr. 1981 Journal of Chromatography 222:171-177

Phthalic acid, dibutyl ester (8 CI)
1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)
84-74-2
C16-H22-04
MW 278.34, BP 340 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5668 Blood, serum		GC/MS	a) 1 b) 5	a) Not applicable b) 0-41 ug/ml	a) 37 ug/ml b) 15.6 ug/ml	a) Controls b) Patients High levels in both groups imply environmental exposure. Surgical patients on parenteral therapy from 12 to 85 days. Control had no intravenous infusions. PHTHALIC ACIDS; BLOOD SERUM; KIDNEY DISEASES; SURGERY	Ching, W.P.H. Jham, G.N. Subbaravan, C. Bowen, D.V. Smit, A.I.C. Jr. Grossi, C.F. Hicks, R.G. Field, F.H. Nealon, T.F. Jr. 1981 Journal of Chromatography 222:171-177

Platinum
7440-06-4
Pt
AtW 195.09, MP 1773.5 C, BP 3827 C, VP 1 mm Hg at 2600 C, 10 mm Hg at 2940 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5669 Blood	Injection	AAS	7	a) 0.10-0.37 ug/ml b) 0.23-0.65 ug/ml c) 3.03-0.09 ug/ml d) 7.54-1.25 ug/ml Cisplatin equivalents	a) Not given b) Not given c) Not given d) Not given	a) RBC lysate, 5 patients, 15 and 60 min after 50 mg cisplatin/sq m, with and without mannitol, IV. Final measurement 0.19-0.25 ug/ml at 240-1440 min. Range of means b) RBC lysate, 2 patients, 15 and 240 min after 100 mg cisplatin/sq m, no mannitol, IV. Final measurement 0.50-0.58 at 360-1440 min. Range of means c) Plasma ultrafiltrate, 1 patient, 5 and 240 min after 50 mg cisplatin/sq m, with mannitol, IV d) Plasma, 1 patient, 5 and 240 min after 50 mg cisplatin/sq m, with mannitol, IV. Final measurement 1.60 ug/ml at 360 min NEOPLASMS; SARCOMAS; BLOOD; BLOOD PLASMA; ERYTHROCYTES; DRUG THERAPY; DRUGS; CHEMOTHERAPY; METALS; PLATINUM	Long, D.F. Patton, T.F. Repta, A.J. 1981 Biopharmaceutics & Drug Disposition 2:137-146

(NEXT PAGE)

Platinum
7440-06-4
Pt
Atw 195.09, MP 1773.5 C, BP 3827 C, VP 1 mm Hg at 2600 C, 10 mm Hg at 2940 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5670 Blood, whole			a) 141 b) 142	a) Not given b) Not given	a) 0.049 ug/100 ml b) 0.180 ug/100 ml	a) Los Angeles, CA, near highway b) Lancaster, CA, rural area Composite blood samples. Individual samples below detectable levels. CALIFORNIA; ADULTS; CHILDREN; BLOOD; HAIR; URINE; COMPARATIVE EVALUATIONS; LEAD; METALS; PALLADIUM; PLATINUM; ATMOSPHERE; POPULATION EXPOSURE; RURAL AREAS; SOILS; URBAN AREAS	Johnson, D.E. Tillery, J.B. Prevost, R.J. 1975 Environmental Health Perspectives 12:27-33
5671 Hair		AAS	283		<0.05 ug/g	Below detectable limits Los Angeles and Lancaster, CA CALIFORNIA; ADULTS; CHILDREN; BLOOD; HAIR; URINE; COMPARATIVE EVALUATIONS; LEAD; METALS; PALLADIUM; PLATINUM; ATMOSPHERE; POPULATION EXPOSURE; RURAL AREAS; SOILS; URBAN AREAS	Johnson, D.E. Tillery, J.B. Prevost, R.J. 1975 Environmental Health Perspectives 12:27-33
5672 Urine			283	Not given	<0.6 ug/l	Below detectable limits for all age groups Los Angeles and Lancaster, CA CALIFORNIA; ADULTS; CHILDREN; BLOOD; HAIR; URINE; COMPARATIVE EVALUATIONS; LEAD; METALS; PALLADIUM; PLATINUM; ATMOSPHERE; POPULATION EXPOSURE; RURAL AREAS; SOILS; URBAN AREAS	Johnson, D.E. Tillery, J.B. Prevost, R.J. 1975 Environmental Health Perspectives 12:27-33

Polybrominated biphenyls (No postings in CHEMLINE).

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5673 Blood, serum	Ingestion	GC	a) 283 b) 40 c) 153 d) 28 e) 55 f) 20 g) 56	a) 0.2-> 1000 ppb b) 0.3-999.9 ppb c) 0.01-89.9 ppb d) 0.2-49.9 ppb e) 1.1->1000 ppb f) <0.2-10 ppb g) Not detected	a) 33.9 +or- 150.6 ppb b) 56.6 +or- 150.1 ppb c) 2.9 +or- 5.4 ppb d) 3.8 +or- 3.7 ppb e) 123.0 +or- 367.0 ppb f) 1.9 +or- 1.7 ppb g) Not applicable	a) Residents, quarantined farms b) Consumers, products from quarantined farms c) Residents, nonquarantined farms d) Consumers, products from nonquarantined farms e) Employees manufacturing PBBs f) Farm residents < 1 yr, or infants < 1 yr old g) Controls, unexposed farm residents Farm feed accidentally contaminated with 2,000 lb PBBs Correlations given for DDT, age and sex. Residents of MI (exposed) and WI (controls) MICHIGAN; WISCONSIN; ADULTS; INFANTS; NEUROLOGIC MANIFESTATIONS; SKIN DISEASES; BLOOD SERUM; DDT; POLYBROMINATED BIPHENYLS; FARMS; FOOD CONTAMINATION; HEALTH HAZARDS; INDUSTRIAL PLANTS; METABOLITES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Selikoff, I.J. 1976 Interim Summary Report to the National Institute of Environmental Health Sciences. PS 00928. EDA 004568, 46 pp.

(NEXT PAGE)

Polybrominated biphenyls (No postings in CHEMLINE).

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5674 Blood, serum	Ingestion	GC	a) 27 b) 18 c) 46	a) < 0.5-500 ppb b) 0.5-1000 ppb c) Not detected	a) Not given b) Not given c) Not detected	a) Exposed MI dairy farm residents, normal lymphoblastogenesis b) Exposed MI dairy farm residents, abnormal lymphoblastogenesis c) Unexposed MI dairy farm residents Farm feed in MI accidentally contaminated with 2,000 lb PBBs. MICHIGAN; WISCONSIN; ADULTS; INFANTS; NEUROLOGIC MANIFESTATIONS; SKIN DISEASES; BLOOD SERUM; DDE; POLYBROMINATED BIPHENYLS; FARMS; FOOD CONTAMINATION; HEALTH HAZARDS; INDUSTRIAL PLANTS; METABOLITES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Selikoff, I.J. 1976 Interim Summary Report to the National Institute of Environmental Health Sciences. ES 00928. PDA 00856R, 86 pp.
5675 Hair				a) Not given b) Not given c) Not given	a) 17 ppm b) 210 ppm c) 100 ppb	a) Hair oil, Staten Island (NY) b) Hair oil, Sayreville (NJ) c) Hair oil, Bayonne (NJ) From locations of PBB production or use in manufacturing NEW JERSEY; NEW YORK; HAIR; POLYBROMINATED BIPHENYLS; INDUSTRIAL PLANTS; URBAN AREAS	Anon 1977 b Pesticide & Toxic Chemical News 5(30):9-10

Polychlorinated quaterphenyls (No postings in CHEMLINE).

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5676 Adipose	Ingestion	GC/MS	a) 3 b) 3	a) 2.2-2400.0 ppb b) 1.3-2.7 ppb	a) Not given b) Not given	a) Yusho victims b) Unexposed individuals 25-70 yr olds, Japan JAPAN; ADULTS; AUTOPSIES; CHILDREN; INFANTS; DISEASES; ADIPOSE TISSUE; BLOOD; INTESTINES; LIVER; MILK; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; POLYCHLORINATED QUATERPHENYLS; FOOD CONTAMINATION; HEALTH HAZARDS	Kashimoto, T. Miyata, H. Kunita, N. 1981 Food and Cosmetics Toxicology 19:335-340
5677 Blood	Ingestion	GC/MS	a) 29 b) 15 c) 8 d) 6 e) 29	a) 0.30-8.92 ppb b) 0.05-4.30 ppb c) 0.05-0.65 ppb d) Not given e) Not given	a) 3.08 +or- 2.11 ppb b) 1.39 +or- 1.34 ppb c) 0.28 +or- 0.19 ppb d) <0.02 ppb e) <0.02 ppb	a) GC pattern indicative of Yusho exposure b) GC pattern similar to that of (a) c) GC pattern of unexposed individuals d) PCB workers e) Unexposed individuals Individuals in a)-c) reported to have consumed Yusho oil Japanese JAPAN; ADULTS; AUTOPSIES; CHILDREN; INFANTS; DISEASES; ADIPOSE TISSUE; BLOOD; INTESTINES; LIVER; MILK; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; POLYCHLORINATED QUATERPHENYLS; FOOD CONTAMINATION; HEALTH HAZARDS	Kashimoto, T. Miyata, H. Kunita, N. 1981 Food and Cosmetics Toxicology 19:335-340

(NEXT PAGE)

Polychlorinated quaterphenyls (No postings in CHEMLINE).

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5678 Intestine	Ingestion	GC/MS	4	24.5-1770.0 ppb	Not given	Yusho victims Stillborn-72 yr olds, Japan JAPAN; ADULTS; AUTOPSIES; CHILDREN; INFANTS; DISEASES; ADIPOSE TISSUE; BLOOD; INTESTINES; LIVER; MILK; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; POLYCHLORINATED QUATERPHENYLS; FOOD CONTAMINATION; HEALTH HAZARDS	Kashimoto, T. Miyata, H. Kunita, N. 1981 Food and Cosmetics Toxicology 19:335-340
5679 Liver	Ingestion	GC/MS	a) 7 b) 3	a) 1.0-393.0 ppb b) 0.6-0.8 ppb	a) Not given b) Not given	a) Yusho victims b) Unexposed individuals Stillborn-72 yr olds, Japan JAPAN; ADULTS; AUTOPSIES; CHILDREN; INFANTS; DISEASES; ADIPOSE TISSUE; BLOOD; INTESTINES; LIVER; MILK; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; POLYCHLORINATED QUATERPHENYLS; FOOD CONTAMINATION; HEALTH HAZARDS	Kashimoto, T. Miyata, H. Kunita, N. 1981 Food and Cosmetics Toxicology 19:335-340
5680 Milk		GC/MS	1	Not applicable	0.3 ppb	PCP worker 37 yr old Japanese JAPAN; ADULTS; AUTOPSIES; CHILDREN; INFANTS; DISEASES; ADIPOSE TISSUE; BLOOD; INTESTINES; LIVER; MILK; COMPARATIVE EVALUATIONS; CHLORINE ORGANIC COMPOUNDS; POLYCHLORINATED BIPHENYLS; POLYCHLORINATED QUATERPHENYLS; FOOD CONTAMINATION; HEALTH HAZARDS	Kashimoto, T. Miyata, H. Kunita, N. 1981 Food and Cosmetics Toxicology 19:335-340

Potassium
7440-09-7
K

At. wt. 39.098, MP 63.2 C, BP 765.5 C, VP 100 mm Hg at 590 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5681 Urine	Ingestion	AAS	a) 10 b) 10	a) 3258-3544 mg b) 4350-5684 mg	a) 3420 mg b) 5023 mg	a) Dietary intake 3900-8386 mg (mean 4181 mg) b) Intake 5184-5941 mg (mean 6039 mg), from food and 1:1 mixture NaCl & KCl Range of means, 28 days 20-47 yr olds MICHIGAN; URINE; POTASSIUM; SODIUM; FOOD ADDITIVES	Nickelsen, O. Makdani, D. Gill, J.L. Frank, N.L. 1977 American Journal of Clinical Nutrition 30:2033-2040

Selenium
77P2-49-2
Se
AtP 78.96, MP 170-217 C, PP 685 C, VP 1 mm Hg at 356 C, 10 mm Hg at 429 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5692 Blood	Ingestion	Fluorometry	292	a) 57-87 ng/ml b) 60-63 ng/ml	a) Not given b) Not given	a) Consumers of wheat products high in Se (> 130 ng/g) b) Consumers of wheat products low in Se Range of means by year for 1973-1980 Healthy, European adults, New Zealand NEW ZEALAND; ADULTS; BLOOD; COMPARATIVE EVALUATIONS; SELENIUM; DIETS; WHEAT	Watkinson, J.H. 1981 American Journal of Clinical Nutrition 34:936-942
5693 Blood		Fluorometry	44	61-111 ug/l	76.68 ug/l	May, 1976 No relationship with 24 hr urinary Hg 7-13 yr olds, Broadlands hydrothermal area, central North Island, New Zealand NEW ZEALAND; CHILDREN; BLOOD; URINE; MERCURY; METALS; SELENIUM; BIOACCUMULATION; DIETS; DRINKING WATER; FISHES; HEALTH HAZARDS; MEATS; CEILO; VEGETABLES; VEGETATION	Pierre, A.P. Gordon, A.C.D. Pybus, J. Lines, D.R. 1977 New Zealand Medical Journal 851(589):868-866
5694 Hair		AAS	a) 139 b) 20 c) 184 d) 57	a) Not given b) Not given c) Not given d) Not given	a) 0.86 +or- 0.10 ppm b) 1.45 +or- 0.11 ppm c) 0.73 +or- 0.03 ppm d) 1.40 +or- 0.09 ppm	a) Controls, girls b) Learning disability, girls c) Controls, boys d) Learning disability, boys Levels significantly elevated in b) and d). Mean air levels 1.6 +or- 0.9 and 1.9 +or- 1.0 ng/cu m at two schools. 9-12 yr olds, Akron, OH CEYLONEW; HAIR; ARSENIC; CADMIUM; LEAD; MERCURY; METALS; SELENIUM; POPULATION EXPOSURE	Ely, D.L. Mostardi, P.A. Woebkenberg, W. Worstell, D. 1981 Environmental Research 2*:325-339
5695 Kidney		XR	a) 9 b) 8 c) 3 d) 8	a) 240-2120 ppb b) 250-1520 ppb c) 340-530 ppb d) 370-1030 ppb	a) 561 +or- 594 ppb b) 746 +or- 44 ppb c) Not given d) 755 +or- 207 ppb	a) Workers with malignancies, employed 30.9 +or- 7.1 yr, 9 smokers b) Workers with cardiovascular disease, employed 32.5 +or- 8.2 yr, 7 smokers c) Workers with other diagnoses, employed 28.8 +or- 10 yr, 2 smokers d) Controls, 1 smoker Autopsies Workers, mean age 66.6 yr, smelter and refinery in northern Sweden Controls, mean age 67.4 yr, rural area 50 km from factory Highest levels in lung cancer cases. Higher As/Se ratio in workers with malignancies ARSENIC; SELENIUM; INDUSTRIAL AREAS; INDUSTRIAL ATMOSPHERES; INDUSTRIAL PLANTS; SMELTERS; SWEDEN; CARCINOMAS; CARDIOVASCULAR DISEASES; OCCUPATIONAL DISEASES; SARCOMAS; KIDNEYS; LIVER; LUNGS	Wester, P.O. Brune, D. Nordberg, G. 1981 British Journal of Industrial Medicine 38:179-184

(NEXT PAGE)

Selen
7782-49-2
Se
Atw 78.96, MP 170-217 C, BP 685 C, VP 1 mm Hg at 356 C, 10 mm Hg at 429 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
9686 Liver		MA	a) 9 b) 8 c) 3 d) 8	a) 140-350 ppb b) 170-270 ppb c) 170-230 ppb d) 140-460 ppb	a) 210 +or- 68 ppb b) 201 +or- 40 ppb c) Not given d) 265 +or- 122 ppb	a) Workers with malignancies, employed 30.9 +or- 7.1 yr, 9 smokers b) Workers with cardiovascular disease, employed 32.5 +or- 8.2 yr, 7 smokers c) Workers with other diagnoses, employed 28.8 +or- 10 yr, 2 smokers d) Controls, 1 smoker Autopsies Workers, mean age 66.6 yr, smelter and refinery in northern Sweden Controls, mean age 67.4 yr, rural area 50 km from factory Highest levels in lung cancer cases. Higher As/Se ratio in workers with malignancies ARSENIC; SELENIUM; INDUSTRIAL AREAS; INDUSTRIAL ATMOSPHERES; INDUSTRIAL PLANTS; SMELTERS; SWEDEN; CARCINOMAS; CARDIOVASCULAR DISEASES; OCCUPATIONAL DISEASES; SARCOMAS; KIDNEYS; LIVER; LUNGS	Wester, P.O. Brune, D. Nordberg, G. 1981 British Journal of Industrial Medicine 38:179-184
9687 Lung		MA	a) 15 b) 17 c) 8 d) 11	a) 68-430 ppb b) 91-8020 ppb c) 93-270 ppb d) 91-700 ppb	a) 159 +or- 89 ppb b) 720 +or- 1912 ppb c) 153 +or- 60 ppb d) 165 +or- 182 ppb	a) Workers with malignancies, employed 30.9 +or- 7.1 yr, 9 smokers b) Workers with cardiovascular disease, employed 32.5 +or- 8.2 yr, 7 smokers c) Workers with other diagnoses, employed 28.8 +or- 10 yr, 2 smokers d) Controls, 1 smoker Autopsies Workers, mean age 66.6 yr, smelter and refinery in northern Sweden Controls, mean age 67.4 yr, rural area 50 km from factory Highest levels in lung cancer cases. Higher As/Se ratio in workers with malignancies ARSENIC; SELENIUM; INDUSTRIAL AREAS; INDUSTRIAL ATMOSPHERES; INDUSTRIAL PLANTS; SMELTERS; SWEDEN; CARCINOMAS; CARDIOVASCULAR DISEASES; OCCUPATIONAL DISEASES; SARCOMAS; KIDNEYS; LIVER; LUNGS	Wester, P.O. Brune, D. Nordberg, G. 1981 British Journal of Industrial Medicine 38:179-184

Silicon
7440-21-3
Si
Atw 28.086, MP 1410 C, BP 2600 C, VP 1 mm Hg at 1724 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
9688 Hair		AAS	1	0-115 ppm	Not given	Data for various body regions. Maximum level in leg hair 23 yr old, United Kingdom ADULTS; HAIR; COMPARATIVE EVALUATIONS; ALUMINUM; CHROMIUM; COBALT; COPPER; IRON; MANGANESE; METALS; NICKEL; SILICON; SILVER; UNITED KINGDOM	Alder, J.F. Samuel, A.V. West, T.S. 1977 Analytica Chimica Acta 92:217-221

Silver
7440-22-4
Ag
AtW 107.868, MP 960.5 C, BP 2000 C, VP 1 mm Hg at 1310 C, 10 mm Hg at 1540 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5689 Hair		AAS	1	0-12 ppm	Not given	Data for various body regions. Maximum level in eyebrow 23 yr old, United Kingdom ADULTS; HAIR; COMPARATIVE EVALUATIONS; ALUMINUM; CHROMIUM; COBALT; COPPER; IRON; MANGANESE; METALS; NICKEL; SILICON; SILVER; UNITED KINGDOM	Alder, J.F. Samuel, A.J. West, T.S. 1977 Analytica Chimica Acta 92:217-221
5690 Teeth		MS	208	a) Not given b) Not given	a) 1.11 +or- 1.04 ppm b) 7.43 +or- 2.73 ppm S.E.	a) High caries donors (>7 decayed, missing, filled teeth (DMFT)), 3 teeth b) Low caries donors (<8 DMFT), 21 teeth Values for enamel a) and b) differed, P<0.05 Premolars, patients <30 yr old, South Carolina ZINCONIUM; NEW HAMPSHIRE; SOUTH CAROLINA; VERMONT; DENTAL CARIES; TEETH; ALUMINUM; BARIUM; COPPER; FINCPINE; YTTRIUM; METALS; SILVER; STRONTIUM; TIN	Curzon, M.E.J. Losee, F.L. 1977 Journal of the American Dental Association 94(6):1146-1150

Sodium
7440-23-5
Na
AtW 22.98977, MP 97.82 C, BP 881.4 C, VP 1 mm Hg at 440 C, 10 mm Hg at 596 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5691 Hair		NA	71	a) 4-46 ug/g b) 4-50 ug/g c) Not given d) Not given e) Not given f) Not given	a) 19 +or- 17 ug/g b) 16 +or- 10 ug/g c) 16.5 ug/g d) 21 ug/g e) 16 ug/g f) 17 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1978 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; WATIS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5692 Nail		NA	Not given	a) Not given b) Not given	a) 170 +or- 150 ug/g b) 135 +or- 100 ug/g	a) Women b) Men Toenail sample of about 6 mg Machakos district, Kenya, 1978 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; WATIS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278

(NEXT PAGE)

Sodium
7440-23-5
Na
Atw 22.98977, MP 97.82 C, BP 881.4 C, VP 1 mm Hg at 440 C, 10 mm Hg at 586 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5693 Urine	Ingestion	AAS	a) 10 b) 10	a) 2014-6925 mg b) 1618-2558 mg	a) 3469 mg b) 2000 mg	a) Intake 2153-7351 mg (mean 3712 mg), regular diet + NaCl b) Intake 1659-2555 mg (mean 2027 mg), low-Na diet and 1:1 mixture of NaCl & KCl Range of means, 28 days 20-47 yr olds MICHIGAN; URINE; POTASSIUM; SODIUM; FOOD ADDITIVES	Nickelsen, O. Makdani, D. Gill, J.L. Frank, R.L. 1977 American Journal of Clinical Nutrition 30:2033-2040

Strontium
7440-24-6
Sr
Atw 87.62, MP 357 C, BP 1366 C, VP 19 mm Hg at 898 C, 1 mm Hg at 740 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5694 Hair		MS	71	a) 10-20 ug/g b) 4-15 ug/g c) Not given d) Not given e) Not given	a) 16 +or- 3 ug/g b) 8 +or- 5 ug/g c) 13 ug/g d) 15 ug/g e) 8 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 18 subjects from b) >12 yr old Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; WATER; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5695 Teeth		MS	204	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given g) Not given h) Not given	a) 128.9 +or- 8.39 ppm b) 156.7 +or- 10.87 ppm c) 108.7 +or- 11.31 ppm d) 166.6 +or- 23.29 ppm e) 90.5 +or- 9.30 ppm f) 188.1 +or- 18.38 ppm g) 104.1 +or- 9.14 ppm h) 194.0 +or- 14.68 ppm S.E.	a) High caries area, New England, 108 teeth b) Low caries area, South Carolina, 100 teeth c) High caries donors (>7 decayed, missing, filled teeth (DMFT) from a), 35 teeth d) Low caries donors (<4 DMFT) from a), 28 teeth e) High caries donors from b), 15 teeth f) Low caries donors from b), 49 teeth g) High caries donors from a) and b), 43 teeth h) Low caries donors from a) and b), 37 teeth Values for enamel a) and b) differed, P<0.05 c) and d) differed, P<0.05 e) and f) differed, P<0.001 g) and h) differed, P<0.001 Premolars extracted, patients <20 yr old ZIRCONIUM; NEW HAMPSHIRE; SOUTH CAROLINA; VERMONT; DENTAL CARIES; TEETH; ALUMINUM; BARIUM; COPPER; FINGERNAIL; LITHIUM; METALS; SILVER; STRONTIUM; TIN	Curzon, M.E.J. Losee, F.L. 1977 Journal of the American Dental Association 94(6):1146-1150

Styrene (8 CI)
Benzene, ethenyl- (9 CI)
100-42-5
C8-H8
MW 104.14, MP -31 C, BP 145-146 C, VP 39.8 atm at 370.8 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5696 Urine	Inhalation	GC	a) 5 b) 5 c) 2 d) 13	a) 149-184 mg/g creatinine b) 930-170 mg/g creatinine c) 961-191 mg/g creatinine d) 1202-279 mg/g creatinine	a) Not given b) Not given c) Not given d) Not given	a) 330 ppm/hr. Total output, 861 mg after 8 days b) 400 ppm/hr. Total output, 651 mg after 8 days c) 890 ppm/hr. Total output, 661 mg after 8 days d) 800 ppm/hr. Total output, 1351 mg after 8 days Dose 50-200 ppm for 6-8 hr 0 and 16 hr after exposure. Measured as mandelic and phenylglyoxylic acids Range of means Volunteers DRINK; STYRENES; INHALATION; METABOLITES	Guillemin, M.P. Bauer, D. 1978 International Archives of Occupational and Environmental Health 40:249-263
5697 Urine	Inhalation	GC/MS	29	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given	a) 19.5 +or- 10.4 nmol/g creatinine b) 8.0 +or- 5.7 nmol/g creatinine c) 7.5 +or- 5.2 nmol/g creatinine d) 0.040 +or- 0.028 nmol/g creatinine e) 0.027 +or- 0.023 nmol/g creatinine f) 0.020 +or- 0.017 nmol/g creatinine	a) Mandelic acid (metabolite), Factory A b) Mandelic acid, Factory B c) Mandelic acid, Factory B, second sample d) 4-vinylphenol (metabolite), Factory A e) 4-vinylphenol, Factory B f) 4-vinylphenol, Factory B, second sample Measured at end of 8 hr shift. Mean air styrene, 130 ppm Workers who rolled polyester plastics by hand or by spray application INDUSTRIAL CHEMICALS; FINLAND; DRINK; INDUSTRIAL MEDICINE; STYRENES; INDUSTRIAL ATMOSPHERES; INHALATION; OCCUPATIONAL HAZARDS	Pfaffli, P. Hesso, A. Vainio, H. Hyvonen, M. 1981 Toxicology and Applied Pharmacology 60:85-90

Sulfur
7704-34-9
S
MW 32.064, MP 115.21 C, BP about 444.6 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5698 Hair		NA	71	a) 22896-40450 ug/g b) 12244-82934 ug/g c) Not given d) Not given e) Not given f) Not given	a) 28900 +or- 6700 ug/g b) 31670 +or- 12000 ug/g c) 29500 ug/g d) 30300 ug/g e) 34900 ug/g f) 27800 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278

Thallium
7440-28-0
Tl
At# 204.37, MP 303.5 C, BP 1457 C, VP 1 mm Hg at 825 C, 10 mm Hg at 1000 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5699 Blood	Ingestion		1	85-20 ug/dl	Not applicable	16 and 56 day after 12 g (20 g thallium iodide). Initial measurement 70 ug/dl at 12 days. 52 yr old Abdominal colic, constipation, severe pain, and motor weakness of the lower extremities in the first week. Severe postural hypotension, marked agitation, confusion, confabulation and short-term memory loss in the second week. Alopecia ADULTS; SUICIDE; BLOOD; URINE; DRUG ABUSE; DRUGS	Koshy, K.T. Lovejoy, F.H. Jr. 1981 Clinical Toxicology 18(5):521-525
5700 Hair	Ingestion	AAS	a) 1163 b) 6 c) 45 d) 7	a) 0.6-565 ng/g b) 8.9-97.8 ng/g c) 38.9-69.1 ng/g d) 3.4-67.7 ng/g	a) 20.3 ng/g b) 29.5 ng/g c) 49.1 ng/g d) 15.1 ng/g	a) Suburban population living near Tl-emitting cement plant. From contamination of home-grown vegetables b) 20-40 yr old cement plant workers c) 40-60 yr old cement plant workers d) >60 yr old cement plant workers Residents of northwest Germany Polyneuritic symptoms, sleep disorders, headache, fatigue and other signs of psychasthenia. No correlation with skin alterations, hair loss, or gastrointestinal dysfunctions. GERMANY; METAL POISONING; HAIR; CRIME; METALS; THALLIUM; DUST; FOOD CONTAMINATION; HEALTH HAZARDS; INDUSTRIAL EMISSIONS; POPULATION EXPOSURE; VEGETABLES; AGE	Brockhaus, A. Dolgner, R. Ewers, U. Kramer, U. Seddemann, H. Wiegand, H. 1981 International Archives of Occupational and Environmental Health 48:375-389
5701 Kidney		AAS	1	Not applicable	<2 ug/g wet wt	Analysis by standard subtilisn tissue degradation technique followed by AAS Autopsy KIDNEYS; LIVER; MEASUREMENT METHODS; CADMIUM; COPPER; LEAD; THALLIUM	Carpenter, P.C. 1981 Analytica Chimica Acta 125:209-213
5702 Liver		AAS	3	<2-<2 ug/g wet wt	<2 ug/g wet wt	Analysis by standard subtilisn tissue degradation technique followed by AAS Autopsies KIDNEYS; LIVER; MEASUREMENT METHODS; CADMIUM; COPPER; LEAD; THALLIUM	Carpenter, P.C. 1981 Analytica Chimica Acta 125:209-213

(NEXT PAGE)

Thallium
7440-28-0
Tl
AtW 204.37, MP 303.5 C, BP 1457 C, VP 1 mm Hg at 825 C, 10 mm Hg at 1000 C

(CONTINUED)

TISSUE	EXPOSURE POSTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5703 Urine	Ingestion	AAS	a) 1265 b) 31 c) 10	a) <0.1-76.5 ug/l b) <0.1-1.2 ug/l c) <0.1-0.9 ug/l	a) 5.2 ug/l b) 0.4 ug/l c) 0.3 ug/l	a) Suburban population living in the vicinity of Tl-emitting cement plant b) Controls, rural area c) Controls, urban area 24 hr samples Uptake of home-grown vegetables contaminated with particulate matter (0.2-0.8 um) containing Tl, probably as TlCl or Tl2r. Residents of northwest Germany Poly-neuritic symptoms, sleep disorders, headache, fatigue and other signs of psychasthenia. No correlation with skin alterations, hair loss, or gastrointestinal dysfunctions. GERMANY; METAL POISONING; HAIR; URINE; METALS; THALLIUM; DUST; FOOD CONTAMINATION; HEALTH HAZARDS; INDUSTRIAL EMISSIONS; POPULATION EFFECTUPF; VEGETABLES	Brockhaus, A. Dolgner, R. Ewers, U. Kramer, U. Soddemann, R. Wiegand, H. 1981 International Archives of Occupational and Environmental Health 48:375-389
5704 Urine	Ingestion		1	11-2 ug/g creatinine	Not applicable	2 and 26 days after 12 g (20 g thallium iodide). 52 yr old Abdominal colic, constipation, severe pain, and motor weakness of the lower extremities in the first week. Severe postural hypotension, marked agitation, confusion, confabulation and short-term memory loss in the second week. Alopecia ADULTS; SUICIDE; BLOOD; URINE; DRUG ABUSE; DRUGS	Koshy, K.M. Lovejoy, F.H. Jr. 1981 Clinical Toxicology 18(5):521-525

Thioether (No postings in CHEMLINE).

TISSUE	EXPOSURE POSTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5705 Urine		Colorimetry	a) 196 b) 69 c) 69 d) 34 e) 37 f) 21 Samples	a) 1.7-7.1 mmol SH/mol creatinine b) 2.1-10.1 mmol SH/mol creatinine c) 2.2-10.5 mmol SH/mol creatinine d) 2.2-7.5 mmol SH/mol creatinine e) 1.8-10.1 mmol SH/mol creatinine f) 1.8-4.2 mmol SH/mol creatinine	a) 3.8 mmol SH/mol creatinine b) 3.8 mmol SH/mol creatinine c) 4.0 mmol SH/mol creatinine d) 3.9 mmol SH/mol creatinine e) 5.1 mmol SH/mol creatinine f) Not given	a) Controls b) Dispatchers (prework period) c) Dispatchers (end of work) d) Incinerators (prework period) e) Incinerators (end of work) f) Analyst 14 employees, chemical waste incineration plant. Number, occupation of controls not given. The Netherlands NETHERLANDS; URINE; INDUSTRIAL HYGIENE; INDUSTRIAL MEDICINE; THIOETHERS; HEALTH HAZARDS; INDUSTRIAL PLANTS; METABOLITES; OCCUPATIONAL HAZARDS; INDUSTRIAL CHEMICALS	Van Doorn, R. Leijdekkers, C.M. Bos, R.P. Brouns, R.M.M. Henderson, P.T. 1981 British Journal of Industrial Medicine 38:187-190

Tin
7440-31-5
Sn
Atw 118.69, MP 231.9 C, BP 2507 C, VP 1 mm Hg at 1610 C, 10 mm Hg at 1890 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5706 Teeth		NS	208	a) Not given b) Not given	a) 0.24 +or- 0.08 ppm b) 1.35 +or- 0.37 ppm S.E.	a) High caries donors (>7 decayed, missing, filled teeth (DMFT)), 21 teeth b) Low caries donors (<3 DMFT), 8 teeth Values for enamel a) and b) differed, P<0.01 Premolars, patients <20 yr old, New England PYRROLINE; NEW HAMPSHIRE; SOUTH CAROLINA; VERMONT; DENTAL CARIES; TEETH; ALUMINUM; BARIUM; COPPER; FLUORINE; LITHIUM; METALS; SILVER; STRONTIUM; TIN	Curzon, M.E.J. Losee, F.L. 1977 Journal of the American Dental Association 94(6):1186-1190

Vanadium
7440-62-2
V
Atw 50.9414, MP 1917 C, BP 3000 C, VP 1 mm Hg at 2290 C, 10 mm Hg at 2570 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5707 Blood, serum		AAS	8	a) 190-790 nmol/l b) 190-490 nmol/l	a) 393 +or- 223 nmol/l b) 255 +or- 93 nmol/l	a) At end of work shift. Mean air levels 0.19 +or- 0.24 mg/cu m b) 10-16 days after end of exposure No significant correlation with air levels Ranges estimated from graph 22-39 yr old V workers (2-3 yr high exposure), Finland INDUSTRIAL CHEMICALS; FINLAND; ADULTS; BLOOD; DRINK; VANADIUM; DUST; INDUSTRIAL ATMOSPHERES; OCCUPATIONAL HAZARDS	Kiviluoto, M. Pyy, L. Pakarinen, A. 1981 International Archives of Occupational and Environmental Health 48:251-256
5708 Hair		NS	71	a) 2.08-9.44 ug/g b) 0.01-3.36 ug/g c) Not given d) Not given e) Not given f) Not given	a) 0.16 +or- 0.1 ug/g b) 0.15 +or- 0.09 ug/g c) 0.126 ug/g d) 0.198 ug/g e) 0.169 ug/g f) 0.121 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1978 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5709 Nail		NS	Not given	a) Not given b) Not given	a) 18.2X10(E-2) +or- 8.7X10(E-2) ug/g b) 17.8X10(E-2) +or- 9.4 X10(E-2) ug/g	a) Women b) Men Toenail sample of about 6 mg Machakos district, Kenya, 1978 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278

(NEXT PAGE)

Vanadium
7440-62-2
V
Atw 50.9414, MP 1917 C, BP 3000 C, VP 1 mm Hg at 2290 C, 10 mm Hg at 2570 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5710 Urine		GC	86	a) 19-179 nmol/mmol creatinine b) 23-95 nmol/mmol creatinine c) 19-61 nmol/mmol creatinine	a) 73 +or- 58 nmol/mmol creatinine b) 49 +or- 36 nmol/mmol creatinine c) 32 +or- 17 nmol/mmol creatinine	a) V workers (8) at start of vacation b) 10-16 days later c) Family members (9) No correlation with factory V air levels. Values in b) significantly higher than c) 22-39 yr old V workers (2-3 yr high exposure), Finland INDUSTRIAL CHEMICALS; FINLAND; ADULTS; BLOOD; URINE; VANADIUM; DUST; INDUSTRIAL ATMOSPHERES; OCCUPATIONAL HAZARDS	Kiviluoto, M. Pyy, L. Pakarinen, A. 1981 International Archives of Occupational and Environmental Health 48:251-256

Zinc
7440-66-6
Zn
Atw 65.38, MP 419.5 C, BP 908 C, VP 1 mm Hg at 487 C, 10 mm Hg at 590 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5711 Blood						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; METALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-378
5712 Blood, cells		Colorimetry	10	Not given	36.9 +or- 2.4 ug/g hemoglobin	Healthy population ERYTHROCYTES; MEASUREMENT METHODS; METALS; ZINC; BLOOD	Carter, P. 1975 Biochemical Medicine 14:378-383
5713 Blood, cells		NA	a) 25 b) 21 c) 10 d) 10 e) 4 f) 4 g) 5	a) 7.8-11.6 ug/g b) 6.7-15.5 ug/g c) Not given d) Not given e) Not given f) Not given g) Not given	a) 10.1 +or- 1.1 ug/g b) 10.1 +or- 1.8 ug/g c) 9.9 +or- 1.7 ug/g d) 9.5 +or- 1.0 ug/g e) 10.0 +or- 0.3 ug/g f) 10.2 +or- 1.0 ug/g g) 10.3 +or- 1.7 ug/g Wet wt	a) Controls, male b) Controls, female c) Acute viral hepatitis, active phase d) Acute viral hepatitis, subsiding phase e) Chronic persistent hepatitis f) Chronic aggressive hepatitis g) Postnecrotic cirrhosis Patients with hepatic disease, Belgium LIVER DISEASES; BLOOD SERUM; ERYTHROCYTES; COPPER; MANGANESE; METALS; ZINC; BELGIUM	Versieck, J. Barbier, F. Speecke, A. Hoste, J. 1976 Clinical Chemistry 20(9):1141-1145

(NEXT PAGE)

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5714 Blood, plasma	Ingestion		a) 5 b) 7	a) 10-110 ug/dl b) 1-30 ug/dl	a) Not given b) Not given	a) 0.5 and 2.0 hr after 25 mg in human milk. Final measurement 65 ug/dl at 4 hr b) 0.5 and 3.0 hr after 25 mg in cow's milk. Final measurement 25 ug/dl at 4 hr Range of means for values above baseline (not given). Bioavailability of Zn significantly higher with human than with cow's milk, or with infant formulas based on cow's milk, soy or casein hydrolysate Healthy adults BLOOD PLASMA; METALS; ZINC; DIETS; FOODS	Casey, C.E. Walravens, P.A. Hambidge, K.M. 1981 Pediatrics 68(3):394-396
5715 Blood, plasma	Ingestion		34	a) 9-20 umol/l b) 2-15 umol/l c) Not given d) Not given e) 5-17 umol/l f) 6-15 umol/l g) Not given h) Not given i) Not given	a) 13.9 +or- 0.8 umol/l b) 9.9 +or- 0.9 umol/l c) 5.8 +or- 0.5 umol/l d) 12.8 +or- 0.3 umol/l e) 10.6 +or- 0.9 umol/l f) 10.1 +or- 0.6 umol/l g) 5.7 +or- 0.8 umol/l h) 11.6 +or- 0.3 umol/l i) 14.3 +or- 0.6 umol/l	a) Maintenance diet b) High energy diets (combined data) c) Soya-based diet d) Cow's milk-based diet e) Maintenance diet (edematous condition relieved) f) High energy diets g) Soya-based diet h) Cow's milk-based diet i) Controls Marasmic (a-d) or Kwashiorkor and marasmic-Kwashiorkor children (e-h) Malnourished 6-31 mo olds, Jamaica Negative correlation between the rate of weight gain and plasma zinc concentration JAMAICA; CHILDREN; NUTRITIONAL DEFICIENCIES; BLOOD PLASMA; ZINC; DIETS	Golden, B.E. Golden, M.H.N. 1981 The American Journal of Clinical Nutrition 34:892-899
5716 Blood, plasma	Ingestion	AAS	5	68-35 ug/dl	Not given	2 and 4 hr after 110 mg Zn SO4.7H2O (25 mg Zn). Initial level, 6.1 mg/dl at 1 hr Range of means, above baseline (not given). Ascorbic acid (0.5-2.0 g) and black bean gruel meal had no significant effect on Zn absorption BLOOD PLASMA; METALS; ZINC; DIETS; FOODS	Solomons, N.W. Jacob, R.A. Pineda, O. Viteri, F.E. 1979 American Journal of Clinical Nutrition 32:2495-2499
5717 Blood, plasma	Ingestion	AAS	a) 5 b) 20 c) 19 d) 11	a) Not given b) Not given c) Not given d) Not given	a) 138 +or- 37 ug/dl b) 110 +or- 28 ug/dl c) 83 +or- 15 ug/dl d) 67 +or- 25 ug/dl	a) <28 wk b) 28-31 wk c) 32-35 wk d) 36 or more wk Gestational ages Admission levels Intake from formula, 0.8 mg/kg/day. Levels declined more rapidly in a) and b). At 6 wk, 14 of 30 infants had levels of 45 mg/dl or less. Premature infants Increased gastric residuals, poor suck, decreased growth in 2 infants PREMATURE INFANTS; INFANTS; NUTRITIONAL DEFICIENCIES; NUTRITIONAL DISORDERS; BLOOD PLASMA; TRACE ELEMENTS; ZINC; DIETS	Thorp, J.W. Boeckx, F.L. Robbins, S. Horn, S. Fletcher, A.B. 1981 American Journal of Clinical Nutrition 34:1056-1060

(NEXT PAGE)

Zinc
7440-66-6
Zn
Atw 65.38, MP 419.5 C, BP 908 C, VP 1 mm Hg at 487 C, 10 mm Hg at 590 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5718 Blood, plasma	Ingestion	AAS	a) 12 b) 6 c) 5	a) 68-73 ug/100 g b) 61-73 ug/100 g c) 72-92 ug/100 g	a) 60 +or- 3 ug/100 g b) 66 +or- 2 ug/100 g c) 80 +or- 4 ug/100 g S.E.	a) Pregnant vegetarians, mean intake 29.6 +or- 10.9 mg/day, diet plus supplement. Crude fiber 8.9 g/day b) Pregnant nonvegetarians, mean intake 16.1 +or- 1.8 mg/day, diet plus supplement. Crude fiber 4.8 g/day c) Nonpregnant vegetarians, mean intake 6.4 +or- 1.3 mg/day Zn not altered by crude fiber <9.0 g/day. a) and c) differed significantly ZINC; BIOACCUMULATION; DIETS; FOODS; PREGNANCY; BLOOD PLASMA; HAIR; URINE	King, J.C. Stein, M. Doyle, M. 1981 American Journal of Clinical Nutrition 34:1049-1055
5719 Blood, serum		AAS	a) 40 b) 15 c) 36 d) 60 e) 18 f) 18 g) 45 h) 28	a) 82-170 ug/100 ml b) 66-228 ug/100 ml c) 89-156 ug/100 ml d) 86-206 ug/100 ml e) 89-156 ug/100 ml f) 89-189 ug/100 ml g) 86-206 ug/100 ml h) 86-99 ug/100 ml	a) 118.74 +or- 22.89 ug/100 ml b) 113.77 +or- 42.16 ug/100 ml c) 93.72 +or- 27.16 ug/100 ml d) 93.83 +or- 25.99 ug/100 ml e) 96.70 +or- 27.31 ug/100 ml f) 91.55 +or- 8.97 ug/100 ml g) 92.27 +or- 34.37 ug/100 ml h) 82.06 +or- 15.21 ug/100 ml	a) Controls b) Suspected silicosis c) p,q,r, (2,3) silicosis (round, regular opacities) d) A,B, and C silicosis (large opacities) e) Second silicosis (p,q,r,) f) Third silicosis (p,q,r) g) Silicotuberculosis h) Active lung tuberculosis p,q,r and A,B,C, international pneumoconioses nomenclature Silicotic patients, coal miners 5 or more yr prior to study, Rumania Serum Cu increased with increasing severity of silicosis. Serum Zn and Fe lowered. ROMANIA; INDUSTRIAL DISEASES; OCCUPATIONAL DISEASES; BLOOD SERUM; COPPER; IRON; METALS; PROTEINS; ZINC; COAL; DUST; MINING	Niculescu, T. Dumitru, E. Burnea, D. 1981 Environmental Research 25:260-268
5720 Blood, serum				a) Not given b) Not given c) Not given d) Not given e) Not given	a) 0.86 +or- 0.13 ug/ml b) 0.89 +or- 0.10 ug/ml c) 0.88 +or- 0.08 ug/ml d) 0.87 +or- 0.10 ug/ml e) 0.84 +or- 0.09 ug/ml	a) 33 oral contraceptive agent (OCA) users b) 24 controls c) 12 subjects, before using OCA d) Same 12, 3 mo OCA use e) Same 12, 6 mo OCA use No significant differences. Healthy 18-23 yr olds ADULTS; BLOOD SERUM; HAIR; COPPER; METALS; ZINC	Vir, S.C. Love, A.H.G. 1981 American Journal of Clinical Nutrition 34:1079-1083
5721 Blood, serum		RIA	a) 25 b) 21 c) 10 d) 10 e) 4 f) 4 g) 5	a) 0.72-1.21 ug/ml b) 0.69-1.15 ug/ml c) Not given d) Not given e) Not given f) Not given g) Not given	a) 0.99 +or- 0.13 ug/ml b) 0.88 +or- 0.11 ug/ml c) 0.90 +or- 0.16 ug/ml d) 0.91 +or- 0.07 ug/ml e) 1.02 +or- 0.16 ug/ml f) 0.79 +or- 0.20 ug/ml g) 0.81 +or- 0.33 ug/ml	a) Controls, male b) Controls, female c) Acute viral hepatitis, active phase d) Acute viral hepatitis, subsiding phase e) Chronic persistent hepatitis f) Chronic aggressive hepatitis g) Postnecrotic cirrhosis Patients with hepatic disease LIVER DISEASES; BLOOD SERUM; ERYTHROCYTES; COPPER; MANGANESE; METALS; ZINC; BELGIUM	Versieck, J. Barbier, F. Speecke, A. Hoste, J. 1974 Clinical Chemistry 20(9):1141-1145

(NEXT PAGE)

Zinc
7440-66-6
Zn
Atw 65.38, MP 419.5 C, BP 909 C, VP 1 mm Hg at 487 C, 10 mm Hg at 590 C

(CONTINUED)

TISSUE	PESTICIDE DOSAGE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5722 Blood, serum		AAS	a) 20 b) 31 c) 87	a) Not given b) Not given c) 44-77 ug/100 ml	a) 96 +or- 20 ug/100 ml b) 98 +or- 20 ug/100 ml c) Not given	a) Healthy controls b) Convalescing patients c) Acutely ill patients Significant decrease in c). In healthy, acutely ill, adrenalectomized and hydroxylase deficient patients ACTH infusion reduced plasma Zn by 10-66 ug/100 ml if initial levels were >70 ug/100 ml. No effect when levels were <70 ug/100 ml. Range of means Healthy 21-50 yr olds, acutely ill 20-86 yr olds ADULTS; DISEASES; ADRENAL GLANDS; BLOOD PLASMA; HORMONES; PROTEINS; ZINC	Palchuk, N.B. 1977 New England Journal of Medicine 296(20):1129-1134
5723 Bone						Review. Discussion of trace elements as inhibitory or causative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGEN; RATS	Schwartz, M.K. 1975 Cancer Research 35:3481-3487
5724 Bone						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; FETALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-378
5725 Breast						Review. Discussion of trace elements as inhibitory or causative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGEN; RATS	Schwartz, M.K. 1975 Cancer Research 35:3481-3487
5726 Esophagus						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; FETALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-373

(NEXT PAGE)

Zinc
7440-66-6
Zn
Atv 65.38, MP 419.5 C, BP 908 C, VP 1 mm Hg at 487 C, 10 mm Hg at 590 C

(CONTINUED)

SYSSOP	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5727 Eye						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; METALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-378
5728 Gall stone		AAS	10	a) Not given b) Not given c) Not given	a) 3.94 +or- 2.87 ug/g b) 1.84 +or- 1.17 ug/g c) 2.89 +or- 1.58 ug/g	a) 5 men b) 5 women c) Total Fukuriku, Japan JAPAN; SEX; GALL STONES; KIDNEYS; COMPARATIVE EVALUATIONS; CADMIUM; COPPER; METALS; ZINC	Yamamoto, I. Itoh, N. Tsubata, S. Takenaka, S. Kiyozumi, M. Kojima, S. 1980 Procedings of the 7th Symposium on Environmental Pollutants and Toxicology, Kobe, Japan, S-68
5729 Hair		NA	71	a) 130-174 ug/g b) 88-201 ug/g c) Not given d) Not given e) Not given f) Not given	a) 145 +or- 18 ug/g b) 126 +or- 3.9 ug/g c) 145 ug/g d) 94 ug/g e) 98 ug/g f) 124 ug/g	a) 31 women b) 40 men c) 16 subjects from a) <12 yr old d) 15 subjects from a) >12 yr old e) 22 subjects from b) <12 yr old f) 18 subjects from b) >12 yr old Machakos district, Kenya, 1974 BARIUM; BROMINE; CALCIUM; CHLORINE; COPPER; GOLD; IODINE; MAGNESIUM; MANGANESE; MERCURY; SODIUM; STRONTIUM; SULFUR; VANADIUM; ZINC; BIOACCUMULATION; HAIR; NAILS; ADOLESCENTS; AGE; CHILDREN; SEX; AFRICA	Othman, I. Spyrou, N.M. 1980 Science of the Total Environment 16:267-278
5730 Hair				a) Not given b) Not given c) Not given d) Not given e) Not given	a) 183.60 +or- 30.60 ug/g b) 175.00 +or- 24.30 ug/g c) 178.17 +or- 21.11 ug/g d) 181.08 +or- 23.99 ug/g e) 171.50 +or- 14.75 ug/g	a) 33 oral contraceptive agent (OCA) users b) 24 controls c) 12 subjects, before using OCA d) Same 12, 3 mo OCA use e) Same as 12, 6 mo OCA use No significant differences. Healthy 18-23 yr olds ADULTS; BLOOD SERUM; HAIR; COPPER; METALS; ZINC	Vir, S.C. Love, A.H.G. 1981 American Journal of Clinical Nutrition 34:1479-1483
5731 Heart						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; METALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-378

(NEXT PAGE)

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5732 Kidney						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; METALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-378
5733 Kidney		AAS	45	a) Not given b) Not given c) Not given Renal calculi	438.0 +or- 60 ug/g b) 354.0 +or- 69 ug/g c) 403.0 +or- 46 ug/g	a) 26 men b) 19 women c) Total Hoburibu, Japan JAPAN; SEX; GALL STONES; KIDNEYS; COMPARATIVE EVALUATIONS; CADMIUM; COPPER; METALS; ZINC	Yamamoto, I. Itoh, M. Tsukada, S. Takenaka, S. Kiyozumi, M. Kojima, S. 1980 Procedings of the 7th Symposium on Environmental Pollutants and Toxicology, Kobe, Japan, S-68
5734 Liver						Review. Discussion of trace elements as inhibitory or causative agents of cancer and diagnostic use of their assay in biological fluids. CARCINOMAS; OSTEOSARCOMAS; SARCOMAS; BLOOD SERUM; BODY; BONES; BREAST; LIVER; PLEURAL FLUID; URINE; COPPER; CHROMIUM; MANGANESE; ZINC; CARCINOGEN; RATS	Schwartz, M.K. 1975 Cancer Research 35:3481-3487
5735 Liver						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; METALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-378
5736 Liver		AAS	16	Not given	293 ng/mg	Normal upper limit estimated to be 800 ng/mg dry wt Autopsies, normal liver AUTOPSIES; LIVER; MEASUREMENT METHODS; CADMIUM; COPPER; ZINC; METALS	Evenson, M.A. Anderson, C.T., Jr. 1975 Clinical Chemistry 21(8):537-583
5737 Lung						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; METALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-378

(NEXT PAGE)

Zinc
7440-66-6
Zn
At# 65.38, BP 919.5 C, MP 908 C, VP 1 mm Hg at 487 C, 10 mm Hg at 590 C

(CONTINUED)

TISSUE	EXPOSURE DURATION	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5738 Muscle						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; METALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-378
5739 Pancreas						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; METALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-378
5740 Prostate						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; METALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-378
5741 Prostate						Review. Cd may interfere with Zn/hormone relationship in the prostate, causing cancer in heavily exposed individuals JAPAN; SWEDEN; UNITED STATES; RACIAL STUDIES; SARCOMAS; KIDNEYS; LIVER; PROSTATE; TESTES; URINE; CADMIUM; ZINC; CARCINOGEN; DIETS; DRINKING WATER; OCCUPATIONAL HAZARDS; RATS	Piscator, M. 1981 Environmental Health Perspectives 40:107-120
5742 Saliva		AAS	10	a) 0.033-0.177 ppm b) 0.037-0.127 ppm c) 0.074-0.129 ppm d) 0.073-0.111 ppm	a) Not applicable b) Not applicable c) Not applicable d) Not applicable	a) Individual range, 8 samples/subject over 8 days b) 8hourly range, samples every 2 hr for 14 hr c) Daily range, 8 days, two 4-day periods one month apart d) Monthly range, two 4-day periods one month apart Daily Zn intake 15-22 mg Saliva flow rate, individual variability, and diurnal effect altered Zn levels. No correlation with dietary Zn. Data differ from previously reported values found with other methods Healthy 17-37 yr olds. SALIVA; METALS; ZINC	Warren, B.C. Lane, H.W. Waren, M. 1981 Biological Trace Element Research 3:99-107

(NEXT PAGE)

Zinc
7440-66-6
Zn
At# 65.38, MP 419.5 C, BP 908 C, VP 1 mm Hg at 487 C, 10 mm Hg at 590 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5743 Sweat	Ingestion	AAS	13	Not given	0.50 +or- 0.38 mg/day	Surface losses after mean dietary intake of 12.7 mg/day (range 6.6-19.6 mg/day) Healthy 19-58 yr olds in controlled environment 4-9 mo ADULTS; SWEAT; COPPER; IRON	Jacob, R.A. Sandstead, H.H. Munoz, J.M. Klevay, L.M. Milne, D.B. 1981 The American Journal of Clinical Nutrition 34:1379-1383
5744 Teeth		AAS	12	Not given	83 +or- 29 ppm	Median, 80.5 ppm Stillborn or neonatal deaths, 1972-73, Bristol, United Kingdom UNITED KINGDOM; AUTOPSIES; NEWBORN; TEETH; CADMIUM; IRON; LEAD; MANGANESE; METALS; NICKEL; ZINC	Stack, M.V. Burkitt, A.J. Nickless, G. 1976 Bulletin of Environmental Contamination and Toxicology 16(6):764-766
5745 Tissues						Review. More information on indices of marginal Zn deficiency and factors affecting availability and utilization of dietary Zn is needed for making recommendations on nutritional requirements and dietary allowances. BLOOD; BONES; ESOPHAGUS; EYE; HEART; KIDNEYS; LIVER; LUNGS; MUSCLES; PANCREAS; PROSTATE; TESTES; REVIEW; METALS; ZINC; DIETS	Halstead, J.A. Smith, J.C. Irwin, M.I. 1974 Journal of Nutrition 104(3):345-378

Zirconium
7440-67-7
Zr
At# 91.22, MP 1852 C, BP 3577 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5746 Teeth		MS	208	a) Not given b) Not given	a) 0.27 +or- 0.10 ppm b) 0.16 +or- 0.09 ppm S.E.	a) High caries donors (>7 decayed, missing, filled teet (DMFT)), 24 teeth b) Low caries donors (<3 DMFT), 29 teeth Values for enamel a) and b) differed, P<0.02 Premolars extracted, patients <20 yr old, South Carolina and New England ZIRCONIUM; NEW HAMPSHIRE; SOUTH CAROLINA; VERMONT; DENTAL CARIES; TEETH; ABORTION; PARITY; COPPER; PIPERINE; FISSION; METALS; SILVER; SUPERFICIAL; TIN	Curzon, M.E.J. Losee, F.L. 1977 Journal of the American Dental Association 94(6):1146-1150

1-Hexadecanol, hydrogen sulfate
143-02-2
C16-H34-O4-S
MW 322.56

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5747 Blood, plasma	Ingestion		a) 1 b) 1	a) 22-1 umol/l b) 3.2-0.2 umol/l	a) Not applicable b) Not applicable	a) 2 and 12 hr after 250 mg b) 2 and 12 hr after 250 mg 1 umol/l or less of metabolite butyric acid-4-sulphate SURFACTANTS; BLOOD PLASMA; URINE; DOGS; METABOLISM; METABOLITES; RATS	Merits, I. 1975 Biochemical Journal 148:219-228
5748 Urine	Ingestion		a) 1 b) 2	a) Not applicable b) Not applicable	a) 80% of dose b) 20% of dose	a) 0-72 hr, 7% in feces b) 0-118 hr, 73% in feces After 250 mg as erythromycin salt. Data for metabolites also given SURFACTANTS; BLOOD PLASMA; URINE; DOGS; METABOLISM; METABOLITES; RATS	Merits, I. 1975 Biochemical Journal 148:219-228

1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI)
1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)
81-07-2
C7-H5-N-O3-S
MW 183.2, MP 228 C (decomp), BP (sublimes)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5749 Blood, plasma	Ingestion	HPLC	a) 1 b) 1	1.0-0.02 ug/ml b) 2-0.03 ug/ml	a) Not applicable b) Not applicable	a) 1 and 9 hr after 100 mg dose, non-user b) 2 and 24 hr after 100 mg dose, regular user. Initial measurement, 1.5 ug/ml at 1 hr. Routine daily use of 50 mg until 10 days before study SEX; BLOOD PLASMA; URINE; FOOD ADDITIVES; SWEETENING AGENTS	Colburn, W.A. Bekersky, I. Blumenthal, H.P. 1981 Journal of Clinical Pharmacology 21:147-151
5750 Blood, plasma	Ingestion	GC	a) 6 b) 6	a) 1.9-0.6 ug/ml b) <0.05-0.35 ug/ml	a) Not given b) Not given	45 and 240 min after 50 mg/60 kg, 0.1% solution. Level at 10 min, 0.23 ug/ml. Estimated from graph b) Level over 24 hr period after 130 mg/60 kg of body wt for 5 days. Area under concentration-time curve, 2.24 +or- 0.39 ug/ml hr Range of means Healthy volunteers ADULTS; BLOOD PLASMA; URINE; FOOD ADDITIVES; SWEETENING AGENTS	Pantarotto, C. Salmona, M. Fanelli, R. Bianchi, M. Szczawinska, K. 1981 Journal of Pharmaceutical Sciences 70(8):871-874
5751 Urine	Ingestion	HPLC	a) 1 b) 1	a) 30-0.2 mg/hr b) 15-0.8 mg/hr	a) Not applicable b) Not applicable	a) Non-user b) Regular user 2 and 18 hr after 100 mg dose Routine daily use of 50 mg until 10 days before study in b) SEX; BLOOD PLASMA; URINE; FOOD ADDITIVES; SWEETENING AGENTS	Colburn, W.A. Bekersky, I. Blumenthal, H.P. 1981 Journal of Clinical Pharmacology 21:147-151
5752 Urine	Ingestion	GC	a) 6 b) 6	a) Not given b) Not given	a) 47.14 +or- 1.62 mg/24 hr b) 89.83 +or- 15.01 mg/24 hr	a) After single of 50 mg/60 kg dose b) After 130 mg/60 kg for 5 days Healthy volunteers ADULTS; BLOOD PLASMA; URINE; FOOD ADDITIVES; SWEETENING AGENTS	Pantarotto, C. Salmona, M. Fanelli, R. Bianchi, M. Szczawinska, K. 1981 Journal of Pharmaceutical Sciences 70(8):871-874

(NEXT PAGE)

1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI)
1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)
81-07-2
C7-H5-N-O3-S
MW 183.2, MP 228 C (decomp), MP (sublimes)

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5753 Urine	Ingestion	HPLC, GC	6	a) 88.1-95.5% of dose b) 86.3-98.6% of dose	a) 92.6 +or- 1.5% of dose b) 94.4 +or- 3.1% of dose	a) 500 mg (labelled), 5.8% excreted in feces 4 subjects b) 500 mg (unlabelled), 6 subjects Healthy 27-60 yr olds FECES; URINE; SWEETENING AGENTS	Byard, J.L. McChesney, E.W. Golberg, L. Coulston, F. 1974 Food and Cosmetics Toxicology 12:175-184

1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-
143-50-0
C10-Cl10-O
MW 490.68, VP <3X10(-7) mm Hg at 25 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5754 Adipose	Ingestion Inhalation Dermal		23	50,000-91,000 ng/g	Not given	Workers with chronic intoxication Employees of Kepone manufacturing plant, southeastern Virginia Tremor, pleuritic chest pain, disturbed vision, arthralgia in proximal joints, mental changes, wt loss, headache, widened gait, rash VIRGINIA; ADULTS; OCCUPATIONAL DISEASES; ADIPOSE TISSUE; BLOOD; LIVER; CHLORINE ORGANIC COMPOUNDS; INSECTICIDES; HEALTH HAZARDS; INDUSTRIAL PLANTS; INHALATION; OCCUPATIONAL HAZARDS	Taylor, J.R. Selhorst, J.R. Houff, S.A. Martinez, A.J. 1978 Neurology 28(7):626-630
5755 Blood	Ingestion Inhalation Dermal		188	a) Not given b) Not given c) 2,000-32,000 ng/ml	a) 2530 ng/ml b) 600 ng/ml c) Not given	a) Workers with symptoms of intoxication b) Asymptomatic employees c) 23 employees with chronic intoxication Employees of Kepone manufacturing plant, southeastern Virginia Tremor, pleuritic chest pain, disturbed vision, arthralgia in proximal joints, mental changes, wt loss, headache, widened gait, rash VIRGINIA; ADULTS; OCCUPATIONAL DISEASES; ADIPOSE TISSUE; BLOOD; LIVER; CHLORINE ORGANIC COMPOUNDS; INSECTICIDES; HEALTH HAZARDS; INDUSTRIAL PLANTS; INHALATION; OCCUPATIONAL HAZARDS	Taylor, J.R. Selhorst, J.R. Houff, S.A. Martinez, A.J. 1978 Neurology 28(7):626-630

(NEXT PAGE)

1,3,6-Methano-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-
143-50-0
C10-Cl10-O
MW 490.68, VP <3X10(E-7) mm Hg at 25 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5756 Liver	Ingestion Inhalation Dermal		21	13,300-173,000 ng/g	Not given	Workers with chronic intoxication Employees of Kepone manufacturing plant, southeastern Virginia Tremor, pleuritic chest pain, disturbed vision, arthralgia in proximal joints, mental changes, wt loss, headache, widened gait, rash VIRGINIA; ADULTS; OCCUPATIONAL DISEASES; ADIPOSE TISSUE; BLOOD; LIVER; CHLORINE ORGANIC COMPOUNDS; INSECTICIDES; HEALTH HAZARDS; INDUSTRIAL PLANTS; INHALATION; OCCUPATIONAL HAZARDS	Taylor, J.P. Selhorst, J.B. Houff, S.A. Martinez, A.J. 1978 Neurology 28(7):626-630

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI)
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)
309-00-2
C12-H8-Cl6
MW 365.93, MP 184 C, VP 6X10(E-6) mm Hg at 25 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5757 Adipose		GC-EC	a) 12 b) 28	a) 0 b) 0-0.881 ppm	a) 0 b) 0.0804 ppm	a) Rural b) Urban Autopsies, Spain SPAIN; AUTOPSIES; ADIPOSE TISSUE; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; DDD; LINDANE; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; ORGANOPHOSPHATES; PESTICIDES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Herrera Marteache, A. Polo Villar, L.M. Jodral Villarejo, M. Polo Villar, G. Mallol, J. Pozo Lora, M. 1978 Revista de Sanidad e Higiene Publica 52, 20 pp.
5758 Blood		GC TLC	a) 25 b) 25	0.0006-0.1435 ppm b) 0.0004-0.0449 ppm	a) 0.0213 +or- 0.0075 ppm b) 0.0149 +or- 0.0026 ppm S.E.	a) Mothers, 24 hr after parturition b) Fetal (cord) blood, parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDT; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NEWBORN	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, D. 1981 Environmental Research 24:24-32
5759 Milk		GC-EC	158	a) 0-0.74 mg/kg fat b) Not given c) Not given	a) 0.041 +or- 0.068 mg/kg fat b) 0.03 +or- 0.03 mg/kg fat c) 0.05 +or- 0.10 mg/kg fat	a) 0.001 +or- 0.003 mg/kg whole milk, all samples b) Rural residents, 99 samples c) Urban residents, 51 samples 3-6 days postpartum. 3% exceeded Codex Alimentarius Commission limits. No correlation with age or place of residence. 18-38 yr olds, Canada ALBERTA; CANADA; AGE; MILK; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; POLYCHLORINATED BIPHENYLS; POPULATION EXPOSURE; RURAL AREAS; SMOKING; URBAN AREAS	Dillon, J.C. Martin, G.B. O'Brien, M.T. 1981 Food and Cosmetics Toxicology 19:437-442

(NEXT PAGE)

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI)
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)
3C9-00-2
C12-H8-C16
MW 365.93, MP 108 C, VP 6X10(E-6) mm Hg at 25 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5760 Milk, whole		GC TLC	25	0.0045-0.1811 ppm	0.0298 +or- 0.0094 ppm S.E.	24 hr after parturition 19-35 yr old mothers, no history of exposure to pesticides. India DDI; DDE; DDT; HEXACHLOROCYCLOHEXANE; LINDANE; BIOACCUMULATION; PESTICIDE RESIDUES; BLOOD; MILK; INDIA; ADULTS; NEWBORN	Siddiqui, M.K.J. Saxena, M.C. Bhargava, A.K. Seth, T.D. Krishna Murti, C.R. Kutty, D. 1981 Environmental Research 24:28-32

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI)
2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)
60-57-1
C12-H8-C16-O
MW 380.93, MP 176-177 C, VP 7.78X10(E-7) mm Hg at 20 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5761 Adipose		GC	11	Not given	0.10 ppm	Autopsies, 1975 Northern Ireland SEWAGE; IRELAND; UNITED KINGDOM; ADIPOSE TISSUE; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEXACHLOROBENZENE; URBAN AREAS; WATER POLLUTION; ADULTS; AUTOPSIES; PESTICIDE RESIDUES	Harper, D.B. Smith, R.V. Gotto, D.M. 1977 Environmental Pollution 12(3):223-233
5762 Adipose			a) 3 b) 2 c) 10 d) 19 e) 3 f) 8 g) 40 h) 96 i) 118 j) 19 k) 3 l) 13 m) 47 n) 587 o) 12	a) 0.05-0.14 ppm b) 0.26-0.36 ppm c) 0.03-0.50 ppm d) 0.08-2.56 ppm e) 0.11-0.50 ppm f) 0.01-0.12 ppm g) 0-0.30 ppm h) 0-0.46 ppm i) 0-0.88 ppm j) 0.03-0.30 ppm k) 0.05-0.07 ppm l) 0.03-1.30 ppm m) 0.01-0.72 ppm n) Trace-0.28 ppm o) 0-0.21 ppm	a) 0.08 ppm b) 0.31 ppm c) 0.16 ppm d) 0.20 ppm e) 0.32 ppm f) 0.07 ppm g) 0.10 ppm h) 0.12 ppm i) 0.12 ppm j) 0.11 ppm k) 0.06 ppm l) 0.17 ppm m) 0.11 ppm n) 0.08 ppm o) 0.08 ppm	a) 1969-70, 0-20 yr olds b) 1969-70, 21-40 yr olds c) 1969-70, 41-60 yr olds d) 1969-70, 61-80 yr olds e) 1969-70, 81-100 yr olds f) 1971-72, 0-20 yr olds g) 1971-72, 21-40 yr olds h) 1971-72, 41-60 yr olds i) 1971-72, 61-80 yr olds j) 1971-72, 81-100 yr olds k) 1973-74, 0-20 yr olds l) 1973-74, 21-40 yr olds m) 1973-74, 41-60 yr olds n) 1973-74, 61-80 yr olds o) 1973-74, 81-100 yr olds In extractable fat Autopsies by year and age group Level of exposure unknown Ontario, Canada INDUSTRIAL CHEMICALS; CANADA; AGE; AUTOPSIES; ADIPOSE TISSUE; MILK; CHLORIDE ORGANIC COMPOUNDS; CHLOROBENZENES; DDT; DIELDRIN; HEXACHLOROBENZENE; PESTICIDES; POLYCHLORINATED BIPHENYLS; PESTICIDE RESIDUES; POPULATION EXPOSURE	Holdrinet, M.V.H. Braun, H.E. Frank, R. Stopps, G.J. Smout, M.S. McWade, J.W. 1977 Canadian Journal of Public Health 68:74-80

(NEXT PAGE)

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI)
2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)
60-57-1
C12-H8-Cl6-O
MW 380.93, MP 176-177 C, VP 7.78X10(E-7) mm Hg at 20 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5763 Adipose		GC-EC	a) 12 b) 28	a) 0-0.408 ppm b) 0-0.477 ppm	a) 0.129 ppm b) 0.159 ppm	a) Rural b) Urban Autopsies, Spain SPAIN; AUTOPSIES; ADIPOSE TISSUE; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; DDT; LINDANE; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; ORGANOPHOSPHATES; PESTICIDES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Herrera Marteache, A. Polo Villar, L.M. Jodral Villarejo, M. Polo Villar, G. Mallol, J. Pozo Lora, R. 1978 Revista de Sanidad e Higiene Publica 52, 20 pp.
5764 Adipose						Review. Data indicate a decline in residue levels in environmental substrates since the mid-1960s, but no corresponding decline in human tissue levels. Residents of the U.S., Canada, United Kingdom, The Netherlands, 1963-1976 CANADA; NETHERLANDS; UNITED KINGDOM; UNITED STATES; ADIPOSE TISSUE; MILK; REVIEW; PESTICIDES; AGRICULTURE; AIR POLLUTION; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; PESTICIDE RESIDUES; POPULATION EXPOSURE; WATER POLLUTION	Ackerman, L. 1980 Pesticides Monitoring Journal 14(2):68-69
5765 Blood			a) 27 b) 25	a) 4.45-58.00 ppb b) 0-3.34 ppb	a) 19.59 ppb b) 0.48 ppb	a) Pest control workers b) Controls Operators and formulators. Controls, roofing plant workers and firemen. South Carolina No clinically important differences in history, physical, specialized neurological tests, or laboratory examination. Exposed group had statistically significant difference in 5 of 58 psychological and psychomotor tests. SOUTH CAROLINA; ADULTS; CASE HISTORIES; BLOOD; DIELDRIN; PESTICIDES; HEALTH HAZARDS; OCCUPATIONAL HAZARDS; PESTICIDE RESIDUES	Sandifer, S.H. Cupp, C.M. Wilkins, W.T. Loadholt, B. Schuman, S.H. 1981 Archives of Environmental Contamination and Toxicology 10:35-45
5766 Milk			a) 48 b) 34 c) 19	a) <0.01-0.25 ppm b) <0.01-0.17 ppm c) <0.01-0.08 ppm	a) 0.09 ppm b) 0.04 ppm c) 0.04 ppm	a) 1969-70 b) 1971-72 c) 1973-74 Sampling periods level of exposure unknown Ontario residents, mean age 24-29 yr INDUSTRIAL CHEMICALS; CANADA; AGE; AUTOPSIES; ADIPOSE TISSUE; MILK; CHLORINE ORGANIC COMPOUNDS; CHLOROBENZENES; DDT; DIELDRIN; HEXACHLOROBENZENE; PESTICIDES; POLYCHLORINATED BIPHENYLS; PESTICIDE RESIDUES; POPULATION EXPOSURE	Holdrinet, M.V.H. Braun, H.E. Frank, R. Stoppa, G.J. Smout, M.S. McWade, J.W. 1977 Canadian Journal of Public Health 68:74-80

(NEXT PAGE)

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI)
2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)
60-57-1
C12-H8-Cl6-O
MW 380.93, BP 176-177 C, VP 7.78X10(E-7) mm Hg at 20 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5767 Milk						Review. Data indicate a decline in residue levels in environmental substrates since the mid-1960s, but no corresponding decline in human tissue levels. Residents of the U.S., Canada, United Kingdom, The Netherlands, 1963-1976 CANADA; NETHERLANDS; UNITED KINGDOM; UNITED STATES; ADIPOSE TISSUE; MILK; REVIEW; PESTICIDES; AGRICULTURE; AIR POLLUTION; BIOACCUMULATION; DRINKING WATER; FOOD CONTAMINATION; PESTICIDE RESIDUES; POPULATION EXPOSURE; WATER POLLUTION	Ackerman, L. 1980 Pesticides Monitoring Journal 14(2):64-69
5768 Milk			1,436 samples	a) Not given b) Not given	a) 97.9 ppb b) 242.3 ppb	a) Northeast b) Southeast, highest level 12,300 ppb Levels >1,750 ppt found in Southeast, North, South, and Midwest UNITED STATES; MILK; DIELDRIN; HEPTACHLOR EPOXIDE; OXYCHLORDANE; PESTICIDE RESIDUES	Anon 1977a Pesticide & Toxic Chemical News 5(8):10-11
5769 Milk		GC	50	0-95 ppb	42 ppb	Extracted lipids, Jan 1979 to Feb 1980, 3-46 days postpartum. No significant correlation with residence, age, weight, number of children previously nursed, household use of non-persistent pesticides, or occupation of spouse. Higher, but nonsignificant levels in women with higher frequency of meat consumption, and in those in homes with pest control treatment. Healthy 18-37 yr old Hawaiians ADULTS; AGE; HAWAII; MILK; CHLORINATED HYDROCARBONS; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; PENTACHLOROBENZENE; LINDANE; NONACHLOR; OXYCHLORDANE; PESTICIDES; POLYCHLORINATED BIPHENYLS; PPTS; LACTATION; PESTICIDE RESIDUES; POPULATION EXPOSURE	Takahashi, W. Saidin, D. Tabei, G. Wong, L. 1981 Bulletin of Environmental Contamination and Toxicology 27:506-511

4,4'-Bipyridinium, 1,1'-dimethyl-
4685-14-7
C12-H14-N2
MW 186, MP 300 C (decomp)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5770 Blood, serum	Ingestion		1	Not applicable	0.022 ug/l	5 days after ingestion of unknown amount. Patient died on 15th day. 25 yr old factory worker. Vomiting, diarrhea, leg cramps, sore throat, nonproductive cough, progressive dyspnea. Bilateral interstitial linear infiltrates seen on chest roentgenogram. Necrosis of pharyngeal membrane. ADULTS; CASE HISTORIES; BLOOD SERUM; LIVER; SPLEEN; URINE; HERBICIDES	Stephens, D.S. Walker, D.H. Schaffner, W. Kaplowitz, L.G. Brashear, H.R. Roberts, P. Spickard, W.A. 1981 Annals of Internal Medicine 94(2):202-204
5771 Urine	Ingestion		1	Not applicable	0.8 ug/l	11 days after ingestion of unknown amount. Patient died on 15th day. 25 yr old factory worker. Vomiting, diarrhea, leg cramps, sore throat, nonproductive cough, progressive dyspnea. Bilateral interstitial linear infiltrates seen on chest roentgenogram. Necrosis of pharyngeal membrane. ADULTS; CASE HISTORIES; BLOOD SERUM; LIVER; SPLEEN; URINE; HERBICIDES	Stephens, D.S. Walker, D.H. Schaffner, W. Kaplowitz, L.G. Brashear, H.R. Roberts, P. Spickard, W.A. 1981 Annals of Internal Medicine 94(2):202-204

4,7-Methano-1H-indene, 1,2,3,4,5,6,7,8,8-nonachloro-2,3,3a,4,7,7a-hexahydro-, (1alpha,2beta,3alpha,3aalpha,4beta,7beta,7aalpha)-
39765-80-5
C10-H5-Cl9
MW 444.23

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5772 Milk		GC	50	0-150 ppb	81 ppb	Extracted lipids, Jan 1979 to Feb 1980, 3-46 days postpartum. No significant correlation with residence, age, weight, number of children previously nursed, household use of non-persistent pesticides, or occupation of spouse. Higher, but nonsignificant levels in women with higher frequency of meat consumption, and in those in homes with pest control treatment. Healthy 18-37 yr old Hawaiins ADULTS; AGE; HAWAII; MILK; CHLORINATED HYDROCARBONS; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; HEXACHLOROBENZENE; LINDANE; NONACHLOR; OXYCHLORDANE; PESTICIDES; POLYCHLORINATED BIPHENYLS; DIETS; LACTATION; PESTICIDE RESIDUES; POPULATION EXPOSURE	Takahashi, W. Saidin, D. Takei, G. Wong, L. 1981 Bulletin of Environmental Contamination and Toxicology 27:506-511

4,7-Methanoindan, 1,2,4,5,6,7,8,8-octachloro-1,2-epoxy-3a,4,7,7a-tetrahydro- (8 CI)
2,5-Methano-2H-indeno(1,2-b)oxirene, 1a,2,3,4,5,6a,7,7-octachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)
26880-48-8
C10-H4-Cl8-O
MW 423.77

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5773 Milk			1,436 samples	a) Not given b) Not given c) 13.2-5700 ppb	a) 80 ppb b) 116 ppb c) Not given	a) Northeast & Midwest, U.S. b) Southeast, U.S., highest level reported was 1858.3 ppb c) Nationwide, highest level from the Southwest region UNITED STATES; MILK; DIELDRIN; HEPTACHLOR EPOXIDE; OXYCHLORDANE; PESTICIDE RESIDUES; PESTICIDES	Anon 1977a Pesticide & Toxic Chemical News 5(8):10-11
5774 Milk		GC	50	11-160 ppb	59 ppb	Extracted lipids, Jan 1979 to Feb 1980, 3-46 days postpartum. No significant correlation with residence, age, weight, number of children previously nursed, household use of non-persistent pesticides, or occupation of spouse. Higher, but nonsignificant levels in women with higher frequency of meat consumption, and in those in homes with pest control treatment. Healthy 18-37 yr old Hawaiians ADULTS; AGE; HAWAII; MILK; CHLORINATED HYDROCARBONS; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; HEXACHLOROBENZENE; LINDANE; MONACHLOR; OXYCHLORDANE; PESTICIDES; POLYCHLORINATED BIPHENYLS; DIETS; LACTATION; PESTICIDE RESIDUES; POPULATION EXPOSURE	Takahashi, W. Saidin, D. Takei, G. Wong, L. 1981 Bulletin of Environmental Contamination and Toxicology 27:506-511

4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI)
2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)
1024-57-3
C10-H5-Cl7-O
MW 389.32

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5775 Adipose		GC-EC	a) 12 b) 28	a) 0-0.058 ppm b) 0-0.137 ppm	a) 0.007 ppm b) 0.019 ppm	a) Rural b) Urban Autopsies, Spain SPAIN; AUTOPSIES; ADIPOSE TISSUE; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; DDT; LINDANE; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; ORGANOPHOSPHATES; PESTICIDES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Herrera Marteache, A. Polo Villar, L.M. Jodral Villarejo, M. Polo Villar, G. Mallol, J. Pozo Lora, M. 1978 Revista de Sanidad e Higiene Publica 52, 20 pp.
5776 Milk			1,436	a) Not given b) Not given c) 15.2-2050 ppb	a) 66.1 ppb b) 128 ppb c) Not given	a) Northwest, U.S. b) Southeast, U.S. c) Nationwide sample, highest level from the Southeast region UNITED STATES; MILK; DIELDRIN; HEPTACHLOR EPOXIDE; OXYCHLORDANE; PESTICIDE RESIDUES; POPULATION EXPOSURE	Anon 1977a Pesticide & Toxic Chemical News 5(8):10-11

(NEXT PAGE)

4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI)
2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)
1024-57-3
C10-H5-Cl7-O
MW 389.32

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5777 Milk		GC	50	1-67 ppb	35 ppb	Extracted lipids, Jan 1979 to Feb 1980, 3-86 days postpartum. No significant correlation with residence, age, weight, number of children previously nursed, household use of non-persistent pesticides, or occupation of spouse. Higher, but nonsignificant levels in women with higher frequency of meat consumption, and in those in homes with pest control treatment. Healthy 18-37 yr old Hawaiians ADULTS; AGE; HAWAII; MILK; CHLORINATED HYDROCARBONS; DDE; DDT; DIELDRIN; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; HEXACHLOROBENZENE; LINDANE; NONACHLOR; OXYCHLORDANE; PESTICIDES; POLYCHLORINATED BIPHENYLS; DIETS; LACTATION; PESTICIDE RESIDUES; POPULATION EXPOSURE	Takahashi, M. Saidin, B. Sakai, S. Wong, L. 1981 Bulletin of Environmental Contamination and Toxicology 27:506-511

4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI)
4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)
76-44-8
C10-H5-Cl7
MW 373.35, MP 95-96 C, VP 3X10(-4) mm Hg at 25 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5778 Adipose			a) 12 b) 20	a) 0.126-0.698 ppm b) 0-1.102 ppm	a) 0.296 ppm b) 0.326 ppm	a) Rural b) Urban Autopsies, Spain SPAIN; AUTOPSIES; ADIPOSE TISSUE; CHLORINE ORGANIC COMPOUNDS; DDE; DDT; DDD; LINDANE; HEXACHLOROCYCLOHEXANE; HEPTACHLOR EPOXIDE; ORGANOPHOSPHATES; PESTICIDES; PESTICIDE RESIDUES; POPULATION EXPOSURE	Herrera Marteache, A. Polo Villar, L.M. Jodral Villarejo, M. Polo Villar, G. Mallol, J. Pozo Lora, R. 1978 Revista de Sanidad e Higiene Publica 52, 20 pp.

9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI)
9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)
19356-17-3
C27-H44-O2
MW 400.65

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5779 Blood, plasma			78	3.0-78.3 nmol/l	33 +or- 12.3 nmol/l	Negative correlation with blood Pb. 2-5 yr old Asians, Birmingham, United Kingdom. UNITED KINGDOM; CHILDREN; BLOOD; BLOOD PLASMA; LEAD; METALS; VITAMIN D; DIETS; URBAN AREAS	Nox, Y. Cherry, N. Waldron, H.A. Dattani, J. Griffiths, K.D. Hill, F.G.H. 1981 Lancet 2(8242):373

DATA BASE

DRUGS

(-)-2-Hydroxy-N-cyclopropylmethylmorphinan (No postings in CHEMLINE).

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5780 Blood, plasma	Injection Ingestion	RIA	a) 6 b) 6	a) 29.5-116 ng/ml b) 23-58 ng/ml	a) 61.5 +or- 8.59 ng/ml b) Not given	a) Peaks, after 25 or 50 mg, oral b) Peaks, after 10, 12.5, or 15 mg, IM Healthy 21-42 yr olds, Caucasians, American Indians, and Blacks, New Jersey NEW JERSEY; ADULTS; BLOOD PLASMA; ANALGESICS; COMPARATIVE EVALUATIONS	Dixon, R. Young, P. Mahacsi, E. Molazo, A. Malarek, D. Borenbaum, M. Moore, J. Parsonnet, M. Kaplan, S. 1978 Clinical Pharmacology and Therapeutics 24(5):622-627

(3,4'-Bipyridin)-6(1H)-one, 5-amino-
60719-84-8
C10-H9-N3-O
MW 187.22

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5781 Blood, plasma	Injection Ingestion	HPLC	a) 3 b) 6 c) 9 d) 14	a) 0.46-<0.20 ug/ml b) 2.2-0.22 ug/ml c) 3.5-<0.20 ug/ml d) 0.17-4.1 ug/ml	a) Not given b) Not given c) Not given d) Not given	a) 20 and 240 min after 0.8-1.2 mg/kg, IV b) 15 and 300 min after 1.4-1.6 mg/kg, IV c) 15 and 300 min after 1.8-2.2 mg/kg, IV d) Peaks, 2.0 hr after 0.36 mg/kg, oral, and at 0.5 hr after 2.9 mg/kg oral ADULTS; BLOOD PLASMA; URINE; DRUGS; MEASUREMENT METHODS; METABOLISM; METABOLITES	Kullberg, M.P. Freeman, G.B. Biddlecome, C. Alousi, A.A. Edelson, J. 1981 Clinical Pharmacology and Therapeutics 29(3):398-401
5782 Urine	Injection	HPLC	9	a) 10.3-40% of dose b) 0.3-1.6% of dose	a) Not given b) Not given	a) 0-24 hr output b) 0-24 hr output, N-acetyl metabolite Dose, 1.2-2.2 mg/kg ADULTS; BLOOD PLASMA; URINE; DRUGS; MEASUREMENT METHODS; METABOLISM; METABOLITES	Kullberg, M.P. Freeman, G.B. Biddlecome, C. Alousi, A.A. Edelson, J. 1981 Clinical Pharmacology and Therapeutics 29(3):398-401

Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)-, D-threo-(+)- (9 CI)
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))- (9 CI)
1°318-49-3
C12-H15-Cl2-N-O5-S
MW 356.2, MP approx 164 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5783 Adrenal gland	Ingestion Placental transfer	GC	a) 1 b) 6 c) 2 d) 3	a) Not applicable b) 0.34-2.0 ug/g c) 0.64-1.0 ug/g d) 0.13-0.28 ug/g	a) 4.1 ug/g b) 1.1 ug/g c) 0.82 ug/g d) 0.19 ug/g	a) 1.5-4 hr b) 6.5-12 hr c) 13-18 hr d) 19-20 hr Time after single oral dose of 500 mg (8-9 mg/kg) given to mother Aborted fetuses Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABORTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Nau, H. Welsch, F. Ulbrich, B. Bass, R. Lange, J. 1981 Toxicology and Applied Pharmacology 60:131-141
5784 Amniotic fluid	Ingestion	GC	a) 1 b) 1 c) 1 d) 1	a) Not applicable b) Not applicable c) Not applicable d) Not applicable	a) 3.7 ug/ml b) 12.8 ug/ml c) 1.2 ug/ml d) 0.21 ug/ml	a) 3 hr 40 min b) 8 hr c) 16 hr 35 min d) 20 hr 20 min Times after single dose of 500 mg (8-9 mg/kg) Sample obtained at time of abortion Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABORTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Nau, H. Welsch, F. Ulbrich, B. Bass, R. Lange, J. 1981 Toxicology and Applied Pharmacology 60:131-141
5785 Blood, serum	Ingestion	GC	a) 5 b) 6 c) 6 d) 4	a) 2.0-7.0 ug/ml b) 0.31-1.9 ug/ml c) 0.06-0.90 ug/ml d) 0.03-0.25 ug/ml	a) 4.6 ug/ml b) 1.1 ug/ml c) 0.36 ug/ml d) 0.13 ug/ml	a) 1.5-4 hr b) 6-12 hr c) 13-18 hr d) 19-20.3 hr Times after single dose of 500 mg (8-9 mg/kg) Maternal sample, obtained at time of abortion Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABORTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Nau, H. Welsch, F. Ulbrich, B. Bass, R. Lange, J. 1981 Toxicology and Applied Pharmacology 60:131-141

(NEXT PAGE)

Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)- , D-threo-(+)- (8 CI)
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxyaethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))- (9 CI)
16218-85-3
C12-H14-Cl2-N-O5-S
MW 356.2, MP approx 164 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GROUPAL INFORMATION	REFERENCE
5706 Brain	Ingestion Placental transfer	GC	a) 3 b) 5 c) 2 d) 2	a) 1.2-2.7 ug/g b) 0.6-8.2 ug/g c) 0.21-22.6 ug/g d) 0.03-3.21 ug/g	a) 1.8 ug/g b) 2.39 ug/g c) 11.40 ug/g d) 0.12 ug/g	a) 1.5-4 hr b) 6.5-12 hr c) 13-19 hr d) 19-20 hr Time after simple oral dose of 500 mg (8-9 mg/kg) given to mother Aborted fetuses Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABORTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Nau, H. Welsch, F. Ulbrich, B. Bass, R. Lange, J. 1991 Toxicology and Applied Pharmacology 60:131-141
5707 Heart	Ingestion Placental transfer	GC	a) 2 b) 4 c) 2 d) 3	a) 2.0-4.5 ug/g b) 0.69-2.0 ug/g c) 0.58-0.70 ug/g d) 0.09-0.24 ug/g	a) 3.2 ug/g b) 1.5 ug/g c) 0.64 ug/g d) 0.15 ug/g	a) 1.5-4 hr b) 6.5-12 hr c) 13-19 hr d) 19-20 hr Time after simple oral dose of 500 mg (8-9 mg/kg) given to mother Aborted fetuses Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABORTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Nau, H. Welsch, F. Ulbrich, B. Bass, R. Lange, J. 1991 Toxicology and Applied Pharmacology 60:131-141
5708 Intestine	Ingestion Placental transfer	GC	a) 2 b) 4 c) 1 d) 3	a) 0.25-2.8 ug/g b) 1.0-1.6 ug/g c) Not applicable d) 0.09-0.31 ug/g	a) 1.12 ug/g b) 1.7 ug/g c) 0.30 ug/g d) 0.21 ug/g	a) 1.5-4 hr b) 6.5-12 hr c) 13-19 hr d) 19-20 hr Time after simple oral dose of 500 mg (8-9 mg/kg) given to mother Aborted fetuses Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABORTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Nau, H. Welsch, F. Ulbrich, B. Bass, R. Lange, J. 1991 Toxicology and Applied Pharmacology 60:131-141

(NEXT PAGE)

Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)-, D-threo-(+)- (8 CI)
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxyethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))- (9 CI)
15318-45-3
C12-H15-Cl2-N-O5-S
MF 356.2, MP approx 168 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	SPECIAL INFORMATION	REFERENCE
5789 Kidney	Ingestion Placental transfer	GC	a) 2 b) 6 c) 1 d) 3	a) 0.81-2.0 ug/g b) 0.34-2.5 ug/g c) Not applicable d) 0.16-0.27 ug/g	a) 1.2 ug/g b) 1.4 ug/g c) 0.36 ug/g d) 0.19 ug/g	a) 1.5-4 hr b) 6.5-12 hr c) 13-18 hr d) 19-20 hr Time after single oral dose of 500 mg (8-9 mg/kg) given to mother Aborted fetuses Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABSORPTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Nau, H. Welsch, F. Ulbrich, B. Haas, P. Lange, J. 1981 Toxicology and Applied Pharmacology 60:131-141
5790 Liver	Ingestion Placental transfer	GC	a) 2 b) 6 c) 2 d) 3	a) 0.23-3.4 ug/g b) 0.57-27.2 ug/g c) 0.32-19.1 ug/g d) 0.04-0.32 ug/g	a) 1.8 ug/g b) 5.74 ug/g c) 9.71 ug/g d) 0.17 ug/g	a) 1.5-4 hr b) 6.5-12 hr c) 13-18 hr d) 19-20 hr Time after single oral dose of 500 mg (8-9 mg/kg) given to mother Aborted fetuses Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABSORPTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Nau, H. Welsch, F. Ulbrich, B. Haas, P. Lange, J. 1981 Toxicology and Applied Pharmacology 60:131-141
5791 Lung	Ingestion Placental transfer	GC	a) 2 b) 5 c) 3 d) 3	a) 0.38-1.6 ug/g b) 0.68-1.6 ug/g c) 0.26-33.0 ug/g d) 0.03-0.20 ug/g	a) 0.99 ug/g b) 1.2 ug/g c) 11.3 ug/g d) 0.12 ug/g	a) 1.5-4 hr b) 6.5-12 hr c) 13-18 hr d) 19-20 hr Time after single oral dose of 500 mg (8-9 mg/kg) given to mother Aborted fetuses Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABSORPTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Nau, H. Welsch, F. Ulbrich, B. Haas, P. Lange, J. 1981 Toxicology and Applied Pharmacology 60:131-141

(NEXT PAGE)

Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)-, D-threo-(+)- (8 CI)
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxyethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))- (9 CI)
15318-45-3
C12-H15-Cl2-N-O5-S
MW 356.2, MP approx 164 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5792 Muscle	Ingestion Placental transfer	GC	a) 8 b) 6 c) 5 d) 1	a) 0.79-6.3 ug/g b) 0.37-5.1 ug/g c) 0.34-60.0 ug/g d) Not applicable	a) 4.45 ug/g b) 1.89 ug/g c) 12.4 ug/g d) 0.16 ug/g	a) 1.5-4 hr b) 6.5-12 hr c) 13-18 hr d) 19-20 hr Time after single oral dose of 500 mg (8-9 mg/kg) given to mother Aborted fetuses Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABSORPTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Hau, H. Welsch, F. Ulbrich, H. Bass, P. Lange, J. 1981 Toxicology and Applied Pharmacology 60:131-141
5793 Placenta	Ingestion	GC	a) 5 b) 2 c) 4 d) 3	a) 6.5-21.3 ug/g b) 1.6-2.8 ug/g c) 0.36-11.1 ug/g d) 0.09-1.31 ug/g	a) 12.8 ug/g b) 2.2 ug/g c) 3.2 ug/g d) .56 ug/g	a) 1 hr 30 min-4 hr b) 6 hr 30 min-12 hr c) 13-18 hr d) 19-20 hr Times after single dose of 500 mg (8-9 mg/kg) Sample obtained at time of abortion Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABSORPTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Hau, H. Welsch, F. Ulbrich, H. Bass, P. Lange, J. 1981 Toxicology and Applied Pharmacology 60:131-141
5794 Stomach	Ingestion Placental transfer	GC	a) 3 b) 4 c) 1 d) 3	a) 1.1-2.6 ug/g b) 1.1-2.8 ug/g c) Not applicable d) 0.16-0.33 ug/g	a) 2.0 ug/g b) 1.9 ug/g c) 0.81 ug/g d) 0.22 ug/g	a) 1.5-4 hr b) 6.5-12 hr c) 13-18 hr d) 19-20 hr Time after single oral dose of 500 mg (8-9 mg/kg) given to mother Aborted fetuses Fetuses, healthy pregnant women, 7-12 wk gestation Inhibited in vitro fetal mitochondrial protein synthesis ABSORPTION; ADULTS; FETUS; ADRENAL GLANDS; AMNIOTIC FLUID; BLOOD SERUM; BRAIN; HEART; INTESTINES; KIDNEYS; LIVER; LUNGS; MUSCLES; PLACENTA; STOMACH; DRUG THERAPY; DRUGS; CHEMOTHERAPY; IN VITRO ANALYSIS; IN VIVO ANALYSIS; PREGNANCY	Hau, H. Welsch, F. Ulbrich, H. Bass, P. Lange, J. 1981 Toxicology and Applied Pharmacology 60:131-141

Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (B CI)
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-,(R-(R*,R*))- (9 CI)
*6-75-7
C11-H12-Cl2-N2-O5
MW 323.14, MP 150.5-151.5 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
*795 Blood, plasma	Ingestion	GC	1	a) Not applicable b) Not applicable c) Not applicable d) Not applicable e) Not applicable f) Not applicable	a) 14 ug/ml b) 19 ug/ml c) 23 ug/ml d) 23 ug/ml e) 18 ug/ml f) 16 ug/ml	a) 0 hr b) 0.5 hr c) 1 hr d) 2 hr e) 3 hr f) 6 hr 50 mg/kg as palmitate over 20 hr, doses 6 hr apart. Measurements began with dose 7. 20 yr old with HAEMOPHILUS INFLUENZAE type b meningitis, after hypophysectomy. ADULTS; INFECTION; BLOOD PLASMA; DRUGS; ANTIBIOTICS; DRUG THERAPY; DRUGS	Bensimer, K.R. Pickering, L.K. Ericsson, C.D. Fraser, W.G. 1981 Lancet 1(8212):165
*796 Cerebrospinal fluid	Ingestion	GC	1	a) Not applicable b) Not applicable c) Not applicable d) Not applicable e) Not applicable f) Not applicable	a) 5.4 ug/ml b) 5.7 ug/ml c) 6.3 ug/ml d) 7.4 ug/ml e) 7.2 ug/ml f) 7.9 ug/ml	a) 0 hr b) 0.5 hr c) 1 hr d) 2 hr e) 3 hr f) 6 hr 50 mg/kg as palmitate over 20 hr, doses 6 hr apart. Measurements began with dose 7. 20 yr old with HAEMOPHILUS INFLUENZAE type b meningitis, after hypophysectomy. ADULTS; INFECTION; BLOOD PLASMA; DRUGS; ANTIBIOTICS; DRUG THERAPY; DRUGS	Bensimer, K.R. Pickering, L.K. Ericsson, C.D. Fraser, W.G. 1981 Lancet 1(8212):165

Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI)
Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)
6673-35-4
C14-H22-N2-O3
MW 264.32, MP 130-136 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
*797 Blood, serum	Ingestion	GC	1	112-1.8 ug/ml	Not applicable	3 and 10 hr after 10 g overdose 15 yr old, wt 52.9 kg ADOLESCENTS; CASE HISTORIES; SUICIDE; BLOOD SERUM; ANALGESICS; DRUG ABUSE; DRUGS	Slattery, J.T. Soup, J.R. Levy, G. 1981 Clinical Toxicology 18(1):111-117

Acetanilide, 4'-hydroxy- (8 CI)
Acetamide, N-(4-hydroxyphenyl)- (9 CI)
103-90-2
C8-H9-N-O2
MP 151.16, MP 169-170.5 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5798 Blood, plasma	Ingestion	HPLC	3	a) 18.55-19.76 ug/ml hr b) 18.08-19.19 ug/ml hr	a) Not given b) Not given	a) Area under concentration/time curve (AUC) before valproate and 2-8 hr after 10 mg/kg paracetamol b) AUC 2 wk after 1750-4000 mg/day valproate and 2-8 hr after 10 mg/kg paracetamol Chronic treatment with carbamazepine and phenytoin Caucasian epileptics 23-43 yr old, wt 66-97 kg CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; URINE; ANTICONVULSANTS; DRUG INTERACTION; DRUGS	Kapetanovic, I.M. Kupferberg, H.J. Theodore, W. Porter, R.J. 1981 British Journal of Clinical Pharmacology 11:391-393
5799 Blood, plasma	Ingestion	GC	3	30.4-43.7 umol/l	37 umol/l	Peak level within 2 hr after 500 mg, fasting. Mean area under concentration-time curve, 352.3 +or- 48.1 umol/l Lactating women, ages 28, 29, and 31 yr ADULTS; BLOOD PLASMA; MILK; ANALGESICS; ANTIPYRETICS; DRUG THERAPY; DRUGS; LACTATION	Pitzen, P.-O. Gustafsson, B. Jostell, K.G. Melander, A. Wahlin-Boll, E. 1981 European Journal of Clinical Pharmacology 20:123-125
5800 Milk	Ingestion	GC	3	26.9-29.1 u mol/l	27 u mol/l	Peak level within 2 hr after 500 mg, fasting. Mean area under concentration-time curve, 115.0 +or- 29.3 umol hr/l Breast feeding need not be discontinued with conventional doses Lactating women, ages 28, 29, and 31 yr ADULTS; BLOOD PLASMA; MILK; ANALGESICS; ANTIPYRETICS; DRUG THERAPY; DRUGS; LACTATION	Pitzen, P.-O. Gustafsson, B. Jostell, K.G. Melander, A. Wahlin-Boll, E. 1981 European Journal of Clinical Pharmacology 20:123-125
5801 Urine	Ingestion	HPLC	3	a) Not given b) Not given	a) 444.5 mg b) 429.5 mg	a) 24 hr excretions after 10 mg/kg and before valproate b) 24 hr excretions after 10 mg/kg and 2 wk of 1750-4000 mg/day valproate Chronic treatment with carbamazepine and phenytoin Caucasian epileptics 23-43 yr old, wt 66-97 kg CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; URINE; ANTICONVULSANTS; DRUG INTERACTION; DRUGS	Kapetanovic, I.M. Kupferberg, H.J. Theodore, W. Porter, R.J. 1981 British Journal of Clinical Pharmacology 11:391-393

Adriamycin (8 CI)
5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9 CI)
23214-92-8
C27-H29-N-O11
C27-H29-N-O11
MW 543.54, MP 189-170.5 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5802 Blood, plasma	Injection	Fluorometry	7	a) 0.35-0.15 umol/l b) 0.28-0.12 umol/l	a) Not given b) Not given	a) Without concurrent delta 9-tetrahydrocannabinol. 8 and 120 hr after dose. Initial measurement 0.32 umol/l at 8 hr. Mean AMC 12.85 +or- 6.04 umol/l hr b) With delta 9-tetrahydrocannabinol. 8 and 120 hr after dose. Initial measurement 0.25 umol/l at 8 hr. Mean AMC 13.56 +or- 3.58 umol/l hr Dose 45 mg/sq m, plus 1 g/sq m cyclophosphamide once and 50 mg/sq m etoposide daily for 5 days (6 patients), or 60 mg/sq m and 75 mg/sq m cisplatin (1 patient) Range of means. Estimated from graph. Cancer patients undergoing chemotherapy. CARCINOMAS; BLOOD PLASMA; DRUG INTERACTION; DRUG THERAPY; DRUGS; ESTROGENIC DRUGS; CHEMOTHERAPY	Riggs, C.E. Jr. Egorin, M.J. Fuks, J.Z. Schnaper, H. Duffey, P. Colvin, O.M. Aisner, J. Wiernik, P.H. Nachur, N.R. 1981 Journal of Clinical Pharmacology 21:985-985

Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI)
Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)
54-31-9
C12-H11-Cl-N2-O5-S
MW 330.77, MP 206 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5803 Blood, plasma	Injection Ingestion	Fluorometry	1	a) 15-0.15 ug/ml b) 0.18-1.3 ug/ml	a) Not given b) Not given	a) 15 and 500 min after 120 mg, IV b) 60 and 200 min after 120 mg, oral. Final measurement 0.6 ug/ml at 500 min Estimated from graph Data suggest delayed absorption after oral dose. Kidney transplant patient KIDNEY DISEASES; BLOOD PLASMA; DIURETICS; DRUGS; DRUG THERAPY	Smith, D.E. Gambertoglio, J.G. Vincenti, F. Benet, L.Z. 1981 Clinical Pharmacology and Therapeutics 30(1):105-113
5804 Urine	Injection	HPLC	10	a) 61.7-65.5 mg b) 5.6-22.5 mg c) 30-50 mg d) 5-12 mg	a) 52.6 +or- 8.1 mg b) 11.4 +or- 5.2 mg c) Not given d) Not given	a) 24 hr excretion after 80 mg b) 24 hr excretion after 80 mg. Glucuronide metabolite c) 0.5 and 24 hr cumulative excretion after 80 mg d) 0.5 and 24 hr cumulative excretion after 80 mg. Glucuronide metabolite c) and d) range of means estimated from graph. Data for excretion of metabolite 4-chloro-5-sulfamoyl anthranilic acid (as % of dose) also given Healthy 20-34 yr olds. DRINK; DRUGS; MEASUREMENT METHODS; METABOLITES	Andreasen, F. Christensen, C.K. Jakobsen, P.K. Mogensen, C.E. 1981 Acta Pharmacologica et Toxicologica 49:223-229

[redacted] (8 CI)
3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)
60-80-0
C11-H12-N2-O
MW 188.22, MP 111-113 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5805 Blood, plasma		GC MS	1	3-2.8 ug/ml	Not given	Estimated from graph Saliva/plasma ratios for four subjects, 0.83-0.9% Saliva can be used in pharmacokinetic studies BLOOD PLASMA; SALIVA; ANALGESICS; ANTICONVULSANTS; ANTIPYRETICS; DIURETICS; DRUG THERAPY; DRUGS; HYPNOTICS; SEDATIVES; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Horning, M.G. Brown, L. Nowlin, J. Lertratanangkoon, K. Kellaway, P. Zion, T.E. 1977 Clinical Chemistry 23(2):157-164
5806 Saliva		GC/MS	1	2.8-2.5 ug/ml	Not given	Level in mixed saliva Estimated from graph Saliva/plasma ratios for four subjects, 0.83-0.9% Saliva can be used in pharmacokinetic studies BLOOD PLASMA; SALIVA; ANALGESICS; ANTICONVULSANTS; ANTIPYRETICS; DIURETICS; DRUG THERAPY; DRUGS; HYPNOTICS; SEDATIVES; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Horning, M.G. Brown, L. Nowlin, J. Lertratanangkoon, K. Kellaway, P. Zion, T.E. 1977 Clinical Chemistry 23(2):157-164

Antipyrine, 4-(dimethylamino)- (9 CI)
3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)
58-15-1
C13-H17-N3-O
MW 231.29, MP 107-109 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5807 Breath	Ingestion		7	a) 1.8-6.8% b) 1.8-5.5%	a) 5.1 +or- 1.9% b) 3.9 +or- 0.9%	a) Controls b) After norethindrone, 350 ug/day Measurements made over 1 wk periods. % of C-14 after 1.0 uCi dose. Data indicate inhibition of drug metabolism Healthy 29-40 yr olds DRUGS; DRUG INTERACTION; DRUG THERAPY; DRUGS; PROGESTOGENS	Field, B. Lu, C. Hepner, G.W. 1979 Clinical Pharmacology and Therapeutics 25(2):196-198
5808 Breath	Ingestion	Radiometry	a) 107 b) 60 c) 23 d) 28 e) 26	a) 4-7% b) 3-11.5% c) 0.2-5.5% d) 0.2-4.8% e) 0.1-5.8%	a) 6.2 +or- 0.8% b) 7.5 +or- 0.5% c) 2.5 +or- 0.6% d) 1.9 +or- 0.2% e) 2.5 +or- 0.1% S.E.	a) Controls b) Patients with cholestasis c) Patients with hepatitis d) Patients with cirrhosis e) Patients with hepatic malignancy % of labelled dose (100-200 nmoles) excreted in 2 hr Estimated from graph DRUGS; LIVER DISEASES; SARCOMAS; ANTIPYRETICS; DRUGS; METABOLISM	Hepner, G.W. Vesell, E.S. 1977 Clinical Pharmacology and Therapeutics 21(5):620-626
5809 Breath	Ingestion	Radiometry	6	a) 2.5-4.5% b) 5.5-9.5%	a) Not given b) Not given	a) Patients with hyperbilirubinemia due to cholestasis, before surgery b) Patients in a) after surgery % of labelled dose (100-200 nmoles) excreted in 2 hr Estimated from graph DRUGS; LIVER DISEASES; SARCOMAS; ANTIPYRETICS; DRUGS; METABOLISM	Hepner, G.W. Vesell, E.S. 1977 Clinical Pharmacology and Therapeutics 21(5):620-626

Attapulgite (VAN)
1337-76-8
EXACT COMPOSITION UNKNOWN OR UNDETERMINED

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5810 Urine	Ingestion	EM	1	Not applicable	300,000 fibers/ml	Patient treated 6 mo with 1 g/day of the drug, ATTAPULGITE(R) 60 yr old, France COST: FIBERS; INHALATION; MINING; FRANCE; OCCUPATIONAL DISEASES; LUNGS; OBTWP; DRUG THERAPY; LAVAGE; DRUGS	Bignon, J. Sebastien, P. Gaudichet, A. Jaurand, M.C. 1980 Biological Effects of Mineral Fibres, Vol. 1, J.C. Wagner. Lyon, France: IARC Scientific Publications No. 30, pp.163-181

Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI)
2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)
76-73-3
C12-H18-N2-O3
MW 334

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5811 Liver	Ingestion		1	Not applicable	29.5 mg/100 ml	Suicide by suffocation. Chlordiazepoxide present New York City NEW YORK; AUTOPSIES; SUICIDE; BLOOD; LIVER; DRUG ABUSE; DRUGS; NARCOTICS; TRANQUILIZERS; ALCOHOLS; CARBON INORGANIC COMPOUNDS	Bastos, M.L. Galante, I. 1976 Journal of Forensic Sciences 21(1):176-186

Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI)
2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)- (9 CI)
76-74-4
C11-H18-N2-O3
MW 226.31

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5812 Liver	Ingestion		2	2.0-11.7 mg/100 ml	Not given	Suicides by suffocation. Alcohol present in one. New York City NEW YORK; AUTOPSIES; SUICIDE; BLOOD; LIVER; DRUG ABUSE; DRUGS; NARCOTICS; TRANQUILIZERS; ALCOHOLS; CARBON INORGANIC COMPOUNDS	Bastos, M.L. Galante, I. 1976 Journal of Forensic Sciences 21(1):176-186

Barbituric acid, 5-ethyl-5-phenyl- (8 CI)
2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)
50-06-6
C12-H12-N2-O3
MW 232.23, MP 174-178 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5813 Blood			1	Not applicable	1.0 mg/100 ml	Dose unknown. Cause of death unknown Autopsy of 65 yr old ADULTS; AUTOPSIES; BLOOD PLASMA; DRUGS; HYPNOTICS; FORENSIC MEDICINE; METABOLITES	Jindrich, E.J. 1977 Journal of Forensic Sciences 22(1):240-241
5814 Blood, plasma		GC	11	15.8-42.8 ug/ml	Not given	Patients on multiple anticonvulsant drugs CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; ANTICONVULSANTS; DRUG THERAPY; MEASUREMENT METHODS	Dhar, A.K. Mutt, H. 1981 Journal of Chromatography 222:203-211
5815 Blood, plasma		GC/MS Enzymatic	3	a) 24.6-27.7 mg/l b) 33.5-36.0 mg/l c) 19.6-22.3 mg/l d) 23.5-26.0 mg/l e) 14.0-16.7 mg/l f) 16.3-18.5 mg/l	a) 26.0 mg/l b) 34.4 mg/l c) 21.1 mg/l d) 25.0 mg/l e) 15.8 mg/l f) 17.6 mg/l	a) Patient 1, GC/MS b) Patient 1, enzyme immunoassay c) Patient 2, GC/MS d) Patient 2, GC/MS e) Patient 3, GC/MS f) Patient 3, enzyme immunoassay 5 measurements over 3 days BLOOD PLASMA; SALIVA; ANALGESICS; ANTICONVULSANTS; ANTIPYRETICS; DIURETICS; DRUG THERAPY; DRUGS; HYPNOTICS; SEDATIVES; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Horning, M.G. Brown, I. Nowlin, J. Lertratanangkoon, K. Kellaway, P. Zion, T.E. 1977 Clinical Chemistry 23(2):157-168
5816 Blood, plasma	Ingestion	GC/MS	1	42.0-47.0 ug/ml	Not applicable	19.33 and 25.67 hr after suspected overdose. Arterial samples. Venous samples 0.5 ug/ml or less. Hemoperfusion started at 20.00 hr. Dose unknown. Diazepam also found 40 yr old overdose victim Respiratory and cardiac arrest ADULTS; CASE HISTORIES; SUICIDE; BLOOD PLASMA; DRUG ABUSE; DRUGS; MEASUREMENT METHODS; METABOLITES	Midha, K.K. Charette, C. McGilveray, I.J. Webb, D. McLean, W.C. 1981 Clinical Toxicology 18(6):713-729
5817 Blood, plasma	Injection	HPLC	49	a) 5-13 ug/ml b) 13-28 ug/ml c) 25-33 ug/ml d) 15-20 ug/ml e) 18-32 ug/ml	a) Not given b) Not given c) 19.4 +or- 3.4 ug/ml d) Not given e) Not given	a) 5-10 mg/kg loading dose, IV b) 15-20 mg/kg loading dose, IV c) 25-30 mg/kg loading dose, IV d) 3-4 mg/kg/day maintaince dose for 22 days after loading dose Minimal therapeutic level about 20 ug/ml. Bioaccumulation seen in e). d) and e) range of means. Estimated from graph. Neonates, gestational age 26-39 wk, being treated for seizure disorders NEWBORN; NERVOUS SYSTEM DISEASES; BLOOD PLASMA; BRAIN; ANTICONVULSANTS; DRUG THERAPY; DRUGS; BIOACCUMULATION; METABOLISM	Painter, M.J. Piggenger, C. Wasterlain, C. Barmada, M. Pitlick, W. Carter, G. Abern, S. 1981 Neurology 31(9):1107-1112

(NEXT PAGE)

Barbituric acid, 5-ethyl-5-phenyl- (8 CI)
2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)
50-06-6
C12-H12-N2-O3
MW 232.23, MP 174-178 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5818 Brain	Injection	HPLC	15	6-25 ug/g	Not given	Fetal plasma levels 13-30 ug/ml, corresponding to a loading dose of 15-20 mg/kg. Estimated from graph Autopsies of neonates, gestational age 26-39 wk, who had been treated for seizure disorders NEWBORN; NERVOUS SYSTEM DISEASES; FETAL PLASMA; BRAIN; ANTICONVULSANTS; DRUG THERAPY; DRUGS; BIOACCUMULATION; METABOLISM; AUTOPSIES	Painter, M.J. Pippenger, C. Wasterlain, C. Namada, M. Pitlick, W. Carter, G. Abern, S. 1981 Neurology 31(9):1107-1112
5819 Saliva		GC/MS Enzymatic	1	a) 7.7-8.9 ug/l b) 9.7-12.5 ug/l	a) 8.15 ug/l b) 10.96 ug/l	a) GC/MS, saliva/plasma ratio 0.31 b) Enzyme immunoassay, saliva/plasma ratio 0.32 Parotid saliva, 5 paired samples level in saliva approximatly 1/3 that of plasma FETAL PLASMA; SALIVA; ANALGESICS; ANTICONVULSANTS; ANTIPYRETICS; DIURETICS; DRUG THERAPY; DRUGS; HYPNOTICS; SEDATIVES; COMPARATIVE EVALUATIONS; MATHEMATICAL METHODS	Horning, M.G. Brown, T. Nowlin, J. Tertratanangkoon, K. Kellaway, P. Zion, T.E. 1977 Clinical Chemistry 23(2):157-164

Benzoic acid, p-(dipropylsulfamoyl)- (8 CI)
Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)
57-66-9
C13-H19-N-O4-S
MW 285.36, MP 194-196 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5820 Blood, plasma	Ingestion	HPLC	4	63.1-84.8 ug/l	71.3 mg/l	1 wk after 500 mg/6 hr + 500 mg clofibrate/12 hr Healthy 18-22 yr olds, wt 65-77 kg BLOOD PLASMA; URINE; DRUG INTERACTION; COMPARATIVE EVALUATIONS; METABOLITES; DRUGS	Veenendaal, J.F. Brooks, P.M. Meffin, P.J. 1981 Clinical Pharmacology and Therapeutics 29(3):351-358

enzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI)
,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)
23031-25-6
C12-H19-N-03
MW 225.32

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5821 Blood, plasma	Injection	GC/MS	10	a) 5.97-2.37 ng/ml b) 2.17-0.51 ng/ml	a) 4.18 ng/ml b) 1.51 ng/ml	a) Maternal blood, at delivery, 7 mothers b) Cord blood, at delivery, 10 infants Delivery occurred 7-90 min after 250 ug Maternal and infant glucose and insulin levels measured before and after infection No short-term (90 min) negative influence on fetal carbohydrate metabolism Healthy women in second stage of term labor ADULTS; NEWBORN; BLOOD PLASMA; DRUG THERAPY; DRUGS; MUSCLE RELAXANTS; PREGNANCY	Ingemarsson, I. Westgren, M. Lindberg, C. Ahren, B. Lundquist, I. Carlsson, C. 1981 American Journal of Obstetrics and Gynecology 139(6):697-701

Beryl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI)
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)
*1-81-2
C8-H11-N-03
MW 169.18, MP 191 C (decomp)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5822 Blood, plasma	Injection	Enzymatic	17	a) 90-280 pg/ml b) 90-210 pg/ml c) 90-180 pg/ml d) 140-300 pg/ml e) 600-50 dpm/ml f) 39000-800 dpm/ml g) &1000-900 dpm/ml h) 800-400 dpm/ml i) 1000-500 dpm/ml	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given g) Not given h) Not given i) Not given	a) Normal steady state levels after 15 mCi/sq m bolus and 0.35 mCi/sq m/min (0.002 ug/min) infusion, 17 cases b) Effect of 125 mg desipramine (oral) on a), 7 cases c) Effect of 500 mg cortisol (IV) on a), 5 cases d) Effect of desipramine plus cortisol on (a), 5 cases e) Same as a), 0 and 40 min post infusion , 17 cases f) 0 and 30 min after 85 m Ci/sq m bolus IV, 6 cases g) Same as f), with 125 mg desipramine (oral), 6 cases h) Same as f), Normetanephrine, 3 and 30 min, 6 cases i) Same as g), normetanephrine, 3 and 30 min, 6 cases Healthy men, mean age 34 +or- 7 yr. ADULTS; BLOOD PLASMA; ANTIDEPRESSIVE AGENTS; AUTONOMIC DRUGS; DRUG INTERACTION; DRUGS; COMPARATIVE EVALUATIONS; METABOLITES	Esler, M. Jackman, G. Leonard, P. Skews, H. Bobik, A. Korner, P. 1981 Clinical Pharmacology and Therapeutics 29(1):12-20

Biguanide, 1-butyl- (8 CI)
Imidodicarbonimidic diamine, N-butyl- (9 CI)
692-13-7
CF-815-NS
BW 157.22

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5823 Bile	Ingestion	GC	1	Not given	6.3 mg/l	Autopsy Dose not given 84 yr old diabetic Death from severe lactic acidosis during therapy PERICARDIAL FLUID; BILE; BLOOD PLASMA; HEART; KIDNEYS; LIVER; LUNGS; DRUG THERAPY; DRUGS; ADULTS; DIABETES; METABOLISM; METABOLITES	De Groot, G. Maes, R.A.A. Sangster, B. van Heijst, A.N.P. Verdonck, L.F. 1980 Journal of Analytical Toxicology 4:281-285
5824 Blood, plasma	Ingestion	GC	1	a) Not given b) Not given	a) 5.5 mg/l b) 3.2 mg/l	a) On admission b) Autopsy Dose not given 84 yr old diabetic Death from severe lactic acidosis during therapy PERICARDIAL FLUID; BILE; BLOOD PLASMA; HEART; KIDNEYS; LIVER; LUNGS; DRUG THERAPY; DRUGS; ADULTS; DIABETES; METABOLISM; METABOLITES	De Groot, G. Maes, R.A.A. Sangster, B. van Heijst, A.N.P. Verdonck, L.F. 1980 Journal of Analytical Toxicology 4:281-285
5825 Heart	Ingestion	GC	1	Not given	3.0 mg/kg	Autopsy Dose not given 84 yr old diabetic Death from severe lactic acidosis during therapy PERICARDIAL FLUID; BILE; BLOOD PLASMA; HEART; KIDNEYS; LIVER; LUNGS; DRUG THERAPY; DRUGS; ADULTS; DIABETES; METABOLISM; METABOLITES	De Groot, G. Maes, R.A.A. Sangster, B. van Heijst, A.N.P. Verdonck, L.F. 1980 Journal of Analytical Toxicology 4:281-285
5826 Kidney	Ingestion	GC	1	Not given	98 mg/kg	Autopsy Dose not given 84 yr old diabetic Death from severe lactic acidosis during therapy PERICARDIAL FLUID; BILE; BLOOD PLASMA; HEART; KIDNEYS; LIVER; LUNGS; DRUG THERAPY; DRUGS; ADULTS; DIABETES; METABOLISM; METABOLITES	De Groot, G. Maes, R.A.A. Sangster, B. van Heijst, A.N.P. Verdonck, L.F. 1980 Journal of Analytical Toxicology 4:281-285
5827 Liver	Ingestion	GC	1	Not given	5.2 mg/kg	Autopsy Dose not given 84 yr old diabetic Death from severe lactic acidosis during therapy PERICARDIAL FLUID; BILE; BLOOD PLASMA; HEART; KIDNEYS; LIVER; LUNGS; DRUG THERAPY; DRUGS; ADULTS; DIABETES; METABOLISM; METABOLITES	De Groot, G. Maes, R.A.A. Sangster, B. van Heijst, A.N.P. Verdonck, L.F. 1980 Journal of Analytical Toxicology 4:281-285

(NEXT PAGE)

Biguanide, 1-butyl- (8 CI)
Imidodicarbonimidic diamine, N-butyl- (9 CI)
692-13-7
C6-H15-N5
MW 157.22

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5828 Lung		GC	1	Not given	2.8 mg/kg	Autopsy Dose not given 88 yr old diabetic Death from severe lactic acidosis during therapy PERICARDIAL FLUID; BILE; BLOOD PLASMA; HEART; KIDNEYS; LIVER; LUNGS; DRUG THERAPY; DRUGS; ADULTS; DIABETES; METABOLISM; METABOLITES	De Groot, G. Maes, R.A.A. Sangster, B. van Heijst, A.N.P. Verdonck, L.F. 1980 Journal of Analytical Toxicology 4:281-285
5829 Pericardial fluid	Ingestion	GC	1	Not given	3.5 mg/l	Autopsy Dose not given 88 yr old diabetic Death from severe lactic acidosis during therapy PERICARDIAL FLUID; BILE; BLOOD PLASMA; HEART; KIDNEYS; LIVER; LUNGS; DRUG THERAPY; DRUGS; ADULTS; DIABETES; METABOLISM; METABOLITES	De Groot, G. Maes, R.A.A. Sangster, B. van Heijst, A.N.P. Verdonck, L.F. 1980 Journal of Analytical Toxicology 4:281-285

Biguanide, 1,1-dimethyl- (8 CI)
Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)
657-24-9
C4-H11-N5
MW 129.17

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5830 Blood, plasma		HPLC		0.2-6.3 mg/l	Not given	Dose not reported Diabetic patients DIABETES; BLOOD PLASMA; URINE; DRUGS; MEASUREMENT METHODS	Charles, B.G. Jacobsen, N.W. Ravenscroft, P.J. 1991 Clinical Chemistry 37(3):430-436
5831 Urine		HPLC		29-1600 mg/l	Not given	Dose not reported Diabetic patients DIABETES; BLOOD PLASMA; URINE; DRUGS; MEASUREMENT METHODS	Charles, B.G. Jacobsen, N.W. Ravenscroft, P.J. 1991 Clinical Chemistry 37(3):430-436

Bismuth
7440-69-9
Bi
MW 208.98, MP 271.5 C, BP 1579 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5832 Blood			a) 1 b) 1 c) Not given	a) Not applicable b) Not applicable c) Not applicable	a) 35 ug/l b) 27.8 ug/l c) < 20 ug/l	a) Maximum level after 6 wk b) Maximum level after 16 wk c) After 8 wk Given as subcitrate, 5 ml 8 x/day Patients with gastritis BLOOD; DRUG THERAPY; DRUGS; BISMUTH	Murray, J.F. 1978 Medical Journal of Australia 1:279-280

Bromide
24959-67-9
Br
MW 79.90, MP -7.2 C, BP 58.78 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5833 Blood, serum			a) 1 b) 1	a) 295-79 mg/100 ml b) 246-33 mg/100 ml	a) Not given b) Not given	a) Mother, 4 days antepartum and 10 days postpartum b) Newborn of a), 6 and 19 days after birth Dose unknown Mother semicomatose, cyanotic. Infant with CNS depression, hypotonic. BROMIDE; PENNSYLVANIA; ADULTS; CASE HISTORIES; NEWBORN; BLOOD SERUM; DRUG ABUSE	Pleasure, J.F. Blackburn, H.G. 1975 Pediatrics 55(4):503-506

Caffeine (8 CI)
1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)
58-08-2
C8-H10-N4-O2
MW 194.19, MP 238 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5838 Saliva	Ingestion	GC/MS	1	4.05-2.2 ug/m	Not given	2-9 hr after 100 mg caffeine Estimated from graph Saliva/plasma ratio, 0.55 Saliva can be used for monitoring. BLOOD PLASMA; SALIVA; ANALGESICS; ANTICONVULSANTS; ANTIPYRETICS; DIURETICS; DRUG THERAPY; DRUGS; HYPNOTICS; SEDATIVES; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS; CAFFEINE	Berning, M.G. Brown, L. Boulin, J. Tertratanangkoon, K. Kellaway, P. Zion, T.E. 1977 Clinical Chemistry 23(2):157-160

(NEXT PAGE)

Caffeine (9 CI)
1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)
58-08-2
CB-810-88-02
MW 194.19, MP 238 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5837 Urine	Ingestion	HPLC CC	4	a) Not given b) Not given	a) 89% of dose b) 1.19 of dose	a) Caffeine plus metabolites excreted within 72 hr after 5 mg/kg b) % of a) excreted as 5-amino-6-formylmethylamino]1,3-dimethyl uracil Data also for 10 other metabolites, expressed as % of total molar excretion 27-37 yr olds, mean wt 70 kg. No coffee, tea, or chocolate 1 wk before or during experiment. METABOLISM; METABOLITES; CAFFEINE; URINE	Latini, P. Bonati, M. Marri, M. Garattini, S. 1981 Toxicology Letters 7:267-272

Cefotaxime (No postings in CAFFEINE).

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5836 Blood, serum	Injection	Microbiological	a) 11 b) 7 c) 5 d) 3	a) 17.2-46 ug/ml b) Not given c) Not given d) Not given	a) 24.9 ug/ml b) 19.5 ug/ml c) 16.5 ug/ml d) 8.9 ug/ml	a) Peak at 60 min b) 1-2 hr c) 2-3 hr d) >3 hr Times after 1g, IM Mean peak by HPLC method slightly higher than that by biological method for 7 patients Patients, mean age 71 yr, Sweden INFECTION; BLOOD SERUM; KIDNEYS; PROSTATE; URINE; ANTIBIOTICS; DRUGS; MEASUREMENT METHODS; SURGERY; SWEDEN	Grabe, M. Andersson, K.-E. Forsgren, A. Hellsten, S. 1981 Infection 9(3):158-159
5837 Kidney	Injection	Microbiological	6	a) 1.9-7.0 ug/g b) 1.9-10.8 ug/g c) 2.3-14.0 ug/g	a) 4.1 ug/g b) 4.2 ug/g c) 6.2 ug/g	a) Outer cortex b) Inner cortex and outer medulla c) Inner medulla 105-155 min after 1 g, IM Patients 7 age 22-73 yr (mean 58 yr), Sweden INFECTION; BLOOD SERUM; KIDNEYS; PROSTATE; URINE; ANTIBIOTICS; DRUGS; MEASUREMENT METHODS; SURGERY; SWEDEN	Grabe, M. Andersson, K.-E. Forsgren, A. Hellsten, S. 1981 Infection 9(3):158-158
5838 Prostate	Injection	Microbiological	16	a) Not given b) Not given	a) 3.9 ug/g b) 2.6 ug/g	a) Superficial tissue, 12 samples, 1->3 hr b) Deep tissue, 16 samples, 1->3 hr Times after 1 g, IM Tissue levels < serum levels taken simultaneously Patients, Sweden INFECTION; BLOOD SERUM; KIDNEYS; PROSTATE; URINE; ANTIBIOTICS; DRUGS; MEASUREMENT METHODS; SURGERY; SWEDEN	Grabe, M. Andersson, K.-E. Forsgren, A. Hellsten, S. 1981 Infection 9(3):158-158

(NEXT PAGE)

Cefotaxime (No postings in CHEMLINE).

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5839 Urine	Injection	Microbiological	4	a) Not given b) Not given c) Not given d) Not given	a) 3,395 ug/ml b) 3,107 ug/ml c) 1,210 ug/ml d) 205 ug/ml	a) 2 hr b) 3 hr, 50% of dose eliminated c) 5 hr, 64% of dose eliminated d) 28 hr, 87% of dose eliminated Times after 1 g, IM Patients, Sweden INFECTION; BLOOD SPRUM; KIDNEYS; PROSTATE; URINE; ANTIBIOTICS; DRUGS; TREATMENT METHODS; SURGERY; SWEDEN	Grabe, M. Anderson, K.-P. Persgren, A. Hellsten, S. 1981 Infection 9(3):156-158

Chloral hydrate (8 CI)
1,1-Ethanediol, 2,2,2-trichloro- (9 CI)
302-17-0
C2-H3-Cl3-O2
MW 165.82, MP 57 C (also reported as 52 C), BP 98 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5840 Blood, plasma	Ingestion		1	Not applicable	10.7 mg/100 ml	Estimated dose 3 g. Cause of death unknown. Trichloroethanol (metabolite) 65 yr old, wt 50 kg. Autopsy ADULTS; AUTOPSIES; BLOOD PLASMA; DRUGS; HYPNOTICS; FORENSIC MEDICINE; METABOLITES	Jindrich, V.J. 1977 Journal of Forensic Sciences 22(1):240-241

Cyclohexylamine (8 CI)
Cyclohexanamine (9 CI)
108-91-8
C6-H13-N
MW 99.17, MP -17.7 C, BP 134.5 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5841 Blood, plasma	Ingestion	GC	a) 5 b) 5 c) 5	a) 0.7-0.15 ug/ml b) 1.7-0.22 ug/ml c) 2.8-0.7 ug/ml	a) Not given b) Not given c) Not given	a) 2 and 9 hr after 2.5 mg/kg. Initial measurement 0.18 ug/ml at 15 min b) 2 and 12 hr after 5 mg/kg. Initial measurement 0.5 ug/ml at 15 min c) 2 and 12 hr after 10 mg/kg. Initial measurement 0.7 ug/ml at 15 min Range of means, estimated from graph Healthy 24-38 yr olds, wt 70-85 kg Increase in arterial blood pressure, plasma free fatty acids and cumulative urinary excretion of catecholamines BLOOD PLASMA; URINE; SWEETENING AGENTS	Pichelbaum, H. Hengstmann, J.H. Rost, H.D. Brecht, T. Dengler, H.J. 1978 Archives of Toxicology 31:243-263

(NEXT PAGE)

Cyclohexylamine (8 CI)
Cyclohexanamine (9 CI)
108-91-8
C6-H13-N
MW 99.17, MP -17.7 C, BP 134.5 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5842 Urine	Ingestion	GC	a) 5 b) 5 c) 5	a) Not given b) Not given c) Not given	a) 95.66 +or- 5.45% of dose b) 86.78 +or- 1.76% of dose c) 96.96 +or- 3.11% of dose	a) 2.5 mg/kg b) 5.0 mg/kg c) 10.0 mg/kg 48 hr cumulative excretion Healthy 20-30 yr olds, wt 70-85 kg Increase in arterial blood pressure, plasma free fatty acids and cumulative urinary excretion of catecholamines BLOOD PLASMA; URINE; SWEETENING AGENTS	Eichelbaum, M. Hengstmann, J.H. Rost, K.D. Brecht, T. Dengler, H.J. 1978 Archives of Toxicology 39:263-269

Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-
1977-10-2
C18-H18-Cl-N3 O
MW 327.81, MP 109-110 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
9843 Blood		GC-MC	1	a) Not applicable b) Not applicable c) Not applicable d) Not applicable e) Not applicable f) Not applicable g) Not applicable h) Not applicable i) Not applicable	a) 1.22 ug/ml b) 1.01 ug/ml c) 1.51 ug/ml d) 0.76 ug/ml e) 0.20 ug/ml f) 0.04 ug/ml g) 1.92 ug/ml h) 1.98 ug/ml i) 0.67 ug/ml	a) Loxapine b) Amoxapine c) Conjugated 8-OH loxapine d) Unconjugated 8-OH loxapine e) Conjugated 7-OH loxapine f) Unconjugated 7-OH loxapine g) Conjugated 8-OH amoxapine h) Unconjugated 8-OH amoxapine i) Conjugated 7-OH amoxapine Dose unknown 41 yr old suicide victim. ADULTS; AUTOPSIES; BLOOD; BRAIN; LIVER; LUNGS; ANTIDEPRESSIVE AGENTS; DRUG ABUSE; DRUGS; FORENSIC MEDICINE	Cooper, T.B. Rost, K. Sunshine, I. 1981 Journal of Analytical Toxicology 5:99-100
9844 Brain		GC-MC	1	a) Not applicable b) Not applicable c) Not applicable d) Not applicable e) Not applicable	a) 0.46 ug/g b) 4.84 ug/g c) 3.80 ug/g d) 0.28 ug/g e) 3.71 ug/g	a) Loxapine b) Amoxapine c) Unconjugated 8-OH loxapine d) Unconjugated 7-OH loxapine e) Unconjugated 8-OH amoxapine Dose unknown 41 yr old suicide victim ADULTS; AUTOPSIES; BLOOD; BRAIN; LIVER; LUNGS; ANTIDEPRESSIVE AGENTS; DRUG ABUSE; DRUGS; FORENSIC MEDICINE	Cooper, T.B. Rost, K. Sunshine, I. 1981 Journal of Analytical Toxicology 5:99-100
9845 Liver		GC-MC	1	a) Not applicable b) Not applicable c) Not applicable d) Not applicable e) Not applicable f) Not applicable g) Not applicable h) Not applicable	a) 11.86 ug/g b) 10.00 ug/g c) 7.98 ug/g d) 4.38 ug/g e) 0.91 ug/g f) 1.89 ug/g g) 25.87 ug/g h) 2.9 ug/g	a) Loxapine b) Amoxapine c) Conjugated 8-OH loxapine d) Unconjugated 8-OH loxapine e) Conjugated 7-OH loxapine f) Conjugated 8-OH amoxapine g) Unconjugated 8-OH amoxapine h) Conjugated 7-OH amoxapine Dose unknown 41 yr old suicide victim ADULTS; AUTOPSIES; BLOOD; BRAIN; LIVER; LUNGS; ANTIDEPRESSIVE AGENTS; DRUG ABUSE; DRUGS; FORENSIC MEDICINE	Cooper, T.B. Rost, K. Sunshine, I. 1981 Journal of Analytical Toxicology 5:99-100

(NEXT PAGE)

Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-
1977-10-2
C18-H18-Cl-N3-O
MW 327.81, MP 109-110 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5846 Lung			1	a) Not applicable b) Not applicable c) Not applicable d) Not applicable e) Not applicable f) Not applicable g) Not applicable h) Not applicable	a) 4.98 ug/g b) 3.80 ug/g c) 1.59 ug/g d) 3.28 ug/g e) 0.47 ug/g f) 1.32 ug/g g) 9.46 ug/g h) 1.7 ug/g	a) loxapine b) Amoxapine c) Conjugated 8-OH loxapine d) Unconjugated 8-OH loxapine e) Conjugated 7-OH loxapine f) Conjugated 8-OH amoxapine g) Unconjugated 8-OH amoxapine h) Conjugated 7-OH amoxapine Dose unknown 41 yr old suicide victim ADULTS; AUTOPSIES; BLOOD; BRAIN; LIVER; LUNGS; ANTIDEPRESSIVE AGENTS; DRUG ABUSE; DRUGS; FORENSIC MEDICINE	Cooper, T.B. Bost, R. Sunshine, I. 1981 Journal of Analytical Toxicology 5:99-100
5847 Spleen		GC-EC	1	a) Not applicable b) Not atplicable c) Not applicable d) Not applicable e) Not applicable f) Not applicable	a) 3.96 ug/g b) 6.30 ug/g c) 0.93 ug/g d) 3.26 ug/g e) 0.53 ug/g f) 14.17 ug/g	a) loxapine b) Amoxapine c) Conjugated 8-OH loxapine d) Unconjugated 8-OH loxapine e) Conjugated 7-OH loxapine f) Unconjugated 8-OH amoxapine Dose unknown 41 yr old suicide victim ADULTS; AUTOPSIES; BLOOD; BRAIN; LIVER; LUNGS; ANTIDEPRESSIVE AGENTS; DRUG ABUSE; DRUGS; FORENSIC MEDICINE	Cooper, T.B. Bost, R. Sunshine, I. 1981 Journal of Analytical Toxicology 5:99-100

Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-
20219-97-4
C18-H20-N2
MW 264.37

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5848 Urine	Ingestion	HPLC TLC GC/MS RMD	2	a) 30.0-41.0% of dose b) 9.9-11.0% of dose c) 5.7-8.0% of dose d) 46.7-58.9% of dose	a) Not given b) Not given c) Not given d) Not given	a) 0-24 hr b) 24-48 hr c) 48-72 hr d) Total urinary excretion After dose of 32.8 mg (107 uCi) as hydrochloride 2 metabolites totalled >60% of urinary radioactivity, conjugated and nonconjugated mianserin, 14C. 24 yr olds, wt 70 and 76 kg RABBITS; URINE; ANTIDEPRESSIVE AGENTS; DRUGS; METABOLISM; METABOLITES; RATS	De Jongh, G.D. van den Wildenberg, H.M. Wieuwenhuyse, H. van der Veen, F. 1981 Drug Metabolism and Disposition 9(1):48-53

Digitoxin (8 CI)
Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-,
(3beta,5beta)- (9 CI)
71-63-6
C41-H64-O13
MW 764.92, MP 256-257 C (anhydrous)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5849 Blood, plasma	Ingestion	RIA	7	50-237 nmol/l	Not given	Maximum levels after severe poisoning with 3-20 mg. Sickness, vomiting, diarrhea, blurred vision, coma, shock, psychosis, thrombocytopenia. Cardiac rhythm and conduction disturbances CASE HISTORIES; SUICIDE; BLOOD PLASMA; ANTIARRHYTHMIC AGENTS; DRUG ABUSE; DRUGS	Hansteen, V. Jacobsen, D. Knudsen, K. Reikvam, A. Skuterud, B. 1981 Clinical Toxicology 18(6):679-692

Digoxin (8 CI)
Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-,
(3beta,5beta,12beta)- (9 CI)
20830-75-5
C41-H64-O14
MW 780.92, MP about 265 C (decomp)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5850 Blood	Injection Ingestion	RIA	a) 1 b) 1	a) 1.0-5.4 nmol/l b) 0.5-4.5 nmol/l	a) Not given b) Not given	a) Variations with change in dose (0.125-0.75 mg/day) over 2 mo. Toxicity diagnosed on 2 occasions b) Variations with change in dose (0.125-1.0 mg/day) over 12 mo. Toxicity diagnosed on 3 occasions Estimated from graph. Patients with cardiac and renal failure, Australia HEART DISEASES; BLOOD; ANTIARRHYTHMIC AGENTS; DRUG THERAPY; DRUGS	Washington, H.G. Fang, K. O'Rourke, H.F. 1978 Medical Journal of Australia 2:368-374
5851 Blood, plasma		RIA	1	0.9-1.7 ng/ml	Not given	1 and 3 days after 0.75 mg/day loading dose and 0.25 mg/day maintenance dose. 1.6 ng/ml after 16 days Estimated from graph No correlation with clinical response in 26 other cases. Cardiac patient Decreases in Rb uptake significantly correlated with decreases in heart rate HEART DISEASES; BLOOD PLASMA; DRUG THERAPY; DRUGS	Zannad, F. Boyer, R.-J. Robert, J. 1981 European Journal of Cardiology 12:275-284
5852 Blood, plasma		RIA	12	a) 0.57-1.46 ng/ml b) 0.39-1.15 ng/ml c) 0.20-0.75 ng/ml	a) 0.89 +or- 0.30 ng/ml b) 0.73 +or- 0.23 ng/ml c) 0.50 +or- 0.16 ng/ml	a) 80 mg verapamil 3X/day for two wk b) 10 mg nifedipine 3X/day for two wk c) Placebo Dose, 0.125 mg 3X/day for 2 wk. Samples taken 12 hr after last dose Healthy 22-32 yr olds ADULTS; BLOOD PLASMA; ANTIARRHYTHMIC AGENTS; DRUG INTERACTION; DRUGS	Belz, G.G. Aust, R.F. Munkes, R. 1981 Lancet 1(8224):844-845

Proline-Rbeta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI)
Proline-9-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (7 CI)
50-37-3
C20-H25-N3-O
MW 323.4

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5853 Blood		Radioimmunoassay	2	a) 1.2-2.1 ug/l b) 1.5-1.8 ug/l	a) 1.6 ug/l b) 1.6 ug/l	a) Meing antisera 1, linked via indole nitrogen b) Meing antisera 2, linked via amide side chain ISD-bovine serum albumin conjugates specific for different parts of ISD molecule Subjects suspected of drug use, dose unknown. Controls below detection limit, 0.4 ug/l. METHOD VERSION: BLOOD; URINE; DRUG ABUSE; DRUGS; PSYCHOTROPIC DRUGS; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Ratcliffe, W.A. Fletcher, S.M. Moffat, A.C. Ratcliffe, J.G. Harland, W.A. Levitt, T.E. 1977 Clinical Chemistry 23(2):169-174
5854 Urine		Radioimmunoassay	a) 10 b) 50	a) 3.8-66.0 ug/l b) 1.3-39.5 ug/l	a) 21.8 ug/l b) 12.3 ug/l	a) Meing antisera 1, linked via indole nitrogen b) Meing antisera 2, linked via amide side chain ISD-bovine serum albumin conjugates specific for different parts of ISD molecule Subjects suspected of drug use, dose unknown. Controls were below detection limit, 0.4 ug/l. METHOD VERSION: BLOOD; URINE; DRUG ABUSE; DRUGS; PSYCHOTROPIC DRUGS; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Ratcliffe, W.A. Fletcher, S.M. Moffat, A.C. Ratcliffe, J.G. Harland, W.A. Levitt, T.E. 1977 Clinical Chemistry 23(2):169-174

Ethyl alcohol (8 CI)
Ethanol (9 CI)
64-17-5
C2-H6-O
MW 46.07, MP -117.3 C, BP 78.32 C, VP 40 mm Hg at 19 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5855 Blood	Ingestion		1	265-123 mmol/l	Not applicable	On admission to hospital and 12 hr later, after consumption of 2.5 bottles of whiskey (exact content not given) 59 yr old Coma, elevated temperature, hypoxemia, acidosis, asystole ADULTS; CASE HISTORIES; SUICIDE; BLOOD; DRUG ABUSE; DRUGS; ALCOHOLS	Berild, D. Hasselbalch, H. 1981 Lancet 2(8242):163

Ethylamine, 1-methyl-2-(2,6-xylyloxy)- (8 CI)
2-Propanamine, 1-(2,6-dimethylphenoxy)- (9 CI)
31828-71-4
C11-H17-N-O
MP 179.2?

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5056 Blood, plasma	Injection Ingestion	GC	6	a) 2.4-0.5 ug/ml b) Not given c) Not given	a) Not given b) 0.77 ug/ml c) 0.38 ug/ml	a) Initial measurement and 12 hr after 8.5 min IV of 200 mg b) Peak, 2.16 hr after 400 mg oral, measurements at 24 hr were 0.05-0.2 ug/ml c) Peak, 9.17 hr after 432 mg oral, sustained-release capsule. Final measurements at 24 hr were 0.12-0.38 ug/ml SCPE values estimated from graph Healthy 27-47 yr olds, wt 69-91 kg ADULTS; BLOOD PLASMA; URINE; ANTIARRHYTHMIC AGENTS; DRUGS; COMPARATIVE EVALUATIONS	Haselbarth, V. Doevendans, J.P. Wolf, M. 1981 Clinical Pharmacology and Therapeutics 29(6):729-737
5057 Urine	Injection Ingestion	GC	6	a) 2.70-16.17% b) 3.19-11.65% c) 2.46-20.98%	a) 8.58 + or-5.13% b) 7.53 + or-3.11% c) 9.22 + or-6.62%	a) 200 mg, 8.5 min IV b) 400 mg, oral c) 432 mg, sustained-release Cumulative output after 72 hr Healthy 27-47 yr olds, wt 69-91 kg ADULTS; BLOOD PLASMA; URINE; ANTIARRHYTHMIC AGENTS; DRUGS; COMPARATIVE EVALUATIONS	Haselbarth, V. Doevendans, J.P. Wolf, M. 1981 Clinical Pharmacology and Therapeutics 29(6):729-737

Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI)
Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride
147-20-0
C17-H21-N-O.Cl-H
MP 291.P, MP 166-170 C, also reported as 168-172 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5058 Blood, plasma	Injection Ingestion	GC	10	a) 140-50 ng/ml b) 81-30 ng/ml c) 85-38 ng/ml d) 53-19 ng/ml	a) Not given b) Not given c) Not given d) Not given	a) 5 Caucasians, 1 and 8 hr after 50 mg/70 kg, IV b) 5 Orientals, 1 and 8 hr after 50 mg/70 kg, IV c) 5 Caucasians, 2 and 8 hr after 50 mg/70 kg, oral. Initial measurement, 68 ng/ml d) 5 Orientals, 2 and 8 hr after 50 mg/70 kg, oral. Initial measurement, 32 ng/ml Range of means Estimated from graph 20-26 yr olds FACIAL STUDIES; BLOOD PLASMA; DRUGS; COMPARATIVE EVALUATIONS	Sector, R. Choudhury, A.K. Chiang, C.-W. Goldberg, M.J. Ghoneim, M.M. 1980 Clinical Pharmacology and Therapeutics 28(3):229-234

Folic acid (9 CI)
L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)
59-30-3
C19-H19-N7-O6
MW 441.40

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5859 Blood, serum			a) 491 b) 75 c) 178 d) 22	a) Not given b) Not given c) Not given d) Not given	a) 5.5 +or- 4.1 ug/ml b) 5.8 +or- 3.3 ug/ml c) 5.0 +or- 4.6 ug/ml d) 5.9 +or- 3.7 ug/ml	a) Caucasian women b) Black women c) Caucasian men d) Black men Baseline levels before experiment with feeding Fe fortified foods. Massachusetts residents > 60 yr old MASSACHUSETTS; AGE; AMINES; BLOOD SERUM; CHOLESTEROLS; IRON; VITAMINS; DIETS; FOOD ADDITIVES	Gershoff, S.N. Brusis, O.A. Wino, M.V. Huber, A.M. 1977 American Journal of Clinical Nutrition 30:226-238

Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-
51481-61-9
C10-H16-N6-S
MW 252.38

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5860 Blood, serum	Injection	HPLC	1	a) 30-2 ng/l b) 0.4-0.10 ng/l c) 1.2-0.7 ng/l	a) Not given b) Not given c) Not given	a) Initial measurement and 5 hr after dose b) Hydroxymethyl cimetidine. 1 and 6 hr after cimetidine. Initial measurement 0.07 ng/l c) Cimetidine sulfoxide. 1 and 6 hr after cimetidine. Initial measurement 0.4 ng/l Dose 1200 mg, IV *Estimated from graph Patient with Zollinger-Ellison syndrome BLOOD SERUM; DRUG THERAPY; DRUGS; METABOLITES	Ziemniak, J.A. Chiarmonte, C.A. Schentag, J.J. 1981 Clinical Chemistry 27(2):272-275

Hexamethylenetetramine (8 CI)
1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)
100-97-0
C6-H12-N4
MW 140.19, MP 285-295 C [sublimes] (also reported: sublimes at 263 C without melting and with partial decomp), BP (sublimes)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5861 Urine	Ingestion	Colorimetry	10	a) <10% of dose b) 15-85% of dose	a) Not given b) Not given	a) At 1 hr b) At 48 hr Total output after 0.439-0.50 g Range of means for 10 different product formulations Healthy 23-36 yr old, wt 63.5-95.3 kg ADULTS; URINE; ANTIBIOTICS; DRUGS	Gollamudi, R. Straughn, A.B. Meyer, M.C. 1981 Journal of Pharmaceutical Sciences 70(6):596-599

Hydantoin, 5,5-diphenyl (8 CI)
2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)
57-41-0
C15-H12-N2-02
MW 252.26, MP 295-298 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5862 Blood, fetal						Review. Pharmacokinetics of fetal and neonatal exposure to drugs, suggestions for minimizing risks FETUS; NEWBORN; BLOOD; ANALGESICS; ANTIDEPRESSIVE AGENTS; DRUGS; REVIEW; PREGNANCY	Levy, G. 1981 Obstetrics and Gynecology 58(5):9S-16S
5863 Blood, plasma		GC	13	3.7-30.3 ug/ml	Not given	Patients on multiple anticonvulsant drugs CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; ANTICONVULSANTS; DRUG THERAPY; MEASUREMENT METHODS	Dhar, A.K. Kutt, H. 1981 Journal of Chromatography 222:203-211
5864 Blood, plasma		GC/MS Enzymatic	7	a) 9.8-26.2 ug/l b) 10.3-33.0 ug/l	a) 18.0 ug/l b) 20.9 ug/l	a) GC/MS, saliva/plasma ratio 0.11 b) Enzymatic immunoassay, saliva/plasma ratio 0.12 Levels in saliva correspond to levels in plasma. Saliva can be used for monitoring. BLOOD PLASMA; SALIVA; ANALGESICS; ANTICONVULSANTS; ANTIPYRETICS; DIURETICS; DRUG THERAPY; DRUGS; HYPNOTICS; SEDATIVES; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Horning, M.G. Brown, L. Nowlin, J. Lertratanangkoon, K. Kellaway, P. Tion, T.E. 1977 Clinical Chemistry 23(2):157-168
5865 Blood, plasma	Ingestion	HPLC	27	a) 4-12 ug/ml b) 7-22 ug/ml	a) Not given b) 14.9 +or- 2.8 ug/ml	a) Dose 10-13 mg/kg b) Dose 14-23 mg/kg Therapeutic level 15 ug/ml Estimated from graph Autopsies of neonates, gestational age 26-39 wk, who had been treated for seizure disorders NEWBORN; NERVOUS SYSTEM DISEASES; BLOOD PLASMA; BRAIN; ANTICONVULSANTS; DRUG THERAPY; DRUGS; BIOACCUMULATION; METABOLISM; AUTOPSIES	Painter, M.J. Piggenger, C. Wasterlain, C. Barmada, M. Pitlick, W. Carter, G. Ahern, S. 1981 Neurology 31(9):1107-1112
5866 Brain	Ingestion	HPLC	11	6-32 ug/g	Not given	Plasma levels 7-22 ug/ml. Estimated from graph Neonates, gestational age 26-39 wk, being treated for seizure disorders NEWBORN; NERVOUS SYSTEM DISEASES; BLOOD PLASMA; BRAIN; ANTICONVULSANTS; DRUG THERAPY; DRUGS; BIOACCUMULATION; METABOLISM	Painter, M.J. Piggenger, C. Wasterlain, C. Barmada, M. Pitlick, W. Carter, G. Ahern, S. 1981 Neurology 31(9):1107-1112
5867 Saliva		GC/MS Enzymatic	7	a) 0.7-3.0 ug/l b) 1.1-3.2 ug/l	a) 2.0 ug/l b) 2.8 ug/l	a) GC/MS, saliva/plasma ratio 0.11 b) Enzymatic immunoassay, saliva/plasma ratio 0.12 Levels in saliva correspond to levels in plasma. Saliva can be used for monitoring. BLOOD PLASMA; SALIVA; ANALGESICS; ANTICONVULSANTS; ANTIPYRETICS; DIURETICS; DRUG THERAPY; DRUGS; HYPNOTICS; SEDATIVES; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Horning, M.G. Brown, L. Nowlin, J. Lertratanangkoon, K. Kellaway, P. Tion, T.E. 1977 Clinical Chemistry 23(2):157-168

hydratropic acid, p-isobutyl- (8 CI)
Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)
15687-27-1
C13-H18-O2
MW 206.27, MP 75-77 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5868 Blood, serum	Ingestion	GC/MS	15	a) 4.0-33.2 ug/ml b) 0.06-0.57 ug/ml	a) 20.2 +or- 9.0 ug/ml b) 0.25 +or- 0.14 ug/ml	a) Total b) Free Dose, 800 mg TX/day for 2 days. 19-77 yr old arthritic patients RHEUMATOID ARTHRITIS; BLOOD SERUM; SYNOVIAL FLUID; ANTI-INFLAMMATORY AGENTS; DRUG THERAPY; DRUGS	Whitlam, J.H. Brown, K.F. Crooks, M.J. Boom, G.F.W. 1981 Clinical Pharmacology and Therapeutics 29(4):487-492
5869 Synovial fluid	Ingestion	GC/MS	15	a) 0.5-16.3 ug/ml b) 0.10-0.38 ug/ml	a) 7.5 +or- 4.8 ug/ml b) 0.19 +or- 0.09 ug/ml	a) Total b) Free Dose 800 mg TX/day for 2 days 19-77 yr old arthritic patients RHEUMATOID ARTHRITIS; BLOOD SERUM; SYNOVIAL FLUID; ANTI-INFLAMMATORY AGENTS; DRUG THERAPY; DRUGS	Whitlam, J.H. Brown, K.F. Crooks, M.J. Boom, G.F.W. 1981 Clinical Pharmacology and Therapeutics 29(4):487-492

Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-
68875-42-3
C10-H7-Cl2-N3-O
MW 256.1

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5870 Blood, plasma	Ingestion	HPLC	5	5-0.3 ug/ml	Not given	Initial measurement (1 hr) and 6 days after 1 mg dose. Total plasma radioactivity in anagrelide equivalents was 50 ng/ml initially Range of means estimated from graph Healthy 19-26 yr olds, wt 63-77 kg ADULTS; BLOOD PLASMA; FECES; URINE; ANTICOAGULANTS; DRUGS	Gaver, R.C. Deeb, G. Pittman, K.A. Smyth, R.D. 1981 Clinical Pharmacology and Therapeutics 29(3):381-386
5871 Urine	Ingestion	HPLC	5	30-72%	Not given	6 hr and 6 days after 1 mg dose Mean cumulative radioactivity Healthy 19-26 yr olds, wt 63-77 kg ADULTS; BLOOD PLASMA; FECES; URINE; ANTICOAGULANTS; DRUGS	Gaver, R.C. Deeb, G. Pittman, K.A. Smyth, R.D. 1981 Clinical Pharmacology and Therapeutics 29(3):381-386

Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI)
1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)
443-48-1
C6-H9-N3-O3
MW 171.16, MP 158-160 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5872 Blood, serum	Ingestion	Electrochem	99	a) 20-3.3 ug/ml b) 17-2.5 ug/ml c) 5.4-1.6 ug/ml d) 4.5-1.1 ug/ml	a) Not given b) Not given c) Not given d) Not given	a) 1.5 and 24 hr after 1.0 g dose. Initial measurement 6 ug/ml at 0.5 hr b) 1.5 and 24 hr after 1.0 g dose. Initial measurement 4.8 ug/ml at 0.5 hr c) 2 and 12 hr after 250 mg dose. Initial measurement 3.5 ug/ml at 0.5 hr d) 2 and 12 hr after 250 mg dose. Initial measurement 2 ug/ml at 0.5 hr Nonpregnant (a,c) and pregnant (b,d) women Range of means Estimated from graph. Patients with TRICHOMONIASIS UROGENITALIS infections ADULTS; INFECTION; BLOOD SERUM; URINE; ANTIBIOTICS; DRUG THERAPY; DRUGS	Anon, I. Anon, F. Franke, G. Mohr, C. 1981 Chemotherapy 27:73-79
5873 Urine	Ingestion	Electrochem	a) 11 b) 6 c) 13 d) 13	a) Not given b) Not given c) Not given d) Not given	a) 51.0% b) 51.8% c) 58.6% d) 68.3%	a) 0-24 hr after 1 g dose, nonpregnant b) 0-24 hr after 1 g dose, pregnant c) 0-24 hr after 250 g dose, nonpregnant d) 0-24 hr after 250 g dose, pregnant Patients with TRICHOMONIASIS UROGENITALIS infections ADULTS; INFECTION; BLOOD SERUM; URINE; ANTIBIOTICS; DRUG THERAPY; DRUGS	Anon, I. Anon, F. Franke, G. Mohr, C. 1981 Chemotherapy 27:73-79

Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI)
1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)
53-86-1
C19-H16-Cl-N-O4
MW 357.81, MP different forms 155 C, 162 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5878 Blood, plasma	Injection	HPLC MS	35	a) 40-1150 ng/ml b) 45-210 ng/ml	a) Not given b) Not given	a) 24 hr after 0.2 mg/kg IV, 35 patients, 45 doses. Additional doses at least 24 hr after previous dose b) Levels at ductus reopening, 5-13 days after 0.2 mg/kg, 6 patients Infants with symptomatic patent ductus arteriosus Ductus reopening associated with significantly faster clearance, shorter half-life and lower plasma levels ($P < 0.05$). INFANTS; HEART DISEASES; BLOOD PLASMA; DRUG THERAPY; DRUGS	Brash, A.R. Hicker, D.F. Graham, T.P. Stahlman, M.T. Oates, J.A. Cotton, R.B. 1981 New England Journal of Medicine 305:67-72

Insulin
9004-10-8
EXACT COMPOSITION UNKNOWN OR UNDETERMINED
850

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5875 Blood, plasma	Injection	RIA	5	a) 30-110 uE/l b) 10-20 uE/l	a) Not given b) Not given	a) Peak values at 15-40 min b) Final measurements at 240-360 min After 20 IU dose Estimated from graph Healthy 26-45 yr olds BLOOD PLASMA; DRUGS; HORMONES	Bottermann, P. Gyarae, P. Wahl, K. Traier, E. Lebenier, A. 1981 Klinische Wochenschrift 59:157-163

Iron
7439-89-6
Fe
AtW 55.847, MP 1535 C (pure), 1000-1300 C (cast), 1500 C (wrought), 1300 C (steel), BP 3000 C, VP 1 mm Hg at 1787 C, 10 mm Hg at 2040 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5876 Blood, serum			a) 489 b) 71 c) 174 d) 23	a) Not given b) Not given c) Not given d) Not given	a) 104 +or- 32 ug/dl b) 102 +or- 32 ug/dl c) 113 +or- 48 ug/dl d) 109 +or- 27 ug/dl	a) Caucasian women b) Black women c) Caucasian men d) Black men Baseline levels before experiment with feeding Fe-fortified foods. Massachusetts residents > 60 yr old MASSACHUSETTS; AGE; ANEMIA; BLOOD SERUM; CHOLESTEROLS; IRON; VITAMINS; GIFTS; FOOD ADDITIVES	Gershoff, S.N. Brusis, O.A. Nino, H.V. Huber, A.M. 1977 American Journal of Clinical Nutrition 30:226-238

Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI)
Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI)
3562-84-3
C17-H12-Br2-O3
MW 424.11, MP 151 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5877 Blood, serum	Ingestion	HPLC	5	0.39-2.2 ug/ml	Not given	1 hr and 3 hr after 20 mg. Final measurement 0.63 ug/ml at 8 hr. With 100 mg allopurinol Range of means Healthy 19-23 yr olds ADULTS; BLOOD SERUM; DRUG INTERACTION; DRUGS; MEASUREMENT METHODS	Nitsche, V. Hascher, M. 1981 Arzneimittel-Forschung 31(1):510-512

Lith
7439-93-2
Li
AtW 6.941, MP 180.54 C, BP 1336 C, VP 1 mm Hg at 723 C, 10 mm Hg at 890 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5878 Blood, cells	Ingestion	AAS	5a	Not given	240 +or- 160 umol/l	Erythrocyte levels after 1300 mg/day as carbonate, 553 determinations Data also for plasma Li and effects of hemolysis. Dose not indicated. ERYTHROCYTES; BLOOD SERUM; MEASUREMENT METHODS; LITHIUM	Misayama, G.R. Cohen, J.L. Nelson, R.W. 1977 Clinical Chemistry 23(1):41-45

Manganese
7439-96-5
Mn
AtW 54.9380, MP 1244 C, BP 2095 C, VP 1 mm Hg at 1292 C, 10 mm Hg at 1510 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5879 Blood		AAS	8+	a) Not applicable b) Not applicable c) 1.1-4.8 ug/dl d) Not given e) Not given f) Not applicable	a) 0.65 ug/dl b) 0.77 ug/dl c) Not given d) 0.85 ug/dl e) 1.45 ug/dl f) 1.2 ug/dl	a) 12 yr old boy with convulsive disorder b) Mother of child in a) c) 6 normal children d) Children examined in convulsive disorders clinic e) Neurologically normal children f) Child in a) after 10 mg/day for several weeks and then 20 mg/day Summary of work done by Y. Tanaka, St. Mary's Hospital, Montreal CANADA; ADULTS; CHILDREN; BEHAVIOR DISORDERS; NEUROLOGIC MANIFESTATIONS; NUTRITIONAL DEFICIENCIES; BLOOD; MANGANESE	Sampson, P. 1977 Journal of American the Medical Association 238(17):1805

Melamine, pentamethyl- (8 CI)
1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N''-pentamethyl- (9 CI)
16268-42-5
C8-H16-N6
MW 196.30

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5880 Blood, plasma	Infection	HPLC	a) 1 b) 1	a) 11-0.2 ug/ml b) 1.5-8.3 ug/ml	a; Not given b) Not given	a) Initial measurement and 24 hr after 1 g/sq m. Normal liver function b) Initial measurement and 20 hr after 600 mg/sq m. Abnormal liver function Data also for demethylated metabolites. Estimated from graph. Patients with advanced solid tumors. CARCINOMAS; LIVER DISEASES; NEOPLASMS; BLOOD PLASMA; DRUGS; DRUG THERAPY; DRUGS; COMPARATIVE EVALUATIONS; CHEMOTHERAPY; MEASUREMENT METHODS; METABOLITES	Benvenuto, J.A. Stewart, D.J. Benjamin, R.S. Loo, T.L. 1981 Cancer Research 41:566-569

(NEXT PAGE)

Melamine, pentamethyl- (8 CI)
1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N''-pentamethyl- (9 CI)
16269-62-9
C8-H16-N6
MW 196.30

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5881 Urine	Injection	HPLC	a) 1 b) 1	a) Not applicable b) Not applicable	a) 0.75% b) 7.8%	a) 24 hr cumulative output after 1 g/sq m b) 24 hr cumulative output, including metabolites, after 1 g/sq m. Patients with advanced solid tumors. CARCINOMAS; LIVER DISEASES; NEOPLASMS; BLOOD PLASMA; URINE; DRUG THERAPY; DRUGS; COMPARATIVE EVALUATIONS; CHEMOTHERAPY; MEASUREMENT METHODS; METABOLITES	Benvenuto, J.A. Stewart, D.J. Benjamin, R.S. Loo, T.L. 1981 Cancer Research 41:566-569

Morphanthridine, 6-(4-methyl-1-piperazinyl)- (8 CI)
11H-Dibenz(b,e)azepine, 6-(4-methyl-1-piperazinyl)- (9 CI)
1977-11-3
C19-H21-N3
MW 291.40, MP 136-138 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5882 Blood, serum	Ingestion	GC	20	a) Not given b) Not given c) Not given	a) 42.4 +or- 12.8 ng/ml b) 33.0 +or- 15.7 ng/ml c) 38.1 +or- 11.8 ng/ml	a) Day 1 following 10 mg in previous evening b) Day 7 after 10 mg daily c) Day 14 after 10 mg daily 17 male and 3 female students, aged 20-25 yr. Impaired eye-hand coordination. With alcohol, enhanced impairment of skills. BLOOD; BLOOD SERUM; FINLAND; DRUG INTERACTION; HYPNOTICS; DRUGS; COMPARATIVE EVALUATIONS	Saario, I. Linnoila, M. Mahi, M. 1979 Journal of Clinical Pharmacology 19:52-59

Morphinan-3-ol, 17-methyl-
77-07-6
C17-H23-N-O
MW 257.38, MP 198-199 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5883 Blood, plasma	Injection Ingestion	RIA	a) 1 b) 1	a) 16-21 ng/ml b) 8-6 ng/ml	a) Not given b) Not given	a) 30 and 120 min after 12 mg oral every 8-6 hr. Predose level, 12 ng/ml. Initial measurement, 20 ng/ml at 15 min b) 60 and 180 min after 2 mg, IM, every 4 hr. Predose level, 4 ng/ml. Initial measurement, 7 ng/ml at 30 min. Cancer patients BLOOD PLASMA; ANALGESICS; DRUG THERAPY; DRUGS; NARCOTICS; MEASUREMENT METHODS	Dixon, R. Crews, T. Mohacsi, P. Taturisi, C. Foley, K. 1980 Research Communications in Chemical Pathology and Pharmacology 29(3):535-547

Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI)
Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9 CI)
76-57-3
C18-H21-N-O3
MW 299.36, MP 158-156 C (after drying at 80 C)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5888 Urine			1	Not applicable	0.4 ug/100 ml	Sex unknown. Cause of death unknown Autopsy of 65 yr old. ADULTS; AUTOPSIES; BLOOD PLASMA; DRUGS; HYPNOTICS; FORENSIC MEDICINE; METABOLITES	Jindrich, V.J. 1977 Journal of Forensic Sciences 22(1):240-244

Morpholine, 2-((2-ethoxyphenoxy)methyl)-
#6217-91-8
C13-H19-N-O3
MW 237.30, MP Hydrochloride 185-186 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5885 Blood, plasma	Ingestion	HPLC	1	830-50 ng/ml	Not given	1 and 16 hr after 50 mg dose. Initial measurement 150 ng/ml at 15 min Estimated from graph BLOOD PLASMA; ANTIDEPRESSIVE AGENTS; DRUGS; PSYCHOTROPIC DRUGS; MEASUREMENT METHODS	Gillilan, R. Mason, W.D. 1981 Journal of Pharmaceutical Sciences 70(2):220-221

Morpholine, 4-(thioxo(3,4,5-trimethoxyphenyl)methyl)-
3°(19-65-9
C14-H19-N-O4-S
MW 297.4

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5846 Blood, plasma	Ingestion	HPLC	1	a) 7-0.6 ug/ml b) 2-0.4 ug/ml c) 1.3-2 ug/ml	a) Not applicable b) Not applicable c) Not applicable	a) Parent compound, 2 and 24 hr. Initial measurement 3 ug/ml at 1 hr b) Sulfur-oxide metabolite, 8 and 12 hr. Initial measurement 0.55 ug/ml at 1 hr c) Amide metabolite, 8 and 24 hr. Initial measurement 1.2 ug/ml at 8 hr Dose 600 mg Estimated from graph Healthy 30 yr old, wt 70 kg, Italy ADULTS; BLOOD PLASMA; URINE; DRUGS; MEASUREMENT METHODS; METABOLITES	Crolla, T. Borsa, M. Pifferi, G. 1981 Journal of Chromatography 222:257-263
5887 Urine	Ingestion	HPLC	1	a) Not applicable b) Not applicable c) Not applicable d) Not applicable	a) 7 mg b) 1.8 mg c) 10.2 mg d) 18 mg	a) Parent compound b) Sulfur-oxide metabolite c) Amide metabolite d) Morpholinol metabolite Total 48 hr output after 600 mg dose Estimated from graph Healthy 30 yr old, wt 70 kg, Italy ADULTS; BLOOD PLASMA; URINE; DRUGS; MEASUREMENT METHODS; METABOLITES	Crolla, T. Borsa, M. Pifferi, G. 1981 Journal of Chromatography 222:257-263

Nicotine (8 CI)
Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI)
54-11-5
C10-H14-N2
MW 162.23, MP <-80 C, BP 247 C (partial decomp) at 745 mm Hg, 123-125 C at 17 mm Hg, VP 1 mm Hg at 61.8 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5888 Blood, serum	Oral absorption	GC	12	a) 0.9-8.6 ng/ml b) 3.6-85.8 ng/ml c) 1.1-861.9 ng/ml d) 16.0-556.0 ng/ml	a) 2.9 +or- 0.5 ng/ml b) 21.6 +or- 4.6 ng/ml c) 137.3 +or- 82.1 ng/ml d) 197.2 +or- 88.0 ng/ml	a) Nicotine level after overnight abstinence b) Nicotine level after 6-8 hr of ad libitum dipping/chewing c) Cotinine (metabolite), group a) d) Cotinine, group b) levels comparable to those four hr in regular cigarette smokers University students, Los Angeles, mean age 19.8 yr (range 19-22 yr) Used tobacco 3.2 yr (mean). 11 dipped snuff, 1 chewed tobacco Dipped/chewed mean of 8.8 wads/day CAFFEINE; BLOOD SERUM; NICOTINE; TOBACCOS	Gritz, E.R. Baer-Weiss, V. Benowitz, N.L. Van Vunakis, H. Jarvik, M.E. 1981 Clinical Pharmacology and Therapeutics 30(2):201-209

o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI)
Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)
15676-16-1
C15-H23-N3-O4-S
MW 341.83, MP 175-182 C (decomp)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5889 Blood, plasma	Ingestion	Fluorometry	15	a) Not given b) Not given	a) 1.58 ug/ml b) 1.86 ug/ml	a) 6 wk b) 12 wk dose, 600 mg 2x/day after long term haloperidol therapy Schizophrenics, mean age 40.3 yr ASSAYS; CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; DRUG THERAPY; DRUGS; PSYCHOTROPIC DRUGS	Rama Rao, V.A. Bailey, J. Bishop, M. Coppen, A. 1981 Psychopharmacology 73:77-80

Phenol, 2,2'-methylenebis(3,4,6-trichloro-
70-30-4
C13-H6-Cl6-O2
MW 406.92, MP 164-165 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5890 Adipose	Dermal	GC-EC	1	Not applicable	6.0 ug/g	Tiss subcutaneous, abdominal wall. Patient had extensive topical applications (3%, diluted and undiluted) for 13 days after uncomplicated, moderate burn. 10 yr old Caucasian Patient did well initially. Confusion, lower-extremity weakness, fever beginning day 9. Apnea, papilledema, bilateral rhonchi day 13. Death day 14. Autopsy: satisfactorily healing burns, pneumonia, cerebral edema. AUTOPSIES; CASE HISTORIES; CHILDREN; CENTRAL NERVOUS SYSTEM DISEASES; ADIPOSE TISSUE; BLOOD; BRAIN; KIDNEYS; LIVER; MUSCLES; SKIN; HEXACHLOROPHENE	Chilcote, R. Curley, A. Loughlin, H.M. Jupin, J.A. 1977 Pediatrics 59(3):857-859
5891 Blood	Dermal	GC-PC	1	a) Not applicable b) Not applicable c) Not applicable	a) 2.2 ug/g b) 4.1 ug/g c) 2.9 ug/g	a) 12 hr after discontinuation b) 36 hr after discontinuation c) Post mortem Extensive topical application (3%, diluted and undiluted) for 13 days after uncomplicated, moderate burn. 10 yr old Caucasian Patient did well initially. Confusion, lower-extremity weakness, fever beginning day 9. Apnea, papilledema, bilateral rhonchi day 13. Death day 14. Autopsy: satisfactorily healing burns, pneumonia, cerebral edema. AUTOPSIES; CASE HISTORIES; CHILDREN; CENTRAL NERVOUS SYSTEM DISEASES; ADIPOSE TISSUE; BLOOD; BRAIN; KIDNEYS; LIVER; MUSCLES; SKIN; HEXACHLOROPHENE	Chilcote, R. Curley, A. Loughlin, H.M. Jupin, J.A. 1977 Pediatrics 59(3):857-859
5892 Blood	Dermal	GC-PC	1	200-750 ng/ml	Not given	0 and 28 hr after second bath with soap containing 1.5% 7 day old premature infant, wt 1250 g. NEWBORN; BLOOD; PHASPHORUS METABOLISM; HEXACHLOROPHENE; DRUGS	Dodson, V.N. Tyrala, E.E. Hillman, R.E. 1977 Clinical Chemistry 23(6):988-987

(NEXT PAGE)

Phenol, 2,2'-methylenebis(3,4,6-trichloro-
70-30-4
C13-H6-Cl6-O2
MF 406.92, MP 168-169° C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	CENTRAL INFORMATION	REFERENCE
5893 Brain	Dermal	GC-EC	1	Not applicable	2.2 ug/g	Patient had extensive topical applications (3%, diluted and undiluted) for 13 days after uncomplicated, moderate burn. 10 yr old Caucasian Patient did well initially. Confusion, lower-extremity weakness, fever beginning day 9. Apnea, papilledema, and bilateral rhonchi on day 13. Death day 14. Autopsy: satisfactorily healing burns, pneumonia, cerebral edema. ADDCPSIPS; CASE HISTORIPS; CHILDREN; CENTRAL NERVOUS SYSTEM DISEASES; ADIPOSE TISSUE; BLOOD; BRAIN; KIDNEYS; LIVER; MUSCLES; SKIN; HEXACHLOROPHENE	Chilcote, R. Curley, A. Loughlin, M.M. Jupin, J.A. 1977 Pediatrics 59(3):457-459
5894 Kidney	Dermal	GC-EC	1	Not applicable	2.2 ug/g	Patient had extensive topical applications (3%, diluted and undiluted) for 13 days after uncomplicated, moderate burn. 10 yr old Caucasian Patient did well initially. Confusion, lower-extremity weakness, fever beginning day 9. Apnea, papilledema, bilateral rhonchi day 13. Death day 14. Autopsy: satisfactorily healing burns, pneumonia, cerebral edema. ADDCPSIPS; CASE HISTORIPS; CHILDREN; CENTRAL NERVOUS SYSTEM DISEASES; ADIPOSE TISSUE; BLOOD; BRAIN; KIDNEYS; LIVER; MUSCLES; SKIN; HEXACHLOROPHENE	Chilcote, R. Curley, A. Loughlin, M.M. Jupin, J.A. 1977 Pediatrics 59(3):457-459
5895 Liver	Dermal	GC-EC	1	Not applicable	0.4 ug/g	Patient: had extensive topical applications (3%, diluted and undiluted) for 13 days after uncomplicated, moderate burn. 10 yr old Caucasian Patient did well initially. Confusion, lower-extremity weakness, fever beginning day 9. Apnea, papilledema, bilateral rhonchi day 13. Death on day 14. Autopsy: satisfactorily healing burns, pneumonia, cerebral edema. ADDCPSIPS; CASE HISTORIPS; CHILDREN; CENTRAL NERVOUS SYSTEM DISEASES; ADIPOSE TISSUE; BLOOD; BRAIN; KIDNEYS; LIVER; MUSCLES; SKIN; HEXACHLOROPHENE	Chilcote, R. Curley, A. Loughlin, M.M. Jupin, J.A. 1977 Pediatrics 59(3):457-459

(NEXT PAGE)

Phenol, 2,2'-methylenebis(3,4,6-trichloro-
70-30-4
C13-H6-Cl6-O2
MW 406.92, MP 164-165 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5896 Muscle	Dermal	GC-EC	1	Not applicable	2.4 ug/g	Patient had extensive topical applications (3%, diluted and undiluted) for 13 days after uncomplicated, moderate burn. 10 yr old Caucasian Patient did well initially. Confusion, lower-extremity weakness, fever beginning day 9. Apnea, papilledema, bilateral rhonchi day 13. Death day 14. Autopsy revealed satisfactorily healing burns, pneumonia, and cerebral edema. AUTOPSIES; CASE HISTORIES; CHILDREN; CENTRAL NERVOUS SYSTEM DISEASES; ADIPOSE TISSUE; BLOOD; BRAIN; KIDNEYS; LIVER; MUSCLES; SKIN; HEXACHLOROPHENE	Chilcote, R. Curley, A. Loughlin, H.M. Jupin, J.A. 1977 Pediatrics 59(3):457-459
5897 Skin	Dermal	GC-EC	1	Not applicable	25.0 ug/g	Patient had extensive topical applications (3%, diluted and undiluted) for 13 days after uncomplicated, moderate burn. 10 yr old Caucasian Patient did well initially. Confusion, lower-extremity weakness, fever beginning day 9. Apnea, papilledema, bilateral rhonchi day 13. Death day 14. Autopsy: satisfactorily healing burns, pneumonia, cerebral edema. AUTOPSIES; CASE HISTORIES; CHILDREN; CENTRAL NERVOUS SYSTEM DISEASES; ADIPOSE TISSUE; BLOOD; BRAIN; KIDNEYS; LIVER; MUSCLES; SKIN; HEXACHLOROPHENE	Chilcote, R. Curley, A. Loughlin, H.M. Jupin, J.A. 1977 Pediatrics 59(3):457-459

Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI)
108-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI)
117-89-5
C21-H24-F3-N3-S
MW 407.49, BP 202-210 C at 0.6 mm Hg

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5898 Blood, plasma	Ingestion	HPLC	1	2.7-8.7 ng/ml	Not given	8 and 48 hr after 5 mg, orally. Initial level 8.7 ng/ml Estimated from graph Healthy volunteer, wt 65 kg ADMIN; BLOOD PLASMA; DRUG THERAPY; DRUGS; PHARMACOKINETICS; MEASUREMENT METHODS	Midha, K.K. Hubbard, J.W. Cooper, J.K. Hawes, E.M. Fournier, G. Young, P. 1981 British Journal of Clinical Pharmacology 12:189-193

(NEXT PAGE)

Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI)
10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI)
117-89-5
C21-H24-F3-N3-S
MW 407.49, BP 202-210 C at 0.6 mm Hg

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5899 Blood, plasma	Ingestion	HPLC	1	a) Not applicable b) Not applicable c) Not applicable d) Not applicable e) Not applicable f) Not applicable	a) 2.1 ng/ml b) 10.4 ng/ml c) 17.9 ng/ml d) 20.8 ng/ml e) 27.5 ng/ml f) 3.8 ng/ml	a) Morning after 80 mg dose, and 5 min before an additional 80 mg dose b) 1 hr after 80 mg dose c) 2 hr after 80 mg dose d) 4 hr after 80 mg dose e) 9 hr after 80 mg dose f) 24 hr after 80 mg dose Treatment of 30 mg daily or 15 mg 2X daily resulted in no measurable plasma levels of the drug. 18 yr old schizophrenic man ADULTS; BLOOD PLASMA; DRUG THERAPY; TRANQUILIZERS; DRUGS	Curry, S.H. Stewart, F.D. Springer, P.F. Pope, T.F. 1981 Lancet 1(8216):194-196

Piperazine, 1-(6-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8 CI)
Piperazine, 1-(6-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9 CI)
19216-56-9
C19-H21-N5-O4
MW 382.42, MP 278-280 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5900 Blood, plasma	Injection Ingestion	HPLC	9	a) 1-7 ng/ml b) 6-13 ng/ml c) 7-19 ng/ml d) 10-33 ng/ml e) 13-22 ng/ml f) Not applicable g) 1-9 ng/ml	a) Not given b) Not given c) Not given d) Not given e) Not given f) 32 ng/ml g) Not given	a) 1.5 mg/day, orally, 8 patients b) 3 mg/day, orally, 8 patients c) 6 mg/day, orally, 7 patients d) 9 mg/day, orally, 5 patients e) 12 mg/day, orally, 3 patients f) 15 mg/day, orally, 1 patient g) Single 0.5 mg dose, IV, 1 patient, corresponding change in systolic standing blood pressure, +3 to -20 mm Hg a)-f) Steady-state levels Estimated from graphs. 28-58 yr old patients with hypertension, no prior antihypertensive therapy 10-18% decrease in blood pressure in 6 patients. No overshoot of blood pressure on withdrawal. ADULTS; HYPERTENSION; BLOOD PLASMA; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY; DRUGS; BLOOD PRESSURE; SMOKING	Seideman, P. Grahnen, A. Haglund, E. Lindstrom, B. von Bahr, C. 1981 Clinical and Pharmacological Therapeutics 30(4):487-494

Piperidine, 2-(2,2-dicyclohexylethyl)-
6621-47-2
C19-H35-N
MW 277.50

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5901 Blood, plasma	Ingestion	HPLC	5	a) 22-116 ng/ml b) 148-438 ng/ml	a) 66.8 + or- 15.8 ng/ml b) 278 + or- 52.8 ng/ml	a) Peaks, 2.5-12 hr after 150 mg. Mean area under concentration/time curve (AUC), 1010 ng hr/ml b) Peaks, 3-18 hr after 300 mg. Mean AUC, 5110 ng hr/ml As maleate 60-75 yr old patients with severe angina pectoris. HEART DISEASES; BLOOD PLASMA; ANTIARRHYTHMIC AGENTS; DRUG THERAPY; DRUGS; MEASUREMENT METHODS	Horowitz, J.D. Morris, P.M. Drummer, O.H. Goble, A.J. Louis, W.J. 1981 Journal of Pharmaceutical Sciences 70(3):320-322

Platinum, diamminedichloro-, cis- (8 CI)
Platinum, diamminedichloro-, (SP-4-2)- (9 CI)
15663-27-1
C12-H6-N2-Pt
MW 300.05

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5902 Blood, plasma	Injection	AAS	20	a) 4.7-1.2 ug/ml b) 4.2-1.2 ug/ml c) 6.2-1.6 ug/ml d) 5.1-1.2 ug/ml e) 2.7-0.18 ug/ml f) 2.2-0.18 ug/ml g) 4.5-0.25 ug/ml h) 4.3-0.30 ug/ml i) 2.3-0.14 ug/ml j) 1.4-0.13 ug/ml k) 3.3-0.18 ug/ml l) 3.1-0.24 ug/ml	a) Not given b) Not given c) Not given d) Not given e) Not given f) Not given g) Not given h) Not given i) Not given j) Not given k) Not given l) Not given	a) Pt 5 min and 6 hr after 50 mg/sq m cisplatin, IV b) Same as a) plus 12.5 g mannitol before and 12.5 g after cisplatin, IV c) Pt 5 min and 6 hr after 100 mg/sq m cisplatin, IV d) Same as c) plus mannitol as in b) e) Filterable Pt 5 min and 2 hr after 50 mg/sq m cisplatin, IV f) Same as e) plus mannitol as in b) g) Filterable Pt 5 min and 2 hr after 100 mg/sq m cisplatin, IV h) Same as g) plus mannitol as in b) i) Cisplatin 5 min and 2 hr after 50 mg/sq m, IV j) Same as i) plus mannitol as in b) k) Cisplatin 5 min and 2 hr after 100 mg/sq m IV l) Same as k) plus mannitol as in b) Mannitol did not effect plasma levels or terminal plasma decline Patients with malignancies CARCINOMAS; NEOPLASMS; SARCOMAS; BLOOD PLASMA; DRUG INTERACTIONS; DRUG THERAPY; DRUGS; PLATINUM; METABOLISM; METABOLITES; CHEMOTHERAPY; METALS	Himmelstein, K.J. Patton, T.F. Belt, R.J. Taylor, S. Repta, A.J. Sternson, L.A. 1981 Clinical Pharmacology and Therapeutics 29(5):658-664

Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI)
Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)
5C-24-8
C21-H28-05
MW 360.44, MP 240-241 C (decomp)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5803 Blood, plasma	Ingestion	Protein binding	8	a) 5-46 ug/dl b) 3-20 ug/dl	a) Not given b) Not given	a) Initial measurement and 2 hr after PO mg. Final measurement 4 ug/dl at 24 hr b) Initial measurement and 2 hr after 100 mg prednimustine. Final measurement 6 ug/dl at 24 hr Range of means, estimated from graph 30-74 yr old cancer patients NEOPLASMS; BLOOD SERUM; DRUG THERAPY; DRUGS; COMPARATIVE EVALUATIONS; CHEMOTHERAPY	Saved, A. Van Hove, W. Vermeulen, A. 1981 Oncology 38:354-356

Prolactin (VAN)
9002-62-4
FIXCT COMPOSITION UNKNOWN OR UNDETERMINED
MW About 23,000

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5804 Blood, plasma	Injection	RIA	a) 9 M 9 c) 2 d) 2	a) 340-3240 mIU/l b) 1070-4060 mIU/l c) 4480-5400 mIU/l d) 4900-6500 mIU/l	a) 1.35 mIU/l b) 2.44 mIU/l c) 4.94 mIU/l d) 5.70 mIU/l	a) After 12.5 mg fluphenazine/wk, 8 wk, men b) After 250 mg fluphenazine/wk, 8 wk, men c) After 12.5 mg fluphenazine/wk, 8 wk, women d) After 250 mg fluphenazine/wk, 8 wk, women ADULTS; BEHAVIOR DISORDERS; BLOOD PLASMA; DRUG THERAPY; TRANQUILIZERS; COMPARATIVE EVALUATIONS	Wiles, D. Franklin, M. Sancher, S.T. Johansson, B. Lundin, L. Malm, U. 1980 Psychopharmacology 71:131-136

Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI)
Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)
882-09-7
C10-H11-C1-03
MW 214.66, MP 118-119 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5805 Blood, plasma	Ingestion	HPLC	4	a) 67.2-78.2 mg/l b) 124.3-142.7 mg/l c) 2.46-2.53 mg/l d) 7.93-10.47 mg/l	a) 72.3 +or- 4.6 mg/l b) 129.2 +or- 9.0 mg/l c) 2.50 +or- 0.03 mg/l d) 9.0 +or- 1.09 mg/l	a) Total clofibric acid, 1 wk after 500 mg/12 hr b) Total clofibric acid, 1 wk after 500 mg/12 hr + 500 mg probenecid/6 hr c) Free clofibric acid, 1 wk after 500 mg/12 hr d) Free clofibric acid, 1 wk after 500 mg/12 hr + 500 mg probenecid/6 hr Range of means Healthy 18-22 yr olds, wt 65-77 kg BLOOD PLASMA; URINE; DRUG INTERACTION; COMPARATIVE EVALUATIONS; METABOLITES; DRUGS	Veenendaal, J.R. Brooks, P.M. Meffin, P.J. 1981 Clinical Pharmacology and Therapeutics 29(3):359-368

(NEXT PAGE)

Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI)
Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)
882-09-7
C10-H11-Cl-03
MW 214.66, MP 118-119 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5906 Urine	Ingestion	HPLC	6	a) 3.8-8.7% b) 2.6-5.7% c) 29.6-44.1% d) 21.7-38.2% e) 65.6-99.5% f) 64.5-98.6% % of dose	a) 5.7 +or- 2.1% b) 4.6 +or- 1.4% c) 34.9 +or- 6.7% d) 28.9 +or- 7.4% e) 89.0 +or- 16.3% f) 87.7 +or- 15.7% % of dose	a) Clofibric acid, after 500 mg/12 hr b) Clofibric acid, after 500 mg/12 hr + 500 mg probenecid/6 hr c) Glucuronide, after 500 mg/12 hr d) Glucuronide, after 500 mg/12 hr + 500 mg probenecid/6 hr e) Acid hydrolysis sample, after 500 mg/12 hr f) Acid hydrolysis sample, after 500 mg/12 hr + 500 mg probenecid/6 hr. Healthy 18-22 yr olds, wt 65-77 kg BLOOD PLASMA; URINE; DRUG INTERACTION; COMPARATIVE EVALUATIONS; METABOLITES; DRUGS	Veenendaal, J.P. Brooks, P.M. Meffin, P.J. 1981 Clinical Pharmacology and Therapeutics 29(3):351-358

Pseudoephedrine, (+)- (8 CI)
Benzenemethanol, alpha-[1-(methylamino)ethyl]-, (S-(R*,R*))- (9 CI)
90-82-4
C10-H15-N-O
MW 165.23, MP 119 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5907 Blood, plasma	Ingestion	GC-EC	1	470-20 ng/ml	Not given	2 hr and 28 hr after dose of 120 mg as hydrochloride. Measurement at 30 min was 250 ng/ml Estimated from graph Healthy fasting male ADULTS; BLOOD PLASMA; URINE; DRUGS; MEASUREMENT METHODS; AUTONOMIC DRUGS; ALKALOIDS; METABOLITES	Lo, I.Y. Land, G. Bye, A. 1981 Journal of Chromatography 222:297-302
5908 Urine	Ingestion	GC-FC	1	a) Not applicable b) Not applicable c) Not applicable d) Not applicable	a) 8.12 mg b) 19.28 mg c) 6.40 mg d) 10.90 mg	a) 0-3.5 hr (plus 0.07 mg norpseudoephedrine) b) 3.5-6 hr (plus 0.31 mg norpseudoephedrine) c) 6-9 hr (plus 0.15 mg norpseudoephedrine) d) 9-24 hr (plus 0.52 mg norpseudoephedrine) Times after 120 mg as hydrochloride ADULTS; BLOOD PLASMA; URINE; DRUGS; MEASUREMENT METHODS; AUTONOMIC DRUGS; ALKALOIDS; METABOLITES	Lo, I.Y. Land, G. Bye, A. 1981 Journal of Chromatography 222:297-302

Pyrimidine, 2,4-diamino-5-(3,4,5,-trimethoxybenzyl)- (8 CI)
2,4-Pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- (9 CI)
738-70-5
C14-H18-N4-03
MW 290.32, MP 199-203 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5909 Blood, serum	Ingestion	Microbiological	6	6.3-0.9 ug/ml	Not given	1st and 8th day after 500 mg on 1st day and 250 mg daily from day 2-8. Range of means, estimated from graph. Close correlation between saliva and serum levels Healthy 20-38 yr olds, wt 58.5-76 kg BLOOD SERUM; SALIVA; ANTIBIOTICS; DRUGS; COMPARATIVE EVALUATIONS	Sardi, A. Vettaro, M.P. Alesina, R. Grasso, S. Meinardi, G. De Carneri, I. Tamassia, V. 1981 European Journal of Clinical Pharmacology 20:113-118
5910 Saliva	Ingestion	Microbiological	6	4.8-0.8 ug/ml	Not given	1st and 8th day after 500 mg on 1st day and 250 mg daily from day 2-8. Range of means, estimated from graph. Close correlation between saliva and serum levels Healthy 20-38 yr olds, wt 58.5-76 kg BLOOD SERUM; SALIVA; ANTIBIOTICS; DRUGS; COMPARATIVE EVALUATIONS	Sardi, A. Vettaro, M.P. Alesina, R. Grasso, S. Meinardi, G. De Carneri, I. Tamassia, V. 1981 European Journal of Clinical Pharmacology 20:113-118

Salicylic acid, ion(1-) (8 CI)
Benzoic acid, 2-hydroxy-, ion(1-) (9 CI) (VAN)
69-36-5
C7-H5-03
MW 138.12, MP 157-159 C, BP about 211 C at 20 mm Hg

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5911 Blood			1	Not applicable	13.9 mg/100 ml	Dose unknown. Cause of death unknown Autopsy of 65 yr old. ADULTS; AUTOPSIES; BLOOD PLASMA; DRUGS; HYPNOTICS; FORENSIC MEDICINE; METABOLITES	Jindrich, W.J. 1977 Journal of Forensic Sciences 22(1):240-241
5912 Blood, fetal						Review. Pharmacokinetics of fetal and neonatal exposure to drugs, suggestions for minimizing risks FETUS; NEWBORN; BLOOD; ANALGESICS; ANTIDEPRESSIVE AGENTS; DRUGS; REVIEW; PREGNANCY	Levy, G. 1981 Obstetrics and Gynecology 58(5):98-165
5913 Blood, serum	Ingestion	Colorimetry	9	a) 14-25 mg/100 ml b) 11-20 mg/100 ml c) 7-25 mg/100 ml d) 7-20 mg/100 ml	a) 19.8 mg/100 ml b) 15.8 mg/100 ml c) 16.6 mg/100 ml d) 13.7 mg/100 ml	a) 6 days after choline salicylate (equivalent to 3.76 or 5.62 g/day aspirin) for 6 days (8 subjects) b) Same as a) with 120 ml Mg-Al hydroxide/day c) Same as a), but including 3 cases with serum levels below 10 mg/100 ml (11 subjects) d) Same as b), including 3 cases with serum levels below 10 mg/100 ml Significant differences between a and b, c and d Ascorbic acid had no effect on levels Estimated from graph Healthy 22-30 yr olds BLOOD SERUM; URINE; ANALGESICS; DRUG INTERACTION; DRUGS	Hansten, P.D. Hayton, W.L. 1980 Journal of Clinical Pharmacology 20(5-6, pt. 1):326-331

(NEXT PAGE)

Salicylic acid, ion(1-) (8 CI)
Benzoic acid, 2-hydroxy-, ion(1-) (9 CI) (VAN)
69-36-5
C7-H5-03
MW 138.12, MP 157-159 C, BP about 211 C at 20 mm Hg

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5914 Urine	Ingestion	Colorimetry	9	a) Not given b) Not given c) Not given	a) 81.5 +or- 8.51% of dose b) 81.1 +or- 3.17% of dose c) 82.3 +or- 5.18% of dose	a) Choline salicylate (3.76 g aspirin/day) plus 1 g ascorbic acid b) Choline salicylate alone c) Choline salicylate plus 120 ml Maalox/day 8 hr output between doses, day 5 to day 6, during 6 day treatment Healthy 22-30 yr olds BLOOD SERUM; URINE; ANALGESICS; DRUG INTERACTION; DRUGS	Hansten, P.D. Hayton, W.L. 1980 Journal of Clinical Pharmacology 20(5-6, pt. 1):326-331

Sisomicin (8 CI)
D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy- (9 CI)
32385-11-8
C19-H37-N5-07
MW 447.55, MP 198-201 C (monohydrate)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5915 Blood, serum	Injection	HPLC	1	0.5-0.3 mg/l	Not given	Range of means, 30 min and 8 hr after 1.07 mg/kg Healthy, 70 kg volunteer NETHERLANDS; ADULTS; BLOOD SERUM; ANTIBIOTICS; MEASUREMENT METHODS;	Barends, D.M. Zwaan, C.L. Pulshoff, A. 1981 Journal of Chromatography 222:316-323

Succinimide, 2-ethyl-2-methyl- (9 CI)
2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)
77-67-8
C7-H11-N-02
MW 141.17, MP 68-65 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5916 Blood, plasma		GC	4	22.9-98.0 mg/ml	Not given	Patients on multiple anticonvulsant drugs CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; ANTICONVULSANTS; DRUG THERAPY; MEASUREMENT METHODS	Dhar, A.F. Hutt, H. 1981 Journal of Chromatography 222:203-211
5917 Blood, plasma		GC/MS	8	11.3-42.7 mg/l	Not given	Mean saliva/plasma ratio 1.08 (range 0.92-114) Saliva can be used for monitoring. BLOOD PLASMA; SALIVA; ANALGESICS; ANTICONVULSANTS; ANTIPYRETICS; FEBRILES; DRUG THERAPY; DRUGS; HYPNOTICS; SEDATIVES; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Morning, M.G. Brown, T. Nowlin, J. Lertratanangkoon, K. Kellaway, P. Zion, T.P. 1977 Clinical Chemistry 23(2):157-164

(NEXT PAGE)

Succinimide, 2-ethyl-2-methyl- (8 CI)
2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)
77-67-8
C7-H11-N-O2
MW 141.1", MP 68-69 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5918 Saliva		GC/MS	4	12.5-45.9 ug/l	Not given	Mean saliva/plasma ratio 1.08 (range 0.92-1.14) Saliva can be used for monitoring. PLASMA; SALIVA; ANALGESICS; ANTICONVULSANTS; ANTIPYRETICS; DIURETICS; DRUG THERAPY; DRUGS; HYPNOTICS; SEDATIVES; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Morning, M.G. Brown, I. Nowlin, J. Lertratanangkoon, K. Kellaway, P. Tjon, T.E. 1977 Clinical Chemistry 23(2):157-160

Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI)
Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)
152-47-6
C11-H12-N4-O3-S
MW 280.3, MP 175-178 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5919 Blood, serum	Ingestion		6	32-65 ug/ml	Not given	1st and 8th day after 400 mg on 1st day and 200 mg on days 2-8. Final measurement, 50 ug/ml at end of day 8. Close correlation between serum and saliva levels. Range of means, estimated from graph. Healthy 28-34 yr olds, wt 58.5-76 kg BLOOD SERUM; SALIVA; ANTIBIOTICS; DRUGS; COMPARATIVE EVALUATIONS	Sardi, A. Vettaro, M.P. Alesina, R. Grasso, S. Meinardi, G. de Carneri, I. Tamassia, V. 1981 European Journal of Clinical Pharmacology 20:113-118
5920 Saliva	Ingestion		6	3-6 ug/ml	Not given	1st and 8th day after 400 mg on 1st day and 200 mg daily on days 2-8. Final measurement, 4.5 ug/ml at end of day 8. Close correlation between serum and saliva levels. Range of means, estimated from graph. Healthy 28-34 yr olds, wt 58.5-76 kg BLOOD SERUM; SALIVA; ANTIBIOTICS; DRUGS; COMPARATIVE EVALUATIONS	Sardi, A. Vettaro, M.P. Alesina, R. Grasso, S. Meinardi, G. de Carneri, I. Tamassia, V. 1981 European Journal of Clinical Pharmacology 20:113-118

Tetrahydrocannabinol cross-reacting cannabinoids (No postings in CHEMLINE).

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5921 Blood, plasma	Inhalation		a) 1 b) 1	a) 105-15 ng/ml b) 90-15 ng/ml	a) Not applicable b) Not applicable	a) 10 and 360 min after 17 mg. Initial measurement 80 ng/ml at 5 min b) 15 and 315 min after 15 mg. Initial measurement 50 ng/ml at 10 min ADULTS; BLOOD PLASMA; URINE; DRUG ABUSE; DRUGS; PSYCHOTROPIC DRUGS	Scherrmann, J.M. Hoellinger, H. Nam, N-.H. Boudet, L. Pichon, J. Thang, D-.C-. 1981 Clinical Toxicology 18(5):565-571

(NEXT PAGE)

Tetra..rocannabinol cross-reacting cannabinoids (No postings in CHEMLINE).

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5922 Urine	Inhalation		5	5-30 ng/ml	Not given	Cannabis smokers, exposure not known ADULTS; BLOOD PLASMA; URINE; DRUG ABUSE; DRUGS; PSYCHOTROPIC DRUGS	Scherrmann, J.M. Boellinger, M. Wan, M-.H. Boudet, L. Pichon, J. Thang, D-.C-. 1981 Clinical Toxicology 18(5):565-571
5923 Urine		RIA	32	a) 0-660 ng/l b) 0-1070 ng/l c) 0-650 ng/l	a) 57 ng/l b) 65 ng/l c) 69 ng/l	a) Day 1 b) Day 2 c) Day 3 Patients from drug dependence clinics, U.K. UNITED KINGDOM; URINE; DRUG ABUSE; DRUGS; PSYCHOTROPIC DRUGS; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Marks, V. Teale, D. Fry, D. 1975 British Medical Journal 3(5979):348-349

Theophylline (8 CI)
1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)
58-55-9
C7-H8-N4-O2
MW 180.17, MP 270-274 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5924 Blood	Ingestion		1	a) 7-3 ug/ml b) 7.7-13.9 ug/ml	a) Not given b) Not given	a) 4 and 8 hr after 90 mg/8 hr (22.5 mg/kg/day), beads from opened capsules mixed with food b) Peak and trough levels after 3 doses of 70 mg/6 hr (23 mg/kg/day), liquid formulation. 19 mo old hospitalized patient, NY. NEW YORK; CHILDREN; DRUG THERAPY; DRUGS	Ben-Zvi, Z. Kattan, M. Adam, P. 1981 New England Journal of Medicine 304(10):613
5925 Blood, plasma	Ingestion	HPLC	12	a) 24-6.3 umol/l b) 32-16 umol/l	a) Not given b) Not given	a) 2 and 12 hr after 200 mg oxtriphylline (equivalent to 128 mg theophylline) b) 2 and 12 hr after oxtriphylline as in a) preceeded by 250 mg erythromycin stearate 3x/day for 10 days Estimated from graph Theophylline elimination impaired after erythromycin. 19-38 yr old, 89.5-86.8 kg, healthy subjects ADULTS; BLOOD PLASMA; URINE; ANTIBIOTICS; AUTONOMIC DRUGS; DRUG INTERACTION; DRUGS; MUSCLE RELAXANTS; ERYTHROMYCINS; THEOPHYLLINES	Benton, R.W. Gray, J.D. Hung, O.R. 1981 Clinical Pharmacology and Therapeutics 30(3):422-426

(NEXT PAGE)

Theophylline (8 CI)
1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)
58-55-9
C7-H8-N4-O2
MW 180.17, MP 270-274 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5926 Blood, serum	Ingestion	HPLC	13	a) 1.86-9.35 ug/ml b) 7.47-14.57 ug/ml c) 1.66-7.94 ug/ml d) 10.19-12.65 ug/ml	a) Not given b) Not given c) Not given d) Not given	a) Initial measurement and 1 hr after first of 4 doses, day 1, conventional tablet b) Initial measurement and 1 hr after first of 4 doses, day 4, conventional tablet c) Initial measurement and 4 hr after first of 2 time-released doses, day 1 d) Initial measurement and 4 hr after first of 2 time-released doses, day 4 Total daily dose, 750 mg Range of means Asthmatics, 19-58 yr old (mean 41 yr) ADULTS; BLOOD SERUM; SALIVA; DRUG THERAPY; COMPARATIVE EVALUATIONS; THEOPHYLLINES	Munch, E.P. Sondergaard, I. Weeke, B. 1981 Allergy 36:89-98
5927 Saliva	Ingestion	HPLC	13	a) 1.2-5.5 ug/ml b) 4.2-8 ug/ml c) 1.3-4.3 ug/ml d) 5.6-7 ug/ml	a) Not given b) Not given c) Not given d) Not given	a) Initial measurement and 1 hr after first of 4 doses, day, 1 conventional tablet b) Initial measurement and 1 hr after first of 4 doses, day 4, conventional tablet c) Initial measurement and 4 hr after first of 2 time-released doses, day 1 d) Initial measurement and 4 hr after first of 2 time-released doses, day 4 Total daily dose, 750 mg Range of means Asthmatics, 19-58 yr old (mean 41 yr) ADULTS; BLOOD SERUM; SALIVA; DRUG THERAPY; COMPARATIVE EVALUATIONS; THEOPHYLLINES	Munch, E.P. Sondergaard, I. Weeke, B. 1981 Allergy 36:89-98
5928 Urine	Ingestion	HPLC	3	a) 70.3-98.0 mg/12 hr b) 54.1-74.3 mg/12 hr	a) 81.8 mg/12 hr b) 58.9 mg/12 hr	a) After 200 mg oxtriphylline (equivalent to 128 mg theophylline), mean 63.9% of dose recovered b) Oxtriphylline as in a) preceeded by 250 mg erythromycin stearate 3x/day for 10 days, mean 86% of dose recovered Theophylline elimination (including all metabolites except 1-methyluric acid) impaired after treatment with erythromycin 19-38 yr old, 49.5-86.4 kg, healthy subjects ADULTS; BLOOD PLASMA; URINE; ANTIBIOTICS; AUTONOMIC DRUGS; DRUG INTERACTION; DRUGS; MUSCLE RELAXANTS; ERYTHROMYCINS; THEOPHYLLINES	Benton, K.W. Gray, J.D. Hung, O.R. 1981 Clinical Pharmacology and Therapeutics 30(3):422-426

Tocopherol
1406-66-2
EXACT COMPOSITION UNKNOWN OR UNDETERMINED

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5929 Blood, plasma		GC	a) 4 b) 6 c) 9 d) 1 e) 2	a) 459-2319 ug/100 ml b) 28-1,111 ug/100 ml c) 395-642 ug/100 ml d) Not applicable e) 1430-1596 ug/100 ml	a) 980 ug/100 ml b) 468 ug/100 ml c) 485 ug/100 ml d) 886 ug/100 ml e) 1,513 ug/100 ml	a) Patients with Spielmeyer-Sjogren type of Batten's disease b) Unaffected relatives of a) c) Controls d) Controls, 200 mg/day supplement e) Controls, 400 mg/day supplement As alpha-Tocopherol levels significantly higher in patients VITAMIN E; CENTRAL NERVOUS SYSTEM DISEASES; DISEASES; BLOOD PLASMA; VITAMINS	Siakotos, A.N. Koppang, N. Youmans, S. Bucana, C. 1974 American Journal of Clinical Nutrition 27:1152-1157
5930 Blood, serum			a) 235 b) 46 c) 68 d) 15	a) Not given b) Not given c) Not given d) Not given	a) 1.3 +or- 0.4 mg/dl b) 1.1 +or- 0.3 mg/dl c) 1.1 +or- 0.4 mg/dl d) 1.2 +or- 0.4 mg/dl	a) Caucasian women b) Black women c) Caucasian men d) Black men Baseline levels before experiment with feeding Fe-fortified foods. Massachusetts residents > 60 yr old MASSACHUSETTS; AGE; ANEMIA; BLOOD SERUM; CHOLESTEROLS; IRON; VITAMINS; DIETS; FOOD ADDITIVES	Gershoff, S.N. Brunin, O.A. Hino, M.V. Huber, A.M. 1977 American Journal of Clinical Nutrition 30:226-234

Toluene (8 CI)
Benzene, methyl- (9 CI)
108-88-3
C7-H8
MW 92.13 MP -95 to -94.5 C, BP 110.6 C, VP 36.7 mm Hg at 30 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5931 Blood	Inhalation	GC	a) 1 b) 1 c) 1 d) 1 e) 1	a) 29.3-22 mg/l b) 21-9.5 mg/l c) 12-7 mg/l d) 9.8-3 mg/l e) 38.2-21.6 mg/l	a) Not given b) Not given c) Not given d) Not given e) Not given	a) 5 and 40 min b) 2 and 100 min c) 15 and 40 min d) 15 and 130 min e) 10 and 70 min Times after cessation of inhalation. Dose unknown. Chronic toluene abusers INDUSTRIAL CHEMICALS; ADULTS; BLOOD; BREATH; INHALATION	Garriott, J.C. Foerster, F. Juarez, I. de la Garza, F. Mendiola, T. Curoe, J. 1981 Clinical Toxicology 18(4):471-479
5932 Breath	Inhalation	GC	1	1.85-1.14 mg/l	Not given	10 and 80 min after cessation of inhalation. Dose unknown Chronic toluene abusers INDUSTRIAL CHEMICALS; ADULTS; BLOOD; BREATH; INHALATION	Garriott, J.C. Foerster, F. Juarez, I. de la Garza, F. Mendiola, T. Curoe, J. 1981 Clinical Toxicology 18(4):471-479

Valeric acid, 2-propyl- (8 CI)
Pentanoic acid, 2-propyl- (9 CI)
99-66-1
C8-H16-02
MW 144.21, BP 120-121 C at 18 mm Hg, 128-130 C at 20 mm Hg

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5933 Blood, plasma	Ingestion	HPLC	3	a) 46-56 ug/ml b) 64-69 ug/ml	a) Not given b) Not given	a) Steady state levels before AM dose, 1250-1400 mg/day b) 2-8 hr after same dose followed by 10 mg/kg paracetamol Chronic treatment with carbamazepine and phenytoin Caucasian epileptics, 23-63 yr old, wt 46-97 kg CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; DRUGS; ANTICONVULSANTS; DRUG INTERACTION; DRUGS	Kapetanovic, I.M. Kupferberg, H.J. Theodore, W. Porter, R.J. 1981 British Journal of Clinical Pharmacology 11:391-393
5934 Blood, plasma		GC	9	1.8-113.6 ug/ml	Not given	Patients on multiple anticonvulsant drugs CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; ANTICONVULSANTS; DRUG THERAPY; MEASUREMENT METHODS	Dhar, A.K. Kupp, H. 1983 Journal of Chromatography 272:203-211

Vitamin A
11103-57-4
EXACT COMPOSITION UNKNOWN OR UNDETERMINED

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5935 Blood, serum			10	a) Not given b) Not given	a) 21 +or- 2 ug/dl b) 36 +or- 8 ug/dl	a) Vitamin A deficiency b) 2-8 wk after 10000-30000 IU/day Therapy increased levels of serum triiodothyronine, thyroxine, retinol binding protein. CIRRHOSIS; LIVER DISEASES; BLOOD SERUM; HORMONES; METALS; VITAMIN A; VITAMINS; ZINC	Morley, J.E. Russell, R.M. Reed, A. Carney, E.A. Hershmann, J.M. 1981 American Journal of Clinical Nutrition 34:1089-1095

Vitamin B12
68-19-9
C63-H88-Co-N14-O14-P
MW 1355.42

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5936 Blood, serum			a) 485 b) 76 c) 179 d) 23	a) Not given b) Not given c) Not given d) Not given	a) 712 +or- 134 pg/ml b) 794 +or- 140 pg/ml c) 738 +or- 86 pg/ml d) 778 +or- 108 pg/ml	a) Caucasian women b) Black women c) Caucasian men d) Black men Baseline levels before experiment with feeding Fe-fortified foods. Massachusetts residents > 60 yr old MASSACHUSETTS; AGE; ANEMIA; BLOOD SERUM; CHOLESTEROLS; IRON; VITAMINS; GIFTS; FOOD ADDITIVES	Gershoff, S.N. Brusis, O.A. Nino, P.V. Huber, A.M. 1977 American Journal of Clinical Nutrition 30:226-234

Zinc
7440-66-6
Zn
At% 65.38, MP 419.5 C, BP 908 C, VP 1 mm Hg at 487 C, 10 mm Hg at 590 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5937 Blood, plasma	Ingestion		30	a) Not given b) Not given c) Not given d) Not given e) 80-95 ug/dl	a) 83.87 ug/dl b) 123.68 ug/dl c) 140.68 ug/dl d) 150 ug/dl e) Not given	a) Pre-study level, 16 patients b) Patients in a) after 220 mg $ZnSO_4$ (50 mg elemental Zn) 3X/day, oral, for 2 wk c) Regimen as in b), 4 wk d) Level of plateau after 4 wk e) Range of means, 14 placebo patients during study. Estimated from graph Patients with senile dementia due to atherosclerosis. Mean age 77 yr in study group and 73 yr for controls. 6 of 16 Zn-treated patients and 1 of 18 placebo patients developed diarrhea. No significant psychometric or behavioral differences between placebo and Zn-treated patients. CHIAHOMA; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; ZINC	Czerwinski, A.W. Clark, M.L. Serafetinides, E.A. Perrier, C. Huber, W. 1978 Clinical Pharmacology and Therapeutics 15(4):436-441
5938 Blood, serum		AAS	27	37-120 ug/dl	Not given	Alcoholic cirrhotic patients. Depressed serum triiodothyronine (T-3) and free T-3 index (FT-3I). Significant positive correlation between Zn and T-3 and FT-3I. Zinc therapy (220 mg/day for 2 wk) decreased thyrotropin levels, but had no effect on other parameters. CIRRHOSIS; LIVER DISEASES; BLOOD SERUM; HORMONES; METALS; VITAMIN A; VITAMINS; ZINC	Morley, J.E. Russell, R.M. Reed, A. Carney, E.A. Hershmann, J.M. 1981 American Journal of Clinical Nutrition 34:1489-1495
5939 Hair	Ingestion	AAS	a) 12 b) 6 c) 5	a) 125-207 ug/g b) 150-189 ug/g c) 139-210 ug/g	a) 177 +or- 7 ug/g b) 178 +or- 6 ug/g c) 179 +or- 12 ug/g S.E.	a) Pregnant vegetarians, mean intake 22.6 +or- 10.9 mg/day, diet plus supplement. Crude fiber 8.9 g/day b) Pregnant nonvegetarians, mean intake 16.1 +or- 1.8 mg/day, diet plus supplement. Crude fiber 9.8 g/day c) Nonpregnant vegetarians, mean intake 6.4 +or- 1.3 mg/day. Crude fiber 6.2 g/day Zn not altered by crude fiber <9.0 g/day. a) and c) differed significantly ZINC; BIOACCUMULATION; DIETS; FOODS; PREGNANCY; BLOOD PLASMA; HAIR; URINE	King, J.C. Stein, P. Doyle, M. 1981 American Journal of Clinical Nutrition 34:1049-1055
5940 Urine	Ingestion	AAS	a) 6 b) 6 c) 5 d) 6	a) Not given b) Not given c) Not given d) Not given	a) 0.63 +or- 0.12 mg b) 0.45 +or- 0.14 mg c) 0.79 +or- 0.11 mg d) 0.60 +or- 0.09 mg	a) Basal diet, added amino acids, 5.5 mg Zn/day b) Basal diet, added amino acids, 10.5 mg Zn/day c) Basal diet, added ammonium citrate, 10.5 mg Zn/day d) Basal diet, added ammonium citrate, 5.5 mg Zn/day 0-24 hr excretions Urinary excretion of nitrogenous compounds not altered by low Zn Preadolescents, Ages 7.5 yr-9.75 yr, mean ht, 132.1 cm, mean wt, 29.8 kg CHILDREN; NUTRITIONAL DEFICIENCIES; URINE; ZINC; DIETS	Meiners, C.R. Taper, L.J. Horslund, M.E. Sitchey, S.J. 1977 American Journal of Clinical Nutrition 30:879-882

(NEXT PAGE)

Zinc
7440-66-6
Zn
At% 66.38, MP 419.5 C, BP 908 C, VP 1 mm Hg at 487 C, 10 mm Hg at 590 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5981 Urine	Ingestion	AAS	a) 12 b) 6 c) 5	a) 0.09-0.69 mg/g creatinine b) 0.21-0.59 mg/g creatinine c) 0.09-0.29 mg/g creatinine	a) 0.39 +or- 0.07 mg/g creatinine b) 0.41 +or- 0.06 mg/g creatinine c) 0.17 +or- 0.04 mg/g creatinine S.E.	a) Pregnant vegetarians, mean intake 20.6 +or- 10.9 mg/day, diet plus supplement. Crude fiber 8.9 g/day b) Pregnant nonvegetarians, mean intake 14.1 +or- 1.9 mg/day, diet plus supplement. Crude fiber 4.9 g/day c) Nonpregnant vegetarians, mean intake 5.8 +or- 1.3 mg/day. Crude fiber 4.2 g/day Zn not altered by crude fiber <9.0 g/da. a) and c) differed significantly ZINC; BIOACCUMULATION; DIETS; FOODS; PREGNANCY; BLOOD PLASMA; HAIR; URINE	King, J.C. Stein, P. Doyle, M. 1981 American Journal of Clinical Nutrition 34:1049-1055

1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl-, (Z)-
52772-82-0
C23-H25-F3-N2-O-S
MW 434.51

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5982 Blood, serum	Injection Ingestion	RIA	3	a) 5.2-8.4 ng/ml b) 0.6-2.5 ng/ml c) 0.8-1.4 ng/ml d) 1.6-8.4 ng/ml e) 0.2-1.2 ng/ml	a) Not given b) Not given c) Not given d) Not given e) Not given	a) 1 and 48 hr after 1 mg IV. Initial measurement, 2.8 ng/ml b) 2 and 7 hr after 8 mg fluopentixol, single dose, as tablets c) 0 and 6 hr after regimen of 1.5 mg flupentixol/day, as tablets d) 0 and 2.5 hr after 8 mg/flupentixol as tablets. Final measurement, 0.7 ng/ml at 48 hr e) 0.5 and 3.5 hr after 10 mg IM as decanoate. Final measurement, 0.3 ng/ml at 21 days after dose Estimated from graphs 20-38 yr olds, Denmark Sedation, restlessness PENNAEV; ADULTS; BLOOD SERUM; PSYCHOTROPIC DRUGS; COMPARATIVE EVALUATIONS	Jorgensen, A. 1980 European Journal of Clinical Pharmacology 18:355-360

1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI)
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)
69-23-8
C22-H26-F3-N3-O-S
MW 437.53, BP 268-274 C at 0.5 mm Hg, 250-252 C at 0.3 mm Hg

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5983 Blood, plasma	Injection	RIA	11	a) 2.07-48.4 ng/ml b) 15.80-75.88 ng/ml	a) 10.78 ng/ml b) 30.59 ng/ml	a) After 12.5 mg/wk, 8 wk b) After 250 mg/wk, 4 wk As enanthate Chronic schizophenics, ages 22-62 yr ADULTS; BEHAVIOR DISORDERS; BLOOD PLASMA; DRUG THERAPY; TRANQUILIZERS; COMPARATIVE EVALUATIONS	Wiles, D. Franklin, M. Dencker, S.J. Johansson, R. Lundin, L. Malm, U. 1980 Psychopharmacology 71:131-136

(NEXT PAGE)

1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI)
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)
69-23-8
C22-H26-F3-N3-O-S
MW 437.52, BP 268-274 C at 0.5 mm Hg, 250-252 C at 0.3 mm Hg

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5944 Blood, plasma	Ingestion	GC	a) 9 b) 3 c) 5 d) 20 e) 1	a) 5.7-0.3 ng/ml b) 0.1-0.5 ng/ml c) 0.2-4.2 ng/ml d) 0.1-4.1 ng/ml e) 1.5 ng/ml	a) Not given b) Not given c) Not given d) Not given e) Not given	a) 2 and 12 hr after 20 mg as hydrochloride b) 5 mg c) 10 mg d) 20 mg e) 40 mg Range (b-e) of mean steady state levels after 2 wk. Benztropine, given to control side effects, had no effect on steady state levels. Patients with schizophrenia or schizo-affective disorders (mean age 28.5 yr for women and 22.4 for men) ADULTS; BEHAVIOR DISORDERS; BLOOD PLASMA; DRUG INTERACTION; DRUG THERAPY; DRUGS; PSYCHOTROPIC DRUGS	Dysken, M.W. Javaid, J.I. Chang, S.S. Schaffer, C. Shahid, A. Davis, J.M. 1981 Psychopharmacology 73:205-210

1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI)
1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)
469-79-4
C15-H21-N-O2
MW 247.33, MP 156-157 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5945 Urine	Injection Ingestion	GC/MS	6	a) 42.7-67.6% of dose b) 33.6-56.4% of dose	a) Not given b) Not given	a) 5 mg, IV b) 5 mg, oral Cumulative 48 hr output, including metabolites. URINE; ANALGESICS; NARCOTICS; METABOLISM; METABOLITES	Bondesson, U. Hartig, P. Danielsson, B. 1981 Drug Metabolism and Deposition 9(4):376-380

1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, cis-(+)-
42399-41-7
C22-H26-N2-O4-S
MW 414.52

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5946 Blood, plasma	Ingestion	GC	a) 12 b) 10 c) 4	a) 72-35 ng/ml b) 35-117 ng/ml c) 12-151 ng/ml	a) Not given b) Not given c) Not given	a) 3 and 8 hr after 60 mg. Initial measurement, 37 ng/ml at 1.5 hr b) 0.5 and 3 hr after 90 mg. Final measurement, 38 ng/ml at 12 hr c) 0.5 and 4 hr after 120 mg. Final measurement, 40 ng/ml at 12 hr Range of means. Estimated from graph Healthy 22-46 yr olds, wt 69.5-88.6 kg Decrease in blood pressure, increase in cardiac PR and QT intervals. Headaches (7 of 13 patients), nausea (2), abdominal pain (1), dizziness (1). BLOOD PLASMA; ANALGESICS; DRUGS; BLOOD PRESSURE	Kinney, E.L. Moskowitz, B.M. Zelis, R. 1981 Journal of Clinical Pharmacology 21:337-342

1alpha*,5a.pha*-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8 CI)
8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, (1R-(exo,exo))- (9 CI)
519-09-5
C16-H19-N-03
MW 249.30, MP Tetrahydrate 86-92 C (decomp 195 C, dry)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5947 Urine	Injection Intranasal	Enzyatic	a) 16 b) 3 c) 1	a) 2.9-23 mg/l b) 1.6-4.8 mg/l c) 4.0-14 mg/l	a) 9 +or- 2 mg/l b) 2.7 mg/l c) 7.8 mg/l	a) Peaks, surgical patients, 7-17 hr after 1.5-1.7 mg/kg cocaine, intranasal b) Peaks, volunteers, 3-17 hr after 0.39 mg/kg cocaine, intranasal c) Peak, volunteer, 1-8 hr after 0.26-0.52 mg/kg cocaine, IV First positive test 1-4 hr after single dose, negative after 19-27 hr. DRUGS; ANESTHETICS; DRUG ABUSE; DRUGS	Van Dyke, C. Byck, R. Baruch, D.S. Matlow, P. 1977 Clinical Chemistry 23(2):241-244

1alpha*,5alpha*-Tropane-2beta-carboxylic Acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI)
8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)
50-36-2
C17-H21-N-04
MW 303.35, MP 98 C, BP 187-189 C at 0.1 mm Hg

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5948 Blood, plasma	Ingestion	Radiometry	a) 1 b) 1	a) 23-52 dpm/ml b) 95-62 dpm/ml	a) Not applicable b) Not applicable	a) 0.67 and 2.0 hr. Final value, 15 dpm/ml at 2.4 hr b) 1 and 4 hr After 10 mg (2.3 uCi) of labelled drug, oral. Ecgonine methyl ester only major metabolite, most present as free cocaine. Estimated from graphs. Healthy 37 and 60 yr olds, no medications for > 2 wk, Canada. DRUGS; ANESTHETICS; URINE; BLOOD PLASMA; SALIVA; METABOLITES; CANADA; ANTIPYRETICS	Inaba, T. Stewart, D.J. Kalow, W. 1978 Clinical Pharmacology and Therapeutics 23(5):547-552
5949 Blood, plasma	Intranasal	HPLC	7	50-100 ng/ml	Not given	15-30 min after 200 mg hydrochloride, powder. 17-34 yr olds BLOOD PLASMA; ANESTHETICS; DRUGS; SURGERY	Masoud, A.N. Krupski, D.M. 1980 Journal of Analytical Toxicology 4:306-310
5950 Saliva	Ingestion	Radiometry	a) 1 b) 1	a) 185-30 dpm/ml b) 160-41 dpm/ml	a) Not applicable b) Not applicable	a) 0.8 and 1.6 hr b) 1.1 and 3.7 hr After 10 mg (2.3 uCi) of labelled drug, oral. Estimated from graph. Healthy 37 and 60 yr olds, no medications for > 2 wk, Canada. DRUGS; ANESTHETICS; URINE; BLOOD PLASMA; SALIVA; METABOLITES; CANADA; ANTIPYRETICS	Inaba, T. Stewart, D.J. Kalow, W. 1978 Clinical Pharmacology and Therapeutics 23(5):547-552

(NEXT PAGE)

1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI)
8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)
50-36-2
C17-H21-N-04
MW 303.35, MP 98 C, BP 187-188 C at 0.1 mm Hg

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5951 Urine	Ingestion	Radiometry	2	65-73% of dose	69% of dose	24 hr 14C excretion after 10 mg labelled dose, oral. Monoexponential elimination in one subject, biexponential in the other. Ecgonine methyl ester 32-49% of radioactivity. Little free cocaine. Healthy 37 and 46 yr olds, no medications for > 2 wk, Canada. DRUGS; ANESTHETICS; URINE; BLOOD PLASMA; SALIVA; METABOLITES; CANADA; ANTIPYRETICS	Inaba, T. Stewart, D.J. Kalow, W. 1978 Clinical Pharmacology and Therapeutics 23(5):547-552

1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1)
57109-80-7
C16-H11-Cl-N2-O3.H-K-O.K
MW 408.9

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5952 Blood, plasma	Ingestion	HPLC	10	1214-2640 ng/ml	1590 +or- 163 ng/ml	Steady state levels after 50 mg, 14 days, P.M. dose 18-37 yr old psychiatric patients, Sweden SWEDEN; ADULTS; BEHAVIOR DISORDERS; BLOOD SERUM; DRUG THERAPY; TRANQUILIZERS	Bertler, A. Lindgren, S. Walagren, H. 1980 Psychopharmacology 71:165-167

1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-
22316-47-8
C16-H13-Cl-N2-O2
MW 300.74, YP crystals 180-182 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5953 Blood, plasma	Ingestion	GC-EC	16	20-197 ng/ml	81.0 +or- 48.9 ng/ml	Dose, 0.3-1.6 mg/kg/day (mean 0.89 +or- 0.38 mg/kg/day) 8-47 yr old patients BLOOD PLASMA; ANTICONVULSANTS; DRUG THERAPY; DRUGS; MEASUREMENT METHODS	Riva, R. Tedeschi, G. Albani, F. Baruzzi, A. 1981 Journal of Chromatography 225:219-224

10H-Phenothiazine-2-sulfonamide, 10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-N,N-dimethyl-
39860-99-6
C24-H33-N3-O3-S2
MW 475.66

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5958 Blood, plasma		GC-EC	5	18.1-57.9 ng/ml	Not given	Initial dose 12.5 mg IM as maleitate. Last dose varied from 25-112.5 mg. Duration of therapy 18-27 wk. Schizophrenics MEASUREMENT METHODS; DRUGS; BLOOD PLASMA; DRUG THERAPY	Cooper, S.F. Lapierre, Y.D. 1981 Journal of Chromatography 222:291-296

2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI)
Benzeneethanol, alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)
469-62-5
C22-H29-N-O2
MW 339.48, MP 75-76 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5955 Blood		GC	5	a) 1-11 ug/ml b) 0-8 ug/ml	a) Not given b) Not given	a) Dextropropoxyphene b) Norpropoxyphene, metabolite Fatal intoxications Alcohol also present, 0-2.1 mg/g (mean 1.1 mg/g) AUTOPSIES; BLOOD; LIVER; URINE; ANALGESICS; DRUGS; MEASUREMENT METHODS	Norheim, G. 1976 Archives of Toxicology 36:89-95
5956 Liver		GC	6	a) 18-108 ug/g b) 0-16 ug/g	a) 55.8 ug/g b) Not given	a) Dextropropoxyphene b) Norpropoxyphene, metabolite Fatal intoxications Promethazine, salicylamide, secobarbital, or diazepam also present in 4 subjects AUTOPSIES; BLOOD; LIVER; URINE; ANALGESICS; DRUGS; MEASUREMENT METHODS	Norheim, G. 1976 Archives of Toxicology 36:89-95
5957 Urine		GC	8	a) 4-41 ug/ml b) 18-136 ug/ml	a) 20.5 ug/ml b) 61.7 ug/ml	a) Dextropropoxyphene, 8 cases b) Norpropoxyphene, metabolite, 3 cases Fatal intoxications AUTOPSIES; BLOOD; LIVER; URINE; ANALGESICS; DRUGS; MEASUREMENT METHODS	Norheim, G. 1976 Archives of Toxicology 36:89-95

2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI)
525-66-6
C16-H21-N-O2
MW 259.34, MP 96 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5958 Blood, plasma	Ingestion	Colorimetry	a) 9 b) 13	a) 41.0-137 ng/ml b) 6.29-27.70 ug/ml	a) Not given b) Not given	a) Patients 0.5-6 hr after 80 mg, peak at 1 hr b) Controls 0.5-6 hr after 40 mg, peak at 2 hr Range of means. Significantly higher levels in patients with celiac disease, Crohn's disease, ulcerative colitis, rheumatoid arthritis and staphylococcal pneumonia. Patients with inflammatory disease (non-cardiovascular) and normal controls. High drug levels associated with elevated erythrocyte sedimentation rate. DRUGS; DISEASES; ADULTS; UNITED KINGDOM	Babb, J. Bishop, M. Schneider, R.F. Hawkins, C.F. Hoare, A.M. 1976 Lancet 1(7978):1013
5959 Blood, plasma	Injection, Ingestion	Fluorometry	8	a) 13.2-72.6 ug/ml b) 24.1-160.0 ug/ml c) 22.5-93.8 ug/ml	a) 41.8 + or - 8.2 ug/ml b) 91.1 + or - 15.3 ug/ml c) 57.1 + or - 8.6 ug/ml S.E.	a) Peak, fasting, mean area under concentration/time curve (AUC) 178.5 + or - 38.5 ng hr/ml S.E. b) Peak, 88% protein plus lipid meal, mean AUC 306.7 + or - 50.4 ng hr/ml S.E. c) Peak, 93% carbohydrate meal, mean AUC 266.7 + or - 49.3 ng hr/ml S.E. Samples up to 9 hr after oral dose 1 mg/kg (6 subjects), IV dose 0.2 mg/kg (2 subjects) Healthy subjects, mean age 25.6 yr (range 18-42), mean wt 64.8 kg (range 47-86) BLOOD PLASMA; URINE; DRUGS; FOODS	McLean, A.J. Isbister, C. Bobik, A. Dudley, F.J. 1981 Clinical Pharmacology and Therapeutics 30(1):31-38
5960 Urine	Ingestion	Radiometry	6	a) 60.0-85.3% dose b) 56.8-90.3% dose c) 79.4-95.6% dose	a) 77.6 +or- 4.2% dose b) 79.2 +or- 6.4% dose c) 88.5 +or- 2.6% dose S.E.	a) Fasting b) 88% protein plus lipid meal c) 93% carbohydrate meal 24 hr after 1 mg/kg labelled drug Healthy subjects, mean age 25.6 yr (range 18-42), mean wt 64.8 kg (range 47-86) BLOOD PLASMA; URINE; DRUGS; FOODS	McLean, A.J. Isbister, C. Bobik, A. Dudley, F.J. 1981 Clinical Pharmacology and Therapeutics 30(1):31-38

2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-, (Z)-
"677"-BP-3
C16-H17-Br-N2
MW 317.25

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5961 Blood, plasma	Injection Ingestion	HPLC	1	a) 110-3.5 ng/ml b) 5-75 ng/ml c) 60-8 ng/ml d) 2.7-12 ng/ml	a) Not applicable b) Not applicable c) Not applicable d) Not applicable	a) 2 and 28 hr after 150 mg, oral. Initial measurement 18 ng/ml at 1 hr b) 1 and 8 hr after 150 mg, oral. Final measurement 32 ng/ml at 28 hr. Metabolite (norzimelidine) c) Initial measurement and 13 hr after 20 mg IV d) Initial measurement and 8 hr after 20 mg IV. Final measurement 9 ng/ml at 28 hr. Metabolite (norzimelidine) Estimated from graph BLOOD PLASMA; URINE; ANTIDEPRESSIVE AGENTS; DRUGS; COMPARATIVE EVALUATIONS; METABOLITES	Love, R.L. Moore, R.G. Thomas, J. Chaturvedi, S. 1981 European Journal of Clinical Pharmacology 20:135-139
5962 Urine	Injection Ingestion	HPLC	1	a) 75-5 ug/hr b) 25-1.5 ug/hr	a) Not applicable b) Not applicable	a) 3 and 24 hr after 150 mg, oral. Initial measurement 40 ug/hr at 2 hr b) 8 and 19 hr after 20 mg IV. Initial measurement 15 ug/hr at 1 hr Estimated from graph Healthy volunteer BLOOD PLASMA; URINE; ANTIDEPRESSIVE AGENTS; DRUGS; COMPARATIVE EVALUATIONS; METABOLITES	Love, R.L. Moore, R.G. Thomas, J. Chaturvedi, S. 1981 European Journal of Clinical Pharmacology 20:135-139

2,4-Oxazolidinedione, 5,5-dimethyl-
695-53-4
C5-H7-N-O3
MW 129.11, MP 76-77 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5963 Blood, plasma		GC	3	46.8-980.0 ug/ml	Not given	Patients on multiple anticonvulsant drugs CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; ANTICONVULSANTS; DRUG THERAPY; MEASUREMENT METHODS	Dhar, A.K. Kutt, H. 1981 Journal of Chromatography 222:203-211

2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI)
Acetamide, 2-(diethylamino)-N-(2,6-diethylphenyl)- (9 CI)
137-58-6
C14-H22-N2-O
MW 234.33, MP 68-69 C, BP 180-181 C at 4 mm Hg, 159-160 C at 2 mm Hg

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5964 Blood, plasma	Injection	Enzymatic immunoassay	17	a) 1.1-5.9 ug/ml b) 1.1-3.2 ug/ml c) 1.3-5.2 ug/ml d) 1.6-4.4 ug/ml	a) 3.07 +or- 1.22 ug/ml b) 2.38 +or- 0.82 ug/ml c) 2.43 +or- 0.73 ug/ml d) 3.06 +or- 0.88 ug/ml	a) At end of loading infusion b) At 60-90 min c) At 6 hr d) At 24 hr Dose, 1.5 mg/kg bolus followed by 120 ug/kg/min rapid infusion for 25 min, then 30 ug/kg/min maintenance infusion Cardiac patients, mean age 66 yr, mean wt 77 kg. CARDIOVASCULAR DISEASES; HEART DISEASES; BLOOD PLASMA; ANTIARRHYTHMIC AGENTS; DRUG THERAPY; DRUGS	Salzer, L.B. Weinrib, A.B. Marina, P.J. Lima, J.J. 1981 Clinical Pharmacology and Therapeutics 29(5):617-624

2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI)
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)
50-18-0
C7-H15-Cl2-N2-O2-P
MW 261.11

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5965 Blood, plasma		GC	7	a) 38-2.2 ug/ml b) 30-0 ug/ml	a) Not given b) Not given	a) Without concurrent treatment with delta 9-tetrahydrocannabinol, 1 and 24 hr after dose. Mean AUC 283.5 +or- 68 ug/ml hr b) With delta-9-tetrahydrocannabinol, 2 and 24 hr after dose. Mean AUC 255.1 +or- 128 ug/ml hr Dose 1 g/sq m, plus 25 mg/sq m doxorubicin once, and 50 mg/sq m etoposide daily for 5 days Range of means. Estimated from graph Cancer patients undergoing chemotherapy. CARCINOMAS; BLOOD PLASMA; DRUG INTERACTION; DRUG THERAPY; DRUGS; PSYCHOTROPIC DRUGS; CHEMOTHERAPY	Riggs, C.E. Jr. Egorin, M.J. Yuks, J.Z. Schnaper, N. Duffey, P. Colvin, O.M. Aisner, J. Wiernik, P.H. Bachur, N.R. 1981 Journal of Clinical Pharmacology 21:90S-98S

2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-
146-22-5
C15-H11-N3-O3
MW 281.26, MP 228-226 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5966 Blood, serum	Ingestion	GC Colorimetry	20	a) Not given b) Not given c) Not given d) Not given e) Not given	a) 41.5 +or- 12.8 ng/ml b) 112.8 +or- 40.2 ng/ml c) 120.9 +or- 32.7 ng/ml d) 150 +or- 35 ng/ml e) 180 +or- 7 ng/ml	a) Day 1 after 10 mg tablet previous evening b) Day 7, after 10 mg daily c) Day 14, after 10 mg daily d) 7-aminoazepam, metabolite, day 7 after 10 mg/day nitrazepam e) 7-aminoazepam, day 18 after 10 mg/day nitrazepam 20-25 yr old students Nitrazepam alone impaired attention, with alcohol was deleterious to psychomotor skills. BIOOT; BLOOD SERUM; FINLAND; DRUG INTERACTION; HYPNOTICS; DRUGS, COMPARATIVE EVALUATIONS	Saario, A. Linnoila, M. Maki, M. 1975 Journal of Clinical Pharmacology 15:52-59

2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro- (8 CI)
2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- (9 CI)
1622-61-3
C15-H10-Cl-N3-O3
MW 315.72, MP 236.5-238.5 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5967 Blood, plasma		GC	14	2.0-80 ng/ml	Not given	Patients on multiple anticonvulsant drugs CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; ANTICONVULSANTS; DRUG THERAPY; MEASUREMENT METHODS	Dhar, A.F. Kutt, H. 1981 Journal of Chromatography 222:203-211
5968 Urine	Ingestion	GC/MS	a) 6 b) 6	a) 18.6-32.0% b) 12.9-24.3%	a) 24.8 +or- 5.1% b) 18.0 +or- 4.2%	a) Subjects with rapid N-acetylation phenotype b) Subjects with slow N-acetylation phenotype % of dose recovered 96 hr after 2 mg preceeded by overnight fast Similar levels of unchanged drug in both Mean ratio % 7-amino clonazepam/% 7-acetamido clonazepam (metabolites), 15.8 in a) and 3.1 in b) Healthy 20-36 yr old caucasians, wt 59-81 kg ADULTS; URINE; ANTICONVULSANTS; DRUGS; GENETIC EFFECTS; METABOLISM; BENZODIAZEPINES	Miller, M.E. Garland, W.A. Min, B.H. Ludwick, P.T. Ballard, R.M. Levy, P.M. 1981 Clinical Pharmacology and Therapeutics 30(3):343-347

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-
439-14-5
C16-H13-Cl-N2-O
MW 284.76, MP 125-126 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5969 Blood, fetal						Review. Pharmacokinetics of fetal and neonatal exposure to drugs, suggestions for minimizing risks FETUS; NEWBORN; BLOOD; ANALGESICS; ANTIDEPRESSIVE AGENTS; DRUGS; REVIEW; PREGNANCY	Levy, G. 1981 Obstetrics and Gynecology 58(5):95-165
5970 Blood, plasma	Ingestion	GC-EC	108	a) 24-960 ng/ml b) 20-1624 ng/ml	a) 258 ng/ml b) 520 ng/ml Medians	a) Daily dose 15-40 mg b) Metabolite (nordiazepam) No correlation between daily dose and high plasma levels. High levels (> 900 ng/ml) were found in 20 subjects and low levels (< 250 ng/ml) in 35 subjects Neurosurgical patients BLOOD PLASMA; ANALGESICS; DRUG THERAPY; DRUGS; MUSCLE RELAXANTS; SEDATIVES; TRANQUILIZERS	Hollister, L.E. Conley, F.K. Britt, R.H. Shuer, L. 1981 Journal of the American Medical Association 246(14):1568-1570
5971 Blood, plasma	Ingestion	GC	6	a) 75-163 ng/ml b) 185-250 ng/ml	a) 138 +or- 33 ng/ml b) 194 +or- 52 ng/ml	a) 5 mg diazepam/day b) 5 mg diazepam/day plus 1000 mg cimetidine/day Minimal steady-state levels Cimetidine impaired hepatic elimination of diazepam Healthy, drug-free subjects, 23-27 yr old, wt 50-82 kg ADULTS; BLOOD PLASMA; DRUG INTERACTION; DRUG THERAPY; DRUGS; TRANQUILIZERS; DIAZEPAMS	Klotz, U. Reimann, I. 1981 Clinical Pharmacology and Therapeutics 30(4):513-517
5972 Blood, plasma	Ingestion	RIA Radioreceptor assay	a) 67 b) 74	a) 69.85-389.02 ng/ml b) 61.26-389.06 ng/ml	a) 164.6 ng/ml 134.01 ng/ml	a) Smokers b) Non-smokers Range wk 0 (before treatment) to wk 4 Mean during treatment (wk 1-4) Dose 15 mg/day 1st wk, 20 mg/day following 3 wk Relationships between clinical change, psychological change, cigarette smoking and plasma levels were not established. Outpatients with depression or anxiety, not psychotic or dependent on drugs or alcohol ADULTS; AGE; SEX; NEUROLOGIC MANIFESTATIONS; BLOOD PLASMA; ANTIDEPRESSIVE AGENTS; DRUG THERAPY; DRUGS; PSYCHOTROPIC DRUGS; TRANQUILIZERS; EXPERIMENTAL PSYCHOLOGY; SMOKING	Johnstone, E.C. Bourne, R.C. Crow, T.J. Frith, C.D. Gamble, S. Lofthouse, P. Owen, F. Owens, D.G.C. Robinson, J. Stevens, M. 1981 Psychopharmacology 72:233-240

(NEXT PAGE)

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-
439-14-5
C16-H13-Cl-N2-O
MW 284.74, MP 125-126 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5973 Blood, plasma	Ingestion	Enzymatic	1	a) 6477.5-375.5 ng/ml b) 597.6-245.9 ng/ml	a) Not applicable b) Not applicable	a) Arterial samples. 19.33 and 25.67 hr after suspected overdose b) Venous samples. 22.67 and 25.67 hr after overdose. Initial measurement 832.6 ng/ml at 19.33 hr Hemoperfusion started at 20 hr. Dose unknown. Phenobarbital also found in sample. 40 yr old Respiratory and cardiac arrest ADULTS; CASE HISTORIES; SUICIDE; BLOOD PLASMA; DRUG ABUSE; DRUGS; MEASUREMENT METHODS; METABOLITES	Midha, K.K. Charette, C. McGilveray, L.J. Webb, D. McLean, M.C. 1981 Clinical Toxicology 18(6):713-729

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-
1088-11-5
C15-H11-Cl-N2-O
MW 270.73

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5974 Blood, plasma		HPLC	10	270-1500 ng/ml	Not given	2 and 12 days after 50 mg/day diprotassium chlorazepate, 10 days, P.M. dose. Final measurement, 275 ng/ml, 4 y 10 Estimated from graph 18-37 yr old psychiatric patients, Sweden SWEDEN; ADULTS; BEHAVIOR DISORDERS; BLOOD SERUM; DRUG THERAPY; TRANQUILIZERS	Bertler, A. Lindgren, S. Malmgren, H. 1980 Psychopharmacology 71:165-167

3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-
76-99-3
C21-H27-N-O
MW 309.49

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5975 Blood, plasma	Ingestion	GC	a) 5 b) 5 c) 4 d) 5	a) Not given b) Not given c) Not given d) Not given	a) 0.201 +or- 0.038 ug/ml b) 0.095 +or- 0.024 ug/ml c) 0.104 +or- 0.030 ug/ml d) 0.138 +or- 0.017 ug/ml S.E.	a) Severe chronic liver disease, mean dose 66.0 +or- 11.77 mg/day. Dose adjusted level 0.0031 ug/ml/mg b) Moderate chronic liver disease, mean dose 88.0 +or- 9.7 mg/day. Dose adjusted level 0.0020 ug/ml/mg c) Mild chronic liver disease, mean dose 93.8 +or- 12.5 mg/day. Dose adjusted level 0.0023 ug/ml/mg d) Controls, mean dose 63.0 +or- 12.2 mg/day. Dose adjusted level 0.0024 ug/ml/mg No significant differences Cirrhosis, hepatitis, and cholestasis patients, New York NEW YORK; ADULTS; CIRRHOSIS; LIVER DISEASES; BLOOD PLASMA; DRUG THERAPY; DRUGS; NARCOTICS	Novick, D.M. Kreek, M.J. Panizza, A.M. Yancovitz, S.R. Gelb, A.M. Stenger, R.J. 1981 Clinical Pharmacology and Therapeutics 30(3):353-362

(NEXT PAGE)

3-Hep...one, 6-(dimethylamino)-4,4-diphenyl-
76-99-3
C21-H27-N-O
MW 309.49

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5976 Blood, plasma	Ingestion	GC	7	a) 0.033-0.433 ug/ml b) 0.040-0.200 ug/ml c) 0.045-0.305 ug/ml	a) 0.155 +or- 0.13 ug/ml b) 0.098 +or- 0.06 ug/ml c) 0.131 +or- 0.09 ug/ml	a) 24 hr after 45-65 mg given daily b) 24 hr after 45-65 mg given daily, plus disulfiram (500 mg Ayrest) daily c) 24 hr after 45-65 mg given daily, after discontinuation of disulfiram Trough levels 24-45 yr old outpatients in methadone maintenance program BLOOD PLASMA; DRUG INTERACTION; DRUG THERAPY; DRUGS; NARCOTICS	Tong, T.G. Benowitz, N.L. Kreek, M.J. 1980 Journal of Clinical Pharmacology 20(8-9):506-513

4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI)
4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)
72-44-6
C16-H14-N2-O
MW 250.29, MP 120 C, also given as 114-116 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5977 Blood, plasma	Ingestion	GC	1	a) 900-70 ng/ml b) 200-150 ng/ml	a) Not applicable b) Not applicable	a) 1 and 24 hr after 250 mg b) Metabolite, 2 and 24 hr after 250 mg methaqualone Estimated from graph BLOOD PLASMA; SALIVA; DRUGS; NARCOTICS; SEDATIVES; MEASUREMENT METHODS; METABOLITES	Peat, M.A. Finkle, B.S. 1980 Journal of Analytical Toxicology 4:114-118
5978 Blood, plasma	Ingestion	GC/MS	1	Not given	3 ug/ml	Dose unknown 25 yr old overdose victim Grade IV coma ADULTS; CASE HISTORIES; SUICIDE; BLOOD PLASMA; DRUG ABUSE; DRUGS; MEASUREMENT METHODS; METABOLITES	Widha, K.K. Charette, C. McGilveray, L.J. Webb, D. Mclean, M.C. 1981 Clinical Toxicology 18(6):713-729
5979 Saliva	Ingestion	GC	1	a) 180-40 ng/ml b) 150-50 ng/ml	a) Not applicable b) Not applicable	a) 1 and 24 after 250 mg b) Metabolite, 9 and 24 hr after 250 mg methaqualone Estimated from graph BLOOD PLASMA; SALIVA; DRUGS; NARCOTICS; SEDATIVES; MEASUREMENT METHODS; METABOLITES	Peat, M.A. Finkle, B.S. 1980 Journal of Analytical Toxicology 4:114-118

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-
34787-01-8
C15-H16-N2-O6-S2
MW 384.45

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5940 Blood, plasma	Injection		a) 6 b) 22 c) 8 d) 7	a) Not given b) Not given c) Not given d) Not given	a) 189 ug/ml b) 159 ug/ml c) 125 ug/ml d) 253 ug/ml	a) 0-7 day old infants, wt < 2000 g. Peaks, 1 hr after 76 mg/kg/8 hr, IV b) 0-7 day old infants, wt > 2000 g. Peaks, 1 hr after 78 mg/kg/8 hr, IV c) 1-8 wk old infants. Peaks, 1 hr after 101 mg/kg/8 hr, IV d) 5-13 yr old children. Peaks, 30 min after 99 mg/kg/6 hr, IV Clearance inversely correlated with age. Patients with chronic PSEUDOMONAS mastoiditis, Texas PSEUDOMONAS eradicated in majority of cases. DRUGS; ANTIBIOTICS; BLOOD PLASMA; INFECTION; NEWBORN; INFANTS; ADULTS; TEXAS; DRUG THERAPY	Nelson, J.D. Kusmiesz, H. Shelton, S. Woodman, E. 1970 Pediatrics 61(6):858-863

4,4'-Stilbenediol, alpha.,alpha'-diethyl-, (E)- (8 CI)
Phenol, 4,4'-(1,2-diethyl-1,2-ethanediyl)bis-, (E)- (9 CI)
56-53-1
C18-H20-O2
MW 269.34, MP 172 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5981 Urine		GP-EC	a) 5 b) 1 c) 3 d) 3	a) 9.7-37.8 ug/ml b) Not applicable c) 32.2-47.3 ug/ml d) <3.0-3.7 ug/ml	a) Not given b) 46.2 ug/ml c) Not given d) Not given	a) 17th day of exposure b) 39th day of exposure c) 47th day of exposure d) 6 days after plant shutdown 0-24 hr excretions Occupationally exposed 22-42 yr olds Tenderness and swelling of breast, with, in some, sexual impotence. ADULTS; INDUSTRIAL DISEASES; URINE; HORMONES; INDUSTRIAL MEDICINE; INDUSTRIAL AREAS; OCCUPATIONAL HAZARDS	Shaunes, F. Burton, D.J. 1981 Journal of Occupational Medicine 23(3):179-182

4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-
125-33-7
C12-H14-N2-O2
MW 218.25, MP 281-282 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5982 Blood, plasma		GC	5	6.1-12.0 ug/ml	Not given	Patients on multiple anticonvulsant drugs CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; ANTICONVULSANTS; DRUG THERAPY; MEASUREMENT METHODS	Dhar, A.K. Kutt, H. 1981 Journal of Chromatography 222:203-211

(NEXT PAGE)

4,6-[redacted]M)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-
125-[redacted]-7
C12-H14-N2-02
MW 218.25, MP 201-202 C

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5983 Blood, plasma		Enzymatic	22	6.8-15.0 ug/l	Not given	Mean saliva/plasma ratio, 0.85 +or- 0.02 (range 0.63-1.09), Correlation coefficient, 0.87. Levels in plasma and saliva correlate well. Saliva can be used for monitoring. BIOD PLASMA; SALIVA; ANALGESICS; ANTICONVULSANTS; ANTIPYRETICS; DIURETICS; DRUG THERAPY; DRUGS; HYPNOTICS; SEDATIVES; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Horning, M.G. Brown, I. Nowlin, J. Lertratanangkoon, K. Kellaway, P. Zion, T.E. 1977 Clinical Chemistry 23(2):157-164
5984 Saliva		Enzymatic	22	5.2-14.0 ug/l	Not given	Mean saliva/plasma ratio, 0.85 +or- 0.02 (range 0.63-1.09), Correlation coefficient, 0.87. Levels in plasma and saliva correlate well. Saliva can be used for monitoring. BIOD PLASMA; SALIVA; ANALGESICS; ANTICONVULSANTS; ANTIPYRETICS; DIURETICS; DRUG THERAPY; DRUGS; HYPNOTICS; SEDATIVES; COMPARATIVE EVALUATIONS; MEASUREMENT METHODS	Horning, M.G. Brown, I. Nowlin, J. Lertratanangkoon, K. Kellaway, P. Zion, T.E. 1977 Clinical Chemistry 23(2):157-164

4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI)
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5aba,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)
1[illegible]-77-8
C18-H28-N2-07
MW 332.35, MP 184-194 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5985 Blood, serum	Injection	Microbiological	a) [illegible] b) 1 c) 2 d) 2	a) 140-59 ug/ml b) 140-20 ug/ml c) 190-9 ug/ml d) 175-4 ug/ml	a) Not given b) Not given c) Not given d) Not given	a) Creatinine clearance <7.0 ml/min/1.73 sq m b) Creatinine clearance 21 ml/min/1.73 sq m c) Creatinine clearance 80-84 ml/min/1.73 sq m d) Creatinine clearance >100 ml/min/1.73 sq m (controls) Initial measurements and 8 hr (d) or 24 hr (a-c) after 30 min IV of 2 g as hydrochloride Volunteers, 19-58 yr old, with normal and insufficient renal function KIDNEY DISEASES; BLOOD SERUM; URINE; ANTIBIOTICS; DRUGS	Kusumi, K. Metzler, C. Pass, K. 1981 Chemotherapy 27:95-98
5986 Urine	Injection	Microbiological	a) 2 b) 1 c) 2 d) 2	a) 6-34* b) 62* c) 65-91* d) 40-83*	a) Not given b) Not given c) Not given d) Not given	a) Creatinine clearance 2.4-6.9 ml/min/1.73 sq m b) Creatinine clearance 20.8 ml/min/1.73 sq m c) Creatinine clearance 40.2-83.9 ml/min/1.73 sq m d) Creatinine clearance 102.0-108.7 ml/min/1.73 sq m * of dose, 0-24 hr after 30 min infusion of 2 g as hydrochloride Volunteers, 19-58 yr old with normal and insufficient renal function KIDNEY DISEASES; BLOOD SERUM; URINE; ANTIBIOTICS; DRUGS	Kusumi, K. Metzler, C. Pass, K. 1981 Chemotherapy 27:95-98

5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-
59729-33-8
C20-H21-F-N2-O
MW 324.42

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5987 Blood, plasma	Injection Ingestion		a) 5 b) 7 c) 7 d) 4	a) 480-40 nmol b) 320-190 nmol c) 200-180 nmol d) 395-35 nmol	a) Not given b) 253 + or-51 nmol c) Not given d) Not given	a) 2 and 32 hr after 50 mg, oral b) 2-4 and 24 hr, steady state, after 50 mg/day for 18 days. Range of means c) As in (b), citalopram metabolite d) 1-2 and 72 hr after 50 mg, IV infusion Healthy 23-34 yr olds ADULTS; BLOOD PLASMA; URINE; ANTIDEPRESSIVE AGENTS; DRUGS; COMPARATIVE EVALUATIONS; METABOLITES	Krauh-Sorensen, P. Overo, K.F. Petersen, O.I. Jensen, K. Parnas, H. 1981 Acta Pharmacologica et Toxicologica 48:53-60
5988 Urine	Ingestion	HPLC	7	Not given	13% of dose	Output during steady state dose interval with 50 mg/day Healthy 23-38 yr olds ADULTS; BLOOD PLASMA; URINE; ANTIDEPRESSIVE AGENTS; DRUGS; COMPARATIVE EVALUATIONS; METABOLITES	Krauh-Sorensen, P. Overo, K.F. Petersen, O.I. Jensen, K. Parnas, H. 1981 Acta Pharmacologica et Toxicologica 48:53-60

5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-
64952-97-2
C20-H20-N6-O9-S
MW 520.52

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5989 Blood, plasma	Injection	Microbiological	a) 6 b) 4	a) 110-35 ug/l b) 150-10 ug/l	a) Not given b) Not given	a) Initial measurement and 4 hr after 1 g dose, during hemodialysis b) Initial measurement and 48 hr after 1 g dose, during interdialytic period Anephric adults, 46-65 yr old, 61.3-95.0 kg. ADULTS; KIDNEY DISEASES; BLOOD PLASMA; ANTIBIOTICS; HEMODIALYSIS	Aronoff, G.R. Sloar, R.S. Mong, S.A. Luft, F.C. Kleit, S.A. 1981 Antimicrobial Agents and Chemotherapy 19(4):575-577
5990 Blood, serum	Injection	Microbiological	8	a) 65-28 ug/ml b) 66-30.3 ug/ml	a) Not given b) Not given	a) 0.25 and 4.5 hr after 1 g IV, during dialysis b) 1 and 28 hr after 1 g IV, between dialyses Patients with end stage renal diseases BLOOD SERUM; ANTIBIOTICS; DRUG THERAPY; DRUGS	Srinivasin, S. Neu, H.C. 1981 Antimicrobial Agents and Chemotherapy 20(3):398-400

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, (6R-cis)-
35607-66-0
C16-H17-N3-O7-S2
MW 427.46, MP 149-150 C (decomp)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5991 Blister fluid	Injection	Microbiological GC	6	a) 80-9 ug/ml b) 50-7 ug/ml	a) Not given b) Not given	a) 2 and 10 hr after 2.05 g IV bolus. Probenecid given 7 or more days before b) 2 and 6 hr after 2.05 g IV bolus. No probenecid pretreatment Blisters produced by topical cantharides Range of means Estimated from graph Healthy 20-49 yr olds, mean wt 69.8 kg BLOOD SERUM; URINE; ANTIBIOTICS; DRUG INTERACTION; DRUGS	Reeves, D.S. Bullock, D.W. Bywater, M.J. Holt, M.A. White, L.O. Thornhill, D.P. 1981 British Journal of Clinical Pharmacology 11:353-359
5992 Blood, plasma	Injection	HPLC	6	a) 140-5 mg/l b) 70-2 mg/l c) 130-12 mg/l d) 95-3 mg/l	a) Not given b) Not given c) Not given d) Not given	a) 0 and 6 hr after first dose of 2 g/6 hr b) 0 and 6 hr after ninth dose of 2 g/6 hr c) 0 and 6 hr after first dose of 2 g/6 hr, plus 1 g probenecid d) 0 and 8 hr after ninth dose of 2 g/6 hr, plus 0.5 g probenecid Several other patients had drug accumulation (20-50 mg/l after the ninth dose). Colo-rectal surgery patients BLOOD PLASMA; ANTIBIOTICS; DRUG INTERACTION; DRUG THERAPY; DRUGS	Arvidsson, A. Borga, O. Fager, L. Pieper, P. 1981 Journal of Antimicrobial Chemotherapy 7:423-430
5993 Blood, serum	Injection	Microbiological GC	6	a) 200-15 ug/ml b) 180-8 ug/ml	a) Not given b) Not given	a) 15 min and 6 hr after 2.05 g IV bolus. Probenecid given at least 7 days before b) 15 min and 8 hr after 2.05 g IV bolus. No probenecid pretreatment Range of means Estimated from graph Healthy 20-49 yr olds, mean wt 69.8 kg BLOOD SERUM; URINE; ANTIBIOTICS; DRUG INTERACTION; DRUGS	Reeves, D.S. Bullock, D.W. Bywater, M.J. Holt, M.A. White, L.O. Thornhill, D.P. 1981 British Journal of Clinical Pharmacology 11:353-359
5994 Urine	Injection	Microbiological GC	6	a) 83-101% of dose b) 60-96% of dose	a) Not given b) Not given	a) 2 and 12 hr cumulative output, without probenecid b) 2 and 12 hr cumulative output. Probenecid given 7 or more days before Range of means Estimated from graph Healthy 20-49 yr olds, mean wt 69.8 kg BLOOD SERUM; URINE; ANTIBIOTICS; DRUG INTERACTION; DRUGS	Reeves, D.S. Bullock, D.W. Bywater, M.J. Holt, M.A. White, L.O. Thornhill, D.P. 1981 British Journal of Clinical Pharmacology 11:353-359

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))-
53994-73-3
C15-H14-Cl-N3-O4-S
MW 367.83

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5995 Blood	Ingestion	Agar diffusion	a) 5 b) 5	a) 0.26-1.70 ug/ml b) 2.60-5.00 ug/ml	a) 0.86 +or- 0.65 ug/ml b) 1.87 +or- 1.81 ug/ml	a) After 250 mg, 2 and 8 hr before surgery. 4 had received additional 1-16 250 mg doses every 8 hr prior to surgery b) After 500 mg, 2 and 8 hr before surgery Prostate/plasma ratio 0.7 Prostatectomy patients, mean age 71.4 yr (range 61-80), mean wt 67.4 kg (range 50-83 kg). PHARMACOKINETICS; BLOOD; PROSTATE; ANTIBIOTICS; DRUG THERAPY; SURGERY; ADULTS; INFECTION; DRUGS	Smith, R.P. Schmid, G.P. Baltch, A.L. Sutphen, W.T. Hammer, M.C. 1981 American Journal of the Medical Sciences 28(1):19-24
5996 Prostate	Ingestion	Agar diffusion	a) 5 b) 5	a) 0.27-0.65 ug/g b) 0.24-1.94 ug/g	a) 0.51 +or- 0.22 ug/g b) 0.78 +or- 0.67 ug/g	a) After 250 mg, 2 and 8 hr before surgery. 4 had received additional 1-16 250 mg doses every 8 hr prior to surgery b) After 500 mg, 2 and 8 hr before surgery Prostate/plasma ratio 0.7 Prostatectomy patients, mean age 71.4 yr (range 61-80), mean wt 67.4 kg (range 50-83 kg). PHARMACOKINETICS; BLOOD; PROSTATE; ANTIBIOTICS; DRUG THERAPY; SURGERY; ADULTS; INFECTION; DRUGS	Smith, R.P. Schmid, G.P. Baltch, A.L. Sutphen, W.T. Hammer, M.C. 1981 American Journal of the Medical Sciences 28(1):19-24

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI)
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)
15686-71-2
C16-H17-N3-O4-S
MW 347.4

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5997 Blood, serum	Ingestion	Microbiological	a) 10 b) 10 c) 10	a) Not given b) 14.2-128.8 ug/ml c) 11.2-59.1 ug/ml d) 25.2-83.2 ug/ml	a) 12.0 +or- 0.8 ug/ml b) Not given c) Not given d) 41.2 ug/ml	a) 2 hr peak after 500 mg dose, controls b) Theoretical initial level, patients with impaired renal function, single 500 mg dose c) Theoretical initial level, patients on hemodialysis, single 500 mg dose d) Theoretical initial concentration in controls, 500 mg dose (Regression lines from plotting logarithmic values of serum levels against time yield theoretical initial levels.) Normal subjects. Patients with renal impairment or on maintenance hemodialysis. FRANCE; ADULTS; KIDNEY DISEASES; BLOOD; BLOOD SERUM; KIDNEYS; URINE; ANTIBIOTICS; HEMODIALYSIS	Brogard, J.M. Pinget, M. Dorner, M. Lavillaureix, J. 1975 Journal of Clinical Pharmacology 15:666-673

(NEXT PAGE)

5-T[illegible]-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI)
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)
15686-71-2
C16-H17-N3-O4-S
MW 347.8

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5998 Urine	Ingestion	Microbiological	10	Not given	64% of dose	Dose, 500 mg. 0-6 hr excretions Normal subjects FRANCE; ADULTS; KIDNEY DISEASES; BLOOD; BLOOD SERUM; KIDNEYS; URINE; ANTIBIOTICS; HEMODIALYSIS	Brogard, J.M. Pinget, M. Dorner, M. Lavillaureix, J. 1975 Journal of Clinical Pharmacology 15:666-673

5H-Dibenz(b,f)azepine-5-carboxamide
298-46-4
C15-H12-N2-O
MW 236.26, MP 204-206 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
5999 Blood, plasma		GC	6	6.0-14.2 ug/ml	Not given	Patients on multiple anticonvulsant drugs CENTRAL NERVOUS SYSTEM DISEASES; BLOOD PLASMA; ANTICONVULSANTS; DRUG THERAPY; MEASUREMENT METHODS	Dhar, A.K. Kutt, H. 1981 Journal of Chromatography 222:203-211

5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8 CI)
5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- (9 CI)
303-49-1
C19-H23-Cl-N2
MW 314.87, BP 160-170 C at 0.3 mm Hg

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
6000 Blood, plasma	Ingestion	GC/MS	1	113.1-20.6 ng/ml	Not given	7 and 108 hr after suspected drug overdose ingestion. Metabolite, N-desmethyl clomipramine also found. Dose unknown. Amitriptyline and maprotiline present. 43 yr old overdose victim Loss of consciousness, respiratory depression. Organic brain syndrome ADULTS; CASE HISTORIES; SUICIDE; BLOOD PLASMA; DRUG ABUSE; DRUGS; MEASUREMENT METHODS; METABOLITES	Midha, K.K. Charette, C. McGilveray, I.J. Webb, D. McLean, M.C. 1981 Clinical Toxicology 18(6):713-729

5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI)
1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)
50-48-6
C20-H23-N
MW 277.39, MP Hydrochloride 196-197 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
6001 Blood			1	a) Not applicable b) Not applicable	a) 950 ug/l b) 157 ug/l	a) Amitriptyline b) Nortriptyline Dose unknown, nonaccidental poisoning 2 mo old CNS depression, dilated pupils, dry mucous membranes, no bowel sounds, bowel dilation, urinary retention, and tachycardia. CASE HISTORIES; INFANTS; BLOOD; DRUGS; METABOLITES	Simon, F.A. Treuting, J.J. 1981 Clinical Toxicology 18(1):37-40
6002 Blood, plasma	Ingestion	RIA	a) 67 b) 74	a) Not given b) Not given	a) 124.08 ng/ml b) 142.89 ng/ml	a) Smokers b) Non-smokers Mean during treatment (wk 1-8) Dose, 100 mg/day 1st wk, 150 mg/day following 3 wk Relationships between clinical change, psychological change, cigarette smoking and plasma levels were not established Outpatients with depression or anxiety, not psychotic or dependent on drugs or alcohol ADULTS; AGE; SEX; NEUROLOGIC MANIFESTATIONS; BLOOD PLASMA; ANTIDEPRESSIVE AGENTS; DRUG THERAPY; DRUGS; PSYCHOTROPIC DRUGS; TRANQUILIZERS; EXPERIMENTAL PSYCHOLOGY; SMOKING	Johnstone, E.C. Bourne, R.C. Crow, T.J. Frith, C.D. Gamble, S. Lofthouse, R. Owen, F. Owens, D.G.C. Robinson, J. Stevens, M. 1981 Psychopharmacology 72:233-240
6003 Blood, plasma	Ingestion	GC/MS	1	a) 566.9-60.5 ng/ml b) 81.5-53.9 ng/ml	a) Not applicable b) Not applicable	a) 7 and 188 hr after suspected overdose ingestion b) 7 and 16 hr after suspected overdose ingestion. Final measurement 74.8 ng/ml at 188 hr. Metabolite (nortriptyline) Clomipramine and maprotiline also found 53 yr old overdose victim Loss of consciousness, respiratory depression. Organic brain syndrome ADULTS; CASE HISTORIES; SUICIDE; BLOOD PLASMA; DRUG ABUSE; DRUGS; MEASUREMENT METHODS; METABOLITES	Midha, K.K. Charette, C. McGilveray, L.J. Webb, D. McLean, M.C. 1981 Clinical Toxicology 18(6):713-729

5H-2,[illegible]benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-
22385-47-7
C22-H26-N2-O4
MW 382.5, MP approx 152 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
6004 Blood, serum	Ingestion	HPLC	9	a) < 30-257 ng/ml b) 24-263 ng/ml c) 0-99 ng/ml	a) 89 +or- 71 ng/ml b) 112 +or- 80 ng/ml c) 50 +or- 27 ng/ml	a) 0.5 hr b) 1 hr c) 2 hr Times after dose of 100 mg Healthy volunteers DRUGS; TRANQUILIZERS; BLOOD SERUM; HUNGARY; MEASUREMENT METHODS	Saigo, M. Gesztesi, A. Sido, T. 1981 Journal of Chromatography 222:303-307

6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-(8 CI)
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- (9 CI)
17560-51-9
C16-H16-Cl-N3-O3-S
MW 365.84, MP 253-259 C (also reported as 246-250 C)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
6005 Blood, plasma	Injection Ingestion	HPLC	1	a) 50-1 ng/ml b) 255-1 ng/ml	a) Not applicable b) Not applicable	a) 2 and 48 hr after 5 mg oral dose. Initial measurement 13 ng/ml b) 1 and 48 hr after 5 mg, IV ADULTS; BLOOD PLASMA; URINE; DIURETICS; DRUGS; MEASUREMENT METHODS	Vose, C.W. Muirhead, D.C. Evans, G.L. Stevens, P.M. Burford, S.R. 1981 Journal of Chromatography 222:311-315
6006 Urine	Injection Ingestion	HPLC	1	a) Not applicable b) Not applicable	a) 75% of dose b) 85% of dose	a) Total 48 hr output after 5 mg oral dose b) Total 48 hr output after 5 mg, IV ADULTS; BLOOD PLASMA; URINE; DIURETICS; DRUGS; MEASUREMENT METHODS	Vose, C.W. Muirhead, D.C. Evans, G.L. Stevens, P.M. Burford, S.R. 1981 Journal of Chromatography 222:311-315

6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-
1972-08-3
C21-H30-O2
MW 314.45

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
6007 Blood, plasma	Injection Ingestion Inhalation	GC/MS	11	a) 220-3 ng/ml b) 77-2 ng/ml c) 6-1.7 ng/ml	a) Not given b) Not given c) Not given	a) Initial measurement and 4 hr after 5 mg IV b) Initial measurement and 4 hr after smoking 11.6-15.6 mg c) 1 and 6 hr after 20 mg, oral. Initial measurement 3 ng/ml at 30 min Range of means, estimated from graph. Healthy 18-35 yr old users of marihuana Levels above 5 ng/ml produced reddened conjunctivae. Increased pulse rate BLOOD PLASMA; DRUGS; PSYCHOTROPIC DRUGS	Ohlsson, A. Lingren, J.E. Wahlen, A. Agurell, S. Hollister, L.E. Gillespie, H.K. 1980 Clinical Pharmacology and Therapeutics 28(3):409-416

(NEXT PAGE)

6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,1(a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-
1972-08-3
C21-H30-02
MW 310.45

(CONTINUED)

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
6008 Blood, plasma	Ingestion	RIA	7	a) Not given b) Not given c) Not given d) Not given	a) 57 +or- 64 ng/ml b) 2 +or- 1 ng/ml c) 107 +or- 126 ng/ml d) 4 +or- 2 ng/ml	a) Average of 6 samples from each of 6 subjects. Samples taken 2 hr after 10 mg/sq m dose/4 hr b) Control for a) c) Mean peaks, 6 subjects. Samples taken 2 hr after 10 mg/sq m/4 hr d) Control for c) No apparent change in pharmacokinetics of cyclophosphamide or doxorubicin administered concurrently Cancer patients undergoing chemotherapy CARCINOMAS; BLOOD PLASMA; DRUG INTERACTION; DRUG THERAPY; DRUGS; PSYCHOTROPIC DRUGS; CHEMOTHERAPY	Biggs, C.E. Jr. Fgorin, M.J. Fuks, Z.Y. Schnaper, N. Duffey, P. Colvin, C.M. Aisner, J. Wiernik, P.H. Wachur, N.R. 1981 Journal of Clinical Pharmacology 21:90S-98S

8-Quinolinol, 5-nitro
4008-48-8
C9-H6-N2-03
MW 190.15, mp 179.5-181.5 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
6009 Blood, plasma	Ingestion	HPLC	a) 1 b) 1 c) 1	a) 5.2-0 ug/ml b) 6.0-0 ug/ml c) 3.6-0 ug/ml	a) Not applicable b) Not applicable c) Not applicable	a) 1 and 12 hr b) 2 and 12 hr c) 3 and 12 hr After 100 mg dose BLOOD PLASMA; URINE; ANTIBIOTICS; DRUGS; MEASUREMENT METHODS	Sorel, P.H.A. Snelleman, C. Hulshoff, A. 1981 Journal of Chromatography 222:241-248
6010 Urine	Ingestion	HPLC	a) 1 b) 1 c) 1	a) Not applicable b) Not applicable c) Not applicable	a) 1.2% b) 0.3% c) 0.3% d) 23.3% e) 41.1% f) 24.1%	a) Subject 1, free nitroxoline b) Subject 2, free nitroxoline c) Subject 3, free nitroxoline d) Subject 1, conjugated nitroxcline e) Subject 2, conjugated nitroxoline f) Subject 3, conjugated nitroxoline 12 hr recovery of 100 mg dose BLOOD PLASMA; URINE; ANTIBIOTICS; DRUGS; MEASUREMENT METHODS	Sorel, P.H.A. Snelleman, C. Hulshoff, A. 1981 Journal of Chromatography 222:241-248

9,h anoanthracene-9(10H)-propylamine, N-methyl- (8 CI)
9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl- (9 CI)
10262-69-8
C20-H23-N
MW 277.41, MP 92-94 C

TISSUE	EXPOSURE ROUTE	ANALYTICAL METHOD	NUMBER OF CASES	RANGE	MEAN	GENERAL INFORMATION	REFERENCE
6011 Blood, plasma	Ingestion	GC/MS	a) 1 b) 1	a) 224.1-63.0 ng/ml b) 450-30 ng/ml	a) Not applicable b) Not applicable	a) 7 and 188 hr after suspected overdose ingestion. Dose unknown b) 40 hr and 13 days after suspected overdose. Hemoperfusion, from 40 to 48 hr, reduced level to 300 ng/ml, returned to >400 ng/ml by day 3. Dose unknown. Amitriptyline and clomipramine also found 53 yr old woman and 67 yr old man Loss of consciousness, respiratory depression. Organic brain syndrome ADULTS; CASE HISTORIES; SUICIDE; BLOOD PLASMA; DRUG ABUSE; DRUGS; MEASUREMENT METHODS; METABOLITES	Midha, K.K. Charette, C. McGilveray, L.J. Webb, D. McLean, M.C. 1981 Clinical Toxicology 18(6):713-729

REFERENCES FOR DATA BASE

(Vol. IV)

Ackerman, L.
1980
Humans: Overview of Human Exposure to Dieldrin Residues in the Environment and Current Trends of Residue Levels in Tissue
Pesticides Monitoring Journal 14(2):68-69

Adams, V.E.; Brown, S.S.; Sunderman, F.W., Jr.; Zachariasen, H.
1978
Interlaboratory Comparisons of Nickel Analysis in Urine by Atomic Absorption Spectrometry
Clinical Chemistry 24(8):862-867

Alder, J.F.; Samuel, A.J.; West, T.S.
1977
The Anatomical and Longitudinal Variation of Trace Element Concentration in Human Hair
Analytica Chimica Acta 92:217-221

Alessio, L.; Castoldi, M.P.; Odone, P.; Franchini, I.
1981
Behaviour of Indicators of Exposure and Effect after Cessation of Occupational Exposure to Lead
British Journal of Industrial Medicine 38: 262-267

Alexander, F.W.; Delves, H.T.
1981
Blood Lead Levels During Pregnancy
International Archives of Occupational and Environmental Health 48:35-39

Amon, I.; Amon, K.; Franke, G.; Mohr, C.
1981
Pharmacokinetics of Metronidazole in Pregnant Women
Chemotherapy 27:73-79

Amos, P.G.; Amos, F.B., Jr.; Thompson, J.C., Jr.
1978
Biological Effects of Environmental Pollutants: Review and Status of Lead and CO Contamination
NSF-RA-E-78-467, 83 pp.

Andreasen, F.; Christensen, C.K.; Jakobsen, P.K.; Mogensen, C.E.
1981
The Use of HPLC to Elucidate the Metabolism and Urinary Excretion of Furosemide and its Metabolic Products
Acta Pharmacologica et Toxicologica 49:223-229

Anon
1975
Lead Exposure and Its Significance
Food and Cosmetics Toxicology 13:277-282

1977a
Breastfed Babies at Risk in Heavy Pesticide Use Areas, Survey Shows
Pesticide & Toxic Chemical News 5(8):10-11

1977b
EPA Finds PBB in Human Hair in New Jersey: Manufacturing Ban May be Imposed
Pesticide & Toxic Chemical News 5(30):9-10

1977c
PCBs and Child Bearing
Pollution 7(1):6

Aronoff, G.R.; Sloan, R.S.; Mong, S.A.; Luft, F.C.; Kleit, S.A.
1981
Moxalactam Pharmacokinetics During Hemodialysis
Antimicrobial Agents and Chemotherapy 19(4):575-577

Arvidsson, A.; Borga, O.; Hager, L.; Pieper, P.
1981
Renal Elimination of Cefoxitin and Effect of Probenecid After Single and Repeated Doses
Journal of Antimicrobial Chemotherapy 7:423-430

Babb, J.; Bishop, M.; Schneider, R.E.; Hawkins, C.F.; Moore, A.M.
1976
Plasma Propranolol Levels in Inflammatory Disease
Lancet 1(7978):1413

Barends, D.M.; Zwaan, C.L.; Mulshoff, A.
1981
Improved Microdeterminations of Gentamicin and Sisomicin in Serum by High-Performance Liquid Chromatography with Ultraviolet Detection
Journal of Chromatography 222:316-323

Barltrop, D.; Thorton, I.; Strehlow, C.D.; Webb, J.S.
1975
Absorption of Lead from Dust and Soil
Postgraduate Medical Journal 51:801-804

Barry, P.S.I.
1981
Concentrations of Lead in the Tissues of Children
British Journal of Industrial Medicine 38:61-71

Barry, P.S.I.; Connolly, R.
1981
Lead Concentrations in Mediaeval Bones
International Archives of Occupational and Environmental Health 48:173-177

Bastos, M.L.; Galante, I.
1976
Toxicological Findings in Victims of Traumatic Deaths
Journal of Forensic Sciences 21(1):176-186

Bell, A.
1981
Blood Lead Levels of Some Children in New South Wales
Medical Journal of Australia 1:23-26

Belz, G.G.; Aust, E.E.; Munkes, R.
1981
Digoxin Plasma Concentrations and Nifedipine
Lancet 1(8224):844-845

Ben-Zvi, Z.; Kattan, M.; Adam, M.
1981
Problems of Oral Therapy with Theophylline
New England Journal of Medicine 304(10):613

Bennett, B.G.
1981
Exposure of Man to Environmental Arsenic - An Exposure Commitment Assessment
Science of the Total Environment 20:99-107

Bentley, D.P.; Jacobs, A.
1975
Accumulation of Storage Iron in Patients Treated for Iron-deficiency Anaemia
British Medical Journal 2(5962):64-66

Benvenuto, J.A.; Stewart, D.J.; Benjamin, R.S.; Loo, T.L.
1981
Pharmacology of Pentamethylmelamine in Humans
Cancer Research 41:566-569

Berild, D.; Hasselbalch, H.
1981
Survival After a Blood Alcohol of 1127 mg/dl
Lancet 2(8242):363

Bertler, A.; Lindgren, S.; Malmgren, R.
1980
Pharmacokinetics of Dipotassium Chlorazepate in Patients after Repeated 50 mg Oral Doses
Psychopharmacology 71:165-167

Bierre, A.B.; Gordon, A.S.D.; Pybus, J.; Lines, D.B.
1977
Mercury Levels in Residents of a Geothermal Area in the Central North Island
New Zealand Medical Journal 851(589):464-466

Bignon, J.; Sebastien, P.; Gaudichet, A.; Jaurand, M.C.
1980
Biological Effects of Attapulgite
Biological Effects of Mineral Fibres, Vol. 1, J.C. Wagner. Lyon, France; IARC Scientific Publications No. 30, pp.163-181

Bitzen, P.-O.; Gustafsson, B.; Jostell, K.G.; Melander, A.; Wahlin-Boll, E.
1981
Excretion of Paracetamol in Human Breast Milk
European Journal of Clinical Pharmacology 20:123-125

Bjorn-Rasmussen, E.; Hallberg, L.; Magnusson, B.; Rossander, L.; Suanberg, B.; Arvidsson, B.
1976
Measurement of Iron Absorption from Composite Meals
American Journal of Clinical Nutrition 29:772-778

Black, J.G.; Howes, T.; Rutherford, T.
1975
Skin Deposition and Penetration of Trichlorocarbanilide
Toxicology 3:253-264

Bondesson, U.; Hartig, P.; Danielsson, B.
1981
Quantitative Determination of the Urinary Excretion of Ketobemidone and Four of its Metabolites after Intravenous and Oral Administration in Man
Drug Metabolism and Deposition 9(4):376-380

Bottermann, P.; Gyarfas, M.; Wahl, K.; Erxler, R.; Lebender, A.
1981
Verhalten der Insulinkonzentration in Peripher-venosen Blut nach Intraperitonealer Bolusgabe von Insulin
Klinische Wochenschrift 59:157-163

Bowering, J.; Sanchez, A.M.; Irwin, M.I.
1976
A Conspectus of Research on Iron Requirements of Man
Journal of Nutrition 106(7):985-1074

Box, V.; Cherry, N.; Waldron, H.A.; Dattani, J.; Griffiths, K.D.; Hill, F.G.H.
1981
Plasma Vitamin D and Blood Lead Concentrations in Asian Children
Lancet 2(8242):373

Brash, A.R.; Hickey, D.E.; Graham, T.P.; Stahlman, M.T.; Oates, J.A.; Cotton, E.B.
1981
Pharmacokinetics of Indomethacin in the Neonate: Relation of Plasma Indomethacin Levels to Response of the Ductus Arteriosus
New England Journal of Medicine 305:67-72

Brockhaus, A.; Dolgner, R.; Ewers, U.; Kramer, U.; Soddemann, H.; Wiegand, H.
1981
Intake and Health Effects of Thallium Among a Population Living in the Vicinity of a Cement Plant Emitting Thallium Containing Dust
International Archives of Occupational and Environmental Health 48:375-389

Brogard, J.M.; Pinget, M.; Dorner, M.; Lavillaureix, J.
1975
Determination of Cefalexin Pharmacokinetics and Dosage Adjustments in Relation to Renal Function
Journal of Clinical Pharmacology 15:666-673

Brudevold, F.; Aasenden, R.; Srinivasian, B.N.; Bakhos, Y.
1977
Lead in Enamel and Saliva, Dental Caries and the Use of Enamel Biopsies for Measuring Past Exposure to Lead
Journal of Dental Research 56(10):1165-1171

Brunekreef, B.; Veenstra, S.J.; Biersteker, K.; Boleij, J.S.M.
1981
The Arnhem Lead Study 1. Lead Uptake by 1- to 3-year-Old Children Living in the Vicinity of a Secondary Lead Smelter in Arnhem, The Netherlands
Environmental Research 25:441-448

Bryce-Smith, D.; Mathews, J.; Stephens, R.
1978
Mental Health Effects of Lead on Children
Ambio 7(5-6):193-203

Buchet, J.P.; Lauwerys, R.; Roels, H.
1981
Urinary Excretion of Inorganic Arsenic and Its Metabolites After Repeated Ingestion of Sodium Metaarsenite by Volunteers
International Archives of Occupational and Environmental Health 48:111-118

Buchet, J.P.; Roels, H.; Bernard, A.; Lauwerys, R.
1980
Assessment of Renal Function of Workers Exposed to Inorganic Lead, Cadmium or Mercury Vapor
Journal of Occupational Medicine 22(11):741-750

Byard, J.L.; McChesney, E.W.; Golberg, L.; Coulston, F.
1978
Excretion and Metabolism of Saccharin in Man: Studies with C-Labeled and Unlabelled Saccharin
Food and Cosmetics Toxicology 12:175-184

Caddell, J.L.; Saier, E.L.; Thomason, C.A.
1975
Parenteral Magnesium Load Tests in Postpartum American Women
American Journal of Clinical Nutrition 28(10):1099-1103

Carpenter, R.C.
1981
The Determination of Cadmium, Copper, Lead and Thallium in Human Liver and Kidney Tissue by Flame Atomic Absorption Spectrometry after Enzymatic Digestion
Analytica Chimica Acta 125:209-213

Carter, P.
1975
Application of Selective Demasking to the Spectrophotometric Assay of Erythrocyte Zinc
Biochemical Medicine 14:378-383

Casey, C.E.; Walravens, P.A.; Hambidge, K.M.
1981
Availability of Zinc: Loading Tests with Human Milk, Cow's Milk and Infant Formulas
Pediatrics 68(3):394-396

Cavalleri, A.; Baruffini, A.; Minoia, C.; Bianco, L.
1981
Biological Response of Children to Low Levels of Inorganic Lead
Environmental Research 25:415-423

Chang, C.C.; Lauwerys, R.; Bernard, A.; Roels, H.; Buchet, J.P.; Garvey, J.S.
1980
Metallothionein in Cadmium-Exposed Workers
Environmental Research 23:422-428

Charlebois, C.T.
1978
High Mercury Levels in Indians and Inuits (Eskimos) in Canada
Ambio 7(5-6):204-210

Charles, B.G.; Jacobsen, N.W.; Ravenscroft, P.J.
1981
Rapid Liquid-Chromatographic Determination of Metformin in Plasma and Urine
Clinical Chemistry 27(3):434-436

Chilcote, R.; Curley, A.; Loughlin, M.H.; Jupin, J.A.
1977
Hexachlorophene Storage in a Burn Patient Associated with Encephalopathy
Pediatrics 59(3):457-459

Ching, M.P.H.; Jhaa, G.N.; Subbarayan, C.; Bowen, D.V.; Smit, A.L.C. Jr.; Grossi, C.E.; Hicks, R.G.; Field, F.H.; Nealon, T.F. Jr.
1981
Gas Chromatographic-Mass Spectrometric Detection of Circulating Plasticizers in Surgical Patients
Journal of Chromatography 222:171-177

Chisolm, J.J.; Barrett, M.B.; Mellits, E.D.
1975
Dose-Effect and Dose-Response Relationships for Lead in Children
Journal of Pediatrics 87(6):1152-1160

Chisolm, J.J., Jr.
1977
Is Lead Poisoning Still a Problem?
Clinical Chemistry 23(2):252-255

Chisolm, J.J., Jr.; Curran, A.S.; Finburg, L.; Hopkins, D.R.; Lin-Fu, J.S.; Piomelli, S.; Reigart, J.R.
1975
Increased Lead Absorption and Lead Poisoning in Young Children
Journal of Pediatrics 87(5):828-830

Christopoulos, G.N.; Kirch, E.P.
1978
Estimation of Fluoroalkane Propellants
Journal of Forensic Sciences 19(1):168-171

Churg, A.; Warnock, M.L.
1977
Correlation of Quantitative Asbestos Body Counts and Occupation in Urban Patients
Archives of Pathological and Laboratory Medicine 101:629-634

Colburn, W.A.; Bekersky, I.; Blumenthal, H.P.
1981
A Preliminary Report on the Pharmacokinetics of Saccharin in Man: Single Oral Dose Administration
Journal of Clinical Pharmacology 21:147-151

Cook, J.D.; Monsen, E.R.
1976a
Food Iron Absorption in Human Subjects. III. Comparison of the Effect of Animal Proteins on Nonheme Iron Absorption
American Journal of Clinical Nutrition 29:859-867

1976b
Food Iron Absorption in Man II. The Effect of EDTA on Absorption of Dietary Non-Heme Iron
American Journal of Clinical Nutrition 29:618-620

Cooper, S.F.; Lapierre, Y.D.
1981
Gas-Liquid Chromatographic Determination of Pipotiazine in Plasma of Psychiatric Patients
Journal of Chromatography 222:291-296

Cooper, T.B.; Bost, R.; Sunshine, I.
1981
Postmortem Blood and Tissue Levels of Loxapine and its Metabolites
Journal of Analytical Toxicology 5:99-100

Crella, T.; Forma, M.; Pifferi, G.
1981
High-Performance Liquid Chromatographic Determination of Trithiozine and Its Neutral Metabolites in Human Plasma and Urine
Journal of Chromatography 222:257-263

Curry, S.H.; Stewart, P.B.; Springer, P.K.; Pope, J.E.
1981
Plasma-Trifluoperazine Concentrations During High Dose Therapy
Lancet 1(8216):395-396

Curzon, M.E.J.; Lomee, F.L.
1977
Dental Caries and Trace Element Composition of Whole Human Enamel: Eastern United States
Journal of the American Dental Association 95(6):1146-1150

Czerwinski, A.W.; Clark, W.L.; Serafetinides, E.A.; Perrier, C.; Huber, W.
1978
Safety and Efficacy of Zinc Sulfate in Geriatric Patients
Clinical Pharmacology and Therapeutics 15(4):436-441

David, O.
1977
The Relationship Between Lead and Hyperactivity
International Symposium, Proceedings of Recent Advances in the Assessment of the Health Effects of Environmental Pollution, Volume 3, Paris, 1978:1549-1555

De Groot, G.; Maes, F.A.A.; Sangster, B.; van Meijst, A.M.P.; Verdonck, L.F.
1980
Gas Chromatographic Determination of Buformin in Body Fluids and Tissues, Using a Nitrogen Phosphorus Detector: Application to a Postmortem Case
Journal of Analytical Toxicology 4:281-285

De Jongh, G.D.; van den Wildenberg, H.M.; Nieuwenhuyse, H.; van der Veen, F.
1981
The Metabolism of Mianserin in Women, Rabbits, and Rats: Identification of the Major Urinary Metabolites
Drug Metabolism and Disposition 9(1):48-53

Dhar, A.K.; Kutt, H.
1981
Improved Gas Chromatographic Procedure for the Determination of Clonazepam Levels in Plasma Using a Nitrogen-Sensitive Detector
Journal of Chromatography 222:203-211

Dillon, J.C.; Martin, G.P.; O'Brien, M.T.
1981
Pesticide Residues in Human Milk
Food and Cosmetics Toxicology 19:437-442

DiVincenzo, G.D.; Kaplan, C.J.
1981
Uptake, Metabolism, and Elimination of Methylene Chloride Vapor by Humans
Toxicology and Applied Pharmacology 59:130-140

Dixon, R.; Crews, T.; Mohacsi, E.; Inturrisi, C.; Foley, K.
1980
Levorphanol: Radioimmunoassay and Plasma Concentration Profiles in Dog and Man
Research Communications in Chemical Pathology and Pharmacology 29(3):535-547

Dixon, R.; Young, R.; Mahacsi, E.; Molazo, A.; Malarek, D.; Borenbaum, H.; Moore, J.; Parsonnet, M.; Kaplan, S.
1978
(-)-2-Hydroxy-N-cyclopropylmethylmorphinan: Radioimmunoassay and Pharmacokinetic Profile
Clinical Pharmacology and Therapeutics 24(5):622-627

Dodson, W.E.; Tyrala, E.E.; Hillman, R.E.
1977
Micromethod for Measuring Hexachlorophene in Whole Blood by Gas-Liquid Chromatography
Clinical Chemistry 23(6):984-987

Dolcourt, J.L.; Finch, C.; Coleman, G.D.; Klimas, A.J.; Milar, C.R.
1981
Hazard of Lead Exposure in the Home from Recycled Automobile Storage Batteries
Pediatrics 68(2):225-230

Dutkiewicz, B.; Konczalik, J.; Warwacki, W.
1980
Skin Absorption and Per Os Administration of Methanol in Men
International Archives of Occupational and Environmental Health 47:81-88

Dysken, M.W.; Javaid, J.I.; Chang, S.S.; Schaffer, C.; Shahid, A.; Davis, J.M.
1981
Fluphenazine Pharmacokinetics and Therapeutic Response
Psychopharmacology 73:205-210

Ealy, J.A.; Bolton, W.E.; McElheny, W.J.; Morrow, R.W.
1978
Determination of Lead in Whole Blood by Graphite Furnace Atomic Absorption Spectrophotometry
American Industrial Hygiene Association Journal 35(9):566-570

Eichelbaum, M.; Hengstmann, J.H.; Rost, K.D.; Brecht, T.; Dengler, H.J.
1978
Pharmacokinetics, Cardiovascular and Metabolic Actions of Cyclohexylamine in Man
Archives of Toxicology 41:249-263

Ely, D.L.; Mostardi, R.A.; Woebkenberg, W.; Worstell, D.
1981
Aerometric and Hair Trace Metal Content in Learning-Disabled Children
Environmental Research 25:325-339

Esler, M.; Jackman, G.; Leonard, P.; Skews, H.; Bobik, A.; Korner, P.
1981
Effect of Norepinephrine Uptake Blockers on Norepinephrine Kinetics
Clinical Pharmacology and Therapeutics 29(1):12-20

Evenson, M.A.; Anderson, C.T., Jr.
1975
Ultramicro Analysis for Copper, Cadmium, and Zinc in Human Liver Tissue by Use of Atomic Absorption Spectrophotometry and the Heated Graphite Tube Atomizer
Clinical Chemistry 21(4):537-543

Falchuk, K.H.
1977
Effect of Acute Disease and ACTH on Serum Zinc Proteins
New England Journal of Medicine 296(20):1129-1134

Fernandez, F.J.
1975
Micromethod for Lead Determination in Whole Blood by Atomic Absorption, with Use of the Graphite Furnace
Clinical Chemistry 21:558-561

Field, B.; Lu, C.; Hepner, G.W.
1979
Inhibition of Hepatic Drug Metabolism by Norethindrone
Clinical Pharmacology and Therapeutics 25(2):196-198

Fine, D.H.; Rounbehler, D.P.; Fan, T.; Ross, R.
1977
Human Exposure to N-nitroso Compounds in the Environment
Cold Springs Harbor Conference on Cell Proliferation, 1977. Origins of Human Cancer, Book A, pp. 293-307

Fisken, R.A.; Heath, D.A.; Somers, S.; Bold, A.M.
1981
Hypercalcaemia in Hospital Patients: Clinical and Diagnostic Aspects
Lancet 1(8213):202-207

Franklin, C.A.; Fenske, R.A.; Greenhalgh, R.; Mathieu, L.; Denley, H.V.; Leffingwell, J.T.; Spear, R.C.
1981
Correlation of Urinary Pesticide Metabolite Excretion with Estimated Dermal Contact in the Course of Occupational Exposure to Guthion
Journal of Toxicology and Environmental Health 7:715-731

Garnys, V.P.; Matousek, J.P.
1975
Correction for Spectral Interference with Determination of Lead in Blood by Non-Flame Atomic Absorption Spectrometry
Clinical Chemistry 21:891-893

Garriott, J.C.; Foerster, E.; Juarez, L.; de la Garza, F.; Mendiola, I.; Curoe, J.
1981
Measurement of Toluene in Blood and Breath in Cases of Solvent Abuse
Clinical Toxicology 18(4):471-479

Gaver, R.C.; Deeb, G.; Pittman, K.A.; Smyth, R.D.
1981
Disposition of Anagrelide, an Inhibitor of Platelet Aggregation
Clinical Pharmacology and Therapeutics 29(3):381-386

Gershoff, S.N.; Brunis, O.A.; Hino, H.V.; Huber, A.M.
1977
Studies of the Elderly in Boston. I. The Effects of Iron Fortification on Moderately Anemic People
American Journal of Clinical Nutrition 30:226-234

Gervais, L.; LaCasse, Y.; Brodeur, J.; P'An, A.
1981
Presence of Cadmium in the Saliva of Adult Male Workers
Toxicology Letters 8:63-66

Gillilan, R.; Mason, W.D.
1981
High-Pressure Liquid Chromatographic Determination of Viloxazine in Human Plasma and Urine
Journal of Pharmaceutical Sciences 70(2):220-221

Golden, B.E.; Golden, M.H.N.
1981
Plasma Zinc, Rate of Weight Gain, and the Energy Cost of Tissue Deposition in Children Recovering from Severe Malnutrition on a Cow's Milk or Soya Protein Based Diet
The American Journal of Clinical Nutrition 34:892-899

Gollamudi, R.; Straughn, A.B.; Meyer, M.C.
1981
Urinary Excretion of Methenamine and Formaldehyde: Evaluation of 10 Methenamine Products in Humans
Journal of Pharmaceutical Sciences 70(6):596-599

Gorsky, J.E.; Dietz, A.A.
1978
Determination of Aluminum in Biological Samples by Atomic Absorption Spectrophotometry with a Graphite Furnace
Clinical Chemistry 24(9):1485-1490

Grabe, M.; Anderson, K.-E.; Forsgren, A.; Hellsten, S.
1981
Concentrations of Cefotaxime in Serum, Urine and Tissues of Urological Patients
Infection 9(3):154-158

Grant, D.L.; Mes, J.; Frank, R.
1976
PCB Residues in Human Adipose Tissue and Milk
Proceedings of the National Conference on Polychlorinated Biphenyls, Chicago, IL, November 19-21, 1975 (pp. 144-146)

Gritz, E.R.; Baer-Weiss, V.; Benowitz, N.L.; Van Vunakis, H.; Jarvik, M.E.
1981
Plasma Nicotine and Cotinine Concentrations in Habitual Smokeless Tobacco Users
Clinical Pharmacology and Therapeutics 30(2):201-209

Guillemin, M.P.; Bauer, D.
1979
Human Exposure to Styrene III. Elimination Kinetics of Urinary Mandelic and Phenylglyoxylic Acids after Single Experimental Exposure
International Archives of Occupational and Environmental Health 44:249-263

Hallson, P.C.; Kanidas, G.P.; Rose, G.A.
1977
Seasonal Variations in Urinary Excretion of Calcium and Oxalate in Normal Subjects in Patients with Idiopathic Hypercalciuria
British Journal of Urology 49(1):1-10

Halstead, J.A.; Smith, J.C.; Irwin, M.I.
1974
A Conspectus of Research on Zinc Requirements of Man
Journal of Nutrition 104(3):345-378

Hansteen, V.; Jacobsen, D.; Knudsen, K.; Reikvam, A.; Skuterud, B.
1981
Acute, Massive Poisoning with Digitoxin: Report of Seven Cases and Discussion of Treatment
Clinical Toxicology 18(6):679-692

Hansten, P.D.; Hayton, W.L.
1980
Effect of Antacid and Ascorbic Acid on Serum Salicylate Concentration
Journal of Clinical Pharmacology 20(5-6, pt. 1):326-331

Harper, D.B.; Smith, P.V.; Gotto, D.M.
1977
BHC Residues of Domestic Origin: A Significant Factor in Pollution of Freshwater in Northern Ireland
Environmental Pollution 12(3):223-233

Haselbarth, V.; Doevendans, J.E.; Wolf, M.
1981
Kinetics and Bioavailability of Mexiletine in Healthy Subjects
Clinical Pharmacology and Therapeutics 29(6):729-737

Hayabuchi, H.; Ikeda, M.; Yoshimura, T.; Masuda, Y.
1981
Relationship Between the Consumption of Toxic Rice Oil and the Long-Term Concentration of Polychlorinated Biphenyls in the Blood of Yusho Patients
Food and Cosmetics Toxicology 19:53-55

Hepner, G.W.; Vesell, E.S.
1977
Aminopyrine Metabolism in the Presence of Hyperbilirubinemia Due to Cholestasis or Hepatocellular Disease: Combined Use of Laboratory Tests to Study Disease-Induced Alterations in Drug Disposition
Clinical Pharmacology and Therapeutics 21(5):620-626

Herber, R.F.M.
1980
Estimation of Blood Lead Values from Blood Porphyrin and Urinary 5-Aminolevulinic Acid Levels in Workers
International Archives of Occupational and Environmental Health 45:169-179

Herrera Marteache, A.; Polo Villar, L.M.; Jodral Villarejo, M.; Polo Villar, G.; Mallol, J.; Pozo Lora, R.
1978
Residuos de Plaguicidas Organoclorados en Grasa Humana en Espana
Revista de Sanidad e Higiene Publica 52, 20 pp.

Hickey, R.J.; Clelland, R.C.; Boyce, D.E.; Harner, E.B.
1974
Carbon Monoxide and Smoking
Lancet 1(7858):409-410

Hillman, L.S.
1981
Serial Serum Copper Concentrations in Premature and SGA Infants During the First 3 Months of Life
Journal of Pediatrics 98(2):305-308

Himmelstein, K.J.; Patton, T.F.; Belt, R.J.; Taylor, S.; Repta, A.J.; Sternson, L.A.
1981
Clinical Kinetics of Intact Cisplatin and Some Related Species
Clinical Pharmacology and Therapeutics 29(5):658-664

Hirayasu, G.H.; Cohen, J.L.; Nelson, F.W.
1977
Determination of Plasma and Erythrocyte Lithium Concentrations by Atomic Absorption Spectrophotometry
Clinical Chemistry 23(1):81-85

Hogstedt, C.; Stahl, F.
1980
Skin Absorption and Protective Gloves in Dynamite Work
American Industrial Hygiene Association Journal 41(5):367-372

Holdrinet, M.V.H.; Braun, H.E.; Frank, F.; Stopps, G.J.; Smout, M.S.; McWade, J.W.
1977
Organochlorine Pesticides in Human Adipose Tissue and Milk from Ontario Residents, 1969-1974
Canadian Journal of Public Health 68:74-80

Hollister, L.E.; Conley, F.K.; Britt, R.H.; Shuer, L.
1981
Long Term Use of Diazepam
Journal of the American Medical Association 246(18):1568-1570

Hooper, P.L.; Caplan, R.H.
1977
Thyroid Uptake of Radioactive Iodine in Hyperthyroidism
Journal of the American Medical Association 238(5):411-413

Horning, M.G.; Brown, L.; Moulin, J.; Lertratanangkoon, K.; Kellaway, P.; Zion, T.E.
1977
Use of Saliva in Therapeutic Drug Monitoring
Clinical Chemistry 23(2):157-164

Horowitz, J.D.; Morris, P.M.; Brunner, O.H.; Goble, A.J.; Louis, W.J.
1981
High-Performance Liquid Chromatographic Assay of Perhexiline Maleate in Plasma
Journal of Pharmaceutical Sciences 70(3):320-322

Inaba, T.; Stewart, D.J.; Kalow, W.
1978
Metabolism of Cocaine in Man
Clinical Pharmacology and Therapeutics 23(5):547-552

Ingemarsson, I.; Westgren, M.; Lindberg, C.; Ahren, B.; Lundquist, I.; Carlsson, C.
1981
Single Injection of Terbutaline in Term Labor: Placental Transfer and Effects on Maternal and Fetal Carbohydrate Metabolism
American Journal of Obstetrics and Gynecology 139(6):697-701

Irwin, M.I.; Hutchins, B.K.
1976
A Conspectus of Research on Vitamin C Requirements of Man
Journal of Nutrition 106(6):823-879

Jacob, R.A.; Sandstead, H.H.; Munoz, J.M.; Klevay, L.M.; Milne, D.B.
1981
Whole Body Surface Loss of Trace Metals in Normal Males
The American Journal of Clinical Nutrition 34:1379-1383

Jarsen, C.; Harrill, I.
1977
Intakes and Serum Levels of Protein and Iron for 70 Elderly Women
American Journal of Clinical Nutrition 30:1818-1822

Jiad'ich, F.J.
1977
Toxic or Tolerant: Chloral and the Drug Dilema
Journal of Forensic Sciences 22(1):240-241

Johnson, D.F.; Tillery, J.B.; Prevost, R.J.
1978
Levels of Platinum, Palladium, and Lead in Populations of Southern California
Environmental Health Perspectives 12:27-33

Johnstone, E.C.; Bourne, R.C.; Crow, T.J.; Frith, C.D.; Gamble, S.; Lofthouse, R.; Owen, F.; Owens, D.G.C.; Robinson, J.; Stevens, M.
1981
The Relationships Between Clinical Response, Psychophysiological Variables and Plasma Levels of Amitriptyline and Diazepam in Neurotic Outpatients
Psychopharmacology 72:233-240

Jorgensen, A.
1980
Pharmacokinetic Studies in Volunteers of Intravenous and Oral Cis(Z)-Flupentixol and Intramuscular Cis(Z)-Flupentixol Decanoate in Viscolec
European Journal of Clinical Pharmacology 18:355-360

Kachny, W.D.; Hegg, A.P.; Alfrey, A.C.
1977
Gastrointestinal Absorption of Aluminum from Aluminum-Containing Antacids
New England Journal of Medicine 296(24):1389-1390

Kalliomaki, K.; Aittoniemi, K.; Kalliomaki, P-L.; Moilanen, M.
1981
Measurement of Lung-Retained Contaminants in Vivo Among Workers Exposed to Metal Aerosols
American Industrial Hygiene Association Journal 42(3):238-238

Kapetanovic, I.M.; Kupferberg, H.J.; Theodore, W.; Porter, R.J.
1981
Lack of Effect of Valproate on Paracetamol (Acetaminophen) Disposition in Epileptic Patients
British Journal of Clinical Pharmacology 11:391-393

Kashimoto, T.; Miyata, H.; Kunita, N.
1981
The Presence of Polychlorinated Quaterphenyls in the Tissues of Yusho Victims
Food and Cosmetics Toxicology 19:335-340

Katz, S.A.; Samitz, M.H.
1978
Determination of Nickel by Instrumental Neutron Activation Analysis in Hair and Its Relationship with Nickel Dermatitis
Transactions of the American Nuclear Society 18:66

King, J.C.; Stein, R.; Doyle, M.
1981
Effect of Vegetarianism on the Zinc Status of Pregnant Women
American Journal of Clinical Nutrition 34:1049-1055

Kinney, F.L.; Moskowitz, R.M.; Zelis, R.
1981
The Pharmacokinetics and Pharmacology of Oral Diltiazem in Normal Volunteers
Journal of Clinical Pharmacology 21:337-342

Kitamura, S.; Sumino, K.; Hayakawa, K.; Shibata, T.
1976
Mercury Content in Human Tissues from Japan
Effects and Dose-Response Relationships of Toxic Metals, G.F. Nordberg (Ed.), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands, (pp 290-298)

Kiviluoto, M.; Pyy, L.; Pakarinen, A.
1981
Serum and Urinary Vanadium of Workers Processing Vanadium Pentoxide
International Archives of Occupational and Environmental Health 48:251-256

Klotz, U.; Reimann, I.
1981
Elevation of Steady-State Diazepam Levels by Cimetidine
Clinical Pharmacology and Therapeutics 30(4):513-517

Koos, B.J.; Longo, L.D.
1976
Mercury Toxicity in the Pregnant Woman, Fetus, and Newborn Infant
American Journal of Obstetrics and Gynecology 126(3):390-409

Koshy, K.M.; Lovejoy, F.H. Jr.
1981
Thallium Ingestion with Survival: Ineffectiveness of Peritoneal Dialysis and Potassium Chloride Diuresis
Clinical Toxicology 18(5):521-525

Kragh-Sorensen, P.; Overo, K.F.; Petersen, O.L.; Jensen, K.; Parnas, W.
1981
The Kinetics of Citalopram: Single and Multiple Dose Studies in Man
Acta Pharmacologica et Toxicologica 48:53-60

Kullberg, M.P.; Freeman, G.E.; Biddlecome, C.; Alousi, A.A.; Edelson, J.
1981
Amrinone Metabolism
Clinical Pharmacology and Therapeutics 29(3):394-401

Kuopulainen, J.; Vuori, E.; Makinen, S.; Kara, R.
1980
Dietary Chromium Intake of Lactating Finnish Mothers: Effect on the Cr Content of Their Breast Milk
British Journal of Nutrition 44:257-263

Kusumi, F.; Metzler, C.; Vass, R.
1981
Pharmacokinetics of Spectinomycin in Volunteers with Renal Insufficiency
Chemotherapy 27:95-98

Lamola, A.A.; Joselow, M.; Yamane, T.
1975
Zinc Protoporphyrin (ZPP): A Simple Sensitive Fluorometric Screening Test for Lead Poisoning
Clinical Chemistry 21(1):93-97

Latini, R.; Bonati, M.; Marzi, E.; Garattini, S.
1981
Urinary Excretion of an Uracilic Metabolite from Caffeine by Rat, Monkey and Man
Toxicology Letters 7:267-272

Lauwerys, R.; Hubermont, G.; Buchet, J.P.; Roels, H.
1977
Domestic Water and Lead Exposure During Pregnancy
Lancet 2(8049):1188

Layrisse, M.; Martinez-Torres, C.; Gonzalez, M.
1974
Measurement of the Total Daily Dietary Iron Absorption by the Extrinsic Tag Model
American Journal of Clinical Nutrition 27(Feb 74):152-162

Layrisse, M.; Martinez-Torres, C.; Renzi, M.
1976
Sugar as Vehicle for Iron Fortification: Further Studies
American Journal of Clinical Nutrition 29:274-279

Layrisse, M.; Martinez-Torres, C.; Renzi, M.; Velez, F.; Gonzalez, H.
1976
Sugar as Vehicle for Iron Fortification
American Journal of Clinical Nutrition 29:8-18

LeGendre, G.R.; Alfrey, A.C.
1976
Measuring Picogram Amounts of Aluminum in Biological Tissue by Flameless Atomic Absorption Analysis of a Chelate
Clinical Chemistry 22(1):53-56

Levy, G.
1981
Pharmacokinetics of Fetal and Neonatal Exposure to Drugs
Obstetrics and Gynecology 58(5):95-165

Lo, L.Y.; Land, G.; Bye, A.
1981
Sensitive Assay for Pseudoephedrine and its Metabolite, Norpseudoephedrine in Plasma and Urine Using Gas-Liquid Chromatography with Electron-Capture Detection
Journal of Chromatography 222:297-302

Long, D.F.; Patton, T.F.; Hepta, A.J.
1981
Platinum Levels in Human Erythrocytes Following Intravenous Administration of Cisplatin: Importance of Erythrocytes as a Distribution Site for Platinum Species
Biopharmaceutics & Drug Disposition 2:137-146

Longo, L.D.
1977
The Biological Effects of Carbon Monoxide on the Pregnant Woman, Fetus, and Newborn Infant
American Journal of Obstetrics and Gynecology 129(69):69-103

Love, B.I.; Moore, M.G.; Thomas, J.; Chaturvedi, S.
1981
Pharmacokinetics of Zimelidine in Humans - Plasma Levels and Urinary Excretion of Zimelidine and Norzimelidine after Intravenous and Oral Administration of Zimelidine
European Journal of Clinical Pharmacology 20:135-139

Marcus, M.; Hollander, M.; Lucas, R.E.; Pfeiffer, M.C.
1975
Micro-Scale Blood Lead Determinations in Screening: Evaluation of Factors Affecting Results
Clinical Chemistry 21(4):533-536

Marks, V.; Teale, D.; Fry, D.
1975
Detection of Cannabis Products in Urine by Radioimmunoassay
British Medical Journal 3(5979):348-349

Masoud, A.N.; Krupski, D.M.
1980
High-Performance Liquid Chromatographic Analysis of Cocaine in Human Plasma
Journal of Analytical Toxicology 4:305-310

McLean, A.J.; Webster, C.; Bobik, A.; Dudley, F.J.
1981
Reduction of First-Pass Hepatic Clearance of Propranolol by Food
Clinical Pharmacology and Therapeutics 30(1):31-34

Meiners, C.R.; Taper, L.J.; Morsland, M.M.; Hitchey, S.J.
1977
The Relationship of Zinc to Protein Utilization in the Preadolescent Child
American Journal of Clinical Nutrition 30:879-882

Merits, I.
1975
Metabolism of Labelled Hexadecyl Sulphate Salts in the Rat, Dog and Human
Biochemical Journal 148:219-228

Nickelsen, O.; Makdani, D.; Gill, J.L.; Frank, R.L.
1977
Sodium and Potassium Intakes and Excretions of Normal Men Consuming Sodium Chloride or a 1:1 Mixture of Sodium and Potassium Chlorides
American Journal of Clinical Nutrition 30:2033-2040

Midha, K.K.; Charette, C.; McGilveray, I.J.; Webb, D.; McLean, H.C.
1981
Application of GLC-AFID and GIC-MS Procedures to Analysis of Plasma in Suspected Cases of Psychotropic Drug Overdose
Clinical Toxicology 18(6):713-729

Midha, K.K.; Hubbard, J.W.; Cooper, J.K.; Hawes, E.M.; Fournier, S.; Young, P.
1981
Radioimmunoassay for Trifluoperazine in Human Plasma
British Journal of Clinical Pharmacology 12:189-193

Miller, M.M.; Garland, W.A.; Min, B.M.; Ludwick, B.T.; Ballard, R.E.; Levy, R.H.
1981
Clonazepam Acetylation in Fast and Slow Acetylators
Clinical Pharmacology and Therapeutics 30(3):343-347

Monsen, E.R.; Cook, J.D.
1976
Food Iron Absorption in Human Subjects IV. The Effects of Calcium and Phosphate Salts on the Absorption of Nonheme Iron
American Journal of Clinical Nutrition 29:1142-1148

Moore, M.R.; Goldberg, A.; Fyfe, W.M.; Richards, W.N.
1981
Maternal Lead Levels After Alterations to Water Supply
Lancet 2(8239):203-204

Morley, J.E.; Russell, R.M.; Reed, A.; Carney, E.A.; Hershmann, J.M.
1981
The Interrelationship of Thyroid Hormones with Vitamin A and Zinc Nutritional Status in Patients with Chronic Hepatic and Gastrointestinal Disorders
American Journal of Clinical Nutrition 34:1489-1495

Munch, E.P.; Sondergaard, I.; Weeke, B.
1981
Theophylline Concentrations in Serum and Saliva after Oral Microcrystalline and Sustained-Release Preparations in Asthmatics
Allergy 36:89-98

Murray, J.R.
1978
Bismuth Neurotoxicity
Medical Journal of Australia 1:279-280

Murray, T.; Walker, B.R.; Spratt, D.M.; Chappelka, R.
1981
Cadmium Nephropathy: Monitoring for Early Evidence of Renal Dysfunction
Archives of Environmental Health 36(4):165-171

National Academy of Science, National Research Council
1975
Nickel
Medical and Biological Effects of Environmental Pollutants, National Academy of Sciences, Washington, DC, 277 pp.

Nau, H.; Welsch, F.; Ulbrich, B.; Baum, R.; Lange, J.
1981
Thiamphenicol during the First Trimester of Human Pregnancy: Placental Transfer IN VIVO, Placental Uptake IN VITRO, and Inhibition of Mitochondrial Function
Toxicology and Applied Pharmacology 60:131-141

Naylor, L.M.; Loehr, R.C.
1981
Increase in Dietary Cadmium as a Result of Application of Sewage Sludge to Agricultural Land
Environmental Science and Technology 15(8):881-886

Nelson, J.D.; Kusmiesz, H.; Shelton, S.; Woodman, E.
1978
Clinical Pharmacology and Efficacy of Ticarcillin in Infants and Children
Pediatrics 61(6):858-863

Niculescu, T.; Dumitru, R.; Burnea, D.
1981
Changes of Copper, Iron, and Zinc in the Serum of Patients with Silicosis, Silicotuberculosis, and Active Lung Tuberculosis
Environmental Research 25:260-268

Nitsche, V.; Mascher, M.
1981
Nachweis von Benzbromaron in Serum bei einer Kombinationsbehandlung mit Allopurinol und Benzbromaron
Arzneimittel-Forschung 31(1):510-512

Noriyasa, F.
1977
Does a Critical Concentration of Cadmium in Human Renal Cortex Exist?
Journal of Toxicology and Environmental Health 3:607-609

Norbeis, G.
1976
Determination of Dextropropoxyphene and Norpropoxyphene in Autopsy Material by Gas Chromatography
Archives of Toxicology 36:89-95

Novick, D.M.; Kreek, M.J.; Hanizsa, A.M.; Yancovitz, S.R.; Gelb, A.M.; Stenger, R.J.
1981
Methadone Disposition in Patients with Chronic Liver Disease
Clinical Pharmacology and Therapeutics 30(3):353-362

Ohlsson, A.; Lingren, J.E.; Wahlen, A.; Agurell, S.; Hollister, L.E.; Gillespie, H.K.
1980
Plasma delta-9-tetrahydrocannabinol Concentrations and Clinical Effects after Oral and Intravenous Administration and Smoking
Clinical Pharmacology and Therapeutics 28(3):409-416

Okonek, S.; Hofmann, A.
1975
On the Question of Extracorporeal Hemodialysis in Diquat Intoxication
Archives of Toxicology 33:251-257

Okonek, S.; Kilbinger, H.
1974
Determination of Acetylcholine, Nitrostigmine and Acetylcholinesterase Activity in Four Patients with Severe Nitrostigmine (E 605 forte) Intoxication
Archives of Toxicology 32:97-108

Othman, I.; Spyrou, N.M.
1980
The Abundance of Some Elements in Hair and Nail from the Machakos District of Kenya
Science of the Total Environment 16:267-278

Painter, M.J.; Piggenger, C.; Masterlain, C.; Barnada, M.; Pitlick, W.; Carter, G.; Abern, S.
1981
Phenobarbital and Phenytoin in Neonatal Seizures: Metabolism and Tissue Distribution
Neurology 31(9):1107-1112

Pantarotto, C.; Salmona, M.; Panelli, M.; Bianchi, M.; Szczawinska, K.
1981
GLC - Mass Fragmentographic Determination of Saccharin in Biological Fluids
Journal of Pharmaceutical Sciences 70(8):871-874

Peat, M.A.; Finkle, B.S.
1980
Determination of Methaqualone and its Major Metabolite in Plasma and Saliva After Single Oral Doses
Journal of Analytical Toxicology 4:114-118

Pfaffli, P.; Hesso, A.; Vainio, H.; Hyvonen, M.
1981
4-Vinylphenol Excretion Suggestive of Arene Oxide Formation in Workers Occupationally Exposed to Styrene
Toxicology and Applied Pharmacology 60:85-90

Piscator, M.
1981
Role of Cadmium in Carcinogenesis with Special Reference to Cancer of the Prostate
Environmental Health Perspectives 40:107-120

Pitkin, R.M.
1975
Calcium Metabolism in Pregnancy: A Review
American Journal of Obstetrics and Gynecology 121(5):724-737

Pleasure, J.R.; Blackburn, W.G.
1975
Neonatal Bromide Intoxication: Prenatal Ingestion of a Large Quantity of Bromides with Transplacental Accumulation in the Fetus
Pediatrics 55(4):503-506

Rama Rao, V.A.; Bailey, J.; Bishop, M.; Coppen, A.
1981
A Clinical and Pharmacodynamic Evaluation of Sulpiride
Psychopharmacology 73:77-80

Narasvamy, S.S.
1975
Relevance of Bio-chemical Parameters as Indicators of Toxic Effects in Workers Exposed to Toxic Chemicals
Environmental Pollution and Human Health: Proceedings of the International Symposium on Industrial Toxicology, pp. 166-177

Ratcliffe, W.A.; Fletcher, S.M.; Moffat, A.C.; Ratcliffe, J.G.; Harland, W.A.; Levitt, T.E.
1977
Radioimmunoassay of Lysergic Acid Diethylamide (LSD) in Serum and Urine by Using Antisera of Different Specificities
Clinical Chemistry 23(2):169-174

Reeves, D.S.; Bullock, D.W.; Bywater, M.J.; Holt, M.A.; White, L.O.; Thornhill, D.P.
1981
The Effect of Probenecid on the Pharmacokinetics and Distribution of Cefoxitin in Healthy Volunteers
British Journal of Clinical Pharmacology 11:353-359

Remsiger, E.P.; Pickering, L.K.; Ericsson, C.D.; Kramer, W.G.
1981
Sequential CSF Concentration of Chloramphenicol after Administration of Oral Chloramphenicol Palmitate
Lancet 1(8212):165

Renton, K.W.; Gray, J.D.; Hung, C.F.
1981
Depression of Theophylline Elimination by Erythromycin
Clinical Pharmacology and Therapeutics 30(3):422-426

Richardson, R.A.
1976
Automated Method for Determination of Mercury in Urine
Clinical Chemistry 22(10):1604-1607

Riggs, C.E. Jr.; Egorin, M.J.; Fuks, J.Z.; Schnaper, H.; Duffey, P.; Colvin, O.M.; Aisner, J.; Wiernik, P.H.; Bachur, N.R.
1981
Initial Observations on the Effects of delta 9-Tetrahydrocannabinol on the Plasma Pharmacokinetics of Cyclophosphamide and Doxorubicin
Journal of Clinical Pharmacology 21:905-985

Riva, R.; Tedeschi, G.; Albani, F.; Baruzzi, A.
1981
Quantitative Determination of Clobazam in the Plasma of Epileptic Patients by Gas-Liquid Chromatography with Electron-Capture Detection
Journal of Chromatography 225:219-224

Robbins, W.B.; DeNoven, R.W.; Caruso, J.A.
1975
Copper in Erythrocytes by Flameless Atomic Absorption Spectroscopy
Biochemical Medicine 14:184-190

Roels, H.A.; Buchet, J.P.; Lauwerys, R.; Hubermont, G.; Bruaux, P.
1975
Response of Heme Biosynthetic Pathway Parameters in Men, Women, and Children Moderately Exposed to Lead
An International Conference on Heavy Metals in the Environment, Toronto, Ontario, Canada, Oct. 27-31, pp. 105-124

Rustam, H.; Von Burg, R.; Asin-Taki, L.; Hassani, S.N.
1975
Evidence for a Neuromuscular Disorder in Methylmercury Poisoning: Clinical and Electrophysiological Findings in Moderate to Severe Cases
Archives of Environmental Health 30(2):190-195

Saario, I.; Linnoila, M.; Maki, M.
1975
Interaction of Drugs with Alcohol on Human Psychomotor Skills Related to Driving: Effect of Sleep Deprivation or Two Weeks' Treatment with Hypnotics
Journal of Clinical Pharmacology 15:52-59

Sajgo, M.; Gesztesi, A.; Sido, T.
1981
Determination of Tofisopam in Serum by High-Performance Liquid Chromatography
Journal of Chromatography 222:303-307

Salzer, T.B.; Weinrib, A.P.; Marino, R.J.; Lima, J.J.
1981
A Comparison of Methods of Lidocaine Administration in Patients
Clinical Pharmacology and Therapeutics 29(5):617-624

Sampson, P.
1977
Low Manganese Level May Trigger Epilepsy
Journal of American the Medical Association 238(17):1805

Sandifer, S.H.; Cupp, C.M.; Wilkins, R.T.; Loadholt, B.; Schuman, S.H.
1981
A Case-Control Study of Persons with Elevated Blood Levels of Dieldrin
Archives of Environmental Contamination and Toxicology 10:35-45

Sauer, G.
1981
The Effect of Parity on Maternal Hair Chromium Concentration and the Changes During Pregnancy
American Journal of Clinical Nutrition 34:853-855

Sardi, A.; Vettaro, M.P.; Alesina, R.; Grasso, S.; Meinardi, G.; de Carneri, I.; Tassassia, V.
1981
Serum and Saliva Levels of a Trimethoprim-Sulfamethopyrazine Combination in Man
European Journal of Clinical Pharmacology 20:113-118

Savolainen, H.; Riihimaki, V.
1981
An Early Sign of Xylene Effect on Human Equilibrium
Acta Pharmacologica et Toxicologica 48:279-283

Sayed, A.; Van Hove, W.; Vermeulen, A.
1981
Prednisolone Plasma Levels after Oral Administration of Prednimustine (N)
Oncology 38:351-355

Scherrmann, J.M.; Moellinger, H.; Nam, H.-H.; Boudet, L.; Pichon, J.; Thang, D.-C.
1981
Detection and Quantitation of Cannabinoids in Biological Fluids: Specificity and Kinetics after Smoking
Clinical Toxicology 18(5):565-571

Schneider, P.P.; Bleijer, M.P.
1976
Mercury: A Health Hazard Associated with Employment of Women as Dental Assistants
Proceedings of a Conference on Women in the Workplace held in Washington, DC, June 17-19, 1976. Sula Binghan (Ed.) Published by Society for Occupational and Environmental Health, pp. 202-213

Schwartz, H.K.
1975
Role of Trace Elements in Cancer
Cancer Research 35:3481-3487

Sebastien, P.; Janson, X.; Riba, G.; Masse, R.; Bonnaud, G.; Bignon, J.
1977
Translocation of Asbestos Fibers through Respiratory Tract and Gastrointestinal Tract According to Fiber Type and Size
Occupational Exposures to Fibrous and Particulate Dust and Their Extension into the Environment, Proceedings of the Conference of the Society for Occupational and Environmental Health, Washington, DC, December 6-7, 1977

Sedivec, V.; Braz, M.; Flek, J.
1981
Biological Monitoring of Persons Exposed to Methanol Vapours
International Archives of Occupational and Environmental Health 48:257-271

Seideman, P.; Grahnen, A.; Naglund, K.; Lindstrom, B.; von Bahr, C.
1981
Prazosin Dynamics in Hypertension: Relationship to Plasma Concentration
Clinical and Pharmacological Therapeutics 30(4):447-454

Selikoff, I.J.
1976
Health Effects of Exposure to Polybrominated Biphenyls: Results of a Clinical Field Survey, November 8-10, 1976
Interim Summary Report to the National Institute of Environmental Health Sciences. ES 00928. FDA 004568, 86 pp.

Servant, J.; Delapart, M.
1981
Blood Lead and Lead-210 Origins in Residents of Toulouse
Health Physics 41(3):483-487

Shaw, J.C.L.
1976
Evidence for Defective Skeletal Mineralization in Low-Birthweight Infants: The Absorption of Calcium and Fat
Pediatrics 57(1):16-25

Shaunes, E.; Burton, D.J.
1981
Urinary Monitoring for Diethylstilbestrol in Male Chemical Workers
Journal of Occupational Medicine 23(3):179-182

Siakotos, A.N.; Koppang, N.; Youmans, S.; Bucana, C.
1978
Blood Levels of alpha-Tocopherol in a Disorder of Lipid Peroxidation: Batten's Disease
American Journal of Clinical Nutrition 27:1152-1157

Siddiqui, M.K.J.; Saxena, M.C.; Mishra, U.K.; Krishna Murti, C.R.; Nag, D.
1981
Long Term Occupational Exposure to DDT
International Archives of Occupational and Environmental Health 48:301-308

Siddiqui, M.K.J.; Saxena, M.C.; Bhargava, A.K.; Krishna Murti, C.R.; Kutty, D.
1981
Chlorinated Hydrocarbon Pesticides in Blood of Newborn Babies in India
Pesticides Monitoring Journal 15(2):77-79

Siddiqui, M.K.J.; Saxena, M.C.; Bhargava, A.K.; Seth, T.D.; Krishna Murti, C.R.; Kutty, D.
1981
Agrochemicals in the Maternal Blood, Milk, and Cord Blood: A Source of Toxicants for Prenates and Neonates
Environmental Research 24:24-32

Simon, F.A.; Treuting, J.J.
1981
Nonaccidental Poisoning in a Two-Month-Old Child
Clinical Toxicology 18(1):37-40

Singh, H.; Gupta, V.P.
1975
Investigation of Health Hazards of Low Hydrogen Electrode
Environmental Pollution and Human Health: Proceedings of the International Symposium on Industrial Toxicology, November 4-7, 1975

Siraj, M.Y.; Hayes, A.W.; Unger, P.D.; Hogan, G.P.; Ryan, M.J.; Wray, B.B.
1981
Analysis of Aflatoxin B-1 in Human Tissues with High Pressure Liquid Chromatography
Toxicology and Applied Pharmacology 58:422-430

Slattery, J.T.; Koup, J.R.; Levy, G.
1981
Acetaminophen Pharmacokinetics after Overdose
Clinical Toxicology 18(1):111-117

Smith, D.E.; Gambertoglio, J.G.; Vincenti, F.; Benet, L.Z.
1981
Furosemide Kinetics and Dynamics after Kidney Transplant
Clinical Pharmacology and Therapeutics 30(1):105-113

Smith, D.L.
1976
Lead Absorption in Police Small-arms Instructors
Society of Occupational Medicine 26:139-140

Smith, R.P.; Schmid, G.F.; Baltch, A.L.; Sutphen, W.T.; Hammer, M.C.
1981
Concentration of Cefaclor in Human Prostatic Tissue
American Journal of the Medical Sciences 281(1):19-24

Snee, R.D.
1981
Evaluation of Studies of the Relationship Between Blood Lead and Air Lead
International Archives of Occupational and Environmental Health 48:219-242

Snodgrass, W.; Sullivan, J.B.; Rumack, B.H.; Hashimoto, C.
1981
Mercury Poisoning from Home Gold Ore Processing: Use of Penicillamine and Dimercaprol
Journal of the American Medical Association 246(17):1929-1931

Solomons, N.W.; Jacob, R.A.; Pineda, O.; Viteri, F.E.
1979
Studies on the Bioavailability of Zinc in Man III. Effects of Ascorbic Acid on Zinc Absorption
American Journal of Clinical Nutrition 32:2495-2499

Sorel, P.H.A.; Snelleman, C.; Hulshoff, A.
1981
High-Performance Liquid Chromatographic Analysis of Nitroxoline in Plasma and Urine
Journal of Chromatography 222:241-248

Souganidis, D.J.; Athanassouli, T.M.N.; Papastathopoulos, D.S.
1981
A Study of IN VIVO Fluoride Uptake by Dental Tissues from Fluoride-Containing Silver Amalgams
Journal of Dental Research 60(2):105-108

Spector, R.; Choudhury, A.K.; Chiang, C.-N.; Goldberg, M.J.; Ghoneim, M.M.
1980
Diphenhydramine in Orientals and Caucasians
Clinical Pharmacology and Therapeutics 28(2):229-234

Spencer, H.; Osis, D.; Wiatrowski, E.
1975
Retention of Fluoride with Time in Man
Clinical Chemistry 21(8):613-618

Srinivasin, S.; Neu, H.C.
1981
Pharmacokinetics of Moxalactam in Patients with Renal Failure and During Hemodialysis
Antimicrobial Agents and Chemotherapy 20(3):398-400

Stack, M.V.; Purkitt, A.J.; Nickless, G.
1976
Trace Metals in Teeth at Birth (1957-1963 and 1972-1973)
Bulletin of Environmental Contamination and Toxicology 16(6):764-766

Steenhout, A.; Pourtois, M.
1981
Lead Accumulation in Teeth as a Function of Age with Different Exposures
British Journal of Industrial Medicine 38:297-303

Stephens, D.S.; Walker, D.H.; Schaffner, W.; Kaplowitz, L.G.; Brashear, H.R.; Roberts, R.; Spickard, W.A.
1981
Pseudodiphtheria: Prominent Pharyngeal Membrane Associated with Fatal Paraquat Ingestion
Annals of Internal Medicine 94(2):202-204

Stewart, M.; Hughes, E.G.; Earltrop, D.
1981
Monitoring Occupational Lead Exposure
Lancet 1(8231):1210-1211

Sunderman, F.W.
1977
Perspectives on Legionnaires' Disease in Relation to Acute Nickel Carbonyl Poisoning
Annals of Clinical and Laboratory Science 7(3):187-200

Takahashi, W.; Saidin, D.; Takei, G.; Wong, L.
1981
Organochloride Pesticide Residues in Human Milk in Hawaii, 1979-80
Bulletin of Environmental Contamination and Toxicology 27:506-511

Tandon, D.S.; Seth, T.D.; Satija, N.K.
1976
Lead Exposure in Mentally Retarded Children from North India
Journal of Pediatrics 88(5):898-899

Taylor, J.R.; Selhorst, J.B.; Houff, S.A.; Martinez, A.J.
1978
Chlordecone Intoxication in Man: I. Clinical Observations
Neurology 28(7):626-630

Thorp, J.W.; Boeckx, R.L.; Hobbins, S.; Horn, S.; Fletcher, A.B.
1981
A Prospective Study of Infant Zinc Nutrition During Intensive Care
American Journal of Clinical Nutrition 34:1056-1060

Tsuchuni, K.; Kawanishi, T.
1975
Relationship Between Activation of Delta-Aminolevulinic Acid Dehydratase by Heating and Blood Lead Level
Archives of Toxicology 34:253-258

Tong, T.G.; Benowitz, N.L.; Kreek, M.J.
1980
Methadone - Disulfiram Interaction During Methadone Maintenance
Journal of Clinical Pharmacology 20(8-9):506-513

Tsang, R.C.; Fallat, R.W.; Glueck, C.J.
1974
Cholesterol at Birth and Age 1: Comparison of Normal and Hypercholesterolemic Neonates
Pediatrics 53(4):458-470

Unger, M.; Olsen, J.
1980
Organochlorine Compounds in the Adipose Tissue of Deceased People with and without Cancer
Environmental Research 23:257-263

Valentour, J.C.; Aggarval, V.; Sunshine, I.
1974
Sensitive Gas Chromatographic Determination of Cyanide
Analytical Chemistry 46(7):924-925

Van Doorn, R.; Leijdekkers, C.M.; Bos, R.P.; Brouns, R.M.E.; Henderson, P.T.
1981
Enhanced Excretion of Thioethers in Urine of Operators of Chemical Waste Incinerators
British Journal of Industrial Medicine 38:187-190

Van Dyke, C.; Byck, R.; Barash, P.G.; Jatlow, P.
1977
Urinary Excretion of Immunologically Reactive Metabolite(s) after Intranasal Administration of Cocaine, as Followed by Enzyme Immunoassay
Clinical Chemistry 23(2):281-284

Veenendaal, J.R.; Brooks, P.M.; Moffin, P.J.
1981
Probenecid-Clofibrate Interaction
Clinical Pharmacology and Therapeutics 29(3):351-358

Versieck, J.; Barbier, F.; Speecke, A.; Hoste, J.
1974
Manganese, Copper, and Zinc Concentrations in Serum and Packed Blood Cells during Acute Hepatitis, Chronic Hepatitis, and Posthepatitic Cirrhosis
Clinical Chemistry 20(9):1141-1145

Versieck, J.; Hoste, J.; Barbier, F.; Steyaert, H.; DeRodder, J.; Nichels, H.
1978
Determination of Chromium and Cobalt in Human Serum by Neutron Activation Analysis
Clinical Chemistry 24(2):303-308

Vir, S.C.; Love, A.H.G.
1981
Zinc and Copper Nutriture of Women Taking Oral Contraceptive Agents
American Journal of Clinical Nutrition 34:1479-1483

Vir, S.C.; Love, A.H.G.; Thompson, W.
1981
Serum and Hair Concentrations of Copper During Pregnancy
American Journal of Clinical Nutrition 34:2382-2388

Vose, C.W.; Muirhead, D.C.; Evans, G.L.; Stevens, P.M.; Burford, S.R.
1981
Quantitation of Metolazone in Plasma and Urine by High-Performance Liquid Chromatography with Fluorescence Detection
Journal of Chromatography 222:311-315

Warren, F.C.; Lane, H.W.; Mares, M.
1981
Variability of Zinc Concentrations in Human Stimulated Parotid Saliva
Biological Trace Element Research 3:99-107

Washington, N.G.; Wang, K.; O'Rourke, M.F.
1978
Plasma Digoxin Measurement in Clinical Practice
Medical Journal of Australia 2:368-374

Watkinson, J.H.
1981
Changes of Blood Selenium in New Zealand Adults with Time and Importation of Australian Wheat
American Journal of Clinical Nutrition 34:936-942

Wessel, M.A.; Dominski, A.
1977
Our Children's Daily Lead
American Scientist 65(3):294-298

Wester, P.O.; Brune, D.; Nordberg, G.
1981
Arsenic and Selenium in Lung, Liver, and Kidney Tissue from Dead Smelter Workers
British Journal of Industrial Medicine 38:179-184

Whitlam, J.B.; Brown, K.F.; Crooks, M.J.; Boom, C.F.W.
1981
Transsynovial Distribution of Ibuprofen in Arthritic Patients
Clinical Pharmacology and Therapeutics 29(4):487-492

Wickizer, T.M.; Brilliant, L.B.
1981
Testing for Polychlorinated Biphenyls in Human Milk
Pediatrics 68(3):411-415

Wiles, D.; Franklin, M.; Deucker, S.J.; Johansson, R.; Lundin, L.; Malm, U.
1980
Plasma Fluphenazine and Prolactin Levels in Schizophrenic Patients During Treatment with Low and High Doses of Fluphenazine Enanthate
Psychopharmacology 71:131-136

Yasamoto, I.; Itoh, M.; Tsukada, S.; Takenaka, S.; Kiyozumi, M.; Kojima, S.
1980
Cadmium, Copper, and Zinc Concentrations in Human Renal Calculus and Gall Stone, and its Analytical Implications
Procedings of the 7th Symposium on Environmental Pollutants and Toxicology, Kobe, Japan, S-68

Yobs, A.R.
1972
Levels of Polychlorinated Biphenyls in Adipose Tissue of the General Population of the Nation
Environmental Health Perspectives 1:79-81

Youssefi, M.; Faust, S.D.; Zenchelsky, S.T.
1978
Rapid Determination of Light Halogenated Hydrocarbons in Urine
Clinical Chemistry 24(7):1109-1111

Zaldivar, F.
1980
High Lithium Concentrations in Drinking Water and Plasma of Exposed Subjects
Archives of Toxicology 46:319-320

Zannad, F.; Boyer, B.-J.; Pobert, J.
1981
Changes in 86-Rubidium Uptake in Erythrocytes of Digoxin-Treated Patients, in Heart Failure with Sinus Rhythm. Relationship to Clinical Effects
European Journal of Cardiology 12:275-284

Ziemniak, J.A.; Chiarsonte, C.A.; Schentag, J.J.
1981
Liquid-Chromatographic Determination of Cimetidine, Its Known Metabolites, and Creatinine in Serum and Urine
Clinical Chemistry 27(2):272-275

REFERENCES FOR PHYSICAL AND CHEMICAL DATA

REFERENCES FOR PHYSICAL AND CHEMICAL DATA

Aldrich Catalog Handbook of Fine Chemicals, 1979-1980. Aldrich Chemical Co., Milwaukee, Wisconsin.

CHEMLINE: On-Line Chemical Dictionary, Toxicology Information Programs, National Library of Medicine, Bethesda, Maryland.

Dean, J. A., ed. 1979. Lange's Handbook of Chemistry. McGraw-Hill Book Co., New York.

Encyclopedia of Occupational Health and Safety. 1971-1972. Vols. 1 and 2. McGraw-Hill Book Co., New York.

Fassett, D. W., D. D. Irish, and F. A. Patty, eds. 1963. Industrial Hygiene and Toxicology. 2nd ed. Vol. 2, Toxicology. Interscience Publishers, New York.

Meister, R. T., ed. 1980. Farm Chemicals Handbook. Meister Publishing Co., Willoughby, Ohio.

Rapport, Z., ed. 1967. Handbook of Tables for Organic Compound Identification. 3rd ed. The Chemical Rubber Co., Cleveland, Ohio.

Sax, N. I., ed. 1979. Dangerous Properties of Industrial Materials. 5th ed. Van Nostrand Reinhold Co., New York.

Sunshine, I., ed. 1969. Handbook of Analytical Toxicology. The Chemical Rubber Co., Cleveland, Ohio.

Weast, R. C., ed. 1979. Handbook of Chemistry and Physics: A Ready-Reference Book of Chemical and Physical Data. 60th ed. The Chemical Rubber Co., Cleveland, Ohio.

Windholz, M., ed. 1976. The Merck Index: An Encyclopedia of Chemicals and Drugs. 9th ed. Merck & Co., Inc., Rahway, New Jersey.

APPENDIX A

Journals Searched

Acta Pharmacologica and Toxicologica
American Industrial Hygiene Association Journal
American Journal of Clinical Nutrition
American Journal of Obstetrics and Gynecology
American Journal of Public Health
American Medical Association, Journal of the
Analytical Chemistry
Analytical Toxicology, Journal of
Annals of Occupational Hygiene
Archives Internationales de Pharmacodynamine et de Therapie
Archives of Environmental Contamination and Toxicology
Archives of Environmental Health
Archives of Toxicology
Biochemical Medicine
British Journal of Industrial Medicine
British Medical Journal
Bulletin of Environmental Contamination and Toxicology
Canadian Medical Association, Journal of the
Cancer Research
Chemosphere
Clinical Pharmacology, Journal of
Clinical Pharmacology and Therapeutics
Drug and Chemical Toxicology
Drug Metabolism and Disposition
Ecotoxicology and Environmental Safety
Environmental Health Perspectives
Environmental Pathology and Toxicology, Journal of
Environmental Research
Environmental Science and Technology
Food and Chemical News
Food and Cosmetics Toxicology
Forensic Sciences, Journal of
International Archives of Occupational and Environmental Health
International Journal of Environmental Studies

Laboratory and Clinical Medicine, Journal of
Lancet
Medical Journal of Australia
Nature
Naunyn-Schmiedeberg's Archives of Pharmacology
New England Journal of Medicine
New York Academy of Sciences, Annals of the
Nutrition, Journal of
Pediatrics
Pediatrics, Journal of
Pesticide and Toxic Chemical News
Pesticides Monitoring Journal
Pharmaceutical Sciences, Journal of
Pharmacological Reviews
Pharmacology and Experimental Therapeutics, Journal of
Pharmacy and Pharmacology, Journal of
Psychopharmacology
Research Communications in Chemical Pathology and Pharmacology
Residue Reviews
Science
Science of the Total Environment
Society of Experimental Biology and Medicine, Proceedings of the
Society of Occupational Medicine, Journal of
Toxicological and Environmental Chemistry Reviews
Toxicology
Toxicology and Applied Pharmacology
Toxicology and Environmental Health, Journal of
Toxicology Letters
Xenobiotica

APPENDIX B

Chemicals (Vols. I-IV) by CAS Preferred Names

(-)-2-Hydroxy-N-cyclopropylmethylmorphinan (No postings in Chemline).

(1,1'-Biphenyl)-4-butanoic acid, gamma-oxo-

(1,3)Dioxolo(4,5-g)cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-

(3,4'-Bipyridin)-6(1H)-one, 5-amino-

Acetaldehyde

Acetamide, N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)- (8 CI); Acetamide, N-(5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl)- (9 CI)

Acetamide, N-amidino-2-(2,6-dichlorphenyl)- (8 CI); Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro- (9 CI)

Acetamide, N-methyl

Acetamide, 2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)- (8 CI); Benzeenacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)- (9 CI)

Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)- , D-threo-(+)- (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)

Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Acetic acid ethyl ester

Acetic acid, (o-(2,6-dichloroanilino)phenyl)-, monosodium salt (8 CI); Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-, monosodium salt (9 CI)

Acetic acid, (2-hydroxyethoxy)-

Acetic acid, (2,3-dichloro-4-(2-thienylcarbonyl)phenoxy)-

Acetic acid, (2,4-dichlorophenoxy)-

Acetic acid, (2,4,5-trichlorophenoxy)-

Acetic acid, (3,4-dihydroxyphenyl)- (8 CI); Benzeneacetic acid, 3,4-dihydroxy- (9 CI)

Acetic acid, (4-(allyloxy)-3-chlorophenyl)- (8 CI); Benzeneacetic acid, 3-chloro-4-(2-propenyloxy)- (9 CI)

Acetic acid, (4-hydroxy-3-methoxyphenyl)- (8 CI); Benzeneacetic acid, 4-hydroxy-3-methoxy- (9 CI)

Acetic acid, allyl ester (8 CI); Acetic acid, 2-propenyl ester (9 CI)

Acetic acid, butyl ester

Acetic acid, cyano-

Acetic acid, octyl ester

Acetic acid, phenyl- (8 CI); Benzeneacetic acid (9 CI)

Acetic acid, phenyl-, ethyl ester (8 CI); Benzeneacetic acid, ethyl ester (9 CI)

Acetic acid, propyl ester

Acetic acid, thio- (8 CI); Ethanethioic acid (9 CI)

Acetic acid, trichloro-

Acetoacetic acid, butyl ester (8 CI); Butanoic acid, 3-oxo-, butyl ester (9 CI)

Acetone (8 CI); 2-Propanone (9 CI)

Acetonitrile

Acetylene, dichloro- (8 CI); Ethyne, dichloro- (9 CI)

Adenosine, cyclic 3',5'-(hydrogen phosphate)

Adriamycin (8 CI); 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9 CI)

Alanine, 3-((carboxymethyl)thio)-, L- (8 CI); L-Cysteine, S-(carboxymethyl)- (9 CI)

Alanine, 3-(methylthio)-, L- (8 CI); L-Cysteine, S-methyl- (9 CI)

Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl-, L- (8 CI); L-Phenylalanine, 4-(bis(2-chloroethyl)amino)- (9 CI)

Alanine, 3-(3,4-dihydroxyphenyl)-, L- (8 CI); L-Tyrosine, 3-hydroxy- (9 CI)

Alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, L- (8 CI); L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo- (9 CI)

Allyl alcohol (8 CI); 2-Propen-1-ol (9 CI)

alpha-[4-(1-Oxo-2-isoindolinyl)phenyl]propionic acid (No postings in CHEMLINE).

Aluminum

Ammonia

Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester) (8 CI); Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl- (9 CI)

Ammonium, (o-bromobenzyl)ethyldimethyl-, p-toluenesulfonate (8 CI); Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1) (9 CI)

Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, L- (8 CI); 1-Propanaminium, 3-(carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, (R)- (9 CI)

Ammonium, trimethyl(1-methyl-2-phenothiazin-10-ylethyl)-, methyl sulfate (8 CI); 10H-Phenothiazine-10-ethanaminium, N,N,N,alpha-tetramethyl-, methyl sulfate (9 CI)

Amphiboles

Aniline (8 CI); Benzenamine (9 CI)

Aniline, 4,4'-methylenebis(2-chloro- (8 CI); Benzenamine, 4,4'-methylenebis(2-chloro- (9 CI)

Aniline, 4,4'-sulfonyldi- (8 CI); Benzeneamine, 4,4'-sulfonylbis- (9 CI)

Anthranilic acid, N-(8-(trifluoromethyl)-4-quinolyl)-, 2,3-dihydroxypropyl ester (8 CI); Benzoic acid, 2-((8-(trifluoromethyl)-4-quinolinyl)amino)-, 2,3-dihydroxypropyl ester (9 CI)

Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Antimony

Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Arochlor 1242 (No postings in CHEMLINE).

Arochlor 1254

Aroclor 1260

Arsenic

Arsenic oxide [As2O3]

Arsine

Arsine oxide, hydroxydimethyl- (8 CI); Arsinic acid, dimethyl- (9 CI)

Asbestos

Attapulgite (VAN)

Barbituric acid, 5-(1-cyclohepten-1-yl)-5-ethyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohepten-1-yl)-5-ethyl- (9 CI)

Barbituric acid, 5-(1-cyclohexen-1-yl)-1,5-dimethyl- (8 CI) (VAN); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl- (9 CI)

Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Barbituric acid, 5-ethyl-5-(p-hydroxyphenyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(4-hydroxyphenyl)- (9 CI)

Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)- (9 CI)

Barbituric acid, 5-ethyl-5-(1-methylbutyl)-, sodium salt (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)-, monosodium salt (9 CI)

Barbituric acid, 5-ethyl-5-isopentyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)- (9 CI)

Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Barbituric acid, 5-sec-butyl-5-ethyl-, sodium salt (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylpropyl)-, monosodium salt (9 CI)

Barbituric acid, 5,5-diethyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl- (9 CI)

Barium

Benzaldehyde

Benzamide, p-amino-N-(2-(diethylamino)ethyl)- (8 CI); Benzamide, 4-amino-N-(2-(diethylamino)ethyl)- (9 CI)

Benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)-

Benzamide, 4-(acetylamino)-N-(2-(diethylamino)ethyl)-

Benzene

Benzene, chloro-

Benzene, ethyl-

Benzene, hexachloro-

Benzene, o-dichloro- (8 CI); Benzene, 1,2-dichloro- (9 CI)

Benzene, o-diethyl- (8 CI); Benzene, 1,2-diethyl- (9 CI)

Benzene, p-dichloro- (8 CI); Benzene, 1,4-dichloro- (9 CI)

Benzene, pentachloro-

Benzene, pentachloronitro-

Benzene, propyl-

Benzene, trimethyl-

Benzeneacetamide, N-(4-chlorophenyl)-N-(1-(1-methylethyl)-4-piperidinyl)-

Benzeneacetic acid, alpha,3-dichloro-4-cyclohexyl-

Benzenebutanoic acid, 2,4,5-triethoxy-gamma-oxo-

Benzeneethanol, alpha-(2-amino-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))-

Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-

Benzenesulfonamide, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)- (8 CI); Benzenesulfonamide, 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)- (9 CI)

Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester (8 CI); Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester (9 CI)

Benzoic acid, 2-((8-(trifluoromethyl)-4-quinolinyl)amino)-

Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester

Benzoic acid, 4-amino-2-chloro-

Benzonitrile

Benzophenone, 4,4'-dichloro- (8 CI); Methanone, bis(4-chlorophenyl)- (9 CI)

Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Benzylamine (8 CI); Benzenemethanamine (9 CI)

Beryllium

beta-D-Glucopyranosiduronic acid, cyanophenylmethyl, (R)-

BHC, Total (No postings in CHEMLINE).

Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

Biphenyl (8 CI); 1,1'-Biphenyl (9 CI)

Biphenyl, chloro (8 CI); 1,1'-Biphenyl, chloro derivs (9 CI)

Biphenyl, 2,3,3',4,4'-pentachloro- (8 CI); 1,1'-Biphenyl, 2,3,3',4,4'-pentachloro- (9 CI)

Biphenyl, 2,3',4,4',5-pentachloro- (8 CI); 1,1'-Biphenyl, 2,3',4,4',5-pentachloro- (9 CI)

Bismuth

Blecaycin

Boron

Brcmide

Brcsine

Butanamide, N-(2,6-dimethylphenyl)-2-(ethylpropylamino)-, (+-)-

Butanamide, N-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, (+-)-

Butane

Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl ester, N-oxide, (1P-(1alpha,7(2R*,3S*),7abeta))-

Butirosin

Butyl alcohol (8 CI); 1-Butanol (9 CI)

Butyric acid, 3-((2-amino-2-carboxyethyl)thio)-, stereoisomer (8 CI); L-Cysteine, S-(2-carboxy-1-methylethyl)- (9 CI)

Butyric acid, 4-(p-(bis(2-chloroethyl)amino)phenyl)- (8 CI); Benzenebutanoic acid, 4-(bis(2-chloroethyl)amino)- (9 CI)

Butyrophenone, 4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-4'-fluoro- (8 CI); 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- (9 CI)

Cadmius

Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Calcius

Camphor (8 CI); Bicyclo(2.2.1)heptan-2-one, 1,7,7-trimethyl- (9 CI)

Cartasic acid, (2-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethyl)-, methyl ester, (+-)-

Cartasic acid, methyl-, o-isopropoxyphenyl ester (8 CI); Phenol, 2-(1-methylethoxy)-, methylcarbamate (9 CI)

Cartasic acid, methyl-, 1-naphthyl ester (8 CI); 1-Naphthalenol, methylcarbamate (9 CI)

Cartasic acid, methyl-, 2,6-pyridinediyldimethylene ester (8 CI); 2,6-Pyridinedimethanol, bis(methylcarbamate) (ester) (9 CI)

Carbanilic acid, m-chloro-, isopropyl ester (8 CI); Carbamic acid, (3-chlorophenyl)-, 1-methylethyl ester (9 CI)

Carbanilide, trichloro- (8 CI); Urea, N,N'-diphenyl-, trichloro deriv. (9 CI)

Carbon disulfide

Carbon monoxide

Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Carbonate

Carbonylhemoglobin

Cefotaxime (No postings in CHEMLINE).

Cerius

Cesius

Cesius, isotope of mass 137

Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Chlordane

Chlorine

Chloroform (8 CI); Methane, trichloro- (9 CI)

Cholecalciferol (8 CI); 9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3beta,5Z,7E)-(9 CI)

Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Cholic acid (8 CI); Cholan-24-oic acid, 3,7,12-trihydroxy-, (3alpha,5beta,7alpha,12alpha)- (9 CI)

Chromius

Chrysotile (8 CI) (VAN); Chrysotile [H8Mg3(Si2O9)] (9 CI)

Citric acid, ion(3-) (8 CI); 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, ion(3-) (9 CI)

Coal (No postings in CHEMLINE).

Cobalt

Colchicine (8 CI): Acetamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-, (S)- (9 CI)

Copper

Cortisol (8 CI): Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Cotinine (8 CI): 2-Pyrrolidinone, 1-methyl-5-(3-pyridinyl-,(S)- (9 CI)

Coumarin (8 CI): 2H-1-Benzopyran-2-one (9 CI)

Coumarin, 3-(alpha-acetonylbenzyl)-4-hydroxy- (8 CI); 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)- (9 CI)

Coumarin, 3-(alpha-acetonylbenzyl)-4-hydroxy-, sodium salt (8 CI); 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, sodium salt (9 CI)

Cresol (8 CI) (VAN): Phenol, methyl- (9 CI)

Cumene (8 CI): Benzene, (1-methylethyl)- (9 CI)

Cyanide

Cyclohexane

Cyclohexane, methyl-

Cyclohexane, 1,2,3,4,5,6-hexachloro-, alpha- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5beta,6beta)- (9 CI)

Cyclohexane, 1,2,3,4,5,6-hexachloro-, beta- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2beta,3alpha,4beta,5alpha,6beta)- (9 CI)

Cyclohexane, 1,2,3,4,5,6-hexachloro-, delta- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3alpha,4beta,5alpha,6beta)- (9 CI)

Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Cyclohexaneethylamine, N,alpha-dimethyl- (8 CI); Cyclohexaneethanamine, N,alpha-dimethyl- (9 CI)

Cyclohexanol

Cyclohexanol, 1-ethynyl-, carbamate

Cyclohexylamine (8 CI); Cyclohexanamine (9 CI)

Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6aalpha,9aalpha-tetrahydro-4-methoxy- (8 CI); Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-4-methoxy-, (6aR-cis)- (9 CI)

Cyclopentane, methyl-

Cyclopentanol

Cyclopropylamine, 2-phenyl-, trans-(+-)- (8 CI); Cyclopropanamine, 2-phenyl-, trans-(+-)- (9 CI)

Cyclotetrasiloxane, 2,2,4,6,6,8-hexamethyl-4,8-diphenyl-, cis-

Cystine

D-Glucose, 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-2-deoxy-

D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N(1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-

D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-2-deoxy-

D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-N(1)-ethyl-

DDT, Total (No postings in CHEMLINE).

Decanal

Decane

Desmethyldoxepin (No postings in CHEMLINE).

Dibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine, N-methyl-, hydrochloride (8 CI); 1-Propanamine, 3-dibenz(b,e)oxepin-11(6H)-ylidene-N-methyl-, hydrochloride (9 CI)

Dibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine, N,N-dimethyl- (8 CI); 1-Propanamine, 3-dibenz(b,e)oxepin-11(6H)-ylidene-N,N-dimethyl- (9 CI)

Dibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine, N,N-dimethyl-, hydrochloride (8 CI); 1-Propanamine, 3-dibenz(b,e)oxepin-11(6H)-ylidene-N,N-dimethyl-, hydrochloride (9 CI)

Dibenz(b,f)(1,4)oxazepin-8-ol, 2-chloro-11-(1-piperazinyl)-

Dibenz(b,f)(1,4)oxazepin-8-ol, 2-chloro-11-(4-methyl-1-piperazinyl)-

Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

Dibenzo(b,e)thiepin-delta(11(6H),gamma)-propylamine, N,N-dimethyl- (8 CI); 1-Propanamine, 3-dibenzo(b,e)thiepin-11(6H)-ylidene-N,N-dimethyl- (9 CI)

Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-

Dibenzo-p-dioxin, 2,3,7,8-tetrachloro- (8 CI); Dibenzo(b,e)(1,4)dioxin, 2,3,7,8-tetrachloro- (9 CI)

Dibenzofuran, hexachloro-

Dibenzofuran, 1,2,4,7,8-pentachloro-

Dibenzofuran, 2,3,4,7,8-pentachloro-

Dibenzofuran, 2,3,6,8-tetrachloro-

Dibenzofuran, 2,3,7,8-tetrachloro-

Dibutylamine (8 CI); 1-Butanamine, n-butyl- (9 CI)

Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI)

Digitoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

Digoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Dimethylamine, N-nitroso- (9 CI); Methanamine, N-methyl-N-nitroso- (9 CI)

Dimethylpolysiloxane (No postings in CHEMLINE).

Dipyrido(1,2-a:2',1'-c)pyrazinediium, 6,7-dihydro-

Dodecane

Dodecylamine, N,N-dimethyl-, N-oxide (8 CI); 1-Dodecanamine, N,N-dimethyl-, N-oxide (9 CI)

DOC079 (No postings in CHEMLINE).

DOC478 (No postings in CHEMLINE).

Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) (8 CI); Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4,6-O-2-thienylmethylene)-beta-D-glucopyranosyl)oxy-, (5R-(5alpha,5abeta,8aalpha,9beta(R*)))- (9 CI)

Ergoline-8-acetonitrile, 2-chloro-6-methyl-, (8beta)-

Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

Erythromycin

Erythromycin, 2'-propionate (8 CI); Erythromycin, 2'-propanoate (9 CI)

Estra-1,3,5(10),6,8-pentaene-3,17alpha-diol (8 CI); Estra-1,3,5(10),6,8-pentaene-3,17-diol, (17alpha)- (9 CI)

Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy-

Estra-1,3,5(10),7-tetraene-3,17alpha-diol (8 CI); Estra-1,3,5(10),7-tetraene-3,17-diol, (17alpha)- (9 CI)

Estra-1,3,5(10),7-tetraene-3,17beta-diol (8 CI); Estra-1,3,5(10),7-tetraene-3,17-diol, (17beta)- (9 CI)

Estradiol (8 CI); Estra-1,3,5(10)-triene-3,17-diol, (17beta)- (9 CI)

Estradiol, 3-(bis(2-chloroethyl)carbamate) dihydrogen phosphate (8 CI); Estra-1,3,5(10)-triene-3,17-diol, (17beta)-, 3-(bis(2-chloroethyl)carbamate) 17-(dihydrogen phosphate) (9 CI)

Estrone (8 CI); Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9 CI)

Estrone, hydrogen sulfate (8 CI); Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)- (9 CI)

Ethane, 1,1-dichloro-

Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8 CI); Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)- (9 CI)

Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

Ethane, 1,1,1-trichloro-

Ethane, 1,1,1-trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8 CI); Benzene, 1-chloro-2-(2,2,2-trichloro-1-(4-chlorophenyl)ethyl)- (9 CI)

Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Ethane, 1,1,1-trichloro-2,2-bis(p-methoxyphenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-methoxy- (9 CI)

Ethane, 1,1,1-trichloro-2,2,2-trifluoro-

Ethane, 1,2-dichloro-

Ethane, 2-bromo-2-chloro-1,1,1-trifluoro-

Ethanol, 2-(2-(4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)- (8 CI); Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- (9 CI)

Ethanol, 2,2,2-trichloro-

Ethanol, 2,2',2'',2'''-((4,8-dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetra- (8 CI); Ethanol, 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis- (9 CI)

Ethene, dichlorodifluoro-

Ethyl alcohol (8 CI); Ethanol (9 CI)

Ethyl ether (8 CI); Ethane, 1-1'-oxybis- (9 CI)

Ethylamine, 1-methyl-2-(2,6-xylyloxy)- (8 CI); 2-Propanamine, 1-(2,6-dimethylphenoxy)- (9 CI)

Ethylamine, 2-(diphenylmethoxy)-N,N-diethyl- (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-diethyl- (9 CI)

Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Ethylene (8 CI); Ethene (9 CI)

Ethylene glycol (8 CI); 1,2-Ethanediol (9 CI)

Ethylene glycol, dinitrate (8 CI); 1,2-Ethanediol, dinitrate (9 CI)

Ethylene, chloro- (8 CI); Ethene, chloro- (9 CI)

Ethylene, chlorofluoro- (8 CI); Ethene, chlorofluoro- (9 CI)

Ethylene, tetrachloro- (8 CI); Ethene, tetrachloro- (9 CI)

Ethylene, trichloro- (8 CI); Ethene, trichloro- (9 CI)

Ethylene, 1,1-dichloro- (8 CI); Ethene, 1,1-dichloro- (9 CI)

Ethylene, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8 CI); Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)- (9 CI)

Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro- (9 CI)

Ferritins

Fluoride

Fluorine

Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Formamide, N-methyl-

Formamide, N,N-dimethyl

Furan

Gallium

Gentamicin

Gentamycin, sulfate (salt) (8 CI); Gentamicin, sulfate (salt) (9 CI)

Germanium

Glucitol, 1,4:3,6-dianhydro-, dinitrate, D- (8 CI); D-Glucitol, 1,4:3,6-dianhydro-, dinitrate (9 CI)

Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)-, L- (8 CI); L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, L-(+)- (8 CI); L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)- (9 CI)

Glutarimide, 2-ethyl-2-phenyl- (8 CI); 2,6-Piperidinedione, 3-ethyl-3-phenyl- (9 CI)

Glycine, N-(2-methylbenzoyl)-

Glyoxylic acid, phenyl- (8 CI); Benzeneacetic acid, alpha-oxo- (9 CI)

Gold

Guanidine, ((2,6-dichlorobenzylidene)amino)- (8 CI); Hydrazinecarboximidamide, 2-((2,6-dichlorophenyl)methylene)- (9 CI)

Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-

Guanidine, 1-benzyl-2,3-dimethyl- (8 CI); Guanidine, N,N'-dimethyl-N''-(phenylmethyl)- (9 CI)

Heptane

Heptane, 2,4-dimethyl-

Heptane, 2,5-dimethyl-

Heptyl alcohol (8 CI); 1-Heptanol (9 CI)

Hexachlorobenzol (No postings in CHEMLINE).

Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Hexane

Hexane, 1-chloro-

Hexane, 2,3-dimethyl-

Hexane, 2,3,5-trimethyl-

Hexane, 3,4-dimethyl-

Hexene

Hippuric acid (8 CI); Glycine, N-benzoyl- (9 CI)

Hippuric acid, m-methyl- (8 CI); Glycine, N-(3-methylbenzoyl)- (9 CI)

Hydantoin, 1-((5-nitrofurfurylidene)amino)- (8 CI); 2,4-Imidazolidinedione, 1-(((5-nitro-2-furanyl)methylene)amino)- (9 CI)

Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Hydracrylic acid, N,N-bis(2-chloroethyl)phosphorodiamidate (8 CI); Propanoic acid, 3-((amino(bis(2-chloroethyl)amino)-phosphinyl)oxy)- (9 CI)

Hydratropic acid, m-benzoyl- (8 CI); Benzeneacetic acid, 3-benzoyl-alpha-methyl- (9 CI)

Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

Hydratropic acid, 3-chloro-4-(3-pyrrolin-1-yl)- (8 CI); Benzeneacetic acid, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)-alpha-methyl- (9 CI)

Hydrazine

Hydroxymethylnitrofurantoin (No postings in CHEMLINE).

Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-

Imidazole-1-ethanol, alpha-(chloromethyl)-2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, alpha-(chloromethyl)-2-methyl-5-nitro- (9 CI)

Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Imidazole-2-thiol, 1-methyl- (8 CI); 2H-Imidazole-2-thione, 1,3-dihydro-1-methyl- (9 CI)

Indene (8 CI); 1H-Indene (9 CI)

Indicine (8 CI); Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl ester, (1R-(1alpha,7(2R*,3S*),7abeta))- (9 CI)

Indigo

Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Insulin

Iodide

Iodine

Iron

Isobutyl alcohol (8 CI); 1-Propanol, 2-methyl- (9 CI)

Isonicotinic acid hydrazide (8 CI); 4-Pyridinecarboxylic acid, hydrazide (9 CI)

Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8 CI); 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester (9 CI)

Isonipecotic acid, 4-phenyl-, ethyl ester (8 CI); 4-Piperidinecarboxylic acid, 4-phenyl-, ethyl ester (9 CI)

Isooctyl alcohol (8 CI); Isooctanol (9 CI)

Isopentyl alcohol (8 CI); 1-Butanol, 3-methyl- (9 CI)

Isoprene (8 CI); 1,3-Butadiene, 2-methyl- (9 CI)

Isopropyl alcohol (8 CI); 2-Propanol (9 CI)

Isoquinoline, 6,7-dimethoxy-1-veratryl- (8 CI); Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy- (9 CI)

Isoquinoline, 7,8-dichloro-1,2,3,4-tetrahydro-, hydrochloride

Isoquinoline, 8-amino-1,2,3,4-tetrahydro-2-methyl-4-phenyl- (8 CI); 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl- (9 CI)

Kenechlor 400

Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI)

L-Ascorbic acid

L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)-

L-threo-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-((1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-, trans-alpha- (8 CI); L-threo-alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, (2S-trans)- (9 CI)

Lactic acid, butyl ester (8 CI); Propanoic acid, 2-hydroxy-, butyl ester (9 CI)

Lactic acid, 3-(1-naphthyloxy)- (8 CI); Propanoic acid, 2-hydroxy-3-(1-naphthalenyloxy)- (9 CI)

Lanthanum

Lead

Leurocristine (8 CI); Vincaleukoblastine, 22-oxo- (9 CI)

Lithium

Lithium, ion (Li(1+))

m-Benzenedisulfonamide, 4-chloro-N(1)-methyl-N(1)-(tetrahydro-2-methyl furfuryl)- (8 CI); 1,3-Benzenedisulfonamide, 4-chloro-N(1)-methyl-N(1)-((tetrahydro-2-methyl-2-furanyl)methyl)- (9 CI)

m-Hydroxyphenylacetic acid (No postings in CHEMLINE).

m-Phenylenediamine, 4-methoxy- (8 CI); 1,3-Benzenediamine, 4-methoxy- (9 CI)

m-Toluamide, N,N-diethyl- (8 CI); Benzamide, N,N-diethyl-3-methyl- (9 CI)

m-Toluic acid, alpha,5-diacetamido-2,4,6-triiodo- (8 CI); Benzoic acid, 3-(acetylamino)-5-((acetylamino)methyl)-2,4,6-triiodo- (9 CI)

m-Tyrosine, I- (8 CI) (VAN); L-Phenylalanine, 3-hydroxy- (9 CI)

m-Xylene (8 CI); Benzene, 1,3-dimethyl- (9 CI)

Magnesium

Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

Malonamide, 2-ethyl-2-phenyl- (8 CI); Propanediamide, 2-ethyl-2-phenyl- (9 CI)

Mandelic acid (8 CI); Benzeneacetic acid, alpha-hydroxy- (9 CI)

Manganese

Melamine, pentamethyl- (8 CI); 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N''-pentamethyl- (9 CI)

Mercury

Mercury(1+), methyl-, ion (8 CI); Mercury(1+), methyl- (9 CI)

Mesitylene (8 CI); Benzene, 1,3,5-trimethyl- (9 CI)

Methane

Methane, dibromochloro-

Methane, dibromodichloro-

Methane, dichloro-

Methane, dichlorodifluoro-

Methane, dichlorofluoro-

Methane, dichloronitro-

Methane, trichlorofluoro-

Methanearsonic acid (8 CI); Arsonic acid, methyl- (9 CI)

Methanesulfonanilide, 4'-(1-hydroxy-2-(isopropylamino)ethyl)- (8 CI); Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)- (9 CI)

Methanol

Methionine, L- (8 CI); L-Methionine (9 CI)

Methyl disulfide (8 CI); Disulfide, dimethyl (9 CI)

Methyl sulfide (8 CI); Methane, thiobis- (9 CI)

Methylsulfone PCB (No postings in CHEMLINE).

Mineral dust (No postings in CHEMLINE).

Mineral fibers (No postings in CHEMLINE).

Molybdenum

Morphanthridine, 6-(4-methyl-1-piperazinyl)- (8 CI); 11H-Dibenz(b,e)azepine, 6-(4-methyl-1-piperazinyl)- (9 CI)

Morphinan-3-ol, 17-methyl-

Morphinan-3,14-diol, 17-(cyclobutylmethyl)- (9 CI)

Morphinan-3,6alpha-diol, 7,8-didehydro-4,5alpha-epoxy-17-methyl- (8 CI); Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)- (9 CI)

Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)- (9 CI)

Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl- (8 CI); Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, (5alpha)- (9 CI)

Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)- (9 CI)

Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy- (8 CI); Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-, (5alpha,6alpha)- (9 CI)

Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9 CI)

Morphinan-6beta-ol, 4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-ol, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6beta)- (9 CI)

Morpholine, 2-((2-ethoxyphenoxy)methyl)-

Morpholine, 4-(thioxo(3,4,5-trimethoxyphenyl)methyl)-

Naphthalene

Naphthalene, dimethyl-

Naphthalene, methyl-

Nickel

Nickel carbonyl [Ni(CO)4] (8 CI); Nickel carbonyl [Ni(CO)4], (T-4)- (9 CI)

Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI)

Nitrate

Nitric acid sodium salt

Nitric acid, gallium salt

Nitrogen

Nitrogen oxide [NO]

Nitroglycerin (8 CI); 1,2,3-Propanetriol, trinitrate (9 CI)

Nitrous acid, sodium salt

Nonane

Norhydrocodone (No postings in CHEMLINE).

Norzimelidine (No postings in CHEMLINE).

o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

o-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)- (8 CI); Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy- (9 CI)

o-Xylene (8 CI); Benzene, 1,2-dimethyl- (9 CI)

Octane

Octanoic acid, pentadecafluoro-, ammonium salt

Octyne

Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo-, hydrogen succinate (8 CI); Olean-12-en-29-oic acid, 3-(3-carboxy-1-oxopropoxy)-11-oxo-, (3beta,20beta)- (9 CI)

Oxalic acid (8 CI); Ethanedioic acid (9 CI)

Oxytocin

p-Acetophenetidide (8 CI); Acetamide, N-(4-ethoxyphenyl)- (9 CI)

p-Cresol, 2,6-di-tert-butyl- (8 CI); Phenol, 2,6-bis(1,1-dimethylethyl)-4-methyl- (9 CI)

p-Cymen-7-ol (8 CI); Benzenemethanol, 4-(1-methylethyl)- (9 CI)

p-Dioxane (8 CI); 1,4-Dioxane (9 CI)

p-Hydroxyphenylacetic acid (No postings in CHEMLINE).

p-Mentha-1,8-diene (8 CI); Cyclohexene, 1-methyl-4-(1-methylethenyl)- (9 CI)

p-Phenylenediamine (8 CI); 1,4-Benzenediamine (9 CI)

p-Tolualdehyde (8 CI); Benzaldehyde, 4-methyl- (9 CI)

p-Xylene (8 CI); Benzene, 1,4-dimethyl- (9 CI)

Palladium

PCT (No postings in CHEMLINE).

Penicillin (VAN)

Pentane, 2-methyl-

Pentane, 2,2,4-trimethyl-

Pentane, 3-ethyl-

Pentane, 3-methyl-

Pentanoic acid, 2-methyl-, ethyl ester

Pentyl alcohol (8 CI); 1-Pentanol (9 CI)

Phenethylamine (8 CI); Benzeneethanamine (9 CI)

Phenethylamine, alpha-methyl-, (+-)- (8 CI); Benzeneethanamine, alpha-methyl-, (+-)- (9 CI)

Phenethylamine, alpha-methyl-3,4-(methylenedioxy)- (8 CI); 1,3-Benzodioxole-5-ethanamine, alpha-methyl- (9 CI)

Phenethylamine, N-ethyl-alpha-methyl-m-(trifluoromethyl)- (8 CI); Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)- (9 CI)

Phenol

Phenol, m-(2-aminoethyl)- (8 CI); Phenol, 3-(2-aminoethyl)- (9 CI)

Phenol, m-chloro- (8 CI); Phenol, 3-chloro- (9 CI)

Phenol, o-chloro- (8 CI); Phenol, 2-chloro- (9 CI)

Phenol, p-amino- (8 CI); Phenol, 4-amino- (9 CI)

Phenol, p-chloro- (8 CI); Phenol, 4-chloro- (9 CI)

Phenol, p-nitro- (8 CI); Phenol, 4-nitro- (9 CI)

Phenol, pentachloro-

Phenol, tert-butyl-4-methoxy- (8 CI); Phenol, (1,1-dimethylethyl)-4-methoxy- (9 CI)

Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Phenol, 2,3,4,5-tetrachloro-

Phenol, 2,3,4,6-tetrachloro-

Phenol, 2,3,5-trichloro-

Phenol, 2,4-dichloro-

Phenol, 2,4,5-trichloro-

Phenol, 2,4,6-trichloro-

Phenol, 4-bromo-2,5-dichloro-

Phenothiazine, 10-[2-(dimethylamino)propyl]- (8 CI); 10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl- (9 CI)

Phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)- (8 CI); 10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfinyl)- (9 CI)

Phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylsulfonyl)- (8 CI); 10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfonyl)- (9 CI)

Phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylthio)- (8 CI); 10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylthio)- (9 CI)

Phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylthio)-, 5-oxide (8 CI); 10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylthio)-, 5-oxide (9 CI)

Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)- (9 CI)

Phenothiazine, 2-chloro-10-[3-(dimethylamino)propyl]- (8 CI); 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl- (9 CI)

Phosphate

Phosphoric acid, diethyl ester

Phosphoric acid, dimethyl ester

Phosphoric acid, dimethyl ester, ester with 3-hydroxy-N-methylcrotonamide, (E)- (8 CI); Phosphoric acid, dimethyl 1-methyl-3-(methylamino)-3-oxo-1-propenyl ester, (E)- (9 CI)

Phosphorodithioic acid, O,O-diethyl ester

Phosphorodithioic acid, O,O-diethyl ester, S-ester with 6-chloro-3-(mercaptomethyl)-2-benzoxazolinone (8 CI); Phosphorodithioic acid, S-[(6-chloro-2-oxo-3(2H)-benzoxazolyl)methyl] O,O-diethyl ester (9 CI)

Phosphorodithioic acid, O,O-dimethyl ester

Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-[(4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl] ester (9 CI)

Phosphorodithioic acid, S-[[(p-chlorophenyl)thio]methyl] O,O-diethyl ester (8 CI); Phosphorodithioic acid, S-[[(4-chlorophenyl)thio]methyl] O,O-diethyl ester (9 CI)

Phosphorodithioic acid, S,S'-methylene O,O,O',O'-tetraethyl ester

Phosphorothioic acid, O-(2,4-dichlorophenyl) O,O-diethyl ester

Phosphorothioic acid, O,O-diethyl ester

Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Phosphorothioic acid, O,O-diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(6-methyl-2-(1-methylethyl)-4-pyrimidinyl) ester (9 CI)

Phosphorothioic acid, O,O-diethyl O-(3,5,6-trichloro-2-pyridyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(3,5,6-trichloro-2-pyridinyl) ester (9 CI)

Phosphorothioic acid, O,O-dimethyl ester

Phosphorothioic acid, O,O-dimethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-dimethyl O-(4-nitrophenyl) ester (9 CI)

Phosphorus

Phthalazine, 1-hydrazino- (8 CI); 1(2H)-Phthalazinone, hydrazone (9 CI)

Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8 CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9 CI)

Piperidine, 1-(1-phenylcyclohexyl)-

Piperidine, 2-(2,2-dicyclohexylethyl)-

Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, trans-(-)-

Piperidine, 3-((4-methoxyphenoxy)methyl)-1-methyl-4-phenyl-, (3R-trans)-

Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate (8 CI); Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta, 17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl-, dibromide (9 CI)

Platinum

Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

Plumbane, chlorotriethyl-

Plumbane, chlorotrimethyl-

Plumbane, tetramethyl-

Plumbane, tetramethyl-

Polybrominated biphenyls (No postings in CHEMLINE).

Polychlorinated dibenzofurans (No postings in CHEMLINE).

Polychlorinated quaterphenyls (No postings in CHEMLINE).

Potassium

Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy-

Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl-, 21-acetate (8 CI); Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-6-methyl-, (6alpha,11beta)- (9 CI)

Pregna-1,4-diene-3,20-dione, 6alpha-fluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8 CI); Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(ox;))-, (6alpha,11beta,16alpha)- (9 CI)

Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-16alpha-methyl- (8 CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)- (9 CI)

Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-16alpha-methyl-, 21-(dihydrogen phosphate) (8 CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, (11beta,16alpha)- (9 CI)

Pregna-1,4,6-triene-3,20-dione, 6-chloro-11beta,17,21-trihydroxy- (8 CI); Pregna-1,4,6-triene-3,20-dione, 6-chloro-11,17,21-trihydroxy-, (11beta)- (9 CI)

Prolactin (VAN)

Proline, 4-hydroxy-, L- (8 CI); L-Proline, 4-hydroxy-, trans- (9 CI)

Propanamide, 2-amino-N-(2,6-dimethylphenyl)-

Propane

Propane, 2-nitro-

Propionanilide, N-(1-phenethyl-4-piperidyl)-, citrate (1:1) (8 CI); Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9 CI)

Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

Propionic acid, 3-mercapto-, ethyl ester (8 CI); Propanoic acid, 3-mercapto-, ethyl ester (9 CI)

Propionitrile, 3-amino- (8 CI); Propanenitrile, 3-amino- (9 CI)

Propiophenone (8 CI); 1-Propanone, 1-phenyl- (9 CI)

Propyl alcohol (8 CI); 1-Propanol (9 CI)

Propyne (8 CI); 1-Propyne (9 CI)

Pseudoephedrine, (+)- (8 CI); Benzeneethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))- (9 CI)

Pyridine, 2-(alpha-(2-(dimethylamino)ethyl)benzyl)- (8 CI); 2-Pyridinepropanamine, N,N-dimethyl-gamma-phenyl- (9 CI)

Pyridine, 2-(p-bromo-alpha-(2-(dimethylamino)ethyl)benzyl)- (8 CI); 2-Pyridinepropanamine, gamma-(4-bromophenyl)-N,N-dimethyl- (9 CI)

Pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethyl)benzyl)- (8 CI); 2-Pyridinepropanamine, gamma-(4-chlorophenyl)-N,N-dimethyl- (9 CI)

Pyridine, 2,6-diamino-3-(phenylazo)- (8 CI); 2,6-Pyridinediamine, 3-(phenylazo)- (9 CI)

Pyridinium, 1-((2-carboxy-8-oxo-7-(2-(2-thienyl)acetamido-)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, hydroxide, inner salt (8 CI) (VAN); Pyridinium, 1-((2-carboxy-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, hydroxide, inner salt, (6R-trans)- (9 CI)

Pyridinium, 2-formyl-1-methyl-, chloride, oxime (8 CI); Pyridinium, 2-((hydroxyimino)methyl)-1-methyl, chloride (9 CI)

Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester) (8 CI); Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl- (9 CI)

Pyridoxol (8 CI); 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl- (9 CI)

Pyrimidine, 2,4-diamino-5-(3,4,5,-trimethoxybenzyl)- (8 CI); 2,4-Pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- (9 CI)

Pyrimido(1,2-a)indol-10-ol, 10-(3-chlorophenyl)-2,3,4,10-tetrahydro-

Pyrrole-2-acetic acid, 1-methyl-5-p-toluoyl- (8 CI); 1H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)- (9 CI)

Pyrrole-2-acetic acid, 5-(p-chlorobenzoyl)-1,4-dimethyl- (8 CI); 1H-Pyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4-dimethyl- (9 CI)

Quartz (8 CI); Quartz (SiO_2) (9 CI)

Quinine (8 CI); Cinchonan-9-ol, 6'-methoxy-, (9S)- (9 CI)

Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)- (8 CI); 1,4-Pentanediamine, N(4)-(7-chloro-4-quinolinyl)-N(1),N(1)-diethyl- (9 CI)

Riboflavin

Rubidium

S-Sulfonate (No postings in CHEMLINE).

Salicylamide (8 CI); Benzamide, 2-hydroxy- (9 CI)

Salicylic acid (8 CI); Benzoic acid, 2-hydroxy- (9 CI)

Salicylic acid acetate (8 CI); Benzoic acid, 2-(acetyloxy)- (9 CI)

Salicylic acid, ion(1-) (8 CI); Benzoic acid, 2-hydroxy-, ion(1-) (9 CI) (VAN)

Salicylic acid, p-aminobenzoate (8 CI); Benzoic acid, 2-((4-aminobenzoyl)oxy)- (9 CI)

Salicylic acid, 4-amino- (8 CI); Benzoic acid, 4-amino-2-hydroxy- (9 CI)

Salicylic acid, 5-((p-(2-pyridylsulfamoyl)phenyl)azo)- (8 CI); Benzoic acid, 2-hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)- (9 CI)

Samarium

Sanguinarine (8 CI); (1,3)Benzodioxolo(5,6-c)-1,3-dioxolo(4,5-i)phenanthridinium, 13-methyl- (9 CI)

Scandium

Selenium

Silane, difluorodimethyl-

Silane, fluorotrimethyl-

Silica

Silicate (No postings in CHEMLINE).

Silicon

Silver

Sisomicin (8 CI); D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy- (9 CI)

Sodium

Sodium, ion ($Na(1+)$)

Sparteine (8 CI); 7,14-Methano-2H,6H-dipyrido(1,2-a:1',2'-e)(1,5)diazocine, dodecahydro-, (7S-(7alpha,7aalpha,14alpha,14abeta))- (9 CI)

Stainless steel

Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-6))-2-deoxy-, D- (8 CI); D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy- (9 CI)

Strontium

Strontium, isotope of mass 90

Strychnine (8 CI); Strychnidin-10-one (9 CI)

Styrene (8 CI); Benzene, ethenyl- (9 CI)

Styrene, octachloro- (8 CI); Benzene, pentachloro(trichloroethenyl)- (9 CI)

Succinamic acid, 3-amino-N-(alpha-carboxyphenethyl)-, N-methyl ester, stereoisomer (8 CI) (VAN); L-Phenylalanine, N-L-alpha-aspartyl-, 1-methyl ester (9 CI)

Succinic acid, mercapto-, diethyl ester, S-ester with O,O-diethyl phosphorodithioate (8 CI); Butanedioic acid, ((diethoxyphosphinothioyl)thio)-, diethyl ester (9 CI)

Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Sulfanilamide, N(1)-(3,4-dimethyl-5-isoxazolyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3,4-dimethyl-5-isoxazolyl)- (9 CI)

Sulfanilamide, N(1)-(4,6-dimethyl-2-pyrimidinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(4,6-dimethyl-2-pyrimidinyl)- (9 CI)

Sulfanilamide, N(1)-(5-methoxy-2-pyrimidinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(5-methoxy-2-pyrimidinyl)- (9 CI)

Sulfanilamide, N(1)-(5-methyl-3-isoxazolyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)- (9 CI)

Sulfanilamide, N(1)-2-pyridyl- (8 CI); Benzenesulfonamide, 4-amino-N-2-pyridinyl- (9 CI)

Sulfanilamide, N(1)-2-pyrimidinyl- (8 CI); Benzenesulfonamide, 4-amino-N-2-pyrimidinyl- (9 CI)

Sulfide (VAN)

Sulfide, methyl propyl (8 CI); Propane, 1-(methylthio)- (9 CI)

Sulfur

Sulfuric acid magnesium salt (1:1), compd. with 2,2'-dithiobis(pyridine) 1,1'-dioxide (1:1)

Technetium, isotope of mass 99

Tellurium

tert-Butyl disulfide (8 CI); Disulfide, bis(1,1-dimethylethyl) (9 CI)

Tetrahydrocannabinol cross-reacting cannabinoids (No postings in CHEMLINE).

Thallium

Theobromine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl- (9 CI)

Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Theophylline, compd. with ethylenediamine (2:1) (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, compd. with 1,2-ethanediamine (2:1) (9 CI)

Theophylline, 7-(2,3-dihydroxypropyl)- (8 CI); 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl- (9 CI)

Thiamine (8 CI); Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl-5-(2-hydroxyethyl)-4-m-ethyl- chloride (9 CI)

Thiazole, 5-(2-chloroethyl)-4-methyl-

Thiocyanic acid, ion(1-) (8 CI); Thiocyanate (9 CI)

Thiocyclopentane (No postings in CHEMLINE).

Thioether (No postings in CHEMLINE).

Thiopyrano(3,4-b)indole-1-ethanamine, 9-ethyl-1,3,4,9-tetrahydro-N,N,1-trimethyl-

Thioxanthene-delta(9,gamma)-propylamine, 2-chloro-N,N-dimethyl-, (E)- (8 CI); 1-Propanamine, 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-, (E)- (9 CI)

Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)- (8 CI); 9H-Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)- (9 CI)

Thymidine

Thyroxine, L- (8 CI); L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo- (9 CI)

Tir

Titanium

Tocopherol

Toluene (8 CI); Benzene, methyl- (9 CI)

Toluene-alpha, 2-diamine, 3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyl- (8 CI); Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl- (9 CI)

Toluene-2-sulphonamide (No postings in CHEMLINE).

Toluene-2,5-diamine (8 CI); 1,4-Benzenediamine, 2-methyl- (9 CI)

Toluene, o-nitro- (8 CI); Benzene, 1-methyl-2-nitro- (9 CI)

Trans-4-nonenal (No postings in CHEMLINE).

Tryptophan, 5-hydroxy-, L- (8 CI); L-Tryptophan, 5-hydroxy- (9 CI)

Tubocurarine (8 CI) (VAN); Tubocuraranium, 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyl- (9 CI)

Tungsten

Uracil, 5-fluoro- (8 CI) (VAN); 2,4(1H,3H)-Pyrimidinedione, 5-fluoro- (9 CI)

Uracil, 6-propyl-2-thio- (8 CI); 4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-2-thioxo- (9 CI)

Uranium

Urea, 1-((p-chlorophenyl)sulfonyl)-3-propyl- (8 CI); Benzenesulfonamide, 4-chloro-N-((propylamino)carbonyl)- (9 CI)

Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

Valeric acid, 2-propyl-, sodium salt (8 CI); Pentanoic acid, 2-propyl-, sodium salt (9 CI)

Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl- (8 CI); Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)- (9 CI)

Valine, 3-mercapto-, D- (8 CI); D-Valine, 3-mercapto- (9 CI)

Vanadium

Vitamin A

Vitamin B12

Zinc

Zinc, (dihydrogen 3,7,12,17-tetramethyl-8,13-divinyl-2,18-porphinedipropionato(2-))- (8 CI); Zinc, (7,12-diethenyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(2-)-N(21),N(22),N(23),N(24))-, (SP-4-2)- (9 CI)

Zirconium

1-(4'-Fluorophenyl)-4-(cyclohexyl-1'-piperazinyl-4'-carboxylate-butan-1-one hydrochloride (No postings in CHEMLINE).

1-Adamantanamine (8 CI); Tricyclo(3.3.1.1(3,7))decan-1-amine (9 CI)

1-Butanol, 2-ethyl-

1-Butanol, 2-methyl-

1-Butanone, 1-(10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-yl)- (8 CI); 1-Butanone, 1-(10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazin-2-yl)- (9 CI)

1-Butene

1-Butyne

1-Hexadecanol, hydrogen sulfate

1-Hexanethiol

1-Hexanol, 2-ethyl-

1-Naphthol (8 CI); 1-Naphthalenol

1-Octene, 2-methyl-

1-Pentanol, 2-ethyl-4-methyl-

1-Pentanol, 2,2-dimethyl-

1-Pentanol, 2,2,4-trimethyl-

1-Penten-4-yn-3-ol, 1-chloro-3-ethyl-

1-Pentene

1-Pentyn-3-ol, 3-methyl-

1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl-, (Z)-

1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-

1-Propanol, 2,2-dimethyl-, acetate

1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

1,1'-Biphenyl, 2,2',3,3',4,4',5-heptachloro-

1,1'-Biphenyl, 2,2',3,4,4',5,5'-heptachloro-

1,1'-Biphenyl, 2,2',3,4,4',5'-hexachloro-

1,1'-Biphenyl, 2,2',4,4',5,5'-hexachloro-

1,1'-Biphenyl, 2,3,3',4,4',5-hexachloro-

1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

1,2-Benzisothiazoline, 1,1-dioxide (8 CI); 1,2-Benzisothiazole, 2,3-dihydro-, 1,1-dioxide (9 CI)

1,2-Propanediol, 3-(p-chlorophenoxy)-, 1-carbamate (8 CI); 1,2-Propanediol, 3-(4-chlorphenoxy)-, 1-carbamate (9 CI)

1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate

1,3,4-Metheno-1H-cyclobuta(cd)pentalene, 1,1a,2,2,3,3a,4,5,5,5a,5b,6-dodecachlorooctahydro-

1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

1,3,5-Cycloheptatriene

1,4-Naphthalenedione, 2-(3,3-dichloro-2-propenyl)-3-hydroxy-

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI); 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, cis-(+)

1alphaH,5alphaH-Nortropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-, methyl ester, (1R-(exo,exo))- (9 CI)

1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester) (8 CI); Benzeneacetic acid, alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2,4))non-7-yl ester, (7(S)-(1alpha,2beta,4beta,5alpha,7beta))- (9 CI)

1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, (1R-(exo,exo))- (9 CI)

1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

1H-Isoindol-1-one, 2,3-dihydro-3-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2-phenyl-, (R*,S*)-(+-)-, (E)-2-butenedioate (1:1) (salt)

1H-Pyrazolo(3,4-d)pyrimidine-4,6(5H,7H)-dione

1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1)

1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-

1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl- (VAN)

10H-Phenothiazine-2-sulfonamide, 10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-N,N-dimethyl-

17alpha-Estradiol (8 CI); Estra-1,3,5(10)-triene-3,17-diol, (17alpha)- (9 CI)

17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol (8 CI); Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol, (17alpha)- (9 CI)

18,19-Dinor-17alpha-pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (+-)- (8 CI); 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)- (9 CI)

19-Nor-17alpha-pregn-4-en-20-yn-3-one, 17-hydroxy- (8 CI); 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17alpha)- (9 CI)

2(1H)-Isoquinolinecarboximidine, 3,4-dihydro- (8 CI); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro- (9 CI)

2(1H)-Pyrimidinone, tetrahydro-4-hydroxy-1-beta-D-ribofuranosyl-

2(1H)-Pyrimidinone, 4-amino-5-fluoro-

2-Butanol, 3-methyl-

2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol, alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)

2-Butanone

2-Butanone, 3,3-dimethyl-

2-Butene, (E)-

2-Butene, (Z)-

2-Ethyl-1-pentanol (No postings in CHEMLINE).

2-Hexanone

2-Hexene

2-Imidazoline, 2-(2,6-dichloroanilino)- (8 CI); Benzenamine, 2,6-dichloro-N-2-imidazolidinylidene- (9 CI)

2-Naphthacenecarboxamide,
4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo (8 CI) (7AM);
2-Naphthacenecarboxamide,
4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,
(4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))- (9 CI)

2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)- (8 CI); 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (S)- (9 CI)

2-Octanol

2-Oxazolidinone, 5-(hydroxymethyl)-3-m-tolyl- (8 CI); 2-Oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)- (9 CI)

2-Pentanone, 4-methyl

2-Piperidineacetic acid, alpha-phenyl-

2-Piperidineacetic acid, alpha-phenyl-, methyl ester

2-Piperidineethanol, alpha-(3,4-dihydroxyphenyl)-, erythro- (8 CI); 1,2-Benzenediol, 4-(hydroxy-2-piperidinylmethyl)-, (R*,S*)- (9 CI)

2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI)

2-Propanol, 1-(o-(allyloxy)phenoxy)-3-(isopropylamino)- (8 CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(2-(2-propenyloxy)phenoxy)- (9 CI)

2-Propanol, 1-(o-allylphenoxy)-3-(isopropylamino)- (8 CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(2-(2-propenyl)phenoxy)- (9 CI)

2-Propanol, 1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)-, (S)-(-)- (8 CI); 2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (S)- (9 CI)

2-Propanol, 1-(2-cyclopentylphenoxy)-3-((1,1-dimethylethyl)amino)-

2-Propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)-

2-Propanol, 1,1,1-trichloro-2-methyl-

2-Propen-1-amine, 3-(4-bromophenyl)-N-methyl-3-(3-pyridinyl)-, (E)-

2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-, (Z)-

2-Pyridineacetamide, alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl- (8 CI); 2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl- (9 CI)

2-Pyrrolidinone, 1-vinyl-, polymers, compd. with iodine (8 CI); 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. with iodine (9 CI)

2,2-Dimethyl-3-hexanone (No postings in CHEMLINE).

2,2-Dimethylhexanol (No postings in CHEMLINE).

2,2-Dimethyloctanol (No postings in CHEMLINE).

2,2,3,3-Tetramethylhexane (No postings in CHEMLINE).

2,3-Dibromopropanol (No postings in CHEMLINE).

2,3-Naphthalenediol, 5-(3,((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-

2,3,3-Trimethylhexane (No postings in CHEMLINE).

2,3,3,4-Tetramethylpentane (No postings in CHEMLINE).

2,4-Oxazolidinedione, 5,5-dimethyl-

2,4-Piperidinedione, 3,3-diethyl-5-methyl-

2,5-Hexanedione

2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11R*)-

2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-, 21-acetate (8 CI); Rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)- (9 CI)

2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide

2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide

2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide

2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide

2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide

2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI); 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro- (8 CI); 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- (9 CI)

2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-

2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(2-(diethylamino)ethyl)-5-(o-fluorophenyl)-1,3-dihydro- (8 CI); 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro- (9 CI)

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(o-chlorphenyl)-1,3-dihydro-3-hydroxy- (8 CI); 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy- (9 CI)

2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-methyl- (8 CI); 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl- (9 CI)

3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester) (8 CI) (VAN); Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester) (9 CI) (VAN)

3-Heptanone, 2-methyl-

3-Heptanone, 5-methyl-

3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

3-Hexanone, 2,4-dimethyl-

3-Hexen-1-ol, (E)-

3-Pentanone, 2-methyl-

3,3-Diethylpentane (No postings in CHEMLINE).

3,4-Dimethylheptane (No postings in CHEMLINE).

3,5-Pyrazolidinedione, 1,2-diphenyl-4-(2-(phenylsulfinyl)ethyl)-

3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl-

3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide (8 CI); 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-, 4-oxide (9 CI)

4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

4-Heptanone

4-Imidazoline-1-carboxylic acid, 3-methyl-2-thioxo-, ethyl ester (8 CI); 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester (9 CI)

4-Piperidinol, 1-(4,4-bis(p-fluorophenyl)butyl)-4-(4-chloro-alpha,alpha,alpha-trifluoro-m-tolyl)- (8 CI); 4-Piperidinol, 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)- (9 CI)

4-Piperidinol, 1,3-dimethyl-4-phenyl-, propionate (ester) (8 CI); 4-Piperidinol, 1,3-dimethyl-4-phenyl-, propanoate (ester), cis- (9 CI)

4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+-)-

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-((((((3-(methylsulfonyl)-2-oxo-1-imidazolidinyl)carbonyl)amino)phenylacetyl)amino)-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((((((2-oxo-1-imidazolidinyl)carbonyl)amino)phenylacetyl)amino)-, (2S-(2alpha,5alpha,6beta(S*)))-

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-, monopotassium salt (8 CI); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenoxyacetyl)amino)-, monopotassium salt, (2S-(2alpha,5alpha,6beta))- (9 CI)

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-, monosodium salt (8 CI) (VAN); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)- (2S-(2alpha,5alpha,6beta))-, monosodium salt (9 CI)

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((((((3-((2-furanylmethylene)amino)-2-oxo-1-imidazolidinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, 1,3-dihydro-3-oxo-1-isobenzofuranyl ester, (2S-(2alpha,5alpha,6beta(S*)))-

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D- (8 CI); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo, (2S-(2alpha,5alpha,6beta(S*)))- (9 CI)

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo, D-(-)- (8 CI); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))- (9 CI)

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo- (8 CI); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2-ethoxy-1-naphthalenyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))- (9 CI)

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo- (8 CI); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))- (9 CI)

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo- (8 CI); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))- (9 CI)

4,4'-Bipyridinium, 1,1'-dimethyl-

4,4'-Bipyridinium, 1,1'-dimethyl-, dichloride

4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

4,7-Methano-1H-indene, 1,2,3,4,5,6,7,8,8-nonachloro-2,3,3a,4,7,7a-hexahydro-, (1alpha,2beta,3alpha,3aalpha,4beta,7beta,7aalpha)-

4,7-Methanoindan, 1,2,4,5,6,7,8,8-octachloro-1,2-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 1a,2,3,4,5,6a,7,7-octachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside

4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI); 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)

4P-Pyrazolo(3,4-d)pyrimidin-4-one, 1,5-dihydro-

4H-s-Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(o-chlorophenyl)-1-methyl- (8 CI); 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl- (9 CI)

4H-1,3,2-Oxazaphosphorin-4-one, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide

5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-alpha-methyl-

5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-

5-Norbornene-2,3-dimethanol, 1,4,5,6,7,7-hexachloro-, cyclic sulfite (8 CI); 6,9-Methano-2,4,3-benzodioxathiepan, 6,7,8,9,10,10-hexachloro-1,5,5a,6,9,9a-hexahydro-, 3-oxide (9 CI)

5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino) 8-oxo, (6R-(6alpha,7beta(Z)))-

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, (6R-cis)-

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-((1H-tetrazol-1-ylacetyl)amino)-, (6R-trans)- (9 CI)

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester) (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-, (6R-trans)- (9 CI)

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester) (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-8-oxo-7-(((4-pyridinylthio)acetyl)amino)-, (6R-trans)- (9 CI)

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-(aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1-H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-trans)-

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methoxy-8-oxo-, (6R-(6alpha,7beta(R*)))-

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))-

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7beta(R*)))-

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-cyanoacetamido)-3-(hydroxymethyl)-8-oxo-, acetate (ester), monosodium salt (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-((cyanoacetyl)amino)-8-oxo-, monosodium salt, (6R-trans)- (9 CI)

5beta-Cardanolide, 3beta-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy- (8 CI); Cardanolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

5beta-Cholan-24-oic acid, 3alpha,7alpha-dihydroxy- (8 CI); Cholan-24-oic acid, 3,7-dihydroxy-, (3alpha,5beta,7alpha)- (9 CI)

5H-Cyclooct(b)indole, 5-(3-(dimethylamino)propyl)-6,7,8,9,10,11-hexahydro- (8 CI); 5H-Cyclooct(b)indole-5-propanamine, 6,7,8,9,10,11-hexahydro-N,N-dimethyl- (9 CI)

5H-Dibenz(b,f)azepine-5-carboxamide

5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)- (8 CI); 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N-methyl- (9 CI)

5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-, monohydrochloride (8 CI); 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N-methyl-, monohydrochloride (9 CI)

5H-Dibenz(b,f)azepine, 3-chloro-10,11-dihydro-5-(3-(methylamino)propyl)- (8 CI); 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N-methyl- (9 CI)

5H-Dibenz(b,f)azepine, 3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro- (8 CI);
5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- (9 CI)

5H-Dibenz(b,f)azepine, 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro- (8 CI);
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl- (9 CI)

5H-Dibenz(b,f)azepine, 5-[3-(dimethylamino)propyl]-10,11-dihydro- (8 CI);
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl- (9 CI)

5H-Dibenz(b,f)azepine, 5-[3-(dimethylamino)propyl]-10,11-dihydro-, monohydrochloride (8 CI);
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride (9 CI)

5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N-methyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methyl- (9 CI)

5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl-, hydrochloride (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-, hydrochloride (9 CI)

5H-Dibenzo(a,d)cycloheptene-5-propylamine, N-methyl- (8 CI); 5H-Dibenzo(a,d)cycloheptene-5-propanamine, N-methyl- (9 CI)

5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-

6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl- (8 CI);
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- (9 CI)

6H-Dibenzo(b,d)pyran-1-ol, 3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-

6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-

7H-Furo(3,2-g)(1)benzopyran-7-one, 9-methoxy-

8-Quinolinol, 5-nitro

9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl- (8 CI); 9,10-Ethanoanthracene-9(10H)-propanamine, N-methyl- (9 CI)

9,10-Secocholesta-5,6,10(19)-triene-1alpha,3beta,25-triol (8 CI);
9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1alpha,3beta,5Z,7E)- (9 CI)

9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)

APPENDIX C

Chemicals (Vol. IV)
by CAS Registry Numbers and Preferred Names

(-)-2-Hydroxy-N-cyclopropylmethylmorphinan (No postings in Chemline).

Cefotaxime (No postings in CHEMLINE).

Polybrominated biphenyls (No postings in CHEMLINE).

Polychlorinated quaterphenyls (No postings in CHEMLINE).

Tetrahydrocannabinol cross-reacting cannabinoids (No postings in CHEMLINE).

Thioether (No postings in CHEMLINE).

50-06-6 Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

50-18-0 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide (8 CI); 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

50-28-8 Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

50-29-3 DDT, total (No postings in CHEMLINE).

Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

50-36-2 1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

50-37-3 Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

50-48-6 5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

50-81-7 L-Ascorbic acid

51-41-2 Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

53-86-1 Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

54-11-5 Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI)

54-31-9 Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]- (9 CI)

55-18-5 Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI)

56-23-5 Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

56-38-2 Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

56-53-1 4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

56-75-7 Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

57-12-5 Cyanide

57-41-0 Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

57-66-9 Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-[(dipropylamino)sulfonyl]- (9 CI)

57-88-5 Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

58-08-2 Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

58-15-1 Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

58-55-9 Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

58-89-9 BHC, Total (No postings in CHEMLINE).

Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

59-30-3 Folic acid (8 CI); L-Glutamic acid,
N-(4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl)- (9 CI)

60-57-1 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-,
endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth[2,3-b]oxirene,
3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-,
(1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

60-80-0 Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

62-75-9 Dimethylamine, N-nitroso- (8 CI); Methanamine, N-methyl-N-nitroso- (9 CI)

63-36-5 Salicylic acid, ion(1-) (8 CI); Benzoic acid, 2-hydroxy-, ion(1-) (9 CI) (VAN)

64-17-5 Ethyl alcohol (8 CI); Ethanol (9 CI)

67-56-1 Methanol

67-66-3 Chloroform (8 CI); Methane, trichloro- (9 CI)

68-19-9 Vitamin B12

69-23-8 1-Piperazineethanol, 4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]- (8 CI);
1-Piperazineethanol, 4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]- (9 CI)

70-30-4 Phenol, 2,2'-methylenebis[3,4,6-trichloro-

71-63-6 Digitoxin (8 CI); Card-20(22)-enolide,
3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2
,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

72-48-6 4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone,
2-methyl-3-(2-methylphenyl)- (9 CI)

72-54-8 Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene,
1,1'-(2,2-dichloroethylidene)bis[4-chloro- (9 CI)

72-55-9 Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(dichloroethenylidene)bis[4-chloro- (9 CI)

75-09-2 Methane, dichloro-

75-15-0 Carbon disulfide

75-43-4 Methane, dichlorofluoro-

75-69-4	Methane, trichlorofluoro-
76-44-8	4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)
76-57-3	Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9 CI)
76-73-3	Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)
76-74-4	Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)- (9 CI)
76-99-3	3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-
77-07-6	Morphinan-3-ol, 17-methyl-
77-67-8	Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)
81-07-2	1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)
84-74-2	Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)
86-50-0	Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)
90-82-4	Pseudoephedrine, (+)- (8 CI); Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))- (9 CI)
99-66-1	Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)
100-42-5	Styrene (8 CI); Benzene, ethenyl- (9 CI)
100-97-0	Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)
103-90-2	Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)
107-06-2	Ethane, 1,2-dichloro-
108-38-3	m-Xylene (8 CI); Benzene, 1,3-dimethyl- (9 CI)
108-88-3	Toluene (8 CI); Benzene, methyl- (9 CI)
108-91-8	Cyclohexylamine (8 CI); Cyclohexanamine (9 CI)
117-81-7	Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)
117-89-5	Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI)
118-74-1	Benzene, hexachloro-
124-48-1	Methane, dibromochloro-
125-33-7	4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-
137-58-6	2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)
143-02-2	1-Hexadecanol, hydrogen sulfate

143-50-0 1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

144-62-7 Oxalic acid (8 CI); Ethanedioic acid (9 CI)

146-22-5 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

147-24-0 Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

152-47-6 Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

298-46-4 5H-Dibenz(b,f)azepine-5-carboxamide

302-17-0 Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

303-49-1 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8 CI); 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- (9 CI)

309-00-2 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI); 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

439-14-5 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

443-48-1 Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

469-62-5 2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzenemethanol, alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)

469-79-4 1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

519-09-5 1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, (1R-(exo,exo))- (9 CI)

525-66-6 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI)

594-18-3 Methane, dibromodichloro-

628-96-6 Ethylene glycol, dinitrate (8 CI); 1,2-Ethanediol, dinitrate (9 CI)

630-08-0 Carbon monoxide

657-24-9 Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

692-13-7 Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

695-53-4 2,4-Oxazolidinedione, 5,5-dimethyl-

738-70-5 Pyrimidine, 2,4-diamino-5-(3,4,5,-trimethoxybenzyl)- (8 CI); 2,4-Pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- (9 CI)

882-09-7 Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

1024-57-3 4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

1088-11-5 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

1162-65-8 Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6aalpha,9aalpha-tetrahydro-4-methoxy- (8 CI); Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-4-methoxy-, (6aR-cis)- (9 CI)

1309-38-2 Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

1332-21-4 Asbestos

1332-40-3 Carbanilide, trichloro- (8 CI); Urea, N,N'-diphenyl-, trichloro deriv. (9 CI)

1336-36-3 Biphenyl, chloro (8 CI); 1,1'-Biphenyl, chloro derivs (9 CI)

1337-76-4 Attapulgite (VAN)

1406-66-2 Tocopherol

1622-61-3 2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro- (8 CI); 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- (9 CI)

1695-77-8 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI); 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)

1972-08-3 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

1977-10-2 Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

1977-11-3 Morphanthridine, 6-(4-methyl-1-piperazinyl)- (8 CI); 11H-Dibenz(b,e)azepine, 6-(4-methyl-1-piperazinyl)- (9 CI)

2768-72-9 Dipyrido(1,2-a:2',1'-c)pyrazinediium, 6,7-dihydro-

3828-82-6 Ethylene, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8 CI); Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)- (9 CI)

3562-88-3 Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI)

4008-48-4 8-Quinolinol, 5-nitro

4685-14-7 4,4'-Bipyridinium, 1,1'-dimethyl-

6621-87-2 Piperidine, 2-(2,2-dicyclohexylethyl)-

6673-35-4 Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)

7429-90-5 Aluminum

7439-89-6 Iron

7439-92-1 Lead

7439-93-2 Lithium

7439-95-4 Magnesium

7439-96-5 Manganese

7439-97-6 Mercury

7440-02-0	Nickel
7440-05-3	Palladium
7440-06-4	Platinum
7440-09-7	Potassium
7440-21-3	Silicon
7440-22-4	Silver
7440-23-5	Sodium
7440-24-6	Strontium
7440-28-0	Thallium
7440-31-5	Tin
7440-38-2	Arsenic
7440-39-3	Barium
7440-43-9	Cadmium
7440-47-3	Chromium
7440-48-4	Cobalt
7440-50-8	Copper
7440-57-5	Gold
7440-62-2	Vanadium
7440-66-6	Zinc
7440-67-7	Zirconium
7440-69-9	Bismuth
7440-70-2	Calcium
7553-56-2	Iodine
7704-34-9	Sulfur
7723-14-0	Phosphorus
7726-95-6	Bromine
7782-41-4	Fluorine
7782-49-2	Selenium
7782-50-5	Chlorine
9002-62-4	Prolactin (VAN)

9004-10-8 Insulin

9041-29-4 Carbonylhemoglobin

10262-69-8 9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl- (8 CI);
9,10-Ethanoanthracene-9(10H)-propanamine, N-methyl- (9 CI)

11103-57-4 Vitamin A

12001-29-5 Chrysotile (8 CI) (VAN); Chrysotile [H8Mg3(Si2O9)] (9 CI)

13463-39-3 Nickel carbonyl [Ni(CO)4] (8 CI); Nickel carbonyl [Ni(CO)4], (T-4)- (9 CI)

15318-45-3 Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)- ,
D-threo-(+)- (8 CI); Acetamide,
2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))-
(9 CI)

15663-27-1 Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

15676-16-1 o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide,
5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

15686-71-2 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid,
7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI);
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid,
7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

15687-27-1 Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

16268-62-5 Melamine, pentamethyl- (8 CI); 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N''-pentamethyl- (9 CI)

16984-48-8 Fluoride

17560-51-9 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-(8 CI);
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- (9 CI)

19216-56-9 Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8 CI); Piperazine,
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9 CI)

19356-17-3 9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI);
9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)

20830-75-5 Digoxin (8 CI); Card-20(22)-enolide,
3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2
,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

22316-47-8 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-

22345-47-7 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-

22967-92-6 Mercury(1+), methyl-, ion (8 CI); Mercury(1+), methyl- (9 CI)

23031-25-6 Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol,
5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

23214-92-8 Adriamycin (8 CI); 5,12-Naphthacenedione,
10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy
-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9 CI)

24219-97-4 Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-

24959-67-9 Bromide

24880-48-8 4,7-Methanoindan, 1,2,4,5,6,7,8,8-octachloro-1,2-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 1a,2,3,4,5,6a,7,7-octachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

31828-71-4 Ethylamine, 1-methyl-2-(2,6-xylyloxy)- (8 CI); 2-Propanamine, 1-(2,6-dimethylphenoxy)- (9 CI)

32385-11-8 Sisomicin (8 CI); D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy- (9 CI)

34787-01-4 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-

35607-66-0 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, (6R-cis)-

35619-65-9 Morpholine, 4-(thioxo(3,4,5-trimethoxyphenyl)methyl)-

39765-80-5 4,7-Methano-1H-indene, 1,2,3,4,5,6,7,8,8-nonachloro-2,3,3a,4,7,7a-hexahydro-, (1alpha,2beta,3alpha,3aalpha,4beta,7beta,7aalpha)-

39860-99-6 10H-Phenothiazine-2-sulfonamide, 10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-N,N-dimethyl-

42399-41-7 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, cis-(+)-

46817-91-8 Morpholine, 2-((2-ethoxyphenoxy)methyl)-

51481-61-9 Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-

53772-82-0 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl-, (Z)-

53994-73-3 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))-

56775-88-3 2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-, (Z)-

57109-90-7 1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1)

59729-33-8 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-

60719-84-8 (3,4'-Bipyridin)-6(1H)-one, 5-amino-

68892-97-2 5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-

68875-42-3 Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-

APPENDIX D

Cross-Referenced Chemical Lists (Vol. IV)

1. CAS Preferred Names – Common Names, page 285
2. Common Names – CAS Preferred Names, Page 301

(-)-2-Hydroxy-N-cyclopropylmethylmorphinan (No postings in Chemline).

(-)-2-Hydroxy-N-cyclopropylmethylmorphinan; MCMM

(3,4'-Bipyridin)-6(1H)-one, 5-amino-

Amrinone; Win 40680

Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)- , D-threo-(+)- (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))- (9 CI)

D-Thiocymetin; D-Thiophenicol; Dextrosulphenidol; Methylsulfonylchloramphenicol; Thiamphenicol; Thiocymetin; Thiophenicol; Win 5063-2; 8065CB

Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Alficetyn; Amphenicol; Amphicol; Amseclor; Austracol; CAF; CAM; CAP; CPh; Catilan; Chemicetin; Chesicetina; Chlomycol; Chloramex; Chloramphenicol; Chloramsaar; Chlorocaps; Chlorocid; Chlorocide; Chlorocidin C; Chlorocidin C tetran; Chloromycetin; Chloromitrin; Cidocetine; Ciplamycetin; Chloramicol; Cloramphicin; Clorocyn; Cloromisan; Cylphenicol; Detreomycin; D-Chloramphenicol; D-(-)-Chloramphenicol; D-threo-Chloramphenicol; D-(-)-threo-Chloramphenicol; Embacetin; Enciol; Enteromycetin; Paraxicetina; Fenicol; Globenicol; I 337A; Intramycetin; Isnicetina; Juvamycetin; Kamaver; Kemicetine; Klorita; Klorocid S; Leukomycan; Leukomycin; Levosicetina; Levomitsetin; Levomycetin; Loromisin; Mastiphen; Micloretin; Microcetina; Mychel; Mycinol; Mormimycin V; Moromycetin; Opclor; Opthochlor; Pantovernil; Paraxin; Quesicetina; Septicol; Sintomicetina; Sintomicetine N; Stanomycetin; Synthomycetine; Tevcocin; Tifomycine; Treomicetina; Unimycetin

Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)

AY 2101; Dalzic; Eraldin; ICI 50172; Practalol; Practolol; Teranol; 1-(4-acetamidophenoxy-3-isopropylamino-2-propanol; 4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide

Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

APAP; Abensanil; Acamol; Acetagesic; Acetalgin; Acetaminofen; Acetaminophen; Algotropyl; Alvedon; Amadil; Anaflon; Anelix; Apamid; Apamide; Bickie-acl; Ben-u-ron; Calpol; Cetadol; Clixodyne; Dial-a-gesic; Dirox; Dymadon; Emeril; Febrilix; Febro-Gesic; Febrolin; Fendon; Finimol; Hedex; Homoclan; Lestemp; Liquagesic; Lonarid; Lyteca; Lyteca syrup; Multin; N-Acetyl-p-aminophenol; N-acetyl-4-aminophenol; NAPA; NAPAP; Napafen; Naprinol; Nobedon; N-(4-Hydroxyphenyl)acetamide; p-Acetamidophenol; p-(Acetylamino)phenol; Paecmo; p-Hydroxyacetanilide; Panadol; Panets; Paracetamol; Paracetamole; Parmol; Pedric; Phendon; Pyrinazine; Tabalgin; Teslo; Tespanal; Tespra; Tralgon; Tussapap; Tylenol; Valadol; Valgesic; 4-Acetamidophenol; 4-Acetaminophenol; 4-Hydroxyacetanilide; 4'-Hydroxyacetanilide

Adriamycin (8 CI); 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9 CI)

Adriblastin; Doxorubicin; F.I. 106; NSC 123127; 14-Hydroxydaunomycin

Aluminum

AA 1099; AA 1199; A 00; A 95; A 99; A995; A999; ADO; AD 1; AD1-N; AE; AO Al; AE2; AV000; AV00; Aluminium; Aluminium Flake; Aluminum; Aluminum Dehydrated; Aluminum Powder; Aluminum A00; Aluminum-27; CI 77000; Epoxy Atomized Aluminum Powder; JISC 3108; JISC 3110; L16; Metana; Metana Aluminium Paste; Noral Aluminium; Noral Extra Fine Lining Grade; Noral Ink Grade Aluminium; PAP-1

Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Aisemide; Beronald; Desdemin; Ercolon; Frusemide; Frusemin; Fulmix; Fuluvamide; Furanthril; Furanthryl; Furantril; Furesis; Furomonid; Furosemide; Furosemid; Furoside; Fusid; Katlex; LB 502; Lasex; Lasilix; Lasix; Lowatron; Macasirool; Nicorol; Prefemin; Radonna; Rosemide; Salix; Seguril; Transit; Trofurit; Urex; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; 4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid

Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Analgesine; Anodynin; Anodynine; Antipirin; Antipyrin; Apirolina; Azophen; Azophene; Dimethyloxychinizin; Dimethyloxyquinazine; Fenazone; Methozin; Oxydimethylquinazine; Phenazon; Phenazone [pharmaceutical]; Phenazone; Phenylon; Phenylone; Pyrazophyl; Sedatin; Sedatine

Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Amidazophen; Amidazophene; Amidofebrin; Amidofen; Amidophen; Amidophenazon; Amidophenazone; Amidopyrazoline; Amidopyrin; Amidopyrine; Aminophenazone; Aminopyrin; Aminopyrine; Anafebrina; Brufaneuxal; Dereuma; Disapyrin; Dimethylamino-analgesine; Dimethylaminoantipyrine; Dimethylaminoazophene; (Dimethylamino)phenazone; Dimethylaminophenyldimethylpyrazolone; Dipirin; Dipyrin; Dipyrine; Febrinina; Febron; Itamidone; Masallet-A; Novamidon; Piridol; Piramidon; Piromidina; Polimalin; Pyradone; Pyramidon; Pyramidone; 4-Dimethylaminophenazone; 4-(Dimethylamino)antipyrine

Arsenic

Arsenic; Arsenic-75; Arsenic black; Grey arsenic; Metallic arsenic

Asbestos

Amianthus; Asbestos; Asbestos fiber

Attapulgite (VAN)

Attaclay; Attacote; Attagel; Attagel 40; Attagel 50; Attagel 150; Attasorb; Min-U-Gel FG; Min-U-Gel 200; Permagel; RVM-FG; X 250; Zeogel; 2000/P-RVM

Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Barbosec; Evronal; Hypotrol; Imenox; Meballymal; Quinalbarbital; Quinalbarbitone; Quinobarbitone; Secotarbital; Secobarbitone; Seconal; 5-Allyl-5-(1-methylbutyl)barbituric acid

Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)- (9 CI)

Ethamiral; Nebubarbital; Nembutal; Neodorm; Pentabarbitone; Pentobarbital; Pentobarbitone; Pentobarbituric acid; Rivadorm; 5-Ethyl-5-(sec-pentyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)barbituric acid

Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Adonal; Agrypnal; Asylofene; Barbenyl; Barbiphenyl; Barbipil; Barbita; Barbivis; Blu-phen; Chinoin; Cratecil; Dormiral; Doscalun; Duneryl; Eukabarb; Etilfen; Eunoryl; Fenemal; Gardenal; Gardepanyl; Hystops; Lepinal; Lepinaletten; Liquital; Lixophen; Lubergal; Luminal; Neurobarb; Noptil; Nunol; Phenaemal; Phenemal; Phenobarbital; Phenobarbitone; Phenobarbituric acid; Phenoluric; Phenonyl; Phenylethylbarbituric acid; Phenylethylmalonylurea; Phenyral; Phob; Sedonal; Sedophen; Sevenal; Somonal; Stental Extentabs; Teolaxin; Triphenatol; Versomnal; 5-Phenyl-5-ethylbarbituric acid; 5-Ethyl-5-phenylbarbituric acid

Barium

Barium

Benzene, hexachloro-

Anatin; Anticarie; Bunt-cure; Bunt-no-more; Co-op Hexa; HCB; Hexachlorobenzene; Julie's carbon chloride; No Bunt; No Bunt Liquid; No Bunt 40; No Bunt 80; Pentachlorophenyl chloride; Perchlorobenzene; Sanocide; Smeciotox

Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Apurina; Benecid; Benemid; Benuryl; Ethamide; Probecid; Proben; Probenecid; Probenecid acid; Prolongine; Synergid B; Tubophan; Uricosid; p-(Dipropylsulfamoyl)benzoic acid; p-(Dipropysulfamyl)benzoic acid; 4-(Diproylsulfamoyl)benzoic acid

Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

Brican; Bricanyl; Bricar; Bricaril; Bricyn; KWD 2019; Terbutalin; Terbutaline; 1-(3,5-dihydroxyphenyl)-2-(tert-butylamino)ethanol

Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Adrenor; Artamin; (-)-alpha(Aminomethyl)protocatechuyl alcohol; Arterenol; Levarterenol; Levoarterenol; Levonoradrenaline; Levorepinephrine; Levophed; Noradrenalin; Noradrenaline; (-)-Noradrenaline; Norartrinal; Norepinephrine; (-)-Norepinephrine; Norepirenamine; Nor-Epirenan; 1-Arterenol; 1-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol; 1-Noradrenaline; 1-Norepinephrine; 1-(-)-Norepinephrine; 1-3,4-Dihydroxyphenylethanolamine; 1-(3,4-Dihydroxyphenyl)-2-aminoethanol; 2-Amino-1-(3,4-dihydroxyphenyl)ethanol

BHC, Total (No postings in CHEMLINE).

BHC, Total; HCH, Total

Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

Buformin; Buformine; Butformin; Butylbiguanide; Butyldiguanide; DBV; Glybigid; H 224; N(1)-Butylbiguanide; N 37; 1-Butylbiguanide

Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

DMGG; Diatetosan; Diabex; Dimethylbiguanide; Flumamine; Flumasine; Gliguanid; Glucophage; Maurymelin; LA 6023; Melbin; Metformin; NNDG; N,N-Dimethylbiguanide; N,N-Dimethyldiguanide; N(1),N(1)-Dimethylbiguanide; 1,1-Dimethylbiguanide

Biphenyl, chloro (8 CI); 1,1'-Biphenyl, chloro deriv (9 CI)

PCB; Biphenyl, chlorinated; Chlorinated diphenyl

Bismuth

Bismuth; Bismuth-209

Bromide

Bromide anion; Bromide ion; Bromide (1-); Bromine, ion (Br(1-)); Bromine ion; Bromine ion(1-); Hydrobromic acid, ion(1-)

Bromine

Bromine

Cadmium

Cadmium; C.I. 77180

Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Alert-Pep; Cafeina; Caffein; Caffeine; Cafipel; Coffeine; Guaranine; Koffein; Mateina; Methyltheobromine; Mc-Dor; Refresh'm; Stim; Thein; Theine; 1,3,7-Trimethylxanthine; 1,3,7-Trimethyl-2,6-dioxopurine

Calcium

Calcium; Dietary calcium; Praval

Carbanilide, trichloro- (8 CI); Urea, N,N'-diphenyl-, trichloro deriv. (9 CI)

Trichlorocarbanilide

Carbon disulfide

Carbon bisulfide; Carbon bisulphide; Carbon disulphide; Carbon sulfide [CS2]; Dithiocarbonic anhydride

Carbon monoxide

Carbon monoxide; Carbon oxide (CO); Exhaust gas; Flue gas

Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Benzinoform; Carbon chloride [CCl4]; Carbona; Flukoids; Necatorina; Perchloromethane; R 10; Tetrachloromethane; Tetrafinol; Tetraform; Tetrasol; Univerm; Vermoestricid

Carbonylhemoglobin

Carboxyhemoglobin

Cefotaxime (No postings in CHEMLINE).

Cefotaxime

Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

910; Bi 3811; Chloral, monohydrate; Chloralderat; Dormal; Hydral; Lorinal; Noctec; Mycoton; Mycton; Phaldrone; Rectules; Somnos; Tosyl; Trawotox; Trichloroacetaldehyde hydrate; Trichloroacetaldehyde monohydrate; 1,1,1-Trichloro-2,2-dihydroxyethane; 2,2,2-Trichloro-1,1-ethanediol

Chlorine

Chlorine

Chlorofora (8 CI); Methane, trichloro- (9 CI)

Trichlorofora; Trichloromethane; R 20 [refrigerant]; R 20

Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Cholest-5-en-3beta-ol; Cholesterin; Cholesterol; (-)-Cholesterol; Cholesterol base H; Cholesteryl alcohol; Cordulan; Dugoran; Dusoline; Dythol; Hydrocerin; Kathro; Lanol; Nisco Cholesterol base H; Nisco cholesterol base No. 712; Provitamin D; Tegolan; Wood alcohols B.P.; 3beta-Hydroxycholest-5-ene; 5:6-Cholesten-3beta-ol

Chromium

Chromium

Chrysotile (8 CI) (VAN); Chrysotile [$H_4Mg_3(SiO_4)_2$] (9 CI)

Avibest C; Calidria RG 100; Calidria RG 144; Calidria RG 600; Cassiar AA; Chrysotile asbestos; Hooker no. 1 chrysotile asbestos; M 6-30; Plastibest 20; RG 600; Serpentine chrysotile; Sylodex; 5R04

Cobalt

C.I. 77320; Cobalt; Cobalt-59

Copper

Alibri Natural Copper; Anac 110; Arwood copper; CDA 101; CDA 102; CDA 110; CDA 122; C.I. Pigment Metal 2; C.I. 77400; CuEP; CuEPP; Cu M3; Copper; Copper M 1; Copper powder; DCuP1; E-Cu57; Kafar copper; M1 [copper]; M2 [copper]; M3 [copper]; M4 [copper]; M31; M35; M 1; M 3; M 4; OFHC Cu; Raney copper; 1721 Gold

Cyanide

Carbon nitride ion ($CN^{(1-)}$); Cyanide anion; Cyanide ($CN^{(1-)}$); Cyanide ion; Cyanide(1-); Cyanide(1-) ion; Hydrocyanic acid, ion(1-); Isocyanide

Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Aalindan; Aficide; Agrocide; Agrocide III; Agrocide WP; Ameisentod; Ameisenmittel merk; Aparasin; Aphtiria; Aplidal; Arbitex; BBH; Ben-Hex; Bentox 10; Bexol; BHC; Celanex; Chlorasene; Codechine; DBH; Detmol-Extrakt; Devoran; Dol Granule; Drilltox-Spezial Aglukon; Entomoxan; ENT 7,796; Forst-Hexen; Gamma benzene hexachloride; gamma-Benzene hexachloride; gamma-BHC; gamma-HCH; gamma-Hexachloran; gamma-Hexachlorane; gamma-Hexachlorobenzene; gamma-Hexachlorocyclohexane; gamma-Lindane; Gammater; gamma-1,2,3,4,5,6-Hexachlorocyclohexane; Gexane; HCC; HCCH; HCH; Heclotox; Hexa; Hexachloran; Hexachlorane; Hexavern; Hexicide; Hexyclan; HGI; Hortex; Hungaria L 7; Jacutin; Kokotine; Kwell; Lendine; Lentox; Lidenal; Lindane; Lindatox; Lindex; Lindosep; Lintox; Linvur; Lorexane; Millol 49; Nexycol ; Neo-Scabicidol; Nexen PB; Nexit; Nexit-stark; Nexol-E; Nicochloran; Omnitox; Ovadziak; Ovadziak; Pedraczak; Pflanzol; Quellada; Sang-gamma; Spritz-Rapidin; Spruehpflanzol; Streunex; Tap 85; Tri-6; Viton; 1,2,3,4,5,6-Hexachlorocyclohexane; 666

Cyclohexylamine (8 CI); Cyclohexanamine (9 CI)

Aminocyclohexane; Aminohexahydrobenzene; Benzenamine, hexahydro; Hexahydroaniline

Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6aalpha,9aalpha-tetrahydro-4-methoxy- (8 CI); Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-4-methoxy-, (6aR-cis)- (9 CI)

Aflatoxin B1

DDT, Total (No postings in CHEMLINE).

DDT, Total

Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

CL-62362; HP-3170; Hydrofluoride 3170; LW-3170; Loxapin; Loxapine; Oxilapine; S-805; SUM-3170; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine

Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-

Mianserin; Mianserine

Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI)

DENA; Diethylnitrosamide; Diethylnitrosamine; Nitrosodiethylamine; N-Ethyl-N-nitrosoethanamine; N-Nitrosodiethylamine; N-Nitroso-N,N-diethylamine

Digitoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

Cardigin; Digilong; Carditoxin; Christapurat; Crystalline digitalin; Crystodigin; Digilong; Digimerck; Digisidin; Digitaline; Digitoksin; Digitophyllin; Digitoxigenin tridigitoroside; Glucodigin; Lanatoxin; Myodigin; Nativelle; Purodigin; Purpurid; Unidigin

Digoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Chloroformic digitalin; Cordioxil; Davoxin; Digacin; Digitalis glycoside; Dixina; Homolle's digitalin; Lanicor; Lanicordin; Lanoxin; Rougoxin

Dimethylamine, N-nitroso- (8 CI); Methanamine, N-methyl-N-nitroso- (9 CI)

DMN; DMNA; Dimethylnitrosamine; N-Methyl-N-nitrosomethanamine; N-Nitrosodimethylamine; N-Nitroso-N,N-dimethylamine

Dipyrido(1,2-a:2',1'-c)pyrazinediium, 6,7-dihydro-

Diquat; 1,1'-Ethylene-2,2'-bipyridinium; 2,2'-Bipyridinium, 1,1'-(1,2-ethanediyl)-; 9,10-Dihydro-8a,10a-diazoniaphenanthrene

Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

Delysid; D-Lysergic acid diethylamide; d-Lysergic acid diethylamide; LSD; LSD [alkaloid]; LSD 25; Lysergic acid diethylamide; Lysergide; N,N-Diethyllysergamide; N,N-Diethyl-D-lysergamide

Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

DDD; Dichlorodiphenyl dichloroethane; Dilene; Ne1700; p,p'-DDD; p,p'-Dichlorodiphenyldichloroethane; p,p'-Dichlorodiphenyl-2,2-dichloroethylene; p,p'-TDE; Rhothane; TDE; Tetrachlorodiphenyl ethane; 1,1-Bis(p-chlorophenyl)-2,2-dichloroethane; 1,1-Bis(4-chlorophenyl)-2,2-dichloroethane; 1,1-Dichloro-2,2-bis(p-chlorophenyl)ethane; 1,1-Dichloro-2,2-bis(4-chlorophenyl)ethane; 2,2-Bis(4-chlorophenyl)-1,1-dichloroethane; 4,4'-DDD

Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Aavero-extra; Agritan; alpha,alpha-Bis(p-chlorophenyl)-beta,beta,beta-trichlorethane; Arkotine; Azotox M-33; Bosan supra; Bovidermol; Chlorophenothane; Chlorphenothan; Chlorphenotoxin; Citox; Clofenotan; Clofenotane; DDT; Deoval; Detox; Detoxan; Dodat; Dibovin; Dichlorodiphenyltrichloroethane; Dicophane; Dykol; ENT-1506; Estonate; Ethane, 1,1,1-trichloro-2,2-bis(4-chlorophenyl); Gesafid; Gesarol; Ivoran; Mutoxan; Neocid; Neocidol; Parachlorocidus; PEB1; Pentachlorin; Penticidus; p,p'-DDT; p,p'-Dichlorodiphenyltrichloroethane; Tafidex; Trichlorobis(4'-chlorophenyl)ethane; Zerdane; 1,1-Bis(p-chlorophenyl)-2,2,2-trichloroethane; 1,1,1-Trichloro-2,2-bis(p-chlorophenyl)ethane; 1,1,1-Trichloro-2,2-bis(4,4'-dichlorodiphenyl)ethane; 2,2-Bis(p-chlorophenyl)-1,1,1-trichloroethane; 4,4'-Dichlorodiphenyltrichloroethane

Ethane, 1,2-dichloro-

alpha,beta-Dichloroethane; Brocide; Dichlor-Mulsion; Dutch liquid; EDC; Ethylene chloride; Ethylene dichloride; Glycol dichloride; sym-Dichloroethane; 1,2-Dichloroethane; 1,2-Dichloroethane

Ethyl alcohol (8 CI); Ethanol (9 CI)

Alcohol; Alcohol anhydrous; Alcosain; Anhydrol; Denatured Ethanol; Ethyl hydrate; Ethyl hydroxide; Jaysol; Jaysol S; Methylcarbinol; SD Alcohol 23-hydrogen; Tecsol

Ethylamine, 1-methyl-2-(2,6-xylyloxy)- (8 CI); 2-Propanamine, 1-(2,6-dimethylphenoxy)- (9 CI)

Mexiletine; 1-(2,6-Dimethylphenoxy)-2-aminopropane; 1-(2',6'-Dimethylphenoxy)-2-aminopropane

Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Allergan; Allergival; Benn; Benadril hydrochloride; Benadryl; Benzhydramine hydrochloride; beta-Dimethylaminoethyl benzhydryl ether hydrochloride; Denydryl; Difenhydramine hydrochloride; Dimedrol; Dimedrol hydrochloride; Diphenhydramine hydrochloride; Benmin; Bestamin; Tena; 2-(Benzhydryloxy)-N,N-dimethylethylamine hydrochloride; 2-Diphenylmethoxy-N,N-dimethylethylamine hydrochloride

Ethylene glycol, dinitrate (8 CI); 1,2-Ethanediol, dinitrate (9 CI)

EGDN; Ethylene dinitrate; Ethylene nitrate; Glycol dinitrate; Nitroglycol

Ethylene, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8 CI); Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)- (9 CI)

o,p'-DDE; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethylene; 2-(2-chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethylene

Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro- (9 CI)

DDE; p,p'-DDE; p,p'-Dichlorodiphenyldichloroethylene; 1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene; 1,1-Dichloro-2,2-di(p-chlorophenyl)ethylene; 2,2-Bis(4-chlorophenyl)-1,1-dichloroethylene; 4,4'-DDE

Fluoride

Fluoride; Fluoride ion; Fluorine ion (1-); Hydrofluoric acid, ion (1-); Perfluoride

Fluorine

Fluorine; Fluorine-19

Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Acifolic; Cytofol; Folacid; Folacin; Folbal; Folcidin; Folettes; Foliamin; Folipac; Folsan; Folsaure; Folsav; Folvite; Incafolic; Liver Lactobacillus casei factor; Millafol; N-(p-((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methylamino)benzoyl)-glutami c acid; N-(p-(((2-amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-glutamic acid; PGA; PteGlu; Pteroylglutamic acid

Gold

Burnish Gold; C.I. Pigment Metal 3; C.I. 77480; Colloidal Gold; Gold Flake; Gold Leaf; Gold Powder; Magnesium Gold Purple; Shell Gold

Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-

Cimetidine; Tagamet

Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Aceto HMT; Aminoform; Aminoformaldehyde; Ammoform; Ammonioformaldehyde; Antihydral; Cystogen; Duiroxol; Ekagon H; Formamine; Formin [heterocycle]; Hexax UTS; Hexerin; Hexa-Flo-Pulver; Hexaform; Hexamethylenamine; Hexamine [heterocycle]; Hexamine; Hexasan; Methenamin; Methenamine; Preparation AF; Urasin; Uratrine; Uritone; Urodeine; Urotropin; Urotropine; Xametrin; 1,3,5,7-Tetraazaadamantane

Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Aleviatin; Denyl; Dihycon; Di-Hydan; Di-Lan; Dilabid; Dintoina; Diphanotin; Diphedan; Diphenylhydantoin; DPH; Hidantal; Lepitoin; Phenytoin; Phenytoine; Sodanton; Zentropil; 5,5-Diphenylhydantoin; 5,5-Diphenyl-2,4-imidazolidinedione

Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

Brufen; IP-82; Ibuprofen; Motrin; N.D. 13621; alpha-(4-Isobutylphenyl)propionic acid; p-Isobutylhydratropic acid; 2-(p-Isobutylphenyl)propionic acid; 2-(4-Isobutylphenyl)propanoic acid; 4-Isobutylhydratropic acid

Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-

Anagrelide

Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Anagiardil; Bayer 5360; Clont; Deflamon; Entizol; Flagesol; Flagil; Flagyl; Gineflavir; Klion; Klont; Metronidazol; Metroridazole; Nexibol; Orvagil; RP 8823; Takimetol; Trichomol; Trichopal; Trivazol; Vagimid

Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Amuno; Artrinovo; Artrivia; Confortid; Dolovia; Inacid; Indacin; Indocid; Indocin; Indomecol; Indomed; Indonee; Indometacin; Indometacine; Indomethacin; Indomethacine; Indomethine; Indo-Rectolmin; Infrocin; Metacen; Metartril; Methazine; Metindol; Mezolin; Reumacide; Sadoneus; 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetic acid

Insulin

Iletin; Endopancrine; Insular; Insuly; Isrilin; Insulin Injection; Decurvon; Insulin (bonito)

Iodine

Brancl; Iodine; Iodine-127; Iodine ((127)I2); Iodine colloidal; Iodine crystals; Iodine sublimed; Iosan Superdip; Molecular iodine

Iron

Araco iron; Ferrovac F; Iron; Loha; E05A; PZh2M; PZh2M2; PZh3; PZh1M1; PZh3M; PZh4M; PZh-2; PZh2M1; PZh-1M3; SUY B-2

Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI)

Benzbromarom; Benzbromarone; Desuric; L 2214; L 2214-Labaz; Minuric; Uricovac

L-Ascorbic acid

Adenex; Allercorb; Antiscorbic vitamin; Antiscorbutic vitamin; Ascoltin; Ascorbajen; Ascorbic acid; Ascorbutina; Ascorin; L-(+)-Ascorbic acid; Ascorteal; Ascorvit; Cantan; Cantaxin; Catavin C; Cebicure; Cebion; Cetione; Cecon; Cegiolan; Ceglion; Celaskan; Celin; Ce-Mi-Lin; Cenagyl; Cenetone; Cereon; Cergona; Cescorbat; Cetamid; Cetemican; Cevalin; Cevatine; Cevex; Cevimin; Ce-Vi-Sol; Cevital; Cevitamic acid; Cevitamin; Cevitan; Cevitex; Ciamin; Cipca; Colascor; Concemin; C-Quin; C-Vimin; Davitamon C; Hybrin; IDO-C; Laroscorbine; Lemascorb; Liqui-Cee; L-Lyxoascorbic acid; L-threo-Hex-2-enonic acid; L-Xyloascorbic acid; L-3-Ketothreohexuronic acid; Planavit C; Proscorbin; Redoxon; Ribena; Scorbu-C; Secorbate; Testascorbic; Vicelat; Vicin; Viforcit; Viscorin; Vitace; Vitacee; Vitacimin; Vitacin; Vitamin C; Vitasisin; Vitascorbol; Xitix; Xyloascorbic acid, L-; 3keto-L-Gulofuranolactone; 3-Oxo-L-gulofuranolactone

Lead

C.I. Pigment Metal 4; C.I. 77575; KS-4; Lead; Lead Flake; Lead S2; S0; S1

Lithium

Lithium

m-Xylene (8 CI); Benzene, 1,3-dimethyl- (9 CI)

m-Dimethylbenzene; m-Xylol; 1,3-Dimethylbenzene; 1,3-Xylene

Magnesium

Magnesium

Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

Black Gold F89; Black Iron BM; E 35; Iron Black; KN 320; Magnetic Black; Magnetic Oxide; Meramec M25; MB-B1; 11557 Black

Manganese

Collcidal manganese; Cutaval; Manganese

Melamine, pentamethyl- (8 CI); 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N''-pentamethyl- (9 CI)

Pentamethylmelamine; UNT 51239

Mercury

Mercury; Quicksilver

Mercury(1+), methyl-, ion (8 CI); Mercury(1+), methyl- (9 CI)

Methylmercury; Methylmercury(1+); Methylmercury(II) cation; Methyl mercury ion; Methylmercury ion(1+)

Methane, dibromochloro-

Chlorodibromomethane; Dibromochloromethane; Dibromomonochloromethane; Monochlorodibromomethane

Methane, dibromodichloro-

Dibromodichloromethane

Methane, dichloro-

Aerothene MM; Dichloromethane; Freon 30; Methylene bichloride; Methylene chloride; Methylene dichloride; Narkolil; Solaesthin; Solmethine

Methane, dichlorofluoro-

Algofrene Type 5; Arcton 7; Dichlorofluoromethane; Dichloromonofluoromethane; F21; FC 21; Fluorodichloromethane; Freon 21; Freon F 21; Genetron 21; Monofluorodichloromethane; R 21 [refrigerant]; R 21

Methane, trichlorofluoro-

Algofrene Type 1; Arcton 9; Electro-CF 11; FC 11 [halocarbon]; FC 11; FKW 11; F11B; Fluorochloroform; Fluorotrichloromethane; Freon MF; Freon F 11; Freon 11; Frigen 11; Frigen 11A; Genetron 11; Isceon 131; Isotron 11; Kaltron 11; Ledon 11; Monofluorotrichloromethane; Propellant 11; R 11 [refrigerant]; R 11; Trichlorofluoromethane; Trichloromonofluoromethane

Methanol

Carbinol; Methyl alcohol; Methyl hydroxide; Methylol; Monohydroxymethane; Wood alcohol; Wood spirit

Morphanthridine, 6-(4-methyl-1-piperazinyl)- (8 CI); 11H-Dibenz(b,e)azepine, 6-(4-methyl-1-piperazinyl)- (9 CI)

Perlapine; 6-(4-Methyl-1-piperazinyl)morphanthridine

Morphinan-3-ol, 17-methyl-

Arymarone; Lemoran; Levo-Dromoran; Levorphan; Levorphanal; Levorphanol; (-)-N-Methylmorphinan-3-ol; Ro 1-5431; (-)-3-Hydroxy-N-methylmorphinan

Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9 CI)

Codeine; Condicept; Methylmorphine; Morphine monomethyl ether; Morphine-3-methyl ether

Morpholine, 2-((2-ethoxyphenoxy)methyl)-

ICI-58834; Viloxazin; Viloxazine; 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine

Morpholine, 4-(thioxo(3,4,5-trimethoxyphenyl)methyl)-

ISF 2001; Morpholine, 4-(3,4,5-trimethoxythiobenzoyl)-; Trithioxine; 4-(3,4,5-Trimethoxythiobenzoyl)morpholine

Nickel

C.I. 77775; Nickel; Ni 270; Ni 4303T; Ni 0901-S (Harshaw); Nickel NP2; Nickel 270; NP2; Raney alloy; Raney nickel; RCH 55/5

Nickel carbonyl [Ni(CO)4] (8 CI); Nickel carbonyl [Ni(CO)4], (T-4)- (9 CI)

Nickel carbonyl; Nickel tetracarbonyl; Tetracarbonyl nickel

Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI)

beta-Pyridyl-alpha-N-methylpyrrolidine; Flux maag; Nicotine; L-Nicotine; (-)-Nicotine; 1-Methyl-2-(3-pyridyl)pyrrolidine; 3-(N-Methylpyrollidine)pyridine

o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Aiglonyl; Dobren; Dogmatil; Dogmatyl; Eglonyl; Guastil; Mirbanil; Misulvan; N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-5-sulfamoylbenzamide; R.D. 1403; Sulpirid; Sulpiride; Sulpyrid

Oxalic acid (8 CI); Ethanedioic acid (9 CI)

Aktisal; Aquisal

Palladium

Palladium

Phenol, 2,2'-methylenebis(3,4,6-trichloro-

AT 7; G 11; Acigena; Almederm; Bilevon; Bis(2-hydroxy-3,5,6-trichlorophenyl)methane; Bis(3,5,6-trichloro-2-hydroxyphenyl)methane; B 32; Cotofila; Distodin; Exofene; Fenia-sin; Postril; Gamophen; Gamophene; Germa-Medica; Hexablan; Hexachlorofen; Hexachlorophen; Hexachlorophene; Hexafen; Hexophene; Hexosan; Nabac; Neosept V; pHisoHex; Ritosept; Septisol; Septofen; Steral; Steraskin; Surgi-Cen; Surofene; Teraseptic; Trichlorophene; 2,2'-Dihydroxy-3,3',5,5',6,6'-hexachlorodiphenylmethane; 2,2'-Methylenebis(3,4,6-trichlorophenol); 2,2',3,3',5,5'-Hexachloro-6,6'-dihydroxydiphenylmethane; 2,2'-Dihydroxy-3,5,6,3',5',6'-tetrachlorodiphenylmethane

Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (9 CI)

BP 7623; Trifluoperazin; Trifluoperazine; Trifluoromethylperazine; Trifluoroperazine; Trifluperazine; Triflurin; Triperazine

Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Azinfos-methyl; Azinophos-methyl; Azinphos; Bayer 17147; Cotneon; Cotnion; ENT 23,233; Gusathion; Gusathion K; Gusathion M; Gusathion methyl; Gusathion-20; Gusation 25; Guthion; Methylgusathion; Methyl guthion; O,O-dimethyl-S-(4-oxobenzotriazino-3-methyl)phosphorothioate

Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

AAT; AATP; Alkron; Alleron; American Cyanamid 3422; Aphamite; Aralo; Bayer E-605; Bladan F; Diethyl parathion; Diethyl p-nitrophenyl phosphorothionate; Diethyl p-nitrophenyl thionophosphate; Diethyl 4-nitrophenylphosphorothionate; DNTP; E 605; E 605 f; ENT 15,108; Ekatox; Ethyl parathion; Etilon; Folidol; Folidol E; Folidol E-605; Folidol oil; Fosferno; Fostox; Gearphos; Lirothion; Niran; Nitrostigmine; Oleofos 20; Oleoparaphene; Oleoparathion; O,O-Diethyl O-(p-nitrophenyl) phosphorothioate; O,O-Diethyl O-p-nitrophenyl thiophosphate; Pacol; Paramar 50; Paraphos; Parathion; Parathion-ethyl; Penncap E; ; Penncap E; RB; Rhodiasol; Rhodiatox; S.N.P.; Super Rodiatox; Thiophos; Thiophos 3422; Vitrex

Phosphorus

Phosphorus; Phosphorus-31; Red phosphorus; White phosphorus; Yellow phosphorus

Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Bisoflex DOP; Bisoflex 81; Bis(2-ethylhexyl)phthalate; Bis(2-ethylhexyl) 1,2-benzenedicarboxylate; Compound 889; DEHP; Di(Ethylhexyl)phthalate; Dioctyl phthalate; Di-(2-Ethylhexyl)-phthalate; DOP; Ethylhexyl phthalate; Eviplast 80; Eviplast 81; Flexirmel; Flexol DOP; Kodaflex DOP; Octoil; Octylphthalate; Palatinol AH; Phthalic acid dioctyl ester; Pittsburgh PX-138; Sicol 150; Staflex DOP; Truflex DOP; Vestinol AH; Vinicizer 80; Witcizer; 1,2-Benzenedicarboxylic acid, bis(ethylhexyl)ester; 2-Ethylhexyl phthalate

Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Butyl phthalate; Celluflex DPB; DBP; Dibutyl phthalate; Di-n-butyl phthalate; Elaol; Genoplast B; Hexaplas M/B; n-Butyl phthalate; Palatinol C; Polycizer DBP; PX 104; Staflex DBP; Unimoll DB; Witcizer 300

Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8 CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9 CI)

Furazosin; Prazosin; 2-[4-(2-furoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline

Piperidine, 2-(2,2-dicyclohexylethyl)-

Perhexilene; Perhexiline; 1,1-Dicyclohexyl-2-(2-piperidyl)ethane; 2-(2,2-Dicyclohexylethyl)piperidine

Platinum

C.I. 77795; Liquid Bright Platinum; Platinum; Platinium Black; PHO

Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

cis-Diaminodichloroplatinum(II); cis-Diamminedichloroplatinum; cis-Diamminedichloroplatinum(II); cis-Dichlorodiammineplatinum; cis-Dichlorodiammineplatinum(II); Cisplatin; cis-Platinous diaminodichloride; cis-Platinum diaminodichloride; cis-Platinumdiammine dichloride; cis-Platinum(II) diamminedichloride; NSC 119875

Polybrominated biphenyls (No postings in CHEMLINE).

PBB; Polybrominated biphenyls

Polychlorinated quaterphenyls (No postings in CHEMLINE).

Polychlorinated quaterphenyls

Potassium

Potassium

Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Codelcortone; Co-Hydeltra; Decortin H; Delta-Cortef; Delta F; Deltacortenol; Deltacortril; Delta-Ef-Cortelan; Deltahydrocortisone; Delta-stab; Deltisilone; delta(1)-Cortisol; delta(1)-Dehydrocortisol; delta(1)-Dehydrohydrocortisone; Di-Adreson F; Dicrotol; Donisolone; Eazolin D; Fernisolone; Hostocrotin H; Hydeltra; Hydeltrone; hydrodeltalone; Hydrodeltisone; Hydroretrocortin; Metacortandralone; Meticortelone; Meti-Derm; Paracortol; Precortancyl; Precortisyl; Predne-Dome; Predsalan; Prednisolone; Predonine; Pronolone; Schurisolon; Steran; Sterane; Sterolone; Ulacort; Ultracorten H; Ultracortene-H; 1-Dehydrohydrocortisone; 1,2-Dehydrohydrocortisone; 1,4-pregnadiene-3,20-dione; 3,20-dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene

Prolactin (VAN)

Adenohypophyseal lutectropin; Anterior pituitary luteotropin; Bovine lactogenic hormone; Galactin; Lactogenic hormone; Lactogen, pituitary; Lactosomatotropic hormone; Luteotrophin; Luteotropic hormone; Luteotropic hormone LTH; Luteotropin; Mammotropin; Paralactin; Pituitary lactogenic hormone

Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

alpha-(p-Chlorophenoxy)isobutyric acid; alpha-(4-Chlorophenoxy)-alpha-methylpropionic acid; alpha-(4-Chlorophenoxy)-isobutyric acid; Chlorfibrinic acid; Chlorofibrinic acid; Chlorophibrinic acid; Clofibrate free acid; Clofibric acid; Clofibrin; Clofibrinic acid; PCIB; PCPIB; (p-Chlorophenoxy)iscbutyric acid; Regadrin; 2-(p-Chlorophenoxy)isobutyric acid; 2-(p-Chlorophenoxy)-2-methylpropionic acid; 2-(4-Chlorophenoxy)-2-methylpropanoic acid; 2-(4-Chlorophenoxy)-2-methylpropionic acid; 4-Chlorophenoxyisobutyric acid

Pseudoephedrine, (+)- (8 CI); Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))- (9 CI)

d-Pseudoephedrine; d-psi-Ephedrine; Isoephedrine; L-(+)-Pseudoephedrine; Pseudoephedrine; (+)-Pseudoephedrine; psi-Ephedrin; psi-Ephedrine; psi-Ephedrine, (+)-; Sudafed; Trans-Ephedrine

Pyrimidine, 2,4-diamino-5-(3,4,5,-trimethoxybenzyl)- (8 CI); 2,4-Pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- (9 CI)

BW 56-72; NIH 204; Syraprim; Trimethoprim; 2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine

Salicylic acid, ion(1-) (8 CI); Benzoic acid, 2-hydroxy-, ion(1-) (9 CI) (VAN)

o-Hydroxybenzoate; Salicylate; Salicylate anion; Salicylate ion

Selenium

C.I. 77805; Selenium

Silicon

Silicon

Silver

Argentum; C.I. 77820; L 3; Shell Silver; Silflake 135; Silver; Silver atom; Silver metal; Sr 999; V 9

Sisomicin (8 CI); D-Streptamine,
O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamin
o-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy- (9 CI)

Antibiotic 66-40; Rickamicin; Sch 13475

Sodium

Natrium; Sodium; Sodium-23; Sodium metal

Strontium

Strontium

Styrene (8 CI); Benzene, ethenyl- (9 CI)

Cinnamene; Cinnamol; Phemethylene; Phenylethene; Phenylethylene; Styrene; Styrol; Styrole; Styrolene; Styropol SC; Vinylbenzene; Vinylbenzol

Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

alpha-Ethyl-alpha-methylsuccinimide; alpha-Methyl-alpha-ethylsuccinimide; Atysmal; Capitus; C.I. 366; Emeside; Ethosuxide; Ethosuximide; Ethymal; Etosuximid; H940; Mesentol; Pemal;1 Petinimid; Petnidan; Piknolepsin; PM 671; Pyknolepsinum; Ronton; Simatin; Succimal; Succinitin; Suxilep; Suximal; Suxinutin; Zarodan; Zarondan; Zarondan-Saft; Zarontin; 2-Ethyl-2-methylsuccinimide; 3-Ethyl-3-methylsuccinimide

Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

AS 18908; F.I. 5978; Kelfizin; Kelfizina; Kelfizine W; Longum; N(1)-(3-Methoxy-2-pyrazinyl)sulfanilamide; Polycinal; SMP 2; Sulfalene; Sulfamethopyrazine; Sulfamethoxypyrazine; Sulfametopyrazine; Sulfapyrazinemethoxine; Sulfapyrazinemethoxyine; Sulfapyrazinemethoxyne; 2-Methoxy-3-sulfanilamidopyrazine; 2-Sulfanilamido-3-methoxypyrazine; 3-Methoxy-2-sulfanilamidopyrazine; 3-Methoxy-2-sulfapyrazine; 3-Methoxypyrazine sulfanilamide

Sulfur

Asulfa-Supra; Atomic sulfur; Bensulfoid; Brimstone; Colloidal sulfur; Cosan; Cosan 80; Elosal; Flowers of sulphur; Ground vocle sulphur; Kolloidschwefel 95; Kolo 100; Micovetsulf; Netzschwefel; Precipitated sulfur; Polsulkol Extra; RC-Schwefel Extra; Sublimed sulfur; Sufran; Sufran D; Sulfex; Sulfidal; Sulfur; Sulfur atom; Sulfur ointment; Sulfur, pharmaceutical; Sulikol; Sulkol; Sultaf; Sulphur; Svovl; Thiovit; Ultra Sulfur

Tetrahydrocannabinol cross-reacting cannabinoids (No postings in CHEMLINE).

Tetrahydrocannabinol cross-reacting cannabinoids; THC-CBC

Thallium

Thallium; Ramor

Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Elixophyllin; Elixophylline; Lanophyllin; Liquophylline; Optiphyllin; Parkophyllin; Pseudotheophylline; Solosin; Theal tabl.; Teofyllamin; Theocin; Theofol; Theograd; Theolair; Theolix; Theophyllin; Theophylline; 1,3-Dimethylxanthine

Thioether (No postings in CHEMLINE).

Thioether

Tin

C.I. Pigment Metal 5; C.I. 77860; Metallic tin; Silver Matt Powder; Tin; Tin Flake; Tin Powder; Wang

Tocopherol

Tocopherol

Toluene (8 CI); Benzene, methyl- (9 CI)

Antisal 1a; Methylbenzene; Methylbenzol; Methacide; Phenylmethane; Toluene; Toluol

Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

Acetic acid, dipropyl-; DPA; Depakine; Dipropylacetic acid; Ergenyl; n-Dipropylacetic acid; Valproic acid; 2-Propylpentanoic acid; 2-Propylvaleric acid; 4-Heptanecarboxylic acid

Vanadium

Vanadium; Vanadium-51

Vitamin A

Acon; Afaxin; Agiolan; Alphalin; Anatola; Anti-infective vitamin; Antixerophthalmic vitamin; Aoral; Apexol; Apostavit; Aquasol A; Atav; Avibon; Avita; Avitol; Axerol; Axerophthol; Biosterol; "Dohyfral" A; Epiteliol; Hydrovit A; Lard-factor; Mio-A-Let; Oleovitamin A; Prepalin; Provitamin A; Retinol; Testavol; Vaflol; Vi-Alpha; Vitamin A; Vitamin A(1); Vitamin A alcohol; Vitavel A; Vitpex; Vogan; Vogan-Neu; 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol

Vitamin B12

Anacobin; Betalin-12; Betaline-12; Betolvex; B-Twelve; B-Twelve Ora; Byladoce; CN-B12; Cobalamin, cyanide; Cobalamin, cyano-; Cobalamin, cyano-5,6-dimethylbenzimidazole-; Cobalin; Cobamide, alpha-5,6-dimethyl-1H-benzimidazolyl-, cyanide; Cobamide, cyano-5,6-dimethyl-1H-benzimidazole; Cobamin; Cobinamide, cyanide hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cotel; Covit; Crystamin; Cyano-B12; Cyanocobalamin; Cyanocobalamine; Cyano-5,6-dimethylbenzimidazolylcobamide; Cycloamin; Cykobemin; Cykobeminet; Cytacon; Cytamen; Cytobion; Depinar; Dobetin; Docemine; Docibin; Docigram; Dodecabee; Dodecavite; Dodex; Ducobee; Duodecibin; Enbiol; Enociclina; Eritrone; Erycytol; Erythrotin; Euhaemon; Extrinsic factor; Factor II; Factor II [vitamin]; Fresmin; Hemo-b-doze; Hemomin; Hepagon; Hepavis; Hepcovite; Lactobacillus lactis dorner factor; LLD factor; Macrabin; Megalovel; Milbedoce; Nagravon; Normocytin; Pernaemon; Pernaevit; Pernipuron; Plecyanin; Poyamin; Betramin; Redamina; Redisol; Rhodacryst; Rubesol; Rubramin; Rubripca; Rubrocitol; Sytobex; Vibalt; Vibisone; Virubra; Vitamin B12 preparation; Vitarubin; Vita-rubra; Vitral; 1H-Benzimidazole, 5,6-dimethyl-1-(3-O-phosphono-alpha-D-ribofuranosyl)-, monoester with cobinamide cyanide hydroxide, inner salt; 5,6-Dimethylbenzimidazolyl cyanocobamide; 5,6-Dimethylbenzimidazolyl-Co-cyanocobamide

Zinc

Blue powder; Zinc

Zirconium

Zirconium

1-Hexadecanol, hydrogen sulfate

Cetyl sulfate; Hexadecyl hydrogen sulfate; Hexadecyl sulfate; Monohexadecyl sulfate; n-Hexadecyl sulfate; Palmityl sulfate; 1-Hexadecyl hydrogen sulfate

1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl-, (Z)-

alpha-Flupenthimol; cis-Flupenthixol; cis-Flupentixol; cis-(Z)-Flupenthixol

1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Eliaol; Fluorfenazine; Fluorophenazine; Fluorphenazine; Fluphenazine; Pacinol; S94; Siqualine; Siqualon; SQ 4918; Tensofin; Trifluomethazine; Valasina; Vespazine;;
1-(2-hydroxyethyl)-4-[3-(trifluoromethyl-10-phenothiazinyl)propyl]-piperazine;
2-(trifluoromethyl)-10-[3-[1-(beta-hydroxyethyl)-4-piperazinyl]propyl]phenothiazine

1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

A 21 Lundbeck; Cetobemidon; Cetobemidone; Ciba 7115; Cliradon; Cliradone; Cymidon; Hoechst 10720; K 4710; Ketobemidone; Ketogan; Ketogin; Win 1539; 4-(m-Hydroxyphenyl)-1-methyl-4-piperidyl ethyl ketone

1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Anhydro-o-sulfaminebenzoic acid; Benzoic sulfimide; Benzoic sulphimide; Benzosulfimide; Benzosulfinide; Garantose; Glucid; Gluside; o-Benzoic sulfimide; o-Benzosulfimide; o-Benzoylsulfimide; o-Sulfobenzimide; o-Sulfobenzoic acid imide; Saccharimide; Saccharin; Saccharin acid; Saccharine; Saccharin insoluble; Saccharinol; Saccharinose; Saccharol; 1,2-Benzisothiazoline-3-one; 1,1-dioxide; 1,2-Dihydro-2-ketobenzisosulfonazole; 2,3-Dihydro-3-oxobenzisosulfonazole; 3-Benzisothiazolinone 1,1-dioxide; 3-Hydroxybenzisothiazole-S,S-dioxide; 550 Saccharine

1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

Chlordecone; Clordecone; Compound 1189; Decachloroketone;
Decachloropentacyclo(5.2.1.0(2,6).0(3,9).0(5),(8))decan-4-one;
Decachlorooctahydro-1,3,4-metheno-2H-cyclobuta[cd]pentalen-2-one; ENT-16391; GC 1189; Kepone; Merex

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI);
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-,
(1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

Aldocit; Aldrin; Compound 118; ENT 15,949; HHDN; Kortofil; Octalene; SD 2794; Seedrin; Tatuzinho; Tipula

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-,
(1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Aldrin Epoxide; Alvit 55; Compound 497; Dieldrin; Dieldrex; Dielmoth; Dildrin; Dorytox; ENT-16225; HEOD; Illoxol; Insectlack; Kombi-Albertan; Moth Snub D; Octalox; Red Shield; SD 3417; Termitox

1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-,
cis-(+)-

Diltiazem

1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8 CI);
8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, (1R-(exo,exo))- (9 CI)

Benzoylecgonine; Benzoylecogonine; Ecgonine benzoate; O-Benzoyl ecgonine; o-Benzoyl-(-)-ecgonine

1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI);
8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

Benzoylmethylecgonine; beta-Cocaine; Cocaine; (-)-Cocaine; Ecgonine, methyl ester, benzoate (ester);
Neurocaine; 1-Cocaine; 2beta-Carbomethoxy-3beta-benzoxytropane; 2beta-Tropanecarboxylic acid,
3beta-hydroxy-, methyl ester, benzoate (ester)

1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd.
with potassium hydroxide (1:1)

AB 35616; Abbott 35616; Bipotassium chlorazepate; CB 4306; Chlorazepam; Chlorazepate; Chlorazepate
dipotassium; Clorazepate dipotassium; Dipotassium chlorazepate; Novrecton;; Tencilan; TR 19119; Transene;
Tranzene; Tranxilen; Tranxilene; Tranxilium

1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-

Clobazam; HR 376; H-4723; Urbanyl;
1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine

10H-Phenothiazine-2-sulfonamide, 10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-N,N-dimethyl-

Piportil; Pipothiazine; Pipotiazine; Piptotiazine; RP 19366; 19 366 R.P.

2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol,
alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)

Algafan; Antalvic; alpha-d-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate; Darvon; Deprosic;
Dextropropoxyphene; d-Propoxyphene; Erantin; Femadol; Propoxyphene

2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol,
1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI)

Avlocardyl; AY 64083; beta-Propranolol; ICI 45,520; Propranolol; Proprasylyt; Reducor

2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-, (Z)-

cis-H 102/09; cis-Zimelidine; Zimelidine

2,4-Oxazolidinedione, 5,5-dimethyl-

AC 1198; BAY 18002; Dimethadion; Dimethadione; DMO; Rapractone; 5,5-Dimethyloxazolidinedione;
5,5-Dimethyloxazolidine-2,4,-dione

2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

alpha-Diethylamino-2,6-acetoxylidide; Anestacon; Duncaine; Gravocain; Isicaine; Isicaina; Leostesin; Lidocaine; Lignocaine; Maricaine; Nucaina; Solcain; Xycaine; Xylestesin; Xylocain; Xylocaine; Xylocitin; Xylotox; 2-(Diethylamino)-2',6'-acetoxylidide

2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI); 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Asta B 518; B 518; Bis(2-chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; Clafen; Calpheme; Cyclophosphamid; Cyclophosphamide; Cyclophosphan; Cyclophosphane; Cytophosphan; Cytoxan; Endoxan; Genoxal; N,N-Bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide; N,N-Bis(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; Procytox; Sendoxan; 1-Bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin

2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Benzalin; Epibenzalin; Epinelbon; Eunoctin; Hipnax; Hipsal; LA-1; Nogadan; Nogadon; Nogadone; Neozepam; Nitrazepam; Nitrenpax; Radedorm; Ro 4-5360; Ro 5-3059; Somebon

2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro- (8 CI); 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- (9 CI)

Clonazepam; Clonopin; Rivotril; Ro 5-4023

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Apaurin; Apozepam; Ansiolisina; Atensine; Atilen; Assival; Bialzepam; Calmocitene; Calmpose; Cercine; Ceregulart; Diacepan; Diapam; Diazepam; Duksen; Duxen; Eridan; Faustan; Horizon; LA 111; Lembrol; Levium; Methyldiazepinone; Moronan; Noan; Paxate; Parel; Quievita; Relanimal; Relanium; Ro 5-2807; Seromet; Seduksen; Seduxen; Setonil; Sibazon; Stenolid, Stenolin; Tranimul; Valeo; Valium; Vival; Vivol; Wy 3467; 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

Chlordesmethyldiazepam; Dealkylprazepam; Desmethyldiazepam; Desalkylprazepam; Desmethyldiazepam; N-Desethyldiazepam; N-Decxydemoxepam; N-Desmethyldiazepam; N(1)-Desmethyldiazepam; Nordiazepam; Ro 52180

3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Algovetin; Amidon; Amidone; Diamison; Dolophin; Heptadone; Heptanon [pharmaceutical]; Ketalgin; Mecodin; Methadone; Phenadone; Physeptone; Polamidone

4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Cateudyl; Dormigoa; Dormigoa-Schlofni; Dormutil; Dormodin; Fadormir; Molodorm; Hymimal; Hypocal; Hyptor; Hypotor base; Ipnofil; MAOA; MTQ; Melsed; Melsedin base; Melsonin; Metakvalon; Metaqualon; Methaqualon; Methaqualone; Methaqualoneinone; Metolquizolone; Mollinox; Motolon; Mozambin; Nobedorm; Noctilene; Normi-Wax; Omnyl; Optinoxan; Orthonal; Ortonal; Parminal; QZ 2; Quaalude; RIC 272; Revonal; Rorer 143; Rorer 714; Roulone; Rouqualone; Sindenvel; Somberol; Somnone; Sonal; Sopor; Soverin; Torinol; TN 495; Tuarcle; Tuazolone; 2-methyl-3-(o-tolyl)-4-quinazolone

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-

Ticarcillin; 6(D(-)alpha-Carboxy-3-thienylacetamido)penicillanic acid

4,4'-Bipyridinium, 1,1'-dimethyl-

Methyl viologen(2+); N,N'-Dimethyl-4,4'-bipyridinium dication; Paraquat dication; Paraquat ion; Paraquat; 1,1'-Dimethyl-4,4'-bipyridinium; 1,1'-Dimethyl-4,4'-bipyridinium cation

4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Agostilben; alpha,alpha'-Diethylstilbenediol; alpha,alpha'-Diethyl-4,4'-stilbenediol; Antigestil; Bio-des; Bufon; Conestrol; Cyren; Cyren A; Dave's destrol; DEB; DES; DES [synthetic estrogen]; DiBestrol "2"; Prenix; Di-Estryl; Diethylbene; Domestrol; Estilbin ''HCO''; Estrobene; Estromenin; Estrosyn; Fonatol; Grafestrol; Hi-Destrol; Incovesco; Menostilbene; Microest; Milestrol; Neo-Oestranol I; Oestrogenine; Oestromenin; Oestromenyl; Pabestrol; Palestrol; Rumestrol 1; Rumestrol 2; Serral; Sexocretin; Sibol; Stil; Stilbestrol; Stilbetin; Stilboefral; Stilboestrofors; Stilboestrol; Stilkap; Stil-Rol; Synestrin; Synthoestrin; Synthofolin; Syntofolin; trans-alpha,alpha'-Diethyl-4,4'-stilbenediol; trans-Diethylstilbesterol; Diethylstilbestrol; trans-Diethylstilbestrol; trans-4,4'-Dihydroxy-alpha,beta-diethylstilbene; 4,4'-Dihydroxydiethylstilbene; 4,4'-Dihydroxy-alpha,beta-diethylstilbene

4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Hexamidine; Lepimidin; Lepsiral; Medi-Peta; Milepsin; Mimodine; Misolyne; Mizodin; Mizolin; Mylepsin; Mylepsinum; Mysedon; Mysoline; Prisaclone; Prisacone; Prispakton; Primadone; Prisidon; Primidone; Pyrisidone; Roe 101; Sertan; 2-Desoxyphenobarbital; 2-Desoxyphenobarbital; 5-ethyl-5-phenylhexahydrcpyrimidine-4,6-dione; 5-phenyl-5-ethylhexahydropyrimidine-4,6-dione

4,7-Methano-1H-indene, 1,2,3,4,5,6,7,8,8-nonachloro-2,3,3a,4,7,7a-hexahydro-, (1alpha,2beta,3alpha,3aalpha,4beta,7beta,7aalpha)-

trans-Nonachlor

4,7-Methanoindan, 1,2,4,5,6,7,8,8-octachloro-1,2-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 1a,2,3,4,5,6a,7,7-octachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

Octachlor epoxide; Oxychlordan; Oxychlordane

4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

ENT 25,584; Epoxyheptachlor; HCE; Heptachlor epoxide; Velsicol 53-CS-17

4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

Aahepta; Agroceres; E 3314; ENT 15,152; GPKh; Hepta; Heptachlor; Heptachlorane; Rhodiachlor; Velsicol 104; 3-Chlorochlordene

4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI); 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)

Actinospectacin; Actinospectocin; Espectinomicina; M 181; Spectam; Spectinomycin; Trobicin; U 18409 E

5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-

Citalopram; Lu 10-171; LU 10-171; Vitalapram

5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-

LY 127935; Moxalactam; Oxa-cephem

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, (6R-cis)-

Cefoxitin; Cephoxitin

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))-

Cefaclor; Lilly 99638

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Cefalexin; Cefaloto; Cephalexin; Ceporex; Ceporexine; Keflex; Keforla; Larixin; Lexibiotico; Lilly 66873; Nadlexin; Neolexina; Sencephalin; S 6437; 7-(D-alpha-aminophenylacetamido)desacetoxycephalosporanic acid; 7-(D-2-amino-2-phenylacetamido)-3-methyl-delta(3)-cephem-4-carboxylic acid

5H-Dibenz(b,f)azepine-5-carboxamide

Carbamazepen; Carbamazepine; Carbazepine; Finlepsin; G 32883; Geigy 32883; Karbamazepin; Neurotol; Tegretal; Tegretol; 5-Carbamoyl-5H-dibenz(b,f)azepine

5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8 CI); 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- (9 CI)

Chlorimipramine; Clomipramine; G 34586; 3-chloro-10,11-dihydro-5-(3-dimethylaminopropyl)-5H-dibenz[b,f]azepine; 5-gamma-dimethylaminopropyl)-3-chloroiminodibenzyl

5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Adepress; Adepril; Amitriptylin; Amitriptyline; Amitryptyline; Damilen; Damitriptyline; Elavil; Flavyl; Lantron; Laroxyl; Lentizol; MK-230; N 750; Proheptadiene; Redomex; Ro 4-1575; Saroten; Seroten; Triptanol; Triptisol; Triptizol; Tryptanol; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropylamine; 5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]cycloheptadiene

5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-

EGYT 341; Grandaxin; Tofisopam

6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl- (8 CI); 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- (9 CI)

Metalozone; Metolazone; SR 720-22; Zaroxolyn

6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-

Abbott 40566; Cannabinol delta(1)-tetrahydro-; delta(1)-Tetrahydrocannabinol; delta(1)-THC; delta(9)-Tetrahydrocannabinol; (-)-delta(1)-Tetrahydrocannabinol; (-)-delta(9)-Tetrahydrocannabinol; (-)-delta(9)-THC; (-)-delta(9)-trans-Tetrahydrocannabinol; (-)-trans-delta(9)-Tetrahydrocannabinol; delta(9)-THC; delta(9)-trans-Tetrahydrocannabinol; SP 108; Tetrahydrocannabinol; (1)-delta(1)-Tetrahydrocannabinol; 1-delta(1)-trans-Tetrahydrocannabinol; 1-trans-delta(9)-Tetrahydrocannabinol

8-Quinolinol, 5-nitro

BAS 58; Nibiol; Nitroxolin; Nitroxoline; Noribiol; 5NOK; 5-Nitro-8-hydroxyquinoline; 5-Nitro-8-oxychinoline; 5-Nitro-8-oxyquinoline; 5-Nitro-8-quinolinol; 5-Nitrox; 5-Nitroxine; 8-Hydroxy-5-nitroquinoline

9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl- (8 CI); 9,10-Ethanoanthracene-9(10H)-propanamine, N-methyl- (9 CI)

Maprotiline; 1-(3-Methylaminopropyl)-dibenzo(b,e)bicyclo(2.2.2)octadiene; 9-(gamma-methylaminopropyl)-9,10-dihydro-9,10-ethanoanthracene

9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)

Calcifediol; 25-Hydrocholecalciferol; 25-Hydroxy D3; 25-Hydroxy-5,6-trans-cholecalciferol; 25-Hydroxycholecalciferol; 25-Hydroxyvitamin D; 25-Hydroxyvitamin D3; 5,6-cis-25-Hydroxy vitamin D3

(+)-Pseudoephedrine
Pseudoephedrine, (+)- (8 CI); Benzenemethanol, alpha-[1-(methylamino)ethyl]-, [S-(R*,R*)]- (9 CI)

(-)-alpha(Aminomethyl)protocatechuyl alcohol
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

(-)-Cholesterol
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

(-)-Cocaine
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

(-)-delta(1)-Tetrahydrocannabinol
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

(-)-delta(9)-Tetrahydrocannabinol
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

(-)-delta(9)-THC
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

(-)-delta(9)-trans-Tetrahydrocannabinol
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

(-)-N-Methylmorphinan-3-ol
Morphinan-3-ol, 17-methyl-

(-)-Nicotine
Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI)

(-)-Noradrenaline
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

(-)-Norepinephrine
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

(-)-trans-delta(9)-Tetrahydrocannabinol
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

(-)-2-Hydroxy-N-cyclopropylmethylmorphinan
(-)-2-Hydroxy-N-cyclopropylmethylmorphinan (No postings in Chemline).

(-)-3-Hydroxy-N-methylmorphinan
Morphinan-3-ol, 17-methyl-

(Dimethylamino)phenazone
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

(p-Chlorophenoxy)isobutyric acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

(1)-delta(1)-Tetrahydrocannabinol
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

"Dchyfral" A
Vitamin A

A 00
Aluminum

A 21 Lundbeck
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

A 95
Aluminum

A 99
Aluminum

AA 1095
Aluminum

AA 1199
Aluminum

Aahepta
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

Aalindan
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

AAT
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

AATP
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Aavero-extra
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

AB 35616
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1)

Abbott 35616
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1)

Abbott 40566
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

Abensanil
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

AC 1198
2,4-Oxazolidinedione, 5,5-dimethyl-

Acamol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Acetagesic
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Acetalgin
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Acetaminofen
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Acetaminophen
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Acetic acid, dipropyl-
Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

Aceto HMT
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Acifolic
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Acigena
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Acon
Vitamin A

Actinospectacin
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI); 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)

Actinospectocin
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI); 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)

AD 1
Aluminum

Adenex
L-Ascorbic acid

Adenohypophyseal luteotropin
Prolactin (VAN)

Adepress
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Adepril
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

ADC
Aluminum

Adonal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Adrenor
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Adriblastin
Adriamycin (8 CI); 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9 CI)

AD1-M
Aluminum

AF
Aluminum

Aerothene MM
Methane, dichloro-

Afaxin
Vitamin A

Aficide
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Aflatoxin B1
Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6aalpha,9aalpha-tetrahydro-4-methoxy- (8 CI); Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-4-methoxy-, (6aR-cis)- (9 CI)

Agiolan
Vitamin A

Agostilben
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Agrican
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Agroceres
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

Agrocide
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Agrocide III
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Agrocide WP
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Agrypnal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Aiglonyl
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Aisemide
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Aktamin
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Aktinal
Oxalic acid (8 CI); Ethanedioic acid (9 CI)

Alcohol
Ethyl alcohol (8 CI); Ethanol (9 CI)

Alcohol anhydrous
Ethyl alcohol (8 CI); Ethanol (9 CI)

Aldocit
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI); 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

Aldrin
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI);
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-,
(1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

Aldrin Epoxide
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo-
(8 CI); 2,7:3,6-Dimethanonaphth[2,3-b]oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-,
(1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Alert-Pep
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Aleviatin
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Alficetyn
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, [R-(R*,R*)]- (9 CI)

Algafan
2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol,
alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)

Algofrene Type 1
Methane, trichlorofluoro-

Algofrene Type 5
Methane, dichlorofluoro-

Algotropyl
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Algovetin
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Algrain
Ethyl alcohol (8 CI); Ethanol (9 CI)

Alkron
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl
O-(4-nitrophenyl) ester (9 CI)

Allbri Natural Copper
Copper

Allercorb
L-Ascorbic acid

Allergan
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine,
2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Allergival
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine,
2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Alleron
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl
O-(4-nitrophenyl) ester (9 CI)

Alsedera
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

alpha-(p-Chlorophenoxy)isobutyric acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

alpha-(4-Chlorophenoxy)-alpha-methylpropionic acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

alpha-(4-Chlorophenoxy)-isobutyric acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

alpha-(4-Isobutylphenyl)propionic acid
Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

alpha-d-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate
2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol,
alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)

alpha-Diethylamino-2,6-acetoxylidide
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

alpha-Ethyl-alpha-methylsuccinimide
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

alpha-Flupenthixol
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl-, (E)-

alpha-Methyl-alpha-ethylsuccinimide
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

alpha,alpha-Bis(p-chlorophenyl)-beta,beta,beta-trichloroethane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

alpha,alpha'-Diethyl-4,4'-stilbenediol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

alpha,alpha'-Diethylstilbenediol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

alpha,beta-Dichloroethane
Ethane, 1,2-dichloro-

Alphalin
Vitamin A

Aluminium
Alusinus

Aluminium Flake
Alusinus

Alusinus
Alusinus

Aluminum A00
Alusinus

Aluminum Dehydrated
Alusinus

Aluminum Powder
Alusinus

Aluminum-27
Alusinus

Alvedon
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Alvit 55
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo-
(8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-,
(1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Amadil
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Amatin
Benzene, hexachloro-

Ameisenmittel merk
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Ameisentod
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

American Cyanamid 3422
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl
O-(4-nitrophenyl) ester (9 CI)

Amianthus
Asbestos

Amidazophen
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Amidazophene
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Amidofebrin
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Amidofen
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Amidon
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Amidone
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Amidophen
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Amidophenazon
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Amidophenazone
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Amidopyrazoline
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Amidopyrin
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Amidopyrine
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Aminocyclohexane
Cyclohexylamine (8 CI); Cyclohexanamine (9 CI)

Aminoform
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Aminoformaldehyde
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Aminohexahydrobenzene
Cyclohexylamine (8 CI); Cyclohexanamine (9 CI)

Aminophenazone
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Aminopyrin
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Aminopyrine
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Amitriptylin
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Amitriptyline
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Amitryptyline
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Ammoform
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Ammonioformaldehyde
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Amphenicol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Amphicol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Amrinone
(3,4'-Bipyridin)-6(1H)-one, 5-amino-

Amseclor
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Amuno
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Amylofene
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Anac 110
Copper

Anacobin
Vitamin B12

Anafebrina
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Anaflon
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Anagiardil
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Anagrelide
Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-

Analgesine
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Anatola
Vitamin A

Anelix
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Anestacon
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Anhydro-o-sulfaminebenzoic acid
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Anhydrol
Ethyl alcohol (8 CI); Ethanol (9 CI)

Anodynin
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Anodynine
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Ansiolisina
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Antalvic
2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol,
alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)

Anterior pituitary luteotropin
Prolactin (VAN)

Anti-infective vitamin
Vitamin A

Antibiotic 66-40
Sisomicin (8 CI); D-Streptamine,
O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamin
o-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy- (9 CI)

Anticarie
Benzene, hexachloro-

Antigestil
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Antihydral
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Antipirin
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Antipyrin
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Antisal 1a
Toluene (8 CI); Benzene, methyl- (9 CI)

Antiscorbic vitamin
L-Ascorbic acid

Antiscorbutic vitamin
L-Ascorbic acid

Antixerophthalmic vitamin
Vitamin A

AC Al
Aluminum

Acral
Vitamin A

Apamid
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Apamide
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

APAP
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Aparasin
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Apaurin
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Apexol
Vitamin A

Aphamite
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Aphtiria
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Apirelina
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Aplidal
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Apostavit
Vitamin A

Apozepam
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Apurina
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Aquasol A
Vitamin A

Aquisal
Oxalic acid (8 CI); Ethanedioic acid (9 CI)

Aralo
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Arbitex
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Arcton 7
Methane, dichlorofluoro-

Arcton 9
Methane, trichlorofluoro-

Argentum
Silver

Arkotine
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Armco iron
Iron

Arnsarone
Morphinan-3-ol, 17-methyl-

Arsenic
Arsenic

Arsenic black
Arsenic

Arsenic-75
Arsenic

Arterenol
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Artrinovo
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Artrivia
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Arwood copper
Copper

AR2
Aluminum

AS 18908
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Asbestos
Asbestos

Asbestos fiber
Asbestos

Ascoltin
L-Ascorbic acid

Ascorbajen
L-Ascorbic acid

Ascorbic acid
L-Ascorbic acid

Ascorbutina
L-Ascorbic acid

Ascorin
L-Ascorbic acid

Ascorteal
L-Ascorbic acid

Ascorvit
L-Ascorbic acid

Assival
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Asta B 518
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI); 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Asulfa-Supra
Sulfur

AT 7
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Atav
Vitamin A

Atensine
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Atilen
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Atomic sulfur
Sulfur

Attaclay
Attapulgite (VAN)

Attacote
Attapulgite (VAN)

Attagel
Attapulgite (VAN)

Attagel 150
Attapulgite (VAN)

Attagel 40
Attapulgite (VAN)

Attagel 50
Attapulgite (VAN)

Attasorb
Attapulgite (VAN)

Atysmal
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Austracol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Avibest C
Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI)

Avibon
Vitamin A

Avita
Vitamin A

Avitol
Vitamin A

Avlocardyl
2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol,
1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI)

AV00
Aluminum

AV000
Aluminum

Axerol
Vitamin A

Axerophthol
Vitamin A

AY 2101
Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide,
N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)

AY 68043
2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol,
1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI)

Azinfos-methyl
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one
(8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Azinophos-methyl
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one
(8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Azinphos
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one
(8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Azophen
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Azophene
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Azotox N-33
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

A999
Aluminum

A999
Aluminum

B 32
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

B 518
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

B-Twelve
Vitamin B12

B-Twelve Ora
Vitamin B12

Barbenyl
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Barbiphenyl
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Barbipil
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Barbita
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Barbivis
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Barbosec
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Barium
Barium

BAS 58
8-Quinolinol, 5-nitro

BAY 18002
2,4-Oxazolidinedione, 5,5-dimethyl-

Bayer P-605
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Bayer 17147
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Bayer 5360
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

BBF
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Ben-Hex
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Ben-u-ron
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Benа
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Benadril hydrochloride
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Benadryl
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Benecid
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Benemid
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Bensulfoid
Sulfur

Bentox 10
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Benuryl
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Benzalin
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Benzbromaron
Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI)

Benzbromarone
Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI)

Benzenamine, hexahydro
Cyclohexylamine (8 CI); Cyclohexanamine (9 CI)

Benzhydramine hydrochloride
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Benzinoform
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Benzoic sulfimide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Benzoic sulphimide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Benzosulfimide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Benzosulfinide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Benzoylecgonine
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, (1R-(exo,exo))- (9 CI)

Benzoylecogonine
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, (1R-(exo,exo))- (9 CI)

Benzoylmethylecgonine
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

Beronald
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

beta-Cocaine
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

beta-Dimethylaminoethyl benzhydryl ether hydrochloride
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

beta-Propranolol
2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI)

beta-Pyridyl-alpha-N-methylpyrrolidine
Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI)

Betalin-12
Vitamin B12

Betaline-12
Vitamin B12

Betolvex
Vitamin B12

Bexol
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

BHC
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

BHC, Total
BHC, Total (No postings in CHEMLINE).

Bi 3811
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Bialzepam
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Bickis-sol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Bilevon
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Bio-des
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Bicsterol
Vitamin A

Biphenyl, chlorinated
Biphenyl, chloro (8 CI); 1,1'-Biphenyl, chloro deriva (9 CI)

Bipotassium chlorazepate
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1)

Bis(2-chloroethyl)phosphamide cyclic propanolamide ester
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Bis(2-ethylhexyl)phthalate
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Bis(2-ethylhexyl)1,2-benzenedicarboxylate
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Bis(2-hydroxy-3,5,6-trichlorophenyl)methane
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Bis(3,5,6-trichloro-2-hydroxyphenyl)methane
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Bismuth
Bismuth

Bismuth-209
Bismuth

Bisoflex DOP
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Bisoflex 81
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Black Gold #89
Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

Black Iron BN
Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

Bladan F
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Blu-phen
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Blue powder
Zinc

Bosan supra
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Bovidersol
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Bovine lactogenic hormone
Prolactin (VAN)

Brican
Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

Bricanyl
Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

Bricar
Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

Bricaril
Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

Bricyn
Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

Brimstone
Sulfur

Brocide
Ethane, 1,2-dichloro-

Bromide (1-)
Bromide

Bromide anion
Bromide

Bromide ion
Bromide

Bromine
Bromine

Bromine ion
Bromide

Bromine ion(1-)
Bromide

Bromine, ion (Br(1-))
Bromide

Brufanecaxal
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Brufen
Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

Bufon
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Bufornin
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

Buformine
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

Bunt-cure
Benzene, hexachloro-

Bunt-no-more
Benzene, hexachloro-

Burnish Gold
Gold

Butformin
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

Butyl phthalate
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Butylbiguanide
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

Butyldiguanide
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

BW 56-72
Pyrimidine, 2,4-diamino-5-(3,4,5,-trimethoxybenzyl)- (8 CI); 2,4-Pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- (9 CI)

Byladoce
Vitamin B12

C.I. Pigment Metal 2
Copper

C.I. Pigment Metal 3
Gold

C.I. Pigment Metal 4
Lead

C.I. Pigment Metal 5
Tin

C.I. 366
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

C.I. 77180
Cadmium

C.I. 77320
Cobalt

C.I. 77400
Copper

C.I. 77480
Gold

C.I. 77575
Lead

C.I. 77775
Nickel

C.I. 77795
Platinum

C.I. 77805
Selenium

C.I. 77820
Silver

C.I. 77860
Tin

C-Quin
I-Ascorbic acid

C-Vimin
I-Ascorbic acid

Cadmium
Cadmium

CAF
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Cafeina
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Caffein
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Caffeine
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Cafipel
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Calcifediol
9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)

Calcium
Calcium

Calidria RG 100
Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI)

Calidria RG 144
Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI)

Calidria RG 600
Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI)

Calsocitene
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Calspose
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Calphene
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Calpol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

CAP
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Cannabinol delta(1)-tetrahydro-
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

Cantan
I-Ascorbic acid

Cantaxin
I-Ascorbic acid

CAP
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-,(R-(R*,R*))- (9 CI)

Capitus
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Carbazazepen
5H-Dibenz(b,f)azepine-5-carboxamide

Carbazazepine
5H-Dibenz(b,f)azepine-5-carboxamide

Carbazepine
5H-Dibenz(b,f)azepine-5-carboxamide

Carbinol
Methanol

Carbon bisulfide
Carbon disulfide

Carbon bisulphide
Carbon disulfide

Carbon chloride [CCl4]
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Carbon disulphide
Carbon disulfide

Carbon monoxide
Carbon monoxide

Carbon nitride ion (CN(1-))
Cyanide

Carbon oxide (CO)
Carbon monoxide

Carbon sulfide [CS2]
Carbon disulfide

Carbona
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Carboxyhemoglobin
Carbonylhemoglobin

Cardigin
Digitoxin (8 CI); Card-20(22)-enolide,
3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy
-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

Carditoxin
Digitoxin (8 CI); Card-20(22)-enolide,
3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy
-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

Cassiar AK
Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI)

Catavin C
I-Ascorbic acid

Catendyl
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Catilan
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-,(R-(R*,R*))- (9 CI)

CB 4306
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd.
with potassium hydroxide (1:1)

CBA 101
Copper

CBA 102
Copper

CBA 110
Copper

CBA 122
Copper

Ce-Mi-Lin
I-Ascorbic acid

Ce-Vi-Sol
I-Ascorbic acid

Cebicure
I-Ascorbic acid

Cetion
I-Ascorbic acid

Cetione
I-Ascorbic acid

Cecon
I-Ascorbic acid

Cefaclor
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))-

Cefalexin
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carbcxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Cefaloto
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Cefotaxime
Cefotaxime (No postings in CHEMLINE).

Cefoxitin
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, (6R-cis)-

Ceglolan
I-Ascorbic acid

Ceglion
I-Ascorbic acid

Celanex
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Celaskan
I-Ascorbic acid

Celin
I-Ascorbic acid

Celluflex DPB
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Cenagyl
I-Ascorbic acid

Cenetone
I-Ascorbic acid

Cephalexin
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Cephoxitin
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, (6R-cis)-

Ceporex
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Ceporexine
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Cercine
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Ceregulart
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Cereon
I-Ascorbic acid

Cergona
I-Ascorbic acid

Cescorbat
I-Ascorbic acid

Cetadol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Cetamid
I-Ascorbic acid

Cetemican
I-Ascorbic acid

Cetobemidon
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

Cetobemidone
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

Cetyl sulfate
1-Hexadecanol, hydrogen sulfate

Cevalin
I-Ascorbic acid

Cevatine
I-Ascorbic acid

Cevex
I-Ascorbic acid

Cevimin
I-Ascorbic acid

Cevital
I-Ascorbic acid

Cevitamic acid
I-Ascorbic acid

Cevitamin
I-Ascorbic acid

Cevitan
I-Ascorbic acid

Cevitex
I-Ascorbic acid

Chemicetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chemicetina
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chinoin
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Chlomycol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chloral, monohydrate
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Chloralderat
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Chloramex
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chloramicol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chloramphenicol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chloramsaar
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chlorazepas
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1)

Chlorazepate
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1)

Chlorazepate dipotassium
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1)

Chlordecone
1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

Chlordesmethyldiazepas
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

Chloresene
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Chlorfibrinic acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

Chlorimipramine
5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8 CI);
5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- (9 CI)

Chlorinated diphenyl
Biphenyl, chloro (8 CI); 1,1'-Biphenyl, chloro derivs (9 CI)

Chlorine
Chlorine

Chlorocaps
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chlorocid
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chlorocide
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chlorocidin C
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chlorocidin C tetran
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chlorodibromomethane
Methane, dibromochloro-

Chlorofibrinic acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

Chloroformic digitalin
Digoxin (8 CI); Card-20(22)-enolide,
3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Chloromycetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chloronitrin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Chlorophenothane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Chlorophibrinic acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

Chlorphenothan
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Chlorphenotoxum
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Cholest-5-en-3beta-ol
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Cholesterin
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Cholesterol
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Cholesterol base N
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Cholesteryl alcohol
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Christapurat
Digitoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

Chromium
Chromium

Chrysotile asbestos
Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI)

CI 77000
Aluminum

Ciasin
L-Ascorbic acid

Cila 711*
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

Cidocetine
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Cimetidine
Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-

Cinnamene
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Cinnamol
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Cipca
L-Ascorbic acid

Ciplasycetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

cis-(Z)-Flupenthixol
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl-, (Z)-

cis-Diamminodichloroplatinum(II)
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

cis-Diamminedichloroplatinum
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

cis-Diamminedichloroplatinum(II)
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

cis-Dichlorodiammineplatinum
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

cis-Dichlorodiammineplatinum(II)
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

cis-Flupenthixol
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl-, (Z)-

cis-Flupentixol
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl-, (Z)-

cis-H 102/09
2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-, (Z)-

cis-Platinous diaminodichloride
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

cis-Platinum diaminodichloride
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

cis-Platinum(II) diamminedichloride
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

cis-Platinumdiammine dichloride
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

cis-Zimelidine
2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-, (Z)-

Cisplatin
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

Citalopram
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-

Citox
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

CI-62362
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

Clafen
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Cliradon
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone,
1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

Cliradone
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone,
1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

Clixodyne
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Clobazam
1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-

Clofenotan
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Clofenotane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Clofibrate free acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

Clofibric acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

Clofibrin
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

Clofibrinic acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

Clomipramine
5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8 CI);
5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- (9 CI)

Clonazepam
2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro- (8 CI); 2H-1,4-Benzodiazepin-2-one,
5-(2-chlorophenyl)-1,3-dihydro-7-nitro- (9 CI)

Clonopin
2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro- (8 CI); 2H-1,4-Benzodiazepin-2-one,
5-(2-chlorophenyl)-1,3-dihydro-7-nitro- (9 CI)

Clont
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Cloramphicin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Clorazepate dipotassium
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd.
with potassium hydroxide (1:1)

Clordecone
1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

Clorocyn
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-,(R-(R*,R*))- (9 CI)

Cloromisan
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-,(R-(R*,R*))- (9 CI)

CN-B12
Vitamin B12

Co-Hydeltra
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione,
11,17,21-trihydroxy-, (11beta)- (9 CI)

Co-op Hexa
Benzene, hexachloro-

Cobalamin, cyanide
Vitamin B12

Cobalamin, cyano-
Vitamin B12

Cobalamin, cyano-5,6-dimethylbenzimidazole-
Vitamin B12

Cobalin
Vitamin B12

Cobalt
Cobalt

Cobalt-59
Cobalt

Cobamide, alpha-5,6-dimethyl-1H-benzimidazolyl-, cyanide
Vitamin B12

Cobamide, cyano-5,6-dimethyl-1H-benzimidazole
Vitamin B12

Cobamin
Vitamin B12

Cobinamide, cyanide hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with
5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole
Vitamin B12

Cocaine
1alpha,5alpha-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI);
8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

Codechine
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Codeine
Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-ol,
7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9 CI)

Codelcortone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione,
11,17,21-trihydroxy-, (11beta)- (9 CI)

Coffeine
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Colascor
L-Ascorbic acid

Colloidal Gold
Gold

Colloidal manganese
Manganese

Colloidal sulfur
Sulfur

Cosestrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Cospound 118
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI);
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-,
(1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

Compound 1189
1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

Compound 497
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Compound 889
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Concesin
I-Ascorbic acid

Condicept
Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9 CI)

Confortid
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Copper
Copper

Copper M 1
Copper

Copper powder
Copper

Cordioxil
Digoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Cordulan
Cholestercl (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Cosan
Sulfur

Cosan 80
Sulfur

Cotel
Vitamin B12

Cotnaon
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Cotnion
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Cotcfila
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Covit
Vitamin B12

CPb
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Cratecil
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Crystalline digitalin
Digitoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

Crystamin
Vitamin B12

Crystodigin
Digitoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

Cu 83
Copper

CuPP
Copper

CuPPP
Copper

Cutaval
Manganese

Cyanide (CN(1-))
Cyanide

Cyanide anion
Cyanide

Cyanide ion
Cyanide

Cyanide(1-)
Cyanide

Cyanide(1-) ion
Cyanide

Cyano-B12
Vitamin B12

Cyano-5,6-dimethylbenzimidazolylcobamide
Vitamin B12

Cyanocobalamin
Vitamin B12

Cyanocobalamine
Vitamin B12

Cycloamin
Vitamin B12

Cyclophosphamid
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Cyclophosphamide
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Cyclophosphan
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Cyclophosphane
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Cykobesin
Vitamin B12

Cykobesinet
Vitamin B12

Cylphenicol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Cyzidon
1-Propanone, 1-(4-(4-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone,
1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

Cyren
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Cyren A
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Cystogen
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Cytacon
Vitamin B12

Cytamen
Vitamin B12

Cytobion
Vitamin B12

Cytofol
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-
(9 CI)

Cytophosphan
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Cytoxan
2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

D-(-)-Chloramphenicol
Acetamide, 2,2-dichloro-N-[beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl]-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-[2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-, [R-(R*,R*)]- (9 CI)

D-(-)-threo-Chloramphenicol
Acetamide, 2,2-dichloro-N-[beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl]-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-[2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-, [R-(R*,R*)]- (9 CI)

D-Chloramphenicol
Acetamide, 2,2-dichloro-N-[beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl]-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-[2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-, [R-(R*,R*)]- (9 CI)

d-Lysergic acid diethylamide
Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide,
9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

D-Lysergic acid diethylamide
Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide,
9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

d-Propoxyphene
2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol,
alpha-[2-(dimethylamino)-1-methylethyl]-alpha-phenyl-, propanoate (ester), [S-(R*,S*)]- (9 CI)

d-Pseudoephedrine
Pseudoephedrine, (+)- (8 CI); Benzenemethanol, alpha-[1-(methylamino)ethyl]-, [S-(R*,R*)]- (9 CI)

d-psi-Ephedrine
Pseudoephedrine, (+)- (8 CI); Benzenemethanol, alpha-[1-(methylamino)ethyl]-, [S-(R*,R*)]- (9 CI)

D-Thiocymetin
Acetamide, 2,2-dichloro-N-[beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl]- , D-threo-(+)-
(8 CI); Acetamide, 2,2-dichloro-N-[2-hydroxy-1-(hydroxymethyl)-2-[4-(methylsulfonyl)phenyl]ethyl]-,
[R-(R*,R*)]- (9 CI)

D-Thiophenicol
Acetamide, 2,2-dichloro-N-[beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl]- , D-threo-(+)-
(8 CI); Acetamide, 2,2-dichloro-N-[2-hydroxy-1-(hydroxymethyl)-2-[4-(methylsulfonyl)phenyl]ethyl]-,
[R-(R*,R*)]- (9 CI)

D-threo-Chloramphenicol
Acetamide, 2,2-dichloro-N-[beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl]-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-[2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-, [R-(R*,R*)]- (9 CI)

Dalzic
Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide,
N-[4-(2-hydroxy-3-[(1-methylethyl)amino]propoxy)phenyl]- (9 CI)

Dasilen
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine,
3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Dasitriptyline
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine,
3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Darvon
2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol,
alpha-[2-(dimethylamino)-1-methylethyl]-alpha-phenyl-, propanoate (ester), [S-(R*,S*)]- (9 CI)

Davitamor C
L-Ascorbic acid

Davoxin
Digoxin (8 CI); Card-20(22)-enolide,
3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy
-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Dawe's destrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

DBH
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

DBP
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

DBV
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

DCuPl
Copper

DDE
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

DDE
Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro- (9 CI)

DDT
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

DDT, Total
DDT, Total (No postings in CHEMLINE).

Desalkylprazepam
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

DES
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Decachlorketone
1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

Decachlorooctahydro-1,3,4-metheno-2H-cyclobuta(cd)pentalen-2-one
1,3,4-Metheno-2H-cyclobuta'cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

Decachloropentacyclo(5.2.1.0(2,6).0(3,9).0(5),(d))decan-4-one
1,3,4-Metheno-2H-cyclobeta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

Decortin H
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Decurvon
Insulin

Deflamon
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

DEHP
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Delta F
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

delta(1)-Cortisol
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

delta(1)-Dehydrocortisol
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

delta(1)-Dehydrohydrocortisone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

delta(1)-Tetrahydrocannabiacl
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

delta(1)-THC
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

delta(9)-Tetrahydrocannabinol
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

delta(9)-THC
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

delta(9)-trans-Tetrahydrocannabinol
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

Delta-Cortef
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Delta-Ff-Cortelan
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Delta-stab
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Deltacortenol
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Deltacortril
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Deltahydrocortisone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Deltisilone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Delysid
Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

Demethyldiazepam
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

DENA
Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI)

Denatured Ethanol
Ethyl alcohol (8 CI); Ethanol (9 CI)

Denydryl
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Denyl
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Decval
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Depakine
Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

Depinar
Vitamin B12

Deprosic
2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol, alpha-[2-(dimethylamino)-1-methylethyl]-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)

Dereuma
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

DES
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

DES [synthetic estrogen]
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Desalkylprazepam
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

Desdemin
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]- (9 CI)

Desmethyldiazepam
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

Desuric
Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI)

Detmol-Extrakt
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Detor
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Detoxan
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Detreocycin
Acetamide, 2,2-dichloro-N-[beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl]-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-[2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-, (R-(R*,R*))- (9 CI)

Devoran
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Dextropropoxyphene
2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol, alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)

Dextrosulphenidol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl) phenethyl)- , D-threo-(+)- (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-(methylsulfonyl) phenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Di(Ethylhexyl)phthalate
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Di-(2-Ethylhexyl)-phthalate
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Di-Adreson F
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Di-Estryl
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Di-Hydan
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Di-Lan
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Di-n-butyl phthalate
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Diabetosan
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

Diabex
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

Diacepan
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Dial-a-gesic
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Diamicon
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Diapax
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Diazepan
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

DiEestrol "2" Premix
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Dibovin
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Dibromochlormethane
Methane, dibromochloro-

Dibromodichloromethane
Methane, dibromodichloro-

Dibromomonochloromethane
Methane, dibromochloro-

Dibutyl phthalate
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Dichlor-Mulsion
Ethane, 1,2-dichloro-

Dichlorodiphenyl dichloroethane
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

Dichlorodiphenyltrichloroethane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Dichlorofluoromethane
Methane, dichlorofluoro-

Dichloromethane
Methane, dichloro-

Dichlorononofluoromethane
Methane, dichlorofluoro-

Dicophane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Dicrotol
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Dieldrex
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Dieldrin
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Dielmoth
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Dietary calcium
Calcium

Diethyl p-nitrophenyl phosphorothionate
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Diethyl p-nitrophenyl thionophosphate
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Diethyl parathion
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Diethyl 4-nitrophenylphosphorothionate
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Diethylnitrosamide
Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI)

Diethylnitrosamine
Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI)

Diethylstilbestrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Difenhydramine hydrochloride
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Digacin
Digoxin (8 CI); Card-20(22)-enolide, 3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Digilong
Digitoxin (8 CI); Card-20(22)-enolide, 3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-14-hydroxy-, (3beta,5beta)- (9 CI)

Digimerck
Digitoxin (8 CI); Card-20(22)-enolide, 3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-14-hydroxy-, (3beta,5beta)- (9 CI)

Digisidin
Digitoxin (8 CI); Card-20(22)-enolide, 3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-14-hydroxy-, (3beta,5beta)- (9 CI)

Digitaline
Digitoxin (8 CI); Card-20(22)-enolide, 3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-14-hydroxy-, (3beta,5beta)- (9 CI)

Digitalis glycoside
Digoxin (8 CI); Card-20(22)-enolide,
3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Digitoksin
Digitoxin (8 CI); Card-20(22)-enolide,
3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-14-hydroxy-, (3beta,5beta)- (9 CI)

Digitophyllin
Digitoxin (8 CI); Card-20(22)-enolide,
3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-14-hydroxy-, (3beta,5beta)- (9 CI)

Digitoxigenin tridigitoxoside
Digitoxin (8 CI); Card-20(22)-enolide,
3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-14-hydroxy-, (3beta,5beta)- (9 CI)

Dihycon
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Dilabid
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Dildrin
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth[2,3-b]oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Dilene
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

Diltiazem
1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, cis-(+)-

Dimapyrin
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Dimedrol
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine,
2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Dimedrol hydrochloride
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine,
2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Dimethadion
2,4-Oxazolidinedione, 5,5-dimethyl-

Dimethadione
2,4-Oxazolidinedione, 5,5-dimethyl-

Dimethylamino-analgesine
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Dimethylaminoantipyrine
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Dimethylaminoazophene
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Dimethylaminophenyldimethylpyrazolone
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Dimethylbiguanide
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

Dimethylnitrosamine
Dimethylamine, N-nitroso- (8 CI); Methanamine, N-methyl-N-nitroso- (9 CI)

Dimethyloxychinizin
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Dimethyloxyquinazine
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Dintoina
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Dioctyl phthalate
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Diphanotin
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Diphedan
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Diphenhydramine hydrochloride
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Diphenylhydantoin
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Dipirin
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Dipotassium chlorazepate
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1)

Dipropylacetic acid
Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

Dipyrin
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Dipyrine
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Diquat
Dipyrido(1,2-a:2',1'-c)pyrazinediium, 6,7-dihydro-

Dirox
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Distilbene
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Distodin
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Dithiocarbonic anhydride
Carbon disulfide

Dixina
Digoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

DMGG
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

DMN
Dimethylamine, N-nitroso- (8 CI); Methanamine, N-methyl-N-nitroso- (9 CI)

DMNA
Dimethylamine, N-nitroso- (8 CI); Methanamine, N-methyl-N-nitroso- (9 CI)

DMO
2,4-Oxazolidinedione, 5,5-dimethyl-

DNTP
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Dobetin
Vitamin B12

Dobren
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Docesine
Vitamin B12

Docibin
Vitamin B12

Docigran
Vitamin B12

Dodat
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Dodecabee
Vitamin B12

Dodecavite
Vitamin B12

Dodex
Vitamin B12

Doganil
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Dogmatyl
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Dol Granule
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Dolophin
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Dolovin
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Donestrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Donisolone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

DOP
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Dorsal
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Dorsigon
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Dorsigon-Schlofai
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Dorsiral
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Dorsutil
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Dorsodin
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Doryton
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Doscalen
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Doxorubicin
Adriamycin (8 CI); 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9 CI)

DPH
Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

DPH
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Drilltox-Spezial Aglukon
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Docobee
Vitamin B12

Dogoran
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Duirezol
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo[3.3.1(3,7)]decane (9 CI)

Duksen
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Durcaine
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Duneryl
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Duodecibin
Vitamin B12

Duscline
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Dutch liquid
Ethane, 1,2-dichloro-

Duzen
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Dykol
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Dymadon
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Dythol
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

E 3314
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene,
1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

E 605
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl
O-(4-nitrophenyl) ester (9 CI)

E 605 f
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl
O-(4-nitrophenyl) ester (9 CI)

E-Cu57
Copper

Eazolin D
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione,
11,17,21-trihydroxy-, (11beta)- (9 CI)

Ecgonine benzoate
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8 CI);
8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, (1R-(exo,exo))- (9 CI)

Ecgonine, methyl ester, benzoate (ester)
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI);
8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

EDC
Ethane, 1,2-dichloro-

EGDN
Ethylene glycol, dinitrate (8 CI); 1,2-Ethanediol, dinitrate (9 CI)

Eglonyl
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide,
5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

EGYT 341
5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-

Ekagon H
Benzmethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Ekatox
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl
O-(4-nitrophenyl) ester (9 CI)

Elacl
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Elavil
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine,
3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Electro-CF 11
Methane, trichlorofluoro-

Elinol
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Elixophyllin
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Elixophylline
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Elosal
Sulfur

Emany Atomized Aluminum Powder
Aluminum

Emtacetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Emtiol
Vitamin B12

Emzide
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Enocicline
Vitamin B12

Enciol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Endopancrine
Insulin

Endoxan
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI); 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Eneril
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

ENT 15,108
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

ENT 15,152
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

ENT 15,949
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI); 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

ENT 23,233
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

ENT 25,584
4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

ENT 7,796
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

ENT-1506
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

ENT-16225
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

ENT-16391
1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

Enterosycetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Entizol
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Entosoxan
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

ECSA
Iron

Epibenzalin
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Epinelton
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Epiteliol
Vitamin A

Epoxyheptachlor
4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI);
2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

Fraldin
Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide,
N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)

Franol
Iodine

Frantin
2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol,
alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)

Frgenyl
Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

Fridan
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Fritrone
Vitamin B12

Frrolon
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid,
5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Frycytol
Vitamin B12

Erythrotin
Vitamin B12

Eskabarb
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Espectinosicina
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI);
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-,
(2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)

Estilbin ''HCO''
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Estonate
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Estrobene
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Estrosenin
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Estrosyn
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Ethamide
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Ethaminal
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione,
5-ethyl-5-(1-methylbutyl)- (9 CI)

Ethane, 1,1,1-trichloro-2,2-bis(4-chlorophenyl)
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Ethosuxide
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Ethosuximide
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Ethyl hydrate
Ethyl alcohol (8 CI); Ethanol (9 CI)

Ethyl hydroxide
Ethyl alcohol (8 CI); Ethanol (9 CI)

Ethyl parathion
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Ethylene chloride
Ethane, 1,2-dichloro-

Ethylene dichloride
Ethane, 1,2-dichloro-

Ethylene dinitrate
Ethylene glycol, dinitrate (8 CI); 1,2-Ethanediol, dinitrate (9 CI)

Ethylene nitrate
Ethylene glycol, dinitrate (8 CI); 1,2-Ethanediol, dinitrate (9 CI)

Ethylhexyl phthalate
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Ethymal
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Etilfen
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Etilon
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Etomuximid
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Euhaemon
Vitamin B12

Euneryl
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Eunoctin
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Eupractone
2,4-Oxazolidinedione, 5,5-dimethyl-

Eviplast 80
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Eviplast 81
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Evronal
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Exhaust gas
Carbon monoxide

Excfene
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Extrinsic factor
Vitamin B12

F.I. 106
Adriamycin (8 CI); 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9 CI)

F.I. 5978
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Factor II
Vitamin B12

Factor II [vitamin]
Vitamin B12

Fadorair
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Farmicetina
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Faustan
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

FC 11
Methane, trichlorofluoro-

FC 11 [halocarbon]
Methane, trichlorofluoro-

FC 21
Methane, dichlorofluoro-

Febrilix
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Febrinina
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Febro-Genic
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Febrolin
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Febron
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Fenadol
2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol,
alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)

Fenazone
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Fendon
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Fenenal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Fenicol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Fenisolone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione,
11,17,21-trihydroxy-, (11beta)- (9 CI)

Ferrovac E
Iron

Fesia-sin
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Firinol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Finlepsin
5H-Dibenz(b,f)azepine-5-carboxamide

FKW 11
Methane, trichlorofluoro-

Flagesol
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Flagil
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Flagyl
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Flavyl
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine,
3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Flexinol
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Flexol DOP
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Flowers of sulphur
Sulfur

Fluamine
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

Flue gas
Carbon monoxide

Fluvoids
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Fluvamine
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

Fluverfenazine
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Fluoride
Fluoride

Fluoride ion
Fluoride

Fluorine
Fluorine

Fluorine ion (1-)
Fluoride

Fluorine-19
Fluorine

Fluorochloroform
Methane, trichlorofluoro-

Fluorodichloromethane
Methane, dichlorofluoro-

Fluorophenazine
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl, propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Fluorotrichloromethane
Methane, trichlorofluoro-

Fluorphenazine
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Fluphenazine
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Flux maag
Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI)

Folacid
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Folacin
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Folbal
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Folcidin
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Folettes
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Folianin
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Folidol
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Folidol E
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Folidol E-605
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Folidol oil
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Folipac
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Folsan
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Folsaure
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Folsav
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Folvite
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Fonstol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Formasine
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo[3.3.1(3,7)]decane (9 CI)

Formin [heterocycle]
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo[3.3.1(3,7)]decane (9 CI)

Forst-Hexen
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Fosferno
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Fostox
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Fostril
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Freon F 21
Methane, dichlorofluoro-

Freon MF
Methane, trichlorofluoro-

Freon F 11
Methane, trichlorofluoro-

Freon 11
Methane, trichlorofluoro-

Freon 21
Methane, dichlorofluoro-

Freon 30
Methane, dichloro-

Fresnin
Vitamin B12

Frigen 11
Methane, trichlorofluoro-

Frigen 11A
Methane, trichlorofluoro-

Frusemide
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Frusemin
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Fulsix
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Feluvamide
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Furanthril
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Furanthryl
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Furantril
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Furazosin
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8 CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9 CI)

Furesis
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Furosemid
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Furosemide
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Furoseмid
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Furoseмide
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Fusid
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

F11P
Methane, trichlorofluoro-

F21
Methane, dichlorofluoro-

G 11
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

G 32883
5H-Dibenz(b,f)azepine-5-carboxamide

G 34586
5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8 CI); 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- (9 CI)

Galactin
Prolactin (VAN)

Gamma benzene hexachloride
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

gamma-Benzene hexachloride
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

gamma-BHC
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

gamma-BCH
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

gamma-Bexachloran
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

gamma-Bexachlorane
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

gamma-Bexachlorobenzene
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

gamma-Hexachlorocyclohexane
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

gamma-Lindane
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

gamma-1,2,3,4,5,6-Hexachlorocyclohexane
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Gammater
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Gamophen
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Gamophene
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Garantose
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Gardenal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Gardepanyl
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

GC 1189
1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

Gearphos
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Geigy 32883
5H-Dibenz(b,f)azepine-5-carboxamide

Genetron 11
Methane, trichlorofluoro-

Genetron 21
Methane, dichlorofluoro-

Genoplast B
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Genoxal
2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide (8 CI); 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Gerax-Medica
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Gesafid
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Gesarol
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Gexane
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Gineflavir
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Gliquasid
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

Glctenicol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-,(R-(R*,R*))- (9 CI)

Glucid
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Glucodigin
Digitoxin (8 CI); Card-20(22)-enolide, 3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-14-hydroxy-, (3beta,5beta)- (9 CI)

Glucophage
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

Glusid
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Glyhigil
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

Glycol dichloride
Ethane, 1,2-dichloro-

Glycol dinitrate
Ethylene glycol, dinitrate (8 CI); 1,2-Ethanediol, dinitrate (9 CI)

Gold Flake
Gold

Gold Leaf
Gold

Gold Powder
Gold

GPPh
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

Grafenstrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Grandaxin
5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-

Gravocain
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Grey arsenic
Arsenic

Ground vocle sulphur
Sulfur

Guaranine
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Guastil
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Guathion
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Guathion M
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Guathion M
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Guathion methyl
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Guathion-20
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Guation 25
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Guthion
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

H 224
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

H 3
Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

H-8723
1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-

Haurysolin
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

HCB
Benzene, hexachloro-

HCC
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

HCCH
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

HCE
4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

HCH
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

HCH, Total
HHC, Total (No postings in CHEMLINE).

HCPH
(-)-2-Hydroxy-N-cyclopropylmethylmorphinan (No postings in Chemline).

Hectotox
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Hedex
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Hemo-b-dose
Vitamin B12

Hexamin
Vitamin B12

HHCI
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Hexagon
Vitamin B12

Hexavis
Vitamin B12

Hexcovite
Vitamin B12

Hexta
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

Heptachlor
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

Heptachlor epoxide
4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

Heptachlorane
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

Heptadone
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Heptanon [pharmaceutical]
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Herax UTS
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Peteria
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Hexa
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Hexa-Flo-Pulver
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Hexablan
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Hexachloran
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Hexachlorane
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Hexachlorobenzene
Benzene, hexachloro-

Hexachlorofen
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Hexachlorophen
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Hexachlorophene
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Hexadecyl hydrogen sulfate
1-Hexadecanol, hydrogen sulfate

Hexadecyl sulfate
1-Hexadecanol, hydrogen sulfate

Hexafen
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Hexafora
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo[3.3.1(3,7)]decane (9 CI)

Hexahydroaniline
Cyclohexylamine (8 CI); Cyclohexanamine (9 CI)

Hexamethylenamine
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo[3.3.1(3,7)]decane (9 CI)

Hexamidine
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Hexamine
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo[3.3.1(3,7)]decane (9 CI)

Hexamine (heterocycle)
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo[3.3.1(3,7)]decane (9 CI)

Hexaplas M/B
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Hexaman
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo[3.3.1(3,7)]decane (9 CI)

Hexavern
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Hexicide
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Hexophene
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Hexosan
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Hexyclan
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

HF-3170
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

HGI
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

HHDN
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI); 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

Hi-Destrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Hidental
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Hipnax
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Hipsal
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Hoechst 10720
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

Holodora
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Hoscolan
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Homolle's digitalin
Digoxin (8 CI); Card-20(22)-enolide,
3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Hooker no. 1 chrysotile asbestos
Chrysotile (8 CI) (VAN); Chrysotile [H8Mg3(Si2O9)] (9 CI)

Horizon
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Hortex
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Hostocrotin H
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

HR 376
1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-

Hungaria L 7
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Hytrin
L-Ascorbic acid

Hydeltra
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Hydeltrone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Hydral
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Hydrobromic acid, ion(1-)
Bromide

Hydrocerin
Cholestenol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Hydrocyanic acid, ion(1-)
Cyanide

Hydrodeltalone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Hydrodeltisone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Hydrofluoric acid, ion (1-)
Fluoride

Hydrofluoride 3170
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

Hydrotetrocortin
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Hydrovit A
Vitamin A

Hyminal
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Hypocal
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Hypotor base
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Hypotrol
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Hyptor
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Hysteps
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

HSAD
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

I 237A
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Ibuprofen
Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

ICI 45,520
2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI)

ICI 50172
Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)

ICI-58838
Morpholine, 2-((2-ethoxyphenoxy)methyl)-

IDC-C
L-Ascorbic acid

Iletin
Insulin

Illexol
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaph(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Imvenox
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Inacid
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Incafolic
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Indacin
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Indo-Rectolmin
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Indocid
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Indocin
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Indocosol
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Indosed
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Indoses
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Indosetacin
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Indomethacine
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Indomethacin
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Indomethacine
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Indomethine
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Infrocin
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Insectlack
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth[2,3-b]oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Insular
Insulin

Insulin (bonito)
Insulin

Insulin Injection
Insulin

Insuly
Insulin

Intramycetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-(threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Iodine
Iodine

Iodine ((127)I2)
Iodine

Iodine colloidal
Iodine

Iodine crystals
Iodine

Iodine sublimed
Iodine

Iodine-127
Iodine

Iosan Superdip
Iodine

IP-82
Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

Ipenofil
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Iron
Iron

Iron Black
Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

Isceon 131
Methane, trichlorofluoro-

Iscovesco
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

ISF 2001
Morpholine, 4-(thioxo(3,4,5-trimethoxyphenyl)methyl)-

Isicaine
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Isicaine
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Isaicetina
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Isocyanide
Cyanide

Isoephedrine
Pseudoephedrine, (+)- (8 CI); Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))- (9 CI)

Isotron 11
Methane, trichlorofluoro-

Isulin
Insulin

Itazidone
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Ivoran
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Jacutin
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Jaysol
Ethyl alcohol (8 CI); Ethanol (9 CI)

Jaysol S
Ethyl alcchol (8 CI); Ethanol (9 CI)

JISC 3108
Alusinus

JISC 3110
Alusinus

Julin's carbon chloride
Benzene, hexachloro-

Juvamycetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

K 8710
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone,
1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

K 6-30
Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI)

Kafar copper
Copper

Kaltron 11
Methane, trichlorofluoro-

Kamaver
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Karbamazepin
5H-Dibenz(b,f)azepine-5-carboxamide

Kathro
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Katlex
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid,
5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Keflex
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D-
(8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid,
7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Keforla
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D-
(8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid,
7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Kelfizin
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9
CI)

Kelfizina
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Kelfizine W
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Kemicetine
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Kepone
1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

Ketalgin
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Ketobemidone
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

Ketogan
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

Ketogin
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

Klion
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Klont
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Klorita
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Klorocid S
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

KM 320
Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

Kodaflex DOP
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Koffein
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Kokctine
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Kolloidschwefel 95
Sulfur

Kolo 100
Sulfur

Kosti-Albertan
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Kortofil
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI); 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

KS-4
Lead

KWD 2019
Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

Kwell
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

L Betinimid
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

L 2214
Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI)

L 2214-Labaz
Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI)

L 3
Silver

L-(+)-Ascorbic acid
I-Ascorbic acid

L-(+)-Pseudoephedrine
Pseudoephedrine, (+)- (8 CI); Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))- (9 CI)

L-Lyxoascorbic acid
I-Ascorbic acid

L-Nicotine
Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI)

L-threo-Hex-2-enonic acid
I-Ascorbic acid

L-Xyloascorbic acid
I-Ascorbic acid

L-3-Ketothreohexuronic acid
I-Ascorbic acid

LA 111
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

LA 6023
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

LA-1
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Lactobacillus lactis dorner factor
Vitamin B12

Lactogen, pituitary
Prolactin (VAN)

Lactogenic hormone
Prolactin (VAN)

Lactosomatotropic hormone
Prolactin (VAN)

Lanatoxin
Digitoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

Lanicor
Digoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Lanicordin
Digoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Larcl
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Lascphyllin
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Lanoxin
Digoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Lantron
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cycloheptan-5-ylidene)-N,N-dimethyl- (9 CI)

Lard-factor
Vitamin A

Larixin
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Larocorbine
I-Ascorbic acid

Laroxyl
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cycloepten-5-ylidene)-N,N-dimethyl- (9 CI)

Lasex
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Lasilix
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Lasix
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

LB 502
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Lead
Lead

Lead Flake
Lead

Lead S2
Lead

Ledon 11
Methane, trichlorofluoro-

Lemascorb
L-Ascorbic acid

Lentrol
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Lesoran
Morphinan-3-ol, 17-methyl-

Lerdine
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Lentizol
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cycloepten-5-ylidene)-N,N-dimethyl- (9 CI)

Lentox
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Leostesin
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Lepimidin
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Lepinal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Lepinaletten
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Lepitoin
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Lepsiral
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Lestemp
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Leukonyan
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Leukomycin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Levarterenol
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Levius
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Levo-Dromoran
Morphinan-3-ol, 17-methyl-

Levoarterenol
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Levomicetina
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Levomitsetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Levomycetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Levonoradrenaline
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Levophed
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Levornorepinephrine
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydrox,-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Levorphan
Morphinan-3-ol, 17-methyl-

Levorphanal
Morphinan-3-ol, 17-methyl-

Levorphanol
Morphinan-3-ol, 17-methyl-

Lexibictico
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Lidenal
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Lidocaine
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Lignocaine
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Lilly 66873
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Lilly 99638
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))-

Lindane
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Lindatox
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Lindex
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Lindosep
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Lintox
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Linvar
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Liquagesic
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Liqui-Cee
I-Ascorbic acid

Liquid Bright Platinum
Platinum

Liquital
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Liquophylline
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Lirethion
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Lithius
Lithium

Liver Lactobacillus casei factor
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Lixophen
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

LLD factor
Vitamin B12

Lcha
Iron

Lonarid
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Longun
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Lorexane
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Lorinal
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Loromisin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Loupatron
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Loxapin
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

Loxapine
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

LSD
Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

LSD [alkaloid]
Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

LSD 25
Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

Lu 10-171
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-

LU 10-171
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-

Lutergal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Luminal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Luteotrophin
Prolactin (VAN)

Luteotropic hormone
Prolactin (VAN)

Luteotropic hormone LTH
Prolactin (VAN)

Luteotropin
Prolactin (VAN)

LY-3170
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

LY 127935
5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid,
7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-

Lysergic acid diethylamide
Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide,
9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

Lysergide
Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide,
9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

Lyteca
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Lyteca syrup
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

LYE
Aluminum

M 1
Copper

M 181
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI);
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-,
(2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)

M 3
Copper

M 4
Copper

m-Dimethylbenzene
m-Xylene (8 CI); Benzene, 1,3-dimethyl- (9 CI)

m-Xylol
m-Xylene (8 CI); Benzene, 1,3-dimethyl- (9 CI)

Macasirool
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid,
5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Macrabin
Vitamin B12

Madlexin
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D-
(8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid,
7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Magnesium
Magnesium

Magnesium Gold Purple
Gold

Magnetic Black
Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

Magnetic Oxide
Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

Magnilet-A
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Mammotropin
Prolactin (VAN)

Manganese
Manganese

MACA
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Maprotiline
9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl- (8 CI); 9,10-Ethanoanthracene-9(10H)-propanamine,
N-methyl- (9 CI)

Maricaire
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Mastiphen
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Mateina
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Metallysal
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione,
5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Metubarbital
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione,
5-ethyl-5-(1-methylbutyl)- (9 CI)

Mecodin
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Medi-Pets
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Megalovel
Vitamin B12

Melbin
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

Melsed
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Melsedin base
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Melsomin
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Mesostilbees
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Meramec M25
Magnetite (8 CI); Magnetite (Fe_3O_4) (9 CI)

Mercury
Mercury

Merez
1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-

Mesentol
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Metacen
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid,
1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Metacortandralone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione,
11,17,21-trihydroxy-, (11beta)- (9 CI)

Metakvalon
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Metallic arsenic
Arsenic

Metallic tin
Tin

Metalozone
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-(8 CI);
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- (9 CI)

Metana
Alusious

Metana Alusious Paste
Alusious

Metaqualon
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Metartril
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid,
1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Metformin
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

Methacide
Toluene (8 CI); Benzene, methyl- (9 CI)

Methadone
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Methaqualon
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Methaqualone
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Methaqualoneimone
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Methazine
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Methenamin
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo[3.3.1(3,7)]decane (9 CI)

Methenamine
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo[3.3.1(3,7)]decane (9 CI)

Methozin
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Methyl alcohol
Methanol

Methyl guthion
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Methyl hydroxide
Methanol

Methyl mercury ion
Mercury(1+), methyl-, ion (8 CI); Mercury(1+), methyl- (9 CI)

Methyl viologen(2+)
4,4'-Bipyridinium, 1,1'-dimethyl-

Methylbenzene
Toluene (8 CI); Benzene, methyl- (9 CI)

Methylbenzol
Toluene (8 CI); Benzene, methyl- (9 CI)

Methylcarbinol
Ethyl alcohol (8 CI); Ethanol (9 CI)

Methyldiazepinone
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Methylene bichloride
Methane, dichloro-

Methylene chloride
Methane, dichloro-

Methylene dichloride
Methane, dichloro-

Methylguathion
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

Methylmercury
Mercury(1+), methyl-, ion (8 CI); Mercury(1+), methyl- (9 CI)

Methylmercury ion(1+)
Mercury(1+), methyl-, ion (8 CI); Mercury(1+), methyl- (9 CI)

Methylmercury(II) cation
Mercury(1+), methyl-, ion (8 CI); Mercury(1+), methyl- (9 CI)

Methylmercury(1+)
Mercury(1+), methyl-, ion (8 CI); Mercury(1+), methyl- (9 CI)

Methylmorphine
Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9 CI)

Methylol
Methanol

Methylsulfonylchloramphenicol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)- , D-threo-(+)- (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Methylthecbromine
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Meti-Cera
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Meticortelone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Metindol
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Metclazone
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-(8 CI); 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- (9 CI)

Metolquizolone
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Metronidazol
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Metronidazole
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Mexibol
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Mexiletine
Ethylamine, 1-methyl-2-(2,6-xylyloxy)- (8 CI); 2-Propanamine, 1-(2,6-dimethylphenoxy)- (9 CI)

Mezolin
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Mf1700
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

Mianserin
Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-

Mianserine
Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-

Micloretin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Micowetsulf
Sulfur

Microcetina
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Microest
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Milbedoce
Vitamin B12

Milepsin
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Milestrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Millafol
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

Millol 49
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Min-U-Gel FG
Attapulgite (VAN)

Min-U-Gel 200
Attapulgite (VAN)

Minuric
Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI)

Mirfamil
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Mirodine
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Mirolyne
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Mirulvan
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Mirzdin
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Mirzlin
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

MK-230
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Mogadan
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Mogadon
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Mogadone
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Molecular iodine
Iodine

Mollinor
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Monochlorodibromomethane
Methane, dibromochloro-

Monofluorodichloromethane
Methane, dichlorofluoro-

Monofluorotrichloromethane
Methane, trichlorofluoro-

Monohexadecyl sulfate
1-Hexadecanol, hydrogen sulfate

Monohydroxymethane
Methanol

Moroxan
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Morphine monomethyl ether
Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9 CI)

Morphine-3-methyl ether
Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9 CI)

Morpholine, 4-(3,4,5-trimethoxythiobenzoyl)-
Morpholine, 4-(thioxo(3,4,5-trimethoxyphenyl)methyl)-

Moth Snub D
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Motolon
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Motrin
Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

Moxalactam
5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-

Mezanbin
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Mezycol
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

MFC
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Multin
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Mutoxan
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Mychel
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Mycinol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Mylepsin
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Mylepsinum
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Mycdigin
Digitoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

Myzadon
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Myzoline
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

N 1 (copper)
Copper

N 2 (copper)
Copper

N 3 (copper)
Copper

N 25
Copper

N 31
Copper

N 4 (copper)
Copper

N 7^0
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

N(1)-(3-Methoxy-2-pyrazinyl)sulfanilamide
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

N(1)-Butylbiguanide
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

N(1)-Desmethyldiazepam
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

N(1),N(1)-Dimethylbiguanide
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

N-(p-(((2-amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-glutamic acid
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

N-(p-((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methylamino)benzoyl)-glutami c acid
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI)

N-(4-Hydroxyphenyl)acetamide
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-5-sulfamoylbenzamide
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

N-Acetyl-p-aminophenol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

N-acetyl-4-aminophenol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

n-Butyl phthalate
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

N-Demethyldiazepam
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

N-Desoxydiazepam
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

N-Desmethyldiazepam
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

n-Dipropylacetic acid
Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

N-Ethyl-N-nitrosoethanamine
Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI)

n-Hexadecyl sulfate
1-Hexadecanol, hydrogen sulfate

N-Methyl-N-nitrosomethanamine
Dimethylamine, N-nitroso- (8 CI); Methanamine, N-methyl-N-nitroso- (9 CI)

N-Nitroso-N,N-diethylamine
Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI)

N-Nitroso-N,N-dimethylamine
Dimethylamine, N-nitroso- (8 CI); Methanamine, N-methyl-N-nitroso- (9 CI)

N-Nitrosodiethylamine
Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI)

N-Nitrosodimethylamine
Dimethylamine, N-nitroso- (8 CI); Methanamine, N-methyl-N-nitroso- (9 CI)

N,N-Bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide
2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

N,N-Bis(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

N,N-Diethyl-D-lysergamide
Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

N,N-Diethyllysergamide
Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI)

N,N-Dimethylbiguanide
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

N,N-Dimethyldiguanide
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

N,N'-Dimethyl-4,4'-bipyridinium dication
4,4'-Bipyridinium, 1,1'-dimethyl-

Nabac
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Nagravon
Vitamin B12

NAPA
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Napafen
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

NAPAP
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Naprinol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Narkolil
Methane, dichloro-

Nativelle
Digitoxin (8 CI): Card-20(22)-enolide,
3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy
-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

Natrium
Sodium

Necatorina
Carbon tetrachloride (8 CI): Methane, tetrachloro- (9 CI)

Nembutal
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI): 2,4,6(1H,3H,5H)-Pyrimidinetrione,
5-ethyl-5-(1-methylbutyl)- (9 CI)

Neo-Centranol I
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI): Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Neo-Scabicidol
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI): Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Neocid
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI): Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Neocidol
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI): Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Neodorm
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI): 2,4,6(1H,3H,5H)-Pyrimidinetrione,
5-ethyl-5-(1-methylbutyl)- (9 CI)

Neoclexina
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D-
(8 CI): 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid,
7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Necompt V
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Neozepan
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Netzschwefel
Sulfur

Neurobarb
Barbituric acid, 5-ethyl-5-phenyl- (8 CI): 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Neurocaine
1alpha H,5alpha H-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI):
8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

Neurotol
5H-Dibenz(b,f)azepine-5-carboxamide

Nevracten
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd.
with potassium hydroxide (1:1)

Nexen FB
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI): Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Nexit
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI): Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Nexit-stark
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI): Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Nexol-E
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI): Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Ni 0901-S(Harshaw)
Nickel

Ni 270
Nickel

Ni 4303T
Nickel

Nitiol
8-Quinolinol, 5-nitro

Nickel
Nickel

Nickel carbonyl
Nickel carbonyl [Ni(CO)4] (8 CI); Nickel carbonyl [Ni(CO)4], (T-4)- (9 CI)

Nickel NF2
Nickel

Nickel tetracarbonyl
Nickel carbonyl [Ni(CO)4] (8 CI); Nickel carbonyl [Ni(CO)4], (T-4)- (9 CI)

Nickel 270
Nickel

Nicochloran
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Nicorol
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Nicotine
Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI)

NIP 204
Pyrimidine, 2,4-diamino-5-(3,4,5,-trimethoxybenzyl)- (8 CI); 2,4-Pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- (9 CI)

Nisco Cholesterol Base B
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Nisco cholesterol Base No. 712
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Nic-A-Let
Vitamin A

Niran
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Nitalapram
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-

Nitrazepam
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Nitrenpax
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Nitroglycol
Ethylene glycol, dinitrate (8 CI); 1,2-Ethanediol, dinitrate (9 CI)

Nitrosodiethylamine
Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI)

Nitrostigmine
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Nitroxolin
8-Quinolinol, 5-nitro

Nitroxoline
8-Quinolinol, 5-nitro

NNDG
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

No Pest
Benzene, hexachloro-

No Pest Liquid
Benzene, hexachloro-

No Pest 40
Benzene, hexachloro-

No Pest 80
Benzene, hexachloro-

No-Doz
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Ncap
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Nchedon
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Nchedora
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Nectec
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Noctilene
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Noptil
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Nor-Epirenan
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Noradrenalin
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Noradrenaline
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Noral Aluminium
Aluminum

Noral Extra Fine Lining Grade
Aluminum

Noral Ink Grade Aluminium
Aluminum

Norartrinal
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Nordiazepam
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

Norepinephrine
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Norepirenamine
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

Norni-Nox
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Norsinycin V
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Norsocytin
Vitamin B12

Noromycetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Novamidon
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Nozibiol
8-Quinolinol, 5-nitro

NPZ
Nickel

NSC 119875
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI)

NSC 123127
Adriamycin (8 CI); 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9 CI)

Numol
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Mycoton
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Mycton
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

o-Benzoic sulfimide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

o-Benzosulfimide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

O-Benzoyl ecgonine
1alpha,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8 CI);
8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, [1R-(exo,exo)]- (9 CI)

o-Benzoyl-(-)-ecgonine
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8 CI);
8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, [1R-(exo,exo)]- (9 CI)

o-Benzoylsulfimide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

o-Hydroxybenzoate
Salicylic acid, ion(1-) (8 CI); Benzoic acid, 2-hydroxy-, ion(1-) (9 CI) (VAN)

o-Sulfobenzimide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

o-Sulfobenzoic acid imide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

O,C-Diethyl O-(p-nitrophenyl) phosphorothioate
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl
O-(4-nitrophenyl) ester (9 CI)

O,C-Diethyl O-p-nitrophenyl thiophosphate
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl
O-(4-nitrophenyl) ester (9 CI)

O,C-dimethyl-S-(4-oxobenzotriazino-3-methyl) phosphorothioate
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one
(8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI)

o,p'-DDE
Ethylene, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8 CI); Benzene,
1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)- (9 CI)

Octachlor epoxide
4,7-Methanoindan, 1,2,3,4,5,6,7,8,8-octachloro-1,2-epoxy-3a,4,7,7a-tetrahydro- (8 CI);
2,5-Methano-2H-indeno(1,2-b)oxirene, 1a,2,3,4,5,6a,7,7-octachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

Octalene
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI);
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-,
(1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

Octalox
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo-
(8 CI); 2,7:3,6-Dimethanonaphth[2,3-b]oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-,
(1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Octcil
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Octylphthalate
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Oestrogenine
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Oestrosenin
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Oestrosensyl
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

OFBC Cu
Copper

Oleofos 20
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl
O-(4-nitrophenyl) ester (9 CI)

Oleoparaphene
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl
O-(4-nitrophenyl) ester (9 CI)

Olecparathion
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Olecvitamin A
Vitamin A

Omnitox
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Ozzyl
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Opclor
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Opthochlor
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Optinoxan
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Optiphyllin
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Orthonal
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Ortonal
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Orvagil
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Ovadziak
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Owadziak
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Oxa-cephem
5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-

Oxilapine
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

Oxychlordan
4,7-Methanoindan, 1,2,4,5,6,7,8,8-octachloro-1,2-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 1a,2,3,4,5,6a,7,7-octachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

Oxychlordane
4,7-Methanoindan, 1,2,4,5,6,7,8,8-octachloro-1,2-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 1a,2,3,4,5,6a,7,7-octachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

Oxydimethylquinazine
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

p-(Acetylamino)phenol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

p-(Dipropylsulfamoyl)benzoic acid
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

p-(Dipropysulfasyl)benzoic acid
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

p-Acetasidophenol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

p-Hydroxyacetanilide
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

p-Isobutylhydratropic acid
Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

p,p'-DDD
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

p,p'-DDE
Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro- (9 CI)

p,p'-DDT
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

p,p'-Dichlorodiphenyl-2,2-dichloroethylene
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

p,p'-Dichlorodiphenyldichloroethane
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

p,p'-Dichlorodiphenyldichloroethylene
Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro- (9 CI)

p,p'-Dichlorodiphenyltrichloroethane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

p,p'-TDE
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

Palestrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Pacinol
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Paccl
Phosphorothioic acid, O,C-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl C-(4-nitrophenyl) ester (9 CI)

Paecmo
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Palatinol AH
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Palatinol C
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Palestrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Palladium
Palladium

Palsityl sulfate
1-Hexadecanol, hydrogen sulfate

Panadol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Panets
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Pantovernil
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

PBF-1
Aluminum

Paracetamol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Paracetamole
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Parachlorocidus
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Paracortol
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Paralactin
Prolactin (VAN)

Paramar 50
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Paraphos
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Paraquat
4,4'-Bipyridinium, 1,1'-dimethyl-

Paraquat dication
4,4'-Bipyridinium, 1,1'-dimethyl-

Paraquat ion
4,4'-Bipyridinium, 1,1'-dimethyl-

Parathion
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Parathion-ethyl
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Parazin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Parkophyllin
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Parminal
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Parsol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Paxate
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Paxel
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

PBB
Polybrominated biphenyls (No postings in CHEMLINE).

PCB
Biphenyl, chloro (8 CI); 1,1'-Biphenyl, chloro deriv. (9 CI)

PCPP
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

PCPPP
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

PDT
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Pedraczak
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Pedric
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Pesal
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Pencap E
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI)

Pentabarbitone
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)- (9 CI)

Pentachlorin
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Pentachlorophenyl chloride
Benzene, hexachloro-

Pentamethylmelamine
Melamine, pentamethyl- (8 CI); 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N''-pentamethyl- (9 CI)

Penticidae
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Pentobarbital
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)- (9 CI)

Pentobarbitone
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)- (9 CI)

Pentobarbituric acid
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)- (9 CI)

Perchlorobenzene
Benzene, hexachloro-

Perchloromethane
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Perfluoride
Fluoride

Perhexilene
Piperidine, 2-(2,2-dicyclohexylethyl)-

Perhexiline
Piperidine, 2-(2,2-dicyclohexylethyl)-

Perlapine
Morphanthridine, 6-(4-methyl-1-piperazinyl)- (8 CI); 11H-Dibenz(b,e)azepine, 6-(4-methyl-1-piperazinyl)- (9 CI)

Permagel
Attapulgite (VAN)

Permaemon
Vitamin B12

Permaevit
Vitamin B12

Pernipuron
Vitamin B12

Petnidan
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Pflanzol
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

PGA
Folic acid (8 CI); L-Glutamic acid, N-(4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl)- (9 CI)

Phaldrone
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Phenadone
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Phenaesal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Phenazon
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Phenazone
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Phenazone [pharmaceutical]
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Phendon
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Phenenal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Phenethylene
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Phenobarbital
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Phenobarbitone
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Phenobarbituric acid
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Phenoleric
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Phenonyl
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Phenylethene
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Phenylethylbarbituric acid
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Phenylethylene
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Phenylethylmalonylurea
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Phenylmethane
Toluene (8 CI); Benzene, methyl- (9 CI)

Phenylon
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Phenylone
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Phenyral
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Phenytoin
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Phenytoine
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

pHisoHex
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Phot
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Phosphorus
Phosphorus

Phosphorus-31
Phosphorus

Phthalic acid dioctyl ester
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Physeptone
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Piknolepsin
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Piportil
10H-Phenothiazine-2-sulfonamide, 10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-N,N-dimethyl-

Pipothiazine
10H-Phenothiazine-2-sulfonamide, 10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-N,N-dimethyl-

Pipotiazine
10H-Phenothiazine-2-sulfonamide, 10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-N,N-dimethyl-

Piptothiazine
10H-Phenothiazine-2-sulfonamide, 10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-N,N-dimethyl-

Pirasidon
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Piridol
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Pironidine
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Pittsburgh PX-138
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Pituitary lactogenic horsone
Prolactin (VAN)

Plasavit C
L-Ascorbic acid

Plastibest 20
Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI)

Platinium Black
Platinum

Platinum
Platinum

Plecyamin
Vitamin B12

PM 671
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Polamidone
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-

Polinalin
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Polsulkol Extra
Sulfur

Polybrominated biphenyls
Polybrominated biphenyls (No postings in CHEMLINE).

Polychlorinated quaterphenyls
Polychlorinated quaterphenyls (No postings in CHEMLINE).

Polycidal
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (6 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Polycizer DBP
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Potassium
Potassium

Poyamin
Vitamin B12

Practalol
Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)

Practolol
Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)

Praval
Calcium

Prazosin
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8 CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9 CI)

Precipitated sulfur
Sulfur

Precortancyl
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Precortisyl
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Predne-Dome
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Prednelan
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Prednisolone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Predonine
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Prefemin
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Prerolone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Prepalin
Vitamin A

Preparation AF
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Prinaclone
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Prinacone
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Prinadone
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Prinidon
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Prinidone
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Prinpaktan
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

PPC
Platinum

Probecid
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Proben
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Probenecid
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Probenecid acid
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Procytox
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Procheptadiene
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Proclongine
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Propellant 11
Methane, trichlorofluoro-

Propoxyphene
2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol, alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI)

Propranolol
2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI)

Proprasylyt
2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI)

Procscorbin
L-Ascorbic acid

Provitamin A
Vitamin A

Provitamin D
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Pseudoephedrine
Pseudoephedrine, (+)- (8 CI); Benzeneethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))- (9 CI)

Pseudotheophylline
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

psi-Ephedrin
Pseudoephedrine, (+)- (8 CI); Benzeneethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))- (9 CI)

psi-Ephedrine
Pseudoephedrine, (+)- (8 CI); Benzeneethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))- (9 CI)

psi-Ephedrine, (+)-
Pseudoephedrine, (+)- (8 CI); Benzeneethanol, alpha-[1-(methylamino)ethyl]-, [S-(R*,R*)]- (9 CI)

PteGlu
Folic acid (8 CI); L-Glutamic acid, N-[4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- (9 CI)

Pteroylglutamic acid
Folic acid (8 CI); L-Glutamic acid, N-[4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- (9 CI)

Purodigin
Digitoxin (8 CI); Card-20(22)-enolide,
3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-14-hydroxy-, (3beta,5beta)- (9 CI)

Purpurid
Digitoxin (8 CI); Card-20(22)-enolide,
3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-14-hydroxy-, (3beta,5beta)- (9 CI)

PX 108
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Pyknolepsinus
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Pyradone
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Pyramidon
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Pyramidone
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Pyrazophyl
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Pyrimidone
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Pyrinazine
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

PZh-1M3
Iron

PZh-2
Iron

PZh1M1
Iron

PZh2M
Iron

PZh2M1
Iron

PZh2M2
Iron

PZh3
Iron

PZh3M
Iron

PZh4M
Iron

Quaalude
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Quellada
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Quesicetina
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, [R-(R*,R*)]- (9 CI)

Quicksilver
Mercury

Quievita
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Quinalbarbital
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Quinalbarbitone
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Quinobarbitone
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

QZ 2
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

R 10
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

R 11
Methane, trichlorofluoro-

R 11 [refrigerant]
Methane, trichlorofluoro-

R 20
Chloroform (8 CI); Methane, trichloro- (9 CI)

R 20 [refrigerant]
Chloroform (8 CI); Methane, trichloro- (9 CI)

R 21
Methane, dichlorofluoro-

R 21 [refrigerant]
Methane, dichlorofluoro-

R.D. 13621
Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

R.E. 1403
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Radedorm
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Radcnna
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Rasor
Thallium

Raney alloy
Nickel

Raney copper
Copper

Raney nickel
Nickel

RE-PL
Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

RC-Schwefel Extra
Sulfur

RCB 55/5
Nickel

Rebrasin
Vitamin B12

Rectulen
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Red phosphorus
Phosphorus

Red Shield
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Redamina
Vitamin B12

Redisol
Vitamin B12

Redomex
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cycloepten-5-ylidene)-N,N-dimethyl- (9 CI)

Redoxon
L-Ascorbic acid

Reducor
2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI)

Refresh'n
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Regadrin
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

Relaxinal
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Relanium
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Remin
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Restamin
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Retinol
Vitamin A

Reumacide
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Revonal
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

RG 600
Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI)

Rhodacrynt
Vitamin B12

Rhodiachlor
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

Rhothane
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

Ribena
L-Ascorbic acid

RIC 272
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Rickamicin
Sisomicin (8 CI); D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy- (9 CI)

Ritosept
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Rivadorn
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)- (9 CI)

Rivotril
2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro- (8 CI); 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- (9 CI)

Ro 1-5431
Morphinan-3-ol, 17-methyl-

Ro 4-1575
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cycloepten-5-ylidene)-N,N-dimethyl- (9 CI)

Ro 4-5360
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Ro 5-2807
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Ro 5-3050
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Ro 5-4023
2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro- (8 CI); 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- (9 CI)

Ro 52180
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-

Rce 101
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Renton
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Rorer 148
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Rorer 718
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Rosemide
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]- (9 CI)

Rougoxin
Digoxin (8 CI); Card-20(22)-enolide, 3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI)

Roulone
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Rowaqualone
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

RP 19366
10H-Phenothiazine-2-sulfonamide, 10-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propyl]-N,N-dimethyl-

RP 7623
Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)- (9 CI)

RP 8823
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Rubesol
Vitamin B12

Rubramin
Vitamin B12

Rubripca
Vitamin B12

Rubrocitol
Vitamin B12

Rucaina
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Rusestrol 1
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Rusestrol 2
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

RVR-PG
Attapulgite (VAN)

S 6437
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

S-805
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

Saccharimide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Saccharin
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Saccharin acid
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Saccharin insoluble
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Saccharine
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Saccharinol
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Saccharinose
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Saccharol
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

Sadcress
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid,
1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

Salicylate
Salicylic acid, ion(1-) (8 CI); Benzoic acid, 2-hydroxy-, ion(1-) (9 CI) (VAN)

Salicylate anion
Salicylic acid, ion(1-) (8 CI); Benzoic acid, 2-hydroxy-, ion(1-) (9 CI) (VAN)

Salicylate ion
Salicylic acid, ion(1-) (8 CI); Benzoic acid, 2-hydroxy-, ion(1-) (9 CI) (VAN)

Salix
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid,
5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]- (9 CI)

Sanq-gamma
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-,
(1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Sanocide
Benzene, hexachloro-

Saronet
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Sarotex
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine,
3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Sch 13875
Sisomicin (8 CI); D-Streptamine,
O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-[2,6-diamin
o-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4)]-2-deoxy- (9 CI)

Scherisolon
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione,
11,17,21-trihydroxy-, (11beta)- (9 CI)

Scorbu-C
L-Ascorbic acid

SD Alcohol 23-hydrogen
Ethyl alcohol (8 CI); Ethanol (9 CI)

SD 2794
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI);
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-,
(1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

SD 3417
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo-
(8 CI); 2,7:3,6-Dimethanonaphth[2,3-b]oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-,
(1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Secobarbital
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione,
5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Secobarbitone
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione,
5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Seconal
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione,
5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

Secorbate
L-Ascorbic acid

Sedatin
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Sedatine
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

Sedonal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Sedophen
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Sedukmen
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Seduxen
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Seedrin
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI);
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-,
(1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

Seguril
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid,
5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Selenium
Selenium

Sercephalin
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D-
(8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid,
7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

Sendoxan
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

Septicol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Septisol
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Septofen
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Seroten
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine,
3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Serpentine chrysotile
Chrysotile (8 CI) (VAN); Chrysotile [$H_4Mg_3(Si_2O_9)$] (9 CI)

Serral
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Sertan
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

Setonil
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Sevenal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Sexocretin
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Shell Gold
Gold

Shell Silver
Silver

Sibazon
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Sibol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

Sicol 150
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Silflake 135
Silver

Silicon
Silicon

Silver
Silver

Silver atom
Silver

Silver Matt Powder
Tin

Silver metal
Silver

Sisatin
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Sindesvel
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Sintomicetina
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Sintomicetine B
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Siqualine
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Siqualon
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

SMP 2
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Smieciotox
Benzene, hexachloro-

Sodanton
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Sodius
Sodium

Sodius metal
Sodium

Sodium-23
Sodium

Solaesthin
Methane, dichloro-

Solcain
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Solmethine
Methane, dichloro-

Solosin
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Sonberol
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Sonone
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Sonos
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Sonoxal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Sonal
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Sonebon
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-

Sepor
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Severin
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

SF 104
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

Spectas
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI); 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4aBeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)

Spectinomycin
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI); 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4aBeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)

Spritz-Rapidin
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Spruehpflanzol
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

SQ 4918
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

SR 720-22
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-(8 CI); 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- (9 CI)

Sr 999
Silver

Staflex DBP
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Staflex DOP
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Stanozucetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Stental Extentabs
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Steral
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Steran
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Sterane
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Steranskin
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Sterolone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Stesolid
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Stesolin
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Stil
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Stil-Rcl
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Stilbestrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Stilbetin
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Stilboefral
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Stilboestrofem
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Stilboestrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Stilkap
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Stim
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Streunex
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Strontius
Strontius

Styrene
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Styrol
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Styrole
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Styrolene
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Styropol 50
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Sublimed sulfur
Sulfur

Succinal
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Succisitin
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Sudafed
Pseudoephedrine, (+)- (8 CI); Benzenemethanol, alpha-[1-(methylamino)ethyl]-, [S-(R*,R*)]- (9 CI)

Sufran
Sulfur

Sufran D
Sulfur

Sulfalene
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Sulfamethopyrazine
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Sulfamethoxypyrazine
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Sulfametopyrazine
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Sulfapyrazinemethoxine
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Sulfapyrazinemethoxyine
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Sulfapyrazinemethoxyne
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

Sulfar
Sulfur

Sulfidal
Sulfur

Sulfur
Sulfur

Sulfur atom
Sulfur

Sulfur ointment
Sulfur

Sulfur, pharmaceutical
Sulfur

Sulikol
Sulfur

Sulkol
Sulfur

Sulphur
Sulfur

Sulpirid
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Sulpiride
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Sulpyrid
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI)

Sultaf
Sulfur

SUN-3170
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

Surgi-Cen
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Surofene
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Suxilep
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Suxinal
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Suxinutin
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

SUY B-2
Iron

Svevl
Sulfur

Sylodex
Chrysotile (8 CI) (VAN); Chrysotile [$H_4Mg_3(Si_2O_9)$] (9 CI)

sym-Dichlorcethane
Ethane, 1,2-dichloro-

Synergid B
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Synestrin
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Synthoestrin
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Synthofolin
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Synthomycetine
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Syntofolin
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Syraprin
Pyrimidine, 2,4-diamino-5-(3,4,5,-trimethoxybenzyl)- (8 CI); 2,4-Pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- (9 CI)

Sytobex
Vitamin B12

S0
Lead

S1
Lead

S9a
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Tabalgin
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Tafidex
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Tagaset
Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-

Takinetol
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Tap 85
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Tatuzinho
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI); 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

TDE
Ethane, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

Tecsol
Ethyl alcohol (8 CI); Ethanol (9 CI)

Tegolan
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Tegretal
5H-Dibenz(b,f)azepine-5-carboxamide

Tegretol
5H-Dibenz(b,f)azepine-5-carboxamide

Teslo
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Tespanal
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Tespra
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Tensofin
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Tecfyllamin
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Teolaxin
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Teranol
Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)

Teraseptic
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Terbutalin
Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

Terbutaline
Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

Tersitox
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI)

Testascorbic
L-Ascorbic acid

Testavol
Vitamin A

Tetracarbonyl nickel
Nickel carbonyl [Ni(CO)4] (8 CI); Nickel carbonyl [Ni(CO)4], (T-4)- (9 CI)

Tetrachlorodiphenyl ethane
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

Tetrachloromethane
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Tetrafinol
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Tetrafora
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Tetrahydrocannabinol
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

Tetrahydrocannabinol cross-reacting cannabinoids
Tetrahydrocannabinol cross-reacting cannabinoids (No postings in CHEMLINE).

Tetrasol
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Tevcocin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Thallium
Thallium

THC-CRC
Tetrahydrocannabinol cross-reacting cannabinoids (No postings in CHEMLINE).

Theal tabl.
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Thein
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Theine
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

Theocin
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Theofol
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Theograd
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Theolair
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Theolix
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Theophyllin
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Theophylline
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

Thiamphenicol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)- , D-threo-(+)- (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-[4-(methylsulfonyl)phenyl]ethyl)-, (R-(R*,R*))- (9 CI)

Thiocysetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)- , D-threo-(+)- (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-[4-(methylsulfonyl)phenyl]ethyl)-, (R-(R*,R*))- (9 CI)

Thicether
Thioether (No postings in CHEMLINE).

Thiophenicol
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)-, D-threo-(+)-(8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Thicvit
Sulfur

Ticarcillin
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-

Tifenycine
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Tin
Tin

Tin Flake
Tin

Tin Powder
Tin

Tipula
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI); 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI)

Tocopherol
Tocopherol

Tofisopam
3H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-

Toluene
Toluene (8 CI); Benzene, methyl- (9 CI)

Tolnol
Toluene (8 CI); Benzene, methyl- (9 CI)

Tcrinol
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Tosyl
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

TR 895
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Tralgon
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Tranimul
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

trans-alpha,alpha'-Diethyl-4,4'-stilbenediol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(',2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

trans-Diethylstilbesterol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

trans-Diethylstilbestrol
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Trans-Ephedrine
Pseudoephedrine, (+)- (8 CI); Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))- (9 CI)

trans-Nonachlor
4,7-Methano-1H-indene, 1,2,3,4,5,6,7,8,8-nonachloro-2,3,3a,4,7,7a-hexahydro-, (1alpha,2beta,3alpha,3aalpha,4beta,7beta,7aalpha)-

trans-4,4'-Dihydroxy-alpha,beta-diethylstilbene
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI)

Transit
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Trawotox
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Treomicetina
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI);
Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Tri-6
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Trichloroacetaldehyde hydrate
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Trichloroacetaldehyde monohydrate
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

Trichlorobis(4'-chlorophenyl)ethane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Trichlorocarbanilide
Carbanilide, trichloro- (8 CI); Urea, N,N'-diphenyl-, trichloro deriv. (9 CI)

Trichlorofluoromethane
Methane, trichlorofluoro-

Trichlorofors
Chlorofors (8 CI); Methane, trichloro- (9 CI)

Trichloromethane
Chlorofors (8 CI); Methane, trichloro- (9 CI)

Trichloromonofluoromethane
Methane, trichlorofluoro-

Trichlorophene
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

Trichosol
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Trichopal
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Triflumethazine
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Trifluoperazin
Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI)

Trifluoperazine
Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI)

Trifluoromethylperazine
Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI)

Trifluoroperazine
Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI)

Trifluperazine
Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI)

Trifluria
Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI)

Trimethoprim
Pyrimidine, 2,4-diamino-5-(3,4,5,-trimethoxybenzyl)- (8 CI); 2,4-Pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- (9 CI)

Triperazine
Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI)

Triphenatol
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Triptanol
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Triptisol
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Triptizol
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Trithiozine
Morpholine, 4-(thioxo(3,4,5-trimethoxyphenyl)methyl)-

Trivazol
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Trobicin
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI); 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)

Trofurit
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Truflex DOP
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Tryptanol
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

Tuazole
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Tuazolone
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

Tuophon
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Tussapap
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Tylenol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

U 18409 E
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI); 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI)

Ulscort
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Ultra Sulfur
Sulfur

Ultracorten B
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Ultracortene-B
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

Unidigin
Digitoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI)

Unimoll DB
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Unisycetin
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Univera
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

UNT 51239
Melamine, pentamethyl- (8 CI); 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N''-pentamethyl- (9 CI)

Urasin
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Uratrine
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Urbanyl
1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-

Urex
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

Uricosid
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI)

Uricovac
Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI)

Uritone
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Urodeine
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Urotropin
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Urotropine
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

V S
Silver

Vaflol
Vitamin A

Vagimid
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI)

Valadol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Valamina
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Valec
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Valgesic
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

Valium
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Valproic acid
Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

Vanadium
Vanadium

Vanadium-51
Vanadium

Velsicol 104
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

Velsicol 53-CS-17
4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI)

Vena
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

Vermoestricid
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI)

Veronmal
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

Vesparine
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI)

Vestinol AH
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Vi-Alpha
Vitamin A

Vibalt
Vitamin B12

Vitisone
Vitamin B12

Vicelat
I-Ascorbic acid

Vicin
I-Ascorbic acid

Viforcit
I-Ascorbic acid

Vilcraxin
Morpholine, 2-((2-ethoxyphenoxy)methyl)-

Vilcraxine
Morpholine, 2-((2-ethoxyphenoxy)methyl)-

Vinicizer 80
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Vinylbenzene
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Vinylbenzol
Styrene (8 CI); Benzene, ethenyl- (9 CI)

Virubra
Vitamin B12

Viscorin
I-Ascorbic acid

Vita-rubra
Vitamin B12

Vitace
I-Ascorbic acid

Vitacee
I-Ascorbic acid

Vitacisin
I-Ascorbic acid

Vitacin
I-Ascorbic acid

Vitamin A
Vitamin A

Vitamin A alcohol
Vitamin A

Vitamin A(1)
Vitamin A

Vitamin B12 preparation
Vitamin B12

Vitamin C
I-Ascorbic acid

Vitamisin
I-Ascorbic acid

Vitarubin
Vitamin B12

Vitascorbol
I-Ascorbic acid

Vitavel A
Vitamin A

Viton
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

Vitpex
Vitamin A

Vitral
Vitamin B12

Vival
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Vivol
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

Vcgan
Vitamin A

Vegan-Neu
Vitamin A

W 37
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

Wang
Tin

White phosphorus
Phosphorus

Win 1539
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

Win 40680
(3,4'-Bipyridin)-6(1H)-one, 5-amino-

Win 5063-2
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)- , D-threo-(+)- (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))- (9 CI)

Witcizer
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

Witcizer 300
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI)

Wood alcohol
Methanol

Wood alcohols B.P.
Cholestercl (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

Wood spirit
Methanol

Wy 3467
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

X 250
Attapulgite (VAN)

Xametrin
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI)

Xitix
L-Ascorbic acid

Xycaine
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Xylestesin
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Xylcascorbic acid, L-
L-Ascorbic acid

Xylocain
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Xylocaine
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Xylocitin
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Xylotox
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

Yellow phosphorus
Phosphorus

Zarodan
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Zarondan
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Zarondan-Saft
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Zarontin
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

Zaroxolyn
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl- (8 CI); 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- (9 CI)

Zentropil
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

Zecgel
Attapulgite (VAN)

Zerdane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

Ziselidine
2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-, (Z)-

Zinc
Zinc

Zircorium
Zirconium

1-(-)-Norepinephrine
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol,
4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetic acid
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid,
1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI)

1-(2,6-Dimethylphenoxy)-2-aminopropane
Ethylamine, 1-methyl-2-(2,6-xylyloxy)- (8 CI); 2-Propanamine, 1-(2,6-dimethylphenoxy)- (9 CI)

1-(2',6'-Dimethylphenoxy)-2-aminopropane
Ethylamine, 1-methyl-2-(2,6-xylyloxy)- (8 CI); 2-Propanamine, 1-(2,6-dimethylphenoxy)- (9 CI)

1-(3-Methylaminopropyl)-dibenzo(b,e)bicyclo(2.2.2)octadiene
9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl- (8 CI); 9,10-Ethanoanthracene-9(10H)-propanamine,
N-methyl- (9 CI)

1-(3,4-Dihydroxyphenyl)-2-aminoethanol
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol,
4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

1-(3,5-dihydroxyphenyl)-2-(tert-butylamino)ethanol
Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol,
5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI)

1-(4-acetamidophenoxy-3-isopropylamino-2-propanol
Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide,
N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)

1-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol,
4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

1-Arterenol
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol,
4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

1-Bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI);
2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI)

1-Butylbiguanide
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI)

1-Cocaine
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI);
8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

1-Dehydrohydrocortisone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione,
11,17,21-trihydroxy-, (11beta)- (9 CI)

1-delta(1)-trans-Tetrahydrocannabinol
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

1-Hexadecyl hydrogen sulfate
1-Hexadecanol, hydrogen sulfate

1-Methyl-2-(3-pyridyl)pyrrolidine
Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI)

1-Noradrenaline
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol,
4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

1-Norepinephrine
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol,
4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine
1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-

1-trans-delta(9)-Tetrahydrocannabinol
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6-9-trimethyl-3-pentyl-, (6aR-trans)-

1-3,4-Dihydroxyphenylethanolamine
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol,
4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

1,1-Bis(p-chlorophenyl)-2,2-dichloroethane
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro-
(9 CI)

1,1-Bis(p-chlorophenyl)-2,2,2-trichloroethane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

1,1-Bis(4-chlorophenyl)-2,2-dichloroethane
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro-
(9 CI)

1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethylene
Ethylene, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8 CI); Benzene,
1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)- (9 CI)

1,1-Dichloro-2,2-bis(p-chlorophenyl)ethane
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro-
(9 CI)

1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene
Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro-
(9 CI)

1,1-Dichloro-2,2-bis(4-chlorophenyl)ethane
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro-
(9 CI)

1,1-Dichloro-2,2-di(p-chlorophenyl)ethylene
Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro-
(9 CI)

1,1-Dicyclohexyl-2-(2-piperidyl)ethane
Piperidine, 2-(2,2-dicyclohexylethyl)-

1,1-Dimethylbiguanide
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI)

1,1-dioxide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

1,1,1-Trichloro-2,2-bis(p-chlorophenyl)ethane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

1,1,1-Trichloro-2,2-bis(4,4'-dichlorodiphenyl)ethane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

1,1,1-Trichloro-2,2-dihydroxyethane
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

1,1'-Dimethyl-4,4'-bipyridinium
4,4'-Bipyridinium, 1,1'-dimethyl-

1,1'-Dimethyl-4,4'-bipyridinium cation
4,4'-Bipyridinium, 1,1'-dimethyl-

1,1'-Ethylene-2,2'-bipyridinium
Dipyrido(1,2-a:2',1'-c)pyrazinediium, 6,7-dihydro-

1,2-Benzenedicarboxylic acid, bis(ethylhexyl)ester
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

1,2-Benzisothiazoline-3-one
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

1,2-Bichloroethane
Ethane, 1,2-dichloro-

1,2-Dehydrohydrocortisone
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione,
11,17,21-trihydroxy-, (11beta)- (9 CI)

1,2-Dichloroethane
Ethane, 1,2-dichloro-

1,2-Dihydro-2-ketobenzisosulfonazole
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

1,2,3,4,5,6-Hexachlorocyclohexane
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

1,3-Dimethylbenzene
m-Xylene (8 CI); Benzene, 1,3-dimethyl- (9 CI)

1,3-Dimethylxanthine
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI)

1,3-Xylene
m-Xylene (8 CI); Benzene, 1,3-dimethyl- (9 CI)

1,3,5,7-Tetraazaadamantane
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo[3.3.1(3,7)]decane (9 CI)

1,3,7-Trimethyl-2,6-dioxopurine
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

1,3,7-Trimethylxanthine
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI)

1,4-pregnadiene-3,20-dione
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

1H-Benzimidazole, 5,6-dimethyl-1-(3-O-phosphono-alpha-D-ribofuranosyl)-, monoester with cobinamide cyanide hydroxide, inner salt
Vitamin B12

10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

11557 Black
Magnetite (8 CI); Magnetite [Fe3O4] (9 CI)

14-Hydroxydaunomycin
Adriamycin (8 CI); 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9 CI)

1721 Gold
Copper

19 366 R.P.
10H-Phenothiazine-2-sulfonamide, 10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-N,N-dimethyl-

2-(Benzhydryloxy)-N,N-dimethylethylamine hydrochloride
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

2-(Diethylamino)-2',6'-acetoxylidide
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI)

2-(p-Chlorophenoxy)-2-methylpropionic acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

2-(p-Chlorophenoxy)isobutyric acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

2-(p-Isobutylphenyl)propionic acid
Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

2-(2-chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethylene
Ethylene, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8 CI); Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)- (9 CI)

2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine
Morpholine, 2-((2-ethoxyphenoxy)methyl)-

2-(2,2-Dicyclohexylethyl)piperidine
Piperidine, 2-(2,2-dicyclohexylethyl)-

2-(4-Chlorophenoxy)-2-methylpropanoic acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

2-(4-Chlorophenoxy)-2-methylpropionic acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

2-(4-Isobutylphenyl)propanoic acid
Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

2-[4-(2-furoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8 CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9 CI)

2-Amino-1-(3,4-dihydroxyphenyl)ethanol
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI)

2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

2-Deoxyphenobarbital
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

2-Desoxyphenobarbital
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

2-Diphenylmethoxy-N,N-dimethylethylamine hydrochloride
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride

2-Ethyl-2-methylsuccinimide
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

2-Ethylhexyl phthalate
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI)

2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

2-Methoxy-3-sulfanilamidopyrazine
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

2-methyl-3-(o-tolyl)-4-quinazolone
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI)

2-Propylpentanoic acid
Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

2-Propylvaleric acid
Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

2-Sulfanilamido-3-methoxypyrazine
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

2,2-Bis(p-chlorophenyl)-1,1,1-trichloroethane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

2,2-Bis(4-chlorophenyl)-1,1-dichloroethane
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI)

2,2-Bis(4-chlorophenyl)-1,1-dichloroethylene
Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro- (9 CI)

2,2,2-Trichloro-1,1-ethanediol
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

2,2'-Bipyridinium, 1,1'-(1,2-ethanediyl)-
Dipyrido(1,2-a:2',1'-c)pyrazinediium, 6,7-dihydro-

2,2'-Dihydroxy-3,3',5,5',6,6'-hexachlorodiphenylmethane
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

2,2'-Dihydroxy-3,5,6,3',5',6'-tetrachlorodiphenylmethane
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

2,2'-Methylenebis(3,4,6-trichlorophenol)
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

2,2',3,3',5,5'-Hexachloro-6,6'-dihydroxydiphenylmethane
Phenol, 2,2'-methylenebis(3,4,6-trichloro-

2,3-Dihydro-3-oxobenzisosulfonazole
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Pyrimidine, 2,4-diamino-5-(3,4,5,-trimethoxybenzyl)- (8 CI); 2,4-Pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- (9 CI)

2beta-Carbomethoxy-3beta-benzoxytropane
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

2beta-Tropanecarboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester)
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI)

2000/P-RVH
Attapulgite (VAN)

25-Hydrocholecalciferol
9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)

25-Hydroxy D3
9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)

25-Hydroxy-5,6-trans-cholecalciferol
9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)

25-Hydroxycholecalciferol
9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)

25-Hydroxyvitamin D
9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)

25-Hydroxyvitamin D3
9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)

3-(N-Methylpyrollidino) pyridine
Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI)

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropylamine
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cycloheptene-5-ylidene)-N,N-dimethyl- (9 CI)

3-Benzisothiazolinone 1,1-dioxide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

3-chloro-10,11-dihydro-5-(3-dimethylaminopropyl)-5H-dibenz[b,f]azepine
5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino) propyl)-10,11-dihydro- (8 CI); 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- (9 CI)

3-Chlorochlordene
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI)

3-Ethyl-3-methylsuccinimide
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI)

3-Hydroxybenzisothiazole-S,S-dioxide
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

3-Methoxy-2-sulfanilamidopyrazine
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

3-Methoxy-2-sulfapyrazine
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

3-Methoxypyrazine sulfanilamide
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI)

3-Oxo-L-gulofuranolactone
L-Ascorbic acid

3,20-dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI)

3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
Vitamin A

3beta-Hydroxycholest-5-ene
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

3keto-L-Gulofuranolactone
L-Ascorbic acid

4-(Dimethylamino) antipyrine
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

4-(Dipropylsulfamoyl) benzoic acid
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino) sulfonyl)- (9 CI)

4-(m-Hydroxyphenyl)-1-methyl-4-piperidyl ethyl ketone
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI)

4-(3,4,5-Triethoxythiobenzoyl) morpholine
Morpholine, 4-(thioxo(3,4,5-triethoxyphenyl) methyl)-

4-Acetamidophenol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

4-Acetaminophenol
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid,
5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI)

4-Chlorophenoxyisobutyric acid
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI)

4-Dimethylaminophenazone
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one,
4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI)

4-Heptanecarboxylic acid
Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI)

4-Hydroxyacetanilide
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

4-Isobutylhydratropic acid
Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI)

4,4'-DDD
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro-
(9 CI)

4,4'-DDE
Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro-
(9 CI)

4,4'-Dichlorodiphenyltrichloroethane
Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene,
1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI)

4,4'-Dihydroxy-alpha,beta-diethylstilbene
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

4,4'-Dihydroxydiethylstilbene
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
(9 CI)

4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide
Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide,
N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI)

4'-Hydroxyacetanilide
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI)

5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine,
3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine,
3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]cycloheptadiene
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine,
3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI)

5-Allyl-5-(1-methylbutyl)barbituric acid
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione,
5-(1-methylbutyl)-5-(2-propenyl)- (9 CI)

5-Carbamoyl-5H-dibenz(b,f)azepine
5H-Dibenz(b,f)azepine-5-carboxamide

5-Ethyl-5-(sec-pentyl)barbituric acid
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione,
5-ethyl-5-(1-methylbutyl)- (9 CI)

5-Ethyl-5-(1-methylbutyl)barbituric acid
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione,
5-ethyl-5-(1-methylbutyl)- (9 CI)

5-Ethyl-5-phenylbarbituric acid
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

5-ethyl-5-phenylhexahydropyrimidine-4,6-dione
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

5-(gamma-dimethylaminopropyl)-3-chloroiminodibenzyl
5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8 CI);
5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- (9 CI)

5-Nitro-8-hydroxyquinoline
8-Quinolinol, 5-nitro

5-Nitro-8-oxychinoline
8-Quinolinol, 5-nitro

5-Nitro-8-oxyquinoline
8-Quinolinol, 5-nitro

5-Nitro-8-quinolinol
8-Quinolinol, 5-nitro

5-Nitrox
8-Quinolinol, 5-nitro

5-Nitroxine
8-Quinolinol, 5-nitro

5-Phenyl-5-ethylbarbituric acid
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI)

5-phenyl-5-ethylhexahydropyrimidine-4,6-dione
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-

5,5-Dimethyloxazolidine-2,4,-dione
2,4-Oxazolidinedione, 5,5-dimethyl-

5,5-Dimethyloxazolidinedione
2,4-Oxazolidinedione, 5,5-dimethyl-

5,5-Diphenyl-2,4-imidazolidinedione
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

5,5-Diphenylhydantoin
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI)

5,6-cis-25-Hydroxy vitamin D3
9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI)

5,6-Dimethylbenzimidazolyl cyanocobamide
Vitamin B12

5,6-Dimethylbenzimidazolyl-Co-cyanocobamide
Vitamin B12

5,6-Cholesten-3beta-ol
Cholestercl (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI)

5NCN
8-Quinolinol, 5-nitro

5PCN
Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI)

5SC Saccharine
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI)

6(D(-)alpha-Carboxy-3-thienylacetamido)penicillanic acid
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid,
6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-

6-(4-Methyl-1-piperazinyl)morphanthridine
Morphanthridine, 6-(4-methyl-1-piperazinyl)- (8 CI); 11H-Dibenz(b,e)azepine, 6-(4-methyl-1-piperaziayl)- (9 CI)

666
Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI)

7-(D-alpha-aminophenylacetamido)desacetoxycephalosporanic acid
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid,
7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

7-(D-2-amino-2-phenylacetamido)-3-methyl-delta(3)-cephem-4-carboxylic acid
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid,
7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI)

7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-

8-Hydroxy-5-nitroquinoline
8-Quinolinol, 5-nitro

8065CB
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)- , D-threo-(+)- (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))- (9 CI)

9-(gamma-methylaminopropyl)-9,10-dihydro-9,10-ethanoanthracene
9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl- (8 CI); 9,10-Ethanoanthracene-9(10H)-propanamine, N-methyl- (9 CI)

9,10-Dihydro-8a,10a-Diazoniaphenanthrene
Dipyrido(1,2-a:2',1'-c)pyrazinediium, 6,7-dihydro-

910
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI)

APPENDIX E

Tissue and Body Fluids (Vols. I-IV)

Adipose
Adrenal gland
Amniotic fluid
Aorta
Ascites fluid
Bile
Bladder
Blister fluid
Blood
Blood, cells
Blood, fetal
Blood, plasma
Blood, serum
Blood, whole
Body
Bone
Bone marrow
Brain
Breast
Breast fluid
Breath
Cartilage
Cerebrospinal fluid
Cerebrospinal/ventricular fluid
Connective tissue
Diaphragm
Ear fluid
Endometrium
Epithelium
Esophagus
Eye
Fetal
Gall bladder
Gall stone
Gastric liquid
Gonads
Gum
Hair
Heart
Integument
Intestine
Kidney
Larynx
Ligament
Liver
Lung
Lymph node
Mammary gland
Menstrual fluid
Milk
Milk, fat
Milk, whole
Muscle
Nail
Nerve
Omentum
Ovary
Oviduct
Pancreas
Pericardial fluid
Pharynx
Pineal gland
Pituitary
Placenta
Pleural fluid
Prostate
Respiratory secretion
Saliva
Salivary gland
Semen
Skin
Soft tissue
Spinal cord
Spinal fluid
Spleen
Sputum
Stomach
Sweat
Synovial fluid
Synovial membrane
Tears
Teeth
Tendon
Testis
Thymus gland
Thyroid gland
Tonsil
Trachea
Umbilical cord
Urine
Uterus
Vitreous humor

INDICES

(Vol. IV)

Author, page 405
Corporate Author, page 413
Tissue, page 423
Keyword, page 425

AUTHOR INDEX

Aasenden, R. 5453, 5503, 5550, 5555

Abern, S. 5817, 5818, 5865, 5866

Ackerman, L. 5764, 5767

Adam, H. 5924

Adams, B.B. 5655

Aggarwal, V. 5405

Agurell, S. 6007

Ahren, B. 5821

Aisner, J. 5802, 5965, 6008

Aittoniemi, K. 5574

Albani, F. 5953

Alder, J.F. 5276, 5376, 5380, 5394, 5472, 5581, 5649, 5688, 5689

Alesina, R. 5909, 5910, 5919, 5920

Alessio, L. 5492, 5561

Alexander, F.W. 5500

Alfrey, A.C. 5272, 5274, 5275, 5277, 5280

Alousi, A.A. 5781, 5782

Amin-Zaki, L. 5590, 5622

Amon, I. 5872, 5873

Amon, M. 5872, 5873

Amos, F.B., Jr. 5362, 5501, 5526, 5540, 5545

Amos, R.G. 5362, 5501, 5526, 5540, 5545

Anderson, C.T., Jr. 5339, 5398, 5736

Anderson, F.-E. 5836-5839

Andreasen, F. 5804

Ange 5320, 5505, 5556, 5562, 5675, 5768, 5773, 5776

Aronoff, G.R. 5989

Arvidsson, A. 5992

Arvidsson, B. 5462

Athanassouli, T.M.M. 5852

Aust, P.E. 5852

Babb, J. 5958

Bachur, N.R. 5802, 5965, 6008

Baer-Weiss, V. 5888

Bailey, J. 5889

Bakhos, Y. 5453, 5503, 5550, 5555

Ballard, B.H. 5968

Baltch, A.L. 5995, 5996

Barash, P.G. 5947

Barbier, F. 5374, 5379, 5382, 5386, 5575, 5577, 5713, 5721

Barends, D.M. 5915

Barltrop, D. 5496, 5510, 5535

Barmada, M. 5817, 5818, 5865, 5866

Barrett, M.B. 5525, 5565

Barry, P.S.I. 5487-5489, 5514, 5527-5533, 5537-5539, 5541, 5543, 5546-5548, 5551-5553, 5559, 5560

Baruffini, A. 5491

Baruzzi, A. 5953

Bass, R. 5783-5794

Bastos, M.L. 5365, 5811, 5812

Bauer, D. 5696

Bekersky, I. 5749, 5751

Bell, A. 5493

Belt, R.J. 5902

Belz, G.G. 5852

Ben-Zvi, Z. 5924

Benet, L.Z. 5803

Benjamin, R.S. 5880, 5881

Bennett, B.G. 5281, 5282, 5284, 5287, 5289-5292

Benowitz, N.L. 5888, 5976

Bentley, D.P. 5469

Benvenuto, J.A. 5880, 5881

Berild, D. 5855

Bernard, A. 5326, 5327, 5346, 5347, 5509, 5563, 5591, 5618

Bertler, A. 5952, 5974

Bhargava, A.K. 5305, 5306, 5309, 5407, 5408, 5411, 5417, 5418, 5422, 5427, 5428, 5430, 5433, 5434, 5438, 5445, 5446, 5451, 5758, 5760

Bianchi, M. 5750, 5752

Bianco, L. 5491

Biddlecome, C. 5781, 5782

Bierre, A.R. 5615, 5683

Biersteker, K. 5490

Bignon, J. 5294, 5297, 5378, 5810

Bishop, M. 5958

Bishop, M. 5889

Bitzen, P.-O. 5799, 5800

Bjorn-Rasmussen, E. 5462

Black, J.G. 5360

Blackburn, M.G. 5833

Blejer, H.P. 5614

Blumenthal, M.P. 5749, 5751

Bobik, A. 5822, 5959, 5960

Boeckx, R.L. 5717

Bold, A.M. 5352

Boleij, J.S.M. 5490

Bolton, M.E. 5524

Bonati, M. 5835

Bondesson, U. 5945

Bonnaud, G. 5294, 5378

Borga, O. 5992

Borsa, M. 5886, 5887

Bos, R.P. 5705

Bost, R. 5843-5847

Bottermann, P. 5875

Boudet, L. 5921, 5922

Bourne, R.C. 5972, 6002

Bowen, D.V. 5667, 5668

Bowering, J. 5460, 5471, 5473-5478, 5480, 5482

Box, V. 5516, 5779

Boxenbaum, H. 5780

Boyce, D.E. 5366, 5368

Brash, A.R. 5874

Brashear, M.R. 5770, 5771

Braun, H.E. 5301, 5302, 5310, 5319, 5415, 5420, 5762, 5766

Brecht, T. 5841, 5842

Brilliant, L.B. 5323

Britt, E.M. 5970

Brockhaus, A. 5700, 5703

Brodeur, J. 5328, 5330, 5343

Brogard, J.M. 5997, 5998

Brooks, P.M. 5820, 5905, 5906

Brouns, R.M.E. 5705

Brown, K.F. 5868, 5869

Brown, L. 5805, 5806, 5815, 5819, 5834, 5864, 5867, 5917, 5918, 5983, 5984

Brown, S.S. 5655

Bruaux, P. 5519

Brudevold, F. 5453, 5503, 5550, 5555

Brune, D. 5285, 5286, 5288, 5685-5687

Brunekreef, B. 5490

Brusis, O.A. 5859, 5876, 5930, 5936

Bryce-Smith, D. 5506, 5557

Bucana, C. 5929

Buchet, J.P. 5293, 5326, 5327, 5346, 5347, 5502, 5509, 5519, 5549, 5563, 5591, 5618

AUTHOR INDEX

Bullock, D.W. 5991, 5993, 5998

Burford, S.P. 6005, 6006

Burkitt, A.J. 5388, 5881, 5558, 5584, 5658, 5788

Burnea, D. 5384, 5469, 5719

Burton, D.J. 5981

Byard, J.L. 5753

Byck, R. 5947

Bye, A. 5907, 5908

Bywater, M.J. 5991, 5993, 5998

Caddell, J.L. 5570, 5573

Caplan, R.H. 5858, 5859

Carlsson, C. 5821

Carney, P.A. 5935, 5938

Carpenter, R.C. 5338, 5341, 5397, 5399, 5542, 5588, 5701, 5702

Carter, G. 5817, 5818, 5865, 5866

Carter, P. 5712

Caruso, J.A. 5381

Casey, C.P. 5718

Castoldi, M.R. 5892, 5561

Cavalleri, A. 5491

Chang, C.C. 5327, 5387

Chang, S.S. 5984

Chappelka, P. 5329, 5333, 5389

Charette, C. 5816, 5973, 5978, 6000, 6003, 6011

Charlebois, C.T. 5623

Charles, B.G. 5830, 5831

Chaturvedi, S. 5961, 5962

Cherry, W. 5516, 5779

Chiang, C.-K. 5858

Chiarmonte, C.A. 5860

Chilcote, R. 5890, 5891, 5893-5897

Ching, N.P.H. 5667, 5668

Chisolm, J.J. 5525, 5565

Chisolm, J.J., Jr. 5498, 5508

Choudhury, A.K. 5858

Christensen, C.K. 5804

Christopoulos, G.N. 5636-5643

Churg, A. 5295, 5296

Clark, M.L. 5937

Clelland, R.C. 5366, 5368

Cohen, J.L. 5878

Colburn, W.A. 5749, 5751

Coleman, G.D. 5511

Colvin, O.M. 5802, 5965, 6008

Conley, F.K. 5970

Connolly, R. 5527

Cook, J.D. 5461, 5468, 5465

Cooper, J.F. 5898

Cooper, S.F. 5954

Cooper, T.B. 5843-5847

Coppen, A. 5889

Cotton, R.B. 5874

Coulston, F. 5753

Crews, T. 5883

Crolla, T. 5886, 5887

Crooks, M.J. 5868, 5869

Crow, T.J. 5972, 6002

Cupp, C.M. 5765

Curley, A. 5890, 5891, 5893-5897

Curoe, J. 5931, 5932

Curran, A.S. 5508

Curry, S.H. 5899

Curzon, M.E.J. 5278, 5299, 5403, 5455, 5568, 5690, 5695, 5706, 5746

Czerwinski, A.W. 5937

Danielsson, B. 5945

Dattani, J. 5516, 5779

David, O. 5512, 5566

Davis, J.M. 5944

de Carneri, I. 5909, 5910, 5919, 5920

De Groot, G. 5823-5829

De Jongh, G.D. 5888

de la Garza, F. 5931, 5932

Deeb, G. 5870, 5871

DeKoven, B.M. 5381

Delapart, M. 5515

Delves, H.T. 5500

Dencker, S.J. 5904, 5943

Dengler, H.J. 5841, 5842

Denley, H.V. 5662

DeRudder, J. 5374, 5379

Dhar, A.K. 5818, 5863, 5916, 5934, 5963, 5967, 5982, 5999

Dietz, A.A. 5273, 5279

Dillon, J.C. 5322, 5410, 5421, 5436, 5449, 5759

DiVincenzo, G.D. 5635

Dixon, R. 5780, 5883

Dodson, W.E. 5892

Doevendans, J.E. 5856, 5857

Dolcourt, J.L. 5511

Dolgner, R. 5700, 5703

Dominski, A. 5504

Dorner, M. 5997, 5998

Doyle, M. 5718, 5939, 5941

Drummer, O.H. 5901

Dudley, F.J. 5959, 5960

Duffey, P. 5802, 5965, 6008

Dumitru, R. 5384, 5468, 5719

Dutkiewicz, B. 5644-5646

Dysken, M.W. 5948

Ealy, J.A. 5524

Edelson, J. 5781, 5782

Egorin, M.J. 5802, 5965, 6008

Eichelbaum, M. 5841, 5842

Ely, D.L. 5283, 5332, 5534, 5596, 5684

Ericsson, C.D. 5795, 5796

Ermler, R. 5875

Esler, M. 5822

Evans, G.L. 6005, 6006

Evenson, M.A. 5339, 5398, 5736

Evers, U. 5700, 5703

Falchuk, K.H. 5722

Fallat, R.W. 5372

Fan, T. 5423, 5424

Fanelli, R. 5750, 5752

Fanizza, A.M. 5975

Fass, R. 5985, 5986

Faust, S.D. 5367, 5371, 5439, 5633, 5634

Fenske, R.A. 5662

Fernandez, F.J. 5513

Field, B. 5807

Field, F.M. 5667, 5668

Finburg, L. 5508

Finch, C. 5511

Fine, D.H. 5423, 5424

Finkle, B.S. 5977, 5979

Fisken, R.A. 5352

Flek, J. 5647

Fletcher, A.B. 5717

Fletcher, S.M. 5853, 5854

Foerster, E. 5931, 5932

AUTHOR INDEX

Foley, K. 5883

Forsgren, A. 5836-5839

Fournier, S. 5898

Franchini, I. 5492, 5561

Frank, P. 5301, 5302, 5310, 5311, 5319, 5415, 5420, 5762, 5766

Frank, R.L. 5681, 5693

Franke, G. 5872, 5873

Franklin, C.A. 5662

Franklin, M. 5904, 5943

Freeman, G.B. 5781, 5782

Frith, C.D. 5972, 6002

Fry, D. 5923

Fuks, J.Z. 5802, 5965, 6008

Fyfe, W.M. 5494

Galante, L. 5365, 5811. 5812

Gambertoglio, J.G. 5803

Gamble, S. 5972, 6002

Garattini, S. 5835

Garland, W.A. 5968

Garnys, V.P. 5518

Garriott, J.C. 5931, 5932

Garvey, J.S. 5327, 5347

Gaudichet, A. 5297, 5810

Gaver, R.C. 5870, 5871

Gelb, A.M. 5975

Gershoff, S.N. 5859, 5876, 5930, 5936

Gervais, L. 5328, 5330, 5343

Gesztesi, A. 6004

Ghoneim, M.M. 5858

Gill, J.I. 5681, 5693

Gillespie, H.K. 6007

Gillilan, R. 5885

Glueck, C.J. 5372

Gotle, A.J. 5901

Golberg, L. 5753

Goldberg, A. 5494

Goldberg, M.J. 5858

Golden, R.E. 5715

Golden, M.H.N. 5715

Gollamudi, R. 5861

Gonzalez, M. 5463, 5466

Gordon, A.S.D. 5615, 5683

Gorsky, J.E. 5273, 5279

Gotto, D.M. 5300, 5304, 5431, 5442, 5761

Gotto, D.T. 5442, 5761

Grabe, M. 5836-5839

Graham, T.P. 5874

Grahnen, A. 5900

Grant, D.L. 5311

Grasso, S. 5909, 5910, 5919, 5920

Gray, J.D. 5925, 5928

Greenhalgh, R. 5662

Griffiths, K.D. 5516, 5779

Gritz, E.R. 5888

Grossi, C.E. 5667, 5668

Guillemin, M.P. 5696

Gupta, V.P. 5585

Gustafsson, B. 5799, 5800

Gyaram, M. 5875

Haglund, K. 5900

Hallberg, L. 5462

Hallson, P.C. 5359, 5658

Halstead, J.A. 5711, 5724, 5726, 5727, 5731, 5732, 5735, 5737-5740, 5745

Hambidge, K.M. 5714

Hamner, M.C. 5995, 5996

Hansteen, V. 5849

Hansten, P.D. 5913, 5914

Harland, W.A. 5853, 5854

Harner, E.B. 5366, 5368

Harper, D.B. 5300, 5304, 5431, 5442, 5761

Harrill, I. 5470

Hartig, P. 5945

Haselbarth, V. 5856, 5857

Hashimoto, C. 5620

Hassani, S.E. 5590, 5622

Hasselbalch, H. 5855

Hawes, E.M. 5898

Hawkins, C.F. 5958

Hayabuchi, H. 5316

Hayakawa, K. 5586, 5588, 5593, 5595, 5599-5603, 5605-5608, 5610-5613, 5621, 5624-5632

Hayes, A.W. 5412-5414

Hayton, W.L. 5913, 5914

Heath, D.A. 5352

Hegg, A.P. 5272, 5280

Hellsten, S. 5836-5839

Henderson, P.T. 5705

Hengstmann, J.H. 5841, 5842

Hepner, G.W. 5807-5809

Herber, R.F.M. 5523

Herrera Marteache, A. 5406, 5416, 5426, 5432, 5441, 5443, 5757, 5763, 5775, 5778

Hershmann, J.M. 5935, 5938

Hesso, A. 5697

Hickey, D.E. 5874

Hickey, R.J. 5366, 5368

Hicks, R.G. 5667, 5668

Hill, F.G.H. 5516, 5779

Hillman, L.S. 5387

Hillman, R.E. 5892

Hirschstein, K.J. 5902

Hisayasu, G.M. 5878

Hoare, A.M. 5958

Hoellinger, H. 5921, 5922

Hofmann, A. 5425

Hogan, G.R. 5412-5414

Hogstedt, C. 5440

Holazo, A. 5780

Holdrinet, M.V.H. 5301, 5302, 5310, 5319, 5415, 5420, 5762, 5766

Hollander, M. 5521

Hollister, L.E. 5970, 6007

Holt, M.A. 5991, 5993, 5994

Hooper, P.L. 5458, 5459

Hopkins, D.R. 5508

Horn, S. 5717

Morning, M.G. 5805, 5806, 5815, 5819, 5834, 5864, 5867, 5917, 5918, 5983, 5984

Morowitz, J.D. 5901

Moste, J. 5374, 5379, 5382, 5386, 5575, 5577, 5713, 5721

Mouff, S.A. 5754-5756

Mowes, T. 5360

Hubbard, J.W. 5898

Huber, A.M. 5859, 5876, 5930, 5936

Huber, W. 5937

Hubermont, G. 5502, 5519, 5549

Hughes, E.G. 5510

Hulshoff, A. 5915, 6009, 6010

Hung, O.R. 5925, 5928

Hutchins, B.K. 5483-5486

Hyvonen, M. 5697

AUTHOR INDEX

Ikeda, M. 5316

Inaba, T. 5948, 5950, 5951

Ingemarsson, I. 5821

Inturrisi, C. 5883

Irwin, M.I. 5860, 5871, 5873-5878, 5880, 5882-5886, 5711, 5724, 5726, 5727, 5731, 5732, 5735, 5737-5740, 5745

Isbister, C. 5959, 5960

Itch, M. 5331, 5337, 5391, 5396, 5728, 5733

Jackman, G. 5822

Jacob, N.A. 5402, 5479, 5716, 5743

Jacobs, A. 5469

Jacobsen, D. 5849

Jacobsen, M.W. 5830, 5831

Jakobsen, P.K. 5804

Jansen, C. 5470

Janson, K. 5298, 5378

Jarvik, M.E. 5888

Jatlow, P. 5947

Jaurand, M.C. 5297, 5810

Javaid, J.I. 5944

Jensen, K. 5987, 5988

Jhaw, G.W. 5667, 5668

Jindrich, E.J. 5813, 5840, 5884, 5911

Jodral Villarejo, M. 5406, 5416, 5426, 5432, 5441, 5443, 5757, 5763, 5775, 5778

Johansson, B. 5904, 5943

Johnson, D.E. 5522, 5536, 5568, 5659-5661, 5670-5672

Johnstone, E.C. 5972, 6002

Jorgensen, A. 5942

Joselow, M. 5520

Jostell, K.G. 5799, 5800

Juaret, L. 5931, 5932

Jupin, J.A. 5890, 5891, 5893-5897

Kaehny, W.D. 5272, 5280

Kager, L. 5992

Kalliomaki, K. 5574

Kalliomaki, P-L. 5574

Kalow, W. 5948, 5950, 5951

Kapetanovic, I.M. 5798, 5801, 5933

Kaplan, C.J. 5635

Kaplan, S. 5780

Kaplowitz, L.G. 5770, 5771

Kara, B. 5377

Karwacki, W. 5644-5646

Kashimoto, T. 5314, 5315, 5317, 5318, 5321, 5676-5680

Kasidas, G.P. 5359, 5658

Kattan, M. 5924

Katz, S.A. 5648

Kawanishi, T. 5495

Kellaway, P. 5805, 5806, 5815, 5819, 5834, 5864, 5867, 5917, 5918, 5983, 5984

Kilbinger, H. 5663

King, J.C. 5718, 5939, 5941

Kinney, E.L. 5946

Kirch, E.R. 5636-5643

Kitamura, S. 5586, 5588, 5593, 5598, 5599-5603, 5605-5608, 5610-5613, 5621, 5624-5632

Kiviluoto, M. 5707, 5710

Kiyozumi, M. 5331, 5337, 5391, 5396, 5728, 5733

Kleit, S.A. 5989

Klevay, L.M. 5402, 5479, 5743

Klimas, A.J. 5511

Klotz, U. 5971

Knudsen, K. 5849

Kojima, S. 5331, 5337, 5391, 5396, 5728, 5733

Konczalik, J. 5644-5646

Koos, B.J. 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617

Koppang, N. 5929

Korner, P. 5822

Korsland, M.K. 5940

Koshy, K.M. 5699, 5704

Koup, J.R. 5797

Kragh-Sorensen, P. 5987, 5988

Kramer, U. 5700, 5703

Krazer, W.G. 5795, 5796

Kreek, M.J. 5975, 5976

Krishna Murti, C.R. 5305-5307, 5309, 5407-5409, 5411, 5417-5419, 5422, 5427-5430, 5433-5435, 5438, 5445, 5446, 5448, 5451, 5758, 5760

Krupski, D.M. 5949

Kullberg, M.P. 5781, 5782

Kumpulainen, J. 5377

Kunita, N. 5314, 5315, 5317, 5318, 5321, 5676-5680

Kupferberg, H.J. 5798, 5801, 5933

Kusmiesz, H. 5980

Kusumi, K. 5985, 5986

Kutt, H. 5814, 5863, 5916, 5934, 5963, 5967, 5982, 5999

Kutty, D. 5305, 5306, 5309, 5407, 5408, 5411, 5417, 5418, 5422, 5427, 5428, 5430, 5433, 5434, 5438, 5445, 5446, 5451, 5758, 5760

LaCasse, Y. 5328, 5330, 5343

Lamola, A.A. 5520

Land, G. 5907, 5908

Lane, M.W. 5742

Lange, J. 5783-5794

Lapierre, Y.D. 5954

Latini, R. 5835

Lauwerys, R. 5293, 5326, 5327, 5346, 5347, 5502, 5509, 5519, 5549, 5563, 5591, 5618

Lavillaureix, J. 5997, 5998

Layrisse, M. 5463, 5466, 5467

Lebender, A. 5875

Leffingwell, J.T. 5662

LeGendre, G.R. 5274, 5275, 5277

Leijdekkers, C.M. 5705

Leonard, P. 5822

Lertratanangkoon, K. 5805, 5806, 5815, 5819, 5834, 5864, 5867, 5917, 5918, 5983, 5984

Levitt, T.E. 5853, 5854

Levy, G. 5797, 5862, 5912, 5969

Levy, R.H. 5968

Lima, J.J. 5964

Lin-Fu, J.S. 5508

Lindberg, C. 5821

Lindgren, S. 5952, 5974

Lindstrom, B. 5900

Lines, D.R. 5615, 5683

Lingren, J.E. 6007

Linnoila, M. 5882, 5966

Lo, L.Y. 5907, 5908

Loadholt, B. 5765

Loehr, R.C. 5334

Lofthouse, R. 5972, 6002

Long, D.F. 5669

Longo, L.D. 5364, 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617

Loo, T.L. 5880, 5881

Lomse, F.L. 5278, 5299, 5403, 5455, 5568, 5690, 5695, 5706, 5746

AUTHOR INDEX

Loughlin, M.M. 5890, 5891, 5893-5897

Louis, W.J. 5901

Love, A.H.G. 5385, 5388, 5393, 5395, 5720, 5730

Love, B.I. 5961, 5962

Lovejoy, F.H. Jr. 5699, 5704

Lu, C. 5807

Lucas, F.E. 5521

Ludwick, B.T. 5968

Luft, F.C. 5989

Lundin, L. 5904, 5943

Lundquist, I. 5821

Maes, E.A.A. 5823-5829

Magnusson, B. 5462

Mahacni, E. 5780

Makdani, D. 5681, 5693

Maki, M. 5882, 5966

Makinen, S. 5377

Malarek, D. 5780

Malloi, J. 5806, 5816, 5826, 5832, 5881, 5883, 5757, 5763, 5775, 5778

Male, U. 5904, 5943

Malmgren, H. 5952, 5974

Mang, K. 5850

Marcus, M. 5521

Mares, M. 5742

Marina, P.J. 5964

Marks, V. 5923

Martin, G.B. 5322, 5410, 5421, 5436, 5449, 5759

Martinez-Torres, C. 5463, 5466, 5467

Martinez, A.J. 5754-5756

Marzi, E. 5835

Mascher, M. 5877

Mason, W.D. 5885

Masoud, A.M. 5949

Masse, R. 5294, 5378

Masuda, Y. 5316

Mathews, J. 5506, 5557

Mathieu, L. 5662

Matousek, J.P. 5518

McChesney, E.W. 5753

McElheny, R.J. 5524

McGilvcray, L.J. 5816, 5973, 5978, 6000, 6003, 6011

McLean, A.J. 5959, 5960

McLean, M.C. 5816, 5973, 5978, 6000, 6003, 6011

McWade, J.W. 5301, 5302, 5310, 5319, 5415, 5420, 5762, 5766

Meffin, P.J. 5820, 5905, 5906

Meinardi, G. 5909, 5910, 5919, 5920

Meiners, C.R. 5940

Melander, A. 5799, 5800

Mellits, E.D. 5525, 5565

Mendiola, I. 5931, 5932

Merits, I. 5747, 5748

Men, J. 5311

Metzler, C. 5985, 5986

Meyer, M.C. 5861

Michels, M. 5374, 5379

Mickelsen, O. 5681, 5693

Midha, K.K. 5816, 5898, 5973, 5978, 6000, 6003, 6011

Milar, C.R. 5511

Miller, M.E. 5968

Milne, D.B. 5402, 5479, 5743

Min, B.M. 5968

Minoia, C. 5491

Mishra, G.K. 5307, 5409, 5419, 5429, 5435, 5448

Miyata, M. 5318, 5315, 5317, 5318, 5321, 5676-5680

Moffat, A.C. 5853, 5854

Mogensen, C.E. 5804

Mohacsi, E. 5883

Mohr, C. 5872, 5873

Moilanen, M. 5574

Mong, S.A. 5989

Monsen, E.R. 5461, 5464, 5465

Moore, J. 5780

Moore, M.R. 5494

Moore, R.G. 5961, 5962

Morley, J.E. 5935, 5938

Morris, P.M. 5901

Morrow, R.W. 5524

Moskovitz, R.M. 5946

Mostardi, R.A. 5283, 5332, 5534, 5596, 5684

Mraz, M. 5647

Muirhead, D.C. 6005, 6006

Munch, E.P. 5926, 5927

Munkes, R. 5852

Munoz, J.M. 5402, 5479, 5743

Murray, J.R. 5832

Murray, T. 5329, 5333, 5349

Nag, D. 5307, 5409, 5419, 5429, 5435, 5448

Nan, N-.H. 5921, 5922

National Academy of Science, National Research Council 5650-5653

Nau, H. 5783-5794

Naylor, L.M. 5334

Nealon, T.F. Jr. 5667, 5668

Nelson, J.D. 5980

Nelson, R.W. 5878

Neu, H.C. 5990

Nickless, G. 5344, 5481, 5554, 5584, 5654, 5744

Niculescu, T. 5384, 5468, 5719

Nieuwenhuyse, M. 5848

Nino, M.V. 5859, 5876, 5930, 5936

Nitsche, V. 5877

Nomiyama, K. 5335

Nordberg, G. 5285, 5286, 5288, 5685-5687

Norheim, G. 5955-5957

Novick, D.M. 5975

Noylin, J. 5805, 5806, 5815, 5819, 5834, 5864, 5867, 5917, 5918, 5983, 5984

O'Brien, M.T. 5322, 5410, 5421, 5436, 5449, 5759

O'Rourke, M.F. 5850

Oates, J.A. 5874

Odone, P. 5492, 5561

Ohlsson, A. 6007

Okonek, S. 5425, 5663

Olsen, J. 5312, 5444

Onis, D. 5454

Othman, I. 5298, 5325, 5355, 5357, 5369, 5370, 5392, 5400, 5456, 5457, 5571, 5572, 5580, 5583, 5597, 5691, 5692, 5694, 5698, 5708, 5709, 5729

Overo, K.F. 5987, 5988

Owen, P. 5972, 6002

Owens, D.G.C. 5972, 6002

P'An, A. 5328, 5330, 5343

Painter, M.J. 5817, 5818, 5865, 5866

Pakarinen, A. 5707, 5710

AUTHOR INDEX

Pantarotto, C. 5750, 5752

Papastathopoulos, D.S. 5452

Parnas, W. 5987, 5988

Parsonnet, W. 5780

Patton, T.F. 5669, 5902

Peat, M.A. 5977, 5979

Perrier, C. 5937

Petersen, O.L. 5987, 5988

Pfaffli, P. 5697

Pfeiffer, H.C. 5521

Pichon, J. 5921, 5922

Pickering, I.M. 5795, 5796

Pieper, P. 5992

Pifferi, G. 5886, 5887

Piggenger, C. 5817, 5818, 5865, 5866

Pineda, O. 5716

Pinget, M. 5997, 5998

Pinelli, S. 5508

Pinsator, M. 5336, 5340, 5342, 5345, 5348, 5741

Pitkin, P.M. 5350, 5351, 5353, 5358, 5665, 5666

Pitlick, W. 5817, 5818, 5865, 5866

Pittman, K.A. 5870, 5871

Pleasure, J.R. 5833

Polo Villar, G. 5406, 5416, 5426, 5432, 5441, 5443, 5757, 5763, 5775, 5778

Polo Villar, L.M. 5406, 5416, 5426, 5432, 5441, 5443, 5757, 5763, 5775, 5778

Pope, J.F. 5899

Porter, R.J. 5798, 5801, 5933

Pourtois, M. 5558

Pozo Lora, R. 5406, 5416, 5426, 5432, 5441, 5443, 5757, 5763, 5775, 5778

Prevost, R.J. 5522, 5536, 5564, 5659-5661, 5670-5672

Pybus, J. 5615, 5683

Pyy, L. 5707, 5710

Rama Rao, V.A. 5889

Ramaswamy, S.S. 5361, 5363, 5619, 5668

Ratcliffe, W.A. 5853, 5858

Ratcliffe, J.G. 5853, 5858

Ravenscroft, P.J. 5830, 5831

Reed, A. 5935, 5938

Reeves, D.S. 5991, 5993, 5994

Reigart, J.R. 5508

Reikvam, A. 5849

Reimann, I. 5971

Rensimer, E.H. 5795, 5796

Renton, K.W. 5925, 5928

Renzi, M. 5866, 5867

Repta, A.J. 5669, 5902

Riba, G. 5298, 5378

Richards, W.N. 5494

Richardson, P.A. 5616

Riggs, C.E. Jr. 5802, 5965, 6008

Riihimaki, V. 5569

Ritchey, S.J. 5980

Riva, R. 5953

Robbins, S. 5717

Robbins, W.B. 5381

Robert, J. 5851

Roberts, R. 5770, 5771

Robinson, J. 5972, 6002

Roels, H. 5293, 5326, 5327, 5346, 5347, 5502, 5509, 5549, 5563, 5591, 5618

Roels, H.A. 5519

Roon, G.F.W. 5868, 5869

Rose, G.A. 5359, 5658

Ross, R. 5423, 5424

Rossander, L. 5462

Rost, H.D. 5841, 5842

Rounbehler, D.P. 5423, 5424

Royer, R.-J. 5851

Rumack, B.H. 5620

Russell, R.M. 5935, 5938

Rustan, H. 5590, 5622

Rutherford, T. 5360

Ryan, W.J. 5412-5414

Saario, I. 5882, 5966

Saidin, D. 5303, 5308, 5328, 5437, 5458, 5769, 5772, 5774, 5777

Saier, F.L. 5570, 5573

Sajgo, M. 6004

Salmona, M. 5750, 5752

Salzer, L.B. 5964

Samitz, M.H. 5648

Sampson, P. 5517, 5879

Samuel, A.J. 5276, 5376, 5380, 5394, 5472, 5581, 5649, 5688, 5689

Sanchez, A.M. 5460, 5471, 5473-5478, 5480, 5482

Sandifer, S.H. 5765

Sandstead, H.H. 5402, 5479, 5743

Saner, G. 5375

Sangster, B. 5823-5829

Sardi, A. 5909, 5910, 5919, 5920

Satija, N.K. 5499

Savolainen, K. 5569

Saxena, M.C. 5305-5307, 5309, 5407-5409, 5411, 5417-5419, 5422, 5427-5430, 5433-5435, 5438, 5445, 5446, 5448, 5451, 5758, 5760

Sayed, A. 5903

Schaffer, C. 5944

Schaffner, W. 5770, 5771

Schentag, J.J. 5860

Scherrmann, J.M. 5921, 5922

Schmid, G.P. 5995, 5996

Schnaper, H. 5802, 5965, 6008

Schneider, P.E. 5614

Schneider, R.E. 5958

Schuman, S.H. 5765

Schwartz, H.K. 5373, 5383, 5389, 5390, 5401, 5404, 5576, 5578, 5579, 5582, 5723, 5725, 5734

Sebastien, P. 5298, 5297, 5378, 5810

Sedivec, V. 5647

Seideman, P. 5900

Selhorst, J.B. 5754-5756

Selikoff, I.J. 5447, 5673, 5674

Serafetinides, E.A. 5937

Servant, J. 5515

Seth, T.D. 5305, 5309, 5407, 5411, 5417, 5422, 5427, 5430, 5433, 5438, 5445, 5451, 5499, 5758, 5760

Shahid, A. 5944

Shaw, J.C.L. 5356, 5358

Shelton, S. 5980

Shibata, T. 5586, 5588, 5593, 5595, 5599-5603, 5605-5608, 5610-5613, 5621, 5624-5632

Shaunes, E. 5981

Shuer, L. 5970

Siakotos, A.N. 5929

Siddiqui, M.K.J. 5307, 5409, 5419, 5429, 5435, 5448

Siddiqui, M.K.J. 5305, 5306, 5309, 5407, 5408, 5411, 5417, 5418, 5422, 5427, 5428, 5430, 5433, 5434, 5438, 5445, 5446, 5451,

AUTHOR INDEX

Siddiqui, M.K.J. 5758, 5760

Sido, T. 6008

Sison, P.A. 6001

Singh, M. 5585

Siraj, M.Y. 5812-5814

Skews, H. 5822

Skutcrud, B. 5849

Slattery, J.T. 5797

Slean, R.S. 5989

Smit, A.L.C. Jr. 5667, 5668

Smith, D.E. 5803

Smith, D.L. 5507

Smith, J.C. 5711, 5728, 5726, 5727, 5731, 5732, 5735, 5737-5740, 5745

Smith, R.P. 5995, 5996

Smith, R.V. 5300, 5304, 5831, 5842, 5761

Smut, M.S. 5301, 5302, 5310, 5319, 5415, 5420, 5762, 5766

Smyth, P.D. 5870, 5871

Snee, R.D. 5897

Snelleman, C. 6009, 6010

Snodgrass, W. 5620

Soddemann, H. 5700, 5703

Solomons, M.W. 5716

Somers, S. 5352

Sondergaard, I. 5926, 5927

Sorel, R.M.A. 6009, 6010

Souganidis, D.J. 5852

Spear, R.C. 5662

Spector, R. 5858

Speecke, A. 5382, 5386, 5575, 5577, 5713, 5721

Spencer, H. 5854

Spickard, W.A. 5770, 5771

Spratt, D.M. 5329, 5333, 5349

Springer, P.K. 5899

Spyrou, N.M. 5298, 5325, 5355, 5357, 5369, 5370, 5392, 5400, 5856, 5857, 5571, 5572, 5580, 5583, 5597, 5691, 5692, 5698, 5698, 5708, 5709, 5729

Srinivasian, R.M. 5853, 5503, 5550, 5555

Srinivasin, S. 5990

Stack, M.V. 5348, 5481, 5558, 5584, 5658, 5744

Stahl, R. 5840

Stahlman, M.T. 5878

Steenhout, A. 5558

Stein, P. 5718, 5939, 5981

Stenger, R.J. 5975

Stephens, D.S. 5770, 5771

Stephens, R. 5506, 5557

Sternson, L.A. 5902

Stevens, M. 5972, 6002

Stevens, P.M. 6005, 6006

Stewart, D.J. 5880, 5881, 5948, 5950, 5951

Stewart, M. 5510

Stewart, R.B. 5899

Steyaert, M. 5378, 5379

Stopps, G.J. 5301, 5302, 5310, 5319, 5415, 5420, 5762, 5766

Straughn, A.B. 5861

Strehlow, C.D. 5496, 5535

Suanberg, B. 5462

Subbarayan, C. 5667, 5668

Sullivan, J.B. 5620

Sumino, K. 5586, 5588, 5593, 5595, 5599-5603, 5605-5608, 5610-5613, 5621, 5629-5632

Sunderman, F.W., Jr. 5655

Sunderman, F.W. 5656, 5657

Sunshine, I. 5405, 5843-5847

Sutphen, M.T. 5995, 5996

Szczawinska, K. 5750, 5752

Takahashi, W. 5303, 5308, 5324, 5437, 5450, 5769, 5772, 5774, 5777

Takei, G. 5303, 5308, 5324, 5437, 5450, 5769, 5772, 5774, 5777

Takenaka, S. 5331, 5337, 5391, 5396, 5728, 5733

Tanassia, V. 5909, 5910, 5919, 5920

Tandon, D.S. 5439

Taper, L.J. 5940

Taylor, J.M. 5754-5756

Taylor, S. 5902

Teale, D. 5923

Tedeschi, G. 5953

Thang, D-.C-. 5921, 5922

Theodore, W. 5798, 5801, 5933

Thomas, J. 5961, 5962

Thomason, C.A. 5570, 5573

Thompson, J.C., Jr. 5362, 5501, 5526, 5540, 5545

Thompson, W. 5388, 5395

Thornhill, D.P. 5991, 5993, 5994

Thorp, J.M. 5717

Thorton, I. 5496, 5535

Tillery, J.B. 5522, 5536, 5564, 5659-5661, 5670-5672

Tomokuni, K. 5495

Tong, T.G. 5976

Treuting, J.J. 6001

Tsang, N.C. 5372

Tsukada, S. 5331, 5337, 5391, 5396, 5728, 5733

Tyrala, E.E. 5892

Ulbrich, B. 5783-5794

Unger, M. 5312, 5444

Unger, P.D. 5812-5814

Vainio, H. 5697

Valentour, J.C. 5405

van den Wildenberg, M.M. 5848

van der Veen, F. 5848

Van Doorn, R. 5705

Van Dyke, C. 5947

van Heijst, A.N.P. 5823-5829

Van Hove, W. 5903

Van Vunakis, H. 5888

Veenendaal, J.R. 5820, 5905, 5906

Veenstra, S.J. 5490

Velez, F. 5466

Verdonck, L.F. 5823-5829

Verseulen, A. 5903

Versieck, J. 5378, 5379, 5382, 5386, 5575, 5577, 5713, 5721

Vesell, E.S. 5808, 5809

Vettaro, M.P. 5909, 5910, 5919, 5920

Vincenti, F. 5803

Vir, S.C. 5385, 5388, 5393, 5395, 5720, 5730

Viteri, F.E. 5716

von Bahr, C. 5900

Von Burg, R. 5590, 5622

Vose, C.W. 6005, 6006

Vuori, E. 5377

Wahl, K. 5875

Wahlen, A. 6007

Wahlin-Boll, E. 5799, 5800

Waldron, H.A. 5516, 5779

Walker, B.E. 5329, 5333, 5349

AUTHOR INDEX

Walker, D.M. 5770, 5771

Walravens, P.A. 5718

Warnock, M.L. 5295, 5296

Warren, D.C. 5742

Washington, H.G. 5850

Wasterlain, C. 5817, 5818, 5865, 5866

Watkinson, J.M. 5682

Webb, D. 5816, 5973, 5978, 6000, 6003, 6011

Webb, J.S. 5495, 5535

Weeke, B. 5926, 5927

Weinrib, A.B. 5964

Welsch, F. 5783-5794

Wessel, M.A. 5504

West, T.S. 5276, 5376, 5380, 5394, 5472, 5581, 5649, 5688, 5689

Wester, P.O. 5285, 5286, 5288, 5685-5687

Westgren, M. 5821

White, L.O. 5991, 5993, 5994

Whitlam, J.B. 5868, 5869

Wiatrowski, E. 5454

Wickizer, T.M. 5323

Wiegand, M. 5700, 5703

Wiernik, P.H. 5802, 5965, 6008

Wiles, D. 5904, 5983

Wilkins, R.T. 5765

Woelkenberg, M. 5283, 5332, 5534, 5596, 5684

Wolf, M. 5836, 5857

Wong, L. 5303, 5308, 5328, 5437, 5450, 5769, 5772, 5774, 5777

Woodman, E. 5980

Worstell, D. 5283, 5332, 5534, 5596, 5684

Wray, B.B. 5812-5814

Yamamoto, I. 5331, 5537, 5391, 5396, 5728, 5733

Yamane, T. 5520

Yancovitz, S.R. 5975

Yeung, P. 5898

Yobs, A.R. 5313

Yoshimura, T. 5316

Yumans, S. 5929

Young, M. 5780

Youssefi, M. 5367, 5371, 5439, 5633, 5638

Zachariasen, M. 5655

Zaldivar, R. 5567

Zannad, F. 5851

Zelis, R. 5946

Zenchelsky, S.T. 5367, 5371, 5439, 5633, 5638

Ziemniak, J.A. 5860

Zion, T.E. 5805, 5806, 5815, 5819, 5838, 5864, 5867, 5917, 5918, 5983, 5984

Zwaan, C.J. 5915

CORPORATE AUTHOR INDEX

A B Leo, Helsingborg, Sweden 5952, 5974

Aarhus Amtssygehus, Medical Department I, DK 8000 5804

Aarhus C, Denmark 5804

Abbott Laboratories, Department of Drug Metabolism, North Chicago, IL 60064 5747, 5748

Academic Hospital, Department of Endocrinology and Hematology, Ghent, Belgium 5903

Agricultural University, Department of Environmental and Tropical Health and Department of Air Pollution, P.O. Box 8129, 6700 EV Wageningen, The Netherlands 5890

Agriculture Canada, Chemical and Biological Research Institute, Ottawa, Ontario, Canada 5662

Albany Medical College, Albany, NY 12208 5711, 5724, 5726, 5727, 5731, 5732, 5735, 5737-5740, 5745, 5995, 5996

Alfred Hospital, Clinical Research Unit and Gastroenterology Diagnostic Service, Prahran, 3181, Melbourne, Australia 5959, 5960

Associated Octel Company Limited, Ellesmere Port, South Wirral L65 4HF, United Kingdom 5527

Associated Octel Company Limited, Ellesmere Port, United Kingdom 5487-5489, 5514, 5528-5533, 5537-5539, 5541, 5543, 5547, 5548, 5551-5553, 5559, 5560

Associated Octel Company Limited, Ellesmere Port, United Kingdom 5546

Astra Lakemedel AB, Medical Department and Research Laboratories, Sodertalje, Sweden 5799, 5800

Astra Lakemedel, Sodertalje, Sweden 6007

Astra Pharmaceuticals Pty Ltd, Medical Department, Sydney, Australia 5961, 5962

Auchinleck House, Broad Street, Birmingham B151DL, United Kingdom 5507

Auckland Hospital, Department of Clinical Chemistry, Park Road, Auckland, New Zealand 5616

Baker Medical Research Institute, Clinical Pharmacology Laboratory, Melbourne, Australia 5959, 5960

Baker Medical Research Institute, Prahran, Victoria, Australia 5822

Baltimore City Hospitals, Baltimore, MD 21224 5498

Baltimore City Hospitals, Department of Pediatrics, 4940 Eastern Ave., Baltimore, MD 21224 5525, 5565

Baylor College of Medicine, Houston, TX 77030 5805, 5806, 5815, 5819, 5834, 5864, 5867, 5917, 5918, 5983, 5984

Bell Laboratories, Murray Hill, NJ 07974 5520

Birmingham Children's Hospital, Birmingham, United Kingdom 5516, 5779

Brandeis University, Department of Biochemistry, Waltham, MA 5888

Bristol-Myers Co., Bristol Laboratories, Department of Drug Metabolism and Pharmacokinetics, Syracuse, NY 5870, 5871

Buffalo Children's Hospital, Clinical Pharmacokinetics Laboratory, Buffalo, NY 5797

C.H. Boehringer Sohn, Divisions of Research and Medicine, D-6507 Ingelheim/Rhein, Federal Republic of Germany 5856, 5857

Cabarrus County Health Department, Concord, NC 5511

California State University, Northridge, Department of Health Science, Medical Services Division, Personnel Department, Los Angeles, CA 5618

Case Western Reserve University, Institute of Pathology, Cleveland, OH 5843-5847

Case Western Reserve University, School of Medicine, Department of Pathology, Cleveland, OH 44106 5805

Center for Disease Control, Communicable Disease Section, Division of Health Services, North Carolina Department of Human Resources, Raleigh, NC 5511

Center for Disease Control, Environmental Health Services Division, Atlanta, GA 30333 5508

Center of Industrial Hygiene and Occupational Diseases, Institute of Hygiene and Epidemiology, Srobarova 48, 100 42 Praha 10, Czechoslovakia 5647

Central Labour Institute, Bombay, India 5361, 5363, 5585, 5619, 5664

Central State Griffen Memorial Hospital, Norman, OK 5937

Centre Hospitalier Intercommunal, Department de Recherches sur les Affections Respiratoires et l'Environnement, Creteil, France 5297, 5810

Centre Hospitalier Intercommunal, Faculte de Medecine de Creteil, Departement de Recherches sur les Affections Respiratoires et l'Environnement, 40, Ave de Verdun, 94010 Creteil, France 5294, 5378

Centre Hospitalo-Universitaire de Strasbourg, Clinique Medicale B, 67005 Strasbourg Cedex, France 5997, 5998

Centre Hospitalo-Universitaire de Strasbourg, Institut d'Hygiene, 67005 Strasbourg Cedex, France 5997, 5998

Centre Hospitalo-Universitaire de Strasbourg, Laboratoire de Pathologie Generale et Experimentale, 67005 Strasbourg Cedex, France 5997, 5998

Centro de Integracion Juvenil, Monterrey, Nuevo Leon, Mexico 5931, 5932

Children's Hospital National Medical Center, Division of Neonatology, 111 Michigan Avenue, N.W., Washington, DC 5717

Children's Hospital Research Foundation, Departments of Pediatrics, Obstetrics and Gynecology, and Medicine, Pels Division of Pediatric Research and Newborn Division, Eliand and Bethesda Avenue, Cincinnati, OH 45229 5372

City University of New York, Mount Sinai School of Medicine, Departments of Medicine and Pathology, Beth Israel Medical Center, New York, NY 5975

City University of New York, Mount Sinai School of Medicine, Environmental Sciences Laboratory, New York, NY 5667, 5673, 5674

Clinical Institute of Phtisiology Bucharest, 90, Sos, Viilor, R-75232, Bucharest, Rumania 5304, 5719

Clinical Institute of Phtisiology Bucharest, 90, Sos, Viilor, R-75232, Burbacest, Rumania 5468

Clinical Research Centre, Division of Psychiatry, Watford Road, Harrow, Middlesex HA1 3UJ, United Kingdom 5972, 6002

Clinical Research Centre, Medical Research Council, Harrow, Middlesex, HA1 3UJ, United Kingdom 5655

College of Medicine and Dentistry of New Jersey, Departments of Preventive Medicine and Pathology, Newark, NJ 07103 5520

Colorado State University, Department of Food Science and Nutrition, Fort Collins, CO 80523 5870

CORPORATE AUTHOR INDEX

Columbia University, College of Physicians and Surgeons, Departments of Medicine and Pharmacology, New York, NY 5990

Columbia University, Department of Neurology, New York, NY 5817, 5818, 5865, 5866

Commissariat a l'Energie Atomique, Department de Protection SPTE, BP 561, 92542 Montrouge Cedex, France 5294, 5378

Cook County Coroner's Laboratory, 1828 W. Polk, Chicago, IL 60612 5636-5643

Cornell University Medical College, Departments of Neurology and Pharmacology, New York, NY 10021 5814, 5863, 5916, 5934, 5963, 5967, 5982, 5999

Cornell University Medical College, New York, NY 10021 5883

Cornell University, Cornell Energy Project, 304 Olin Hall, Ithaca, NY 14850 5362, 5501, 5526, 5540, 5545

Cornell University, Division of Nutritional Sciences, Ithaca, NY 14853 5460, 5471, 5473-5478, 5480, 5482

Cornell University, Ithaca, NY 5334

Coronel Laboratory for Occupational and Environmental Hygiene, le Constantijn Huygensstraat 20, Amsterdam, The Netherlands 5523

Cuyahoga County Coroner's Office, Cleveland, OH 5843-5847

Cuyahoga County Coroner's Office, Cleveland, OH 44106 5805

Daiichi College of Pharmaceutical Sciences, Minami-ku, Fukuoka 815, Japan 5316

Dalhousie University, Department of Medicine, Halifax, Nova Scotia, Canada 5925, 5928

Dalhousie University, Department of Pharmacology, Halifax, Nova Scotia, Canada 5925, 5928

Dartmouth-Hitchcock Medical Center, Department of Medicine, Division of Neurology, Hanover, NH 03755 5499

Denver General Hospital, Rocky Mountain Poison Center, Denver, CO 5620

Denver Veterans Administration Hospital, Renal Section, Denver, CO 80220 5272, 5278, 5275, 5277, 5280

Department of Agriculture (N.I.), Freshwater Biological Investigation Unit, Greenmount Rd., Muckamore, Antrim BT41 4PY, Northern Ireland 5300, 5304, 5431, 5442, 5761

Department of Community Care Sciences, Dalby, Sweden 5799, 5800

Department of Industrial Hygiene and Toxicology, Institute of Occupational Health, Helsinki, Finland 5697

Direction des Affaires Sanitaires et Sociales de Paris, Paris, France 5294, 5297, 5378, 5810

Division of Medical Oncology, Department of Medicine, Kansas City, KS 5902

Dr. Margarete Fischer-Bosch-Institut fur Klinische Pharmakologie, Auerbachstr. 112, 7000 Stuttgart 50, Federal Republic of Germany 5971

E.I. duPont de Nemours & Co., Inc., Engineering Department, Wilmington, DE 5497

Eastman Dental Center, 800 Main St. E, Rochester, NY 14603 5278, 5299, 5403, 5455, 5568, 5690, 5695, 5706, 5746

Eastman Kodak Company, Health, Safety and Human Factors Laboratory, Rochester, New York 14650 5635

EGYT Pharmacochemical Works, Biochemical Laboratory, P. O. Box 100, H-1475 Budapest, Hungary 6004

Environmental Protection Agency, Chamblee Toxicology Laboratory, Chamblee, GA 5890, 5891, 5893-5897

EPS-Environment Canada, Contaminants Control Branch, Ottawa, Canada 5623

Faculte de Medecine de Nancy, Laboratories de Pharmacologie B et de Medecine Nucleaire, B.P. 1000, 54019 Nancy Cedex, France 5851

Falconbridge Nikkelverk Aktieselskap, 4601 Kristiansand S., Norway 5655

Farmitalia Carlo Erba S.p.A., Research Laboratories, Milan, Italy 5909, 5910, 5919, 5920

Firma Gerot Pharmazeutika, Abteilung fur Biopharmazie und Pharmakokinetik, Arnethgasse 3, A-1160 Wien, Osterreich 5877

Fondazione Clinica del Lavoro, Pavia, Italy 5491

Fordham Hospital, Misericordia-Fordham Affiliation, Department of Pathology and Pediatrics, Bronx, NY 10458 5521

Forsyth Dental Center, 140 Fenway, Boston, MA 20115 5453, 5503, 5550, 5555

Franciscan School of Theology, Berkeley, CA 5718, 5939, 5941

Freie Universitat Berlin, Institut fur Toxikologie und Embryopharmakologie, Garystrasse 1-9, 1000 Berlin 33, Federal Republic of Germany 5783-5794

G.D. Searle & Co., Metabolic Studies, High Wycome, Buckinghamshire, United Kingdom 6005, 6006

George Washington University School of Medicine and Health Sciences, Department of Child Health and Development, Washington, DC 5717

Gerhard Domagk Research Group for Cancer Epidemiology and Environmental Hygiene, 5055 NW 7th St, Suite 606, Miami, FL 33126 5567

Gist Brocades Australia Pty Ltd., 77 Pacific Highway, North Sydney, New South Wales, Australia 5832

Gunderson Clinic, Ltd., Department of Internal Medicine, 1836 South Avenue, La Crosse, WI 54601 5458, 5459

H. Lundbeck and Company, Biochemical Department, DK-2500 Copenhagen, Denmark 5982, 5987, 5988

Hahnemann Medical College and Hospital, Philadelphia, PA 19102 5656, 5657

Harbor/UCLA Medical Center, Division of Gastroenterology, Torrance, CA 90509 5807

Harvard Medical School, Boston Hospital for Women, Lying-In Division, 221 Longwood Ave., Boston, MA 02115 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617

Harvard Medical School, Boston, MA 5699, 5704

Harvard Medical School, Department of Biological Chemistry, Biophysics Research Laboratory, Boston, MA 5722

Harvard Medical School, Department of Medicine, Boston, MA 5722

Harvard School of Public Health, Department of Nutrition, Boston, MA 02115 5483-5486, 5859, 5876, 5930, 5936

Health and Welfare Canada, Environmental Health Directorate, Ottawa, Ontario, Canada 5662

Health and Welfare Canada, Health Protection Branch, Drug Research Laboratories, Tunney's Pasture, Ottawa, Canada 5816, 5973, 5978, 6000, 6003, 6011

CORPORATE AUTHOR INDEX

Health and Welfare Canada, Health Protection Branch, Foods Directorate, Toxicological Evaluation Division, Ottawa, Ontario, Canada 5311

Health Commission of New South Wales, Division of Occupational Health and Radiation Control, Clontarf, New South Wales, Australia 5693

Hoffmann-LaRoche Inc., Department of Biochemistry and Drug Metabolism, Nutley, NJ 5968

Hoffmann-LaRoche Inc., Department of Pharmacokinetics and Biopharmaceutics and the Department of Clinical Pharmacology, Nutley, NJ 5749, 5751

Hoffmann-LaRoche Inc., Nutley, NJ 07110 5883

Hoffmann-LaRoche, Inc., Departments of Biochemistry and Drug Metabolism, Chemical Research, and Clinical Pharmacology, Nutley, NJ 5780

Hokuriku University, School of Pharmacy, Kanazawa 920-11, Japan 5331, 5337, 5391, 5396, 5728, 5733

Home Office Central Research Establishment, Aldermaston, Reading, Berkshire RG7 4PN, United Kingdom 5853, 5854

Home Office Central Research Establishment, Aldermaston, Reading, Berkshire, RG7 4PN, United Kingdom 5338, 5341, 5397, 5399, 5542, 5544, 5701, 5702

Hopital Fernand Widal, 75475 Paris Cedex 10, France 5921, 5922

Hospital of the University of Pennsylvania, Renal-Electrolyte Section, Philadelphia, PA 5329, 5333, 5349

Houston Baptist University, Department of Chemistry, Houston, TX 5742

Huddinge University Hospital, Department of Clinical Pharmacology, Huddinge, Sweden 5900

Huddinge University Hospital, Department of Internal Medicine, S-141 86 Huddinge, Sweden 5900

Huddinge University Hospital, Karolinska Institute, Departments of Clinical Pharmacology and Surgery, S-141 86 Huddinge, Sweden 5992

Hungarian Academy of Sciences, Biological Research Center, Institute of Enzymology, P.O. Box 7, H-1502 Budapest, Hungary 6004

I.S.P.-Laboratories for Biomedical Research, 20090 Trezzano s/N, Milan, Italy 5886, 5887

Illinois State Psychiatric Institute, Chicago, IL 5948

Imperial College of Science and Technology, Chemistry Department, South Kensington, London SW7 2AY, United Kingdom 5276, 5376, 5380, 5394, 5472, 5581, 5649, 5688, 5689

Imperial College, Applied Geochemistry Research Group, London, United Kingdom 5496, 5535

Imperial College, Department of Engineering, London, United Kingdom 5506, 5557

IMCO Europe Ltd., Clydach, Swansea, SA6 5QR, United Kingdom 5655

Indiana University School of Medicine, Department of Medicine, Indianapolis, IN 5989

Indiana University School of Medicine, Department of Pathology, Indianapolis, IN 5929

Industrial Toxicology Research Centre, Lucknow, India 5307, 5408

Industrial Toxicology Research Centre, Lucknow, India 5305, 5306, 5309, 5407, 5409, 5411, 5417-5419, 5422, 5427-5430, 5433-5435, 5438, 5445, 5446, 5448, 5451, 5499, 5758, 5760

Institut fur Toxikologie der Eidgenossischen Technischen Hochschule und der Universitat Zurich, Arbeitsarztlicher Dienst des Bundesamtes fur Industrie, Gewerbe und Arbeit, CH-8603, Schwerzenbach, Switzerland 5696

Institut National de la Sante et de la Recherche Medicale, 101 rue de Tolbiac, 75645 Paris Cedex 13, France 5921, 5922

Institut Universitaire de Medecine Sociale et Preventive, Centre de Recherche sur l'Environement Professionnel et les Pollusants Chimiques, La Clochatte, CH-1052 Le Mont-sur-Lausanne, Switzerland 5696

Institute for Cardiovascular Therapy, 6200 Wiesbaden, Federal Republic of Germany 5852

Institute of Hygiene and Public Health Bucharest, Medical School and Pneumoconioses Department, Occupational Health Chair, 1-3 Dr. Leonte Str., R-76256, Bucharest, Rumania 5384, 5468, 5719

Institute of Nutrition of Central America and Panama, Division of Human Nutrition and Biology, Guatemala City, Guatemala 5716

Institute of Occupational Health, Helsinki, Finland 5574

Institute of Toxicologie, E. Merck, D-6100 Darmstadt, Postfach 4119, Federal Republic of Germany 5825

Institute of Urology, London, United Kingdom 5359, 5658

Instituti Clinici di Perfezionamento di Milano, Laboratorio di Recerche Chiniche, Milan, Italy 5492

Instituto de Zootecnia del Consejo Superior de Investigaciones Cientficas, Cordoba, Spain 5406, 5416, 5426, 5432, 5441, 5443, 5757, 5763, 5775, 5778

Instituto di Ricerche Farmacologiche Mario Negri, Via Eritrea, Milan, Italy 5750, 5752, 5835

Instituto Venezolano de Investigaciones Cientificas, Apartado 1827, Caracas, Venezuela 5463, 5466, 5467

Jichi Medical School, Department of Environmental Health, Minamikawachi-Machi, Tochiga-Ken, Japan 5335

John F. Kennedy Institute, Baltimore, MD 5525, 5565

John Hopkins University School of Medicine, Department of Pediatrics, Baltimore, MD 5525, 5565

Johns Hopkins Oncology Center, Baltimore, MD 5802, 5965, 6008

Johnson, Matthey & Co. Ltd., Medical Department, London, NW4 6HY, United Kingdom 5510

Justus Liebig University, Department of Medicine, Giessen, Federal Republic of Germany 5841, 5842

Kansas University Medical Center, Department of Medicine, Division of Hematology, Kansas City, KS 66103 5461, 5465

Kansas University, Medical Center, Department of Medicine, Division of Hematology, Kansas City, KS 66103 5464

Karolinska Institute, Department of Environmental Hygiene, S-104 01 Stockholm, Sweden 5336, 5340, 5342, 5345, 5348, 5741

Karolinska Institute, Department of Pharmacology, Stockholm, Sweden 6007

Karolinska Institute, Stockholm, Sweden 5900

King George's Medical College, Department of Neurology, Lucknow, India 5307, 5409, 5419, 5429, 5435, 5448

King George's Medical College, Department of Obstetrics and Gynecology, Lucknow, India 5305, 5309, 5407,

CORPORATE AUTHOR INDEX

King George's Medical College, Department of Obstetrics and Gynecology, Lucknow, India 5408, 5411, 5417, 5418, 5422, 5427, 5428, 5430, 5433, 5434, 5438, 5445, 5446, 5451, 5758, 5760

King George's Medical College, Department of Obstetrics of Gynecology, Lucknow, India 5306

Kreisgesundheitsamt Steinfurt, Ochtrupperstr. 11, D-4630 Steinfurt, Federal Republic of Germany 5700, 5703

Kumamoto University, Faculty of Pharmaceutical Sciences, Kumamoto, Japan 5331, 5337, 5391, 5396, 5728, 5733

Kyushu University, Faculty of Medicine, Department of Public Health, Fukuoka, 812, Japan 5316

La Crosse Lutheran Hospital, La Crosse, WI 5458, 5459

Laboratoire de Biopathologie Pulmonaire, INSERM U 139, CHU Henri Mondor, Creteil, France 5297, 5810

Lillhagen Hospital, Department II, Gothenburg, Sweden 5904, 5943

Loma Linda University, School of Medicine, Departments of Gynecology, Obstetrics, and Physiology, Division of Perinatal Biology, Loma Linda, CA 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617

Loma Linda University, School of Medicine, Departments of Gynecology, Obstetrics, and Physiology, Division of Perinatal Biology, Loma Linda, CA 92354 5364

London School of Hygiene and Tropical Medicine, T.U.C. Centenary Institute of Occupational Health, and Department of Human Nutrition, London, WC 1E7 HT, United Kingdom 5516, 5779

Louvain University, Unite de Toxicologie Industrielle et Medicale, Brussels, Belgium 5327, 5347

Loyola University of Chicago, Stritch School of Medicine, Department of Biochemistry and Biophysics, Maywood, IL 60153 5273, 5279

M.D. Anderson Hospital and Tumor Institute, University of Texas System Cancer Center, Department of Developmental Therapeutics, Section of Pharmacology, Houston, TX 5880, 5881

M.R.C. Dental Unit, Dental School, Bristol, United Kingdom 5348, 5481, 5554, 5584, 5654, 5744

Magee Women's Hospital, Pittsburgh, PA 5817, 5818, 5865, 5866

Malmo General Hospital, Department of Clinical Pharmacology, S-21401 Malmo, Sweden 5799, 5800

Malmo General Hospital, Department of Urology, S-214 01 Malmo, Sweden 5836-5839

Marin County, San Rafael, CA 5813, 5840, 5884, 5911

Medical College of Georgia, Department of Pediatrics, Augusta, GA 5412-5414

Medical College of Ohio, Department of Psychiatry, Toledo, OH 5944

Medical College of Pennsylvania, Department of Pediatrics, 3300 Henry Ave, Philadelphia, PA 19129 5833

Medical College of Virginia, Department of Neurology, Richmond, VA 5754-5756

Medical College of Virginia, Department of Neuropathology, Richmond, VA 5754-5756

Medical University of South Carolina, Preventive Medicine Division, 171 Ashley Ave., Charleston, SC 5765

Memorial Sloan-Kettering Cancer Center, Department of Biochemistry, New York, NY 10021 5375, 5383, 5389, 5390, 5401, 5408, 5576, 5578, 5579, 5582, 5723, 5725,

Memorial Sloan-Kettering Cancer Center, Department of Biochemistry, New York, NY 10021 5738

Memorial Sloan-Kettering Cancer Center, New York, NY 5883

Michigan State University, Department of Dairy Science, East Lansing, MI 48824 5681, 5693

Michigan State University, Department of Food Science and Human Nutrition, East Lansing, MI 48824 5681, 5693

Millard Fillmore Hospital, Clinical Pharmacokinetics Laboratory, 3 Gates Circle, Buffalo, NY 14209 5860

Ministere de la Sante Publique, Institut d'Hygiene et d' Epidemiologie, rue Juliette Wijtsman 14, B-1050 Brussels, Belgium 5519

Moji National Rail Way Hospital, Fukuoka 800, Japan 5331, 5337, 5391, 5396, 5728, 5733

Mt. Sinai School of Medicine, New York, NY 10029 5924

Municipal Health Center, Lohja, Finland 5697

National Board of Health and Welfare, Department of Drugs, Uppsala, Sweden 5900, 5945

National Institute for Occupational Safety and Health, Cincinnati, OH 5981

National Institute for Occupational Safety and Health, Occupational Health Program, City of Hope Medical Center, Duarte, CA 5614

National Institute of Environmental Medicine, S-104 01 Stockholm, Sweden 5336, 5340, 5342, 5345, 5348, 5741

National Institutes of Health, National Institute of Neurological and Communicative Disorders and Stroke, Experimental Therapeutics Branch and Epilepsy Branch, Bethesda, MD 20205 5798, 5801, 5933

NCI, Baltimore Cancer Research Program DCT, Laboratory of Clinical Pharmacology, Baltimore, MD 5802, 5965, 6008

NCI, Baltimore Cancer Research Program, Clinical Oncology Branch, Section on Medical Oncology, Baltimore, MD 5802, 5965, 6008

New Cross Hospital, Poisons Unit, London, United Kingdom 5853, 5854

New Hanover Memorial Hospital, Department of Pediatrics, Wilmington, NC 5511

New York University, Department of Forensic Medicine, New York, NY 5365, 5811, 5812

Newcastle General Hospital, Department of Paediatrics, Westgate Road, Newcastle upon Tyne, United Kingdom 5500

Newforge Lane, Belfast, Northern Ireland 5300, 5304, 5431, 5442, 5761

Nitro Nobel Company, S-710 30, Gyttorp, Sweden 5440

Oak Ridge National Laboratory, Oak Ridge, TN 37830 5524

Oak Ridge Y-12 Plant, Oak Ridge, TN 37830 5524

Odense University Hospital, Department of Psychiatry, DK-5000 Odense C, Denmark 5987, 5988

Odense University, School of Medicine, Department of Community Health and Environmental Medicine, J.B. Winslowsvej 19, 5000 Odense C, Denmark 5312, 5444

Ohio State University College of Medicine, Department of Medicine, Division of Infectious Diseases, Columbus, OH 5985, 5986

CORPORATE AUTHOR INDEX

Ohio State University, Colleges of Pharmacy and Medicine, Divisions of Pharmacy Practice and Cardiology, Columbus, OH 5964

Okayama Rosai Hospital, Clinical Laboratory, Okayama, Japan 5495

Okayama University, Medical School, Department of Public Health, 2-5-1 Shikata, Okayama, Japan 5495

Ontario Ministry of Agriculture and Food, Provincial Pesticide Residue Testing Laboratory, Guelph, Ontario N1G 2W1, Canada 5301, 5302, 5310, 5319, 5415, 5420, 5762, 5766

Ontario Ministry of Agriculture and Food, Provincial Pesticide Residue Testing Laboratory, Guelph, Ontario, Canada 5311

Ontario Ministry of Health, Community Health Division, Environmental Health, Ontario, M8H 1A9, Canada 5301, 5302, 5310, 5319, 5415, 5420, 5762, 5766

Organon Scientific Development Group, Drug Metabolism R&D Laboratories, P.O. Box 20, 5340 BH Oss, The Netherlands 5848

Osaka Prefectural Institute of Public Health, 3-69, 1-Chome, Nakasichi, Higashinari-ku, Osaka, 537, Japan 5314, 5315, 5317, 5318, 5321, 5676-5680

Ottawa General Hospital, Drug Information Service, Ottawa, Canada 5973

Ottawa General Hospital, Drug Information Service, Ottawa, Ontario, Canada 5816, 5978, 6000, 6003, 6011

Oulu Regional Institute of Occupational Health, SF-90100 Oulu 10, Finland 5707, 5710

Outokumpu Oy, Espoo, Finland 5574

Pennsylvania State University College of Medicine, Departments of Medicine and Pharmacology, Hershey, PA 5808, 5809

Pennsylvania State University, Milton S. Hershey Medical Center, Department of Medicine, Hershey, PA 5946

Peter Bent Brigham Hospital, Division of Medical Biology, Boston, MA 5722

Pratt Institute School of Architecture, New Haven, CT 5504

Prince of Wales Hospital, Psychiatric Unit, Sydney, Australia 5961, 5962

Princess Alexandra Hospital, Department of Clinical Pharmacology, Brisbane, Australia 5830, 5831

Queen Elizabeth Hospital Medical Centre, Birmingham, United Kingdom 5958

Queen Elizabeth Hospital, Clinical Chemistry Department, Birmingham B15 2TH, United Kingdom 5352

Queen Elizabeth Hospital, University of Birmingham, Department of Medicine, Birmingham B15 2TH, United Kingdom 5352

Queen's University of Belfast, Department of Agricultural and Food Chemistry 5300, 5431, 5442, 5761

Queen's University of Belfast, Department of Agricultural and Food Chemistry, Belfast, Northern Ireland 5304

Queen's University of Belfast, Department of Medicine, Belfast, Northern Ireland 5385, 5388, 5393, 5395, 5720, 5730

Queen's University of Belfast, Department of Zoology, Belfast, Northern Ireland 5300, 5304, 5431, 5442, 5761

Rachel Forster Hospital, Redfern, Australia 5868, 5869

Regional Hospital, Department of Occupational Medicine, S-701 85 Orebro, Sweden 5440

Research-Analytical Department of Food Industry, Lodz, Poland 5644-5646

Rijksuniversiteit Gent, Academisch Ziekenhuis, Division of Gastroenterology, Department of Internal Medicine, De Pintelaan 135, B-9000 Gent, Belgium 5374, 5379

Rijksuniversiteit Gent, Division of Mathematical Statistics, Krijgslaan 273, B-9000 Gent, Belgium 5374, 5379

Rijksuniversiteit Gent, Institute for Nuclear Sciences, Laboratory for Analytical Chemistry, Proeftuinstraat 86, B-9000 Gent, Belgium 5374, 5379

Rockefeller University, New York, NY 5975, 5976

Rockland Research Institute, Orangeburg, NY 5843-5847

Rohm & Haas Company, Bristol, PA 5329, 5333, 5349

Royal Victoria Hospital, Belfast, Northern Ireland 5385, 5393, 5720, 5730

Ruakura Soil and Plant Research Station, Private Bag, Hamilton, New Zealand 5682

Rush Medical College, Department of Psychiatry, Chicago, IL 5944

Rutgers - The State University, Departments of Chemistry and Environmental Sciences, New Brunswick, NJ 08903 5367, 5371, 5439, 5633, 5634

Rutgers University, Newark, NJ 5648

San Francisco General Hospital Medical Center, Clinical Pharmacology Unit of the Medical Service, San Francisco, CA 5976

Scandinavian Institute of Dental Materials, Oslo, Norway 5285, 5286, 5288, 5685-5687

Southampton General Hospital, Department of Pathology and Human Metabolism, Southampton, United Kingdom 5500

Southmead Hospital, Department of Medical Microbiology, Bristol, United Kingdom 5991, 5993, 5994

Southwest Research Institute, P.O. Drawer 28510, San Antonio, TX 78284 5522, 5536, 5564, 5659-5661, 5670-5672

Southwestern Institute of Forensic Sciences, Dallas, TX 5931, 5932

St. Louis Children's Hospital, Division of Medical Genetics, St. Louis, MO 63110 5892

St. Louis Children's Hospital, Division of Neonatology, St. Louis, MO 63110 5387, 5892

St. Louis Children's Hospital, Division of Neurology, St. Louis, MO 63110 5892

St. Louis University School of Medicine, Departments of Pediatrics, Pathology and Gynecology and Obstetrics, 1402 South Grand Blvd., St. Louis, MO 63104 5570, 5573

St. Mary's Hospital Medical School, Paediatric Unit, London, United Kingdom 5496, 5535

St. Peter's Hospital, London, United Kingdom 5359, 5658

St. Vincent's Hospital and Medical Center of New York, Department of Anesthesiology, 153 West 11th Street, New York, NY 10011 5667, 5668

St. Vincent's Hospital and Medical Center of New York, Department of Surgery, 153 West 11th Street, New York, NY 10011 5667, 5668

CORPORATE AUTHOR INDEX

St. Vincent's Hospital, Medical Professorial Unit, Darlinghurst, New South Wales 2010, Australia 5850

Stanford University Medical Center, Department of Pathology, Stanford, CA 94305 5295, 5296

Stanford University Medical School, Palo Alto, CA 5718, 5939, 5941

State University Hospital, Department of Internal Medicine, Utrecht, The Netherlands 5823-5829

State University Hospital, Department of Reanimation and Clinical Toxicology, Utrecht, The Netherlands 5823-5829

State University of Ghent, Academic Hospital, Division of Gastroenterology, Department of Internal Medicine, De Pintelaan 135, B-9000 Ghent, Belgium 5382, 5386, 5575, 5577, 5713, 5721

State University of Ghent, Institute for Nuclear Sciences, Laboratory for Analytical Chemistry, Proeftuinstraat 86, B-9000 Ghent, Belgium 5382, 5386, 5575, 5577, 5713, 5721

State University of New York at Buffalo, School of Pharmacy, Department of Pharmaceutics, Amherst, NY 5797, 5860, 5862, 5912, 5969

State University of New York, Downstate Medical Center, Brooklyn, NY 5512, 5566

State University, Centre for Human Toxicology, Vondellaan 14, 3521 GE Utrecht, The Netherlands 5823-5829

Sterling-Winthrop Research Institute, Department of Drug Metabolism and Disposition, Rensselaer, NY 5781, 5782

Stobhill General Hospital, Division of Pediatrics, Glasgow, Scotland, U.K. 5494

Stobhill General Hosptial, Radioimmunoassay Unit, Glasgow, Scotland, U.K. 5853, 5854

Strathclyde Water Department, Balmore Road, Glasgow, Scotland, U.K. 5494

Syracuse University, Biological Research Laboratories, 130 College Place, Syracuse, NY 13210 5327, 5347

Technischen Universitat Munchen, Medizinische Klinik and Poliklinik, Ismaningerstr. 22, D-8000 Munchen 80, Bundesrepublik, Deutschland 5875

The Flinders University of South Australia, Departments of Clinical Pharmacology and Medicine, Bedford Park, South Australia 5820, 5905, 5906

The Perkin-Elmer Corporation, Main Ave., Norwalk, CT 06856 5513

The Rockefeller University Mass Spectrometic Biotechnology Resource, 1230 York Avenue, New York, NY 10021 5667, 5668

The University of Akron, Department of Biology, Akron, OH 5283, 5332, 5534, 5596, 5684

The University of Kansas, School of Pharmacy, Department of Pharmaceutical Chemistry, Lawrence, KS 66044 5669

The University of Manitoba, Faculty of Pharmacy, Winnipeg, Manitoba, R3T 2N2, Canada 5898

Thermo Electron Research Center, Cancer Research Department, Waltham, MA 02154 5423, 5424

U.E.R. de Biologie Humaine et Experimentale Laboratoire de Biochemie 5921, 5922

U.P.S., C.P.A., Physique des Aerosols et Echanges Atmospheriques, 118 Route de Narbonne, 31062 Toulouse, Cedex, France 5515

U.S. Department of Agriculture, Agricultural Research Service, Nutrition Institute, Beltsville, MD 20705 5460, 5471, 5473-5478, 5480, 5482-5486, 5711, 5724, 5726, 5727, 5731, 5732, 5735, 5737-5740, 5745

U.S. Department of Agriculture, Science and Education Administration, Grand Forks Human Nutrition Center, Grand Forks, ND 5402, 5479, 5763

U.S. Environmental Protection Agency, Office of Pesticide Programs, Benefits and Field Studies Division, Washington, DC 20460 5764, 5767

U.S. Environmental Protection Agency, Office of Pesticides Program, Division of Pesticide Community Studies, State Services Branch, 4770 Buford Highway, Chamblee, GA 5313

UCLA/Harbor General Hospital, Division of Gastroenterology, Torrence, CA 90509 5808, 5809

Ulleval Hospital, Medical Department 7 and 8, and Division of Clinical Pharmacology and Toxicology, Oslo, Norway 5849

Umea University, Departments of Medicine and Hygiene, Umea, Sweden 5285, 5286, 5288, 5685-5687

Unilever Research Laboratory, Environmental Safety Division, Colworth House, Sharnbrook, Bedford, United Kingdom 5360

Union Hospital, Lynn, MA 5699, 5704

Union University, Albany Medical College, Institute of Comparative and Human Toxicology, Center of Experimental Pathology and Toxicology, Albany, NY 12208 5753

United States Department of Agriculture, Science and Education Administration, Human Nutrition Laboratory, Grand Forks, ND 58201 5716

Universidad Central de Venezuela, Caracas, Venezuela 5863, 5866

Universidad de Cordoba, Facultad de Veterinaria, Departamento de Higiene, Inspeccion y Microbiologia de los Alimentos, Cordoba, Spain 5406, 5416, 5426, 5432, 5441, 5443, 5757, 5763, 5775, 5778

Universita di Milano, Clinica del Lavoro "L Devoto", 20122 Milan, Italy 5492, 5561

Universita di Modena, Cattedra di Medicina del Lavoro, Modena, Italy 5491

Universita di Parma, Cattedra di Medicina del Lavoro, Parma, Italy 5492

Universita di Parma, Cattedra di Medicina del Lavoro, Parma, Italy, Instituti Clinici di Perfezionamento di Milano, Laboratorio di Recerche Cliniche, Milan, Italy 5561

Universita di Pavia, Cattedra di Medicina del Lavoro, Pavia, Italy 5491

Universita di Pavia, Instituto di Medicina del Lavoro, Pavia, Italy 5491

Universitat Dusseldorf, Medizinisches Institt fur Umwelthygiene, 53, D-4000 Dusseldorf, Federal Republic of Germany 5700, 5703

Universite de Louvain, Unite de Toxicologie Industrielle et Medicale, Clos Chapelle-aux-Champs, 30.54, B-1200 Bruxelles, Belgium 5293

Universite du Quebec, Institut National de la Recherche Scientifique, Centre de Recherche en Sciences de la Sante, 7401 rue Hochelaga, Montreal, Quebec H 1N-3N5, Canada 5954

Universite Libre de Bruxelles, Laboratoire Traitement des Eaux et Pollution, and Laboratoire de Stomatologie, Brussels, Belgium 5558

CORPORATE AUTHOR INDEX

Universite' de Montreal, Faculte de Medicine, Department de Medicine du Travail et d'Hygiene du Milieu, C.P. 6128, Succursale A, Montreal, Quebec, Canada 5328, 5330, 5343

Universite' Laval, Centre de Recherche en Nutrition, Cite Universitaire, Quebec, Canada 5322, 5410, 5421, 5436, 5449, 5759

University College Hospital Medical School, Department of Paediatrics, London, United Kingdom 5356, 5358

University Department of Medicine, Western Infirmary, Glasgow, Scotland, U.K. 5494

University Hospital of Copenhagen, Medical Department TA for Allergology, Copenhagen, Denmark 5926, 5927

University Hospital of Gentofte, Medicine Department C, DK-2900 Hellerup, Denmark 5855

University Hospital, Department of Anesthesia, Lund, Sweden, AB Draco, Astra, Sweden 5821

University Hospital, Department of Obstetrics and Gynecology, S-221 85 Lund, Sweden 5821

University Hospital, Department of Occupational Medicine, S-581 85 Linkoping, Sweden 5440

University Hospital, Department of Pharmacology, Lund, Sweden 5821

University Hospital, Hospital Pharmacy, Uppsala, Sweden 5985

University Medical School of Silesia, Institute of Medical Chemistry and Physics, Department of Analytical Chemistry, 41-200 Sosnowiec, Jagiellonska 4, Poland 5644-5646

University of Aarhus, Institute of Pharmacology, Division of Clinical Pharmacology, DK 8000, Aarhus C. , Denmark 5804

University of Assiut, Faculty of Medicine, Assiut, Egypt 5903

University of Athens, Dental School and Laboratory of Analytical Chemistry, Departments of Operative Dentistry and Preventive Dentistry, Athens, Greece 5452

University of Auckland, School of Medicine, Department of Pediatrics, Auckland, New Zealand 5615, 5683

University of Baghdad, College of Medicine, Departments of Pediatrics and Neurology, Baghdad, Iraq 5590, 5622

University of Birmingham Medical School, Department of Therapeutics and Clinical Pharmacology, Birmingham, United Kingdom 5958

University of Birmingham, Department of Medicine, Birmingham, United Kingdom 5958

University of Birmingham, Department of Organic Chemistry, Birmingham, United Kingdom 5506, 5557

University of Bologna, School of Medicine, Institute of Neurology, Via Foscolo 7, 40123 Bologna, Italy 5953

University of Bristol, School of Chemistry, Bristol, United Kingdom 5384, 5481, 5554, 5584, 5654, 5744

University of California at Davis, Department of Psychiatry, Sacramento, CA 5984

University of California at Los Angeles, School of Medicine, Department of Neurology, Los Angeles, CA 5817, 5818, 5865, 5866

University of California, Department of Medicine, Wadsworth VA Hospital, Endocrine Research Laboratory, Los Angeles, CA 5935, 5938

University of California, Department of Nutritional Sciences, Berkeley, CA 5718, 5939, 5941

University of California, Department of Pharmacology, Los Angeles, CA 5888

University of California, Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA 5888

University of California, San Francisco General Medical Center, Division of Clinical Pharmacology, San Francisco, CA 5888

University of California, School of Medicine, Department of Medicine and Psychiatry, San Francisco, CA 5976

University of California, School of Medicine, Department of Medicine, San Francisco, CA 5803

University of California, School of Pharmacy, Department of Pharmacy, San Francisco, CA 5803

University of California, School of Pharmacy, Division of Clinical Pharmacy, San Francisco, CA 5976

University of California, School of Public Health, Department of Biomedical and Environmental Health Sciences, Berkeley, CA 5662

University of Chicago, Department of Psychiatry, Chicago, IL 5948

University of Cincinnati, Department of Chemistry, Cincinnati, OH 45221 5381

University of Cincinnati, School of Medicine, General Clinical Research Center, Lipoprotein Research Laboratory 5372

University of Colorado Health Sciences Center School of Medicine, Departments of Pediatrics, Emergency Medicine and Medicine, Denver, CO 5620

University of Colorado Medical Center, Division of Renal Medicine, Denver, CO 80220 5272, 5274, 5275, 5277, 5280

University of Colorado, Health Sciences Center, Department of Pediatrics, Denver, CO 5714

University of Connecticut School of Medicine, Farmington, CT 06032 5655

University of Florida, College of Medicine, Department of Psychiatry, Gainesville, FL 32610 5899

University of Florida, College of Pharmacy, Gainesville, FL 32610 5899

University of Glasgow, Department of Forensic Medicine, Glasgow, Scotland, U.K. 5853, 5854

University of Goteborg, Sahlgrenska Sjukhuset, Sweden 5862

University of Greifswald, Faculty of Medicine, Department of Clinical Pharmacology and Obstetrics and Gynecology, Fr.-Loeffler-Str. 23d, DDR-2200 Greifswald (GDR) 5873

University of Greifswald, Faculty of Medicine, Department of Clinical Pharmacology and Obstetrics and Gynecology, Fr.-Loeffler-Str. 23d, DDR-2200 Greifswald, German Democratic Republic 5872

University of Hawaii, Pacific Biomedical Research Center, Pesticide Hazard Assessment Project, Honolulu, HI 5303, 5308, 5324, 5437, 5450, 5769, 5772, 5774, 5777

University of Helsinki, Department of Food Chemistry and Technology, Helsinki 71, Finland 5377

University of Helsinki, Department of Nutrition, Helsinki 71, Finland 5377

University of Helsinki, Department of Pharmacology, Helsinki, Finland 5569, 5882, 5966

University of Helsinki, Department of Public Health Science, Helsinki 29, Finland 5377

CORPORATE AUTHOR INDEX

University of Houston, College of Pharmacy, Department of Pharmaceutics, Houston, TX 5795, 5796

University of Iowa Hospitals, Department of Obstetrics and Gynecology, Iowa City, IA 5350, 5351, 5353, 5354, 5665, 5666

University of Iowa, College of Medicine, Departments of Medicine, Pharmacology, and Anesthesia, Iowa City, IA 52242 5858

University of Istanbul, Department of Pediatrics, Capa, Istanbul, Turkey 5375

University of Kansas, Department of Chemical and Petroleum Engineering, Lawrence, KS 5902

University of Kansas, Department of Pharmaceutical Chemistry, Lawrence, KS 5902

University of Linkoping, University Hospital, Department of Clinical Pharmacology, Helsingborg, Sweden 5952, 5974

University of Liverpool, Department of Anatomy, Liverpool, United Kingdom 5527

University of London, Chelsea College, Monitoring and Assessment Research Centre, 859A Fulham Road, London SW10 OQX, United Kingdom 5281, 5282, 5284, 5287, 5289-5292

University of Louvain, Faculty of Medicine, Industrial and Medical Toxicology Unit, 3054 Clos Chapelle-aux-Champs, B-1200 Brussels, Belgium 5326, 5346, 5509, 5563, 5591, 5618

University of Louvain, Industrial and Medical Toxicology Unit, B-1200 Brussels, Belgium 5519

University of Louvain, Medical and Industrial Toxicology Unit, 1200 Brussels, Belgium 5502, 5549

University of Lund, Department of Clinical Bacteriology, Malmo General Hospital, S-214 01 Malmo, Sweden 5836-5839

University of Lund, Department of Clinical Pharmacology, S-221 01 Lund, Sweden 5836-5839

University of Lund, Lund, Sweden 5799, 5800

University of Mainz, II. Medical Clinic and Department of Pharmacology, Mainz, Federal Republic of Germany 5663

University of Mainz, II. Medical Clinic, Centre for Detoxication and Poisons Information, D-6500 Mainz, Langenbeckstrasse 1, Federal Republic of Germany 5825

University of Maryland, Baltimore Cancer Research Program, Psychiatry Section, Baltimore, MD 5802, 5965, 6008

University of Maryland, School of Medicine, VA Medical Center, Department of Medicine, Baltimore, MD 5935, 5938

University of Melbourne, Austin Hospital, Departments of Cardiology Clinical Pharmacology, Heidelberg, 3084, Victoria, Australia 5901

University of Michigan, School of Public Health, Department of Public Health Planning and Administration, Ann Arbor, MI 5323

University of Minnesota, Department of Medicine, Minneapolis VA Hospital, Endocrine-Metabolic Section, Minneapolis, MN 5935, 5938

University of Mississippi Medical Center, Departments of Pharmacology and Toxicology and Pediatrics, Jackson, MS 5812-5814

University of Missouri-Kansas City, Schools of Pharmacy and Medicine, Pharmacokinetics Laboratory, Kansas City, MO 5885

University of Nebraska Medical Center, Department of Anesthesiology, 42nd and Dewey Avenue, Omaha, NB 68105 5949

University of New South Wales, Department of Analytical Chemistry, Sydney, New South Wales, Australia 5518

University of Nijmegen, Institute of Pharmacology and Toxicology, Nijmegen, The Netherlands 5705

University of North Carolina School of Medicine, Department of Pediatrics and Division of Disorders of Development and Learning, Chapel Hill, NC 5511

University of North Carolina School of Medicine, Departments of Pathology and Medicine, Chapel Hill, NC 5770, 5771

University of Occupational and Environmental Health, School of Medicine, Department of Human Ecology, 1-1, Iseigaoka, Kitakyushu 807, Japan 5316

University of Oklahoma Health Sciences Center, Department of Medicine, Division of Clincial Pharmacology, Oklahoma City, OK 5937

University of Oslo, Institute of Forensic Medicine, Rikshospitalet, Oslo 1, Norway 5955-5957

University of Ottawa, Royal Ottawa Hospital, 1145 Carling Avenue, Ottawa, Ontario K1Z-7K4, Canada 5954

University of Oulu, Department of Clinical Chemistry, SF-90220 Oulu 22, Finland 5707, 5710

University of Oulu, Department of Public Health Sciences, SF-90220 Oulu 22, Finland 5707, 5710

University of Oulu, Oulu, Finland 5574

University of Oxford, Department of Psychiatry, Littlemore Hospital, Oxford, United Kingdom 5904, 5943

University of Pavia, Institute of Phthisiology and Respiratory Diseases, Pavia, Italy 5909, 5910, 5919, 5920

University of Pennsylvania, College of Arts and Sciences, Anthropology Department, Philadelphia, PA 5366, 5368

University of Pennsylvania, Philadelphia, PA 5648

University of Pittsburgh School of Medicine, Departments of Neurology, Pediatrics and Pathology, Pittsburgh, PA 5817, 5818, 5865, 5866

University of Queensland, Department of Organic Chemistry, St. Lucia, Australia 5830, 5831

University of Reading, Department of Chemistry, Whiteknights, Reading, United Kingdom 5506, 5557

University of Rochester School of Medicine and Dentistry, Departments of Pediatrics and Pathology, Rochester, NY 5890, 5891, 5893-5897

University of Rochester, Department of Pharmacology and Toxicology, Rochester, NY 5590, 5622

University of Saskatchewan, College of Pharmacy, Saskatoon, Saskatchewan, Canada 5816, 5898, 5973, 5978, 6000, 6003, 6011

University of Southern California, School of Pharmacy, Clinical Pharmacokinetic Laboratory, 1985 Zonal Ave., Los Angeles, CA 90033 5878

University of Surrey, Department of Biochemistry, Surrey, Guildford GU2 5XH, United Kingdom 5923

University of Surrey, Department of Physics, Medical and Environmental Physics Group, Guildford, Surrey, United Kingdom 5298, 5325, 5355, 5357, 5369, 5370, 5392, 5400, 5456, 5457, 5571, 5572, 5580, 5583, 5597, 5691, 5692, 5694, 5698, 5708, 5709, 5729

CORPORATE AUTHOR INDEX

University of Sydney, Department of Pharmacy, Sydney, Australia 5868, 5869, 5961, 5962

University of Tennessee, Center for the Health Sciences, College of Pharmacy, Departments of Pharmaceutics and Medicinal Chemistry, Memphis, TN 5861

University of Texas Health Sciences Center, Program in Nutrition and Dietetics, Houston, TX 5742

University of Texas Medical School at Houston, Departments of Pediatrics and Pathology, Houston, TX 77025 6001

University of Texas Southwestern Medical School at Dallas, Department of Pediatrics, Dallas, TX 5980

University of Texas Southwestern Medical School, Dallas, TX 5931, 5932

University of Texas, Health Science Center at Houston, Division of Infectious Diseases, Houston, TX 77025 5795, 5796

University of the West Indies, Tropical Metabolism Research Unit, Kingston, Jamaica 5715

University of Toronto, Faculty of Medicine, Department of Pharmacology, Toronto, Ontario M5S 1A8, Canada 5948, 5950, 5951

University of Uppsala, Biomedical Center, Pharmaceutical Chemistry, Uppsala, Sweden 5945

University of Utah Medical Center, Department of Pathology, Salt Lake City, UT 5977, 5979

University of Utah, Center for Human Toxicology, Salt Lake City, UT 5977, 5979

University of Utrecht, Department of Analytical Pharmacy, Catharijnesingel 60, 3511 GH Utrecht, The Netherlands 5915, 6009, 6010

University of Washington, Department of Medicine, Division of Hematology, Seattle, WA 5461

University of Washington, Department of Medicine, Division of Hematology, Seattle, WA 98195 5464, 5465

University of Washington, Department of Medicine, Seattle, WA 5968

University of Washington, Division of Medical Genetics, Seattle, WA 5968

University of Washington, School of Pharmacy, Seattle, WA 5968

University of Washington, School of Public Health and Community Medicine, Department of Health Services, Seattle, WA 5323

University of Wisconsin Hospitals, Departments of Medicine, Pathology and Toxicology Laboratories, Madison, WI 53706 5339, 5398, 5736

University of Zimbabwe, Department of Clinical Pharmacology, Salisbury, Zimbabwe, Africa 5991, 5993, 5994

Upjohn Co., Kalamazoo, MI 5985, 5986

Vanderbilt University Medical School, Department of Pediatrics, Nashville, TN 37232 5674

Vanderbilt University School of Medicine, Department of Medicine, Division of Infectious Diseases, Nashville, TN 37232 5770, 5771

Veterans Administration Hospital, Metabolic Section, Hines, IL 60141 5454

Veterans Administration Hospital, Research Service, Hines, IL 60141 5273, 5279

Veterans Administration Hospital, Trace Element Research Laboratory, Washington, DC 20422 5711, 5724, 5726, 5727, 5731, 5732, 5735, 5737-5740, 5745

Veterans Administration Hospital, 1201 NW 126th Street, Miami, FL 5940

Veterans Administration Medical Center and Stanford University School of Medicine, Departments of Medicine and Neurosurgery, Palo Alto, CA 5970

Veterans Administration Medical Center Brentwood, Los Angeles, CA 5888

Veterans Administration Medical Center, Division of Infectious Diseases, Department of Medicine, Albany, NY 12208 5995, 5996

Veterans Administration Medical Center, Kansas City, MO 5902

Veterans Administration Medical Center, 3801 Miranda Avenue, Palo Alto, CA 94304 6007

Victoria Hospital, London, Ontario, Canada 5301, 5302, 5310, 5319, 5415, 5420, 5762, 5766

Virginia Polytechnic Institute and State University, Department of Human Nutrition and Foods, Blacksburg, VA 24061 5940

Washington State University, College of Pharmacy, Pullman, WA 99164 5913, 5914

Washington University School of Medicine, Department of Neurology, St. Louis, MO 5892

Washington University School of Medicine, Edward Mallinckrodt Department of Pediatrics, St. Louis, MO 5387, 5892

Wellcome Research Laboratories, Department of Clinical Pharmacology, Beckenham, Kent BR3 3BS, United Kingdom 5907, 5908

Welsh National School of Medicine, University Hospital of Wales, Cardiff, United Kingdom 5469

West Park Hospital, Epsom Hospital Laboratories, Epsom, United Kingdom 5923

West Park Hospital, MRC Neuropsychiatry Laboratory, Epsom, Surrey KT19 8PB, United Kingdom 5889

Westminster Medical School, Department of Child Health, London, SW1P 2NS, United Kingdom 5510

Wharton School, Management and Behavioral Science Center, Department of Statistics and Operations Research, and Regional Science Department, Philadelphia, PA 5366, 5368

Wilmington Medical Center, Department of Pathology, Wilmington, DE 19899 5712

Yale University School of Medicine, Department of Anesthesiology, New Haven, CT 06510 5947

Yale University School of Medicine, Department of Laboratory Medicine, New Haven, CT 06510 5947

Yale University School of Medicine, Departments of Psychiatry and Pharmacology, New Haven, CT 06510 5947

Yale University School of Medicine, New Haven, CT 5504

TISSUE INDEX

Adipose 5300, 5301, 5308, 5310-5318, 5406, 5415, 5416, 5426, 5431, 5432, 5441-5448, 5487, 5676, 5758, 5757, 5761-5764, 5775, 5778, 5890

Adrenal gland 5488, 5586, 5783

Amniotic fluid 5587, 5788

Aorta 5489

Bile 5823

Blister fluid 5991

Blood 5281, 5305, 5315, 5326, 5327, 5362-5365, 5368, 5372, 5405, 5407, 5412, 5417, 5423, 5428, 5427, 5433, 5445, 5460-5467, 5483, 5490-5517, 5569, 5588-5591, 5621-5623, 5635, 5636, 5640, 5669, 5677, 5682, 5683, 5699, 5711, 5755, 5758, 5765, 5813, 5832, 5843, 5850, 5853, 5855, 5879, 5891, 5892, 5911, 5928, 5931, 5955, 5995, 6001

Blood, cells 5381, 5382, 5575, 5712, 5713, 5878

Blood, fetal 5306, 5350, 5408, 5418, 5428, 5438, 5446, 5862, 5912, 5969

Blood, plasma 5272, 5328, 5567, 5570, 5663, 5714-5718, 5787, 5749, 5750, 5779-5781, 5795, 5798, 5799, 5802, 5803, 5805, 5810-5817, 5820-5822, 5824, 5830, 5840, 5841, 5849, 5851, 5852, 5856, 5858, 5863-5865, 5870, 5874, 5875, 5880, 5883, 5885, 5886, 5889, 5898-5905, 5907, 5916, 5917, 5921, 5925, 5929, 5933, 5934, 5937, 5943, 5944, 5946, 5948, 5949, 5952-5958, 5958, 5959, 5961, 5963-5965, 5967, 5970-5978, 5980, 5982, 5983, 5987, 5989, 5992, 5999, 6000, 6002, 6003, 6005, 6007-6009, 6011

Blood, serum 5273, 5307, 5329, 5351, 5352, 5373, 5376, 5379, 5383-5388, 5409, 5419, 5425, 5429, 5435, 5887, 5440, 5468-5470, 5576, 5577, 5665, 5667, 5668, 5673, 5674, 5707, 5719-5722, 5770, 5785, 5797, 5833, 5836, 5859, 5860, 5868, 5872, 5876, 5877, 5882, 5888, 5909, 5913, 5915, 5919, 5926, 5930, 5935, 5936, 5938, 5942, 5966, 5985, 5990, 5993, 5997, 6004

Blood, whole 5316, 5330, 5440, 5518-5525, 5659, 5670

Body 5389, 5471, 5484, 5592

Bone 5274, 5282, 5353, 5526-5530, 5578, 5723, 5728

Brain 5275, 5531, 5593, 5598, 5628, 5637, 5641, 5786, 5818, 5844, 5866, 5893

Breast 5390, 5579, 5725

Breath 5366, 5644, 5807-5809, 5932

Cartilage 5532

Cerebrospinal fluid 5796

Connective tissue 5533

Esophagus 5726

Eye 5727

Fetal 5358, 5666

Gall stone 5331, 5391, 5728

Hair 5276, 5283, 5284, 5298, 5325, 5332, 5333, 5355, 5369, 5375, 5376, 5380, 5392-5395, 5456, 5457, 5472, 5534-5536, 5571, 5580, 5581, 5595-5598, 5625, 5648, 5649, 5660, 5671, 5675, 5684, 5688, 5689, 5691, 5694, 5698, 5700, 5708, 5729, 5730, 5939

Heart 5537, 5599, 5626, 5650, 5731, 5787, 5825

Intestine 5317, 5538, 5539, 5600, 5627, 5678, 5788

Kidney 5285, 5334-5338, 5396, 5397, 5580-5582, 5601, 5628, 5651, 5685, 5701, 5732, 5733, 5789, 5826, 5837, 5898

Liver 5286, 5287, 5318, 5339-5341, 5398, 5399, 5413, 5473, 5583, 5584, 5582, 5602, 5629, 5638, 5642, 5652, 5656, 5679, 5686, 5702, 5734-5736, 5756, 5790, 5811, 5812, 5827, 5845, 5895, 5956

Lung 5288, 5289, 5294-5297, 5378, 5585, 5586, 5574, 5603, 5630, 5639, 5643, 5653, 5657, 5687, 5737, 5791, 5828, 5846

Menstrual fluid 5474

Milk 5302, 5303, 5308, 5319-5324, 5356, 5377, 5410, 5420, 5421, 5436, 5437, 5449, 5450, 5475, 5485, 5604, 5680, 5759, 5766-5769, 5772-5774, 5776, 5777, 5800

Milk, whole 5309, 5411, 5422, 5430, 5438, 5451, 5760

Muscle 5277, 5290, 5587, 5605, 5631, 5738, 5792, 5896

Nail 5291, 5357, 5370, 5400, 5476, 5572, 5583, 5692, 5709

Ovary 5606

Pancreas 5548, 5607, 5632, 5739

Pericardial fluid 5829

Pituitary 5608

Placenta 5549, 5609, 5793

Pleural fluid 5401

Prostate 5342, 5740, 5741, 5838, 5996

Saliva 5343, 5550, 5742, 5806, 5819, 5834, 5867, 5910, 5918, 5920, 5927, 5950, 5979, 5984

Skin 5292, 5360, 5477, 5551, 5610, 5645, 5897

Spleen 5478, 5552, 5611, 5847

Stomach 5553, 5794

Sweat 5402, 5479, 5880, 5743

Synovial fluid 5869

Teeth 5278, 5299, 5344, 5403, 5452, 5453, 5455, 5481, 5554-5558, 5568, 5584, 5659, 5690, 5695, 5706, 5744, 5746

Testes 5345, 5612, 5745

Thymus 5559

Thyroid gland 5458, 5560

Trachea 5613

Urine 5279, 5280, 5293, 5346-5349, 5358, 5359, 5361, 5367, 5371, 5404, 5414, 5439, 5454, 5459, 5482, 5486, 5561-5566, 5573, 5585, 5614-5620, 5633, 5634, 5646, 5647, 5655, 5658, 5661, 5662, 5668, 5672, 5681, 5693, 5696, 5697, 5703-5705, 5710, 5748, 5751-5753, 5771, 5782, 5801, 5804, 5810, 5831, 5835, 5839, 5842, 5848, 5858, 5857, 5861, 5871, 5873, 5881, 5884, 5887, 5906, 5908, 5914, 5922, 5923, 5928, 5940, 5941, 5945, 5947, 5951, 5957, 5960, 5962, 5968, 5981, 5986, 5988, 5994, 5998, 6006, 6010

KEYWORD INDEX

ABCPTION 5783-5794

ADOLESCENTS 5298, 5325, 5355, 5357, 5369, 5370, 5392, 5400, 5456, 5457, 5460, 5471, 5473-5478, 5480, 5482-5489, 5514, 5528-5533, 5537-5539, 5541, 5543, 5546-5548, 5551-5553, 5559, 5560, 5571, 5572, 5580, 5583, 5597, 5691, 5692, 5694, 5698, 5708, 5709, 5729, 5797

ADULTS 5276, 5293, 5300, 5303-5305, 5307-5309, 5311, 5313-5315, 5317, 5318, 5321, 5323, 5324, 5328-5330, 5333, 5343, 5349-5351, 5353, 5358, 5366-5368, 5371, 5376, 5380, 5385, 5388, 5393-5395, 5402, 5407, 5409, 5411, 5417, 5419, 5422, 5427, 5429-5431, 5433, 5435, 5437-5439, 5442, 5445, 5447, 5448, 5450, 5451, 5453, 5458-5461, 5463, 5465, 5469-5480, 5482-5489, 5492, 5494, 5496, 5503-5505, 5507, 5510, 5511, 5516, 5518, 5517-5520, 5522, 5527-5533, 5535-5539, 5541, 5543, 5546-5548, 5550-5553, 5555, 5556, 5558-5562, 5564, 5567, 5569, 5581, 5590, 5616, 5620, 5622, 5633-5635, 5647, 5649, 5656, 5657, 5659-5662, 5665, 5666, 5670-5674, 5676-5680, 5682, 5688, 5689, 5699, 5708, 5707, 5710, 5720, 5722, 5730, 5743, 5750, 5752, 5754-5756, 5758, 5760, 5761, 5765, 5769-5772, 5774, 5777, 5780-5796, 5799, 5800, 5813, 5816, 5821-5829, 5833, 5840, 5843-5847, 5852, 5855-5857, 5861, 5870-5873, 5877, 5879, 5884, 5886, 5887, 5889, 5898-5900, 5904, 5907, 5908, 5911, 5915, 5921, 5922, 5925-5928, 5931, 5932, 5942-5948, 5952, 5958, 5968, 5971-5975, 5978, 5980, 5981, 5987-5989, 5995-5998, 6000, 6002, 6003, 6005, 6006, 6011

AFRICA 5298, 5325, 5355, 5357, 5369, 5370, 5392, 5400, 5456, 5457, 5572, 5580, 5583, 5597, 5650-5653, 5691, 5692, 5698, 5698, 5708, 5709, 5729

AGE 5298, 5301-5303, 5306, 5308, 5310, 5311, 5319, 5322, 5324, 5325, 5355, 5357, 5369, 5370, 5372, 5387, 5392, 5400, 5408, 5410, 5415, 5418, 5420, 5421, 5428, 5434, 5436, 5437, 5446, 5449, 5450, 5456, 5457, 5460, 5470, 5471, 5473-5478, 5480, 5482-5489, 5514, 5528-5533, 5537-5539, 5541, 5543, 5546-5548, 5551-5553, 5558-5560, 5571, 5572, 5580, 5583, 5597, 5648, 5691, 5692, 5698, 5698, 5700, 5708, 5709, 5729, 5759, 5762, 5766, 5769, 5772, 5778, 5777, 5859, 5876, 5930, 5936, 5972, 6002

AGRICULTURE 5338, 5662, 5764, 5767

AIR POLLUTION 5281, 5282, 5284, 5287, 5289-5292, 5335, 5362, 5368, 5423, 5424, 5497, 5501, 5504, 5506, 5507, 5519, 5526, 5540, 5545, 5557, 5656, 5657, 5764, 5767

ALASKA 5650-5653

ALCOHOLS 5365, 5644-5647, 5811, 5812, 5855

ALDRIN 5322, 5410, 5421, 5436, 5449, 5759

ALKALOIDS 5907, 5908

AMINO ACIDS 5523

ANALGESICS 5780, 5797, 5799, 5800, 5805, 5806, 5815, 5819, 5834, 5862, 5864, 5867, 5883, 5912-5914, 5917, 5918, 5945, 5946, 5955-5957, 5969, 5970, 5983, 5984

ANEMIA 5460, 5469-5471, 5473-5478, 5480, 5482, 5506, 5557, 5859, 5876, 5930, 5936

ANESTHETICS 5947-5951

ANTI-INFLAMMATORY AGENTS 5868, 5869

ANTIARRHYTHMIC AGENTS 5849, 5850, 5852, 5856, 5857, 5901, 5964

ANTIBIOTICS 5795, 5796, 5836-5839, 5861, 5872, 5873, 5909, 5910, 5915, 5919, 5920, 5925, 5928, 5980, 5985, 5986, 5989-5998, 6009, 6010

ANTICOAGULANTS 5870, 5871

ANTICONVULSANTS 5798, 5801, 5805, 5806, 5814, 5815, 5817-5819, 5834, 5863-5867, 5916-5918, 5933, 5934, 5953, 5963, 5967, 5968, 5982-5984, 5999

ANTIDEPRESSIVE AGENTS 5822, 5843-5848, 5862, 5885, 5912, 5961, 5962, 5969, 5972, 5987, 5988, 6002

ANTIHYPERTENSIVE AGENTS 5900

ANTIPIRETICS 5799, 5800, 5805, 5806, 5808, 5809, 5815, 5819, 5834, 5864, 5867, 5917, 5918, 5948, 5950, 5951, 5983, 5984

ARIZONA 5412-5414

ARSENIC ORGANIC COMPOUNDS 5293

ATMOSPHERE 5362, 5490, 5497, 5501, 5506, 5515, 5522, 5526, 5536, 5540, 5545, 5557, 5564, 5659-5661, 5670-5672

AUSTRALIA 5493

AUTOMOTIVE 5366, 5368, 5506, 5557

AUTONOMIC DRUGS 5822, 5907, 5908, 5925, 5928

AUTOPSIES 5274, 5275, 5277, 5294-5296, 5300-5302, 5304, 5310-5315, 5317-5319, 5321, 5335, 5339, 5344, 5365, 5378, 5398, 5405, 5406, 5415, 5416, 5420, 5426, 5431, 5432, 5441-5444, 5481, 5487-5489, 5514, 5528-5533, 5537-5539, 5541, 5543, 5546-5548, 5551-5554, 5559, 5560, 5584, 5586, 5588, 5593, 5595, 5599-5603, 5605-5608, 5610-5613, 5654, 5676-5680, 5736, 5744, 5757, 5761-5763, 5766, 5775, 5778, 5811-5813, 5818, 5840, 5843-5847, 5865, 5886, 5890, 5891, 5893-5897, 5911, 5955-5957

BEHAVIOR DISORDERS 5512, 5517, 5566, 5879, 5904, 5943, 5944, 5952, 5974

BELGIUM 5327, 5347, 5382, 5386, 5502, 5549, 5558, 5575, 5713, 5721

BENZENES 5569

BIOACCUMULATION 5298, 5305, 5309, 5311-5313, 5325, 5355, 5357, 5369, 5370, 5377, 5392, 5400, 5407, 5411, 5417, 5422, 5427, 5430, 5433, 5438, 5444, 5445, 5451, 5453, 5456, 5457, 5460, 5471, 5473-5478, 5480, 5482, 5500, 5503, 5504, 5506, 5515, 5550, 5555, 5557, 5567, 5571, 5572, 5580, 5583, 5587, 5589, 5592, 5594, 5597, 5598, 5604, 5609, 5615, 5617, 5623, 5683, 5691, 5692, 5694, 5698, 5708, 5709, 5718, 5729, 5758, 5760, 5764, 5767, 5817, 5818, 5865, 5866, 5939, 5941, 5995, 5996

BIOINDICATORS 5523

BIOPSIES 5335

BIPHENYL COMPOUNDS 5316

BLOOD PRESSURE 5440, 5900, 5946

BONE DISEASES 5454

BROMINATED HYDROCARBONS 5367, 5371, 5439, 5633, 5634

CADAVERS 5527

CALIFORNIA 5366, 5368, 5522, 5536, 5564, 5614, 5659-5661, 5670-5672, 5888

CANADA 5301, 5302, 5310, 5311, 5319, 5322, 5328, 5330, 5343, 5410, 5415, 5420, 5421, 5436, 5449, 5517, 5623, 5650-5653, 5662, 5759, 5762, 5764, 5766, 5767, 5879, 5948, 5950, 5951

CARBON INORGANIC COMPOUNDS 5361-5366, 5368, 5501, 5526, 5540, 5545, 5619, 5664, 5811, 5812

CARCINOGEN 5295, 5296, 5336, 5340, 5342, 5345, 5348, 5373, 5383, 5389, 5390, 5401, 5404, 5423, 5424, 5576, 5578, 5579, 5582, 5656, 5657, 5723, 5725, 5734, 5741

CARCINOMAS 5285, 5286, 5288, 5298-5296, 5312, 5352, 5373, 5378, 5383, 5389, 5390, 5401, 5404, 5412-5414, 5444, 5576, 5578, 5579, 5582, 5685-5687, 5723, 5725, 5734, 5802, 5880, 5881, 5902, 5965, 6008

CARDIOVASCULAR DISEASES 5285, 5286, 5288, 5372, 5685-5687, 5937, 5964

CASE HISTORIES 5510, 5590, 5620, 5622, 5663, 5765, 5770, 5771, 5797, 5816, 5833, 5849, 5855, 5890, 5891, 5893-5897, 5973, 5978, 6000, 6001, 6003, 6011

CENTRAL NERVOUS SYSTEM DISEASES 5623, 5798, 5801, 5818, 5863, 5889-5891, 5893-5897, 5916, 5929, 5933, 5934, 5937, 5963, 5967, 5982, 5999

CHELATING AGENTS 5465

CHEMOTHERAPY 5669, 5783-5794, 5802, 5880, 5881, 5902, 5903, 5965, 6008

CHILDREN 5283, 5298, 5314, 5315, 5317, 5318, 5321, 5325, 5332, 5355, 5357, 5369, 5370, 5392,

KEYWORD INDEX

CHILDREN 5400, 5453, 5456, 5457, 5460, 5471, 5473-5478, 5480, [illegible], 5493, 5496, 5498, 5499, 5503-5506, 5508, 5511, 5512, 5514, 5516-5522, 5525, 5527-5539, 5541, 5543, 5546-5548, 5550-5553, 5555-5560, 5562, 5568-5567, 5571, 5572, 5580, 5583, 5590, 5596, 5597, 5615, 5620, 5622, 5659-5661, 5670-5672, 5676-5680, 5683, 5684, 5691, 5692, 5694, 5698, 5708, 5709, 5715, 5729, 5779, 5879, 5890, 5891, 5893-5897, 5924, 5940

CHILE 5567

CHLORINATED HYDROCARBONS 5303, 5308, 5324, 5367, 5371, 5437, 5439, 5450, 5633-5643, 5769, 5772, 5774, 5777

CHLORINE ORGANIC COMPOUNDS 5301, 5302, 5306, 5310, 5313-5315, 5317-5319, 5321-5323, 5360, 5406, 5408, 5410, 5415, 5416, 5418, 5420, 5421, 5426, 5428, 5432, 5436, 5436, 5441, 5443, 5446, 5449, 5636-5643, 5676-5680, 5758-5757, 5759, 5762, 5763, 5766, 5775, 5778

CHLOROBENZENES 5301, 5302, 5310, 5319, 5415, 5420, 5762, 5766

CHOLESTEROLS 5372, 5859, 5876, 5930, 5936

CIRRHOSIS 5935, 5938, 5975

COAL 5384, 5468, 5719

COMPARATIVE EVALUATIONS 5273, 5276, 5279, 5306, 5314-5318, 5321, 5325, 5331, 5337, 5386, 5372, 5376, 5380, 5387, 5391, 5394, 5396, 5408, 5418, 5428, 5438, 5446, 5469, 5472, 5497, 5509, 5520, 5522, 5536, 5563, 5564, 5567, 5581, 5591, 5618, 5689, 5655, 5659-5661, 5670-5672, 5676-5680, 5682, 5688, 5689, 5728, 5733, 5780, 5805, 5806, 5815, 5819, 5820, 5822, 5838, 5853, 5854, 5856-5858, 5864, 5867, 5880-5882, 5903-5906, 5909, 5910, 5917-5920, 5923, 5926, 5927, 5942, 5943, 5961, 5962, 5966, 5983, 5988, 5987, 5988

CONNECTICUT 5513

CONNECTIVE TISSUE 5487, 5488, 5514, 5528-5533, 5537-5539, 5541, 5543, 5546-5548, 5551-5553, 5559, 5560

CROP DUSTING 5662

DENMARK 5312, 5484, 5942

DENTAL CARIES 5278, 5299, 5403, 5453, 5455, 5503, 5550, 5555, 5568, 5690, 5695, 5706, 5746

DENTISTRY 5452, 5614

DIABETES 5823-5831

DIAZEPAM 5971

DIFIS 5281, 5282, 5284, 5287, 5289-5292, 5303, 5306, 5308, 5328, 5336, 5340, 5342, 5345, 5348, 5350, 5351, 5353, 5354, 5356, 5358, 5359, 5372, 5377, 5408, 5418, 5428, 5434, 5437, 5446, 5458, 5458-5464, 5466, 5470, 5471, 5473-5478, 5480, DIETS 5482-5486, 5505, 5516, 5556, 5562, 5570, 5573, 5615, 5658, 5665, 5666, 5682, 5683, 5711, 5715-5718, 5728, 5726, 5727, 5731, 5732, 5735, 5737-5741, 5745, 5769, 5772, 5774, 5777, 5779, 5859, 5876, 5930, 5936, 5939-5941

DISEASES 5294, 5314, 5315, 5317, 5318, 5321, 5352, 5378, 5458, 5459, 5676-5680, 5722, 5929, 5958

DIURETICS 5359, 5658, 5803, 5805, 5806, 5815, 5819, 5834, 5864, 5867, 5917, 5918, 5983, 5984, 6005, 6006

DRINKING WATER 5281, 5282, 5284, 5287, 5289-5292, 5336, 5340, 5342, 5345, 5348, 5362, 5367, 5371, 5423, 5424, 5439, 5490, 5494, 5501, 5502, 5504, 5506, 5519, 5526, 5540, 5545, 5549, 5557, 5567, 5587, 5589, 5592, 5594, 5598, 5598, 5604, 5609, 5615, 5617, 5633, 5634, 5683, 5741, 5768, 5767

DRUG ABUSE 5365, 5699, 5708, 5797, 5811, 5812, 5816, 5833, 5843-5847, 5849, 5853-5855, 5921-5923, 5947, 5973, 5978, 6000, 6003, 6011

DRUG INTERACTION 5798, 5801, 5802, 5807, 5820, 5822, 5852, 5877, 5882, 5902, 5905, 5906, 5913, 5918, 5925, 5928, 5933, 5944, 5965, 5966, 5971, 5976, 5991-5994, 6008

DRUG THERAPY 5297, 5359, 5454, 5469, 5658, 5669, 5783-5796, 5799, 5800, 5802, 5803, 5805-5807, 5810, 5814, 5815, 5817-5819, 5821, 5823-5829, 5832, 5834, 5850, 5851, 5860, 5863-5869, 5872-5874, 5880, 5881, 5883, 5889, 5898-5904, 5916-5918, 5924, 5926, 5927, 5934, 5943, 5944, 5952-5954, 5963-5965, 5967, 5970-5972, 5974-5976, 5980, 5982-5984, 5990, 5992, 5995, 5996, 5999, 6002, 6008

DRUGS 5272, 5280, 5359, 5365, 5454, 5483-5486, 5658, 5669, 5699, 5704, 5781-5813, 5815-5832, 5834, 5836-5840, 5843-5858, 5860-5862, 5864-5875, 5877, 5880-5887, 5889, 5892, 5898-5903, 5905-5914, 5917-5925, 5928, 5933, 5944, 5946-5951, 5953-5962, 5964-5966, 5968-5973, 5975-5980, 5983-5988, 5990-5996, 6000-6011

DUST 5297, 5329, 5333, 5335, 5349, 5362, 5388, 5468, 5490, 5496, 5501, 5507, 5526, 5535, 5540, 5545, 5574, 5700, 5703, 5707, 5710, 5719, 5810

EGYPT 5650-5653

ENZYMES 5362, 5495, 5501, 5526, 5540, 5545

ERYTHROMYCINS 5925, 5928

ESKIMOS 5623

EXPERIMENTAL PSYCHOLOGY 5972, 6002

FARMS 5447, 5673, 5674

FECES 5753, 5870, 5871

FETUS 5350, 5351, 5353, 5354, FETUS 5364, 5502, 5549, 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617, 5665, 5666, 5783-5794, 5862, 5912, 5969

FIBERS 5294-5297, 5378, 5810

FINLAND 5377, 5506, 5557, 5574, 5697, 5707, 5710, 5882, 5966

FISHES 5364, 5615, 5623, 5683

FOOD 5467

FOOD ADDITIVES 5458-5460, 5464, 5465, 5467, 5471, 5473-5478, 5480, 5482, 5681, 5693, 5749-5752, 5859, 5876, 5930, 5936

FOOD CONTAMINATION 5314-5318, 5321, 5377, 5447, 5506, 5557, 5587, 5589, 5590, 5592, 5594, 5598, 5604, 5609, 5617, 5622, 5673, 5674, 5676-5680, 5700, 5703, 5764, 5767

FOOD PRESERVATIVES 5423, 5424, 5465

FOODS 5334, 5362, 5423, 5424, 5460, 5461, 5463, 5465-5467, 5471, 5473-5478, 5480, 5482-5486, 5501, 5506, 5515, 5526, 5540, 5545, 5557, 5623, 5714, 5716, 5718, 5939, 5941, 5959, 5960

FORENSIC MEDICINE 5636-5643, 5813, 5840, 5843-5847, 5884, 5911

FOSSIL FUELED POWER PLANTS 5362, 5501, 5526, 5540, 5545

FRANCE 5297, 5515, 5810, 5997, 5998

FUMES 5335, 5366, 5368, 5506, 5557, 5574, 5585, 5620

FUNGAL TOXIN 5412-5414

GALL STONES 5331, 5337, 5391, 5396, 5728, 5733

GENETIC EFFECTS 5372, 5968

GERMANY 5506, 5557, 5700, 5703

GERMICIDE 5360

GUINEA PIGS 5483-5486

HAWAII 5303, 5308, 5324, 5437, 5450, 5769, 5772, 5778, 5777

HEALTH HAZARDS 5295, 5296, 5307, 5314, 5315, 5317, 5318, 5321, 5323, 5326, 5328-5330, 5333, 5343, 5346, 5349, 5361, 5363, 5368, 5409, 5419, 5429, 5435, 5447, 5448, 5491, 5492, 5498, 5499, 5504, 5508, 5509, 5511, 5561, 5563, 5567, 5569, 5591, 5615, 5618, 5619, 5623, 5635, 5656, 5657, 5662, 5668, 5673, 5678, 5676-5680, 5683, 5700, 5703, 5705, 5754-5756, 5765

HEART DISEASES 5567, 5850, 5851, 5874, 5901, 5964

HEMODIALYSIS 5989, 5997, 5998

HERBICIDES 5425, 5770, 5771

HEXACHLOROCYCLOHEXAN 5774

HONG KONG 5650-5653

HORMONES 5722, 5875, 5935, 5938,

KEYWORD INDEX

HORMONES 5981

HUNGARY 6004

HYPERTENSION 5900

HYPNOTICS 5805, 5806, 5813, 5815, 5819, 5834, 5840, 5864, 5867, 5882, 5884, 5911, 5917, 5918, 5966, 5983, 5984

ILLINOIS 5504

IN VITRO ANALYSIS 5783-5794

IN VIVO ANALYSIS 5574, 5783-5794

INDIA 5305-5307, 5309, 5407-5409, 5411, 5417-5419, 5422, 5427-5430, 5433-5435, 5438, 5445, 5446, 5448, 5451, 5499, 5650-5653, 5758, 5760

INDIANS 5623

INDUSTRIAL ACCIDENTS 5423, 5424, 5656, 5657

INDUSTRIAL AREAS 5285, 5286, 5288, 5487-5489, 5491, 5493, 5518, 5528-5533, 5537-5539, 5541, 5543, 5546-5548, 5551-5553, 5558-5560, 5585, 5685-5687, 5981

INDUSTRIAL ATMOSPHERES 5285, 5286, 5288, 5335, 5685-5687, 5697, 5707, 5710

INDUSTRIAL CHEMICALS 5301, 5302, 5310, 5313, 5319, 5361, 5363, 5415, 5420, 5510, 5569, 5585, 5619, 5635-5643, 5647, 5668, 5697, 5705, 5707, 5710, 5762, 5766, 5931, 5932

INDUSTRIAL DISEASES 5384, 5468, 5719, 5981

INDUSTRIAL EMISSIONS 5423, 5424, 5505, 5506, 5519, 5556, 5557, 5562, 5700, 5703

INDUSTRIAL HYGIENE 5480, 5523, 5635, 5705

INDUSTRIAL MEDICINE 5328-5330, 5333, 5343, 5349, 5361, 5363, 5510, 5585, 5619, 5668, 5697, 5705, 5981

INDUSTRIAL PLANTS 5285, 5286, 5288, 5326, 5327, 5346, 5347, 5487, 5509, 5563, 5578, 5591, 5618, 5673-5675, 5685-5687, 5705, 5754-5756

INDUSTRIAL POLLUTION 5362, 5501, 5526, 5540, 5545, 5623

INFANTS 5314, 5315, 5317, 5318, 5321, 5323, 5350, 5351, 5353, 5354, 5356, 5358, 5372, 5387, 5447, 5460, 5471, 5473-5478, 5480, 5482-5489, 5504, 5505, 5514, 5528-5533, 5537-5539, 5541, 5543, 5546-5548, 5551-5553, 5556, 5559, 5560, 5562, 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617, 5665, 5666, 5673, 5678, 5676-5680, 5717, 5874, 5980, 6001

INFECTION 5795, 5796, 5836-5839, 5872, 5873, 5980, 5995, 5996

INHALATION 5281, 5282, 5284, 5287, 5289-5292, 5297, 5362, 5364, 5366, 5368, 5501, 5504, 5506, 5507, 5515, 5526, 5540, 5545, 5557, 5569, 5585, 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617, 5620, 5635, 5656, 5657, 5696, 5697, 5754-5756, 5810, 5931, 5932

INSECTICIDES 5662, 5663, 5754-5756

IOWA 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617

IRAQ 5587, 5589, 5590, 5592, 5594, 5598, 5604, 5609, 5617, 5622

IRELAND 5390, 5308, 5388, 5395, 5431, 5442, 5761

ITALY 5491, 5492, 5506, 5557, 5561

JAMAICA 5715

JAPAN 5314-5318, 5321, 5331, 5336, 5337, 5340, 5342, 5345, 5348, 5391, 5396, 5586-5589, 5592-5595, 5598-5613, 5617, 5621, 5624-5632, 5650-5653, 5676-5680, 5728, 5733, 5741

KIDNEY DISEASES 5327, 5335, 5347, 5359, 5658, 5667, 5668, 5803, 5985, 5986, 5989, 5997, 5998

LACTATION 5303, 5308, 5323, 5324, 5377, 5437, 5450, 5460, 5471, 5473-5478, 5480, 5482-5486, 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617, 5769, 5772, 5774, 5777, 5799, 5800

LAVAGE 5297, 5810

LEAD POISONING 5453, 5498, 5503-5506, 5550, 5555-5557, 5562

LEBANON 5650-5653

LEVULINIC ACIDS 5492, 5519, 5523, 5561

LIVER DISEASES 5382, 5386, 5575, 5577, 5713, 5721, 5808, 5809, 5880, 5881, 5935, 5938, 5975

MARYLAND 5498, 5525, 5565

MASSACHUSETTS 5453, 5503, 5505, 5550, 5555, 5556, 5562, 5859, 5876, 5930, 5936

MEASUREMENT METHODS 5273, 5279, 5338, 5339, 5341, 5367, 5371, 5378, 5379, 5381, 5397-5399, 5405, 5412-5414, 5439, 5513, 5518, 5520, 5521, 5524, 5542, 5568, 5574, 5616, 5633, 5634, 5636-5643, 5648, 5655, 5701, 5702, 5712, 5736, 5781, 5782, 5804-5806, 5814-5816, 5819, 5830, 5831, 5834, 5836-5839, 5853, 5854, 5863, 5864, 5867, 5877, 5878, 5880, 5881, 5883, 5885-5887, 5892, 5898, 5901, 5907, 5908, 5915-5918, 5923, 5934, 5953-5957, 5963, 5967, 5973, 5977-5979, 5982-5984, 5989, 6000, 6003-6006, 6009-6011

MEATS 5423, 5424, 5461, 5615, 5683

MENSTRUATION 5460, 5471, 5473-5478, 5480, 5482-5486

MENTAL RETARDATION 5368, 5499, 5505, 5506, 5556, 5557, 5562, 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617

MERCURY INGESTION 5621, 5624-5632

MERCURY INORGANIC COMPOUNDS 5590, 5622

MERCURY ORGANIC COMPOUNDS 5586, 5588, 5590, 5593, 5595, 5599-5603, 5605-5608, 5610-5613, 5622

METABOLISM 5350, 5351, 5353, 5354, 5665, 5666, 5747, 5748, 5781, 5782, 5808, 5809, 5817, 5818, 5823-5829, 5835, 5848, 5865, 5866, 5902, 5945, 5968

METABOLITES 5447, 5483-5486, 5662, 5673, 5678, 5696, 5705, 5747, 5748, 5781, 5782, 5804, 5813, 5816, 5820, 5822-5829, 5835, 5840, 5848, 5860, 5880, 5881, 5884, 5886, 5887, 5902, 5905-5908, 5911, 5945, 5948, 5950, 5951, 5961, 5962, 5968, 5973, 5977-5979, 5987, 5988, 6000, 6001, 6003, 6011

METAL POISONING 5327, 5329, 5333, 5335, 5347, 5349, 5362, 5501, 5508, 5510-5512, 5518, 5525, 5526, 5540, 5545, 5565, 5566, 5587, 5589, 5590, 5592, 5598, 5598, 5604, 5609, 5617, 5620, 5622, 5623, 5656, 5657, 5700, 5703

METALLOPROTEINS 5327, 5347

METALS 5273-5279, 5283, 5299, 5326-5338, 5337-5339, 5381, 5383, 5384, 5386, 5387, 5389, 5361-5363, 5378-5377, 5379-5382, 5384-5388, 5391, 5393-5396, 5398, 5399, 5403, 5453, 5455, 5460-5469, 5471-5478, 5480-5482, 5490-5501, 5503-5506, 5508-5513, 5515, 5516, 5518-5526, 5534-5536, 5540, 5545, 5550, 5554-5558, 5561-5569, 5574, 5575, 5577, 5581, 5584, 5586-5596, 5598-5622, 5624-5632, 5648, 5649, 5654, 5655, 5659-5661, 5664, 5669-5672, 5683, 5684, 5688-5690, 5695, 5700, 5703, 5706, 5711-5714, 5716, 5719-5721, 5724, 5726-5728, 5730-5733, 5735-5740, 5742, 5744-5746, 5779, 5902, 5935, 5938

METHYL MERCURY COMPOUNDS 5621, 5624-5632

METHYL RADICALS 5586, 5588, 5593, 5595, 5599-5603, 5605-5608, 5610-5613

MICHIGAN 5323, 5447, 5673, 5674, 5681, 5693

MINING 5297, 5384, 5468, 5650-5653, 5719, 5810

MISSISSIPPI 5412-5414

MISSOURI 5570, 5573

MUSCLE RELAXANTS 5821, 5925, 5928, 5970

NARCOTICS 5365, 5811, 5812, 5883, 5985, 5975-5977, 5979

NEOPLASMS 5298, 5378, 5669, 5880, 5881, 5902, 5903

NERVOUS SYSTEM DISEASES 5362, 5501, 5526, 5540, 5545, 5817, 5818, 5865, 5866

NETHERLANDS 5490, 5523, 5705, 5764, 5767, 5915

NEUROLOGIC MANIFESTATIONS 5447, 5505, 5517, 5556, 5562, 5673,

KEYWORD INDEX

NEUROLOGIC MANIFESTATIONS 5674, 5879, 5972, 6002

NEW HAMPSHIRE 5278, 5299, 5403, 5455, 5568, 5690, 5695, 5706, 5746

NEW JERSEY 5520, 5675, 5780

NEW MEXICO 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617

NEW YORK 5327, 5347, 5365, 5512, 5521, 5566, 5675, 5811, 5812, 5928, 5975

NEW ZEALAND 5615, 5682, 5683

NEWBORN 5305, 5306, 5309, 5384, 5388, 5372, 5387, 5407, 5408, 5411, 5417, 5418, 5422, 5427, 5428, 5430, 5433, 5434, 5438, 5445, 5446, 5451, 5481, 5487-5489, 5500, 5502, 5506, 5514, 5528-5533, 5537-5539, 5541, 5543, 5546-5549, 5551-5558, 5557, 5559, 5560, 5584, 5654, 5744, 5758, 5760, 5817, 5818, 5821, 5833, 5862, 5865, 5866, 5892, 5912, 5969, 5980

NITROSAMINES 5423, 5424

NORTH CAROLINA 5320, 5511

NUTRITIONAL DEFICIENCIES 5350, 5351, 5353, 5354, 5356, 5358, 5517, 5570, 5573, 5665, 5666, 5715, 5717, 5875, 5980

NUTRITIONAL DISORDERS 5350, 5351, 5353, 5354, 5665, 5666, 5717

OCCUPATIONAL DISEASES 5285, 5286, 5288, 5297, 5327, 5347, 5384, 5468, 5685-5687, 5719, 5754-5756, 5810

OCCUPATIONAL HAZARDS 5294-5296, 5307, 5326, 5328-5330, 5333, 5336, 5340, 5342, 5343, 5345, 5346, 5348, 5349, 5361-5363, 5366, 5368, 5378, 5409, 5419, 5429, 5435, 5440, 5448, 5492, 5501, 5504, 5507, 5509, 5510, 5523, 5526, 5540, 5545, 5561, 5563, 5574, 5585, 5591, 5618, 5616, 5618, 5619, 5635, 5655-5657, 5662, 5664, 5697, 5705, 5707, 5710, 5741, 5754-5756, 5765, 5981

OHIO 5812-5814

OKLAHOMA 5937

ORAL CONTRACEPTIVES 5483-5486

ORAL DISEASES 5483-5486

ORGANOPHOSPHATES 5361, 5363, 5406, 5416, 5426, 5432, 5681, 5683, 5619, 5662-5664, 5757, 5763, 5775, 5778

OSTEOSARCOMAS 5373, 5383, 5389, 5390, 5401, 5404, 5576, 5578, 5579, 5582, 5723, 5725, 5734

PAINTS 5362, 5501, 5504-5506, 5526, 5540, 5545, 5556, 5557, 5562

PARATHYROID DYSFUNCTION 5352

PARTICULATES 5574

PENNSYLVANIA 5656, 5657, 5833

PERICARDIAL FLUID 5823-5829

PESTICIDE RESIDUES 5300-5310, 5312, 5319, 5324, 5406-5409, 5411, 5415-5420, 5422-5424, 5426-5435, 5437, 5438, 5441-5448, 5450, 5451, 5662, 5673, 5674, 5757, 5758, 5760-5769, 5772-5778

PESTICIDES 5301-5303, 5306, 5308, 5310, 5319, 5324, 5406, 5408, 5415, 5416, 5418, 5420, 5426, 5428, 5432, 5434, 5437, 5441, 5443, 5446, 5450, 5757, 5762-5767, 5769, 5772-5775, 5777, 5778

PHILIPPINES 5650-5653

PHTHALIC ACIDS 5667, 5668

PICA 5496, 5535

PIGS 5460, 5471, 5473-5478, 5480, 5482

POLYBROMINATED BIPHENYLS 5447, 5673-5675

POLYCHLORINATED BIPHENYLS 5301-5303, 5308, 5310-5324, 5410, 5415, 5420, 5421, 5436, 5437, 5448, 5449, 5450, 5676-5680, 5759, 5762, 5766, 5769, 5772, 5774, 5777

POLYCHLORINATED QUATERPHENYLS 5314, 5315, 5317, 5318, 5321, 5676-5680

POPULATION EXPOSURE 5283, 5301-5303, 5306, 5308, 5310, 5313, 5319, 5322, 5324, 5326, 5332, 5334, 5346, 5406, 5408, 5410, 5415, 5416, 5418, 5420, 5421, 5423, 5424, 5426, 5428, 5432, 5434, 5436, 5437, 5441, 5443, 5446, 5447, 5449, 5450, 5487-5490, 5493, 5496, 5497, 5504, 5508, 5509, 5514, 5515, 5519, 5520, 5522, 5528-5539, 5541, 5543, 5546-5548, 5551-5553, 5558-5560, 5563, 5564, 5590, 5591, 5596, 5618, 5622, 5648, 5656, 5657, 5659-5662, 5670-5674, 5684, 5700, 5703, 5757, 5759, 5762-5764, 5766, 5767, 5769, 5772, 5774-5778

PORPHYRINS 5491, 5523

PREGNANCY 5350, 5351, 5353, 5354, 5364, 5375, 5388, 5395, 5460, 5471, 5473-5478, 5480, 5482-5486, 5500, 5502, 5506, 5549, 5557, 5570, 5573, 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617, 5665, 5666, 5718, 5783-5794, 5821, 5862, 5912, 5939, 5941, 5969

PREMATURE INFANTS 5717

PROGESTOGENS 5807

PROTEINS 5384, 5468, 5719, 5722

PROTOPORPHYRINS 5491, 5492, 5508, 5519, 5520, 5521

PSYCHOTROPIC DRUGS 5802, 5853, 5854, 5885, 5889, 5921-5923, 5982, 5984, 5985, 5972, 6002, 6007, 6008

RABBITS 5848

RACIAL STUDIES 5313, 5336, 5340, 5342, 5345, 5348, 5741, 5838

RADIOISOTOPES 5458-5460, 5471, 5473-5478, 5480, 5482-5486

RATS 5336, 5340, 5342, 5345, 5348, 5364, 5373, 5383, 5389, 5390, 5401, 5404, 5460, 5471, 5473-5478, 5480, 5482, 5576, 5578, 5579, 5582, 5656, 5657, 5723, 5725, 5734, 5741, 5747, 5748, 5848

REVIEW 5323, 5361-5363, 5460, 5471, 5473-5478, 5480, 5482-5486, 5497, 5498, 5501, 5504-5506, 5508, 5526, 5540, 5545, 5556, 5557, 5562, 5574, 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617, 5619, 5650-5653, 5664, 5711, 5724, 5726, 5727, 5731, 5732, 5735, 5737-5740, 5745, 5764, 5767, 5862, 5912, 5969

REYE'S SYNDROME 5412-5414

RHEUMATOID ARTHRITIS 5868, 5869

ROMANIA 5384, 5468, 5719

RURAL AREAS 5281, 5282, 5284, 5287, 5289-5292, 5306, 5322, 5408, 5410, 5418, 5421, 5428, 5434, 5436, 5446, 5449, 5491, 5496, 5500, 5502, 5504-5506, 5515, 5519, 5522, 5535, 5536, 5549, 5556-5558, 5562, 5564, 5659-5661, 5670-5672, 5759

SARCOMAS 5285, 5286, 5288, 5336, 5340, 5342, 5345, 5348, 5373, 5383, 5389, 5390, 5401, 5404, 5576, 5578, 5579, 5582, 5669, 5685-5687, 5723, 5725, 5734, 5741, 5808, 5809, 5902

SCOTLAND 5494

SEDATIVES 5805, 5806, 5815, 5819, 5834, 5864, 5867, 5917, 5918, 5970, 5977, 5979, 5983, 5984

SEWAGE 5300, 5304, 5431, 5442, 5761

SEX 5298, 5311, 5313, 5325, 5331, 5337, 5355, 5357, 5369, 5370, 5391, 5392, 5396, 5400, 5456, 5457, 5483-5486, 5519, 5567, 5571, 5572, 5580, 5583, 5597, 5648, 5691, 5692, 5694, 5698, 5708, 5709, 5728, 5729, 5733, 5749, 5751, 5972, 6002

SKIN DISEASES 5447, 5483-5486, 5673, 5674

SHELTERS 5285, 5286, 5288, 5326, 5327, 5346, 5347, 5490, 5491, 5493, 5509, 5519, 5563, 5591, 5618, 5685-5687

SMOKING 5322, 5326, 5334, 5346, 5361, 5364, 5366, 5368, 5388, 5395, 5410, 5421, 5423, 5424, 5436, 5449, 5483-5486, 5501, 5509, 5526, 5540, 5545, 5563, 5591, 5618, 5759, 5900, 5972, 6002

SOILS 5281, 5282, 5284, 5287, 5289-5292, 5334, 5490, 5496, 5515, 5522, 5527, 5535, 5536, 5564, 5615, 5659-5661, 5670-5672, 5683

SOUTH CAROLINA 5278, 5299, 5403, 5455, 5498, 5568, 5690, 5695, 5706, 5746, 5765

SPAIN 5406, 5416, 5426, 5432,

KEYWORD INDEX

SPAIN 5441, 5443, 5757, 5763, 5775, 5778

STIPENDS 5696, 5697

SUICIDE 5365, 5405, 5425, 5663, 5699, 5704, 5797, 5811, 5812, 5816, 5849, 5855, 5973, 5978, 6000, 6003, 6011

SURFACTANTS 5747, 5748

SURGERY 5295, 5296, 5667, 5668, 5836-5839, 5949, 5995, 5956

SWEAT 5402, 5479, 5783

SWEDEN 5285, 5286, 5288, 5336, 5340, 5342, 5345, 5348, 5440, 5506, 5557, 5587, 5589, 5592, 5598, 5598, 5604, 5609, 5617, 5685-5687, 5741, 5836-5839, 5952, 5574

SWEETENING AGENTS 5749-5753, 5841, 5842

SWITZERLAND 5364, 5650-5653

SYNOVIAL FLUID 5868, 5869

TAIWAN 5650-5653

TENNESSEE 5587, 5589, 5592, 5594, 5598, 5604, 5609, 5617

TEXAS 5498, 5980

THEOPHYLLINES 5925-5928

THIALAND 5650-5653

THIOETHERS 5705

THINUS 5487, 5488, 5518, 5528-5533, 5537-5539, 5541, 5543, 5546-5548, 5551-5553, 5559, 5560

TOBACCOS 5423, 5424, 5888

TRACE ELEMENTS 5462-5465, 5467, 5470, 5717

TRANQUILIZERS 5365, 5811, 5812, 5898, 5899, 5904, 5943, 5952, 5970-5972, 5974, 6002, 6004

TURKEY 5375

UNITED KINGDOM 5276, 5300, 5304, 5344, 5352, 5356, 5358, 5376, 5380, 5394, 5431, 5442, 5472, 5481, 5487-5489, 5496, 5500, 5506, 5507, 5518, 5516, 5527-5533, 5535, 5537-5539, 5541, 5543, 5546-5548, 5551-5554, 5557, 5559, 5560, 5581, 5584, 5649, 5654, 5688, 5689, 5744, 5761, 5764, 5767, 5779, 5853, 5854, 5923, 5958

UNITED STATES 5313, 5320, 5327, 5336, 5340, 5342, 5345, 5347, 5348, 5387, 5498, 5741, 5764, 5767, 5768, 5773, 5776

URBAN AREAS 5281, 5282, 5284, 5287, 5289-5292, 5295, 5296, 5300, 5304, 5306, 5322, 5364, 5408, 5410, 5418, 5421, 5428, 5431, 5434, 5436, 5442, 5446, 5449, 5494, 5500, 5508-5506, 5516, 5518-5520, 5522, 5536, 5556-5558, 5562, 5568, 5659-5661, 5670-5672, 5675, 5759, 5761, 5779

VEGETABLES 5334, 5362, 5501, 5506, 5515, 5526, 5540, 5545, 5557, 5615, 5683, 5700, 5703

VEGETATION 5362, 5501, 5526, 5540, 5545, 5615, 5683

VENEZUELA 5463, 5466

VERMONT 5278, 5299, 5403, 5455, 5568, 5690, 5695, 5706, 5746

VIRGINIA 5754-5756

VITAMINS 5483, 5486, 5859, 5876, 5929, 5930, 5935, 5936, 5938

WATER POLLUTION 5300, 5304, 5423, 5424, 5431, 5442, 5623, 5761, 5768, 5767

WHEAT 5590, 5622, 5682

WISCONSIN 5447, 5458, 5459, 5673, 5674

DIRECTORY OF CHEMICALS (Vol. IV)

1. CAS Preferred Names, page 433
2. Formulas, page 439

DIRECTORY - CAS PREFERRED NAMES

(-)-2-Hydroxy-N-cyclopropylmethylmorphinan (No postings in CHEMLINE). 5780

(3,4'-Bipyridin)-6(1H)-one, 5-amino- 5781

Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)- , D-threo-(+)- (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*, R*))- (9 CI) 5783

Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitropheryl)ethyl)-,(R-(R*,R*))- (9 CI) 5795

Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI) 5797

Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI) 5798

Adriamycin (8 CI); 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9 CI) 5802

Aluminum 5272

Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI) 5803

Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI) 5805

Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI) 5807

Arsenic 5281

Asbestos 5294

Attapulgite (VAN) 5297, 5810

Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI) 5811

Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)- (9 CI) 5812

Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI) 5813

Barium 5298

Benzene, hexachloro- 5300

Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI) 5820

Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI) 5821

Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI) 5822

BHC, Total (No postings in CHEMLINE). 5304

Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI) 5823

Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI) 5830

Biphenyl, chloro (8 CI); 1,1'-Biphenyl, chloro derivs (9 CI) 5310

Bismuth 5832

Bromide 5833

Bromine 5325

Cadmium 5326

Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI) 5834

Calcium 5350

Carbanilide, trichloro- (8 CI); Urea, N,N'-diphenyl-, trichloro deriv. (9 CI) 5360

Carbon disulfide 5361

Carbon monoxide 5362

Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI) 5367

Carbonylhemoglobin 5368

Cefotaxime (No postings in CHEMLINE). 5836

Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI) 5840

DIRECTORY - CAS PREFERRED NAMES

Chlorine 5369

Chloroform (8 CI); Methane, trichloro- (9 CI) 5371

Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI) 5372

Chromium 5374

Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI) 5378

Cobalt 5379

Copper 5381

Cyanide 5405

Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI) 5406

Cyclohexylamine (8 CI); Cyclohexanamine (9 CI) 5841

Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6aalpha,9aalpha-tetrahydro-4-methoxy- (8 CI); Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-4-methoxy-, (6aR-cis)- (9 CI) 5412

DDT, Total (No postings in CHEMLINE). 5415

Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)- 5843

Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl- 5848

Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI) 5423

Digitoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI) 5849

Digoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI) 5850

Dimethylamine, N-nitroso- (8 CI); Methanamine, N-methyl-N-nitroso- (9 CI) 5424

Dipyrido(1,2-a:2',1'-c)pyrazinediium, 6,7-dihydro- 5425

Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI) 5853

Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI) 5426

Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI) 5431

Ethane, 1,2-dichloro- 5439

Ethyl alcohol (8 CI); Ethanol (9 CI) 5855

Ethylamine, 1-methyl-2-(2,6-xylyloxy)- (8 CI); 2-Propanamine, 1-(2,6-dimethylphenoxy)- (9 CI) 5856

Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride 5858

Ethylene glycol, dinitrate (8 CI); 1,2-Ethanediol, dinitrate (9 CI) 5440

Ethylene, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8 CI); Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)- (9 CI) 5441

Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro- (9 CI) 5442

Fluoride 5452

Fluorine 5455

Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI) 5859

Gold 5456

Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)- 5860

Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI) 5861

Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI) 5862

Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI) 5868

Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro- 5870

DIRECTORY - CAS PREFERRED NAMES

Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethano., 2-methyl-5-nitro- (9 CI) 5872

Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI) 5874

Insulin 5875

Iodine 5457

Iron 5460, 5876

Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI) 5877

L-Ascorbic acid 5483

Lead 5487

Lithium 5567, 5878

m-Xylene (8 CI); Benzene, 1,3-dimethyl- (9 CI) 5569

Magnesium 5570

Magnetite (8 CI); Magnetite [Fe3O4] (9 CI) 5574

Manganese 5575, 5879

Melamine, pentamethyl- (8 CI); 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N''-pentamethyl- (9 CI) 5880

Mercury 5586

Mercury(1+), methyl-, ion (8 CI); Mercury(1+), methyl- (9 CI) 5621

Methane, dibromochloro- 5633

Methane, dibromodichloro- 5634

Methane, dichloro- 5635

Methane, dichlorofluoro- 5636

Methane, trichlorofluoro- 5640

Methanol 5644

Morphanthridine, 6-(4-methyl-1-piperazinyl)- (8 CI); 11H-Dibenz(b,e)azepine, 6-(4-methyl-1-piperazinyl)- (9 CI) 5882

Morphinan-3-ol, 17-methyl- 5883

Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9 CI) 5884

Morpholine, 2-((2-ethoxyphenoxy)methyl)- 5885

Morpholine, 4-(thioxo(3,4,5-trimethoxyphenyl)methyl)- 5886

Nickel 5648

Nickel carbonyl [Ni(CO)4] (8 CI); Nickel carbonyl [Ni(CO)4], (T-4)- (9 CI) 5656

Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI) 5888

o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI) 5889

Oxalic acid (8 CI); Ethanedioic acid (9 CI) 5658

Palladium 5659

Phenol, 2,2'-methylenebis(3,4,6-trichloro- 5890

Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI) 5898

Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI) 5662

Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI) 5663

Phosphorus 5665

Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI) 5667

Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI) 5668

DIRECTORY - CAS PREFERRED NAMES

Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8 CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9 CI) 5900

Piperidine, 2-(2,2-dicyclohexylethyl)- 5901

Platinum 5669

Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI) 5902

Polybrominated biphenyls (No postings in CHEMLINE). 5763

Polychlorinated quaterphenyls (No postings in CHEMLINE). 5676

Potassium 5681

Pregna-1,4-diene-7,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI) 5903

Prolactin (VAN) 5904

Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI) 5906

Pseudoephedrine, (+)- (8 CI); Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))- (9 CI) 5907

Pyrimidine, 2,4-diamino-5-(3,4,5,-trimethoxybenzyl)- (8 CI); 2,4-Pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- (9 CI) 5909

Salicylic acid, ion(1-) (8 CI); Benzoic acid, 2-hydroxy-, ion(1-) (9 CI) (VAN) 5911

Selenium 5682

Silicon 5688

Silver 5689

Sisomicin (8 CI); D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamin o-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy- (9 CI) 5915

Sodium 5691

Strontium 5694

Styrene (8 CI); Benzene, ethenyl- (9 CI) 5696

Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI) 5916

Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI) 5919

Sulfur 5698

Tetrahydrocannabinol cross-reacting cannabinoids (No postings in CHEMLINE). 5921

Thallium 5699

Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI) 5924

Thioether (No postings in CHEMLINE). 5705

Tin 5706

Tocopherol 5929

Toluene (8 CI); Benzene, methyl- (9 CI) 5931

Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI) 5933

Vanadium 5707

Vitamin A 5935

Vitamin B12 5936

Zinc 5711, 5937

Zirconium 5746

1-Hexadecanol, hydrogen sulfate 5747

1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl-, (Z)- 5942

1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI) 5943

1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI) 5945

1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI) 5749

DIRECTORY - CAS PREFERRED NAMES

1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro- 5754

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI); 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI) 5757

1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI) 5761

1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, cis-(+)- 5946

1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, (1R-(exo,exo))- (9 CI) 5947

1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI) 5948

1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1) 5952

1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl- 5953

10H-Phenothiazine-2-sulfonamide, 10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-N,N-dimethyl- 5954

2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol, alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI) 5955

2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI) 5958

2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-, (Z)- 5961

2,4-Oxazolidinedione, 5,5-dimethyl- 5963

2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI) 5964

2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI); 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI) 5965

2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl- 5966

2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro- (8 CI); 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- (9 CI) 5967

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- 5969

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl- 5974

3-Heptanone, 6-(dimethylamino)-4,4-diphenyl- 5975

4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI) 5977

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))- 5980

4,4'-Bipyridinium, 1,1'-dimethyl- 5770

4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI) 5981

4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl- 5982

4,7-Methano-1H-indene, 1,2,3,4,5,6,7,8,8-nonachloro-2,3,3a,4,7,7a-hexahydro-, (1alpha,2beta,3alpha,3aalpha,4beta,7beta,7aalpha)- 5772

4,7-Methanoindan, 1,2,4,5,6,7,8,8-octachloro-1,2-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 1a,2,3,4,5,6a,7,7-octachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI) 5773

4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI) 5775

4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI) 5778

4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI); 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI) 5985

5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro- 5987

5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo- 5989

DIRECTORY - CAS PREFERRED NAMES

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, (6R-cis)- 5991

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))- 5995

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI) 5997

5H-Dibenz(b,f)azepine-5-carboxamide 5999

5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8 CI); 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- (9 CI) 6000

5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI) 6001

5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl- 6004

6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-(8 CI); 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- (9 CI) 6005

6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)- 6007

8-Quinolinol, 5-nitro 6009

9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl- (8 CI); 9,10-Ethanoanthracene-9(10H)-propanamine, N-methyl- (9 CI) 6011

9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI) 5779

DIRECTORY - FORMULAS

(-)-2-Hydroxy-N-cyclopropylmethylmorphinan (No postings in CHEMLINE). 5780

Cefotaxime (No postings in CHEMLINE). 5836

Polybrominated biphenyls (No postings in CHEMLINE). 5673

Polychlorinated quaterphenyls (No postings in CHEMLINE). 5676

Tetrahydrocannabinol cross-reacting cannabinoids (No postings in CHEMLINE). 5921

Thioether (No postings in CHEMLINE).

Ag
Silver 5689

Al
Aluminum 5272

As
Arsenic 5281

Au
Gold 5456

Ba
Barium 5298

Bi
Bismuth 5832

Br
Bromide 5833

Bromine 5325

C-Br2-Cl2
Methane, dibromodichloro- 5634

C-Cl3-F
Methane, trichlorofluoro- 5640

C-Cl4
Carbon tetrachloride (8 CI); Methane, tetrachloro- (9 CI) 5367

C-H-Br2-Cl
Methane, dibromochloro- 5633

C-H-Cl2-F
Methane, dichlorofluoro- 5636

C-H-Cl3
Chloroform (8 CI); Methane, trichloro- (9 CI) 5371

C-H2-Cl2
Methane, dichloro- 5635

C-H3-Hg
Mercury(1+), methyl-, ion (8 CI); Mercury(1+), methyl- (9 CI) 5621

C-H4-O
Methanol 5644

C-N
Cyanide 5405

C-O
Carbon monoxide 5362

C-S2
Carbon disulfide 5361

Ca
Calcium 5350

Cd
Cadmium 5326

Cl
Chlorine 5369

Cl2-H6-N2-Pt
Platinum, diamminedichloro-, cis- (8 CI); Platinum, diamminedichloro-, (SP-4-2)- (9 CI) 5902

Co
Cobalt 5379

Cr
Chromium 5373

DIRECTORY - FORMULAS

Cu
Copper 5781

C10-Cl10-O
1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro- 5754

C10-H11-Cl-O3
Propionic acid, 2-(p-chlorophenoxy)-2-methyl- (8 CI); Propanoic acid, 2-(4-chlorophenoxy)-2-methyl- (9 CI) 5905

C10-H12-N3-O3-P-S2
Phosphorodithioic acid, O,O-dimethyl ester, S-ester with 3-(mercaptomethyl)-1,2,3-benzotriazin-4(3H)-one (8 CI); Phosphorodithioic acid, O,O-dimethyl S-((4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl) ester (9 CI) 5662

C10-H14-N-O5-P-S
Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl) ester (8 CI); Phosphorothioic acid, O,O-diethyl O-(4-nitrophenyl) ester (9 CI) 5663

C10-H14-N2
Nicotine (8 CI); Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (9 CI) 5888

C10-H15-N-O
Pseudoephedrine, (+)- (8 CI); Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))- (9 CI) 5907

C10-H16-N6-S
Cimetidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)- 5860

C10-H4-Cl8-O
4,7-Methanoindan, 1,2,4,5,6,7,8,8-octachloro-1,2-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 1a,2,3,4,5,6a,7,7-octachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI) 5773

C10-H5-Cl7
4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (8 CI); 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro- (9 CI) 5778

C10-H5-Cl7-O
4,7-Methanoindan, 1,4,5,6,7,8,8-heptachloro-2,3-epoxy-3a,4,7,7a-tetrahydro- (8 CI); 2,5-Methano-2H-indeno(1,2-b)oxirene, 2,3,4,5,6,7,7-heptachloro-1a,1b,5,5a,6,6a-hexahydro- (9 CI) 5775

C10-H5-Cl9
4,7-Methano-1H-indene, 1,2,3,4,5,6,7,8,8-nonachloro-2,3,3a,4,7,7a-hexahydro-, (1alpha,2beta,3alpha,3aalpha,4beta,7beta,7aalpha)- 5772

C10-H7-Cl2-N3-O
Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro- 5870

C10-H9-N3-O
(3,4'-Bipyridin)-6(1H)-one, 5-amino- 5781

C11-H12-Cl2-N2-O5
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, D-threo-(-)-, (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-,(R-(R*,R*))- (9 CI) 5795

C11-H12-N2-O
Antipyrine (8 CI); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI) 5805

C11-H12-N4-O3-S
Sulfanilamide, N(1)-(3-methoxypyrazinyl)- (8 CI); Benzenesulfonamide, 4-amino-N-(3-methoxypyrazinyl)- (9 CI) 5919

C11-H17-N-O
Ethylamine, 1-methyl-2-(2,6-xylyloxy)- (8 CI); 2-Propanamine, 1-(2,6-dimethylphenoxy)- (9 CI) 5856

C11-H18-N2-O3
Barbituric acid, 5-ethyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)- (9 CI) 5812

C12-H11-Cl-N2-O5-S
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl- (8 CI); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- (9 CI) 5805

C12-H12-N2
Dipyrido(1,2-a:2',1'-c)pyrazinediium, 6,7-dihydro- 5425

C12-H12-N2-O3
Barbituric acid, 5-ethyl-5-phenyl- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9 CI) 5813

C12-H14-N2
4,4'-Bipyridinium, 1,1'-dimethyl- 5770

C12-H14-N2-O2
4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl- 5532

C12-H15-Cl2-N-O5-S
Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-(methylsulfonyl)phenethyl)- , D-threo-(+)- (8 CI); Acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,R*))- (9 CI) 5785

DIRECTORY - FORMULAS

C12-H18-N2-03
Barbituric acid, 5-allyl-5-(1-methylbutyl)- (8 CI); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)- (9 CI) 5811

C12-H19-N-03
Benzyl alcohol, alpha-((tert-butylamino)methyl-3,5-dihydroxy- (8 CI); 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9 CI) 5821

C12-H8-C16
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo,exo- (8 CI); 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- (9 CI) 5757

C12-H8-C16-0
1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-, endo,exo- (8 CI); 2,7:3,6-Dimethanonaphth(2,3-b)oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta,7aalpha)- (9 CI) 5761

C13-H17-N3-0
Antipyrine, 4-(dimethylamino)- (8 CI); 3H-Pyrazol-3-one, 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl- (9 CI) 5807

C13-H18-02
Hydratropic acid, p-isobutyl- (8 CI); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)- (9 CI) 5868

C13-H19-N-03
Morpholine, 2-((2-ethoxyphenoxy)methyl)- 5885

C13-H19-N-04-S
Benzoic acid, p-(dipropylsulfamoyl)- (8 CI); Benzoic acid, 4-((dipropylamino)sulfonyl)- (9 CI) 5820

C13-H6-C16-02
Phenol, 2,2'-methylenebis(3,4,6-trichloro- 5890

C13-H9-C13-N2-0
Carbanilide, trichloro- (8 CI); Urea, N,N'-diphenyl-, trichloro deriv. (9 CI) 5360

C14-H10-C14
Ethane, 1,1-dichloro-2,2-bis(p-chlorphenyl)- (8 CI); Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-chloro- (9 CI) 5426

C14-H18-N4-03
Pyrimidine, 2,4-diamino-5-(3,4,5,-trimethoxybenzyl)- (8 CI); 2,4-Pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- (9 CI) 5909

C14-H19-N-04-S
Morpholine, 4-(thioxo(3,4,5-trimethoxyphenyl)methyl)- 5886

C14-H22-N2-0
2',6'-Acetoxylidide, 2-(diethylamino)- (8 CI); Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9 CI) 5964

C14-H22-N2-03
Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)- (8 CI); Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)- (9 CI) 5797

C14-H24-N2-07
4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)- (8 CI); 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- (9 CI) 5985

C14-H8-C14
Ethylene, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8 CI); Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)- (9 CI) 5441

Ethylene, 1,1-dichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(dichloroethenylidene)bis(4-chloro- (9 CI) 5442

C14-H9-C15
DDT, Total (No postings in CHEMLINE). 5415

Ethane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)- (8 CI); Benzene, 1,1'-(2,2,2-trichloroethylidene)bis(4-chloro- (9 CI) 5431

C15-H10-C1-N3-03
2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro- (8 CI); 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- (9 CI) 5967

C15-H11-C1-N2-0
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl- 5969

C15-H11-N3-03
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl- 5966

C15-H12-N2-0
5H-Dibenz(b,f)azepine-5-carboxamide 5999

C15-H12-N2-02
Hydantoin, 5,5-diphenyl- (8 CI); 2,4-Imidazolidinedione, 5,5-diphenyl- (9 CI) 5862

DIRECTORY - FORMULAS

C15-H14-Cl-N3-04-S
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))- 5995

C15-H16-N2-06-S2
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))- 5980

C15-H21-N-02
1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)- (8 CI); 1-Propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)- (9 CI) 5945

C15-H23-N3-04-S
o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl- (8 CI); Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy- (9 CI) 5889

C16-H11-Cl-N2-03.H-K-O.K
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1) 5952

C16-H13-Cl-N2-O
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- 5974

C16-H13-Cl-N2-02
1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl- 5953

C16-H14-N2-O
4(3H)-Quinazolinone, 2-methyl-3-o-tolyl- (8 CI); 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)- (9 CI) 5977

C16-H16-Cl-N3-03-S
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-(8 CI); 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- (9 CI) 6005

C16-H17-Br-N2
2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-, (Z)- 5961

C16-H17-N3-04-S
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-methyl-8-oxo-, D- (8 CI); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- (9 CI) 5997

C16-H17-N3-07-S2
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, (6R-cis)- 5991

C16-H19-N-04
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, (1R-(exo,exo))- (9 CI) 5947

C16-H21-N-02
2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (8 CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9 CI) 5958

C16-H22-04
Phthalic acid, dibutyl ester (8 CI); 1,2-Benzenedicarboxylic acid, dibutyl ester (9 CI) 5668

C16-H34-04-S
1-Hexadecanol, hydrogen sulfate 5747

C17-H12-Br2-03
Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl (8 CI); Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)- (9 CI) 5877

C17-H12-06
Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6aalpha,9aalpha-tetrahydro-4-methoxy- (8 CI); Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-4-methoxy-, (6aR-cis)- (9 CI) 5412

C17-H21-N-O.Cl-H
Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8 CI); Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride 5858

C17-H21-N-04
1alphaH,5alphaH-Tropane-2beta-carboxylic acid, 3beta-hydroxy-, methyl ester, benzoate (ester) (8 CI); 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- (9 CI) 5948

C17-H23-N-O
Morphinan-3-ol, 17-methyl- 5883

C18-H18-Cl-N3-O
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)- 5843

C18-H20-N2
Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl- 5848

C18-H20-02
4,4'-Stilbenediol, alpha,alpha'-diethyl-, (E)- (8 CI); Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)- (9 CI) 5981

DIRECTORY - FORMULAS

C18-H21-N-O3
Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8 CI); Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9 CI) 5864

C19-H16-Cl-N-O4
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8 CI); 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9 CI) 5874

C19-H19-N7-O6
Folic acid (8 CI); L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- (9 CI) 5859

C19-H21-N3
Morphanthridine, 6-(4-methyl-1-piperazinyl)- (8 CI); 11H-Dibenz(b,e)azepine, 6-(4-methyl-1-piperazinyl)- (9 CI) 5882

C19-H21-N5-O4
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8 CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9 CI) 5900

C19-H23-Cl-N2
5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8 CI); 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- (9 CI) 6000

C19-H35-N
Piperidine, 2-(2,2-dicyclohexylethyl)- 5901

C19-H37-N5-O7
Sisomicin (8 CI); D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy- (9 CI) 5915

C2-H2-O4
Oxalic acid (8 CI); Ethanedioic acid (9 CI) 5658

C2-H3-Cl3-O2
Chloral hydrate (8 CI); 1,1-Ethanediol, 2,2,2-trichloro- (9 CI) 5840

C2-H4-Cl2
Ethane, 1,2-dichloro- 5439

C2-H4-N2-O6
Ethylene glycol, dinitrate (8 CI); 1,2-Ethanediol, dinitrate (9 CI) 5440

C2-H6-N2-O
Dimethylamine, N-nitroso- (8 CI); Methanamine, N-methyl-N-nitroso- (9 CI) 5424

C2-H6-O
Ethyl alcohol (8 CI); Ethanol (9 CI) 5855

C20-H20-N6-O9-S
5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo- 5989

C20-H21-F-N2-O
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro- 5987

C20-H23-N
5H-Dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-N,N-dimethyl- (8 CI); 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9 CI) 6001

9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl- (8 CI); 9,10-Ethanoanthracene-9(10H)-propanamine, N-methyl- (9 CI) 6011

C20-H25-N3-O
Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8 CI); Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)- (9 CI) 5853

C21-H24-F3-N3-S
Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- (8 CI); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-(9 CI) 5898

C21-H27-N-O
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl- 5975

C21-H28-O5
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8 CI); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- (9 CI) 5905

C21-H30-O2
6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)- 6007

C22-H26-F3-N3-O-S
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- (8 CI); 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- (9 CI) 5943

C22-H26-N2-O4
5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl- 6004

DIRECTORY - FORMULAS

C22-H26-N2-O4-S
1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, cis-(+)- 5946

C22-H29-N-O2
2-Butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), (2S,3R)- (8 CI); Benzeneethanol, alpha-(2-(dimethylamino)-1-methylethyl)-alpha-phenyl-, propanoate (ester), (S-(R*,S*))- (9 CI) 5955

C23-H25-F3-N2-O-S
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl-, (Z)- 5942

C24-H33-N3-O3-S2
10H-Phenothiazine-2-sulfonamide, 10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-N,N-dimethyl- 5954

C24-H38-O4
Phthalic acid, bis(2-ethylhexyl) ester (8 CI); 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester (9 CI) 5667

C27-H29-N-O11; C27-H29-N-O11
Adriamycin (8 CI); 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9 CI) 5802

C27-H44-O2
9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol (8 CI); 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- (9 CI) 5779

C27-H46-O
Cholesterol (8 CI); Cholest-5-en-3-ol (3beta)- (9 CI) 5372

C4-H10-N2-O
Diethylamine, N-nitroso- (8 CI); Ethanamine, N-ethyl-N-nitroso- (9 CI) 5423

C4-H11-N5
Biguanide, 1,1-dimethyl- (8 CI); Imidodicarbonimidic diamide, N-N-dimethyl- (9 CI) 5830

C4-Ni-O4
Nickel carbonyl [Ni(CO)4] (8 CI); Nickel carbonyl [Ni(CO)4], (T-4)- (9 CI) 5656

C41-H64-O13
Digitoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9 CI) 5849

C41-H64-O14
Digoxin (8 CI); Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9 CI) 5850

C5-H7-N-O3
2,4-Oxazolidinedione, 5,5-dimethyl- 5963

C6-Cl6
Benzene, hexachloro- 5300

C6-H12-N4
Hexamethylenetetramine (8 CI); 1,3,5,7-Tetraazatricyclo(3.3.1(3,7))decane (9 CI) 5851

C6-H13-N
Cyclohexylamine (8 CI); Cyclohexanamine (9 CI) 5841

C6-H15-N5
Biguanide, 1-butyl- (8 CI); Imidodicarbonimidic diamine, N-butyl- (9 CI) 5823

C6-H6-Cl6
BHC, Total (No postings in CHEMLINE). 5304

Cyclohexane, 1,2,3,4,5,6-hexachloro-, gamma- (8 CI); Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1alpha,2alpha,3beta,4alpha,5alpha,6beta)- (9 CI) 5406

C6-H8-O6
L-Ascorbic acid 5483

C6-H9-N3-O3
Imidazole-1-ethanol, 2-methyl-5-nitro- (8 CI); 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9 CI) 5872

C63-H88-Co-N14-O14-P
Vitamin B12 5936

C7-H11-N-O2
Succinimide, 2-ethyl-2-methyl- (8 CI); 2,5-Pyrrolidinedione, 3-ethyl-3-methyl- (9 CI) 5916

C7-H15-Cl2-N2-O2-P
2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide (8 CI); 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9 CI) 5965

C7-H5-N-O3-S
1,2-Benzisothiazolin-3-one, 1,1-dioxide (8 CI); 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide (9 CI) 5749

DIRECTORY - FORMULAS

C7-H5-O3
Salicylic acid, ion(1-) (8 CI); Benzoic acid, 2-hydroxy-, ion(1-) (9 CI) (VAN) 5911

C7-H8
Toluene (8 CI); Benzene, methyl- (9 CI) 5931

C7-H8-N4-O2
Theophylline (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9 CI) 5924

C8-H10
m-Xylene (8 CI); Benzene, 1,3-dimethyl- (9 CI) 5569

C8-H10-N4-O2
Caffeine (8 CI); 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9 CI) 5834

C8-H11-N-O3
Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)- (8 CI); 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9 CI) 5822

C8-H16-N6
Melamine, pentamethyl- (8 CI); 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N''-pentamethyl- (9 CI) 5880

C8-H16-O2
Valeric acid, 2-propyl- (8 CI); Pentanoic acid, 2-propyl- (9 CI) 5933

C8-H8
Styrene (8 CI); Benzene, ethenyl- (9 CI) 5696

C8-H9-N-O2
Acetanilide, 4'-hydroxy- (8 CI); Acetamide, N-(4-hydroxyphenyl)- (9 CI) 5798

C9-H6-N2-O3
8-Quinolinol, 5-nitro 6009

F
Fluoride 5452

Fluorine 5455

Fe
Iron 5460, 5876

Fe3-O4
Magnetite (8 CI); Magnetite [Fe3O4] (9 CI) 5574

Hg
Mercury 5586

H10-O9-Si2.3Mg
Chrysotile (8 CI) (VAN); Chrysotile [H4Mg3(Si2O9)] (9 CI) 5378

I
Iodine 5457

K
Potassium 5681

Li
Lithium 5567, 5878

Mg
Magnesium 5570

Mn
Manganese 5575, 5879

Na
Sodium 5691

Ni
Nickel 5648

P
Phosphorus 5665

Pb
Lead 5487

Pd
Palladium 5659

Pt
Platinum 5669

DIRECTORY - FORMULAS

S
Sulfur 5698

Se
Selenium 5682

Si
Silicon 5688

Sn
Tin 5706

Sr
Strontium 5694

Tl
Thallium 5699

V
Vanadium 5707

Zn
Zinc 5711, 5937

Zr
Zirconium 5746

EXACT COMPOSITION UNKNOWN OR UNDETERMINED

Asbestos 5294

Attapulgite (VAN) 5297, 5810

Biphenyl, chloro (8 CI); 1,1'-Biphenyl, chloro derivs (9 CI) 5310

Carbonylhemoglobin 5368

Insulin 5875

Prolactin (VAN) 5904

Tocopherol 5929

Vitamin A 5935

50272-101

REPORT DOCUMENTATION PAGE	1. REPORT NO. EPA 560/5-82-002	2. EIS-163/V4	3. Recipient's Accession No.

4. Title and Subtitle

Chemicals Identified in Human Biological Media, A Data Base, Interim Report, May, 1982

5. Report Date

6.

7. Author(s) M. Virginia Cone, Margaret F. Baldauf, Dennis M. Opresko, and Mary S. Uziel

8. Performing Organization Rept. No.

9. Performing Organization Name and Address

Chemical Effects Information Center
Information Center Complex
Information Division
Oak Ridge National Laboratory
Oak Ridge, Tennessee 37830

10. Project/Task/Work Unit No.

11. Contract(C) or Grant(G) No.
(C) EPA IAG No. 78-D-X383
(G)

12. Sponsoring Organization Name and Address

U.S. Environmental Protection Agency
Office of Toxic Substances
Exposure Evaluation Division (TS-798)
Washington, D.C. 20460

13. Type of Report & Period Covered
Report 9/81-5/82

14.

15. Supplementary Notes

16. Abstract (Limit: 200 words)

A comprehensive data base of chemicals identified in human biological media (tissues and body fluids) has been established under the direction of the Environmental Protection Agency's Office of Toxic Substances Exposure Evaluation Division. This centralized resource of body-burden information was inspired by the concern of government scientists over continuing reports of toxic chemicals in human tissues and body fluids.

Body burden is a reflection of exposures to food, air, and water contaminants, as well as pharmaceuticals. The systematic acquisition of body-burden data will facilitate a more relevant assessment of human exposure to toxic chemicals and xenobiotics than was previously possible using environmental contamination levels.

Data were obtained primarily from the open literature through manual searches of selected journals. Retrospective searching to 1974 is complete and has yielded 4000 pertinent documents of which approximately 2000 have been entered into the data base as of this report. These sources identify over 950 chemicals which have been found in human biological media.

17. Document Analysis a. Descriptors

Body burden
Human tissues/body fluids
Residues

b. Identifiers/Open-Ended Terms

c. COSATI Field/Group

18. Availability Statement	19. Security Class (This Report)	21. No. of Pages
RELEASE TO PUBLIC	UNCLASSIFIED	460
	20. Security Class (This Page) UNCLASSIFIED	22. Price

(See ANSI-Z39.18) See Instructions on Reverse

OPTIONAL FORM 272 (4-77)
(Formerly NTIS-35)
Department of Commerce

EPA 560/5-82-002
ORNL/EIS-163/V4

INTERNAL DISTRIBUTION

1. S. I. Auerbach
2. M. F. Baldauf
3. M. V. Cone
4. J. T. Ensminger
5. W. Fulkerson
6. H. B. Gerstner
7. D. M. Opresko
8. C. R. Richmond
9. G. D. Robbins
10. M. S. Uziel
11. Biology Library
12-13. Central Research Library
14. Document Reference Section
15. ICC Publications Office, 2001
16-25. ICC Resource Center, 2001
26-27. Laboratory Records
28. Laboratory Records, RC
29. ORNL Patent Office

EXTERNAL DISTRIBUTION

30. Executive Director, Oak Ridge Associated Universities, P.O. Box 117, Oak Ridge, Tennessee 37830.
31. Office of Assistant Manager, Energy Research and Development, Department of Energy, Oak Ridge Operations Office, Oak Ridge, Tennessee.
32-58. Technical Information Center, Department of Energy, Oak Ridge, Tennessee 37830.

* U.S. GOVERNMENT PRINTING OFFICE 1982-546-067/54